<SEC-DOCUMENT>0001193125-19-267053.txt : 20191015
<SEC-HEADER>0001193125-19-267053.hdr.sgml : 20191015
<ACCEPTANCE-DATETIME>20191015063925
ACCESSION NUMBER:		0001193125-19-267053
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		38
FILED AS OF DATE:		20191015
DATE AS OF CHANGE:		20191015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Phathom Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001783183
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824151574
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-234020
		FILM NUMBER:		191149005

	BUSINESS ADDRESS:	
		STREET 1:		2150 E. LAKE COOK ROAD, SUITE 800
		CITY:			BUFFALO GROVE
		STATE:			IL
		ZIP:			60089
		BUSINESS PHONE:		650-325-5156

	MAIL ADDRESS:	
		STREET 1:		2150 E. LAKE COOK ROAD, SUITE 800
		CITY:			BUFFALO GROVE
		STATE:			IL
		ZIP:			60089
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d63338ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>As filed with the Securities and Exchange Commission on October 15, 2019 </B></FONT></P>
  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-234020</FONT> </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:2px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>AMENDMENT NO. 1
</B></FONT></P>   <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>TO </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="3"><B>REGISTRATION STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>UNDER </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>THE SECURITIES ACT OF 1933 </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="5"><B>PHATHOM PHARMACEUTICALS,
INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>2834</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><FONT STYLE="white-space:nowrap">82-4151574</FONT></B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>2150 E. Lake Cook Road, Suite 800 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Buffalo Grove, Illinois 60089 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">650-325-5156</FONT></FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Address, including zip code, and telephone number, including area code, of
registrant&#146;s principal executive offices) </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>David Socks
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>President and Chief Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Phathom Pharmaceuticals, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>2150 E. Lake Cook Road, Suite 800 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Buffalo Grove, Illinois 60089 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-325-5156</FONT></FONT> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Copies to: </I></B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Cheston J. Larson</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Matthew T. Bush</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Anthony A. Gostanian</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Latham&nbsp;&amp; Watkins LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>12670 High Bluff Drive</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>San
Diego, California 92130</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>(858) <FONT STYLE="white-space:nowrap">523-5400</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Charles S. Kim</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Sean M. Clayton</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Jonie I. Kondracki</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Will H. Cai</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Cooley
LLP</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>4401 Eastgate Mall</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>San Diego, California 92121</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>(858)
<FONT STYLE="white-space:nowrap">550-6000</FONT></B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement is declared
effective. </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="1">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule
415 under the Securities Act of 1933, check the following box. <FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT> </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="1">If this
Form is filed to register additional securities for an offering pursuant to Rule 462(b)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. <FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="1">If this Form is
a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT
STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="1">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148;
and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1">Large accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1">Accelerated&nbsp;filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9746;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9746;</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9746;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="1">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9746;</FONT> </FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>CALCULATION OF REGISTRATION FEE </B></FONT></P>  <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Title of Each Class of&nbsp;Securities To Be Registered</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Amount to be</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Registered<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Proposed<BR>Maximum Offering<BR>Price Per Share</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering
Price<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Amount of<BR>Registration
Fee<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="1">Common Stock, $0.0001 par value per share</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">9,085,000 shares</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$20.00</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$181,700,000</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$23,585</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>      <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Includes 1,185,000 shares of common stock that the underwriters have the option to purchase. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) under the Securities Act of 1933, as amended.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">$12,120 of this registration fee was previously paid by the Registrant in connection with the filing of its Registration Statement on Form S-1 on
September 30, 2019. </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>The Registrant hereby
amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2" COLOR="#cc062a">The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in
any state or other jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2" COLOR="#cc062a">Subject to Completion. Dated October 15, 2019. </FONT></P>   <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4"><B>7,900,000 Shares
</B></FONT></P>  <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g45n03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:20px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4">Common Stock </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This is an initial
public offering of shares of common stock of Phathom Pharmaceuticals, Inc. We are offering 7,900,000&nbsp;shares of our common stock. </FONT></P>   <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Prior to this offering, there has been no public market for our common stock. It is currently estimated that the initial public offering price per share will be between $18.00 and $20.00. </FONT></P>
<P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have applied to list our common stock on the Nasdaq Global Market under the symbol &#147;PHAT.&#148; </FONT></P>
<P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are an &#147;emerging growth company&#148; as defined under the federal securities laws and, as such, we have elected to comply with certain
reduced public company reporting requirements for this prospectus and may elect to do so in future filings. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;
</P></center>  <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See &#147;<A HREF="#toc63338_2">Risk Factors</A>&#148; beginning on page 13 to read about factors you should consider before
buying shares of our common stock. </I></FONT></P>  <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Neither the Securities
and Exchange Commission nor any other state securities commission has approved or disapproved of these securities or passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Per&nbsp;Share</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Total</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Initial public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Underwriting
discount</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Proceeds, before expenses, to Phathom Pharmaceuticals, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">See the section titled &#147;Underwriting&#148; for additional information regarding compensation payable to the underwriters.
</FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To the extent that the underwriters sell more than 7,900,000 shares of common stock, the underwriters have the
option to purchase up to an additional 1,185,000 shares from us at the initial price to the public less the underwriting discount. </FONT></P>  <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>   <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters
expect to deliver the shares against payment in New York, New York on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>Jefferies&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>Evercore&nbsp;ISI</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:10px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Needham &amp; Company </B></FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.
</FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_1">Prospectus Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_2">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_3">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_4">Market and Industry Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_5">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_6">Dividend Policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_7">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_8">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_9">Selected Combined Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_10">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_11">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_12">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_13">Executive and Director Compensation</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_14">Certain Relationships and Related Person Transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_15">Principal Stockholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_16">Description of Capital Stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_17">Shares Eligible for Future Sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_18">Material United States Federal Income Tax Consequences to Non-U.S. Holders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_19">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_20">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_21">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_22">Where You Can Find More Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_23">Index to Combined Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or any free
writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the
underwriters are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its date,
regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession
or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and
observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our common stock. You should read this entire prospectus carefully, especially the section titled &#147;Risk Factors&#148; and our combined financial statements and related notes included elsewhere in this prospectus,
before making an investment decision. As used in this prospectus, unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;the Company,&#148; &#147;Phathom Pharmaceuticals&#148; and
&#147;Phathom&#148; refer to Phathom Pharmaceuticals, Inc. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Overview </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI,
diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker, or <FONT STYLE="white-space:nowrap">P-CAB.</FONT> <FONT STYLE="white-space:nowrap">P-CABs</FONT> are a novel class of medicines that
block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux
disease, or GERD, and in combination with antibiotics for the treatment of <I>Helicobacter pylori, </I>or <I>H. pylori,</I> infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in nine
countries in Asia and Latin America. Vonoprazan generated over $500&nbsp;million in net sales in its fourth full year on the market since its approval in Japan in late 2014. In May 2019, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the
U.S.,&nbsp;European, and Canadian rights to vonoprazan from Takeda. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe we can leverage Takeda&#146;s extensive clinical data,
including results from 17 Phase&nbsp;3 clinical trials, to advance vonoprazan through pivotal trials in the United States and Europe. We plan to initiate two pivotal Phase 3 clinical trials in the fourth quarter of 2019 for vonoprazan: one for the
treatment of erosive GERD, also known as erosive esophagitis, and a second for the treatment of <I>H. pylori</I> infection. We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021. We believe that the
successful completion of our Phase 3 clinical trials, together with the existing clinical data, will support regulatory submissions in 2021 and 2022 for marketing approval for the treatment of <I>H. pylori </I>infection and erosive esophagitis,
respectively. In August 2019, we received qualified infectious disease product, or QIDP, designation from the U.S. Food and Drug Administration, or FDA, for vonoprazan in combination with certain antibiotics for the treatment of <I>H. pylori
</I>infection which provides, among other benefits, extension of any regulatory exclusivity and potential eligibility for priority review. Vonoprazan has the potential to be the first gastric anti-secretory agent from a novel class approved in the
United States, Europe, or Canada in over 30&nbsp;years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Pipeline </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The following chart summarizes our current development programs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g74s47.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Overview of Acid-Related GI Diseases </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GI diseases where treatment is related to acid control, such as GERD and <I>H. pylori</I> infection, are significant medical problems because of
their high prevalence, chronic nature, and clinical sequelae. GERD results from the effects of acid on compromised mucosal defenses in the gastrointestinal tract. The reflux of gastric acid into the esophagus produces frequent and/or severe
heartburn, indigestion, and reflux symptoms. Chronic GERD may damage esophageal tissue and progress to more severe diseases including erosive esophagitis, Barrett&#146;s esophagus, and esophageal cancer. In <I>H. pylori </I>infection, gastric acid
limits the effectiveness of antibiotics used to eradicate infection. Chronic <I>H. pylori </I>infection can lead to dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GERD and <I>H. pylori</I> infection are two of the most common acid-related GI diseases and impact millions of people. The prevalence of GERD is
estimated to be 20% of the U.S. population and 15% of the population in the five major countries in the European Union (France, Germany, Italy, Spain, and the United Kingdom, or the EU5). We estimate that there are approximately 65&nbsp;million
individuals in the United States and 50&nbsp;million individuals in the EU5 with GERD. Approximately 30% of GERD patients have erosive esophagitis. <I>H. pylori</I> is a bacterial pathogen that infects approximately 35% of the U.S. population and
45% of the EU5 population. We estimate that there are approximately 115&nbsp;million individuals in the United States and 145&nbsp;million individuals in the EU5 infected with <I>H. pylori</I>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Current Standard of Care for GERD and </B><B><I>H. pylori</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Over the last thirty years, the proton pump inhibitor, or PPI, class, has been the standard of care for the treatment of acid-related GI diseases. PPIs are generally used as a single agent for the treatment of GERD
and in combination with antibiotics<I> </I>for the treatment of <I>H. pylori</I> infection. The PPI class includes drugs such as Prilosec (omeprazole), Nexium (esomeprazole), and Prevacid (lansoprazole). Prior to the introduction of generic and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> or OTC, alternatives, annual PPI class sales reached approximately $12.5&nbsp;billion in the United States, and peak sales for individual brands were
approximately $3.7&nbsp;billion for Prilosec, $3.5&nbsp;billion for Nexium, and $3.4&nbsp;billion for Prevacid in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While PPIs are the current standard of care and have experienced significant commercial success, they have significant limitations that result in a
large unmet medical need. In GERD, PPI therapy is suboptimal for many patients due to the slow onset and insufficient duration of acid control which can lead to inadequate symptom relief. Approximately 15% to 45% of GERD patients remain inadequately
treated with PPIs. In the treatment of <I>H.&nbsp;pylori </I>infection, the standard of care consists of a combination of a PPI and at least two oral antibiotics. However, increasing antibiotic resistance has resulted in declining eradication rates
with <FONT STYLE="white-space:nowrap">PPI-based</FONT> therapy. We believe these unmet medical needs are in part driven by limitations associated with the mechanism of action and pharmacokinetics of PPIs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Gastric acid is secreted by proton pumps that are expressed on the channeled surfaces of parietal cells in the stomach. Proton pumps are
continuously synthesized and switch between active and inactive states in response to various stimuli, such as food. When activated, proton pumps increase acid secretion. PPIs reduce gastric acid secretion by irreversibly binding to and inhibiting
active proton pumps expressed on the parietal cells. PPIs require activation by gastric acid, but they are unstable in the presence of acid. This instability, combined with the short circulating half-life of PPIs, limits their efficacy.
Additionally, because proton pumps continuously switch between active and inactive states, multiple doses of PPIs are required to inhibit enough proton pumps to achieve a clinical benefit. As a result, PPIs have a relatively slow onset of action and
limited potency and duration of </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
effect, which may result in patients experiencing only partial relief, increasing PPI dosage, and/or cycling through multiple PPIs seeking relief. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Solution: Vonoprazan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has a
differentiated mechanism of action from PPIs. Unlike PPIs, vonoprazan: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">does not require activation by gastric acid; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">is stable in the presence of acid; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">binds with a slow dissociation rate to both active and inactive proton pumps; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">has a long plasma half-life that replenishes the drug at the site of action over the course of the day. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">These factors have enabled vonoprazan to demonstrate more rapid and potent acid suppression versus the PPI esomeprazole in human subjects two hours
after oral dosing and maintain target acid inhibition over a <FONT STYLE="white-space:nowrap">24-hour</FONT> period in a randomized, open-label, crossover clinical trial. In contrast, PPIs require three to five days to reach steady state acid
suppression and do not reliably maintain target acid inhibition over a <FONT STYLE="white-space:nowrap">24-hour</FONT> period. In addition, vonoprazan demonstrated approximately 10-to-100-fold better acid control compared to esomeprazole.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe that vonoprazan&#146;s anti-secretory profile may demonstrate clinically meaningful advantages over PPIs, such as:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">faster, more complete, and more durable healing of erosive esophagitis; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">faster, more complete, and more durable control of GERD symptoms; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">higher <I>H. pylori</I> eradication rates in combination with antibiotics compared to standard of care triple therapy and the potential for antibiotic-sparing
dual therapy; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">more flexible dosing, including dosing independent of food and time of day, and the potential for rapid symptom relief through
<FONT STYLE="white-space:nowrap">on-demand</FONT> dosing. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan generated over $500&nbsp;million in net sales in
its fourth full year on the market in Japan, a 20% increase over the previous year. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Clinical Data </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has demonstrated clinical advantages over PPIs in the treatment of erosive esophagitis and <I>H.</I><I></I><I>&nbsp;pylori</I> infection
in completed Phase 3 clinical trials conducted in Japan and other Asian countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Erosive
esophagitis</B><B>.</B>&nbsp;&nbsp;&nbsp;&nbsp;In two Phase 3 clinical trials conducted in Japan assessing vonoprazan versus the PPI lansoprazole in the healing and maintenance of healing of erosive esophagitis, vonoprazan met its primary endpoint
in demonstrating <FONT STYLE="white-space:nowrap">non-inferiority</FONT> to lansoprazole. In a post hoc analysis of the healing trial, vonoprazan demonstrated faster healing and a superior overall healing rate compared to lansoprazole in patients
with more severe erosive esophagitis. After two weeks of treatment, 88% of erosive esophagitis patients with more severe disease were healed after treatment with vonoprazan versus 64% with lansoprazole (p&#061;0.0008). In the maintenance of healing
trial, vonoprazan demonstrated lower recurrence rates of erosive esophagitis six months after treatment versus lansoprazole across all grades of severity of erosive esophagitis. Vonoprazan demonstrated a 2% recurrence rate compared to 17% for
lansoprazole (p&lt;0.0001). </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>H. pylori</I></B><B>.</B>&nbsp;&nbsp;&nbsp;&nbsp;A Phase 3 clinical trial was conducted in
Japan assessing vonoprazan in combination with the antibiotics amoxicillin and clarithromycin versus lansoprazole in combination with these same antibiotics in first line treatment of <I>H. pylori </I>infection. In this trial, the vonoprazan-based
regimen met its primary endpoint in demonstrating a non-inferior eradication rate of 93% compared to 76% for lansoprazole-based regimen (p&lt;0.0001) and was also superior in a post hoc analysis of this trial (p&lt;0.0001). In patients who failed
first line therapy, vonoprazan in combination with the antibiotics metronidazole and amoxicillin demonstrated a 98% eradication rate as second line therapy. A p-value is the probability that the reported result was achieved purely by chance, such
that a <FONT STYLE="white-space:nowrap">p-value</FONT> of less than or equal to 0.05 or 0.01 means that there is a 5.0% or 1.0% or less probability, respectively, that the difference between the control group and the treatment group is purely due to
chance. A p-value of 0.05 or less typically represents a statistically significant result. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Safety.</B>&nbsp;&nbsp;&nbsp;&nbsp;As of
December 2018, 6,683 subjects have been exposed to vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120&nbsp;mg with durations up to one year. The most commonly reported adverse events, or
AEs, in the clinical development program for vonoprazan, as reflected in the Japanese prescribing information published by Japan&#146;s Pharmaceuticals and Medical Devices Agency, were diarrhea, constipation, nausea, elevated liver enzymes, rash,
and eosinophilia. All such events had an incidence rate of less than 5.0%, other than diarrhea in the treatment of <I>H. pylori</I> which had an incidence rate of 10.6% in combination with antibiotics. No dose-related increase in treatment-emergent
AEs, or TEAEs, or serious AEs, or SAEs, was observed. The safety profile of vonoprazan and incidence of TEAEs, drug-related TEAEs, and TEAEs leading to drug discontinuation were similar between vonoprazan and lansoprazole across studies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The most recent post-marketing safety report from December 2018 includes an estimated 23&nbsp;million patients who have received vonoprazan in
Japan since its launch. Based on the post-marketing experience, the clinically significant adverse reactions section of the Japanese prescribing information for vonoprazan was updated to include skin reactions such as toxic epidermal necrolysis,
Steven-Johnson syndrome, and erythema multiforme. The incidence of these skin reactions was considered extremely rare (less than 1 in 100,000 patients) and a causal relationship to vonoprazan could not be ruled out. We believe the overall
post-marketing safety and tolerability profile of vonoprazan has been consistent with that observed in clinical trials. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Strategy </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our goal is to be a leader in the development and commercialization of novel treatments for GI diseases. Our strategy is initially focused on
developing and commercializing vonoprazan as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">P-CAB</FONT> in the United States, Europe, and Canada for the
treatment of acid-related GI diseases. Key elements of this strategy include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Advance the clinical development of vonoprazan in erosive esophagitis and H. pylori infection and seek marketing
approval</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We believe we can leverage the existing clinical data and post-marketing experience, as well as our management team&#146;s experience with vonoprazan, to advance vonoprazan through a single pivotal
Phase 3 clinical trial in each of erosive esophagitis and <I>H. pylori</I> infection beginning in the fourth quarter of 2019, and we expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Commercialize vonoprazan in the United States</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We plan to independently commercialize vonoprazan, if approved, in the
United States by building a leading specialty gastroenterology commercial infrastructure to support the adoption of vonoprazan. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Seek commercial partnerships to maximize the vonoprazan opportunity outside of the United States</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We believe there is
a significant commercial opportunity for vonoprazan in Europe and Canada. To address these markets, we plan to seek one or more partners with existing commercial infrastructure and expertise in these markets. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Expand the development of vonoprazan across indications, dosing regimens, and alternative formulations and packaging</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;We
plan to pursue vonoprazan lifecycle extension strategies in areas with clear unmet need, clinical rationale, and commercial justification. These strategies may include additional indications, flexible dosing regimens, and alternative formulations
and packaging. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-license</FONT> or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases
in a capital efficient manner</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We intend to take advantage of our management team&#146;s GI expertise to opportunistically <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional innovative
therapies for diseases treated by gastroenterologists. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Team </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our founders and management team have deep expertise in developing GI therapeutics, including anti-secretory agents, and direct experience
developing vonoprazan at Takeda. Our Chairman, Tadataka (Tachi) Yamada, M.D., is the former Chief Medical Officer and Chief Scientific Officer at Takeda. He is the former President of the American Gastroenterological Association and former Chief of
Gastroenterology and Internal Medicine at the University of Michigan. Our Chief Executive Officer, David Socks, is the former Chief Executive Officer of Outpost Medicine, LLC, a GI and urology focused company. Mr.&nbsp;Socks was also President and
Chief Operating Officer of Incline Therapeutics Inc. through its sale to The Medicines Company in 2013, and Senior Vice President, Corporate Development and Strategy of Cadence Pharmaceuticals, Inc. Azmi Nabulsi, M.D., M.P.H., our Chief Operating
Officer, is the former Deputy Chief Medical and Scientific Officer at Takeda. Our Head of Regulatory, Tom Harris, is the former Senior Vice President and Head of Global Regulatory at Takeda. Dr.&nbsp;Yamada, Dr.&nbsp;Nabulsi, and Mr.&nbsp;Harris
were extensively involved with the development of vonoprazan at Takeda. Our investors include Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors and BVF Partners LP.
</FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As part of a planned transition, we expect that Terrie Curran, a member of our board of directors, will succeed Mr.&nbsp;Socks as
Chief Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by Bristol-Myers Squibb Company. Ms.&nbsp;Curran has served as President, Global Inflammation and Immunology (I&amp;I) Franchise and
as a member of the Executive Committee at Celgene since 2017. Ms.&nbsp;Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&amp;I Franchise and built the capabilities and recruited the teams that executed the launch of OTEZLA.
Following Ms.&nbsp;Curran&#146;s appointment as CEO, Mr.&nbsp;Socks will serve as interim Chief Financial Officer and continue to serve as a member of our board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Financial Update </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We estimate that our cash and cash equivalents were approximately
$74.5&nbsp;million as of September&nbsp;30, 2019. This amount is unaudited and preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ from the amount that will be reflected in our financial
statements as of and for the quarter ended September&nbsp;30, 2019. Our financial statements for the quarter ended September&nbsp;30, 2019 will not be available until after this offering is completed, and consequently will not be available to you
prior to investing in this offering. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Business </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our ability to execute our business strategy is subject to numerous risks, as more fully described in the section titled &#147;Risk Factors&#148;
immediately following this Prospectus Summary. These risks include, among others: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable
future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all,
could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We currently depend entirely on the success of vonoprazan, which is our only product candidate. Our assumptions about vonoprazan&#146;s development and
commercial potential are based in large part on the development, including data from clinical trials conducted by Takeda and independent investigators, and commercial experience of vonoprazan in Japan and other Asian countries, which data the FDA or
comparable foreign regulatory authorities may not accept to support approval. If we are unable to advance vonoprazan in clinical development, obtain regulatory approval and ultimately commercialize vonoprazan, or experience significant delays in
doing so, our business will be materially harmed. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We rely on our license agreement with Takeda to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada. If the
license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of prior clinical trials and other
investigator-initiated clinical trials of vonoprazan are not necessarily predictive of our future results. Vonoprazan may not have favorable results in our clinical trials, or receive regulatory approval on a timely basis, if at all.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Any difficulties or delays in the commencement or completion, or termination or suspension, of our planned clinical trials could result in increased costs to us,
delay or limit our ability to generate revenue and adversely affect our commercial prospects. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We intend to enroll patients in Europe in both of our planned Phase&nbsp;3 clinical trials. However, the FDA and other comparable foreign regulatory authorities
may not accept data from such trials, in which case our clinical development plans will be delayed, which could materially harm our business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We rely on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may
not perform satisfactorily. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more
effective, our ability to develop and successfully commercialize products may be adversely affected. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Our success depends on our ability to protect our intellectual property and our proprietary technologies. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">After this offering, our executive officers, directors, and principal stockholders, if they choose to act together, will continue to have the ability to control
or significantly influence all matters submitted to stockholders for approval. Furthermore, many of our current directors were appointed by our principal stockholders. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Corporate Information </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We were originally incorporated under the laws of the state of Delaware on January&nbsp;9, 2018 under the name North Bridge IV, Inc. On
March&nbsp;13, 2019, we changed our name to Phathom Pharmaceuticals, Inc. and merged YamadaCo IIA, Inc., a Delaware corporation, with and into our company, with Phathom Pharmaceuticals, Inc. as the surviving entity, or the Merger. References
throughout this registration statement to Phathom Pharmaceuticals, Inc. include North Bridge IV, Inc. prior to the Merger. Our principal executive offices are located at 2150 E. Lake Cook Road, Suite 800, Buffalo Grove, Illinois 60089, and our
telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-325-5156.</FONT></FONT> Our website address is www.phathompharma.com<I>.</I> The information contained in, or accessible through, our website does not
constitute part of this prospectus. We have included our website address as an inactive textual reference only. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">We
use our pending trademark Phathom Pharmaceuticals in this prospectus. This prospectus also includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to
in this prospectus appear without the <FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and <FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the
applicable owner will not assert its rights, to these trademarks and tradenames. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Presentation of Japanese Sales Numbers
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">All Japanese sales numbers presented in this prospectus are shown in U.S. dollars based on the June&nbsp;30, 2019 conversion ratio
of 0.009 yen to one dollar. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not
limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with
correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley Act;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or
a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, unless the SEC determines the new rules are necessary for protecting the public; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reduced disclosure obligations regarding executive compensation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may take advantage of these provisions until the last day of our fiscal year following the
fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such fifth anniversary will occur in 2024. However, if certain events occur prior to the end of
such five-year period, including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, or the Exchange Act, our annual gross revenues exceed
$1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have elected to take advantage of certain of the reduced disclosure obligations in this prospectus and in the registration statement
of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information in this prospectus and that we provide to our stockholders in the future may be different than
what you might receive from other public reporting companies in which you hold equity interests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, the JOBS Act provides
that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to
the same new or revised accounting standards as other public companies that are not emerging growth companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also a smaller
reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting
companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>The Offering </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock offered by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">7,900,000 shares.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Underwriters&#146; option to purchase additional shares from us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE=0><BR></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to a total of 1,185,000 additional shares of our common
stock.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock to be outstanding immediately after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE=0><BR></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="2">25,883,458 shares (27,068,458 shares if the underwriters exercise their option to purchase additional shares of common stock in full).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Use of proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">We intend to use the net proceeds of this offering to fund the clinical development of vonoprazan and for working capital and general corporate purposes, including <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> activities. See &#147;Use of Proceeds.&#148;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Risk factors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">See &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common
stock.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Directed share program</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">At our request, the underwriters have reserved up to 3.0% of the shares of common stock to be offered by this prospectus for sale, at the initial public offering price, to certain of our
directors, officers, employees, and their friends and family members through a directed share program. If these persons purchase reserved shares, this will reduce the number of shares available for sale to the general public. Any reserved shares
that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares offered by this prospectus.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Proposed Nasdaq Global Market symbol</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;PHAT&#148;</FONT></TD></TR>
</TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The number of shares of our common stock to be outstanding after this offering set forth above is based on
17,983,458 shares of our common stock outstanding as of June&nbsp;30, 2019, including 4,657,250 shares subject to forfeiture or our right of repurchase, and gives effect to the automatic conversion of $90.3&nbsp;million of aggregate principal
amount, plus accrued interest thereon, of convertible promissory notes we issued in May 2019, or the May 2019 Notes, into an aggregate of 6,106,940 shares of our common stock immediately prior to the closing of this offering (based on an assumed
initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on October 28, 2019), and excludes: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">7,588,000 shares of common stock issuable to Takeda upon the exercise of an outstanding warrant, or the Takeda Warrant, as of June&nbsp;30, 2019, at an exercise
price of $0.00004613 per share; </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">1,400,528 shares of common stock issuable upon exercise of stock options granted after June&nbsp;30, 2019, at a weighted-average exercise price of $9.10 per
share; </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">2,700,000 shares of common stock reserved for future issuance under our 2019 Equity Incentive Plan, or the 2019 Plan, which will become effective in connection
with this offering (which number does not include any potential evergreen increases pursuant to the terms of the 2019 Plan); </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">270,000 shares of common stock reserved for future issuance under our 2019 Employee Stock Purchase Plan, or ESPP, which will become effective in connection with
this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP); and </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">16,446 shares of common stock which may become issuable to the lenders under our loan and security agreement, or the Loan Agreement, upon the exercise of
warrants outstanding as of June&nbsp;30, 2019, or the Lender Warrants, at an exercise price of $15.20 per share (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of
this prospectus), which warrants will only become exercisable if and when we borrow an additional $25.0 million under our Loan Agreement. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws, each of which will
occur immediately prior to the closing of this offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the issuance of 6,106,940 shares of common stock upon the automatic conversion of the May 2019 Notes immediately prior to the closing of this offering (based on
an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on October 28, 2019); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the expiration of the right granted to Takeda to receive an additional common stock warrant, or the Takeda Warrant Right, upon the closing of this offering
(based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover of this prospectus, as further described below in the section titled &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#151;Overview&#151;License Agreement with Takeda&#148;); </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a<B> </B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1,559.1183-for-1</FONT></FONT> forward stock split of our common stock effected on
March&nbsp;13, 2019; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a subsequent <FONT STYLE="white-space:nowrap">2.168-for-1</FONT> forward stock split of our common stock, which we effected on October&nbsp;11, 2019;
</FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">no exercise of the outstanding options or warrants described above; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">no exercise by the underwriters of their option to purchase 1,185,000 additional shares of our common stock. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A $1.00 increase in the assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of
this prospectus, would decrease the number of shares of our common stock issued upon conversion of the May 2019 Notes by 305,346 shares. A $1.00 decrease in the assumed initial public offering price of $19.00 per share would increase the number of
shares of our common stock issued upon conversion of the May 2019 Notes&nbsp;by 339,275 shares. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">10 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Summary Combined Financial Data </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following tables set forth a summary of our historical combined financial data as of, and for the periods ended on, the dates indicated. The
combined financial statements include the accounts of our company and YamadaCo IIA, Inc., both of which were entities under common control prior to the Merger. We have derived the summary combined statements of operations data for the year ended
December&nbsp;31, 2018 from our audited combined financial statements included elsewhere in this prospectus. We have derived the summary combined statements of operations data for the six months ended June&nbsp;30, 2018 and 2019 and the summary
combined balance sheet data as of June&nbsp;30, 2019 from our unaudited combined financial statements included elsewhere in this prospectus. The unaudited combined financial statements have been prepared on a basis consistent with our audited
combined financial statements included in this prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary to fairly state our results of operations for the six months ended
June&nbsp;30, 2018 and 2019 and financial position as of June&nbsp;30, 2019. You should read these data together with our combined financial statements and related notes included elsewhere in this prospectus and the sections titled &#147;Selected
Combined Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not necessarily indicative of our future results. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year
Ended<BR>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six Months Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Combined Statements of Operations Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative (includes related party amounts of $321, $124 and $18, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense (includes related party amounts of $(13), $(4) and $(82), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities (includes related party amounts of $0, $0 and $(1,277), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes (includes related party amounts of $(50), $(4) and $(502),
respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss per share, basic and diluted</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Weighted-average shares of common stock outstanding, basic and diluted</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,051,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,331,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,640,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss per share, basic and diluted (unaudited)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(9.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma weighted-average shares of common stock outstanding, basic and diluted
(unaudited)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,098,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,578,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">See Note&nbsp;1 to our combined financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the
historical and pro forma net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">11 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>As of</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro<BR>Forma<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro
Forma<BR>As<BR>Adjusted<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Combined Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">219,710</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Working capital
(deficit)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(60,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">219,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">221,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes payable at fair value (including accrued interest)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">93,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, including final payment fee and net of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">58,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">195,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Gives effect to the (i)&nbsp;automatic conversion of the May 2019 Notes into an aggregate of 6,106,940 shares of our common stock immediately prior to
the closing of this offering (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on October 28, 2019), and
(ii)&nbsp;the reclassification of the Takeda Warrant to stockholders&#146; equity (deficit). </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Gives effect to (i)&nbsp;the pro forma adjustments set forth in footnote (1)&nbsp;above, and (ii)&nbsp;the issuance and sale of 7,900,000 shares of our
common stock in this offering at the assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $19.00 per share would increase (decrease) the pro forma as adjusted amount of each of our cash and cash equivalents, working
capital, total assets and total stockholders&#146; equity (deficit) by approximately $7.3 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price of $19.00 per
share would increase (decrease) the pro forma as adjusted amounts of each of our cash and cash equivalents, working capital, total assets and total stockholders&#146; equity (deficit) by approximately $17.7 million, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">The pro forma and pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual initial public
offering price and other terms of our initial public offering determined at pricing. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">We define working capital (deficit) as current assets less current liabilities. See our combined financial statements included elsewhere in this
prospectus for further details regarding our current assets and current liabilities. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">12 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_2"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below,
together with all of the other information in this prospectus, including our combined financial statements and related notes included elsewhere in this prospectus and the section titled &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; before making an investment decision. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that
event, the trading price of our common stock could decline and you could lose part or all of your investment. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Limited
Operating History, Financial Position and Capital Requirements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We have a limited operating history, have incurred significant operating losses
since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a late clinical-stage
biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2018, and to date, we have focused primarily on organizing and staffing our company, business planning,
raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> our initial product candidate, vonoprazan, meeting with regulatory authorities, and preparing for our planned Phase 3 clinical trials of vonoprazan. As a company, we have not yet
demonstrated an ability to successfully complete any clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for
successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have incurred significant operating losses since our inception. If vonoprazan is not successfully developed and approved in the
United States, Europe and/or Canada, we may never generate any revenue. Our net losses were $1.3&nbsp;million and $89.0&nbsp;million for the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019, respectively. As of
June&nbsp;30, 2019, we had an accumulated deficit of $90.3&nbsp;million. Substantially all of our losses have resulted from expenses incurred in connection with <FONT STYLE="white-space:nowrap">in-licensing</FONT> and developing vonoprazan and from
general and administrative costs associated with our operations. Vonoprazan and any future product candidates will require substantial additional development time and resources before we will be able to apply for or receive regulatory approvals and
begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for, and
potentially commercialize vonoprazan and seek to identify, assess, acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or develop additional product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities,
including completing clinical trials and preclinical studies of vonoprazan and any future product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products. We are only in the
preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to
successfully overcome many of the risks and uncertainties frequently encountered by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">13 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product
development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a
quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, continue our product development efforts, diversify our product
candidate pipeline or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at
all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our planned Phase 3 clinical
trials of vonoprazan and seek regulatory approval for vonoprazan. In addition, if vonoprazan receives approval and is commercialized, we will be required to make milestone and royalty payments to Takeda, from whom we have <FONT
STYLE="white-space:nowrap">in-licensed</FONT> the rights to develop and commercialize vonoprazan in the United States, Europe, and Canada pursuant to the license agreement, dated May&nbsp;7, 2019, between us and Takeda, or the Takeda License.
Furthermore, if and to the extent we seek to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates in the future, we may be required to make significant upfront payments, milestone payments, and/or licensing
payments. If we obtain regulatory approval for vonoprazan or any future product candidate, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any
clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of vonoprazan or any future product candidate. Furthermore, following the completion of
this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when
needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operations for at least the next 24&nbsp;months. In particular, we expect that
the net proceeds from this offering will allow us to complete our planned Phase&nbsp;3 clinical trials of vonoprazan in the treatment of erosive esophagitis and <I>H. pylori</I> infection. We have based these estimates on assumptions that may prove
to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds
sooner than planned, through public or private equity or debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market
conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop vonoprazan or any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our future capital requirements will depend on many factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the initiation, type, number, scope, results, costs and timing of, our clinical trials of vonoprazan, and preclinical studies or clinical trials of other
potential product candidates we may choose to pursue in the future, including feedback received from regulatory authorities; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">14 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs and timing of manufacturing for vonoprazan or any future product candidates, including commercial scale manufacturing if any product candidate is
approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs, timing and outcome of regulatory review of vonoprazan or any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls
over financial reporting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers, clinical development
personnel and commercial personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and amount of the milestone or other payments we must make to Takeda and any future licensors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs and timing of establishing or securing sales and marketing capabilities if vonoprazan or any future product candidate is approved;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any
approved products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">patients&#146; willingness to pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for any approved products in the
absence of coverage and/or adequate reimbursement from third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs associated with any products or technologies that we may <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Conducting clinical trials and preclinical studies is a time consuming, expensive, and uncertain process that takes years to complete, and we may
never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, vonoprazan and other potential product candidates, if approved, may not achieve commercial success. Our commercial revenues,
if any, would initially be derived from sales of vonoprazan, which we do not expect to be commercially available in our licensed territories for many years, if at all. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may
seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or
product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash
needs through equity offerings, our loan and security agreement, or the Loan Agreement, with Silicon Valley Bank, or SVB, as administrative and collateral agent, and lenders SVB and WestRiver Innovation Lending Fund VIII, L.P., or WestRiver, debt
financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will
be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Our Loan Agreement includes, and any future debt financing and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">15 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we raise funds through future collaborations, licenses and other similar arrangements,
we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our management, as of December&nbsp;31, 2018, and our independent registered public accounting firm, in their report on our combined
financial statements as of and for the fiscal year ended December&nbsp;31, 2018, have concluded that there is substantial doubt as to our ability to continue as a going concern. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our audited combined financial statements for the fiscal year ended December&nbsp;31, 2018 were prepared assuming that we will continue as a going
concern. The going concern basis of presentation assumes that we will continue in operation for the foreseeable future and will be able to realize our assets and satisfy our liabilities in the normal course of business and do not include any
adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from our inability to continue as a going concern. As of December&nbsp;31, 2018, our
management concluded that, based on our expected operating losses, negative cash flows and maturities of outstanding convertible promissory notes, there is substantial doubt about our ability to continue as a going concern for the twelve months
after the date the combined financial statements were issued. Our ability to continue as a going concern is subject to our ability to obtain sufficient financing. If we cannot continue as a going concern, we may have to liquidate our assets and may
receive less than the value at which those assets are carried on our combined financial statements, and it is likely that our stockholders may lose some or all of their investment in us. After this offering, we may not raise the funding we require
such that substantial doubt about our ability to continue as a going concern continues. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going
concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms or at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">16 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to the Development and Regulatory Approval of Product Candidates </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We currently depend entirely on the success of vonoprazan, which is our only product candidate. If we are unable to advance vonoprazan in clinical
development, obtain regulatory approval and ultimately commercialize vonoprazan, or experience significant delays in doing so, our business will be materially harmed. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We currently only have one product candidate, vonoprazan, which we <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Takeda. Our business presently depends entirely on our ability to successfully develop,
obtain regulatory approval for, and commercialize vonoprazan in a timely manner. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development that may be able to better sustain
failure of a lead product candidate. We plan to initiate two pivotal Phase 3 clinical trials in the fourth quarter of 2019 for vonoprazan: one for the treatment of erosive esophagitis, and a second for the treatment of <I>H. pylori </I>infection.
Our assumptions about vonoprazan&#146;s development and commercial potential are based in large part on the development and commercial experience of vonoprazan in Japan and other Asian countries. However, our assumptions may prove to be wrong, and
we may encounter a materially and adversely different development and commercial experience. The success of vonoprazan will depend on several factors, including the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">acceptance by the FDA or by comparable foreign regulatory authorities of our proposed design of the planned Phase&nbsp;3 clinical trials of vonoprazan and any
future clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">successful enrollment in clinical trials and completion of clinical trials with favorable results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the willingness of the FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities to accept the data from our planned Phase
3 clinical trials conducted in Europe and preclinical studies and clinical trials conducted outside of our licensed territories by Takeda and independent investigators as part of the basis for review and approval of vonoprazan;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">demonstrating safety and efficacy to the satisfaction of applicable regulatory authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA, and other comparable foreign regulatory authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">receipt of marketing approvals from applicable regulatory authorities, including one or more new drug applications, or NDAs, from the FDA and maintaining such
approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">making arrangements with Takeda or any future third-party manufacturers for, or establishing, commercial manufacturing capabilities and receiving/importing
commercial supplies approved by FDA and other regulators from Takeda or any future third-party manufacturer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">establishing sales, marketing and distribution capabilities and commercializing vonoprazan, if approved, whether alone or in collaboration with others;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">establishment and maintenance of patent and trade secret protection or regulatory exclusivity for vonoprazan; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">maintaining an acceptable safety profile of vonoprazan following approval; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">maintaining and growing an organization of people who can develop and, if approved, commercialize, market, and sell vonoprazan to physicians, patients,
healthcare payors, and others in the medical community. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The success of our business, including our ability to finance
our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of vonoprazan, which may never occur. We have not yet succeeded and may not succeed in demonstrating
efficacy and safety for vonoprazan in clinical trials or in obtaining marketing approval thereafter. It may be several years, if at all, before we have demonstrated the safety and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">17 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
efficacy of a treatment sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize
vonoprazan, we may not be able to generate sufficient revenue to continue our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Clinical drug development involves a lengthy and
expensive process with an uncertain outcome, and the results of prior clinical trials and other investigator-initiated clinical trials of vonoprazan are not necessarily predictive of our future results. Vonoprazan may not have favorable results in
our clinical trials, or receive regulatory approval on a timely basis, if at all. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Clinical drug development is expensive and can
take many years to complete, and its outcome is inherently uncertain. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process.
Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The results from clinical trials or preclinical studies of a product candidate may not predict the results of later clinical trials of the product
candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed
through preclinical studies and initial clinical trials. In particular, while vonoprazan has been studied in an extensive clinical program by Takeda, including 17 Phase 3 clinical trials, we do not know how vonoprazan will perform in future clinical
trials, including as a result of differences between the clinical trials conducted to date by Takeda or other third parties and our planned Phase 3 clinical trial designs. These differences include, among other things: including higher doses of
antibiotics and longer duration of treatment and inclusion of a dual therapy arm in our planned Phase 3 clinical trial for the treatment of <I>H. pylori</I> infection, and conducting a single Phase 3 clinical trial for both the healing and
maintenance of erosive esophagitis, rather than two separate trials. Further, the large majority of the clinical development of vonoprazan was conducted in Asian subjects, who naturally have differences in height, weight, drug metabolism, and
potentially, acid-secretory capacity from Western populations. Although there are data across two Phase 1 clinical trials in healthy volunteers showing that the vonoprazan pharmacokinetic and pharmacodynamic profile is similar in Japanese and <FONT
STYLE="white-space:nowrap">non-Japanese</FONT> subjects, our clinical trials of vonoprazan in a broader population comprised of patients in the United States and Europe may not yield the same results as prior clinical trials. Additionally, Western
patients may be more likely to deviate from clinical trial protocols or drop out of clinical trials than Japanese patients, which may negatively impact the results of our clinical trials. Further, in our planned Phase 3 clinical trial for the
treatment of <I>H. pylori</I> infection, the vonoprazan dual therapy arm will not be double-blinded because patients in this arm will be administered amoxicillin three times daily, versus twice daily for the triple therapy regimens. Both triple
therapy regimens will be double-blinded. The inability to double-blind the dual therapy arm may impact the results of this trial and how regulatory agencies or healthcare payors interpret such results. For example, the EMA has noted that it expects
additional analyses of treatment compliance and drop-out rates in the dual therapy arm because it will not be double-blinded. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A number
of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after the product candidate achieved promising results in earlier clinical trials. The results of our planned trials may
not be comparable to those achieved previously, whether as a result of differences in trial design, patient population or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, the FDA, the EMA, or other comparable foreign regulatory authorities may not view the data from clinical trials conducted by Takeda and
other third parties discussed above, together with our single planned Phase&nbsp;3 clinical trial in each of erosive esophagitis and <I>H. pylori</I> infection, as sufficient to support the regulatory approval of vonoprazan for the treatment of
erosive esophagitis or <I>H.&nbsp;pylori</I> infection. The FDA, EMA, or other comparable foreign regulatory authorities may also disagree with the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">18 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
adequacy of our trial designs, including as a result of the differences between our designs and those of Takeda&#146;s Phase&nbsp;3 clinical trials discussed above. As a result, we could be
required to conduct additional clinical trials prior to seeking and obtaining regulatory approval and our planned development timeline could materially change. In addition, in July 2019, we received scientific advice from the EMA on our planned
Phase&nbsp;3 clinical trial of vonoprazan in the healing and maintenance of healing of erosive esophagitis. For the healing phase of the study, the EMA recommended that we include an endoscopy to assess healing at Week&nbsp;4 in addition to the
planned endoscopies at Week&nbsp;2 and Week&nbsp;8 because the summary of product characteristics for lansoprazole suggests four weeks of treatment to assess healing in erosive esophagitis. We have decided not to incorporate this change into the
study design given the additional burden on study subjects to return for a third endoscopy in an eight-week period. This decision may impact the future summary of product characteristics for vonoprazan or may cause the EMA to require us to conduct
additional clinical trials for vonoprazan to support marketing approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, Takeda, a third party over which we have no
control, has the right to develop and commercialize vonoprazan outside of the United States, Europe, and Canada. Takeda has marketing approval for vonoprazan in certain countries in Asia and Latin America, and Takeda has ongoing clinical trials of
vonoprazan in certain indications that we are also pursuing. If such ongoing trials fail to meet their primary endpoints, have serious adverse events or encounter other problems, the development potential of vonoprazan could be materially and
adversely affected. In addition, if serious adverse events or other problems occur with patients using vonoprazan marketed outside of our licensed territories, or if the results of ongoing or future clinical trials of vonoprazan conducted by Takeda
or others generate negative results or results that conflict with the results of our clinical trials, the FDA, EMA, or other regulatory authorities may delay, limit, or deny approval of vonoprazan, require us to conduct additional clinical trials as
a condition to marketing approval, or withdraw their approval of vonoprazan or otherwise restrict our ability to market and sell vonoprazan, if approved. In addition, treating physicians may be less willing to prescribe vonoprazan due to concerns
over such trial results or adverse events, which would limit our ability to commercialize vonoprazan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For the foregoing reasons, our
planned clinical trials may not be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of vonoprazan or any future product candidates in those and
other indications, which could have a material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Any difficulties or
delays in the commencement or completion, or termination or suspension, of our planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Before obtaining marketing approval from regulatory authorities for the sale of vonoprazan or any future product candidates, we
must conduct extensive clinical trials to demonstrate the safety and efficacy of vonoprazan or any future product candidates in humans. In August 2019, we submitted three separate INDs to the FDA for vonoprazan: one for erosive esophagitis; a second
for dual therapy treatment of <I>H. pylori</I> infection; and a third for triple therapy treatment of <I>H. pylori </I>infection. These three INDs were accepted by the FDA in September 2019. We plan to initiate two pivotal Phase&nbsp;3 clinical
trials in the fourth quarter of 2019 for vonoprazan: one for the treatment of erosive esophagitis and a second for the treatment of <I>H. pylori</I> infection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We will have to submit the results of preclinical studies to the FDA along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial
protocol, as part of an IND for any future product candidates that we advance to clinical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">19 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
development, and we may also be required to submit regulatory filings to foreign regulatory authorities to the extent we initiate clinical trials outside of the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical
trials can be delayed for a number of reasons, including delays related to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the FDA, EMA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials and reaching consensus among the
FDA and EMA over the design of the same clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any failure or delay in obtaining regulatory authorizations to commence a trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any failure or delay in reaching an agreement with contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to
extensive negotiation and may vary significantly among different CROs and trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">institutional review boards, or IRBs, refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional
subjects, or withdrawing their approval of the trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">changes to clinical trial protocols; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">clinical sites deviating from trial protocols or dropping out of a trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">manufacturing or obtaining sufficient quantities of vonoprazan and any future product candidates and obtaining sufficient quantities of lansoprazole, which will
be used in both of our planned Phase 3 clinical trials, and/or antibiotics for use in clinical trials, including amoxicillin and clarithromycin, which will be used in our planned Phase 3 clinical trial of vonoprazan for the treatment of <I>H.
pylori</I> infection; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post- treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subjects choosing an alternative treatment for the indication for which we are developing vonoprazan and any future product candidates, or participating in
competing clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">lack of adequate funding to continue the clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subjects experiencing severe or unexpected drug-related adverse effects; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">occurrence of serious adverse events in trials of the same class of agents conducted by other companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a facility manufacturing vonoprazan or any future product candidates or any of their components being ordered by the FDA or comparable foreign regulatory
authorities to temporarily or permanently shut down due to violations of current good manufacturing, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any changes to our manufacturing process that may be necessary or desired; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated
schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">third-party contractors not performing data collection or analysis in a timely or accurate manner; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">20 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of
regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being
conducted or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements
or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug,
changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to
comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing, or successful completion of a clinical trial. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, conducting clinical trials in foreign countries, as we may do for vonoprazan or any future product candidates, presents additional risks
that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional
administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Moreover, principal investigators for our clinical trials currently serve and may continue to serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such
services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship
between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the clinical trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at
the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the
case may be, and may ultimately lead to the denial of marketing approval of vonoprazan or any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we
experience delays in the completion of, or termination of, any clinical trial of vonoprazan or any future product candidates, the commercial prospects of vonoprazan and any future product candidates will be harmed, and our ability to generate
product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to
commence product sales and generate revenues. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, many of the factors that cause, or lead to, termination or suspension of, or
a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. We may make formulation or manufacturing changes to vonoprazan or any future product candidates, in
which case we may need to conduct additional preclinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive
right to commercialize vonoprazan or any future product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of vonoprazan and any future product candidates could be significantly reduced.
Any of these occurrences may harm our business, financial condition, and prospects significantly. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">21 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling
patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may
not be able to initiate or continue clinical trials for vonoprazan or any future product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar
regulatory authorities outside the United States. Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical
sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies
and experience, competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may
be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. Potential patients for any planned clinical
trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. For example, a key secondary analysis in our planned Phase 3 clinical trial for the treatment of <I>H.
pylori </I>infection is the eradication rate in clarithromycin-resistant patients. However, because the process of assessing antibiotic resistance to <I>H. pylori</I> takes several weeks, we believe it is not practical to use resistance as an
enrollment criteria in our clinical trial. Therefore, the percentage of clarithromycin-resistant patients enrolled in this clinical trial is unpredictable and may affect the results of the trial. We also may encounter difficulties in identifying and
enrolling patients with a stage of disease appropriate for our planned clinical trials and monitoring such patients adequately during and after treatment. For example, in our Phase 3 clinical trial of vonoprazan in erosive esophagitis, we intend for
30% of the patients to have Los Angeles Class&nbsp;C or D erosive esophagitis, which are the most severe forms of erosive esophagitis and are estimated to only represent approximately 10 to 20% of erosive esophagitis patients. We may not be able to
initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and
diagnosing patients may prove costly as these patients are required to undergo an endoscopy before being diagnosed as having Los Angeles Class&nbsp;C or D erosive esophagitis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT>
periods. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants. If patients are unwilling to participate in our trials for any reason, including the existence of concurrent
clinical trials for similar patient populations, if they are unwilling to enroll in a clinical trial with a placebo-controlled design or the availability of approved therapies, or we otherwise have difficulty enrolling a sufficient number of
patients, the timeline for recruiting patients, conducting trials and obtaining regulatory approval of vonoprazan and any future product candidates may be delayed. Our inability to enroll a sufficient number of patients for any of our future
clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our assumptions
used in determining expected clinical trial timelines may not be correct, and we may experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">22 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Use of vonoprazan or any future product candidates could be associated with side effects, adverse events or
other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative
consequences that could severely harm our business, prospects, operating results and financial condition. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As is the case with
pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with vonoprazan&#146;s or any future product candidates&#146; use. Results of our clinical trials could reveal a high and unacceptable severity and
prevalence of side effects or unexpected characteristics. Undesirable side effects caused by vonoprazan and any future product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or
result in potential product liability claims. Any of these occurrences may harm our business, financial condition, and prospects significantly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Moreover, if vonoprazan or any other future product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development
or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial
expectations for the product candidate, if approved. We may also be required to modify our study plans based on findings in our clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As of December 2018, 6,683 subjects have been exposed to vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120 mg with durations up to one year. The most
commonly reported AEs in the clinical development program for vonoprazan, as reflected in the Japanese prescribing information published by Japan&#146;s Pharmaceutical and Medical Devices Agency, or PMDA, were diarrhea, constipation, nausea,
elevated liver enzymes, rash, and eosinophilia. All such events had an incidence rate of less than 5.0% other than diarrhea in the treatment of <I>H. pylori</I> which had an incidence rate of 10.6% in combination with antibiotics. No dose-related
increase in TEAEs or SAEs was observed. The safety profile of vonoprazan and incidence of TEAEs, drug-related TEAEs, and TEAEs leading to drug discontinuation were similar between vonoprazan and lansoprazole across studies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Certain earlier generation <FONT STYLE="white-space:nowrap">P-CABs</FONT> previously under development by other companies may have been
discontinued in part due to their hepatic safety profile. These hepatic safety concerns may be compound-specific and not generalizable to the <FONT STYLE="white-space:nowrap">P-CAB</FONT> class. Vonoprazan has had a similar hepatic safety profile to
lansoprazole across all clinical studies conducted by Takeda, in which 1.0% of subjects treated with vonoprazan 10 mg or 20 mg and 0.8% of subjects treated with lansoprazole 15 mg or 30&nbsp;mg had ALT or AST elevations greater than three times the
upper limit of normal or bilirubin elevations greater than two times the upper limit of normal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The most recent post-marketing safety
report from December 2018 includes an estimated 23&nbsp;million patients who have received vonoprazan in Japan since launch. Based on the post-marketing experience, the clinically significant adverse reactions section of the Japanese prescribing
information for vonoprazan was updated to include skin reactions such as toxic epidermal necrolysis, Steven-Johnson syndrome, and erythema multiforme. The incidence of these skin reactions was considered extremely rare (less than 1 in 100,000
patients) and a causal relationship to vonoprazan could not be ruled out. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Serious hepatic adverse events have also been observed among
patients exposed to vonoprazan in Japan in the post-marketing setting. These cases were typically confounded by comorbidities or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">23 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
other concomitant medications and are believed to be idiosyncratic reactions. The incidence of these events was considered extremely rare (less than 1 in 100,000 patients). The post-marketing
safety data, including the December 2018 post-marketing safety report and the reported hepatic safety events, have been submitted to the PMDA. To date, there have been no changes to the Japan prescribing information related to hepatic safety. We may
also observe hepatic-related events in our clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">It is possible that as we test vonoprazan and any future product candidates
in our clinical trials, or as the use of vonoprazan and any future product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as
well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and
prospects significantly. Further, if a serious safety issue is identified in connection with use of vonoprazan commercially or in third-party clinical trials in Asia or elsewhere, such issues may adversely affect the development potential of
vonoprazan or result in regulatory authorities restricting our ability to develop vonoprazan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, if vonoprazan or any future
product candidate receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against its manufacturer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may be required to recall a product or change the way such product is administered to patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulatory authorities may require additional warnings on the label, such as a &#147;black box&#148; warning or a contraindication; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for
distribution to patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may be required to change the way a product is distributed or administered, conduct additional clinical trials or change the labeling of a product or be
required to conduct additional post-marketing studies or surveillance; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we could be sued and held liable for harm caused to patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">sales of the product may decrease significantly or the product could become less competitive; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could
significantly harm our business, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>As a company, we have never conducted a clinical trial or submitted an NDA
or comparable foreign regulatory filing, and may be unable to do so for vonoprazan or any future product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are
early in our development efforts for vonoprazan, and we will need to successfully complete pivotal clinical trials in order to obtain FDA, EMA or comparable foreign regulatory approval to market vonoprazan or any future product candidates. Carrying
out late-stage clinical trials and the submission of a successful new drug application, or NDA, is a complicated process. As an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">24 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
organization, we plan to commence pivotal Phase 3 clinical trials of vonoprazan in erosive esophagitis and <I>H. pylori </I>infection<I> </I>in the fourth quarter of 2019. We have not yet
conducted any clinical trials for vonoprazan or any other product candidates and have limited experience as a company in preparing, submitting and prosecuting regulatory filings. As a company, we have not previously submitted an NDA, whether for one
or multiple indications, or other comparable foreign regulatory submission for any product candidate. In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of vonoprazan or any other product
candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of vonoprazan
or any future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our
planned clinical trials, could prevent us from or delay us in submitting NDAs for and commercializing vonoprazan or any future product candidates. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan and any future product candidates are subject to extensive regulation and compliance obligations, which is costly and time consuming, and such
regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize vonoprazan and any future product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of vonoprazan and any future product candidates are subject to
extensive regulation by the FDA in the United States, the EMA in the European Union and by comparable foreign regulatory authorities in other foreign markets. In the United States, we are not permitted to market vonoprazan and any future product
candidates until we receive regulatory approval from the FDA and in Europe, we are not permitted to market vonoprazan and any future product candidates until we receive regulatory approval from the EMA. The process of obtaining regulatory approval
is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population.
The ability of the FDA and EMA to review and approve new products can be affected by a variety of factors, including government budget and funding levels and the ability to hire and retain key personnel. In addition, approval policies or regulations
may change, and the FDA and EMA have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development
of product candidates, regulatory approval is never guaranteed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to obtaining approval to commercialize a product candidate in the
United States or internationally, we must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe
and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for vonoprazan and any future product candidates are promising,
such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or
clinical trials for vonoprazan and any future product candidates either prior to or post-approval, or may object to elements of our clinical development program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The FDA, EMA or other comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may disagree with the design or implementation of our clinical trials; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">25 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA, EMA, or other
comparable foreign regulatory agencies for approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or in clinical trials conducted by Takeda or others
outside of our licensed territories, or by patients using vonoprazan or drugs similar to vonoprazan; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially
different from that of the United States; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may be unable to demonstrate to the satisfaction of such authorities that a product candidate is safe and effective for its proposed indication and that a
product candidate&#146;s clinical and other benefits outweigh its safety risks; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may not agree that the data collected from clinical trials of vonoprazan, including data collected from clinical trials conducted by Takeda and
independent investigators outside of our licensed territories, and any future product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval, and such authorities may impose
requirements for additional preclinical studies or clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may disagree regarding the formulation, labeling and/or the specifications of vonoprazan and any future product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on
distribution and use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may find deficiencies in the manufacturing processes or facilities of Takeda or any future third-party manufacturers with which we contract for
clinical and commercial supplies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#146; clinical data insufficient
for approval; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product
testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA, EMA, and other comparable
foreign regulatory authorities in reviewing new drugs based on safety, efficacy, or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable
regulatory approvals would prevent us or any of our potential future collaborators from commercializing vonoprazan and any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Of the large number of drugs in development, only a small percentage successfully complete the FDA, EMA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the
unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market vonoprazan and any future product candidates, which would significantly harm our business, financial condition, results of operations
and prospects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">26 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Even if we eventually complete clinical trials and receive approval of an NDA or foreign
marketing application for vonoprazan and any future product candidates, the FDA, EMA or other comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including confirmatory Phase
3 clinical trials, Phase 4 clinical trials, and/or the implementation of a REMS, which may be required to ensure safe use of the drug after approval. The FDA, EMA or other comparable foreign regulatory authority also may approve a product candidate
for a more limited indication or patient population than we originally requested, and the FDA, EMA or other comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful
commercialization of a product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Designation of vonoprazan as a QIDP, and the potential to receive priority review or fast track designations, may not actually lead to a faster
development or regulatory review, and would not assure FDA approval of vonoprazan or any future product candidates which may receive such designations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has been designated as a QIDP by the FDA for the treatment of <I>H. pylori</I> infection in combination with both amoxicillin and clarithromycin, and with amoxicillin alone, respectively, and we may seek
QIDP designation for future product candidates. A QIDP is an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by either (1)&nbsp;an antibacterial or antifungal resistant
pathogen, including novel or emerging infectious pathogens, or (2)&nbsp;a so-called &#147;qualifying pathogen&#148; found on a list of potentially dangerous, drug-resistant organisms to be established and maintained by the FDA under the Generating
Antibiotic Incentives Now, or GAIN Act. The benefits of QIDP designation include potential eligibility for priority review and fast track designation, and an extension by an additional five years of any non-patent exclusivity period awarded, such as
a five-year exclusivity period awarded for a new chemical entity. This extension is in addition to any pediatric exclusivity extension that may be awarded. Receipt of QIDP status also does not assure ultimate approval by the FDA or related GAIN Act
exclusivity benefits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While QIDP designation makes vonoprazan potentially eligible for priority review and fast track designation, the
FDA has broad discretion, so even if we believe vonoprazan or any future product candidate is eligible for fast track designation or priority review status, the FDA could decide not to grant it. The fast track program is intended to expedite or
facilitate the process for reviewing new drug candidates that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended, alone or in combination with one or more drugs, to treat a serious or
life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the drug candidate and the specific indication for which it is
being studied. With a fast track drug candidate, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA,
the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. Priority review means the FDA&#146;s goal is to take action on
an application within 6 months (compared to 10&nbsp;months under standard review). The FDA automatically grants priority review to the first application or efficacy supplement submitted for a specific drug and indication that has received the QIDP
designation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Obtaining a QIDP designation, priority review, or fast track designation does not change the standards for product
approval, but may expedite the development or approval process. Even though the FDA has granted QIDP designation for vonoprazan, and even if vonoprazan receives priority review or fast track designations, it may not actually result in faster
clinical development or regulatory review or approval. Furthermore, QIDP designation, priority review, and fast track designation do not increase the likelihood that vonoprazan will receive marketing approval in the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">27 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may not be successful in our efforts to expand our pipeline by identifying additional indications and
formulations for which to investigate vonoprazan in the future. We may expend our limited resources to pursue a particular indication or formulation for vonoprazan and fail to capitalize on product candidates, indications or formulations that may be
more profitable or for which there is a greater likelihood of success. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Because we have limited financial and managerial
resources, we focus on specific indications and formulations for vonoprazan. As a result, we may fail to generate additional clinical development opportunities for vonoprazan for a number of reasons, including, vonoprazan may in certain indications,
on further study, be shown to have harmful side effects, limited to no efficacy, or other characteristics that suggest it is unlikely to receive marketing approval and achieve market acceptance in such additional indications. For example, we believe
the rapid onset of action of vonoprazan may enable <FONT STYLE="white-space:nowrap">on-demand,</FONT> or as needed, use for the management of <FONT STYLE="white-space:nowrap">non-erosive</FONT> reflux disease, or NERD. However, two Phase 3 clinical
trials of vonoprazan in Japanese patients with endoscopically confirmed NERD conducted by Takeda did not demonstrate a statistically significant difference in symptom scores between vonoprazan and placebo. We believe that this result may be due to
the selection of patients with mild to moderate symptoms rather than more frequent and severe symptoms. In addition, Takeda conducted a Phase 2 clinical trial in Europe in 256 patients with NERD who were partial responders to high dose PPIs.
Patients were randomized to receive vonoprazan 20 mg, vonoprazan 40 mg, or esomeprazole 40 mg for four weeks. Neither vonoprazan dose demonstrated a benefit versus esomeprazole on the primary endpoint of the percentage of heartburn free days over
the treatment period. We believe this result may be due to patient selection. Specifically, the trial may not have adequately selected for patients with NERD and may have included patients with functional GI disorders that are unrelated to acid,
such as functional dyspepsia or functional heartburn. We may be incorrect in our beliefs regarding the results of such trials and any future clinical trials we conduct in NERD patients may not succeed for similar or other reasons, including as a
result of our design and enrollment criteria. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Furthermore, research programs to identify additional indications for vonoprazan require
substantial technical, financial and human resources. We may also pursue additional formulations and packaging for vonoprazan, such as orally disintegrating tablets and other oral dosage forms for patients with difficulty swallowing, an intravenous
formulation for <FONT STYLE="white-space:nowrap">in-hospital</FONT> applications, and <FONT STYLE="white-space:nowrap">pre-packaged</FONT> convenience packs for the treatment of <I>H. pylori </I>infection. However, we may not successfully develop
these additional formulations for chemistry-related, stability-related or other reasons. If we do not accurately evaluate the commercial potential or target market for vonoprazan or any future product candidates, we may relinquish valuable rights to
that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, we may pursue additional <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of development-stage assets
or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or
license of a particular product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our resources with no resulting benefit. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We intend to enroll patients in Europe in both of our planned Phase 3 clinical trials. Additionally, we may conduct future clinical trials outside of the United States. However, the FDA and other comparable
foreign regulatory authorities may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We plan to enroll patients in Europe in both of our planned Phase 3 clinical trials, and we may conduct one or more of our future clinical trials outside the United States. Although the FDA may
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">28 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the FDA requires the clinical trial
to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. In addition, when clinical trials are conducted only at sites
outside of the United States, the FDA generally does not provide advance comment on the clinical protocols for the trials, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial was inadequate, which would likely require us to conduct additional clinical trials. The FDA may not accept data from clinical trials conducted outside of the United States. If the FDA does
not accept data from our clinical trials of vonoprazan and any future product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of
vonoprazan and any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Conducting clinical trials outside the United States also exposes us to additional risks,
including risks associated with: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">additional foreign regulatory requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">foreign exchange fluctuations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">compliance with foreign manufacturing, customs, shipment and storage requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">cultural differences in medical practice and clinical research; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">diminished protection of intellectual property in some countries. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Interim, top-line and preliminary data from clinical trials that we or others announce or publish from time to time may change as more patient data become available and are subject to audit and verification
procedures that could result in material changes in the final data. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From time to time, we or others, such as Takeda, may
publicly disclose preliminary or top-line data from clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review
of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all
data.&nbsp;As a result, the top-line results that we or others report may differ from future results of the same clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully
evaluated.&nbsp;Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously published. As a result, top-line data should be viewed with
caution until the final data are available. From time to time, we or others may also disclose interim data from clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially
change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or
may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the
information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">29 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the top-line data that we report differ from actual results, or if others,
including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, vonoprazan and any future product candidates may be harmed, which could harm our business, operating results, prospects,
or financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Reliance on Third Parties </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We rely on the Takeda License to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada. If the license agreement is terminated, we would lose our rights to develop
and commercialize vonoprazan. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to the Takeda License, we have secured an exclusive license from Takeda to commercialize
vonoprazan products using specified formulations for all human therapeutic uses in the United States, Europe, and Canada, and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to develop and manufacture vonoprazan products anywhere in
the world (subject to Takeda&#146;s consent as to each country) for the purposes of commercializing the vonoprazan products in the United States, Europe, and Canada. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Takeda License will continue until the expiration of the obligation to pay royalties in all countries and on all products, unless terminated earlier. We may terminate the Takeda License in its entirety without
cause upon prior written notice. We and Takeda may terminate the Takeda License in the case of the other party&#146;s insolvency or for the other party&#146;s material uncured breach. Takeda may terminate the Takeda License in its entirety if we
challenge the licensed patents, or if we assist any third party in challenging such patents. In addition, if any of the regulatory milestones or other cash payments become due under the terms of the Takeda License, we may not have sufficient funds
available to meet our obligations, which would allow Takeda to terminate the Takeda License. If the license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan, which in turn would have a material adverse effect
on our business, operating results and prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We intend to rely on third parties to conduct our clinical trials. Any failure by a third party
to conduct the clinical trials according to GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize vonoprazan and any future product candidates.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We will be dependent on third parties to conduct our preclinical and clinical trials, including our planned Phase 3 clinical
trials of vonoprazan. Specifically, we intend to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs,
investigators and other third parties will play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have
limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance
on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory
authorities for vonoprazan and any future product candidates that reach clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs
or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the
regulatory approval process. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">30 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">CROs, investigators or other third parties may not devote adequate time and resources to such
trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be
extended, delayed, or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug
development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in
connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the
integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA we submit by the FDA. Any such delay or
rejection could prevent us from commercializing vonoprazan and any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If any of our relationships with these
third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and
requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we
carefully manage our relationships with our CROs, investigators and other third parties, we may encounter challenges or delays in the future and these delays or challenges may have a material adverse impact on our business, financial condition and
prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We currently rely on Takeda for the manufacture of vonoprazan for clinical development and expect to continue to do so for the
foreseeable future. This reliance on a third party increases the risk that we will not have sufficient quantities of vonoprazan or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization
efforts. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale
manufacturing capabilities. Pursuant to the Takeda License, we entered in a clinical manufacturing and supply agreement with Takeda for the supply of vonoprazan for our clinical trials. In addition, we have the option to negotiate in good faith to
enter into a commercial supply agreement with Takeda for the commercial supply of vonoprazan, and we are exploring additional options for commercial supply of vonoprazan from other third party contract manufacturers. As a result, we currently rely,
and expect to continue to rely, on Takeda for the manufacture of vonoprazan and related raw materials for clinical development, as well as for commercial manufacture if vonoprazan receives marketing approval. However, we may not be able to enter
into a commercial supply agreement with Takeda or other third parties on acceptable terms, or at all. The facilities used by Takeda to manufacture vonoprazan must be approved by the FDA for the manufacture of vonoprazan pursuant to inspections that
may be conducted after we submit marketing authorizations to the FDA and comparable foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, Takeda for compliance with cGMP requirements for
manufacture of drug products. If Takeda, or any other third party manufacturer we contract with in the future, cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others,
including requirements related to the manufacturing of high potency compounds, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over Takeda&#146;s ability to
maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">31 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
not approve of facilities of the third-party manufacturer for the manufacture of vonoprazan or if it withdraws any such approval in the future, we may need to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market vonoprazan, if approved. Our failure, or Takeda&#146;s failure, to comply with applicable regulations could result in sanctions being
imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could
significantly and adversely affect supplies of our products. Furthermore, Takeda may choose to prioritize the manufacture of vonoprazan for its markets over the manufacture of vonoprazan for our licensed markets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our or Takeda&#146;s failure, or the failure of any future third-party manufacturer, to execute on our manufacturing requirements, to do so on
commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an inability to initiate and continue clinical trials of vonoprazan or any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">delay in submitting regulatory applications, or receiving marketing approvals, for vonoprazan and any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">requirements to cease development or to recall batches of vonoprazan and any future product candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">in the event of approval to market and commercialize vonoprazan or any future product candidates, an inability to meet commercial demands for vonoprazan or any
future product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Reliance on third-party manufacturers entails additional risks, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">breach of the manufacturing agreement by the third party; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">failure to manufacture our product according to our specifications; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">failure to manufacture our product according to our schedule or at all; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities.
Moreover, there may be a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Any performance failure on the part of Takeda or any future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time consuming to implement. We
do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of vonoprazan and any future product candidates. If Takeda cannot perform as agreed, we may be required to
replace Takeda and we may be unable to replace them on a timely basis or at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">32 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our current and anticipated future dependence upon others for the manufacture of vonoprazan or
any future product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our reliance on third parties, including Takeda, requires us to share our trade secrets, which increases the possibility that a competitor will discover them
or that our trade secrets will be misappropriated or disclosed. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Because we currently rely on Takeda to manufacture vonoprazan
and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality
agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or
disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our
competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our
<FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets and despite our efforts to protect our trade secrets, a competitor&#146;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure
would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may seek to enter into collaborations, licenses and other similar arrangements and may not be successful in doing so, and even if we are, we may not
realize the benefits of such relationships. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may seek to enter into collaborations, joint ventures, licenses and other similar
arrangements for the development or commercialization of vonoprazan and any future product candidates, due to capital costs required to develop or commercialize vonoprazan and any future product candidates or manufacturing constraints. We may not be
successful in our efforts to establish such collaborations for vonoprazan and any future product candidates because vonoprazan and any future product candidates may be deemed to be at too early of a stage of development for collaborative effort or
third parties may not view vonoprazan and any future product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate
strategic partners, and the negotiation process can be time consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. Following a strategic transaction
or license, we may not achieve an economic benefit that justifies such transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Even if we are successful in our efforts to
establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed, the safety of a product
candidate is questioned or sales of an approved product candidate are unsatisfactory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, any potential future collaborations
may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and
commercialization of vonoprazan and any future product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into
collaborations related to vonoprazan or any future product candidates, could delay the development and commercialization of vonoprazan or any future product </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">33 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Commercialization of Vonoprazan and Any Future Product Candidates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Even if we receive regulatory approval for vonoprazan and any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant
additional expense. Additionally, vonoprazan and any future product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with
regulatory requirements or if we experience unanticipated problems with vonoprazan and any future product candidates, if approved. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following potential approval of vonoprazan or any future product candidates, the FDA, EMA or other comparable regulatory authority may impose
significant restrictions on a product&#146;s indicated uses or marketing or impose ongoing requirements for potentially costly and time consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy
of the product. The FDA may also require a REMS as a condition of approval of vonoprazan or any future product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe
use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or a comparable foreign regulatory authority approves vonoprazan or any future product candidates, the manufacturing
processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include
submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown
problems with our products, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">refusal by the FDA or comparable foreign regulatory authority to approve pending applications or supplements to approved applications filed by us or suspension
or revocation of approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">product seizure or detention, or refusal to permit the import or export of our products; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">injunctions or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The occurrence of any event or penalty described above may inhibit our ability to commercialize vonoprazan and any future product candidates and generate revenue and could require us to expend significant time and
resources in response and could generate negative publicity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, if vonoprazan or any future product candidate is approved,
our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be
promoted for uses that are not approved by the FDA as reflected in the product&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">34 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. If we receive marketing approval
for vonoprazan or any future product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such
<FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
<FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant sanctions. The federal government has levied large
civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent
decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The FDA&#146;s and other regulatory
authorities&#146; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of vonoprazan and any future product candidates. If we are slow or unable to adapt to changes in
existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or
executive action, either in the United States or internationally. The policies of the FDA and of other regulatory authorities may change and additional governmental regulations may be enacted that could prevent, limit or delay regulatory approval of
vonoprazan or any future product candidates. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, the current U.S. administration has taken several executive actions, including the issuance
of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of
guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its
regulatory authority. If these executive actions impose constraints on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to
maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. <FONT
STYLE="white-space:nowrap">Non-compliance</FONT> by us or any future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric
population can also result in significant financial penalties. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The commercial success of vonoprazan or any future product candidates will depend
upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Vonoprazan and any future product candidates may not be commercially successful. The commercial success of vonoprazan or any future product candidates, if approved, will depend significantly on the broad adoption
and use of such product by physicians and patients for approved indications. The degree of market acceptance of vonoprazan or any future products, if approved, will depend on a number of factors, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">demonstration of clinical efficacy and safety compared to other more-established products; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">35 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the indications for which vonoprazan or any future product candidates are approved; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the limitation of our targeted patient population and other limitations or warnings contained in any <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
labeling; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">acceptance of a new drug for the relevant indication by healthcare providers and their patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and
Medicaid, private health insurers and other third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the willingness of patients to pay all, or a portion of, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs
associated with our products in the absence of sufficient third-party coverage or adequate reimbursement; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any restrictions on the use of our products, and the prevalence and severity of any adverse effects; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">potential product liability claims; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing of market introduction of our products as well as competitive drugs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the effectiveness of our or any of our potential future collaborators&#146; sales and marketing strategies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">unfavorable publicity relating to the product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">If vonoprazan or any future product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from
that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to vonoprazan, Takeda has the right to develop and commercialize the product outside of the United States, Europe, and Canada and has
received marketing approval for vonoprazan in certain countries in Asia and Latin America. We have little or no control over Takeda&#146;s commercialization activities with respect to vonoprazan outside of our licensed territories even though those
activities could impact our ability to successfully commercialize vonoprazan.&nbsp;For example, Takeda can make statements or use promotional materials with respect to vonoprazan outside of our licensed territories that are inconsistent with our
positioning of the product in the United States, Europe, and Canada, and could sell vonoprazan in foreign countries at prices that are dramatically lower than the prices we would charge in our licensed territories.&nbsp;These activities and
decisions, while occurring outside of our licensed territories, could harm our commercialization strategy.&nbsp;In addition, product recalls or safety issues with vonoprazan outside our licensed territories could result in serious damage to the
brand and impair our ability to successfully market vonoprazan in our licensed territories. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The FDA and other regulatory agencies actively
enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. If we are found or alleged to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become
subject to significant liability. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The FDA and other regulatory agencies strictly regulate the promotional claims that may be
made about prescription products, as vonoprazan and any future product candidates would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the
product&#146;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">36 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
inconsistent with the approved label. If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The federal
government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that
companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of vonoprazan or any future product candidates, if approved, we could
become subject to significant liability, which would materially adversely affect our business and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The successful
commercialization of vonoprazan or any future product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies.
Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs, such as Medicare and Medicaid, private health
insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as vonoprazan or any future product candidate, if approved. Our ability to achieve coverage and acceptable levels of
reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates
may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United&nbsp;States, the European Union or elsewhere will be
available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an
equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in
demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a
given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at
limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the
Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices
or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as
models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States.
Therefore, coverage and reimbursement for products can differ significantly from payor </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">37 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
to payor. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these
rules and regulations are likely. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Outside the United States, international operations are generally subject to extensive governmental
price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the
prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign
price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the
United States and may be insufficient to generate commercially reasonable revenue and profits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Moreover, increasing efforts by
governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover
or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and
additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to
the entry of new products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We face significant competition, and if our competitors develop technologies or product candidates more rapidly than
we do or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our
competitors have developed, are developing or may develop products, product candidates and processes competitive with vonoprazan. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new
therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of GI diseases for which we may attempt to
develop vonoprazan or any future product candidates. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research
institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively
affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling patients for clinical trials and in identifying and
<FONT STYLE="white-space:nowrap">in-licensing</FONT> new product candidates. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect that vonoprazan, if approved for the treatment of erosive esophagitis and treatment of <I>H. pylori </I>infection, will
primarily compete with generic PPIs marketed by multiple pharmaceutical companies in both the prescription and OTC markets. Additionally, RedHill Biopharma Ltd. is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">38 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
developing Talicia, a <FONT STYLE="white-space:nowrap">co-formulated</FONT> capsule comprising generic omeprazole, amoxicillin, and rifabutin for the treatment of <I>H. pylori</I> infection, and
filed an NDA in the United States in May 2019. Ironwood Pharmaceuticals, Inc. is developing <FONT STYLE="white-space:nowrap">IW-3718,</FONT> a bile acid sequestrant, currently in Phase 3 clinical trials as an adjunct to PPIs for the treatment of
patients with persistent GERD. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also aware of other <FONT STYLE="white-space:nowrap">P-CABs</FONT> in territories outside of the
United States that, if developed and approved in our territories, may compete with vonoprazan. Revaprazan is marketed by Yuhan Corporation in South Korea. Tegoprazan is marketed by CJ Healthcare Corp. in South Korea and is currently in Phase 3
development in Japan by RaQualia Pharma, Inc. Daewoong Pharmaceutical Co., Ltd.&#146;s DWP14012 has been studied in Phase 2 clinical trials in South Korea, and Cinclus Pharma AG&#146;s X842 has completed a Phase 1 clinical trial in Europe.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, we are aware of several clinical-stage PPIs in territories outside of the United States that if developed and approved in
our licensed territories may compete with vonoprazan. These include Dexa Medica&#146;s DLBS-2411, currently in Phase 3 clinical trials in Indonesia, Sihuan Pharmaceutical&#146;s anaprazole, currently in Phase 3 clinical trials in China, Eisai&#146;s
azeloprazole, currently in a Phase 2 clinical trial in Japan, and Sidem Pharma&#146;s tenatoprazole, currently in Phase 2 clinical trials in Europe and Canada. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In July 2012, the Food and Drug Administration Safety and Innovation Act was passed, which included the GAIN Act. The GAIN Act is intended to provide incentives for the development of new, qualified infectious
disease products. In December&nbsp;2016, the 21st Century Cures Act was passed, providing additional support for the development of new infectious disease products. These incentives may result in more competition in the market for new antibiotics
and may cause pharmaceutical and biotechnology companies with more resources than we have to shift their efforts towards the development of product candidates that could be competitive with vonoprazan or any future product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we
do. If we successfully obtain approval for vonoprazan or any future product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be
administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price,
reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may
develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing vonoprazan or any future product candidates. If we are unable to compete effectively, our
opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If the market
opportunities for vonoprazan or any future products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The precise incidence and prevalence for all the conditions we aim to address with vonoprazan or any future product candidates are unknown. Our projections of both the number of people who have these diseases, as
well as the subset of people with these diseases who have the potential to benefit from treatment of vonoprazan or any future product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources,
including the scientific literature, surveys of clinics or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">39 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
vonoprazan and any future product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of vonoprazan and any future product
candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of vonoprazan and any future product candidates relative to such alternative treatments, acceptance by the
medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with
our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are
unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If vonoprazan or any future product
candidates ultimately receive regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and
time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We plan
to independently commercialize vonoprazan in the United States by building a leading specialty gastroenterology commercial infrastructure to support the adoption of vonoprazan and we plan to seek one or more partners with existing commercial
infrastructure and expertise in Europe and Canada. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a marketing and sales
organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and
marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire
consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties
for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell
and market our products effectively. If we are not successful in commercializing vonoprazan or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product
revenue and we would incur significant additional losses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our future growth may depend, in part, on our ability to operate in foreign markets,
particularly Europe and Canada, where we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our future growth may depend, in part, on our ability to develop and commercialize vonoprazan and any future product candidates in foreign markets,
particularly Europe and Canada. We are not permitted to market or promote vonoprazan and any future product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such
regulatory approvals for vonoprazan or any future product candidates. To obtain separate regulatory approval in any other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among
other things, clinical trials, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">40 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
commercial sales, pricing and distribution of vonoprazan and any future product candidates. If we obtain regulatory approval of vonoprazan and any future product candidates and ultimately
commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">different regulatory requirements for approval of drugs in foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the existence of additional third-party patent rights of potential relevance to our business; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">unexpected changes in tariffs, trade barriers and regulatory requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">economic weakness, including inflation, or political instability in particular foreign economies and markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">compliance with tax, employment, immigration and labor laws for employees living or traveling internationally; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in
another country; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">foreign reimbursement, pricing and insurance regimes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">workforce uncertainty in countries where labor unrest is common; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities internationally; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Business Operations and Industry </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may
provide. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our
future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to vonoprazan or any
future product candidates, which may change from time to time; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">coverage and reimbursement policies with respect to vonoprazan or any future product candidates, if approved, and potential future drugs that compete with such
products, if approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the cost of manufacturing vonoprazan or any future product candidates, which may vary depending on the quantity of production and the terms of our agreements
with Takeda and any future third-party manufacturers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and amount of the milestone or other payments we will be required to pay to Takeda pursuant to the Takeda License; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the level of demand for any approved products, which may vary significantly; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">41 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">future accounting pronouncements or changes in our accounting policies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and success or failure of preclinical studies or clinical trials for vonoprazan or any future product candidates or competing product candidates, or
any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for
any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or
investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our indebtedness may limit our flexibility in operating our business and adversely affect our financial health and competitive position, and all of our
obligations under our indebtedness are&nbsp;secured by&nbsp;substantially all of our assets, excluding our intellectual property and certain other assets. If we default on these obligations, our lenders could foreclose on our assets.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019, we entered into the Loan Agreement with SVB and WestRiver. We borrowed $25.0&nbsp;million, or Term Loan&nbsp;A, at
the inception of the Loan Agreement and have the right to borrow an additional $25.0&nbsp;million, or Term Loan B, and which we collectively refer to as the Term Loans. Term Loan B is available through March&nbsp;31, 2020, provided that (i)&nbsp;we
have received at least $150.0&nbsp;million of net cash proceeds in connection with the issuance and sale, subsequent to April&nbsp;1, 2019, of our equity securities and subordinated debt, (ii)&nbsp;we have initiated Phase 3 clinical trials for
vonoprazan, and (iii)&nbsp;no event of default has occurred. All obligations under the Term Loans are secured by a first priority lien on substantially all of our assets, excluding intellectual property and certain other assets. We have agreed not
to encumber our intellectual property assets without SVB&#146;s prior written consent unless a security interest in the underlying intellectual property is necessary to have a security interest in the accounts and proceeds that are part of the
assets securing the Term Loans, in which case our intellectual property will automatically be included within the assets securing the Term Loans. As a result, if we default on any of our obligations under the Loan Agreement, SVB could foreclose on
its security interest and liquidate some or all of the collateral, which would harm our business, financial condition and results of operations and could require us to reduce or cease operations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In order to service this indebtedness and any additional indebtedness we may incur in the future, we need to generate cash from our operating
activities. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. Our business may not be
able to generate sufficient cash flow from operations, and future borrowings or other financings may not be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are
required to use cash from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital, capital expenditures or other general corporate purposes, we will be less able to plan for, or react to,
changes in our business, industry and in the economy generally. This could place us at a competitive disadvantage compared to our competitors that have less indebtedness. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Loan Agreement contains customary affirmative and negative covenants that limit our ability to engage in certain transactions that may be in our long-term best interest. The affirmative covenants
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">42 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
include, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain
requirements regarding our operating accounts. The negative covenants include, among others, limitations on our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other
companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions.</FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While we believe we are currently in compliance with the covenants contained in the Loan Agreement, we may breach these covenants in the future.
Our ability to comply with these covenants may be affected by events and factors beyond our control. In the event that we breach one or more covenants, the lenders may choose to declare an event of default and require that we immediately repay all
amounts outstanding under the Loan Agreement, terminate any commitment to extend further credit and foreclose on the collateral. The occurrence of any of these events could have a material adverse effect on our business, financial condition and
results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We are dependent on the services of our current management and other clinical and scientific personnel, and if we are not
able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific
personnel.&nbsp;We are highly dependent upon our current senior management team, our Chairman and our development personnel. The loss of services of any of these individuals or personnel could delay or prevent the successful development of our
product pipeline, initiation or completion of our planned clinical trials or the commercialization of vonoprazan or any other future product candidates. Although we have executed employment agreements or offer letters with each member of our senior
management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#147;key person&#148; life insurance on the lives of our
executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In addition, we expect that Terrie Curran, a member of our board of directors, will become our Chief Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by
Bristol-Myers Squibb Company. In the event Ms. Curran succeeds Mr. Socks as Chief Executive Officer, Mr. Socks will serve as interim Chief Financial Officer and continue to serve on our board of directors. If Ms. Curran decides not to join us as
Chief Executive Officer, our board of directors will evaluate additional candidates for the position, during which time David Socks will continue to serve as our Chief Executive Officer. Although this is a planned management transition, we may
experience business disruptions and our ability to achieve our development objections could be adversely affected. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We will continue
to expand and need to effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company
culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses. Our industry has
experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will
significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">43 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We have recently substantially increased the size of our organization, and we may encounter difficulties in
managing our growth and expanding our operations successfully. </I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have substantially increased our organization from four
employees in February 2018 to 16&nbsp;full-time employees as of September&nbsp;30, 2019. As we continue development and pursue the potential commercialization of vonoprazan and any future product candidates, as well as function as a public company,
we will continue to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage
additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize vonoprazan and any future product candidates and to compete effectively will
depend, in part, on our ability to manage our recent substantial growth and any future growth effectively. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We are subject to various
foreign, federal, and state healthcare and privacy laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient
organizations and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare and privacy laws and regulations. These laws may constrain the business or financial arrangements and relationships through
which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include, but are not limited to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or
providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease,
or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person
or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the U.S. civil and criminal federal false claims and civil monetary penalties laws, including the civil False Claims Act, which can be enforced through civil
whistleblower or qui tam actions, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly
making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the U.S.
federal government; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things,
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection
with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or
specific intent to violate it in order to have committed a violation; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">44 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, also impose
obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information of covered entities subject to the rule, such as health plans, healthcare
clearinghouses and certain healthcare providers as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is
available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to certain payments and other
&#147;transfers of value&#148; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and
their immediate family members; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not
limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by the
patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict
payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and
other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives; state and foreign laws governing the privacy and
security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA; state and foreign governments that have enacted or proposed requirements regarding the collection,
distribution, use, security, and storage of personally identifiable information and other data relating to individuals (including the EU General Data Protection Regulation 2016/679, or GDPR, and the California Consumer Privacy Act, or CCPA), and
federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data, thus complicating compliance efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may also be subject to additional regulation in the conduct of our business. For example, we may be subject to the U.S. Foreign Corrupt
Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value
to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, California recently enacted the CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and
places increased privacy and security obligations on entities handling certain personal data of consumers or households. The CCPA will require covered companies to provide new disclosure to consumers about such companies&#146; data collection, use
and sharing practices, provide such consumers new ways to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales or transfers of personal information, and provide consumers with additional causes of action. The CCPA goes into effect on
January&nbsp;1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July&nbsp;1, 2020. The CCPA was amended on September&nbsp;23, 2018, and it remains
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">45 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and exemplifies the
vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations could
involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil,
criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual
damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these
laws, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time consuming and may require significant financial and personnel resources. Therefore, even if we are
successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with
applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to
operate our business and our results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Enacted and future legislation and healthcare reform measures may increase the difficulty and
cost for us to obtain marketing approval for and commercialize vonoprazan and any future product candidates and may affect the prices we may set. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system, including
cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and
continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, was enacted in the United States.
Among the provisions of the Affordable Care Act of importance to our potential product candidates, the Affordable Care Act includes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, which is apportioned among
these entities according to their market share in certain government healthcare programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price
for branded and generic drugs, respectively; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">46 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled,
implanted or injected; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an extension of a manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding
for such research; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending,
potentially including prescription drug spending. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Since its enactment, there have been judicial and political
challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision
repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part
of a year that is commonly referred to as the &#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual mandate is a critical
and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. While the Texas District Court Judge, as well as the Trump
Administration and CMS, have stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our
business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These
changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018,
will remain in effect through 2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers,
including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent
congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform
government program reimbursement methodologies for products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">At the federal level, the Trump administration&#146;s budget proposal for
fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain
drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. While proposed measures will require
authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">47 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">At the state level, legislatures have increasingly passed legislation and implemented regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers
will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.
These reforms could reduce the ultimate demand for vonoprazan and any future product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and
prospects. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try
Act of 2017, or Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial. Under certain
circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available
to eligible patients as a result of the Right to Try Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect that these new laws and other healthcare reform measures that may
be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other
government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize vonoprazan and any future product candidates, if approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We and any of our third-party manufacturers or suppliers may use potent
chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be
dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use,
generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product
development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general
liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with
fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Although we maintain
workers&#146; compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against
potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">48 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, we may incur substantial costs in order to comply with current or future
environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws
and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We face an inherent risk of product liability as a result of the clinical trials of vonoprazan and any future product candidates
and will face an even greater risk if we commercialize vonoprazan and any future product candidates. For example, we may be sued if vonoprazan and any future product candidates allegedly cause injury or are found to be otherwise unsuitable during
product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability
and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer
protection acts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or
be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">decreased demand for our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">injury to our reputation and significant negative media attention; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">costs to defend the related litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a diversion of management&#146;s time and our resources; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">substantial monetary awards to trial participants or patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">product recalls, withdrawals or labeling, marketing or promotional restrictions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">significant negative financial impact; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the inability to commercialize vonoprazan and any future product candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a decline in our stock price. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We currently do not have product liability insurance coverage, but will need to obtain such coverage as we begin our clinical trials or if we
commence commercialization of vonoprazan and any future product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential
product liability claims could prevent or inhibit the commercialization of vonoprazan and any future product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or
settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability
claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient
capital to pay such amounts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">49 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We and others, including any of our potential future collaborators, will be required to report to
regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we or any of our potential future collaborators are successful in commercializing vonoprazan or any future product candidates, the FDA and
foreign regulatory authorities would require that we and Takeda (with respect to vonoprazan) and any of our current or potential future collaborators, report certain information about adverse medical events if those products may have caused or
contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We, Takeda and any of our potential future collaborators or CROs may
fail to report adverse events within the prescribed timeframe. If we, Takeda or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including
criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or
suffer security breaches, which could result in a material disruption of our product development programs. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The United States
federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and
state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data. Despite the implementation of security measures, our internal computer systems and those of our current and any
future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an
event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as GDPR),
it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include
obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have
formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and <FONT STYLE="white-space:nowrap">follow-up</FONT> actions related to a security breach could
impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss
of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture vonoprazan
and any future product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our
data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development and commercialization of vonoprazan and any future product candidates could be delayed, and we could be
subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">50 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs
and expenses. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages,
floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce
vonoprazan and any future product candidates. Our ability to obtain clinical supplies of vonoprazan and any future product candidates could be disrupted if the operations of these suppliers were affected by a
<FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are exposed to the risk that our
employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or
other unauthorized activities that violate: (i)&nbsp;the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies,
(ii)&nbsp;manufacturing standards, including cGMP requirements, or (iii)&nbsp;federal and state healthcare, security, fraud and abuse laws, data privacy and security laws, and other similar <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;laws</FONT>
that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of
fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by
employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are
instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil,
criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight
and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which
could adversely affect our ability to operate our business and our results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We are subject to U.S. and certain foreign export and
import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal
liability and other serious consequences for violations, which could harm our business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are subject to export control and
import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls,
and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">51 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and
anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors and other collaborators and
partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials
outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with
officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, clinical research organizations,
contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and
penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and
<FONT STYLE="white-space:nowrap">out-licensing</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of intellectual property, products or technologies, similar to our approach in <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
acquiring our current product candidates. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt,
contingent liabilities, amortization expenses or acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional
potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future
acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the
integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although we may not
undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and
prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Intellectual Property </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Our success depends on our ability to protect our intellectual property and our proprietary technologies. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for vonoprazan and any future product candidates, proprietary technologies and their uses
as well as our ability to operate without infringing upon the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or vonoprazan or any
future product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to vonoprazan or any future product candidates,
proprietary technologies and their uses that are important to our business. We do not currently own any issued patents or pending patent applications. We also seek to protect our proprietary position by acquiring or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">52 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
<FONT STYLE="white-space:nowrap">in-licensing</FONT> relevant issued patents or pending patent applications from third parties. We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> from
Takeda a number of United States, European, and Canadian patents and patent applications relating to the compound vonoprazan as well as the use and manufacture of vonoprazan products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until,
patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our future patent applications or the patent applications of our current and future licensors will result in
patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around or invalidated by third
parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by
third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any
competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to vonoprazan and any future product candidates could have a material adverse effect on our financial
condition and results of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We cannot be certain that the claims in our licensor&#146;s U.S. pending patent applications,
corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and
courts in foreign countries, nor can we be certain that the claims in our licensor&#146;s issued patents will not be found invalid or unenforceable if challenged. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting vonoprazan and any
future product candidates by obtaining and defending patents. These risks and uncertainties include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during
the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">patent applications may not result in any patents being issued; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may
seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell vonoprazan and any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside
the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better
opportunity to create, develop and market competing products. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">53 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The patent prosecution process is also expensive and time consuming, and we and our licensor may
not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensor will
fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances such as under the Takeda License, we do not have the right to control the preparation,
filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensors in order to enforce the licensed patent rights, and such
cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by
our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could
cause us to lose rights in any applicable intellectual property that we <FONT STYLE="white-space:nowrap">in-license,</FONT> and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may
be unable to prevent competitors from making, using and selling competing products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, although we enter into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party
manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, including our rights in
vonoprazan licensed from Takeda, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are a party to the Takeda License under which we are granted rights to intellectual property that are important to our business and we may enter
into additional license agreements in the future with other third parties. The Takeda License imposes, and we expect that any future license agreements where we <FONT STYLE="white-space:nowrap">in-license</FONT> intellectual property, will impose on
us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related
proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. Additionally, if a future license agreement includes a sublicense from a third party who is not the
original licensor of the intellectual property at issue, then we must rely on our direct licensor to comply with its obligations under the primary license agreements under which such licensor obtained rights in the applicable intellectual property,
where we may have no relationship with the original licensor of such rights. If such a licensor fails to comply with its obligations under its upstream license agreement, the original third-party licensor may have the right to terminate the original
license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be
able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize vonoprazan and any future product candidates incorporating the relevant intellectual property. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may need to obtain further licenses from third parties to advance our research or allow commercialization of vonoprazan and any future product
candidates, and we cannot provide any assurances that third-party patents do not exist which might be enforced against vonoprazan and any future product candidates in the absence of such a license. We may fail to obtain any of these licenses
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">54 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the
same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product
candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties
and/or other forms of compensation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Licensing of intellectual property is of critical importance to our business and involves complex
legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the scope of rights granted under the license agreement and other interpretation-related issues; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our right to sublicense patents and other rights to third parties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of vonoprazan and any future
product candidates, and what activities satisfy those diligence obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our right to transfer or assign the license; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of intellectual property by our
licensors and us and our partners. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If disputes over intellectual property that we have licensed prevent or impair our
ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those
transactions, or may limit our ability to pursue certain activities. For example, if we choose to sublicense or assign to any third parties our rights under our existing license agreement with Takeda with respect to any licensed product, we may be
required to wait for a certain period or until the occurrence of certain funding or development milestones. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If the scope of any patent protection
we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the
subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending and future patent
applications may not result in patents being issued which protect vonoprazan or any future product candidates or which effectively prevent others from commercializing competitive product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted
after issuance. Even if patent applications we own in the future or license currently issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with
us, or otherwise provide us with any competitive advantage. Any future patents that we own or license, now </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">55 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
or in the future, may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether vonoprazan
or any future product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our future patents or the patents of our current and future licensors by
developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which could materially adversely affect our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our future patents or the patents of our
current and future licensors may not cover vonoprazan or any future product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party
<FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar
proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain
that there is no invalidating prior art, of which we or our predecessors and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications has been found. There is also no assurance that there is not prior art of which we, our predecessors or licensors are aware, but which we do not believe affects the
validity or enforceability of a claim in our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse
determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize vonoprazan or any future product candidates and compete directly
with us, without payment to us. It is possible that defects of form in the preparation or filing of our or our current and future licensors&#146; patents or patent applications may exist, or may arise in the future, for example with respect to
proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, or enforcement of our future patents or future patent applications or our current and
future licensors&#146; patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Any loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical
technology and products, or limit the duration of the patent protection of vonoprazan or any future product candidates, which could materially and adversely impact our business. Such proceedings also may result in substantial cost and require
significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our future patents and future patent applications or the patents and patent
applications of our current and future licensors is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize vonoprazan or any future product candidates. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The patent protection and patent prosecution for vonoprazan or any future product candidates may be dependent on third parties. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property
under certain current and future license agreements, such as the Takeda License. Under such arrangements, we may not have primary control over these activities for certain of licensed patents or patent applications and other intellectual property
rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">56 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
intellectual property rights. In addition, our current and future licensors may not be fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent
rights, which could compromise such patent rights. We may in the future enter into license agreements where the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these
patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such
patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual
property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering vonoprazan or any future product
candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, even where we have the right to control prosecution of patent applications or enforcement of patents we have acquired or licensed from
third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over such activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Third parties may retain certain rights to the technology that they license to us, including the right to use the underlying technology for
noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. For example, under the
Takeda License, Takeda retained the rights to the inventions in all countries other than the United States, Europe, and Canada. Takeda also retained the right to development certain drug products that contain vonoprazan where vonoprazan is not the
only active pharmaceutical ingredient. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the
event of misuse. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical <FONT
STYLE="white-space:nowrap">in-licensed</FONT> technology, we may be unable to successfully develop, <FONT STYLE="white-space:nowrap">out-license,</FONT> market and sell our products, which could prevent or delay new product introductions. Our
business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, <FONT
STYLE="white-space:nowrap">out-license</FONT> or market and sell our product candidate. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Intellectual property rights do not necessarily address
all potential threats to our competitive advantage. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The degree of future protection afforded by our intellectual property rights
is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">others may be able to develop products that are similar to vonoprazan or any future product candidates but that are not covered by the claims of the patents that
we own in the future or license; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we or our current and future licensors or predecessors might not have been the first to make the inventions covered by the issued patents or patent applications
that we own in the future or license; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we or our current and future licensors or predecessors might not have been the first to file patent applications covering certain of the claimed inventions;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">57 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">it is possible that the pending patent applications we own or license will not lead to issued patents; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">issued patents that we own in the future or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such
activities to develop competitive products for sale in our major commercial markets; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may not develop additional proprietary technologies that are patentable; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the patents of others may have an adverse effect on our business. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Should any of these events occur, it could significantly harm our business, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims
by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims
that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale
or import vonoprazan and any future product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and
other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S.
and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or
methods for treatment related to the use or manufacture of vonoprazan and any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As the biopharmaceutical
industry expands and more patents are issued, the risk increases that vonoprazan and any future product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as
confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of vonoprazan and any future product candidates, and we cannot be certain that
we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued
patents that vonoprazan and any future product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in
terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims
of patent infringement asserted by third parties would be time consuming and could: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">result in costly litigation that may cause negative publicity; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">58 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">divert the time and attention of our technical personnel and management; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">cause development delays; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">prevent us from commercializing vonoprazan and any future product candidates until the asserted patent expires or is held finally invalid or not infringed in a
court of law; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be possible on a cost-effective basis;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subject us to significant liability to third parties; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to the same technology. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Although no third party has asserted a claim of patent infringement against us as of the date of this prospectus, others may hold proprietary rights that could prevent vonoprazan and any future product candidates
from being marketed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to
vonoprazan and any future product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop
vonoprazan and any future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we
would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the
rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign vonoprazan and any future product candidates or processes to avoid
infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing vonoprazan and any future product
candidates, which could harm our business, financial condition and operating results. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Parties making claims against us may be able to
sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation
or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material
adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We may not be successful in obtaining or maintaining necessary rights to vonoprazan and any future product candidates through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT>
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Because our development programs may in the future require the use of proprietary rights held by other third parties, the growth
of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or use these third-party proprietary rights. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any
compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for vonoprazan and any future product candidates. The licensing and acquisition of third-party intellectual
property rights is a competitive area, and a number of more established </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">59 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage
over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to
license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain
the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We may be involved in lawsuits to protect or enforce our future patents or the patents of our current and future licensors, which could be expensive, time consuming and unsuccessful. Further, our future
issued patents or the patents of our current and future licensors could be found invalid or unenforceable if challenged in court. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Competitors may infringe our intellectual property rights or those of our current and future licensors. To prevent infringement or unauthorized use,
we and/or any such licensors may be required to file infringement claims, which can be expensive and time consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable
and/or is not infringed. If we or any of our current and future licensors were to initiate legal proceedings against a third party to enforce a patent directed at vonoprazan and any future product candidates, the defendant could counterclaim that
our patent or the patent of our current or future licensor is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity
challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, <FONT STYLE="white-space:nowrap">non-enablement,</FONT> or obviousness-type double patenting. Grounds
for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the
patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our future patents and future patent applications or those of our current and future licensors is threatened, it could dissuade companies
from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant
expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or
any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or
proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal
proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">60 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the
market price of our common shares to decline. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">During the course of any intellectual property litigation, there could be public
announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of
our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which
could have a material adverse effect on our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Derivation or interference proceedings may be necessary to determine priority of
inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Derivation or interference proceedings provoked by third parties or brought by us or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions
with respect to our future patents or future patent applications or those of our current and future licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing
party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management
and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary
technology from third parties or enter into development or manufacturing partnerships that would help us bring vonoprazan and any future product candidates to market. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our future patent applications or those of our current and future licensors and the enforcement or
defense of our future issued patents or those of our current and future licensors. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On September&nbsp;16, 2011, the Leahy-Smith
America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect
patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#147;first inventor to file&#148; system in which, assuming that other requirements of patentability are met, the first inventor to file
a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a
patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability
to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other
countries are confidential for a period of time after filing or until issuance, we may not be certain that we or our current and future licensors are the first to either (1)&nbsp;file any patent application related to vonoprazan and any future
product candidates or (2)&nbsp;invent any of the inventions claimed in the patents or patent applications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Leahy-Smith Act also
includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">61 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and
derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to
invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a
district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus,
the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our future patent applications or those of our current and future licensors and the enforcement or defense of our future issued
patents or those of our current and future licensors, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect vonoprazan and any future product candidates.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly
patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain.
Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of
patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our future patents or in third-party patents. In addition, Congress or other foreign legislative bodies
may pass patent reform legislation that is unfavorable to us. For example, a new bill (Terminating the Extension of Rights Misappropriated Act H.R. 3199) percolating through the United States Congress aims to reduce the term of certain drug patents
in order to ease generic entry and increase competition. Evolving judicial interpretation of patent law could also adversely affect our business. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing
the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of
events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing
patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce the existing licensed patents and the patents we might obtain or license in the future. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may be subject to claims challenging the inventorship or ownership of our future patents, the patents of our current and future licensors, or other
intellectual property. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may also be subject to claims that former employees or other third parties have an ownership interest
in our future patents,<I> </I>the patents of our current and future licensors or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any
such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation
could result in substantial costs and distraction to management and other employees. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">62 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Patent terms may be inadequate to protect our competitive position on vonoprazan and any future product
candidates for an adequate amount of time. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Patents have a limited lifespan. In the United States, if all maintenance fees are
timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it
affords, is limited. Even if patents covering vonoprazan and any future product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the
development, testing and regulatory review of product candidates, patents protecting vonoprazan and any future product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If we do not obtain patent term
extension for vonoprazan and any future product candidates, our business may be materially harmed. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Depending upon the timing,
duration and specifics of FDA marketing approval of vonoprazan and any future product candidates, one or more of our U.S. patents or those of our current and future licensors, may be eligible for limited patent term restoration under the Drug Price
Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch- Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA
regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent
beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain
foreign countries upon regulatory approval of vonoprazan and any future product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of
relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration
or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may
take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We may not be able to protect our intellectual property rights throughout our licensed territories. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Although we have issued patents and pending patent applications in the United States and certain other countries in which we intend to commercialize our products, filing, prosecuting and defending patents in all
relevant countries throughout the could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign
countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own
products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with vonoprazan or any future product
candidates, and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">63 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
our patents, the patents of our current and future licensors or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal
systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our intellectual property rights or marketing of competing
products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our future
patents or the patents of our current and future licensors at risk of being invalidated or interpreted narrowly and our future patent applications or the patent applications of our current and future licensors at risk of not issuing and could
provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government
agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant
to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our
patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the
lifetime of our future patents and/or future applications and those of our current and future licensors. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and
various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and
in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse
of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, we rely on the protection of our trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and
other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> including entering into confidentiality agreements with
third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and
disclose our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">64 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a
trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to
prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position
would be harmed. If we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to protect our trade secret information may be jeopardized. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged
confidential information or trade secrets of their former employers. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As is common in the biopharmaceutical industry, in addition
to our employees, we engage the services of consultants to assist us in the development of vonoprazan and any future product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously
provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise
used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a
distraction to our management team and other employees. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able
to build name recognition in our markets of interest and our business may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We intend to use registered or
unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to
protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby
impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations
of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely
affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our
trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade
secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">65 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Any collaboration arrangements that we have or may enter into in the future may not be successful, which
could adversely affect our ability to develop and commercialize our products. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The success of our collaboration arrangements will
depend heavily on the efforts and activities of our collaborators and partners. Under the Takeda License, for example, Takeda has certain obligations with respect to assisting with the transition of information and materials to us as well as
providing clinical and commercial supply of the vonoprazan product. Collaborations and partnerships are subject to numerous risks, which may include that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs
based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing
priorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform
satisfactorily in carrying out these activities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that
gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future
products or that results in costly litigation or arbitration that diverts management attention and resources; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the
applicable current or future products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our products that results from our collaborating with
them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a collaborator&#146;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal
proceedings. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Intellectual property discovered through government funded programs may be subject to federal regulations such as <FONT
STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may acquire or license in the future intellectual property rights
that have been generated through the use of U.S. government funding or grant. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">66 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these inventions to a third party if it determines that: (i)&nbsp;adequate steps have not been taken to commercialize the invention; (ii)&nbsp;government action is necessary to meet
public health or safety needs; or (iii)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred to as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). The U.S. government
also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property
generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these
inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the
intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances
domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> product manufacturers for products covered by such intellectual property.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Common Stock and This Offering </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>An active, liquid and orderly market for our common stock may not develop, and you may not be able to resell your common stock at or above the public offering price. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to this offering, there has been no public market for our common stock. Although we expect to list our common stock on Nasdaq, an active
trading market for our common stock may never develop or be sustained following this offering. We and the representatives of the underwriters will determine the initial public offering price of our common stock through negotiation. This price will
not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. In addition, an active trading market may not develop following the consummation of this offering or, if it is
developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital
by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our stock price is likely to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in particular have
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public offering price.
The market price for our common stock may be influenced by those factors discussed in this &#147;Risk Factors&#148; section and many others, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our ability to enroll patients in our planned clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">results of our clinical trials and preclinical studies, the results of clinical trials conducted by Takeda and others for vonoprazan, and the results of trials
of our competitors or those of other companies in our market sector; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulatory approval of vonoprazan and any future product candidates, or limitations to specific label indications or patient populations for its use, or changes
or delays in the regulatory review process; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">67 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any termination or loss of rights under the Takeda License; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulatory developments in the United States and foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the success or failure of our efforts to acquire, license or develop additional product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">innovations or new products developed by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">manufacturing, supply or distribution delays or shortages; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">achievement of expected product sales and profitability; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">variations in our financial results or those of companies that are perceived to be similar to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">market conditions in the biopharmaceutical sector and issuance of securities analysts&#146; reports or recommendations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">trading volume of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an inability to obtain additional funding; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">sales of our stock by insiders and stockholders, including Takeda; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">general economic, industry and market conditions other events or factors, many of which are beyond our control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">additions or departures of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">intellectual property, product liability or other litigation against us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">changes in accounting standards, policies, guidelines, interpretations or principles. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in
the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#146;s attention and resources, which could have a material adverse effect on our business,
financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our failure to meet the continued listing requirements of the Nasdaq could result in a delisting
of our common stock. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If, after listing, we fail to satisfy the continued listing requirements of the Nasdaq, such as the
corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to
sell or purchase our common stock when you wish to do so. In the event of a delisting, any action taken by us to restore compliance with listing requirements may not allow our common stock to become listed again, stabilize the market price or
improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s listing requirements.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">68 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may allocate the net proceeds from this offering in ways that you and other stockholders may not
approve. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our management will have broad discretion in the application of the net proceeds from this offering, including for any
of the purposes described in the section titled &#147;Use of Proceeds.&#148; Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their
currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by our management to apply these funds effectively could harm our business. Pending their use, we
may invest the net proceeds from this offering in short- and intermediate-term, investment grade interest-bearing instruments. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from
this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our stock price to decline. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>You
will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase. </I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The initial
public offering price of our common stock is substantially higher than the pro forma as adjusted net tangible book value per share of our outstanding common stock immediately after the completion of this offering. Purchasers of common stock in this
offering will experience immediate dilution of approximately $11.46 per share, assuming an initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>After this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the ability to
control or significantly influence all matters submitted to stockholders for approval. Furthermore, many of our current directors were appointed by our principal stockholders. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the completion of this offering, our executive officers, directors and greater than 5% stockholders, in the aggregate, will own
approximately 47.9% of our outstanding common stock (assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options, warrants or other rights, and without giving effect to any purchases
that these holders may make through our directed share program), assuming an initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. Furthermore, many of our current
directors were appointed by our principal stockholders. As a result, such persons or their appointees to our board of directors, acting together, will have the ability to control or significantly influence all matters submitted to our board of
directors or stockholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. In addition, if any of our
executive officers, directors and greater than 5% stockholders purchase shares in this offering, or if any of our other current investors purchase shares in this offering and become greater than 5% stockholders as a result, the ability of such
persons, acting together, to control or significantly influence such matters will increase. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or
other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on
appreciation, if any, in the price of our common stock. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have never declared or paid any cash dividend on our common stock. We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">69 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, under the terms of the Loan Agreement, we are prohibited from paying any cash dividends without
the consent of the lenders. Any return to stockholders will therefore be limited to the appreciation of their stock. Shares of our common stock may not appreciate in value or even maintain the price at which stockholders have purchased their shares.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Sales of a substantial number of shares of our common stock by our existing stockholders, including Takeda, in the public market could cause our
stock price to fall. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Sales of a substantial number of shares of our common stock in the public market or the perception that
these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Based on shares of common stock outstanding as of June&nbsp;30, 2019, upon the closing of this offering, we will have outstanding a total of
25,883,458 shares of common stock after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options, warrants or other rights. Of these shares, only the 7,900,000 shares
of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable, without restriction, in the public market immediately following this offering,
unless they are purchased by one of our affiliates. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, immediately following the completion of this offering, Takeda
will beneficially own 25.9%&nbsp;of our outstanding shares of common stock, including 7,588,000 shares of common stock issuable pursuant to the Takeda Warrant (or 25.0%&nbsp;if the underwriters exercise their option to purchase additional shares in
full). The sale by Takeda of a substantial number of shares after this offering, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our officers, directors and holders of substantially all of our outstanding securities have entered into
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters pursuant to which they may not, with limited exceptions, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any
of our securities, without the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. The underwriters may permit our officers, directors and other securityholders who are subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, subject to limitations. Sales of these shares, or perceptions that they will be sold,
could cause the trading price of our common stock to decline. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, up to an additional 17,983,458 shares of common stock will be eligible for sale in the public market of which
12,399,381 shares are held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule 144 under the Securities Act. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In addition, as of June&nbsp;30, 2019, up to 9,819,925&nbsp;shares of common stock that are either subject to outstanding options, warrants or other rights or reserved for future issuance under our employee benefit
plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, exercise limitations, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the
Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After this offering, the holders of 12,068,938 shares of our outstanding common stock, or approximately 46.6% of our total outstanding common stock
as of June&nbsp;30, 2019, will be entitled to rights with respect to the registration of their shares under the Securities Act, subject to vesting and the <FONT STYLE="white-space:nowrap">180-day</FONT>
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. In addition, upon the closing of this offering Takeda will be entitled to the same rights with respect to the registration of 7,588,000 shares of our common stock
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">70 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
underlying the Takeda Warrant. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for
shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and
smaller reporting company may make our common stock less attractive to investors. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are an emerging growth company, as defined
in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period,
including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and
intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with
correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting pursuant to the
Sarbanes-Oxley Act; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or
a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, unless the SEC, determines the new rules are necessary for protecting the public; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reduced disclosure obligations regarding executive compensation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not
previously approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have taken advantage of reduced reporting burdens in this prospectus. In particular, we have
not included all of the executive compensation related information that would be required if we were not an emerging growth company. Investors may find our common stock less attractive if we rely on these exemptions. If some investors find our
common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an
extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have irrevocably
elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no
longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common
stock held by non-affiliates is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">71 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As a public company, we will incur significant legal, accounting and other expenses that we did not
incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial
condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and
maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and
regulations in these areas, such as mandatory &#147;say on pay&#148; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of
government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently
anticipate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial
compliance costs and to make some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business,
financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For
example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We
cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our
board of directors, our board committees or as executive officers. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If securities or industry analysts do not publish research or reports or
publish unfavorable research or reports about our business, our stock price and trading volume could decline. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The trading market
for our common stock will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities
and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the
analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock
price or trading volume to decline. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If we fail to maintain proper and effective internal control over financial reporting, our ability to produce
accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to Section&nbsp;404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over
financial reporting beginning with our second annual report after this offering. When we lose our status as an &#147;emerging growth company&#148; and reach an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">72 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules
governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting
company under the Exchange Act, we will need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if
required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There could be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to
maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting
is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section&nbsp;404 reviews, investors may
lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to
remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment
of management. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect
immediately prior to the consummation of this offering will contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of
our board of directors. The provisions in our charter documents will include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board
of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created
by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote to remove a director for cause, and the
prohibition on removal of directors without cause; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares,
including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote to adopt, amend or repeal our amended and
restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">73 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force
consideration of a proposal or to take action, including the removal of directors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at
a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise attempting to obtain control of us.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also subject to the anti-takeover provisions contained in Section&nbsp;203 of the Delaware General Corporation
Law. Under Section&nbsp;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of
directors has approved the transaction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our amended and restated certificate of incorporation and amended and restated bylaws will provide that
the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or
our directors, officers or employees. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and amended and restated bylaws will
provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf under Delaware statutory or common law, including any action asserting a breach of fiduciary duty, any
action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by
the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts have exclusive
jurisdiction. To the extent that any such claims may be based upon federal law claims, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or
the rules and regulations thereunder. The choice of forum provisions in our amended and restated certificate of incorporation may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or
our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with
the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is
possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an
action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Our ability to use net operating loss carryforwards and other tax attributes may be limited in connection with this offering or other ownership changes. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve
profitability. To the extent that we continue to generate </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">74 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire (if at all). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under recently enacted U.S. tax legislation, federal net operating loss, or NOL, carryforwards generated in periods after December&nbsp;31, 2017,
may be carried forward indefinitely but may only be used to offset 80% of our taxable income annually. Our NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service, or the IRS, and state tax authorities. Under
Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, our federal NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders
over a three-year period in excess of 50 percentage points. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential
changes in connection with this offering. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from this offering or other transactions, or any resulting limitations
on our ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future tax liability to us and our future cash flows could be adversely affected. We have recorded a full
valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Tax Act has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate and revising the rules governing NOLs. Many of these changes
became effective beginning in 2018, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as
interpretations and implementing regulations by the U.S. Treasury Department and the IRS, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will
affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">There may be other material adverse effects resulting from the legislation that we have not yet identified. While some of the changes made by the tax legislation may adversely affect us in one or more reporting
periods and prospectively, other changes may be beneficial on a going forward basis. We continue to work with our tax advisors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult
with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We could
be subject to securities class action litigation. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the past, securities class action litigation has often been brought against
a company following a decline in the market price of its securities. This risk is especially relevant for us, because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such
litigation, it could result in substantial costs and a diversion of management&#146;s attention and resources, which could harm our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">75 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus,
including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our planned clinical trials for vonoprazan, our only
product candidate, the timing and likelihood of regulatory filings and approvals for vonoprazan, our ability to commercialize vonoprazan, if approved, the pricing and reimbursement of vonoprazan, if approved, the potential to develop future product
candidates, the potential benefits of strategic collaborations and our intent to enter into any strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated
product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In some cases, you can identify
forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148;
&#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus
are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which
are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors
and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or
otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See the section titled &#147;Where You Can Find More Information.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements
should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon them. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">76 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_4"></A>MARKET AND INDUSTRY DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research, as
well as from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. Internal estimates are derived
from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market,
which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data
of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this
prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section titled &#147;Risk Factors.&#148; These and other
factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">77 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_5"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We estimate that the net proceeds to us from the sale of the common stock that we are offering will be approximately $136.8 million (or $157.7
million if the underwriters exercise their option to purchase additional shares in full), assuming an initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Each $1.00
increase (decrease) in the assumed initial public offering price of $<B></B>19.00<B> </B>per share would increase (decrease) the net proceeds to us from this offering by approximately $<B></B><B></B><B></B><B></B>7.3<B> </B>million, assuming the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of
1.0&nbsp;million shares in the number of shares offered by us would increase (decrease) the net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by
approximately $17.7 million, assuming the assumed initial public offering price stays the same. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The principal purposes of this
offering are to obtain additional capital to support our operations, to create a public market for our common stock and to facilitate our future access to the public equity markets. We intend to use approximately $100.0&nbsp;million of the net
proceeds from this offering to fund the clinical development of vonoprazan and the remainder for working capital and general corporate purposes, including <FONT STYLE="white-space:nowrap">pre-commercial</FONT> activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may also use a portion of the remaining net proceeds and our existing cash and cash equivalents to
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe, based on our current operating plan, that the net proceeds from this offering together with our existing cash and cash equivalents,
will be sufficient to fund our operations for at least the next 24&nbsp;months, although there can be no assurance in that regard. In particular, we expect that the net proceeds from this offering will allow us to complete our planned Phase 3
clinical trials of vonoprazan in the treatment of erosive esophagitis and <I>H. pylori</I> infection. However, our expected use of proceeds from this offering described above represents our current intentions based on our present plans and business
condition. We cannot predict with certainty all of the particular uses of the net from this offering or the actual amounts that we will spend on the uses set forth above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The amounts and timing of our actual expenditures will depend on numerous factors, including the time and cost necessary to conduct our planned clinical trials, the results of such trials, and other factors
described in the section titled &#147;Risk Factors,&#148; as well as the amount of cash used in our operations and any unforeseen cash needs. Therefore, our actual expenditures may differ materially from the estimates described above. We may find it
necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, investment grade interest-bearing instruments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">78 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_6"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of
our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results
of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, under the terms of our Loan Agreement, we
are prohibited from paying any cash dividends without the consent of the lenders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">79 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_7"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table sets forth our cash and cash equivalents and capitalization as of June&nbsp;30, 2019: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">on an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">on a pro forma basis to reflect (i)&nbsp;the automatic conversion of the May 2019 Notes into an aggregate of 6,106,940 shares of our common stock immediately
prior to the closing of this offering (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on October 28, 2019),
(ii) the reclassification of the Takeda Warrant to stockholders&#146; equity (deficit), and (iii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the closing of this offering; and
</FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">on a pro forma as adjusted basis to give further effect to our issuance and sale of <B></B><B></B>7,900,000 shares of our common stock in this offering at an
assumed initial public offering price of $19.00 per share, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The pro forma and pro forma as adjusted information below is illustrative only, and our cash and cash equivalents and capitalization following the
closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our combined financial statements and related
notes included in this prospectus and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and other financial information contained in this prospectus. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>As of June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands, except share and par value data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro Forma</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro
Forma<BR>As<BR>Adjusted<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">219,710</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Capitalization:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes payable at fair value (including accrued interest)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">93,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, including final payment fee and net of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Stockholders&#146; equity (deficit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Preferred stock, $0.0001 par value; no shares authorized, issued and outstanding, actual; 40,000,000&nbsp;shares authorized and no shares
issued and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock, $0.0001 par value; 50,000,000&nbsp;shares authorized, 11,876,518&nbsp;shares issued and 7,219,268&nbsp;shares outstanding,
actual; 400,000,000&nbsp;shares authorized, 17,983,458 shares issued and 13,326,208 shares outstanding, pro forma; 400,000,000&nbsp;shares authorized, 25,883,458&nbsp;shares issued and 21,226,208 shares outstanding, pro forma as
adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">148,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">285,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">58,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">195,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">83,283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">83,283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">220,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">80 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Each $1.00 increase (decrease) in the assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover
page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of our cash and cash equivalents, total stockholders&#146; equity (deficit) and total capitalization by approximately $7.3 million, assuming that the number
of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of
1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price of $19.00 per share would increase (decrease) the pro forma as adjusted amount of each of our cash and cash equivalents, total
stockholders&#146; equity (deficit) and total capitalization by approximately $17.7&nbsp;million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The number of shares of common stock issued and outstanding pro forma and pro forma as adjusted in the table above is based on 17,983,458
shares of our common stock outstanding as of June&nbsp;30, 2019, including 4,657,250 shares subject to forfeiture or our right of repurchase, and gives effect to the automatic conversion of the May 2019 Notes into an aggregate of 6,106,940 shares of
our common stock immediately prior to the closing of this offering (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion
occurs on October 28, 2019), and excludes: </FONT></P>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">7,588,000 shares of common stock issuable to Takeda upon the exercise of the Takeda Warrant as of June 30, 2019, at an exercise price of $0.00004613 per share;
</FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">1,400,528&nbsp;shares of common stock issuable upon exercise of stock options granted after June&nbsp;30, 2019, at a weighted-average exercise price of $9.10 per
share; </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">2,700,000 shares of our common stock reserved for future issuance under our 2019 Plan, which will become effective in connection with this offering (which number
does not include any potential evergreen increases pursuant to the terms of the 2019 Plan); </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">270,000 shares of common stock reserved for future issuance under our ESPP, which will become effective in connection with this offering (which number does not
include any potential evergreen increases pursuant to the terms of the ESPP); and </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">16,446 shares of our common stock which may become issuable to the lenders under our Loan Agreement upon the exercise of the Lender Warrants, at an exercise
price of $15.20 per share (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus), which warrants will only become exercisable if and when we borrow an
additional $25.0 million under our Loan Agreement. </FONT></P></TD></TR></TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A $1.00 increase in the assumed initial public offering
price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, would decrease the number of shares of our common stock issued upon conversion of the May 2019 Notes by 305,346 shares. A $1.00 decrease in
the assumed initial public offering price of $19.00 per share would increase the number of shares of our common stock issued on conversion of the May 2019 Notes&nbsp;by 339,275 shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">81 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the
initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, our historical net tangible book value (deficit) was $(84.4) million, or $(7.11) per share of our common stock, based on 11,876,518&nbsp;shares of common stock issued and outstanding as of
such date, including 4,657,250&nbsp;shares subject to forfeiture or our right of repurchase as of such date. Our historical net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of
common stock outstanding at June&nbsp;30, 2019. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On a pro forma basis, after giving effect to (i)&nbsp;the automatic conversion
of the May 2019 Notes into an aggregate of 6,106,940 shares of our common stock immediately prior to the closing of this offering (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on
the cover page of this prospectus, and assuming the conversion occurs on October&nbsp;28, 2019), and (ii)&nbsp;the reclassification of the Takeda Warrant to stockholders&#146; equity (deficit), our pro forma net tangible book value as of
June&nbsp;30, 2019 would have been approximately $58.3 million, or approximately $3.24 per share of our common stock. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After
giving further effect to the sale of 7,900,000 shares of common stock in this offering at an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2019 would have been approximately $195.1 million, or approximately
$7.54 per share. This amount represents an immediate increase in pro forma net tangible book value of approximately $4.30 per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately $11.46
per share to new investors purchasing shares of common stock in this offering. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Dilution per share to new investors is determined
by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise
by the underwriters of their option to purchase additional shares): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Assumed initial public offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">19.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Historical net tangible book value (deficit) per share as of June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(7.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma increase in historical net tangible book value per share as of June&nbsp;30, 2019 attributable to the pro forma adjustments
described above</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">10.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net tangible book value per share as of June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Increase in pro forma net tangible book value per share attributable to new investors participating in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma as adjusted net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Dilution per share to new investors participating in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">11.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A $1.00 increase in the assumed initial public offering price of $19.00 per share, the midpoint of the
price range set forth on the cover page of this prospectus, would decrease the number of shares of our common stock issued upon conversion of the May 2019 Notes&nbsp;by 305,346 shares, and would increase the pro forma as adjusted net tangible book
value per share after this offering by approximately $0.38, and decrease the dilution in pro forma net tangible book value per share to new </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">82 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
investors by approximately $0.38, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated
underwriting discounts and commissions and the estimated offering expenses payable by us. A $1.00 decrease in the assumed initial public offering price of $19.00 per share would increase the number of shares of our common stock issued upon
conversion of the May 2019 Notes&nbsp;by 339,275 shares, and would decrease the pro forma as adjusted net tangible book value per share after this offering by approximately $0.38, and increase the dilution in pro forma net tangible book value per
share to new investors by approximately $0.38, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and the
estimated offering expenses payable by us. </FONT></P>     <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Each increase of 1.0&nbsp;million shares in the number of shares offered
by us would increase our pro forma as adjusted net tangible book value per share after this offering by approximately $0.38 and decrease the dilution to investors participating in this offering by approximately $0.38, assuming that the assumed
initial public offering price of $19.00 per share remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. Each decrease of 1.0 million shares in the number of
shares offered by us would decrease our pro forma as adjusted net tangible book value per share after this offering by approximately $0.41 and increase the dilution to investors participating in this offering by approximately $0.41, assuming that
the assumed initial public offering price of $19.00 per share remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If the underwriters exercise their option to purchase additional shares of our common stock in full in this offering, the pro forma as adjusted net
tangible book value after the offering would be approximately $7.98 per share, the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be approximately $4.74 and the dilution per share to new investors
would be $11.02, in each case assuming an initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table summarizes on the pro forma as adjusted basis described above, as of June&nbsp;30, 2019, the differences between the number of
shares purchased from us, the total consideration paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The calculations
below are based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of the prospectus, before deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Shares</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Purchased</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Consideration</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Weighted-<BR>Average<BR>Price</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Per
Share</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Existing stockholders before this offering</FONT><FONT STYLE="font-family:ARIAL" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">17,983,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,826,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">New investors participating in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7,900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">150,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">19.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">25,883,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">242,926,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>     <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If the Takeda Warrant and Lender Warrants had been exercised as of June&nbsp;30, 2019, the pro
forma as adjusted net tangible book value after this offering would be approximately $195.4&nbsp;million, or approximately $5.83 per share, and total dilution per share to new investors would be approximately $13.17 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">83 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If the underwriters exercise their option to purchase additional shares of our common stock in
full: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the percentage of shares of common stock held by existing stockholders before this offering will decrease to approximately 66% of the total number of shares of
our common stock outstanding after this offering; and </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of shares held by new investors participating in this offering will increase to 9,085,000, or approximately 34% of the total number of shares of our
common stock outstanding after this offering. </FONT></P></TD></TR></TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The foregoing tables and calculations on a pro forma and pro
forma as adjusted basis are based on 17,983,458 shares of our common stock outstanding as of June&nbsp;30, 2019, including 4,657,250 shares subject to forfeiture or our right of repurchase, and gives effect to the automatic conversion of the May
2019 Notes into an aggregate of 6,106,940 shares of our common stock immediately prior to the closing of this offering (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover
page of this prospectus, and assuming the conversion occurs on October 28, 2019) and excludes: </FONT></P>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">7,588,000 shares of common stock issuable to Takeda upon the exercise of the Takeda Warrant as of June 30, 2019, at an exercise price of $0.00004613 per share;
</FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">1,400,528 shares of common stock issuable upon exercise of stock options granted after June&nbsp;30, 2019, at a weighted-average exercise price of $9.10 per
share; </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">2,700,000 shares of our common stock reserved for future issuance under our 2019 Plan, which will become effective in connection with this offering (which number
does not include any potential evergreen increases pursuant to the terms of the 2019 Plan); </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">270,000 shares of common stock reserved for future issuance under our ESPP, which will become effective in connection with this offering (which number does not
include any potential evergreen increases pursuant to the terms of the ESPP); and </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">16,446 shares of our common stock which may become issuable to the lenders under our Loan Agreement upon the exercise of the Lender Warrants, at an exercise
price of $15.20 per share (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus) which warrants will only become exercisable if and when we borrow an
additional $25.0 million under our Loan Agreement. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To the extent any outstanding options, warrants or other
rights are exercised, or we issue additional equity or convertible securities in the future, there will be further dilution to new investors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">84 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_9"></A>SELECTED COMBINED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following tables set forth our selected historical combined financial data as of, and for the periods ended on, the dates indicated. The
combined financial statements include the accounts of our company and YamadaCo IIA, Inc., both of which were entities under common control prior to the Merger. We have derived the selected combined statements of operations data for the year ended
December&nbsp;31, 2018 and the selected combined balance sheet data as of December&nbsp;31, 2018 from our audited combined financial statements included elsewhere in this prospectus. We have derived the selected combined statements of operations
data for the six months ended June&nbsp;30, 2018 and 2019 and the selected combined balance sheet data as of June&nbsp;30, 2019 from our unaudited combined financial statements included elsewhere in this prospectus. The unaudited combined financial
statements have been prepared on a basis consistent with our audited combined financial statements included in this prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary to
fairly state our results of operations for the six months ended June&nbsp;30, 2018 and 2019 and financial position as of June&nbsp;30, 2019. You should read these data together with our combined financial statements and related notes included
elsewhere in this prospectus and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not necessarily indicative of our future
results. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year
Ended<BR>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six Months Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Combined Statements of Operations Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative (includes related party amounts of $321, $124 and $18, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense (includes related party amounts of $(13), $(4) and $(82), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities (includes related party amounts of $0, $0 and $(1,277), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes (includes related party amounts of $(50), $(4) and $(502),
respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss per share, basic and diluted</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Weighted-average shares of common stock outstanding, basic and diluted</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,051,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,331,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,640,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss per share, basic and diluted<BR>(unaudited)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(9.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma weighted-average shares of common stock outstanding, basic and diluted
(unaudited)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,098,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,578,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">See Note 1 to our combined financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the historical
and pro forma net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">85 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>As of<BR>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>As of<BR>June&nbsp;30,<BR>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Combined Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Working capital
(deficit)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(60,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes payable at fair value (including accrued interest)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">93,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, including final payment fee and net of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">We define working capital (deficit) as current assets less current liabilities. See our combined financial statements included elsewhere in this
prospectus for further details regarding our current assets and current liabilities. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">86 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>You should read the following discussion and analysis of our financial condition and results of operations
together with our combined financial statements and related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis are set forth elsewhere in this prospectus, including information with respect
to our plans and strategy for our business and related financing, and includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section titled &#147;Risk
Factors,&#148; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are a late clinical-stage biopharmaceutical company focused on developing and
commercializing novel treatments for GI diseases. Our initial product candidate, vonoprazan, is an oral small molecule <FONT STYLE="white-space:nowrap">P-CAB.</FONT> <FONT STYLE="white-space:nowrap">P-CABs</FONT> are a novel class of medicines that
block acid secretion in the stomach. Vonoprazan has rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over the current standard of care as a single agent in the treatment of GERD, and in combination with
antibiotics for the treatment of <I>H.</I><I>&nbsp;pylori</I> infection. Takeda developed vonoprazan and has received marketing approval in nine countries in Asia and Latin America. Vonoprazan generated over $500&nbsp;million in net sales in its
fourth full year on the market since its approval in Japan in late 2014. In May 2019, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the U.S., European, and Canadian rights to vonoprazan from Takeda. We plan to initiate two pivotal Phase 3
clinical trials of vonoprazan in the fourth quarter of 2019. We believe that the successful completion of our Phase 3 clinical trials, together with the existing clinical data, will support regulatory submissions in 2021 and 2022 for marketing
approval for the treatment of <I>H. pylori</I> infection and erosive esophagitis, respectively. If approved, we plan to independently commercialize vonoprazan in the United States. We also plan to seek commercial partnerships for vonoprazan in
Europe and Canada, expand development of vonoprazan across indications, dosing regimens and alternative formulations and packaging, and <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional clinical or commercial stage product
candidates for the treatment of GI diseases in a capital efficient manner. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We commenced our operations in 2018 and have devoted
substantially all of our resources to date to organizing and staffing our company, business planning, raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> our initial product candidate, vonoprazan, meeting with regulatory
authorities, preparing for our planned Phase 3 clinical trials of vonoprazan, and providing other general and administrative support for these operations. Our operations to date have been funded primarily through the issuance of convertible
promissory notes and commercial bank debt. From our inception through June&nbsp;30, 2019, we have raised aggregate gross proceeds of $90.3&nbsp;million from the issuance of convertible promissory notes and $25.0&nbsp;million of commercial bank debt.
As of June&nbsp;30, 2019, we had cash and cash equivalents of $82.9&nbsp;million. Based on our current operating plan, we believe that our existing cash and cash equivalents, together with the estimated net proceeds from this offering, will be
sufficient to meet our anticipated cash requirements through at least the next 24&nbsp;months.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not have any products approved for
sale and have incurred net losses since our inception. Our net losses for the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019 were $1.3&nbsp;million and $89.0&nbsp;million, respectively. As of June&nbsp;30, 2019, we had
an accumulated deficit of $90.3&nbsp;million. Our net losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our clinical development activities, other research and development activities and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities. We expect
our expenses and operating losses will increase substantially as we advance vonoprazan through clinical trials, seek regulatory approval for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">87 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
vonoprazan, expand our clinical, regulatory, quality, manufacturing and commercialization capabilities, incur significant commercialization expenses for marketing, sales, manufacturing and
distribution if we obtain marketing approval for vonoprazan, protect our intellectual property, expand our general and administrative support functions, including hiring additional personnel, and incur additional costs associated with operating as a
public company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have never generated any revenue and do not expect to generate any revenues from product sales unless and until we
successfully complete development and obtain regulatory approval for vonoprazan, which will not be for several years, if ever. Accordingly, until such time as we can generate significant revenue from sales of vonoprazan, if ever, we expect to
finance our cash needs through equity offerings, our existing Loan Agreement, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds
or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay,
limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Financial Operations Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our
combined financial statements include the accounts of Phathom (the receiving entity) and YamadaCo IIA prior to being merged into a single entity effective March&nbsp;13, 2019. Phathom and YamadaCo IIA were entities under common control of Frazier,
as a result of, among other things, Frazier&#146;s: (i)&nbsp;ownership of a majority of the outstanding capital stock of both companies; (ii)&nbsp;financing of both companies; (iii)&nbsp;control of the board of directors of both companies; and
(iv)&nbsp;management of both companies. Both Phathom and YamadaCo IIA were formed for the purpose of identifying potential assets around which to form an operating company. As the merged entities were under common control, the combined financial
statements report the financial position, results of operations and cash flows of Phathom and YamadaCo IIA as though the transfer of net assets and equity interests had occurred at the beginning of 2018. All intercompany accounts and transactions
have been eliminated in combination. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>License Agreement with Takeda </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7,&nbsp;2019, we and Takeda entered into the Takeda License, pursuant to which we <FONT STYLE="white-space:nowrap">in-licensed</FONT>
the U.S., European, and Canadian rights to vonoprazan. During the term of the Takeda License, we and our affiliates are not permitted to commercialize any pharmaceutical product, other than vonoprazan, that treats acid-related disorders, except for
certain generic and OTC competing products in specified circumstances. We will be responsible at our cost for the development, manufacture and commercialization of vonoprazan products. We are required to use commercially reasonable efforts to
develop and commercialize the vonoprazan products in our licensed territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the Takeda License, Takeda has the sole right and
authority, with our input, to prepare, file, prosecute, and maintain all Takeda and joint patents on a worldwide basis at its own cost. We are responsible, at our cost, for preparing, filing, prosecuting, and maintaining patents on inventions made
solely by us in connection with vonoprazan, subject to input from Takeda. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We paid Takeda upfront consideration consisting of a cash
fee of $25.0&nbsp;million, 1,084,000 shares of our common stock, a warrant to purchase 7,588,000 shares of our common stock at an exercise price of $0.00004613 per share, or the Takeda Warrant, and issued Takeda a right to receive an additional
common stock warrant, or the Takeda Warrant Right, if Takeda&#146;s fully-diluted ownership of the Company represents less than a certain specified percentage of the fully-diluted capitalization,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">88 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
including shares issuable upon conversion of outstanding convertible promissory notes, calculated immediately prior to the closing of our initial public offering. We agreed to make milestone
payments to Takeda upon achieving certain tiered aggregate annual net sales of licensed products in the United States, Europe and Canada up a total maximum milestone amount of $250.0&nbsp;million. We also agreed to make tiered royalty payments at
percentages in the very low to mid double digits on net sales of licensed products, subject to specified offsets and reductions. Royalties will be payable, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis from the first commercial sale of such
product in such country, until the latest of expiration of the licensed patents covering the applicable product, expiration of regulatory exclusivity in such country, or 15 years following first commercial sale in such country. For additional
information regarding the Takeda License, see &#147;Business&#151;Intellectual Property&#151;License Agreement with Takeda Pharmaceutical Company Limited.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Components of Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Operating Expenses </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Research and Development </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">To date, our research and development expenses have related to the development of vonoprazan. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services
to be used in research and development are capitalized until the goods or services are received. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development expenses
include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in research and development efforts;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">external research and development expenses incurred under agreements with contract research organizations, or CROs, and consultants to conduct and support our
planned clinical trials of vonoprazan; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">costs related to manufacturing vonoprazan clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of vonoprazan. We cannot determine with certainty the timing of initiation, the
duration or the completion costs of current or future clinical trials and nonclinical studies of vonoprazan or any future product candidates due to the inherently unpredictable nature of clinical and preclinical development. Clinical and preclinical
development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be
secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our future
clinical development costs may vary significantly based on factors such as:<B> </B> </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">per patient trial costs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of trials required for approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of sites included in the trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the countries in which the trials are conducted; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the length of time required to enroll eligible patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of patients that participate in the trials; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">89 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of doses evaluated in the trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">potential additional safety monitoring requested by regulatory agencies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the phase of development of the product candidate; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the efficacy and safety profile of the product candidate. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT
STYLE="white-space:nowrap">In-process</FONT> research and development expenses relate to the Takeda License, and include the $78.9&nbsp;million purchase price of the acquired research and development assets. The purchase price of the Takeda License
consisted of the following: (i) $25.0&nbsp;million in cash; (ii)&nbsp;issuance to Takeda of 1,084,000 shares of our common stock at a fair value of $5.9&nbsp;million; (iii)&nbsp;issuance of the Takeda Warrant at an initial fair value of
$47.9&nbsp;million; (iv)&nbsp;issuance of the Takeda Warrant Right, with a nominal initial fair value due to the low probability of issuance; and (v) $0.1&nbsp;million of transaction costs incurred by us. The fair value of the Takeda Warrant and
Takeda Warrant Right were determined using the methodologies described below under &#147;Change in Fair Value of Warrant Liabilities,&#148; and the fair value of the common stock was determined using the methodologies described below under
&#147;Critical Accounting Policies and Significant Judgments and Estimates&#151;Common Stock Valuations.&#148; </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>General and
Administrative </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative expenses consist of salaries and employee-related costs, including stock-based
compensation, for personnel in executive, finance and other administrative functions, legal fees relating to intellectual property and corporate matters, and professional fees for accounting and consulting services. We anticipate that our general
and administrative expenses will increase in the future to support our continued research and development activities, <FONT STYLE="white-space:nowrap">pre-commercial</FONT> preparation activities for vonoprazan and, if any future product candidate
receives marketing approval, commercialization activities. We also anticipate increased expenses related to audit, legal, regulatory, and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with
exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Interest Income </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income consists of interest on our money market fund.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Interest Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense consists of (i)&nbsp;interest on our outstanding convertible promissory notes at per annum interest rates ranging from 1.68% to
6.00% and (ii)&nbsp;interest on our outstanding commercial bank debt at a floating per annum interest rate (7.25% as of June&nbsp;30, 2019) and amortization of the commercial bank debt discount recorded in connection with the fair value of warrants
issued to the lenders, debt issuance costs incurred and the obligation to make a final payment fee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Change in Fair Value of Warrant Liabilities
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Takeda License, we issued the Takeda Warrant and Takeda Warrant Right, or together the Takeda Warrants.
In connection with our commercial bank debt, we issued the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">90 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
lenders warrants to purchase our capital stock, or the Lender Warrants. The Takeda Warrants are accounted for as liabilities as they do not meet all the conditions for equity classification due
to (i)&nbsp;insufficient authorized shares for the Takeda Warrant and (ii)&nbsp;the Takeda Warrant Right is not indexed to our own stock. The Lender Warrants are accounted for as liabilities as they contain a holder put right under which the lenders
could require us to pay cash in exchange for the warrants. We adjust the carrying value of our warrant liabilities to their estimated fair value at each reporting date, with any change in fair value of the warrant liabilities recorded as an increase
or decrease to change in fair value of warrant liabilities in the combined statements of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The fair value of the Takeda
Warrants is derived from the model used to estimate the fair value of our common stock and the fair value of the Lender Warrants is estimated using a probability-weighted model considering initial public offering and
<FONT STYLE="white-space:nowrap">non-initial</FONT> public offering scenarios. The initial public offering scenarios utilize a binomial lattice model to estimate a distribution of total equity values as of a projected initial public offering date.
The <FONT STYLE="white-space:nowrap">non-initial</FONT> public offering scenario utilizes the repurchase price associated with the warrant put right discounted to present value based on venture capital rates of return and the term associated with
the put right. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon the closing of this offering, (i)&nbsp;the Takeda Warrant will become reclassified to stockholders&#146; equity
and require a final adjustment to fair value, (ii)&nbsp;the Takeda Warrant Right (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover of this prospectus) will expire without
effect since no fair value has been allocated to it, and (iii)&nbsp;the Lender Warrants, as a result of a put option, will continue as warrant liabilities adjusted to fair value at each reporting date. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Change in Fair Value of Convertible Promissory Notes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We issued convertible promissory notes in 2018 and 2019 for which we have elected the fair value option. We adjust the carrying value of our convertible promissory notes to their estimated fair value at each
reporting date, with any change in fair value of the convertible promissory notes recorded as an increase or decrease to change in fair value of convertible promissory notes in our combined statements of operations. All outstanding convertible
promissory notes and related accrued interest will convert to shares of our common stock upon the closing of this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to
their exchange into convertible promissory notes issued in May 2019, the fair value of convertible promissory notes issued from inception through April 2019 was estimated using a scenario-based analysis that estimated the fair value of the
convertible promissory notes based on the probability-weighted present value of expected future investment returns, considering possible outcomes available to the noteholders, including conversions in subsequent equity financings, change of control
transactions, settlement and dissolution. The fair value of the convertible promissory notes issued in May 2019 is estimated using a scenario-based analysis that estimates the fair value of the convertible promissory notes based on the
probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the noteholders, including various initial public offering, settlement, equity financing, corporate transaction and
dissolution scenarios. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">91 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Comparison of the Six Months Ended June&nbsp;30, 2018 and 2019 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table
summarizes our results of operations for each of the periods indicated (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">83,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(83,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(88,499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Research and Development Expenses.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We had no research and development expenses
for the six months ended June&nbsp;30, 2018 as we had not yet identified or in-licensed a product candidate. The $3.2&nbsp;million of research and development expenses for the six months ended June&nbsp;30, 2019 consisted of $3.0&nbsp;million of
clinical development of vonoprazan and $0.2&nbsp;million of personnel-related expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development Expenses.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We had no <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development expenses for the six months ended June&nbsp;30, 2018. The $78.9&nbsp;million of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses for the six
months ended June&nbsp;30, 2019 consisted of the purchase price for the research and development assets we acquired as part of the Takeda License. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>General and Administrative Expenses.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses were $0.5&nbsp;million and $2.1&nbsp;million for the six months ended June&nbsp;30, 2018 and 2019,
respectively. The increase of $1.6&nbsp;million was due to increases of $0.6&nbsp;million in legal fees related to corporate and intellectual property matters, $0.4&nbsp;million in professional services expenses for accounting, audit, tax, valuation
and other services, $0.3&nbsp;million in personnel-related expenses, $0.2&nbsp;million of consulting services expenses, and $0.1&nbsp;million of other operating expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Other Income (Expense).</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Other expense of $8,000 for the six months ended June&nbsp;30, 2018 consisted of $4,000 of interest expense on our outstanding convertible promissory
notes and $4,000 of other expense related to the increase in fair value of those convertible promissory notes. Other expense of $4.8&nbsp;million for the six months ended June&nbsp;30, 2019 consisted of $2.4&nbsp;million of other expense related to
the increase in the fair value of our convertible promissory notes, $1.3&nbsp;million of other expense related to the increase in the fair value of warrant liabilities, $0.9&nbsp;million of interest expense on our outstanding convertible promissory
notes, $0.3&nbsp;million of interest expense on outstanding commercial bank debt, and partially offset by $0.1&nbsp;million of interest income. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">92 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of June&nbsp;30, 2019, we had cash and cash
equivalents of $82.9&nbsp;million. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Commercial Bank Debt </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;14, 2019, we entered into the Loan Agreement with SVB, as administrative and collateral agent, and lenders SVB and WestRiver. We borrowed $25.0&nbsp;million, or Term Loan A, at the inception of the Loan
Agreement and have the right to borrow an additional $25.0&nbsp;million, or Term Loan B, and which we collectively refer to as the Term Loans. Term Loan B is available through March&nbsp;31, 2020, provided that (i)&nbsp;we have received at least
$150.0&nbsp;million of net cash proceeds in connection with the issuance and sale, subsequent to April&nbsp;1, 2019, of our equity securities and subordinated debt, (ii)&nbsp;we have initiated Phase 3 clinical trials for vonoprazan, and
(iii)&nbsp;no event of default has occurred. As of June&nbsp;30, 2019, we had outstanding Term Loans of $25.0&nbsp;million and accrued interest of $0.2&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Term Loans bear interest at a floating rate of the higher of the Wall Street Journal Prime rate plus 1.75% (7.25% at June&nbsp;30, 2019) or 7.25%. The monthly payments consist of interest-only through
June&nbsp;1, 2021 or, in the event of positive data with respect to our Phase 3 clinical trials in both indications for vonoprazan sufficient to file an NDA with the FDA, through June&nbsp;1, 2022. Subsequent to the interest-only period, the Term
Loans will be payable in equal monthly installments of principal, plus accrued and unpaid interest through the maturity date of May&nbsp;1, 2024. In addition, we are obligated to pay a final payment fee of 8.25% of the original principal amount of
the Term Loans. We may elect to prepay all or a portion of the Term Loans prior to maturity, subject to a prepayment fee of up to 2.0% of the then outstanding principal balance and payment of a pro rata portion of the final payment fee. After
repayment, no Term Loan amounts may be borrowed again. The borrowings under the Loan Agreement are collateralized by substantially all of our assets, excluding intellectual property and certain other assets. We have agreed not to encumber our
intellectual property assets without SVB&#146;s prior written consent unless a security interest in the underlying intellectual property is necessary to have a security interest in the accounts and proceeds that are part of the assets securing the
Term Loans, in which case our intellectual property will automatically be included within the assets securing the Term Loans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Loan
Agreement contains certain customary affirmative and negative covenants and events of default. The affirmative covenants include, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain
financial reports, maintain insurance coverage and satisfy certain requirements regarding our operating accounts. The negative covenants include, among others, limitations on our ability to incur additional indebtedness and liens, merge with other
companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified
transactions. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by us would begin to bear interest at a rate that is 4.00% above the rate effective immediately before the event of default and may be
declared immediately due and payable by SVB, as collateral agent. As of June&nbsp;30, 2019, we were in compliance with all applicable covenants under the Loan Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In connection with the Loan Agreement, we issued the Lender Warrants, which become exercisable only if we borrow Term Loan B, and the number, class and per share exercise price of the shares subject to the warrants
is dependent on the terms of certain future equity financing transactions of the Company, including an initial public offering. The Lender Warrants expire ten years from the date of issuance, subject to earlier termination on September&nbsp;30, 2020
if we do not draw down Term Loan B </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">93 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
on or before March&nbsp;31, 2020. The Lender Warrants include a put option pursuant to which, in the event that we do not draw down Term Loan B on or before March&nbsp;31, 2020, the warrant
holders may require us to repurchase the warrants for a total aggregate repurchase price of $0.5&nbsp;million. The put right is exercisable through September&nbsp;30, 2020. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Convertible Note Financings </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From January 2018 to April 2019, we issued an aggregate of
$2.4&nbsp;million of convertible promissory notes to Frazier, or the Frazier Notes, bearing interest at per annum rates ranging from 1.68% to 2.55%. In May 2019, these notes and related accrued interest were exchanged, at their then fair value of
$2.4&nbsp;million, for the May 2019 convertible promissory notes described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, we entered into a note purchase
agreement under which we issued an aggregate of $90.3&nbsp;million of unsecured convertible promissory notes, or the May 2019 Notes, resulting in gross proceeds to us of $87.8&nbsp;million in cash and $2.4&nbsp;million related to the exchange of the
Frazier Notes. Including the conversion of the Frazier Notes, Frazier purchased $20.0&nbsp;million of the May 2019 Notes. The May 2019 Notes bear interest at a rate of 6% per annum and are subordinated to borrowings under our Loan Agreement. The May
2019 Notes become payable upon demand of the holders of at least 60% of the outstanding principal amount of the May 2019 Notes, including Frazier, on May&nbsp;7, 2020, or the Maturity Date, and become due and payable on May&nbsp;7, 2022, subject to
earlier conversion or repayment in the event we complete certain equity financings or a change of control. The note purchase agreement includes certain customary covenants and events of default. The May 2019 Notes will automatically convert into
shares of our common stock immediately prior to the completion of this offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Funding Requirements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Based on our current operating plan, we believe that our existing cash and cash equivalents, together with the estimated net proceeds from this
offering, will be sufficient to meet our anticipated cash requirements through at least the next 24&nbsp;months. In particular, we expect the net proceeds from this offering will allow us to complete our planned Phase 3 clinical trials of vonoprazan
in the treatment of erosive esophagitis and <I>H.&nbsp;pylori</I> infection. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves
risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product
candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our future capital
requirements will depend on many factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the initiation, type, number, scope, results, costs and timing of, our clinical trials of vonoprazan, and preclinical studies or clinical trials of other
potential product candidates we may choose to pursue in the future, including feedback received from regulatory authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs and timing of manufacturing for vonoprazan or any future product candidates, including commercial scale manufacturing if any product candidate is
approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs, timing and outcome of regulatory review of vonoprazan or any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls
over financial reporting; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">94 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development
personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and amount of the milestone or other payments we must make to Takeda and any future licensors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs and timing of establishing or securing sales and marketing capabilities if vonoprazan or any future product candidate is approved;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any
approved products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">patients&#146; willingness to pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for any approved products in the
absence of coverage and/or adequate reimbursement from third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">costs associated with any products or technologies that we may <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs
through equity offerings, the Loan Agreement, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt
financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we
raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may
not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or
future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves. We have prepared cash flow forecasts which indicate that based
on our expected operating losses and negative cash flows, there is substantial doubt about our ability to continue as a going concern without raising additional capital within 12 months after the date that the combined financial statements for the
year ended December&nbsp;31, 2018 and for the six months ended June&nbsp;30, 2019 are issued. Our independent registered public accounting firm also included an explanatory paragraph in its report on our combined financial statements as of and for
the year ended December&nbsp;31, 2018 indicating that there is substantial doubt about our ability to continue as a going concern. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">95 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Cash Flows </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The following table sets forth a summary of the net cash flow activity for each of the periods indicated (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year
Ended<BR>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six Months</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash provided by (used in):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(6,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(25,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">113,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net increase in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;82,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Operating Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Net cash used in operating activities was approximately $1.0&nbsp;million for the year ended December&nbsp;31, 2018, and $0.5&nbsp;million and $6.0&nbsp;million for the six months ended June&nbsp;30, 2018 and 2019,
respectively. The net cash used in operating activities for the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 was primarily due to our net loss in each period. The net cash used in operating activities for the six
months ended June&nbsp;30, 2019 was due to our net loss of $89.0&nbsp;million, adjusted for $82.7&nbsp;million of noncash charges and a $0.3&nbsp;million net change in operating assets and liabilities. Noncash charges consisted of our <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development charges of $78.9&nbsp;million related to the Takeda License, $2.4&nbsp;million related to the change in fair value of convertible promissory notes, $1.3&nbsp;million related to
the change in fair value of warrant liabilities, and $0.1&nbsp;million of amortization of debt discounts on our commercial bank debt. The net change in operating assets and liabilities related to a $1.0&nbsp;million increase in accrued interest on
our outstanding convertible promissory notes and commercial bank debt and a $0.9&nbsp;million increase in accounts payable and accrued expenses in support of the growth in our operating activities, partially offset by a $1.6&nbsp;million increase in
prepaid clinical activities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Investing Activities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash used in investing activities for the six months ended June&nbsp;30, 2019 was primarily due to the cash we paid, including transaction
costs, to acquire the Takeda License. We had no investing activities for the year ended December&nbsp;31, 2018. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Financing
Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash provided by financing activities for the year ended December&nbsp;31, 2018 and the six months ended
June&nbsp;30, 2018 was primarily due to proceeds from our issuance of convertible promissory notes. Net cash provided by financing activities for the six months ended June&nbsp;30, 2019 was $113.2&nbsp;million, due to $88.3&nbsp;million of net
proceeds from our issuance of convertible promissory notes and $24.9&nbsp;million of net proceeds from our commercial bank debt. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">96 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Contractual Obligations and Commitments </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table summarizes our contractual obligations as of June&nbsp;30, 2019 (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Payments Due by Period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Less&nbsp;than<BR>1 Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>1-3 Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>3-5 Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>More&nbsp;than<BR>5 Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, including interest and final payment fee</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">33,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">12,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">19,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes, including interest</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">95,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">95,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">129,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">97,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">12,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">19,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Our outstanding long-term debt bears interest at a variable rate. The interest amounts included herein are based on the interest rate in effect as of
June&nbsp;30, 2019. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Our outstanding convertible promissory notes become payable upon demand of the holders of at least 60% of the outstanding principal amount of the notes
on May&nbsp;7, 2020, and become due and payable on May&nbsp;7, 2022, subject to earlier conversion or repayment in the event we complete certain equity financings or a change of control. The amounts herein assume repayment on May&nbsp;7, 2020.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the Takeda License, we have milestone payment obligations that are contingent upon the achievement of specified
levels of product sales and are required to make certain royalty payments in connection with the sale of products developed under the agreement. As of June&nbsp;30, 2019, we are unable to estimate the timing or likelihood of achieving the milestones
or making future product sales and, therefore, any related payments are not included in the table above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We enter into contracts in the
normal course of business for contract research services, contract manufacturing services, professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and,
therefore, are cancelable contracts and not included in the table above. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Critical Accounting Policies and Significant Judgments and Estimates
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our combined
financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our combined financial statements requires us to make estimates and assumptions that affect
the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our combined financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our
estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While our
significant accounting policies are more fully described in Note 1 to our combined financial statements included elsewhere in this prospectus, we believe that the following accounting policies are the most critical for fully understanding and
evaluating our financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Accrued Research and Development Expenses </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As part of the process of preparing our combined financial statements, we are required to estimate our accrued expenses as of each balance sheet
date. This process involves reviewing open </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">97 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost
incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically
confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in
connection with research and development activities for which we have not yet been invoiced. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We base our expenses related to research
and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to
negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development
expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our
estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been
received rather than when the payment is made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Although we do not expect our estimates to be materially different from amounts actually
incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there
have been no material differences between our estimates of such expenses and the amounts actually incurred. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We evaluate whether acquired intangible assets are a business under applicable accounting standards. Additionally, we evaluate whether the acquired assets have a future alternative use. Intangible assets that do
not have future alternative use, such as the Takeda License, are considered acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development. When the acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Fair Value of Warrant Liabilities and Convertible Promissory Notes </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As described above, our warrant liabilities and convertible promissory notes are revalued at each reporting period with changes in the fair value of
the liabilities recorded as a component of other income (expense) in the combined statements of operations. There are significant judgments and estimates inherent in the determination of the fair value of these liabilities. If we had made different
assumptions including, among others, those related to the timing and probability of various corporate scenarios, discount rates, volatilities and exit valuations, the carrying values of our warrant liabilities and convertible promissory notes, and
our net loss and net loss per common share could have been significantly different. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stock-Based Compensation Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of
the awards (generally the vesting period) on a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">98 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
straight-line basis with forfeitures recognized as they occur. Through June&nbsp;30, 2019, our stock-based compensation expense primarily consisted of our issuance of restricted stock awards, or
RSAs, for which the fair value is determined based on the fair value of the underlying common stock. As of June&nbsp;30, 2019, the unrecognized stock-based compensation expense was $59,000, which is expected to be recognized as expense over a
weighted-average period of approximately 0.7 years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Common Stock Valuations </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to obtaining the Takeda License in May 2019 and entering into the May 2019 Notes, the fair value of our common stock was nominal because we
were not sufficiently capitalized and held no assets that could be used to generate future revenues. Subsequent to obtaining the Takeda License and entering into the May 2019 Notes, we estimated the fair value of our common stock using
methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide: <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>, or the Practice
Aid. The Practice Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. We
utilized a scenario-based analysis that estimated the fair value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, including various initial
public offering, stay private and dissolution scenarios, and applying a discount for lack of marketability. We considered various stay private scenarios using the income approach and allocated the indicated equity value to each class of equity based
on the current-value method. We also considered various initial public offering scenarios based on expected equity values in an initial public offering and allocated the indicated equity value to each class of equity on a fully-diluted basis
considering the dilutive impacts of the May 2019 Notes and the Lender Warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We considered various objective and subjective factors
to determine the fair value of our common stock, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">valuations of our common stock performed with the assistance of independent third-party valuation specialists; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our stage of development and business strategy, including the status of research and development efforts of vonoprazan, and the material risks related to our
business and industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our results of operations and financial position, including our levels of available capital resources; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the valuation of publicly-traded companies in the life sciences and biotechnology sectors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the lack of marketability of our common stock as a private company; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering or a sale of our company, given prevailing
market conditions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">trends and developments in our industry; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">external market conditions affecting the life sciences and biotechnology industry sectors. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates
include assumptions regarding our future operating performance, the time to complete an initial public offering or other liquidity event and the determination of the appropriate valuation methods. If we had made different assumptions, our net loss
and net loss per common share could have been significantly different. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the completion of this offering, the fair value of our
common stock will be based on the closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">99 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>JOBS Act </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As an emerging growth company under the JOBS Act, we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the
adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of
Section&nbsp;404(b) of Sarbanes-Oxley. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We will remain an emerging growth company until the earliest of (i)&nbsp;the last day of the
fiscal year following the fifth anniversary of the consummation of this offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in
which we are deemed to be a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Recent Accounting Pronouncements
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">See Note 1 to our combined financial statements included elsewhere in this prospectus. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">During the periods presented we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined under SEC rules. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Quantitative and Qualitative Disclosures about Market Risk </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Interest Rate Risk </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our cash and cash
equivalents consist of cash in readily available checking accounts and money market funds. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes. Our outstanding convertible promissory notes bear interest at
a fixed rate. Our long-term debt bears interest at a variable rate. A 10% increase or decrease in the interest rate on our long-term debt would not have a material effect on our financial position, results of operations or cash flows. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Effects of Inflation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Inflation
generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">100 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_11"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are a late clinical-stage
biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker, or <FONT
STYLE="white-space:nowrap">P-CAB.</FONT> <FONT STYLE="white-space:nowrap">P-CABs</FONT> are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has
demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux disease, or GERD, and in combination with antibiotics for the treatment of <I>Helicobacter pylori, </I>or <I>H. pylori,</I>
infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in nine countries in Asia and Latin America. Vonoprazan generated over $500&nbsp;million in net sales in its fourth full year on
the market since its approval in Japan in late 2014. In May 2019, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the U.S., European, and Canadian rights to vonoprazan from Takeda. We intend to initiate two pivotal Phase 3 clinical trials of
vonoprazan in the fourth quarter of 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe we can leverage Takeda&#146;s extensive clinical data, including results from 17
Phase&nbsp;3 clinical trials, to advance vonoprazan through pivotal trials in the United States and Europe. We plan to initiate two pivotal Phase 3 clinical trials in the fourth quarter of 2019 for vonoprazan: one for the treatment of erosive GERD,
also known as erosive esophagitis, and a second for the treatment of <I>H.&nbsp;pylori</I> infection. We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021. We believe that the successful completion of
our Phase 3 clinical trials, together with the existing clinical data, will support regulatory submissions in 2021 and 2022 for marketing approval for the treatment of <I>H.&nbsp;pylori </I>infection and erosive esophagitis, respectively. In August
2019, we received qualified infectious disease product, or QIDP, designation from the U.S. Food and Drug Administration, or FDA, for vonoprazan in combination with certain antibiotics for the treatment of <I>H. pylori </I>infection which provides,
among other benefits, extension of any regulatory exclusivity and potential eligibility for priority review. Vonoprazan has the potential to be the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or
Canada in over 30 years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GERD and <I>H. pylori</I> infection are two of the most common acid-related GI diseases and impact millions of
people. The prevalence of GERD is estimated to be 20% of the U.S. population and 15% of the population in the five major countries in the European Union (France, Germany, Italy, Spain and the United Kingdom, or the EU5). GERD is a disease that
develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. Approximately 30% of GERD patients have erosive esophagitis. <I>H. pylori</I> is a bacterial pathogen that infects approximately 35% of the U.S.
population and 45% of the EU5 population. As a result of the chronic inflammation induced by <I>H. pylori</I> infection, approximately 20% of infected patients will develop a range of pathologies, including dyspepsia, peptic ulcer disease, gastric
cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Over the last thirty years, the proton pump inhibitor, or PPI, class,
has been the standard of care for the treatment of acid-related GI diseases. PPIs are generally used as a single agent for the treatment of GERD and in combination with antibiotics<I> </I>for the treatment of <I>H. pylori</I> infection. The PPI
class includes drugs such as Prilosec (omeprazole), Nexium (esomeprazole), and Prevacid (lansoprazole). Prior to the introduction of generic and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> or
OTC, alternatives, annual PPI class sales reached approximately $12.5&nbsp;billion in the United States, and peak sales for individual brands were approximately $3.7&nbsp;billion for Prilosec, $3.5&nbsp;billion for Nexium, and $3.4&nbsp;billion for
Prevacid in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While PPIs are the current standard of care and have experienced significant commercial success, they
have significant limitations that result in a large unmet medical need. In GERD, PPI </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">101 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
therapy is suboptimal for many patients due to the slow onset and insufficient duration of acid control which can lead to inadequate symptom relief. Approximately 15% to 45% of GERD patients
remain inadequately treated with PPIs. In the treatment of <I>H. pylori </I>infection, the standard of care consists of a combination of a PPI and at least two oral antibiotics. However, increasing antibiotic resistance has resulted in declining
eradication rates with <FONT STYLE="white-space:nowrap">PPI-based</FONT> therapy. We believe these unmet medical needs are in part driven by limitations associated with the mechanism of action and pharmacokinetics of PPIs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">PPIs reduce gastric acid secretion by irreversibly binding to and inhibiting active proton pumps expressed on the parietal cells. PPIs require
activation by gastric acid, but they are unstable in the presence of acid. This instability, combined with the short circulating half-life of PPIs, limits their efficacy. Additionally, because proton pumps continuously switch between active and
inactive states, multiple doses of PPIs are required to inhibit enough proton pumps to achieve a clinical benefit. As a result, PPIs have a relatively slow onset of action and limited potency and duration of effect, which may result in patients
experiencing only partial relief, increasing PPI dosage, and/or cycling through multiple PPIs seeking relief. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has a
differentiated mechanism of action from PPIs. Unlike PPIs, vonoprazan: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">does not require activation by gastric acid; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">is stable in the presence of acid; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">binds with a slow dissociation rate to both active and inactive proton pumps; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">has a long plasma half-life that replenishes the drug at the site of action over the course of the day. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">These factors have enabled vonoprazan to demonstrate more rapid and potent acid suppression versus the PPI esomeprazole in human subjects two hours
after oral dosing and maintain target acid inhibition over a <FONT STYLE="white-space:nowrap">24-hour</FONT> period in a randomized, open-label, crossover clinical trial. In contrast, PPIs require three to five days to reach steady state acid
suppression and do not reliably maintain target acid inhibition over a <FONT STYLE="white-space:nowrap">24-hour</FONT> period. In addition, vonoprazan demonstrated approximately 10-to-100-fold better acid control compared to esomeprazole.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe that vonoprazan&#146;s anti-secretory profile may demonstrate clinically meaningful advantages over PPIs, such as:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">faster, more complete, and more durable healing of erosive esophagitis; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">faster, more complete, and more durable control of GERD symptoms; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">higher <I>H. pylori</I> eradication rates in combination with antibiotics compared to standard of care triple therapy and the potential for antibiotic-sparing
dual therapy; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">more flexible dosing, including dosing independent of food and time of day, and the potential for rapid symptom relief through
<FONT STYLE="white-space:nowrap">on-demand</FONT> dosing. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has demonstrated clinical advantages over PPIs
in the treatment of erosive esophagitis and <I>H.&nbsp;pylori</I> infection in completed Phase 3 clinical trials conducted in Japan and other Asian countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Erosive esophagitis.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>In two Phase 3 clinical trials<B> </B>conducted in Japan assessing vonoprazan versus the PPI lansoprazole in the healing and maintenance of healing of
erosive esophagitis, vonoprazan met its primary endpoint in demonstrating <FONT STYLE="white-space:nowrap">non-inferiority</FONT> to lansoprazole. In a post hoc analysis of the healing trial, vonoprazan demonstrated faster healing and a superior
overall healing rate compared to lansoprazole in patients with more severe erosive esophagitis. After two weeks of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">102 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
treatment, 88% of erosive esophagitis patients with more severe disease were healed after treatment with vonoprazan versus 64% with lansoprazole (p&#061;0.0008). In the maintenance of healing
trial, vonoprazan demonstrated lower recurrence rates of erosive esophagitis six months after treatment versus lansoprazole across all grades of severity of erosive esophagitis. Vonoprazan achieved a 2% recurrence rate compared to 17% for
lansoprazole (p&lt;0.0001). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>H. pylori.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>A Phase 3 clinical trial was conducted in Japan assessing
vonoprazan in combination with the antibiotics amoxicillin and clarithromycin versus lansoprazole in combination with these same antibiotics in first line treatment of <I>H. pylori </I>infection. In this trial, the vonoprazan-based regimen met its
primary endpoint in demonstrating a non-inferior eradication rate of 93% compared to 76% for lansoprazole-based regimen (p&lt;0.0001) and was also superior in a post hoc analysis of this trial (p&lt;0.0001). In patients who failed first line
therapy, vonoprazan in combination with the antibiotics metronidazole and amoxicillin demonstrated a 98% eradication rate as second line therapy. A <FONT STYLE="white-space:nowrap">p-value</FONT> is the probability that the reported result was
achieved purely by chance, such that a <FONT STYLE="white-space:nowrap">p-value</FONT> of less than or equal to 0.05 or 0.01 means that there is a 5.0% or 1.0% or less probability, respectively, that the difference between the control group and the
treatment group is purely due to chance. A <FONT STYLE="white-space:nowrap">p-value</FONT> of 0.05 or less typically represents a statistically significant result. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We have used this clinical experience to inform our planned Phase 3 clinical development program in these indications. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our company was founded as a collaboration between Takeda and Frazier Healthcare Partners. Our founders and management team have deep expertise in developing GI therapeutics, including anti-secretory agents, and
direct experience developing vonoprazan at Takeda. Our Chairman, Tadataka (Tachi) Yamada, M.D., is the former Chief Medical Officer and Chief Scientific Officer at Takeda. He is the former President of the American Gastroenterological Association
and former Chief of Gastroenterology and Internal Medicine at the University of Michigan. Our Chief Executive Officer, David Socks, is the former Chief Executive Officer of Outpost Medicine, LLC, a GI and urology focused company. Mr.&nbsp;Socks was
also President and Chief Operating Officer of Incline Therapeutics Inc. through its sale to the Medicines Company in 2013, and Senior Vice President, Corporate Development and Strategy of Cadence Pharmaceuticals, Inc. Azmi Nabulsi, M.D., M.P.H., our
Chief Operating Officer, is the former Deputy Chief Medical and Scientific Officer at Takeda. Our Head of Regulatory, Tom Harris, is the former Senior Vice President and Head of Global Regulatory at Takeda. Dr.&nbsp;Yamada, Dr.&nbsp;Nabulsi, and
Mr.&nbsp;Harris were extensively involved with the development of vonoprazan at Takeda. Our investors include Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors and BVF
Partners LP. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As part of a planned transition, we expect that Terrie Curran, a member of our board of directors, will succeed Mr.
Socks as Chief Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by Bristol-Myers Squibb Company. Ms. Curran has served as President, Global Inflammation and Immunology (I&amp;I) Franchise
and as a member of the Executive Committee at Celgene since 2017. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&amp;I Franchise and built the capabilities and recruited the teams that executed the launch of OTEZLA. Following
Ms.&nbsp;Curran&#146;s appointment as CEO, Mr.&nbsp;Socks will serve as interim Chief Financial Officer and continue to serve as a member of our board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">103 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Pipeline </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The following chart summarizes our current development programs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g74s47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our goal is to be a leader in the development and commercialization of novel treatments for GI diseases. Our strategy is initially focused on developing and commercializing vonoprazan as a potential <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">P-CAB</FONT> in the United States, Europe, and Canada for the treatment of acid-related GI diseases. Key elements of this
strategy include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Advance the clinical development of vonoprazan in erosive esophagitis and H. pylori infection and seek marketing
approval</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We believe we can leverage the existing clinical data and post-marketing experience, as well as our management team&#146;s experience with vonoprazan, to advance vonoprazan through our planned pivotal
Phase&nbsp;3 clinical trials. We plan to initiate a single pivotal Phase 3 clinical trial of vonoprazan in each of erosive esophagitis and <I>H.&nbsp;pylori</I> infection beginning in the fourth quarter of 2019. We expect to report <FONT
STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021, and if successful, file regulatory submissions for marketing approval for the treatment of <I>H. pylori </I>infection in 2021 and for erosive esophagitis in 2022. If approved
by the FDA as a new chemical entity, vonoprazan would receive a five-year period of marketing exclusivity within the United States and vonoprazan&#146;s QIDP designation would extend the U.S. marketing exclusivity for an additional five years.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Commercialize vonoprazan in the United States</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We plan to independently commercialize vonoprazan, if approved, in the
United States by building a leading specialty gastroenterology commercial infrastructure to support the adoption of vonoprazan. We believe we can successfully launch vonoprazan in the United States with a focused specialty sales force targeting high
prescribers of PPIs, particularly gastroenterologists. PPI prescribing is highly concentrated, with approximately 1.5% of U.S. PPI prescribers (approximately 12,000 total) accounting for approximately 20% of PPI prescriptions and approximately 6.0%
of U.S. PPI prescribers (approximately 50,000 total) accounting for approximately 50% of PPI prescriptions, according to IQVIA. We believe we have an opportunity to achieve significant share of voice and exposure to physicians given the scarcity of
actively marketed anti-secretory medicines. Given the limitations of PPIs and current unmet need, we believe the commercial opportunity for vonoprazan is substantial. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Seek commercial partnerships to maximize the vonoprazan opportunity outside of the United States</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We believe there is
a significant commercial opportunity for vonoprazan in Europe and Canada. To address these markets, we plan to seek one or more partners with existing commercial infrastructure and expertise in these markets. We believe this strategy will allow us
to realize the value of the market opportunity in Europe and Canada while focusing our resources on the U.S. market. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">104 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Expand the development of vonoprazan across indications, dosing regimens, and alternative formulations and packaging</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;We
plan to pursue vonoprazan lifecycle extension strategies in areas with clear unmet need, clinical rationale, and commercial justification. These strategies may include: (i)&nbsp;additional indications, including treatment of gastric ulcers and
duodenal ulcers, Barrett&#146;s esophagus, and eosinophilic esophagitis; (ii)&nbsp;flexible dosing regimens, such as <FONT STYLE="white-space:nowrap">on-demand</FONT> therapy for symptom relief of GERD; and (iii)&nbsp;alternative formulations and
packaging, such as orally disintegrating tablets and other oral dosage forms for patients with difficulty swallowing, an intravenous formulation for <FONT STYLE="white-space:nowrap">in-hospital</FONT> applications, and
<FONT STYLE="white-space:nowrap">pre-packaged</FONT> convenience packs for the treatment of <I>H. pylori </I>infection. Additionally, we believe that vonoprazan has the ideal profile for an OTC product, including the potential for <FONT
STYLE="white-space:nowrap">on-demand</FONT> symptom relief and a well-tolerated safety profile. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-license</FONT> or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases
in a capital efficient manner</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We intend to take advantage of our management team&#146;s GI expertise to opportunistically <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional innovative
therapies for diseases treated by gastroenterologists. We plan to leverage our development and planned commercial infrastructure to support multiple assets targeting GI indications. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Acid-Related GI Diseases </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Gastric acid is a digestive fluid formed in the stomach. The highly acidic environment of the stomach causes the unfolding, or denaturing, of food
proteins that are subsequently broken down by gastric enzymes. Gastric acid is secreted by the hydrogen potassium ATPase enzyme, which is known as the proton pump. Proton pumps are expressed on the channeled surfaces, or canaliculi, of parietal
cells in the stomach, which secrete acid. Proton pumps are continuously synthesized and switch between active and inactive states in response to various stimuli, such as food. When activated, proton pumps increase acid secretion. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GI diseases where treatment is related to acid control, such as GERD, peptic ulcer disease, Zollinger Ellison syndrome, and <I>H. pylori</I>
infection, are significant medical problems because of their high prevalence, chronic nature and clinical sequelae. GERD results from the effects of acid on compromised mucosal defenses in the gastrointestinal tract. The reflux of gastric acid into
the esophagus produces frequent and/or severe heartburn, indigestion, and reflux symptoms. Chronic GERD may damage esophageal tissue and progress to more severe diseases including erosive esophagitis, Barrett&#146;s esophagus, and esophageal cancer.
GERD and related diseases are associated with impaired quality of life and substantial costs to the healthcare system given their chronic nature and sequelae. In <I>H. pylori </I>infection, gastric acid limits the effectiveness of antibiotics used
to eradicate infection. Chronic <I>H. pylori </I>infection can lead to dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">105 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Prevalence </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The prevalence of GI diseases is high. Approximately 20% to 40% of Western adults report chronic heartburn or regurgitation symptoms potentially related to GERD. We estimate that there are approximately
65&nbsp;million individuals in the United States and 50&nbsp;million individuals in the EU5 with GERD. In the United States, GERD is the most common gastroenterology-related outpatient diagnosis. Additionally, approximately 35% of the U.S.
population and 45% of the EU5 population are infected with <I>H. pylori</I>. We estimate that there are approximately 115&nbsp;million individuals in the United States and 145&nbsp;million individuals in the EU5 infected with <I>H.&nbsp;pylori</I>.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Prevalence of GERD and </B><B><I>H. pylori </I></B><B>Infection </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g19t07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Treatments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Treatments of acid-related GI diseases aim to provide relief of acute symptoms, healing of damaged tissue, and prevention of long-term clinical sequelae associated with chronic acid exposure. Gastric acidity is
measured by the pH scale, a logarithmic scale where 7.0 describes a neutral state and lower levels indicate a higher level of acidity. The pH of the stomach typically ranges from 1.5 to 3.5. In patients with acid-related GI diseases, increasing
gastric pH has been shown to improve mucosal healing rates and provide more rapid symptom relief for patients. For example, the duration of time that intra-gastric acidity is greater than pH 3.0 correlates with the healing of duodenal and gastric
ulcers, and pH greater than 4.0 is correlated with the healing of erosive esophagitis. Similarly, in patients with <I>H. pylori</I> infection, a more neutral gastric pH of 5.0 to 7.6 preserves antibiotic function and is optimal for successful
eradication. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Drug-induced gastric acid suppression is a key component of the management of acid-related GI diseases. Three classes of
drugs with distinct mechanisms of action are principally used for treatment in the United States and Europe: antacids, histamine receptor antagonists, or H2RAs, and PPIs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Antacids </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Antacids, first commercially available in the 1930s, directly neutralize gastric acid
to raise intra-gastric pH and can alleviate intermittent, mild symptoms of acid-related GI diseases, such as heartburn, but they are only effective for a short duration and require frequent administrations per day. In addition, antacids do not
significantly help heal or prevent complications of acid-related diseases. Antacids include commonly-known OTC products, such as Alka-Seltzer, Pepto-Bismol, Rolaids, and TUMS. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Histamine Receptor Antagonists (H2RAs) </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">H2RAs, first commercially available in the 1970s,
decrease gastric acid secretion in order to raise gastric pH. H2RAs represented a dramatic improvement over antacids in the control of gastric acid and consequently in the management of acid-related GI diseases. H2RAs are also generally safe and
well-tolerated. Among the H2RA class were the first commercial blockbuster drugs, Pepcid (famotidine), Tagamet (cimetidine), and Zantac (ranitidine). Zantac was the world&#146;s highest-selling prescription drug
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">106 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
in the <FONT STYLE="white-space:nowrap">mid-1990s,</FONT> with global sales of $3.7&nbsp;billion and U.S. sales of $2.2&nbsp;billion. Prior to the launch of generic H2RAs and increasing
competition from PPIs, the H2RA class achieved sales of approximately $3.5&nbsp;billion in the United States. H2RAs achieved commercial success despite clinical limitations, including unreliable <FONT STYLE="white-space:nowrap">24-hour</FONT> acid
control, poor control of post-meal symptoms, and loss of efficacy over time. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Proton Pump Inhibitors (PPIs) </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">PPIs, first commercially available in 1989, offered improved acid control over H2RAs. Pharmacodynamic data demonstrated that PPIs maintain gastric
pH above target levels for a longer duration than H2RAs. A commonly used benchmark of anti-secretory activity is the percentage of time in a <FONT STYLE="white-space:nowrap">24-hour</FONT> period that gastric pH exceeds 4.0, which we refer to as
time above pH 4.0, which ranges from 40% to 71% for PPIs versus 33% for H2RAs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Given this improved pharmacodynamic profile, PPIs
demonstrated improved clinical symptom relief and healing over H2RAs. In a meta-analysis of results from 33 randomized clinical trials with over 3,000 GERD patients, a reduction in symptoms was achieved in 83% of patients taking PPIs versus 60% of
those on H2RAs. In a second meta-analysis, the eight-week healing rate in patients with erosive esophagitis was 82% for PPIs versus 52% for H2RAs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT
STYLE="font-family:ARIAL" SIZE="2">The PPI class is currently the first-line treatment of acid-related GI diseases. Prior to the introduction and adoption of generic and OTC alternatives, annual PPI class sales reached approximately
$12.5&nbsp;billion in the United States, and peak sales for individual brands were approximately $3.7&nbsp;billion for Prilosec, $3.5&nbsp;billion for Nexium, and $3.4&nbsp;billion for Prevacid. As recently as 2015, the last branded PPI, Dexilant
(dexlansoprazole), reached approximately $530&nbsp;million in sales in the United States</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> </SUP></FONT><FONT
STYLE="font-family:ARIAL" SIZE="2">despite limited differentiation from other PPIs. While Dexilant demonstrated a modest improvement in time above pH 4.0 compared to other PPIs, the approved dose did not demonstrate consistent superiority in Phase 3
trials against other PPIs on the healing of erosive esophagitis and has not been tested against PPIs in other indications. We believe that the commercial success of Dexilant highlights the value to physicians and patients of even incremental
improvements over other PPIs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>History of Pharmaceutical Agents for Control of Gastric Acid </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g79w07.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">107 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><U>PPI Limitations </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">While PPIs provide clinically meaningful symptom relief and healing for millions of patients suffering from acid-related GI diseases, they are inadequate for many patients. The suboptimal anti-secretory profile of
PPIs results in slow onset of symptom relief, breakthrough nighttime or postprandial heartburn, and treatment failure. Approximately 15% to 45% of GERD patients are inadequately treated with PPIs, experiencing persistent, troublesome symptoms, such
as heartburn and regurgitation. In approximately two thirds of symptomatic GERD patients, reflux symptoms are not adequately controlled after the first dose of a PPI, and nearly 50% of patients still suffer from symptoms three days later. Given
these limitations, more than 20% of GERD patients on PPI therapy take their PPI twice daily, which is not FDA approved, or purchase OTC heartburn treatments in addition to their prescription medicine. In a survey of approximately 1,000 GERD patients
and 1,000 physicians, approximately one third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy and 35% of physicians perceived patients as somewhat satisfied to completely dissatisfied with PPI treatment. In
addition, in July 2019 we conducted a U.S. market research study of 100 gastroenterologists and 100 primary care physicians who commonly prescribe PPIs and treat patients with GERD and <I>H. pylori</I> infection. Surveyed physicians reported that
approximately 25% of patients are not satisfied on PPIs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In patients with more severe grades of erosive esophagitis, studies with PPIs
have reported failure rates of healing of esophageal erosions exceeding 25%. Additionally, recurrence of erosions is common in healed erosive esophagitis patients receiving maintenance PPI therapy. One study reported recurrence in 15% to 23% of
patients with less severe erosive esophagitis and 24% to 41% of patients with more severe erosive esophagitis. We believe that these limitations of PPIs are in part driven by their mechanism of action and pharmacokinetics. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Mechanistic Differences Between PPIs and Vonoprazan </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>PPIs </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After oral dosing, PPIs reach
the gastric parietal cells through the bloodstream. PPIs are prodrugs that are converted to their active form in the acidic environment of the secretory canaliculus of the parietal cell but degrade quickly because their active form is unstable in
acid. For example, the half-life of omeprazole (Prilosec) is less than 10 minutes at pH 2.0. The active form of a PPI blocks acid production by covalently binding to active proton pumps that have moved to the surface of the secretory canaliculi
after activation of the parietal cell with stimuli, such as a meal. Because PPIs bind only to actively secreting pumps, it is generally recommended that they be administered 30 to 60 minutes before a meal to achieve maximal efficacy. Once covalently
bound to the proton pumps, the active PPI molecule is no longer available to bind to newly synthesized or activated proton pumps. Furthermore, given the relatively short plasma half-life of most PPIs of one to two hours, resupply of additional PPI
molecules from the bloodstream is limited, and newly activated pumps are not inhibited. Due to this profile, PPI dosing over several days is required to inhibit enough proton pumps to increase gastric pH to a clinically meaningful threshold, and
PPIs have a limited window of efficacy leading to incomplete acid suppression over the <FONT STYLE="white-space:nowrap">24-hour</FONT> dosing interval. In addition, PPIs are primarily metabolized by CYP2C19, an enzyme which has significant
interpatient metabolic variability based on genotype. As a result, PPI exposure levels in some patients may not achieve target levels, potentially reducing clinical efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has a differentiated mechanism of action from PPIs. When
vonoprazan reaches gastric parietal cells from the bloodstream, it accumulates in the secretory canaliculus where the proton pumps are present in their active state. In contrast to most PPIs, vonoprazan does not require gastric acid for activation,
is stable in the presence of gastric acid, reversibly binds to proton pumps in both </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">108 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
their inactive and active states, and remains in the secretory canaliculus where it continues to inhibit acid secretion over an extended period. Vonoprazan&#146;s prolonged effect is also
maintained through a slow dissociation rate from the proton pumps and resupply from the bloodstream due to its seven-hour half-life. These characteristics allow vonoprazan to rapidly achieve target <FONT STYLE="white-space:nowrap">24-hour</FONT>
acid suppression within two hours of a single dose, unlike PPIs that require three to five days to achieve stable acid suppression. In addition, vonoprazan is primarily metabolized by CYP3A4/5, an enzyme which has less genetic variability than
CYP2C19, and may exhibit more consistent activity than PPIs across U.S. and European populations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The mechanistic and pharmacologic
differences of PPIs and vonoprazan are summarized in the table below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g35q69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Pharmacodynamics vs. PPIs </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Vonoprazan&#146;s more rapid, potent, and durable anti-secretory effects versus the PPI esomeprazole (Nexium) were demonstrated in a randomized, open-label, crossover clinical trial comparing 20 mg of once daily,
or QD, vonoprazan to 20 mg QD of esomeprazole in 20 healthy volunteers. As shown below, vonoprazan achieved rapid and potent pH control on Day 1 relative to esomeprazole (left). Vonoprazan maintained pH approximately 1 to 2 units higher than
esomeprazole at Day 7 (right), which represents a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10-to-100-fold</FONT></FONT></FONT> reduction in acidity. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">109 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Improved Onset and Potency of pH Control of Vonoprazan vs. Esomeprazole at Day&nbsp;1 and
Day&nbsp;7 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g03h86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This improved potency and duration of pH control with vonoprazan, as measured by time above pH&nbsp;4.0, was
evident not only at Day&nbsp;1, but also at Day&nbsp;7 when esomeprazole had reached its steady-state (see table below). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Improved
Time Above pH 4.0 of Vonoprazan vs. Esomeprazole at Day 1 and Day 7 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g76g88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan for the Potential Treatment of Acid-Related GI Diseases </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Given the shortcomings of PPI therapy, we believe that there is a significant unmet medical need for a safe and effective anti-secretory agent with
rapid, potent, and durable activity. Vonoprazan was developed in markets outside of the United States by Takeda through an extensive clinical program, including 17 Phase 3 clinical trials. As of December 2018, 6,683 subjects were exposed to
vonoprazan in completed and ongoing clinical trials. In <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> Phase 3 trials versus a PPI, vonoprazan demonstrated faster onset of healing in more severe erosive
esophagitis patients, lower recurrence rates of erosions in erosive esophagitis patients across all levels of severity, and a superior eradication rate in combination with antibiotics in patients with <I>H. pylori</I> infection than <FONT
STYLE="white-space:nowrap">PPI-based</FONT> triple therapy. Vonoprazan received marketing approval in Japan in late 2014 and generated over $500&nbsp;million in net sales in its fourth full year on the market in Japan. We plan to initiate a single
pivotal Phase&nbsp;3 clinical trial of vonoprazan in each of erosive esophagitis and <I>H.&nbsp;pylori</I> infection in the fourth quarter of 2019. We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021,
and if successful, file regulatory submissions for marketing approval for the treatment of <I>H. pylori </I>infection in 2021 and for erosive esophagitis in 2022. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">110 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan in GERD </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Based on the significant unmet medical need, previous Phase 3 trial results, and commercial potential, we have prioritized the development of vonoprazan in GERD in: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the healing of erosive esophagitis and relief of heartburn; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the maintenance of healing of erosive esophagitis and relief of heartburn. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>GERD Disease Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GERD is one of the most prevalent diseases of any kind and is the
most prevalent GI disease, affecting approximately 20% of the U.S. population and approximately 15% of the European population. We estimate there are approximately 65&nbsp;million individuals with GERD in the United States and 50&nbsp;million
individuals with GERD in the EU5. GERD is a disease that develops when the reflux of acidic stomach contents into the esophagus causes troublesome symptoms and/or complications, and the term covers a spectrum of diseases, including erosive
esophagitis, <FONT STYLE="white-space:nowrap">non-erosive</FONT> reflux disease, and Barrett&#146;s esophagus. These diseases are detailed below: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Erosive esophagitis</I></B>:<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>Approximately 30% of GERD patients have erosive esophagitis, which is classified by erosions in
the gastric mucosa caused by acidic reflux of stomach contents into the esophagus. Erosive esophagitis is commonly graded by the Los Angeles classification system, which characterizes the extent of erosions in the esophagus and is graded on a scale
of increasing severity from A to D, with D being the most severe. Approximately 10% to 20% of erosive esophagitis patients have the more severe Los Angeles Class&nbsp;C or D disease. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-erosive</FONT> reflux disease (NERD)</I></B>:<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>Approximately 60% of GERD patients have
NERD, which is classified by an endoscopically normal esophagus, but abnormal gastric acid exposure in the esophagus and persistent symptoms. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Barrett&#146;s esophagus</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;Approximately 10% of GERD patients have Barrett&#146;s esophagus, which is classified by<B>
</B>endoscopic and histological evidence of metaplasia or dysplasia in the mucosal cell lining in the lower portion of the esophagus; approximately 1% of patients annually progress to esophageal cancer. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g25i85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GERD patients typically present with heartburn and reflux symptoms. Based on these symptoms, patients are
typically treated first-line with PPIs prior to a diagnostic endoscopy for specific disease classification of erosive esophagitis, NERD or Barrett&#146;s esophagus. Clinical guidelines suggest that endoscopy only be performed in patients who
continue to have symptoms despite a four- to-eight-week course of daily PPIs or have alarm symptoms, including GI bleeding, anemia, weight loss, chest pain, or difficult or painful swallowing. Our market research suggests that most patients are
treated empirically based on symptoms rather than based on endoscopic characterization of disease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">111 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>GERD Treatment Paradigm </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Approximately 80% of GERD patients are pharmacologically treated with prescription or OTC medications. PPIs are currently the most effective anti-secretory agents available in the United States and Europe for
relieving GERD symptoms and healing erosions in gastric mucosa. Our market research suggests that approximately 80% of patients who are pharmacologically treated receive PPIs, and approximately 75% of PPI use is prescription rather than OTC. The
majority of PPI use is chronic, with more than 70% of patients prescribed PPIs for daily use. According to IQVIA NDTI, there were approximately 120&nbsp;million oral PPI prescriptions written in the United States and 6.1&nbsp;billion doses
prescribed for the 12&nbsp;months ended May&nbsp;31, 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While PPIs provide clinically meaningful symptom relief and healing for
millions of patients suffering from acid-related GI diseases, they are inadequate for many patients. The suboptimal anti-secretory profile of PPIs results in slow onset of symptom relief, breakthrough nighttime or postprandial heartburn, and
treatment failure. Approximately 15% to 45% of GERD patients are inadequately treated with PPIs, experiencing persistent, troublesome symptoms, such as heartburn and regurgitation. In approximately two thirds of symptomatic GERD patients, reflux
symptoms are not adequately controlled after the first dose of a PPI, and nearly 50% of patients still suffer from symptoms three days later. Given these limitations, more than 20% of GERD patients on PPI therapy are taking their PPI twice daily,
which is not FDA approved, or purchasing OTC heartburn treatments in addition to their prescription medicine. In a survey of approximately 1,000 GERD patients and 1,000 physicians, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of
GERD patients reported persistent symptoms and were dissatisfied with PPI therapy and 35% of physicians perceived patients as somewhat satisfied to completely dissatisfied with PPI treatment. In our U.S. market research study, physicians highlighted
control of nighttime and daytime heartburn symptoms and efficacy in the healing and maintenance of healing of esophageal erosions as key unmet needs in GERD and reported that approximately 25% of patients are not satisfied on PPIs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There are few treatment options for GERD patients who are inadequately managed on PPI therapy. Our U.S. market research survey reported that 26% of
patients who are unsatisfied with therapy on a given PPI will switch to a different PPI to improve symptom control or heal esophageal erosions; however, physicians surveyed did not believe there are meaningful differences in outcomes between PPIs.
Even though safety and efficacy of twice daily dosing of PPIs has not been evaluated in large controlled clinical studies and is not included on the label for any PPIs, surveyed physicians reported that 23% of patients resort to this dosing regimen
given dissatisfaction of once daily PPIs. A limited number of patients proceed to a surgical procedure, such as Nissen fundoplication. However, this procedure results in postoperative morbidity of 5% to 20%, as well as a two- to <FONT
STYLE="white-space:nowrap">six-week</FONT> recovery period and a median hospital stay of two days. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has the potential to be
the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years. Our U.S. market research survey reported that physicians would prefer to use vonoprazan in 59% of all of their GERD patients
and believe that vonoprazan&#146;s mechanism of action and gastric pH control is meaningfully improved over PPIs, that vonoprazan could be a more effective treatment than PPIs in healing and maintenance of healing of esophageal erosions, and that
vonoprazan would improve their ability to treat GERD patients. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Clinical Data for Vonoprazan in GERD </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Four Phase 3 clinical trials have been completed comparing vonoprazan to PPIs in erosive esophagitis: a healing trial in Japan; a maintenance of
healing trial in Japan; a healing trial in Asia (China, Taiwan, and Korea); and a maintenance of healing trial in Asia. In addition to these Phase 3 trials, several published investigator-sponsored studies have compared vonoprazan to PPIs across
dosing regimens and endpoints. Results of these clinical trials are summarized below. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">112 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Healing of Erosive Esophagitis Clinical Trials in Japan and Asia </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In a Phase 3 multicenter, randomized, double-blind, parallel group trial, 409 patients in Japan with endoscopically confirmed erosive esophagitis
were randomized to receive vonoprazan 20 mg QD or lansoprazole 30 mg QD for up to eight weeks. The primary endpoint was the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of the percent of patients with healed erosive esophagitis up to Week
8, as assessed by endoscopy. <FONT STYLE="white-space:nowrap">Non-inferiority</FONT> is intended to show that the effect of a new treatment is not worse than the active control by more than a specified margin, while superiority is intended to show
that one treatment is more effective than a comparator by any margin. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design of Japan Phase 3 Clinical Trial for the Healing of
Erosive Esophagitis </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g60n53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan achieved the primary endpoint of <FONT STYLE="white-space:nowrap">non-inferiority</FONT> versus
lansoprazole on the percent of patients with healed erosive esophagitis up to Week 8 (99% vs. 96%, p&lt;0.0001). Further, a post hoc analysis demonstrated that vonoprazan was superior to lansoprazole on the percent of patients with healed erosive
esophagitis up to Week 8 (p&#061;0.0337). In the subset of 147 patients with more severe erosive esophagitis of Los Angeles Class&nbsp;C or D, vonoprazan healing was also shown to be superior (99% vs. 88%, p&#061;0.0082). We believe this result is
due to the improved acid control of vonoprazan over lansoprazole, and we believe lansoprazole is representative of the PPI class. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan further demonstrated a more rapid clinical effect versus lansoprazole with a superior healing rate at Week 2 (91% vs. 82%, p&lt;0.0001
for <FONT STYLE="white-space:nowrap">non-inferiority</FONT> and p&#061;0.0132 in a post hoc superiority analysis). The treatment effect was more pronounced in the more severe patients with Los Angeles Class&nbsp;C or D disease (88% vs. 64%,
p&#061;0.0008 for superiority). Of the seven patients who failed lansoprazole treatment and continued into the additional treatment period, six healed with four weeks of treatment of 40 mg vonoprazan QD. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">113 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Japan Phase 3 Clinical Trial in the Healing of Erosive Esophagitis </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g06o81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, in the lead-in period of the Japan Phase 3 maintenance of healing clinical trial discussed below,
patients were treated with vonoprazan 20&nbsp;mg for up to eight weeks before proceeding into treatment for the maintenance of healing of erosive esophagitis. The healing rate at Week 2 and through Week 8 during this lead-in healing period was 91%
and 99%, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In another multicenter, randomized, double-blind, parallel group Phase 3 clinical trial in China, Taiwan, Korea,
and Malaysia, 481 patients with endoscopically confirmed erosive esophagitis were randomized to receive vonoprazan 20 mg QD or lansoprazole 30 mg QD for eight weeks. Vonoprazan achieved the primary endpoint of
<FONT STYLE="white-space:nowrap">non-inferiority</FONT> versus lansoprazole on the percent of patients with healed erosive esophagitis up to Week 8, 92% and 91%, respectively (95% confidence interval of treatment difference of -3.8% to 6.1%). The
difference in healing rates of 1% between the treatment groups had a confidence interval of -3.8 to 6.1, which means that statistically there is 95% certainty that the true difference in healing rates lies within this range of values.
Non-inferiority was established in this trial as the lower bound (-3.8%) of the confidence interval was greater than the pre-established non-inferiority margin of -10%. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Maintenance of Healing of Erosive Esophagitis Clinical Trials in Japan and Asia </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In a
multicenter, randomized, double-blind, parallel-group Phase 3 clinical trial in Japan, 627 patients with erosive esophagitis were treated with vonoprazan 20 mg QD for two, four, or eight weeks. After this
<FONT STYLE="white-space:nowrap">lead-in</FONT> period, a total of 607 patients with healed erosive esophagitis, of whom 124 had Los Angeles Class&nbsp;C or D disease, were randomized to receive vonoprazan 10 mg QD, vonoprazan 20 mg QD, or
lansoprazole 15 mg QD for 24 weeks. The primary endpoint was the percent of patients with recurrence of erosive esophagitis at Week 24 as assessed by endoscopy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">114 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design of Japan Phase 3 Clinical Trial in Maintenance of Healing of Erosive Esophagitis
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g10h25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan achieved the primary endpoint of <FONT STYLE="white-space:nowrap">non-inferiority</FONT> versus
lansoprazole on the percent of patients with recurrence of erosive esophagitis during the <FONT STYLE="white-space:nowrap">24-week</FONT> maintenance period. Patients on lansoprazole had a 17% recurrence rate of erosive esophagitis after 24 weeks of
daily treatment, versus 5% for patients on vonoprazan 10 mg and 2% for patients on vonoprazan 20 mg (p&lt;0.0001 for <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of both vonoprazan doses vs. lansoprazole). Both vonoprazan doses were
superior to lansoprazole in a post hoc analysis (p&#061;0.0002 for vonoprazan 10 mg and p&lt;0.0001 for vonoprazan 20 mg). As shown below, the superiority of each dose of vonoprazan to lansoprazole was demonstrated in both Los Angeles Class&nbsp;A
and B patients, as well as the more severe Los Angeles Class&nbsp;C and D patients. We believe this result demonstrates the improved potency and durability of vonoprazan versus lansoprazole in all patients with erosive esophagitis. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Japan Phase 3 Clinical Trial in Maintenance of Healing of Erosive Esophagitis </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g12v65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A second multicenter, randomized, double-blind, parallel group Phase 3 clinical trial was conducted in China,
Taiwan, and Korea in 703 patients with healed erosive esophagitis, who were randomized to receive vonoprazan 20 mg QD, vonoprazan 10 mg QD, or lansoprazole 15 mg QD for 24 weeks. This trial has been completed, but final results are not yet
available. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">115 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Symptom Relief </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We believe the rapid pharmacodynamic effects of vonoprazan may provide complete and sustained heartburn relief more quickly compared to PPIs. A double-blind, randomized, investigator-sponsored clinical trial in 32
patients with erosive esophagitis compared the effects of vonoprazan 20&nbsp;mg and lansoprazole 30 mg on the time to achieve complete heartburn relief, defined as seven days without heartburn symptoms. Vonoprazan demonstrated a faster time to
complete heartburn relief than lansoprazole, and this complete relief was most pronounced for nighttime heartburn. The results of the trial are summarized below. We plan to evaluate a similar endpoint in our planned Phase 3 clinical trial.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Faster Onset and Higher Rate of Complete Heartburn Relief </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g17p85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">On-Demand</FONT> Dosing </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe the rapid onset of action of vonoprazan may also enable <FONT STYLE="white-space:nowrap">on-demand,</FONT> or as needed, use for the
relief of symptoms as an alternative to chronic daily treatment. In two open-label, investigator-sponsored clinical trials in Japan, one in erosive esophagitis and a second in NERD, the effectiveness of vonoprazan as an <FONT
STYLE="white-space:nowrap">on-demand</FONT> therapy was compared to that of daily PPI therapy with a number of different PPIs. In both clinical trials, patients utilized approximately 80% fewer doses of vonoprazan compared to PPIs but demonstrated
similar levels of patient satisfaction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our Erosive Esophagitis Phase 3 Program </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We plan to initiate a single Phase&nbsp;3 clinical trial of vonoprazan to assess the healing of erosive esophagitis and relief of heartburn, and the
maintenance of healing of erosive esophagitis and relief of heartburn in the fourth quarter of 2019. Our IND for vonoprazan in erosive esophagitis was accepted by the FDA in September 2019. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We plan to enroll approximately 1,000 patients with endoscopically confirmed erosive esophagitis in this clinical trial and enrich the clinical
trial for more severe patients, targeting 30% Los Angeles Class&nbsp;C or D patients. The clinical trial will have both a healing phase and a maintenance phase. As patients will be <FONT STYLE="white-space:nowrap">re-randomized</FONT> between the
healing phase and the maintenance phase, each phase will be analyzed independently and have independent primary and secondary endpoints. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">116 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Healing phase</I></B><I>:</I><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>During the healing phase, patients will be randomized 1:1 to receive either vonoprazan 20 mg QD
or lansoprazole 30 mg QD for up to eight weeks. The lansoprazole 30 mg QD dose is recommended in the FDA prescribing information for lansoprazole. The primary endpoint for this phase will be the percentage of patients with complete healing of
erosive esophagitis by Week 8 as assessed by endoscopy with a primary analysis of <FONT STYLE="white-space:nowrap">non-inferiority.</FONT> If <FONT STYLE="white-space:nowrap">non-inferiority</FONT> is demonstrated, then an analysis for superiority
will also be performed. Key secondary endpoints will include: the percentage of patients with complete healing of erosive esophagitis at Week 2; percentage of patients with Los Angeles Class&nbsp;C or D erosive esophagitis disease with complete
healing at Week 2 and Week 8; percentage of patients with onset of complete heartburn relief by Day 3 of treatment; and the percentage of <FONT STYLE="white-space:nowrap">24-hour</FONT> heartburn free days over the healing phase.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Maintenance phase</I></B><I>:&nbsp;&nbsp;&nbsp;&nbsp;</I>Patients with complete healing of erosive esophagitis at Week 2 or Week 8 in the healing phase
will be <FONT STYLE="white-space:nowrap">re-randomized</FONT> 1:1:1 into the maintenance phase. During this phase, patients will receive either vonoprazan 10 mg QD, vonoprazan 20 mg QD, or lansoprazole 15 mg QD for 24 weeks. The lansoprazole 15 mg
QD dose is recommended in the FDA prescribing information for the maintenance of healing indication. The primary endpoint for this phase will be the percent of patients who maintain complete healing after 24 weeks as assessed by endoscopy with a
primary analysis of <FONT STYLE="white-space:nowrap">non-inferiority.</FONT> If <FONT STYLE="white-space:nowrap">non-inferiority</FONT> is demonstrated, then an analysis for superiority will also be performed. Key secondary endpoints will include
the percentage of patients with Los Angeles Class&nbsp;C or D erosive esophagitis disease who maintain complete healing after 24 weeks and the percentage of <FONT STYLE="white-space:nowrap">24-hour</FONT> heartburn free days over the maintenance
phase. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our Phase 3 trial design is modeled after the successful Phase 3 clinical trials conducted in Japan and Asia
with limited differences other than combining both the healing and maintenance of erosive esophagitis into a single study. In Japan and Asia, separate clinical trials were conducted for each of these indications. We believe we can simplify patient
recruitment by conducting a single clinical trial and <FONT STYLE="white-space:nowrap">re-randomizing</FONT> patients between phases. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design for Planned Phase 3 Erosive Esophagitis Clinical Trial </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g14x63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in 2021 and, if
successful, file a regulatory submission for marketing approval in 2022. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">117 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan in Combination with Antibiotics for the Treatment of </B><B><I>H. pylori</I></B><B> Infection
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Disease Burden and Outcomes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>H. pylori</I> is a bacterial pathogen that infects approximately 35% of the U.S. population and 45% of the EU5 population. We estimate that there are approximately 115&nbsp;million individuals in the United
States and 145&nbsp;million individuals in the EU5 infected with <I>H. pylori</I>, and we believe there are approximately 2.5&nbsp;million patients treated for <I>H. pylori </I>infection in the United States each year. As a result of the chronic
inflammation induced by <I>H. pylori</I> infection, approximately 20% of infected patients develop a range of pathologies including dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. Gastric
cancer is the third most common cause of cancer-related death worldwide, and over 80% of gastric cancers are attributed to <I>H. pylori</I> infection. Globally there are more than one million new cases of gastric cancer and approximately 782,000
deaths each year. Eradication of <I>H. pylori</I> infection has been proven to reduce the incidence of gastric cancer, and the American College of Gastroenterologists, or ACG, guidelines recommend treatment for all patients diagnosed with <I>H.
pylori </I>infection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>H.</I><I></I><I>&nbsp;pylori </I>eradication rates have fallen from &gt;90% in the 1990s to current rates of
&lt;80% due to increasing antibiotic resistance. In 2017, the World Health Organization (WHO) listed <I>H. pylori</I> among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated <I>H.&nbsp;pylori</I> as a
Class&nbsp;1 carcinogen, meaning that it is a definite known cause of cancer. In 2014, the FDA added <I>H. pylori </I>to the agency&#146;s list of qualifying pathogens that have the potential to pose a serious threat to public health under the GAIN
Act. We believe that <FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> treatment regimens have the potential to restore eradication rates to greater than 90% in the United States and Europe given the clinical and post-marketing experience in
the Japanese market. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A recent study compiled real-world health insurance claims data in Japan from 2008 to 2016 for <I>H. pylori
</I>eradication. Prior to vonoprazan&#146;s approval in late 2014, the <I>H. pylori </I>eradication rate across Japan fell to below 80% as shown in the figure below. Approximately one year after vonoprazan&#146;s launch, the eradication rate
increased to greater than 85%. From January 2015 to March 2016, the eradication rate with <FONT STYLE="white-space:nowrap">PPI-containing</FONT> regimens in Japan was between 78% and 82% while the eradication rate with
<FONT STYLE="white-space:nowrap">vonoprazan-containing</FONT> regimens was 91% across all claims in this analysis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Eradication Rate
of </B><B><I>H. pylori</I></B><B> Infection in Japan Before and After Launch of Vonoprazan </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g38z28.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">118 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In Japan, <FONT STYLE="white-space:nowrap">vonoprazan-containing</FONT> regimens have become the
most common first line treatment. <FONT STYLE="white-space:nowrap">One-year</FONT> post launch, approximately 80% of all treated <I>H. pylori-</I>infected<I> </I>patients received <FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> regimens as
shown below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Current Treatment Paradigm in the United States and Europe </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The ACG treatment guidelines for <I>H. pylori</I> infection recommend using PPIs in conjunction with antibiotics to improve antibiotic efficacy against <I>H. pylori</I> infection. The use of anti-secretory agents
enhances the effect of antibiotics in two ways. First, anti-secretory agents increase gastric pH, which in turn increases the stability of the antibiotics. For example, amoxicillin and clarithromycin are chemically unstable at the low pH typically
found in the human stomach. Second, several antibiotics, including amoxicillin and clarithromycin, are most potent against <I>H.</I><I></I><I>&nbsp;pylori </I>at the time of maximum bacterial replication, which occurs at pH 6.0 to 7.0.
<I>H.</I><I></I><I>&nbsp;pylori </I>is in a dormant state at lower pH values, which reduces the effectiveness of the antibiotics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT
STYLE="font-family:ARIAL" SIZE="2">The table below shows the minimum inhibitory concentration of antibiotic required to eradicate 90% of <I>H. pylori in vitro</I>, or MIC</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">90</SUB></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"><I>. </I>As pH increases, the amount of antibiotic required for 90% eradication decreases substantially. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B></B><B><I>H. pylori</I></B><B>
MIC<FONT STYLE="font-family:ARIAL" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">90</SUB></FONT> Values as a Function of pH </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g25v11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A triple therapy regimen (PPI, clarithromycin, and either amoxicillin or metronidazole) is the most commonly
used in clinical practice for the first-line treatment of <I>H. pylori </I>infection. However, <I>H. pylori</I> eradication rates with PPI triple therapy have fallen from &gt;90% in the 1990s to current levels of &lt;80%, primarily due to increased
resistance of <I>H. pylori</I> to clarithromycin and metronidazole. A recent meta-analysis indicates that U.S. resistance rates measured from 2012 to 2016 were 20% for clarithromycin, 29% for metronidazole, and 19% for levofloxacin. These figures
represent a marked increase from 2009 to 2011 for both clarithromycin and metronidazole, for which resistance was 9% for clarithromycin, 21% for metronidazole, and 11% for levofloxacin. <I>H. pylori</I> resistance to amoxicillin remains low despite
its use in most triple therapy regimens; resistance is generally &lt;2% among isolates in the United States and Europe. There is a similar trend of increasing resistance to key antibiotics in Europe. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Given the declining eradication rates for <I>H. pylori,</I> quadruple therapy is recommended as first-line treatment in areas with known high rates
of clarithromycin or metronidazole resistance; however, our U.S. market research study reported that physicians prescribe quadruple therapy to only 17% of first-line patients. The surveyed physicians are concerned with patient adherence to treatment
and patient compliance and tolerability issues associated with dosing multiple drugs at multiple times throughout the day. Further, geographic patterns of resistance in the United States are poorly understood and treatment is largely empiric, with
susceptibility testing rarely conducted prior to first-line treatment. Our U.S. market research study reported that only 8% and 16% of physicians conduct resistance testing prior to prescribing treatment for first-line and second-line <I>H.
pylori</I> infection, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">119 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In our U.S. market research study, physicians highlighted the need for more effective and simpler
first-line treatment options. For the treatment of <I>H. pylori </I>infection, surveyed physicians highlighted the declining eradication rate and low patient compliance rate with treatment regimens as key unmet needs, and 93% of these physicians
believe that vonoprazan offers clinically meaningful benefits over PPIs. Surveyed physicians reported that they would prefer to use vonoprazan dual or triple therapy in, on average, 67% of first-line and 69% of second-line patients with <I>H. pylori
</I>infection. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Phase 3 Clinical Trial in Japan of Vonoprazan in Combination with Antibiotics to Treat H. pylori Infection </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A randomized, double-blind, multicenter Phase 3 clinical trial in <I>H. pylori-</I>positive patients was completed in Japan. Patients with <I>H.
pylori </I>infection and a history of gastric or duodenal ulcer who had not previously received <I>H. pylori </I>treatment were eligible for inclusion in the clinical trial. A total of 650&nbsp;patients were randomized to receive seven days of:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>vonoprazan triple therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;vonoprazan 20&nbsp;mg twice daily, or BID, amoxicillin 750&nbsp;mg BID, and clarithromycin
(200&nbsp;mg or 400&nbsp;mg) BID; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>lansoprazole triple therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;lansoprazole 30&nbsp;mg BID, amoxicillin 750&nbsp;mg BID, and clarithromycin (200&nbsp;mg or
400&nbsp;mg) BID. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Patients who did not achieve <I>H. pylori</I> eradication after first-line treatment received a
second-line regimen of vonoprazan 20 mg BID, amoxicillin 750 mg BID, and metronidazole 250 mg BID for seven days. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design of Japan
Phase 3 </B><B><I>H. pylori</I></B><B> Treatment Clinical Trial </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g27k60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">The primary endpoint of the clinical trial was confirmed <I>H. pylori </I>eradication
determined by </FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">13</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">C-urea</FONT> breath test, a
standard test for the diagnosis of <I>H. pylori</I>, four weeks after the completion of treatment. The primary analysis was <FONT STYLE="white-space:nowrap">non-inferiority,</FONT> and key secondary endpoints included the second line eradication
rate and eradication rate in antibiotic-resistant subgroups. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">Vonoprazan-based</FONT> triple therapy
demonstrated a <FONT STYLE="white-space:nowrap">non-inferior</FONT> eradication rate of 93% compared to 76% for <FONT STYLE="white-space:nowrap">lansoprazole-based</FONT> triple therapy (p&lt;0.0001). Post hoc analyses indicated that <FONT
STYLE="white-space:nowrap">vonoprazan-based</FONT> triple therapy was superior to <FONT STYLE="white-space:nowrap">lansoprazole-based</FONT> triple therapy (p&lt;0.0001). Patients who were not eradicated on
<FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> triple therapy or <FONT STYLE="white-space:nowrap">lansoprazole-based</FONT> triple therapy were treated with a triple therapy regimen of vonoprazan, amoxicillin, and metronidazole. In this
second-line setting, the <I>H.</I><I></I><I>&nbsp;pylori</I> eradication rate with vonoprazan triple therapy was 98%. Across </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">120 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
first- and second-line patients, the <I>H. pylori</I> eradication rate in clarithromycin resistant strains was higher with <FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> triple therapy
(82%) than with <FONT STYLE="white-space:nowrap">lansoprazole-based</FONT> triple therapy (40%) as shown below. We believe that this result is significant, as <I>H. pylori </I>antibiotic resistance testing is rare in the United States, and <I>H.
pylori </I>treatment is generally empiric. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Japan Phase 3 Clinical Trial in the Treatment of </B><B><I>H. pylori</I></B><B>
Infection </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g28q09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Other Studies of Vonoprazan in H. pylori Treatment </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A meta-analysis of 14 studies in Japan with over 14,636 patients found that the pooled eradication rates of
<FONT STYLE="white-space:nowrap">vonoprazan-containing</FONT> regimens were superior to those of <FONT STYLE="white-space:nowrap">PPI-containing</FONT> regimens in a first-line setting (85% vs. 68%, p&lt;0.00001). Subgroup analysis further indicated
the superiority of vonoprazan in patients with either clarithromycin-resistant strains (82% vs. 41%, p&lt;0.00001) or clarithromycin-susceptible strains (95% vs 90%, p&#061;0.006). A second study retrospectively confirmed that empiric <FONT
STYLE="white-space:nowrap">vonoprazan-based</FONT> triple therapy was <FONT STYLE="white-space:nowrap">non-inferior</FONT> to <FONT STYLE="white-space:nowrap">PPI-based</FONT> triple therapy based on <I>H. pylori </I>antibiotic susceptibility
testing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition to demonstrating superiority to PPIs in triple therapy regimens, vonoprazan was studied in a dual therapy regimen
with amoxicillin in two investigator-initiated clinical trials in Japan. The first trial involving 67 Japanese patients assessed vonoprazan dual therapy (vonoprazan 20 mg BID in combination with amoxicillin 500 mg three times daily, or TID, for
seven days) compared to vonoprazan triple therapy (vonoprazan 20 mg BID in combination with amoxicillin 750 mg BID and clarithromycin 200 mg BID for seven days). As shown below, vonoprazan dual therapy was similarly efficacious to vonoprazan triple
therapy (eradication rates of 94% in both treatment arms). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">121 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Vonoprazan Dual and Triple Therapy in the Treatment of </B><B><I>H.
pylori</I></B><B> Infection </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g30a16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A second clinical trial compared <FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> dual therapy to
esomeprazole or rabeprazole <FONT STYLE="white-space:nowrap">PPI-based</FONT> triple therapy. This clinical trial enrolled 81 Japanese patients including 40 first-line treatment patients and 41 second-line treatment patients who had failed standard
therapy and compared vonoprazan dual therapy and PPI triple therapy in both first- and second-line therapy. Patients assigned to vonoprazan dual therapy were treated with vonoprazan 20 mg BID in combination with amoxicillin 500 mg TID for
seven&nbsp;days. Patients assigned to PPI triple therapy were treated first-line with esomeprazole 20 mg or rabeprazole 10 mg BID, amoxicillin 750 mg BID, and clarithromycin 200 mg BID or second-line with esomeprazole 20 mg or rabeprazole 10&nbsp;mg
BID, amoxicillin 750 mg BID, and metronidazole 250 mg BID for seven days. As shown below, dual therapy with vonoprazan was efficacious in both first- and second-line therapy with eradication rates of 95% and 90%, respectively, versus 81% and 85% for
<FONT STYLE="white-space:nowrap">PPI-based</FONT> triple therapies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Vonoprazan Dual and PPI Triple Therapy in the
Treatment of </B><B><I>H. pylori</I></B><B> Infection </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g29j70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Antibiotic resistance is a significant clinical issue, and we believe that vonoprazan has the potential to
address the growing resistance to <I>H. pylori</I> by eradicating infection after first-line of treatment. Vonoprazan dual therapy has further potential for improved convenience and compliance
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">122 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
over triple or quadruple therapy regimens, and importantly, spares the use of clarithromycin, metronidazole, and levofloxacin, representing an opportunity both for effective treatment and sound
antibiotic stewardship through the avoidance of additional antibiotics to which <I>H. pylori</I> is known to acquire resistance. Less frequent use of these antibiotics, which have important roles aside from the treatment of <I>H. pylori</I>
infection, may help to limit the spread of resistance among other pathogenic bacteria within populations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our H. pylori Phase 3 Program
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We plan to initiate a Phase&nbsp;3 clinical trial of vonoprazan for the treatment of <I>H. pylori</I> infection. Our INDs for
vonoprazan in treatment of <I>H.&nbsp;pylori</I> infection were accepted by the FDA in September 2019. In August 2019, we received QIDP designation from the FDA for vonoprazan in combination with both amoxicillin and clarithromycin and in
combination with amoxicillin alone for the treatment of <I>H. pylori</I> infection. Subject to limited exceptions, QIDP designation extends any non-patent marketing exclusivity by an additional five years, and also provides potential eligibility for
priority review and fast track designation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">We plan to enroll approximately 975 patients with <I>H. pylori
</I>infection as assessed by </FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">13</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">C-urea</FONT>
breath test in this clinical trial. The clinical trial will compare vonoprazan dual therapy and vonoprazan triple therapy regimens each <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> with a standard of
care lansoprazole triple therapy regimen. Patients will be randomized in a 1:1:1 manner into the three treatment arms as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>vonoprazan dual therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;vonoprazan 20 mg BID and amoxicillin 1 g TID for 14&nbsp;days; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>vonoprazan triple therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;vonoprazan 20 mg BID, amoxicillin 1 g BID and clarithromycin 500 mg BID for 14 days; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>PPI triple therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;lansoprazole 30 mg BID, amoxicillin 1 g BID and clarithromycin 500 mg BID for 14 days.
</FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">The primary endpoint for this trial will be the percentage of patients with successful
eradication of <I>H. pylori </I>infection as assessed by </FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">13</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT
STYLE="white-space:nowrap">C-urea</FONT> breath test four weeks after completion of treatment. The primary analysis will assess the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of vonoprazan dual therapy to lansoprazole triple therapy and
vonoprazan triple therapy to lansoprazole triple therapy excluding patients who have <I>H.&nbsp;pylori</I> infection that is resistant to clarithromycin or amoxicillin. We will also conduct secondary analyses for superiority in all patients
regardless of antibiotic resistance and in patients with clarithromycin-resistant <I>H. pylori </I>infection. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our Phase 3 trial
design is modeled after the successful Phase 3 clinical trial conducted in Japan. Key differences include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Inclusion of patients with H. pylori infection and dyspeptic symptoms</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Our clinical trial will enroll patients with
active <I>H. pylori </I>infection and dyspeptic symptoms. The Japan Phase 3 trial enrolled patients with <I>H. pylori </I>infection and a history of gastric or duodenal ulcers; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Treatment duration and antibiotic doses</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Standard of care regimens in Western countries include higher doses of
antibiotics and a longer duration of treatment (typically 14 days) than in Japan (typically seven days); and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Inclusion of dual therapy arm</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Vonoprazan dual therapy has only been studied in investigator-initiated clinical
trials and not yet in a pivotal trial. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our clinical trial design conforms to standard of care treatment regimens in
the United States and Europe and follows the ACG treatment guidelines. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">123 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design for Planned Phase 3 </B><B><I>H. pylori</I></B><B> Clinical Trial </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g34u44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in 2021 and, if
successful, file a regulatory submission for marketing approval in 2021. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Pharmacokinetics and Pharmacodynamics in Japanese vs. <FONT
STYLE="white-space:nowrap">non-Japanese</FONT> Subjects </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The vonoprazan pharmacokinetic and pharmacodynamic profile is similar
between Japanese and <FONT STYLE="white-space:nowrap">non-Japanese</FONT> subjects as assessed in two randomized, double-blind, placebo-controlled Phase 1 clinical trials in healthy volunteers. Sixty Japanese subjects in the first study and 48 <FONT
STYLE="white-space:nowrap">non-Japanese</FONT> subjects in the second study, of whom 85% were Caucasian, received doses from 10 mg up to 40 mg QD for seven consecutive days. At all doses, pharmacokinetics between the two populations were similar. In
addition, the pharmacodynamics were similar between Japanese and <FONT STYLE="white-space:nowrap">non-Japanese</FONT> subjects as shown in the figure below. On Day 7, mean time above pH 4.0 for vonoprazan 20 mg QD was 83% for Japanese subjects and
85% for <FONT STYLE="white-space:nowrap">non-Japanese</FONT> subjects. Night-time <FONT STYLE="white-space:nowrap">12-hour</FONT> time above pH 4.0 was 73% for Japanese subjects and 75% for <FONT STYLE="white-space:nowrap">non-Japanese</FONT>
subjects. We believe that these results show that vonoprazan has a similar profile in Japanese and <FONT STYLE="white-space:nowrap">non-Japanese</FONT> subjects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Comparative Pharmacodynamics of Vonoprazan in Japanese and <FONT STYLE="white-space:nowrap">non-Japanese</FONT> Subjects </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g35m07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Summary of Vonoprazan Safety Data </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Safety in Clinical Studies </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December 2018, 6,683 subjects have been exposed to
vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120 mg with durations up </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">124 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
to one year. The most commonly reported adverse events, or AEs, in the clinical development program for vonoprazan, as reflected in the Japanese prescribing information published by Japan&#146;s
Pharmaceuticals and Medical Devices Agency, or PMDA, were diarrhea, constipation, nausea, elevated liver enzymes, rash, and eosinophilia. All such events had an incidence rate of less than 5.0% other than diarrhea in the treatment of <I>H.
pylori</I> which had an incidence rate of 10.6% in combination with antibiotics. No dose-related increase in treatment-emergent AEs, or TEAEs, or serious AEs was observed. The safety profile of vonoprazan and incidence of TEAEs, drug-related TEAEs,
and TEAEs leading to drug discontinuation were similar between vonoprazan and lansoprazole across studies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Certain earlier generation <FONT
STYLE="white-space:nowrap">P-CABs</FONT> previously under development by other companies may have been discontinued <FONT STYLE="white-space:nowrap">in-part</FONT> due to their hepatic safety profile. These hepatic safety concerns may be
compound-specific and not generalizable to the <FONT STYLE="white-space:nowrap">P-CAB</FONT> class. It is notable that vonoprazan is based on a pyrrole chemical structure and is chemically distinct from previously discontinued <FONT
STYLE="white-space:nowrap">P-CABs</FONT> that were based on an imidazole structure. Vonoprazan has had a similar hepatic safety profile to lansoprazole across all clinical studies conducted by Takeda, in which 1.0% of subjects treated with
vonoprazan 10 mg or 20 mg and 0.8% of subjects treated with lansoprazole 15 mg or 30 mg had ALT or AST elevations greater than three times the upper limit of normal or bilirubin elevations greater than two times the upper limit of normal.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan Post-Marketing Safety in Japan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The most recent post-marketing safety report from December 2018 includes an estimated 23&nbsp;million patients who have received vonoprazan in Japan since its launch. Based on the post-marketing experience, the
clinically significant adverse reactions section of the Japanese prescribing information for vonoprazan was updated to include skin reactions such as toxic epidermal necrolysis, Steven-Johnson syndrome, and erythema multiforme. The incidence of
these skin reactions was considered extremely rare (less than 1 in 100,000 patients) and a causal relationship to vonoprazan could not be ruled out. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Serious hepatic adverse events have also been observed among patients exposed to vonoprazan in Japan in the post-marketing setting. These cases were typically confounded by comorbidities or other concomitant
medications and believed to be idiosyncratic reactions. The incidence of these events was considered extremely rare (less than 1 in 100,000 patients). The post-marketing safety data, including the December 2018 post-marketing safety report and the
reported hepatic safety events, have been submitted to the PMDA. To date, there have been no changes to the Japan prescribing information related to hepatic safety. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Launch in Japan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan Regulatory Status </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan first received approval in Japan on December&nbsp;26, 2014 as TAKECAB<FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for the following indications: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Healing and maintenance of healing of erosive esophagitis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Adjunct to antibiotics in <I>H. pylori</I> treatment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Gastric ulcer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Duodenal ulcer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Prevention of recurrence of gastric ulcer or duodenal ulcer during <FONT STYLE="white-space:nowrap">low-dose</FONT> aspirin administration; and
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">125 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Prevention of recurrence of gastric ulcer or duodenal ulcer during nonsteroidal anti-inflammatory drug (NSAID) administration. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan was subsequently approved in Japan in February 2016 for the treatment of <I>H.&nbsp;pylori </I>in combination packs with antibiotics
(Vonosap Pack 400, Vonosap Pack 800, and Vonopion Pack), and as VOCINTI in the Philippines (October 2017), Singapore (March 2018), Thailand (July 2018), Argentina (September 2018), Peru (September 2018), South Korea (March 2019), Taiwan (March
2019), and Malaysia (May 2019). Vonoprazan is currently under review for approval by regulatory authorities in additional countries in Latin America and Asia, including China. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan Commercialization in Japan </I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan was approved in Japan in December
2014. In its fourth full year on the market vonoprazan generated $524&nbsp;million in net sales, a 20% increase over the prior year. In addition, in the quarter ended June&nbsp;30, 2019, vonoprazan generated $164.7&nbsp;million in net sales, a 28%
increase over the corresponding quarter from the prior fiscal year. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Net Sales Since Approval </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g70f21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe that the market dynamic for anti-secretory agents in Japan is similar to that in the United States.
In both countries, the anti-secretory market is largely genericized. Ahead of the vonoprazan launch in Japan, all PPIs, other than Nexium, were available as generics. As of 2017, generic drugs in Japan represent approximately 70% of the market by
volume, compared to the United&nbsp;States where generics are approximately 90% of the market by volume. Additionally, the Japanese government set a goal to increase generic use to 80% by 2020. Although vonoprazan and Dexilant are priced at a
premium to generic PPIs in Japan and the United States, respectively, both have experienced commercial success. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Commercial Opportunity
and Strategy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The market for prevention and treatment of acid-related GI diseases in the United States and Europe is large. There
were approximately 120&nbsp;million oral PPI prescriptions written in the United States and 6.1&nbsp;billion doses prescribed for the 12&nbsp;months ended May&nbsp;31, 2019. We estimate there are approximately 65&nbsp;million individuals with GERD
in the United States and 50&nbsp;million individuals with GERD in the EU5, of whom 15% to 45% are inadequately treated with PPIs. In addition, we estimate that there are approximately 115&nbsp;million individuals in the United States, of which
2.5&nbsp;million are treated each year, and 145&nbsp;million individuals in the EU5 infected with <I>H. pylori</I>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">126 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Over many decades of use, multiple drug classes and individual drugs have demonstrated the
substantial commercial opportunity for therapies treating acid-related GI diseases. H2RAs including Axid, Pepcid, Tagamet, and Zantac provided the first significant improvement in disease management over antacids and as a class reached
$3.5&nbsp;billion in annual sales. After H2RAs, PPIs emerged as the new standard of care. Prior to the introduction of generic and OTC alternatives, annual PPI class sales reached approximately $12.5&nbsp;billion in the United States, and peak sales
for individual brands were approximately $3.7&nbsp;billion for Prilosec, approximately $3.5&nbsp;billion for Nexium, and $3.4&nbsp;billion for Prevacid. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT
STYLE="font-family:ARIAL" SIZE="2">As recently as 2015, the last branded PPI, Dexilant, reached approximately $530&nbsp;million in sales in the United States</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> </SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2">despite limited differentiation from other PPIs. As of June&nbsp;30, 2019, Dexilant was priced at a significant premium to generic
PPIs on the market. Even with premium pricing, Dexilant obtained broad insurance coverage and favorable access. As of June&nbsp;30,</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">
</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2">2019, approximately 90% of commercially covered lives and 80% of Medicare covered lives had access to Dexilant. Furthermore, of those commercially covered lives, 65% had unrestricted access to
the drug without prior authorization or step edits and 35% of patients had access at the lowest branded cost tier. We believe that, if approved in our markets, vonoprazan will be the first of the next generation of anti-secretory therapies to
improve the standard of care for acid-related GI diseases by providing a safe and effective treatment option for the millions of patients in need of more potent, rapid, or durable acid suppression. Additionally, we believe the potential
differentiation of vonoprazan compared to PPIs could result in attractive market access and formulary positioning. <B></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In July
2019, we conducted a U.S. market research study which surveyed 100 gastroenterologists and 100 primary care physicians who commonly prescribe PPIs and treat patients with GERD and <I>H. pylori</I> infection. For the treatment of GERD, surveyed
physicians highlighted control of nighttime and daytime heartburn symptoms and efficacy in the healing and maintenance of healing of esophageal erosions as key unmet needs. These physicians reported that vonoprazan&#146;s mechanism of action and
gastric pH control is considered meaningfully improved over PPIs and that vonoprazan could be a more effective treatment than PPIs in healing and maintenance of healing of esophageal erosions. These physicians would prefer to use vonoprazan in, on
average, 59% of all of their GERD patients. For the treatment of <I>H. pylori</I> infection, surveyed physicians highlighted the declining eradication rate and low patient compliance rate with treatment regimens as key unmet needs, and 93% of these
physicians believe that vonoprazan offers clinically meaningful benefits over PPIs. Surveyed physicians reported that they would prefer to use vonoprazan dual or triple therapy in, on average, 67% of first-line and 69% of second-line patients with
<I>H. pylori</I> infection. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Sales and Marketing </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We do not currently have our own marketing, sales, or distribution capabilities. We plan to independently commercialize vonoprazan in the United States by building a leading specialty gastroenterology-focused
commercial infrastructure to support the adoption of vonoprazan. We believe we can successfully launch vonoprazan in the United States with a focused specialty sales force targeting high prescribers of PPIs, particularly gastroenterologists. PPI
prescribing is highly concentrated with approximately 1.5% of U.S. PPI prescribers (approximately 12,000 total) accounting for approximately 20% of PPI prescriptions and approximately 6.0% of U.S. PPI prescribers (approximately 50,000 total)
accounting for approximately 50% of PPI prescriptions, according to IQVIA. We believe we have an opportunity to achieve significant share of voice and exposure to physicians given the scarcity of actively marketed anti-secretory medicines.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To address the commercial opportunity for vonoprazan in Europe and Canada, we plan to seek one or more partners with existing
commercial infrastructure and expertise in these markets. Additional clinical trials of vonoprazan may be required to obtain regulatory approval and/or ensure access to these markets. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">127 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Additional Vonoprazan Development Opportunities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Indications </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While we are initially focused on the development of vonoprazan for the
treatment of erosive esophagitis and the treatment of <I>H. pylori </I>infection, we believe there are opportunities to expand the use of vonoprazan to other indications in our licensed territories. For example, in Japan, vonoprazan is also approved
for the treatment of gastric ulcers, treatment of duodenal ulcers, prevention of recurrence of gastric ulcer or duodenal ulcer during <FONT STYLE="white-space:nowrap">low-dose</FONT> aspirin administration, and prevention of recurrence of gastric
ulcer or duodenal ulcer during NSAID administration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition to those indications for which vonoprazan is approved in Japan, we
believe there are additional opportunities to develop vonoprazan for the treatment of GI diseases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>NERD.</I></B> We believe that
there is opportunity to broadly position vonoprazan&#146;s use in GERD with an indication in NERD, also known as symptomatic GERD, in addition to an indication in erosive esophagitis. We may develop vonoprazan in NERD with daily and/or <FONT
STYLE="white-space:nowrap">on-demand,</FONT> or <FONT STYLE="white-space:nowrap">as-needed,</FONT> dosing regimens. We believe the rapid onset of action of vonoprazan may enable <FONT STYLE="white-space:nowrap">on-demand</FONT> use for the
management of GERD-related symptoms as an alternative to chronic daily treatment with PPIs. An <FONT STYLE="white-space:nowrap">on-demand</FONT> dosing regimen may be especially attractive in NERD, as NERD patients have symptoms related to acid, but
do not have esophageal erosions which require chronic treatment for healing. In an open-label, investigator-sponsored clinical trial in Japan in NERD patients, <FONT STYLE="white-space:nowrap">on-demand</FONT> treatment with vonoprazan was compared
to daily treatment with PPIs. Patients utilized approximately 80% fewer doses of vonoprazan compared to PPIs, but demonstrated similar levels of satisfaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Takeda conducted two Phase 3 multicenter, randomized, double-blind, parallel group trials with vonoprazan in Japanese patients with endoscopically confirmed NERD. In the first clinical trial, vonoprazan
demonstrated a significant reduction in symptom severity versus placebo (p&#061;0.0139), and in the second trial, vonoprazan demonstrated a faster onset of symptom relief versus placebo (p&#061;0.0003). However, the studies did not show a
statistically significant difference in the primary endpoint of proportion of days over a 4-week period without heartburn between vonoprazan and placebo (p&#061;0.0504 and p&#061;0.0643). In the first clinical trial, Takeda enrolled patients with
symptoms including a three-week history of heartburn or regurgitation with two or more days of heartburn per week, or a three-week history of any acid-reflux symptoms of moderate or higher severity. In the second clinical trial, patients with a
three-week history of recurrent heartburn with two or more days of heartburn per week were enrolled. We believe that these results may be due to the selection of patients with a limited history of symptoms, a low threshold for frequency of symptoms
of two or more days per week, and with mostly mild to moderate symptoms rather severe symptoms. In contrast, all PPIs approved for NERD in the United States enrolled subjects with greater than six-month history of heartburn and heartburn on at least
four of the seven days immediately preceding randomization. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, in a Phase&nbsp;2 clinical trial in European patients with
NERD who were partial responders to high dose PPIs, vonoprazan did not demonstrate superiority versus esomeprazole in the primary endpoint of the percentage of heartburn free days over the four-week treatment period. We believe this result may have
been due to inclusion of patients with GI disorders unrelated to acid. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Other Indications</I></B>. Barrett&#146;s esophagus and
Zollinger Ellison syndrome are severe diseases related to acid secretion where PPIs are the current standard of care. The improved acid control of vonoprazan relative to PPIs may lead to improved results over PPIs. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Eosinophilic esophagitis is an autoimmune disease with significant unmet need. Although not approved for this indication, PPIs are prescribed for
the treatment of eosinophilic esophagitis. Vonoprazan demonstrated similar efficacy to PPIs in an investigator-sponsored clinical trial in Japan. In </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">128 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
this clinical trial, 112 patients with eosinophilic esophagitis were treated with vonoprazan, or the PPI rabeprazole or esomeprazole. Of patients treated with vonoprazan, 82% had complete relief
of symptoms compared to 70% for esomeprazole and <FONT STYLE="white-space:nowrap">76-78%</FONT> for rabeprazole. Similarly, 35% of patients treated with vonoprazan demonstrated complete remission of eosinophilic esophagitis by histology, compared to
37% for esomeprazole and <FONT STYLE="white-space:nowrap">31-38%</FONT> for rabeprazole. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Formulations and Packaging </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Orally Disintegrating Tablet</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;An orally disintegrating tablet, or ODT, formulation for vonoprazan is
currently in development by Takeda. We may conduct one or more Phase I trials to support potential approval of the ODT formulation. We believe that the ODT represents a meaningful commercial opportunity for patients with difficulty swallowing, as
estimated peak U.S. sales of the lansoprazole ODT formulation were over $450&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Intravenous
Formulation</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We are exploring the potential to develop an intravenous formulation of vonoprazan for use in acute bleeding, critically ill patients, or other <FONT STYLE="white-space:nowrap">in-hospital</FONT>
applications. Several PPIs have approved intravenous formulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Pediatric
Formulation</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We are exploring the potential to develop an oral formulation, in addition to an ODT formulation, for pediatric use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Convenience Pack for H.&nbsp;pylori</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;In Japan, vonoprazan is marketed both as a stand-alone medicine as well as in <FONT STYLE="white-space:nowrap">pre-packaged</FONT>
convenience packs with either clarithromycin and amoxicillin (Vonosap) or metronidazole and amoxicillin (Vonopion). <FONT STYLE="white-space:nowrap">Pre-packaged</FONT> products for the treatment of <I>H.&nbsp;pylori</I> infection may improve
patient adherence and treatment outcomes, and we believe there is a meaningful market opportunity for such a product. In the United States, PrevPac was formerly marketed as a <FONT STYLE="white-space:nowrap">pre-packaged</FONT> convenience pack of
lansoprazole, clarithromycin, and amoxicillin and achieved peak sales of $150&nbsp;million. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Over the Counter Use </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe that vonoprazan has the ideal profile for an OTC product, including the potential for <FONT STYLE="white-space:nowrap">on-demand</FONT>
symptom relief and a well-tolerated safety profile. The market for OTC heartburn relief is substantial, with 2018 sales of $3.2&nbsp;billion in the United States. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The biopharmaceutical industry is characterized by rapidly advancing technologies,
intense competition and strong emphasis on proprietary products. We face potential competition from many sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and government agencies and
public and private research institutions. If vonoprazan receives marketing approval in the United States, Europe or Canada, it will compete with existing therapies and new therapies that may become available in the future. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Some of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources and
significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. These same competitors may invent technology that competes with
vonoprazan. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and
retaining qualified scientific and management personnel and establishing clinical trial sites and subject recruitment for clinical trials, as well as in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">129 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our commercial opportunity could be reduced or eliminated if our competitors develop
and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their
products more rapidly than we may obtain approval for vonoprazan, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, we expect that vonoprazan, if approved, will be priced
at a premium over competitive generic products and our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">We expect that vonoprazan, if approved for the treatment of erosive esophagitis and treatment of <I>H.&nbsp;pylori</I>
infection, will primarily compete with generic PPIs marketed by multiple pharmaceutical companies in both the prescription and OTC markets. Additionally, RedHill Biopharma Ltd. is developing Talicia, a
<FONT STYLE="white-space:nowrap">co-formulated</FONT> capsule comprising generic omeprazole, amoxicillin, and rifabutin for the treatment of <I>H.&nbsp;pylori</I> infection, and filed a new drug application, or NDA, in the United States in May 2019.
Ironwood Pharmaceuticals, Inc. is developing <FONT STYLE="white-space:nowrap">IW-3718,</FONT> a bile acid sequestrant, currently in Phase&nbsp;3 clinical trials as an adjunct to PPIs for the treatment of patients with persistent GERD. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also aware of other <FONT STYLE="white-space:nowrap">P-CABs</FONT> in territories outside of the United States that, if developed and
approved in our territories, may compete with vonoprazan. Revaprazan is marketed by Yuhan Corporation in South Korea. Tegoprazan is marketed by CJ Healthcare Corp. in South Korea and is currently in Phase 3 development in Japan by RaQualia Pharma,
Inc. Daewoong Pharmaceutical Co., Ltd.&#146;s DWP14012 has been studied in Phase 2 clinical trials in South Korea, and Cinclus Pharma AG&#146;s X842 has completed a Phase 1 clinical trial in Europe. To our knowledge, none of these compounds have
demonstrated superiority to PPIs on clinical endpoints. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, we are aware of several clinical-stage PPIs in territories
outside of the United States that if developed and approved in our licensed territories may compete with vonoprazan. These include Dexa Medica&#146;s DLBS-2411, currently in Phase 3 clinical trials in Indonesia, Sihuan Pharmaceutical&#146;s
anaprazole, currently in Phase 3 clinical trials in China, Eisai&#146;s azeloprazole, currently in a Phase 2 clinical trial in Japan, and Sidem Pharma&#146;s tenatoprazole, currently in Phase 2 clinical trials in Europe and Canada. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Manufacturing </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not currently own or
operate manufacturing facilities for the production of clinical or commercial quantities of vonoprazan. Vonoprazan is a small molecule that can be manufactured using commercially available technologies. We currently rely on Takeda to supply us with
vonoprazan drug product for clinical use. We intend to enter into a commercial supply agreement with Takeda, and we are exploring additional options for commercial supply of vonoprazan from other third party contract manufacturers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to any future product candidates, we expect to continue to rely on third-party contract manufacturers to manufacture clinical supplies
and commercial quantities of any approved product. Although we rely on contract manufacturers, we have personnel with manufacturing experience to oversee our relationship with Takeda. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Intellectual property, including patents, trade secrets, trademarks and
copyrights, is important to our business. Our commercial success depends in part on our ability to obtain and maintain proprietary </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">130 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
intellectual property protection for vonoprazan, as well as for future product candidates and novel discoveries, product development technologies, and
<FONT STYLE="white-space:nowrap">know-how.</FONT> Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy
is to develop and maintain protection of our proprietary position by, among other methods, licensing or filing U.S. and foreign patents and applications relating to our technology, inventions, and improvements that are important to the development
and implementation of our business. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our patent portfolio, comprising patents and patent applications exclusively licensed to us, is
built with a goal of establishing broad protection that generally includes, for the product candidate compound, claims directed to composition of matter, pharmaceutical compositions or formulations, methods of synthesis, and methods of treatment
using such pharmaceutical compositions or formulations. As of September&nbsp;30, 2019, our patent portfolio covering vonoprazan consists solely of exclusively licensed patents and patent applications from Takeda. Subject to the terms of the license
agreement we entered into with Takeda on May&nbsp;7, 2019, or the Takeda License, we have licensed from Takeda exclusive rights in the United States, Europe, and Canada to patents and patent applications covering the composition of matter,
formulation, use and/or manufacture of vonoprazan. Our patent portfolio comprises 11 distinct patent families protecting the technology relating to the compound vonoprazan and its synthetic intermediates, methods of synthesizing vonoprazan and
related compounds, various formulations of vonoprazan products, as well as methods of treating diseases with vonoprazan and related compounds. As of September 30, 2019, our portfolio consists of approximately 17 issued U.S. patents, 6 pending U.S.
applications, 9 issued European patents subsequently validated in individual European countries, 6 pending European applications, 3 issued Canadian patents, 5 pending Canadian applications, and one pending PCT application. The issued patents and
pending applications have nominal expiration dates ranging from 2024 to 2038, without accounting for any available patent term adjustments or extensions. The issued U.S. patent covering the composition of matter of vonoprazan is expected to expire
in August 2028, not including patent term extension. The issued U.S. patent covering the formulation of vonoprazan is expected to expire in August 2030, not including patent term extension. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The term of individual patents in our portfolio depends upon the legal term of patents in the countries in which they are obtained. In most
countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United&nbsp;States, the term of a patent may
be eligible for patent term adjustment, which permits patent term restoration as compensation for delays incurred at the USPTO during the patent prosecution process. In addition, for patents that cover an
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. While
the length of the patent term extension is related to the length of time the drug is under regulatory review, patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only
one patent per approved drug may be extended under the Hatch-Waxman Act. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products
receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek any available patent term extension to any issued patents we may be granted in any jurisdiction where such extensions are
available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. The relevant
patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">131 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from
making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. We cannot
guarantee that patents will be granted with respect to any of our licensed pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us or Takeda in
the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, issued patents do not guarantee the right to practice our technology in relation to the commercialization of our
products. Issued patents only allow us to block potential competitors from practicing the claimed inventions of the issued patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, patents and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and
uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing vonoprazan and any future product candidates and practicing our proprietary technology, and any issued patents may be
challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for vonoprazan and any future product candidates. In
addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies
that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to vonoprazan and any future product candidates. Moreover, because of the extensive time required for development,
testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following
commercialization, thereby reducing the commercial advantage the patent provides. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">It is our policy to require our employees,
consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us, and for employees and consultants to enter into
invention assignment agreements with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual&#146;s relationship with us is to be kept confidential and not
disclosed to third parties except in specific circumstances. Where applicable, the agreements provide that all inventions to which the individual contributed as an inventor shall be assigned to Phathom, and as such, will become our property. There
can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, we have filed for and are pursuing trademark protection for our company name &#147;Phathom Pharmaceuticals&#148; in the United States and
foreign jurisdictions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>License Agreement with Takeda Pharmaceutical Company Limited </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7,&nbsp;2019, we and Takeda entered into the Takeda License. Pursuant to the Takeda License, Takeda granted us an exclusive,
sublicensable (with Takeda&#146;s reasonable consent) license under certain patents and know how relating to vonoprazan and owned or controlled by Takeda during the term of the Takeda License to commercialize vonoprazan products using specified
formulations for all human therapeutic uses in the United States, Europe and Canada, and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under such patents and know how to develop and manufacture such vonoprazan products anywhere in
the world (subject to Takeda&#146;s consent as to each country) for the purposes of commercializing the vonoprazan products in the United States, Europe and Canada. We granted Takeda a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">132 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
royalty-free, sublicensable license under our rights in any patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that are necessary or useful to enable Takeda to develop and manufacture
vonoprazan products anywhere in the world for the purposes of commercialization outside United States, Europe and Canada. We also granted Takeda an exclusive, royalty-free license under our rights in certain patents and <FONT
STYLE="white-space:nowrap">know-how</FONT> owned or controlled by us and necessary for the exploitation of vonoprazan products, in each case for Takeda to commercialize any vonoprazan product outside of the United States, Canada, and Europe and for
purposes other than human therapeutic use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">During the term of the Takeda License, we and our affiliates are not permitted to
commercialize any pharmaceutical product, other than vonoprazan, that treats acid-related disorders, except for certain generic and OTC competing products in specified circumstances. We will be responsible, at our cost, for the development,
manufacture and commercialization of the vonoprazan products. We are required to use commercially reasonable efforts to develop and commercialize the vonoprazan products in our licensed territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the Takeda License, Takeda has the sole right and authority, with our input, to prepare, file, prosecute, and maintain all Takeda and joint
patents on a worldwide basis at its own cost. We are responsible, at our cost, for preparing, filing, prosecuting, and maintaining patents on inventions made solely by us in connection with vonoprazan, subject to input from Takeda. We have the first
right to enforce the licensed patent rights with respect to certain infringing products in the United States, Europe and Canada. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We
paid Takeda upfront consideration consisting of a cash payment of $25.0&nbsp;million, 1,084,000 shares of common stock and a warrant to purchase 7,588,000 shares of common stock, or the Takeda Warrant. In the event that Takeda&#146;s fully-diluted
ownership, including the Takeda Warrant, represents less than a certain specified percentage of our fully-diluted capitalization, including shares issuable upon conversion of outstanding convertible promissory notes, calculated immediately prior to
the closing of this offering, we further agreed to issue an additional warrant to purchase shares of common stock such that Takeda would hold a certain specified percentage of the fully-diluted capitalization immediately before the closing of this
offering. We agreed to make milestone payments to Takeda upon achieving certain tiered aggregate annual net sales of licensed products in the United States, Europe and Canada up a total maximum milestone amount of $250.0&nbsp;million. We also agreed
to make tiered royalty payments in the low double digits to the mid-teens on net sales of licensed products, subject to specified offsets and reductions. Royalties will be payable, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis from the first commercial sale of such
product in such country, until the latest of expiration of the licensed patents covering the applicable product, expiration of regulatory exclusivity in such country, or 15 years following first commercial sale in such country. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Takeda License will continue until the expiration of the obligation to pay royalties in all countries and on all products. We may terminate the
Takeda License in its entirety without cause upon six months&#146; prior written notice. We and Takeda may terminate the Takeda License in the case of the other party&#146;s insolvency, or upon prior written notice within a specified time period for
the other party&#146;s material uncured breach. Takeda may terminate the Takeda License in its entirety if we challenge the licensed patents, or if we assist any third party in challenging such patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Takeda License, we entered into a clinical manufacturing and supply agreement with Takeda whereby Takeda provides certain
quantities of vonoprazan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Government Regulation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">133 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new
drug must be approved by the FDA through the NDA process before it may be legally marketed in the United States. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>U.S. Drug Development Process
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to
comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#146;s
refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with Good Laboratory Practice, or GLP, regulations and other
applicable regulations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice, or GCP, regulations to establish the safety and
efficacy of the proposed drug for its intended use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">submission to the FDA of an NDA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">satisfactory completion of an FDA advisory committee review, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current GMP, or
cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical
tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA
as part of the IND. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the
clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND
automatically becomes effective 30 days after receipt by the FDA, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">134 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about <FONT STYLE="white-space:nowrap">on-going</FONT> or proposed clinical
trials or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. Submission of an IND therefore may or may not
result in FDA authorization to begin a clinical trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">All clinical trials must be conducted under the supervision of one or more
qualified investigators in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. They must be conducted under protocols
detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND as well
as any subsequent protocol amendments, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An IRB at each institution participating in the clinical trial must review and approve
each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study
until completed and otherwise comply with IRB regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Human clinical trials are typically conducted in three sequential phases
that may overlap or be combined: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Phase 1</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;The product candidate is initially introduced into healthy human volunteers and tested for safety, dosage
tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may
be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. Sponsors sometimes designate their Phase 1 clinical trials as Phase 1a or Phase 1b. Phase 1b clinical trials are
typically aimed at confirming dosing, pharmacokinetics and safety in larger number of patients. Some Phase 1b studies evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Phase 2</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;This phase involves clinical trials in a limited patient population to identify possible adverse effects and safety
risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Phase 3</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient
population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval.
These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or
patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if
the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee.
Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">135 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">During the development of a new drug, sponsors are given opportunities to meet with the FDA at
certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about
the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results
and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Concurrent with
clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity,
strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its
shelf life. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and
nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings
from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <I>in vitro </I>testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious
suspected adverse reaction compared to that listed in the protocol or investigator brochure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There are also requirements governing the
reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products are required to register and disclose specified clinical
trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as
part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>NDA Review and Approval Process </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The results of product development, preclinical and other <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials, along with descriptions of the manufacturing process, analytical tests
conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user
fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to
assure and preserve the product&#146;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a
standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision after
it the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA
may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">136 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and
provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. Before
approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP
requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes
commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A
Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related
to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA or, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and
information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If a product receives regulatory
approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct
Phase 4 testing, which involves clinical trials designed to further assess a drug&#146;s safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been
commercialized. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA
must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or if problems occur following initial marketing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original
NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric
subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric
subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be
collected before the pediatric clinical trials begin. The FDA must send a <FONT STYLE="white-space:nowrap">non-compliance</FONT> letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request
for approval of a pediatric formulation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">137 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Expedited Development and Review Programs </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#146;s review and approval of new drugs and
biological products that meet certain criteria. The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for
Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Unique to a fast track product, the FDA may consider
for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the
schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any product
submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is
eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a
serious disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with
priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals. Priority review designation does not change the scientific/medical standard for
approval or the quality of evidence necessary to support approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, a product may be eligible for accelerated approval.
Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical
benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the
severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled
post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial
launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The FDA can also designate a drug as a &#147;breakthrough therapy.&#148; A sponsor may seek FDA designation of a product candidate as a
&#147;breakthrough therapy&#148; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take
actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive
communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced
review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">138 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or
more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. The designation includes all of the fast track program features, which means that the sponsor may
file sections of the NDA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA
may initiate a review. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough
therapy, the FDA will work to expedite the development and review of such drug. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Fast track designation, priority review and
breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets
the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for vonoprazan and any future product candidates as appropriate. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Post-Approval Requirements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Once an
approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in
restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are
subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject
to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an
NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any drug products manufactured or distributed by us or our partners pursuant to FDA approvals will be subject to pervasive and continuing
regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying
with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the
market and imposes requirements and restrictions on drug manufacturers, such as those related to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, the prohibition on promoting products
for uses or in patient populations that are not described in the product&#146;s approved labeling (known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;), industry-sponsored scientific and educational activities, and promotional
activities involving the internet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Discovery of previously unknown problems or the failure to comply with the applicable regulatory
requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the
product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">139 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement
of profits, or civil or criminal penalties. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Marketing Exclusivity </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a
five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not
previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated
new drug application, or ANDA, or an NDA submitted under Section&nbsp;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as
the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a
certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the innovator NDA holder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored
by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received
approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity
will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials
necessary to demonstrate safety and effectiveness. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pediatric exclusivity is another type of marketing exclusivity available in the
United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The
issuance of a written request does not require the sponsor to undertake the described clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, under the GAIN
Act, the FDA may designate a product as a &#147;qualified infectious disease product,&#148; or QIDP. In order to receive this designation, a drug must qualify as an antibacterial or antifungal drug for human use intended to treat serious or
life-threatening infections, including those caused by either (1) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens, or (2) a so-called &#147;qualifying pathogen&#148; found on a list of potentially
dangerous, drug-resistant organisms established and maintained by the FDA under the law. A sponsor must request such designation before submitting a marketing application. FDA granted QIDP designation for vonoprazan for the treatment of <I>H.
pylori</I> infection in combination with both amoxicillin and clarithromycin, and with amoxicillin alone, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The benefits of
QIDP designation include potential eligibility for priority review and fast track designation, and an extension by an additional five years of any non-patent marketing exclusivity period awarded, such as a five-year exclusivity period awarded for a
new molecular entity. This </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">140 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
extension is in addition to any pediatric exclusivity extension that may be awarded, and the extension will be awarded only to a drug first approved on or after the date of enactment. The GAIN
Act provisions prohibit the grant of an exclusivity extension where the application is a supplement to an application for which an extension is in effect or has expired, is a subsequent application for a specified change to an approved product, or
is an application for a product that does not meet the definition of QIDP based on the uses for which it is ultimately approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>U.S. Healthcare
Fraud and Abuse Laws and Compliance Requirements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition to FDA regulation of pharmaceutical products, U.S. federal and
state healthcare laws and regulations restrict business practices in the pharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and constrain the
business or financial arrangements and relationships with healthcare providers and other parties. These laws include anti-kickback and false claims laws, civil monetary penalties laws, data privacy and security laws, and physician payment
transparency laws. In addition to the federal laws summarized below, we may also be subject to similar state and local laws and regulations that may apply to business practices, including but not limited to, research, distribution, sales and
marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting
or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable
under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert
that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws prohibit, among other
things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, knowingly making, using or causing to be made or used a false record or statement material to a false or
fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to
defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the
delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific
intent to violate it in order to have committed a violation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, HIPAA, as amended by the Health Information Technology for
Economic and Clinical Health Act, and their implementing regulations, imposes certain requirements relating to the privacy, security and transmission of protected health information on HIPAA covered entities, which include certain healthcare
providers, health plans and healthcare clearinghouses, and their business associates who conduct certain activities for or on their behalf involving protected health information on their behalf. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">141 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS,
information related to payments or other transfers of value made to physicians and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by
physicians and their immediate family members. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Similar state and local laws and regulations may also restrict business practices in the
pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or
services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and
regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities;
state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Violation of any of such laws or any other
governmental regulations that apply may result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate
integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from
participation in government healthcare programs and the curtailment or restructuring of our operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>U.S. Coverage and Reimbursement
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek
regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the
Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for vonoprazan and any future product candidates can be subject to challenge, reduction or denial by
third-party payors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The process for determining whether a third-party payor will provide coverage for a product is typically separate
from the process for setting the reimbursement rate that the payor will pay for the product. In the United States, there is no uniform policy among payors for coverage or reimbursement. Decisions regarding whether to cover any of a product, the
extent of coverage and amount of reimbursement to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. Third-party payors often rely upon Medicare coverage policy and payment
limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage
determination process is often a time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately, with no assurance that coverage and adequate
reimbursement will be applied consistently or obtained in the first instance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">142 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Third-party payors are increasingly challenging the price and examining the medical necessity and
cost-effectiveness of medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could further limit sales of any product that receives approval. Third-party payors may not consider vonoprazan and any future product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate
percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in
third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>U.S. Healthcare Reform </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the United States, there has been, and continues to be,
several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of
product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Among policy makers and payors in the United States, there is significant interest in promoting changes in
healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by
major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, or the Affordable Care Act, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and
significantly affected the pharmaceutical industry. The Affordable Care Act, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid
managed care organizations; required manufacturers to participate in a coverage gap discount program, in which manufacturers must agree to offer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts
off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; imposed a
<FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or importers who sell certain &#147;branded prescription drugs&#148; to specified federal government programs, implemented a new methodology by which
rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes
Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the CMS to test innovative payment and service
delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Since its enactment, there
have been judicial and political challenges to certain aspects of the Affordable Care Act. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision repealing, effective January&nbsp;1, 2019, the
<FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act, on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
&#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the Affordable
Care Act, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the Affordable Care Act, are invalid as well. While the Texas District Court Judge, as well as the Trump Administration and CMS, have stated that
the ruling will have no immediate effect, and on December&nbsp;30, 2018 the Texas District Court Judge issued an order staying the judgment pending appeal, it is unclear how this </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">143 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act, will impact the Affordable Care Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes included aggregate
reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through
2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Moreover,
there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Further,
the Trump Administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal
healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of pharmaceutical products paid by consumers. Individual states in the United States have also become increasingly active in
implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be
included in their healthcare programs Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Foreign Regulation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In order to
market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical
trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can
commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, or EU, the approval
process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer
than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively
impact the regulatory process in others. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To market a medicinal product in the European Economic Area, or EEA (which is comprised of the
28 Member States of the EU plus Norway, Iceland and Liechtenstein), we must obtain a Marketing Authorization, or MA. There are two types of marketing authorizations: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for
Human Use of </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">144 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:ARIAL" SIZE="2">
the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan
medicinal products, advanced therapy products, and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes,
<FONT STYLE="white-space:nowrap">auto-immune</FONT> and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic,
scientific or technical innovation or which are in the interest of public health in the EU; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products
not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition
Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an
assessment of the <FONT STYLE="white-space:nowrap">risk-benefit</FONT> balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Data and marketing exclusivity </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the EEA, new products authorized for marketing, or reference
products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on
which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10&nbsp;years have elapsed from the initial
authorization of the reference product in the EU. The <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10&nbsp;years, the marketing
authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Pediatric investigation plan </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In
the EEA, marketing authorization applications for new medicinal products not authorized have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the
EMA&#146;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the
obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the
PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not
represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization is obtained in all Member States of the EU and study results are included in the product information, even when negative,
the product is eligible for six months&#146; supplementary protection certificate extension. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">145 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Clinical trials </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on
GCPs. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union,
it must appoint an entity within the European Union to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#145;no fault&#146; compensation to any
study subject injured in the clinical trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial
authorization from the competent authority, and a positive opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational
medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member
State in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to take effect in 2019, there will be a centralized application procedure where one national authority takes the lead in reviewing
the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant
competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements also apply. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Privacy and data protection laws </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are
also subject to laws and regulations in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries covering data privacy and the protection of health-related and other personal information. EU member states and other jurisdictions have adopted data
protection laws and regulations, which impose significant compliance obligations. Laws and regulations in these jurisdictions apply broadly to the collection, use, storage, disclosure, processing and security of personal information that identifies
or may be used to identify an individual, such as names, contact information, and sensitive personal data such as health data. These laws and regulations are subject to frequent revisions and differing interpretations, and have generally become more
stringent over time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of May&nbsp;25, 2018, Regulation 2016/676, known as the General Data Protection Regulation, or GDPR, replaced
the Data Protection Directive with respect to the processing of personal data in the European Union. The GDPR imposes many requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent
from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention and secondary use of information,
increased requirements pertaining to health data and pseudonymised (i.e., <FONT STYLE="white-space:nowrap">key-coded)</FONT> data and additional obligations when we contract third-party processors in connection with the processing of the personal
data. The GDPR allows EU member states to make additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of GDPR and the applicable national data protection laws of
the EU member states may result in fines of up to <FONT STYLE="font-family:SANS-SERIF" SIZE="2" COLOR="#000000">&#128;</FONT><FONT STYLE="font-family:ARIAL" SIZE="2"></FONT>20,000,000 or up to 4% of the total worldwide annual turnover of the
preceding financial year, whichever is higher, and other administrative penalties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">146 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Employees </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As of September 30, 2019, we had 16&nbsp;full-time employees, 3 of whom have a Ph.D. or M.D. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our
relationship with our employees to be good. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Legal Proceedings </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We are not currently subject to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the
outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">147 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_12"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Executive Officers and Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
following table sets forth the name, age and position of each of our executive officers and directors as of September&nbsp;30, 2019. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Executive Officers</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">David Socks</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">President, Chief Executive Officer, Treasurer, Secretary and Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Azmi Nabulsi, M.D., M.P.H.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Chief Operating Officer</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Aditya Kohli, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Chief Business Officer</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B></B><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Tadataka Yamada,
M.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Chairman</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Michael F.
Cola</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Terrie Curran</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Jonathan Edwards,
Ph.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Heidi
Kunz</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Chris
Slavinsky</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">James Topper, M.D.,
Ph.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Member of the compensation committee </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Member of the audit committee </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Member of the nominating and corporate governance committee </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Executive Officers </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>David Socks</I> is our
<FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief Executive Officer, Treasurer and Secretary, and as a member of our board of directors since January 2018, and as our President since March 2019. As part of a planned
transition, Terrie Curran, a member of our board of directors, will succeed Mr. Socks as Chief Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by Bristol-Myers Squibb Company. Following
Ms.&nbsp;Curran&#146;s appointment as CEO, Mr.&nbsp;Socks will serve as interim Chief Financial Officer and continue to serve as a member of our board of directors. Since August 2014, Mr.&nbsp;Socks has been a Venture Partner at Frazier Healthcare
Partners, or Frazier, a venture capital firm. In this capacity, he <FONT STYLE="white-space:nowrap">co-founded</FONT> Arcutis, Inc., Nexcida Therapeutics, Inc., Outpost Medicine, LLC, Passage Bio, Inc., Recida Therapeutics, Inc., and Scout Bio, Inc.
Mr.&nbsp;Socks served as Chief Executive Officer of Nexcida Therapeutics, Outpost Medicine and Scout Bio. Mr.&nbsp;Socks also serves as Executive Chairman of the board of directors of Recida Therapeutics and as a board member of Outpost Medicine.
Prior to joining Frazier, Mr.&nbsp;Socks <FONT STYLE="white-space:nowrap">co-founded</FONT> Incline Therapeutics, Inc. in 2010 and served as its President and Chief Operating Officer from 2010 until its sale to The Medicines Company in 2013. He also
<FONT STYLE="white-space:nowrap">co-founded</FONT> Cadence Pharmaceuticals, Inc. in 2004 and served as its Vice President of Business Development and then as its Senior Vice President, Corporate Development and Strategy from 2004 until 2010. From
2000 to 2004, Mr.&nbsp;Socks was a Venture Partner at Windamere Venture Partners, a venture capital firm founding and investing in early stage life science companies, where he <FONT STYLE="white-space:nowrap">co-founded</FONT> several
biopharmaceutical companies including Avera Pharmaceuticals, Inc. and Kanisa Pharmaceuticals, Inc. Previously, he worked at Neurocrine Biosciences, EFO Holdings, L.P., an investment firm, and Kaiser Associates, Inc., a strategic management
consulting firm. Mr.&nbsp;Socks holds a B.S. from Georgetown University and an M.B.A. from Stanford University. Mr.&nbsp;Socks&#146; knowledge of our business and significant experience as a biopharmaceutical executive and board member, contributed
to our board of directors&#146; conclusion that he should serve as a director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Azmi Nabulsi, M.D., M.P.H.</I> is our <FONT
STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief Operating Officer since March 2019. Dr.&nbsp;Nabulsi has been an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">entrepreneur-in-residence</FONT></FONT> at
Frazier since October 2018. Also, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">148 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
since January 2019, Dr.&nbsp;Nabulsi has served as a business and clinical advisor to Saama Technologies, Inc., a clinical data and analytics company. Previously, through October 2018,
Dr.&nbsp;Nabulsi spent fourteen years at Takeda. Dr.&nbsp;Nabulsi held a number of leadership positions at Takeda, most recently as the Deputy Chief Medical&nbsp;&amp; Scientific Officer and Head of Global Development from 2014 until October 2018.
In his roles at Takeda, Dr.&nbsp;Nabulsi oversaw global drug development for both early and late stage product candidates and led global medical, analytic and operational functions responsible for bringing new medicines in multiple therapeutic areas
to many markets. Prior to joining Takeda, Dr.&nbsp;Nabulsi held numerous positions at Abbott Laboratories, including Head of Immunology and Oncology Ventures from 1998 to 2002. Dr.&nbsp;Nabulsi has an M.D. from
<FONT STYLE="white-space:nowrap">Ain-Shams</FONT> University in Cairo and a M.P.H. from the University of Minnesota. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Aditya Kohli,
Ph.D.</I><B> </B>is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief Business Officer since March 2019. Since January 2018, Dr.&nbsp;Kohli has served as Vice President of Frazier. From September 2016 to December
2017, Dr.&nbsp;Kohli served as Senior Associate of Frazier. In this capacity, he has <FONT STYLE="white-space:nowrap">co-founded</FONT> Passage Bio, Scout Bio, and Recida Therapeutics, Inc., and also served as VP, Business Development and serves on
the board of directors of Scout Bio. Prior to joining Frazier, Dr.&nbsp;Kohli worked at McKinsey&nbsp;&amp; Company as an Engagement Manager from June 2016 until September 2016 and as an Associate from September 2014 until May 2016, where he
consulted with biopharmaceutical companies on business development, research and development, and marketing and sales strategy. Dr.&nbsp;Kohli received his Ph.D. from the UC Berkeley and UC San Francisco joint graduate program in bioengineering and
holds B.S. and M.Eng. degrees in biological engineering from the Massachusetts Institute of Technology. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Tadataka Yamada, M.D.</I> has served as Chairman of our board of directors since March 2019. Dr.&nbsp;Yamada currently serves as a Venture Partner on the Life Sciences team of Frazier. From June 2011 to June
2015, Dr.&nbsp;Yamada served as the Chief Medical and Scientific Officer and as a member of the board of directors of Takeda. Dr.&nbsp;Yamada has served since 2011 as a member of the board of directors of Agilent Technologies, a global scientific
instrument manufacturing and clinical diagnostics company listed on the New York Stock Exchange. Since June 2016, Dr.&nbsp;Yamada has served on the board of directors of CSL Limited, a biotechnology company that is publicly traded on the Australian
Securities Exchange. Dr.&nbsp;Yamada previously served as President of the Global Health Program of the Bill&nbsp;&amp; Melinda Gates Foundation from June 2006 to June 2011. From 2000 to 2006, Dr.&nbsp;Yamada was Chairman of Research and Development
and a member of the board of directors of GlaxoSmithKline Inc. and prior to that, he held research and development positions at SmithKline Beecham. Prior to joining SmithKline Beecham, Dr.&nbsp;Yamada was Chairman of the Department of Internal
Medicine at the University of Michigan Medical School and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Physician-in-Chief</FONT></FONT> of the University of Michigan Medical Center. Dr.&nbsp;Yamada serves as chair of the board
of directors at the Clinton Health Access Initiative and a member of the National Academy of Medicine. He is also a Fellow of the Imperial College of Medicine, a Master of the American College of Physicians, a Fellow of the Royal College of
Physicians, a Member of the American Academy of Arts and Sciences and a past-President of the American Gastroenterological Association and the Association of American Physicians. Dr.&nbsp;Yamada received his M.D. from New York University School of
Medicine and a B.A. in History from Stanford University. He has authored over 150 manuscripts in peer reviewed journals and is the editor of The Textbook of Gastroenterology. He has been the recipient of numerous awards including the Distinguished
Achievement Award in Gastrointestinal Physiology from the American Physiological Society, the Friedenwald Medal from the American Gastroenterological Association, and the Watanabe Prize in Translational Research from Indiana University and Eli
Lilly&nbsp;&amp; Co. Dr.&nbsp;Yamada&#146;s extensive research and experience in gastrointestinal drug development, particularly his involvement in the development of vonoprazan at Takeda, as well as his service as a director or officer of other
healthcare companies, contributed to our board of directors&#146; conclusion that he should serve as Chairman of our board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">149 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Michael F. Cola</I> has served as a member of our board of directors since September 2019.
Mr.&nbsp;Cola has served as Chief Executive Officer and President of Aevi Genomic Medicine, Inc. since September 2013. Mr.&nbsp;Cola served as President of Shire plc&#146;s Specialty Pharmaceuticals business from 2007 until April 2012. Mr.&nbsp;Cola
joined Shire in July 2005 as Executive Vice President for Global Therapeutic Business Units and Portfolio Management prior to being named President of the Specialty Pharmaceuticals business. Prior to joining Shire, Mr.&nbsp;Cola spent more than five
years at Safeguard Scientifics, where he served as President of the Life Sciences Group. As part of his role with Safeguard Scientifics, Mr.&nbsp;Cola served as Chairman and CEO of Clarient, a cancer diagnostics company, and Chairman of Laureate
Pharma, a full service contract manufacturing organization serving research based biologics companies. Prior to joining Safeguard Scientifics, Mr.&nbsp;Cola held progressively senior positions in product development and commercialization at
AstraMerck, and later with AstraZeneca. Mr.&nbsp;Cola currently serves on the board of directors of Aevi Genomic Medicine, Inc., Sage Therapeutics, Inc. and Vanda Pharmaceuticals Inc. Mr.&nbsp;Cola received his Bachelor of Arts degree in biology and
physics from Ursinus College and his Master of Science degree in biomedical science from Drexel University. Mr.&nbsp;Cola&#146;s executive experience in the biopharmaceutical industry, knowledge of our business and service as a director of other
biopharmaceutical companies contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Terrie Curran</I> has served as a member of our board of directors since August 2019. As part of a planned transition, Ms. Curran will succeed
Mr. Socks as Chief Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by Bristol-Myers Squibb Company. Ms.&nbsp;Curran has served as the President, Global Inflammation and Immunology
Franchise at Celgene and a member of the Executive Committee since April 2017. Ms.&nbsp;Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&amp;I Franchise and built the capabilities and recruited the teams that executed the
successful launch of OTEZLA, before becoming Head of Worldwide Markets. Prior to joining Celgene, she served as Senior Vice President and General Manager - Global Women&#146;s Health at Merck &amp; Co. Before joining Merck, Ms.&nbsp;Curran held a
number of Country General Manager positions at Schering-Plough and Pharmacia across Europe and Asia Pacific. She currently serves on the board of Myovant Sciences Ltd., a biotechnology company, and previously served on the board of H.&nbsp;Lundbeck
A/S, a global pharmaceutical company. Ms.&nbsp;Curran holds a Graduate Diploma of Marketing and a Bachelor of Applied Science (B.A.S.) from the University of Technology, Sydney. Ms.&nbsp;Curran&#146;s extensive 22 year biopharmaceutical industry
experience contributed to our board of directors&#146; conclusion that she should serve as a director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Jon Edwards,
Ph.D.</I> has served as a member of our board of directors since May 2019. Dr.&nbsp;Edwards is a Partner at Medicxi, a life sciences-focused investment firm. Dr.&nbsp;Edwards was part of the Medicxi co-founding team and joined the firm&#146;s
investment team as an Associate in February 2016. Prior to joining Medicxi, Dr.&nbsp;Edwards was an Associate in the investment team at Index Ventures, a venture capital firm, from September 2014 until February 2016. Dr.&nbsp;Edwards currently
serves on the board of a number of private U.S. and European biotechnology and biopharmaceutical companies, including Palladio Biosciences Inc., Xenikos B.V., UltraHuman Limited, Breakpoint Therapeutics GmbH and Sydnexis Inc. Prior to joining Index
Ventures, Dr.&nbsp;Edwards was a life sciences strategy consultant at ClearView Healthcare Partners from January 2013 until September 2014. Dr.&nbsp;Edwards received a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at
Chapel Hill and conducted postdoctoral research at the Massachusetts Institute of Technology. Dr.&nbsp;Edwards&#146; knowledge of our business and prior service as a director of multiple biopharmaceutical and biotechnology companies contributed to
our board of directors&#146; conclusion that he should serve as a director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Heidi Kunz</I> has served as a member of
our board of directors since September 2019. Ms.&nbsp;Kunz served as Executive Vice President and Chief Financial Officer of Blue Shield of California from </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">150 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
September 2003 until her retirement in December 2012. Prior to joining Blue Shield of California, she served as Executive Vice President and Chief Financial Officer of Gap, Inc. from 1999 to
January 2003. From 1995 to 1999, Ms.&nbsp;Kunz served as the Chief Financial Officer of ITT Industries, Inc. She has also held senior financial management positions at General Motors Corporation, including Vice President and Treasurer during her <FONT
STYLE="white-space:nowrap">16-year</FONT> tenure from 1979 to 1995. Ms.&nbsp;Kunz currently serves as a director of Agilent Technologies Inc., a global scientific instrument manufacturing and clinical diagnostics company and Avanos Medical, Inc., a
public medical device company, and previously served as a director of Financial Engines, Inc., an investment advisement company. Ms.&nbsp;Kunz received an MBA in Finance and Accounting from Columbia Business School and a bachelor&#146;s degree in
Russian Language from Georgetown University. Ms.&nbsp;Kunz&#146;s extensive experience as a chief financial officer and service as a director of other public companies contributed to our board of directors&#146; conclusion that she should serve as a
director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Chris Slavinsky</I> has served as a member of our board of directors since August 2019. Since December
2018, Mr.&nbsp;Slavinsky has served as Vice President, Takeda Center for External Innovation as well as Head, Gastroenterology Business Development, Externalization and Special Projects at Takeda. From June 2003 to December 2018, Chris served in a
number of capacities at Pfizer, Inc., including as Chief Counsel of several Pfizer business units starting in 2011. Mr.&nbsp;Slavinsky received a J.D. from the Washington University in St. Louis School of Law, an M.S. in biochemistry and molecular
biology from Thomas Jefferson University (Philadelphia), and a B.S. in biochemistry from the State University of New York at Stony Brook. Mr.&nbsp;Slavinsky&#146;s knowledge of our business and experience in the biopharmaceutical industry has
contributed to our board of directors&#146; conclusion that he should serve as director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>James Topper, M.D.,
Ph.D.</I> has served as a member of our board of directors since January 2018. Since 2005, Dr.&nbsp;Topper has also served as the Managing General Partner at Frazier with whom he served as a Partner from 2003 to 2005. Prior to that, from 2002 to
2003, Dr.&nbsp;Topper served as head of the Cardiovascular Research and Development Division at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Dr.&nbsp;Topper has served as a member of the board of directors of Allena
Pharmaceuticals, Inc., a biopharmaceutical company, since September 2011, Alpine lmmunosciences Inc., a biotechnology company, since June 2016, Aptinyx Inc., a biopharmaceutical company, since May 2016, and Amunix Pharmaceuticals, Inc., a
pharmaceutical company, since October 2018. In addition, from April 2014 to March 2017, Dr.&nbsp;Topper served as a member of the board of directors of Sierra Oncology, Inc. (formerly ProNai Therapeutics, Inc.), an oncology company, and since 2007,
Dr.&nbsp;Topper has served as a member of the board of directors of AnaptysBio, Inc., a biotechnology company. From March 2011 to December 2013, Dr.&nbsp;Topper served as a member of the board of directors of Portola Pharmaceuticals, Inc., a
biopharmaceutical company, and from 2004 to April 2015 as a member of the board of directors of Amicus Therapeutics, Inc., a biopharmaceutical company. Dr.&nbsp;Topper received a B.S. in Biology from the University of Michigan and an M.D. and a
Ph.D. in Biophysics from the Stanford University School of Medicine. He did his postgraduate training in internal medicine and cardiovascular disease at the Brigham and Women&#146;s Hospital in Boston and was board certified in both disciplines.
Dr.&nbsp;Topper&#146;s extensive service as a director of other biopharmaceutical companies contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Board Composition and Election of Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Director
Independence </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors currently consists of eight members. Our board of directors has determined that
Dr.&nbsp;Yamada, Mr.&nbsp;Cola, Dr.&nbsp;Edwards, Ms.&nbsp;Kunz and Dr.&nbsp;Topper are independent directors in accordance with the listing requirements of the Nasdaq Global Market, or Nasdaq. The
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">151 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the
director nor any of his or her family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no
relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of the director. In making these determinations, our board of directors reviewed and
discussed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors
or executive officers. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Classified Board of Directors </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In accordance with the terms of our amended and restated certificate of incorporation that will go into effect immediately prior to the closing of this offering, our board of directors will be divided into three
classes with staggered, three-year terms. At each annual meeting of stockholders, the directors whose terms then expire will be eligible for reelection until the third annual meeting following reelection. Effective upon the closing of this offering,
our directors will be divided among the three classes as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the Class&nbsp;I directors will be Terrie Curran and Jonathan Edwards, Ph.D., and their terms will expire at our first annual meeting of stockholders following
this offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the Class&nbsp;II directors will be Michael F. Cola, Chris Slavinsky and James Topper, M.D., Ph.D., and their terms will expire at our second annual meeting of
stockholders following this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the Class&nbsp;III directors will be Heidi Kunz, David Socks and Tadataka Yamada, M.D., and their terms will expire at our third annual meeting of stockholders
following this offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation that will go into effect immediately
prior to the closing of this offering will provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be
distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered three-year
terms may delay or prevent a change of our board of directors or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of
our outstanding voting stock then entitled to vote in an election of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Board Leadership Structure </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors is currently led by its chairman, Dr.&nbsp;Yamada. Our board of directors recognizes that it is important to determine an
optimal board leadership structure to ensure the independent oversight of management as the company continues to grow. We separate the roles of chief executive officer and chairman of the board of directors in recognition of the differences between
the two roles. The chief executive officer is responsible for setting the strategic direction for our company and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> leadership and performance of our
company, while the chairman of the board of directors provides guidance to the chief executive officer and presides over meetings of the full board of directors. We believe that this separation of responsibilities provides a balanced approach to
managing the board of directors and overseeing our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors has concluded that our current leadership structure
is appropriate at this time. However, our board of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">152 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Role of Board in Risk Oversight Process </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors has responsibility for the oversight of our risk management processes and, either as a whole or through its committees,
regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and members of senior
management to enable our board of directors to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and
reputational risk. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The audit committee reviews information regarding liquidity and operations, and oversees our management of financial
risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and
discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of our compensation policies or
programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the board of directors, corporate disclosure practices and potential conflicts of
interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board of directors is regularly informed through committee reports about such risks. Matters of significant strategic
risk are considered by our board of directors as a whole. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Board Committees and Independence </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors has established three standing committees&#151;audit, compensation and nominating and corporate governance&#151;each of which
operates under a charter that has been approved by our board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Audit Committee </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The audit committee&#146;s main function is to oversee our accounting and financial reporting processes and the audits of our financial statements.
This committee&#146;s responsibilities include, among other things: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">appointing our independent registered public accounting firm; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">evaluating the qualifications, independence and performance of our independent registered public accounting firm; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">approving the audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our critical accounting policies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">discussing with management and the independent registered public accounting firm the results of our annual audit and the review of our quarterly unaudited
combined financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to
financial statements or accounting matters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our board of directors any changes to such investment policy;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">153 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing with management and our auditors any earnings announcements and other public announcements regarding our results of operations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">preparing the report that the SEC requires in our annual proxy statement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of conduct and ethics; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing and evaluating, at least annually, the performance of the audit committee and its members including compliance of the audit committee with its charter.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The members of our audit committee are Ms.&nbsp;Kunz, Mr.&nbsp;Cola and Mr.&nbsp;Slavinsky. Ms.&nbsp;Kunz serves as
the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has determined that Ms.&nbsp;Kunz is an
&#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq listing standards. Our board of directors has determined each of Ms.&nbsp;Kunz and
Mr.&nbsp;Cola is independent under the applicable rules of the SEC and Nasdaq. Under the applicable Nasdaq rules, we are permitted to phase in our compliance with the independent audit committee requirements of Nasdaq on the same schedule as we are
permitted to phase in our compliance with the independent audit committee requirements pursuant to Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, which requires all members to be independent within one year of listing. We
will comply with the <FONT STYLE="white-space:nowrap">phase-in</FONT> requirements of the Nasdaq rules and within one year of our listing on Nasdaq, all members of our audit committee will be independent under Nasdaq rules and Rule <FONT
STYLE="white-space:nowrap">10A-3.</FONT> Upon the listing of our common stock on Nasdaq, the audit committee will operate under a written charter that satisfies the applicable standards of the SEC and Nasdaq. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Compensation Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our
compensation committee approves policies relating to compensation and benefits of our officers and employees. The compensation committee approves corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other
executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of these officers based on such evaluations. The compensation committee also approves the issuance of stock options
and other awards under our equity plans. The compensation committee will review and evaluate, at least annually, the performance of the compensation committee and its members, including compliance by the compensation committee with its charter.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The members of our compensation committee are Mr.&nbsp;Cola, Dr.&nbsp;Edwards, Dr.&nbsp;Topper and Dr.&nbsp;Yamada. Mr.&nbsp;Cola
serves as the chairperson of the committee. Our board of directors has determined that each member of this committee is independent under the applicable Nasdaq listing standards, is a &#147;non-employee director&#148; as defined in Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. Upon the listing of our common stock on Nasdaq, the compensation committee will operate under a written charter, which the compensation committee will review and evaluate at
least annually. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Nominating and Corporate Governance Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The nominating and corporate governance committee is responsible for assisting our board of directors in discharging the board of directors&#146; responsibilities regarding the identification of qualified
candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of stockholders at which directors are to be elected), and the selection of candidates to fill any
vacancies on our board of directors and any committees thereof. In addition, the nominating and corporate governance committee is responsible for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">154 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
overseeing our corporate governance policies, reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of
directors. The members of our nominating and corporate governance committee are Dr.&nbsp;Edwards, Dr.&nbsp;Topper and Dr.&nbsp;Yamada. Dr.&nbsp;Edwards serves as the chairperson of the committee. Our board of directors has determined that each
member of this committee is independent under the applicable Nasdaq listing standards. Upon the listing of our common stock on Nasdaq, the nominating and corporate governance committee will operate under a written charter, which the nominating and
corporate governance committee will review and evaluate at least annually. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Compensation Committee Interlocks and Insider Participation
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">None of the members of our compensation committee has ever been one of our officers or employees. None of our executive officers
currently serves, or has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Board Diversity </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon the closing of this
offering, our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and
its individual members. In evaluating the suitability of individual candidates (both new candidates and current members) for election or appointment, the nominating and corporate governance committee and the board of directors will take into account
many factors, including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">personal and professional integrity, ethics and values; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">experience in corporate management, such as serving as an officer or former officer of a publicly-held company; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">experience as a board member or executive officer of another publicly-held company; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">strong finance experience; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">experience relevant to our business industry and with relevant social policy concerns; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">relevant academic expertise or other proficiency in an area of our business operations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Currently, our board of directors evaluates, and following the closing of this offering will evaluate, each individual in the context of the board
of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">155 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Code of Conduct and Ethics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We have adopted a written code of conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions, which will be effective upon the closing of this offering. Upon the closing of this offering, our code of conduct and ethics will be available under the Corporate Governance section of our website
at www.phathompharma.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code. The reference to our
website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">156 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This section discusses the material components of the executive compensation program for our named executive officer who is named in the
&#147;Summary Compensation Table&#148; below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For 2018, our only &#147;named executive officer&#148; was David Socks, our President,
Chief Executive Officer, Treasurer and Secretary, and member of our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This discussion may contain forward-looking
statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the closing of this offering may differ materially from the
currently planned programs summarized in this discussion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are an &#147;emerging growth company,&#148; as that term is used in the
JOBS Act, and have elected to comply with the reduced compensation disclosure requirements available to emerging growth companies under the JOBS Act. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following
table presents summary information regarding the total compensation that was awarded to, earned by or paid to our named executive officer for services rendered during the year ended December&nbsp;31, 2018. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Salary<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Bonus<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Stock<BR>Awards<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>All
Other<BR>Compensation<BR>($)<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>David Socks<BR>President, Chief Executive Officer, Treasurer, Secretary and Director</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">153,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">16,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">170,145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Represents benefit costs paid on behalf of Mr.&nbsp;Socks by our company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Narrative Disclosure to Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Annual Base Salary </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The compensation of our executive officers is generally determined and approved at the time of their commencement of employment by our board of
directors or the compensation committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The annual base salary for Mr.&nbsp;Socks for his service as our Chief Executive Officer was
$160,000 for 2018. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Takeda License and Mr.&nbsp;Socks&#146; increased responsibilities as our President and Chief
Executive Officer, our board of directors increased his base salary to $340,000, effective May&nbsp;1, 2019. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Bonus Compensation
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From time to time our board of directors or compensation committee may approve bonuses for our executive officers based on
individual performance, company performance or as otherwise determined appropriate. No formal bonus plan was in effect during 2018. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">157 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Equity-Based Incentive Awards </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our equity-based incentive awards are designed to align our interests and the interests of our stockholders with those of our employees and
consultants, including our named executive officer. Our board of directors or the compensation committee approves equity grants. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On
February&nbsp;13, 2018, we issued and sold to Mr.&nbsp;Socks, 1,686,704&nbsp;shares of our common stock for a per share purchase price of $0.0002958. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">On March&nbsp;13, 2019, we entered into a stock restriction agreement with Mr.&nbsp;Socks whereby Mr.&nbsp;Socks&#146; previously-acquired 1,686,704 shares of our common stock were subjected to new vesting
conditions, such that 421,676 shares were deemed vested as of March&nbsp;13, 2019 and the remaining 1,265,028 shares were converted into unvested shares of restricted stock that vest in equal monthly installments over the 48 months thereafter ending
on March&nbsp;13, 2023, subject, in each case, to continued employment or status as a service provider. Any unvested shares held by Mr.&nbsp;Socks upon a termination of employment or service (after giving effect to any accelerated vesting provisions
described further below), will be subject to repurchase by us at the original purchase price. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under Mr.&nbsp;Socks&#146; stock
restriction agreement, 100% of any unvested shares will automatically accelerate and vest upon (i)&nbsp;a termination of service by us without cause or by him for good reason following a change in control, or (ii)&nbsp;the refusal by us to enter
into a consulting agreement with him in connection with his resignation, subject to his continued employment or service through the date of such event. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Defined Terms Applicable to Stock Restriction Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">For purposes of the stock restriction agreement with Mr.&nbsp;Socks, &#147;change in control&#148; generally has the same meaning given to such term in our Existing Incentive Plan, as described below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of the stock restriction agreement with Mr.&nbsp;Socks, &#147;good reason&#148; means the occurrence of any of the following events or
conditions without his consent: (i)&nbsp;a material diminution in authority, duties or responsibilities; (ii)&nbsp;a material diminution in base compensation, unless such reduction is imposed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">across-the-board</FONT></FONT> to senior management of the Company; (iii)&nbsp;a material change in the geographic location at which he must perform his duties (and the parties acknowledge that a relocation of our
principal executive offices to a location more than fifty (50)&nbsp;miles from our then-current offices at which the individual is providing services (excepting reasonable travel on business) shall constitute a material change for purposes of this
clause (iii)); or (iv)&nbsp;any other action or inaction that constitutes a material breach by us or any successor or affiliate of our obligations to him under the stock restriction agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of the stock restriction agreement with Mr.&nbsp;Socks, &#147;cause&#148; means one or more of the following has occurred, as
determined in good faith by us in our reasonable discretion: (i)&nbsp;conviction of, or plea of nolo contendere to, any felony or of any crime involving either moral turpitude or dishonesty; (ii)&nbsp;intentional participation in a fraud or
intentional act of dishonesty against our company or any of our customers or business partners; (iii)&nbsp;material breach of duties; (iv)&nbsp;material breach of any written agreement with us if such breach has not been cured, or services ceased,
within thirty (30)&nbsp;days of receiving written notice thereof; and (v)&nbsp;failure to comply with the reasonable and lawful directives of management. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">158 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Employment Letters with our Executive Officers </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In 2018, none of our executive officers were parties to employment agreements or other similar arrangements with us. Each of our executive
officers&#146; employment is &#147;at will&#148; and may be terminated at any time, subject to our contractual obligations to them as described below. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Employment Letter with David Socks </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We entered into an employment letter with Mr.&nbsp;Socks setting forth the terms of his employment, effective May&nbsp;7, 2019 in connection with
entering into the Takeda License. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The employment letter for Mr.&nbsp;Socks provides for an annual base salary of $340,000, and an
annual bonus with a target amount equal to 50% of Mr.&nbsp;Socks&#146; annual base salary. Under the employment letter for Mr.&nbsp;Socks, he will devote at least 80% of his time to our company. Additionally, under the employment letter,
Mr.&nbsp;Socks is eligible to participate in all employee benefit plans and programs generally available to similarly situated employees of our company and is entitled to vacation benefits in accordance with our policies. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Employment Letter with Terrie Curran </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have entered into an employment letter with Ms. Curran, pursuant to which we have appointed her as a member of our board of directors and offered
her employment as our Chief Executive Officer. Under the terms of the employment letter, Ms.&nbsp;Curran must commence full-time employment with us as our Chief Executive Officer within two weeks after the completion of the planned acquisition of
her current employer but in no event later than December&nbsp;31, 2019, or the Start Date Deadline. In the event Ms.&nbsp;Curran has not commenced full-time employment with us as our Chief Executive Officer prior to such deadline, the employment
offer will cease to be outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The employment letter for Ms. Curran provides for an initial annual base salary of $500,000, and an
annual bonus with a target amount equal to 50% of her annual base salary. Her annual bonus for 2019 will be pro-rated based on the portion of the year she is employed by us. Additionally, under the employment letter, Ms.&nbsp;Curran will be eligible
to participate in all employee benefit plans and programs generally available to similarly situated employees of our company and is entitled to vacation benefits in accordance with our policies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Effective August&nbsp;29, 2019, we appointed Ms.&nbsp;Curran to our board of directors. In connection with her appointment to the board, we granted
her stock options to purchase 867,200 shares of our common stock under the Existing Incentive Plan. The stock options have a ten-year term and an exercise price of $6.95 per share, which our board of directors determined was equal to the fair market
value per share of our common stock on the date of grant. Ms.&nbsp;Curran&#146;s options will vest over a four-year period, with 25% of the stock options vesting on the first anniversary of her commencement of employment with us and the remaining
stock options vesting in 36 equal monthly installments thereafter, subject to her continued employment or service on each vesting date. In the event Ms.&nbsp;Curran does not commence employment with us as our Chief Executive Officer prior to the
Start Date Deadline, all of the stock options granted to her in connection with her appointment to the board will terminate immediately, regardless of her continued service on the board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Regardless of the manner in which Ms.&nbsp;Curran&#146;s employment terminates, she will be entitled to receive amounts previously earned during
her term of employment, including unpaid salary and accrued but unused vacation. In addition, Ms.&nbsp;Curran will be entitled to certain severance benefits under her employment letter, subject to her execution of a release of claims, returning of
all company property, compliance with post-termination obligations and resignation from positions with us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">159 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Ms.&nbsp;Curran&#146;s employment letter provides for severance benefits for certain terminations
that arise during and outside a change in control period (as defined below). Upon a termination without cause or resignation for good reason outside of a change in control period, Ms.&nbsp;Curran will be entitled to: (1)&nbsp;continuation of her
base salary for 12&nbsp;months (such applicable period, the &#147;severance period&#148;), (2)&nbsp;a lump sum equal to her target bonus for the year during which such termination occurs, plus any unpaid annual bonus for the calendar year prior to
the year in which her termination occurs, to the extent she is entitled to such bonus and if such bonus has not already been paid, (3)&nbsp;payment of the COBRA premiums for her and her eligible dependents until the earliest of (a)&nbsp;the end the
severance period, (b)&nbsp;expiration of her eligibility under for continuation coverage under COBRA, or (c)&nbsp;the date she becomes eligible for health insurance coverage in connection with her new employment, and (4)&nbsp;acceleration of the
vesting of all outstanding equity awards that would have vested during the severance period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon a termination without cause or
resignation for good reason that occurs during the period that is three months prior to or any time on or after a change in control (such period, the &#147;change in control period&#148;), Ms. Curran will be entitled to all of the same severance
benefits described above, except (1)&nbsp;the severance period is increased from 12&nbsp;months to 18&nbsp;months, (2)&nbsp;Ms.&nbsp;Curran will be entitled to a lump sum payment equal to 1.5&nbsp;times her target bonus for the year during which
such termination occurs, plus any unpaid annual bonus for the calendar year prior to the year in which her termination occurs, to the extent she is entitled to such bonus and if such bonus has not already been paid, and (3)&nbsp;all unvested and
outstanding equity awards will become fully vested on the later of the date her release of claims becomes effective or the date of the change in control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of Ms. Curran&#146;s employment letter: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;cause&#148; means (1)&nbsp;her commission of an act of fraud, embezzlement or dishonesty, or the commission of some other illegal act, that has a
demonstrable adverse impact on us or any successor or affiliate thereof; (2)&nbsp;her conviction of, or plea of &#147;guilty&#148; or &#147;no contest&#148; to, a felony or any crime involving fraud, dishonesty or moral turpitude under the laws of
the United States or any state thereof; (3)&nbsp;any intentional, unauthorized use or disclosure by her of the confidential information or trade secrets of the company or any successor or affiliate thereof; (4)&nbsp;her gross negligence,
insubordination or material violation of any duty of loyalty to us or any successor or affiliate thereof, or any other demonstrable material misconduct on her part; (5)&nbsp;her ongoing and repeated failure or refusal to perform or neglect of her
duties as required by the employment letter or her ongoing and repeated failure or refusal to comply with the instructions given to her by the board of directors, which failure, refusal or neglect continues for 15&nbsp;days following her receipt of
written notice from the board of directors stating with specificity the nature of such failure, refusal or neglect; or (6)&nbsp;her willful, material breach of any material company policy or any material provision of the employment letter or her
proprietary information and inventions assignment agreement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;change in control&#148; has the same meaning given to such term in our Existing Incentive Plan; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;good reason&#148; means any of the following without her written consent: (1) a material diminution in her authority, duties or responsibilities; (2) a
material diminution in her base compensation (and any diminution of 10% or more shall be considered material for this purpose, regardless of whether such diminution occurs due to a single reduction or a series of reductions in her base
compensation), unless such a reduction is imposed across-the-board to senior management; (3) a material change in the geographic location at which she must perform her duties; or (4) any other action or inaction that constitutes a material breach by
us or any successor or affiliate of its obligations to her under the employment letter. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">160 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Employment Letters with Other Executives </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have also entered into employment letters with each of our other executive officers, Aditya Kohli, Ph.D., our Chief Business Officer, and Azmi
Nabulsi, M.D., M.P.H., our Chief Operating Officer. Each employment letter sets forth the terms of their employment, each effective on May&nbsp;7, 2019 in connection with entering into the Takeda License. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The employment letters for Drs. Kohli and Nabulsi each provide for an annual base salary of $180,000 and $470,000, respectively, and an annual
bonus with a target amount equal to 35% and 40% of the executive&#146;s annual base salary, respectively. Pursuant to his employment letter, Dr.&nbsp;Kohli&#146;s base salary will increase to $220,000, effective August&nbsp;1, 2019. Under his
employment letter, Dr.&nbsp;Nabulsi will work for our company on a full-time basis. Under his employment letter, Dr.&nbsp;Kohli will devote at least 80% of his time to our company. Additionally, under the employment letters, each executive is
eligible to participate in all employee benefit plans and programs generally available to similarly situated employees of our company and is entitled to vacation benefits in accordance with our policies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In September 2019, we amended and restated the employment letter for Dr.&nbsp;Nabulsi to provide certain severance benefits under his employment
letter, subject to his execution of a release of claims, returning of all company property, compliance with post-termination obligations and resignation from positions with us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Dr.&nbsp;Nabulsi&#146;s amended and restated employment letter provides for severance benefits for certain terminations that arise during and
outside a change in control period (as defined below). Upon a termination without cause or resignation for good reason outside of a change in control period, Dr.&nbsp;Nabulsi will be entitled to: (1)&nbsp;continuation of his base salary for 9 months
(such applicable period, the &#147;severance period&#148;), (2)&nbsp;a lump sum equal to his prorated target bonus for the year during which such termination occurs, plus any unpaid annual bonus for the calendar year prior to the year in which his
termination occurs, to the extent he is entitled to such bonus and if such bonus has not already been paid, (3)&nbsp;payment of the COBRA premiums for him and his eligible dependents until the earliest of (a)&nbsp;the end the severance period,
(b)&nbsp;expiration of his eligibility under for continuation coverage under COBRA, or (c)&nbsp;the date he becomes eligible for health insurance coverage in connection with his new employment, and (4)&nbsp;acceleration of the vesting of all
outstanding equity awards that would have vested during the severance period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon a termination without cause or resignation for good
reason that occurs during the period that is three months prior to or the 24 months following a change in control (such period, the &#147;change in control period&#148;), Dr.&nbsp;Nabulsi will be entitled to all of the same severance benefits
described above, except (1)&nbsp;the severance period is increased from 9 months to 12 months, (2)&nbsp;Dr.&nbsp;Nabulsi will be entitled to a lump sum payment equal to his target bonus for the year during which such termination occurs, plus any
unpaid annual bonus for the calendar year prior to the year in which his termination occurs, to the extent he is entitled to such bonus and if such bonus has not already been paid, and (3)&nbsp;all unvested and outstanding equity awards will become
fully vested on the later of the date his release of claims becomes effective or the date of the change in control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of
Dr.&nbsp;Nabulsi&#146;s amended and restated offer letter, &#147;cause&#148;, &#147;change in control&#148; and &#147;good reason&#148; have the same definitions as set forth in Ms.&nbsp;Curran&#146;s employment letter described above. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our named executive officer did not hold any unvested equity awards granted as of December&nbsp;31, 2018. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">161 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Other Elements of Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Perquisites, Health, Welfare and Retirement Benefits </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We generally do not maintain
employee benefit plans or provide perquisites or personal benefits to our executive officers. We do, however, reimburse certain of our executive officers for costs related to health and welfare benefits they receive pursuant to other sources. Our
board of directors may elect to adopt qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> benefit plans in the future if it determines that doing so is in our best interests. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Nonqualified Deferred Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not maintain nonqualified defined contribution
plans or other nonqualified deferred compensation plans. Our board of directors may elect to provide our officers and other employees with <FONT STYLE="white-space:nowrap">non-qualified</FONT> defined contribution or other nonqualified deferred
compensation benefits in the future if it determines that doing so is in our best interests. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Change in Control Benefits </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our named executive officer may become entitled to certain benefits or enhanced benefits in connection with a change in control of our company. The
stock restriction agreement with our named executive officer provides for accelerated vesting of all outstanding equity awards upon a qualifying termination in connection with a change in control of our company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Incentive Award Plans </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>2019 Incentive Award Plan
</I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors and stockholders have adopted the 2019 Plan, which will become effective in connection with this
offering. Under the 2019 Plan, we may grant cash and equity incentive awards to eligible employees, directors and consultants in order to attract, motivate and retain the talent for which we compete. The material terms of the 2019 Plan are
summarized below. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Eligibility and Administration </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our employees, consultants and directors, and employees and consultants of our subsidiaries, will be eligible to receive awards under the 2019 Plan. Following our initial public offering, the 2019 Plan will
generally be administered by our board of directors with respect to awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and by our compensation committee with respect to other participants, each of which may delegate its duties
and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that may be imposed under the 2019 Plan, Section&nbsp;16 of the Exchange Act and/or stock
exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the administration of, the 2019 Plan, subject to its express
terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2019 Plan, including any vesting and vesting acceleration conditions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Limitation on Awards and Shares Available </I></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">An aggregate of 2,700,000&nbsp;shares of our
common stock will initially be available for issuance under awards granted pursuant to the 2019 Plan. The number of shares initially available for issuance will be increased by (i)&nbsp;the number of shares subject to stock options or similar awards
granted under our existing 2019 Equity Incentive Plan, or the Existing Incentive Plan, that expire or otherwise </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">162 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under our Existing Incentive Plan, that are
forfeited to or repurchased by us after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i)&nbsp;above equal to 1,416,788&nbsp;shares, and (ii)&nbsp;an annual increase on
January&nbsp;1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a)&nbsp;5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b)&nbsp;such smaller number of
shares as determined by our board of directors. No more than 40,000,000 shares of common stock may be issued upon the exercise of incentive stock options under the 2019 Plan. Shares issued under the 2019 Plan may be authorized but unissued shares,
shares purchased in the open market or treasury shares. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If an award under the 2019 Plan or the Existing Incentive Plan expires,
lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, any shares subject to such award will, as applicable, become or again be available for new grants under the 2019 Plan.
Further, shares delivered to us to satisfy the applicable exercise or purchase price of an award under the 2019 Plan or the Existing Incentive Plan and/or to satisfy any applicable tax withholding obligations (including shares retained by us from
the award under the 2019 Plan or the Existing Incentive Plan being exercised or purchased and/or creating the tax obligation) will become or again be available for award grants under the 2019 Plan. Awards granted under the 2019 Plan upon the
assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under
the 2019 Plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Awards </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019
Plan provides for the grant of stock options, including incentive stock options, or ISOs, and nonqualified stock options, or NSOs, restricted stock, dividend equivalents, restricted stock units, or RSUs, stock appreciation rights, or SARs, and other
stock or cash-based awards. Certain awards under the 2019 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may impose additional requirements on the terms and conditions of such awards.
All awards under the 2019 Plan will be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. A brief description of each
award type follows. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Stock Options</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock options provide for the purchase of shares of our common stock
in the future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are
satisfied. The exercise price of a stock option will not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to
certain substitute options granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined
by the plan administrator may apply to stock options and may include continued service, performance and/or other conditions. ISOs generally may be granted only to our employees and employees of our parent or subsidiary corporations, if any.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>SARs</I>.&nbsp;&nbsp;&nbsp;&nbsp;SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of
the shares subject to the award between the grant date and the exercise date. The exercise price of a SAR will not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to certain substitute
SARs granted in connection with a corporate transaction), and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance and/or other
conditions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">163 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Restricted Stock and RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock is an award of
nontransferable shares of our common stock that remain forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which
may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. Delivery of
the shares underlying RSUs may be deferred under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be based on continuing service,
the attainment of performance goals and/or such other conditions as the plan administrator may determine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Other Stock or Cash-Based
Awards.</I>&nbsp;&nbsp;&nbsp;&nbsp;Other stock or cash-based awards are awards of cash, fully vested shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other
stock or cash-based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise
payable to any individual who is eligible to receive awards. The plan administrator will determine the terms and conditions of other stock or cash-based awards, which may include vesting conditions based on continued service, performance and/or
other conditions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Performance Awards </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Performance awards include any of the foregoing awards that are granted subject to vesting and/or payment based on the attainment of specified performance goals or other criteria the plan administrator may
determine, which may or may not be objectively determinable. Performance criteria upon which performance goals are established by the plan administrator may include: net earnings or losses (either before or after one or more of interest, taxes,
depreciation, amortization and <FONT STYLE="white-space:nowrap">non-cash</FONT> equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits
(including, but not limited to, gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation
of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total
stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or
maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial or strategic milestones or developments; market share;
economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of
litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital
raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may
be based solely by reference to our performance or the performance of a subsidiary, division, business segment or business unit, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of
performance relative to performance of other companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">164 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Provisions of the 2019 Plan Relating to Director Compensation </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Plan provides that the plan administrator may establish compensation for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
from time to time subject to the 2019 Plan&#146;s limitations. Prior to commencing this offering, our stockholders approved the initial terms of our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, which is
described below under the heading &#147;&#151;Director Compensation.&#148; Our board of directors or its authorized committee may modify the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the
exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation or other compensation and the grant date fair value (as
determined in accordance with ASC 718, or any successor thereto) of any equity awards granted as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any fiscal year may not exceed $750,000, increased
to $1,000,000, in the fiscal year of a <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director. The plan administrator may make exceptions to this limit
for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the plan administrator may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director
receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Certain Transactions </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with
certain transactions and events affecting our common stock, including a change in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2019 Plan to prevent the
dilution or enlargement of intended benefits, facilitate such transaction or event, or give effect to such change in applicable laws or accounting principles. This includes canceling awards in exchange for either an amount in cash or other property
with a value equal to the amount that would have been obtained upon exercise or settlement of the vested portion of such award or realization of the participant&#146;s rights under the vested portion of such award, accelerating the vesting of
awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares available, replacing awards with other rights or property or terminating awards under the 2019 Plan. In the event of a
change in control where the acquirer does not assume awards granted under the 2019 Plan, awards issued under the 2019 Plan shall be subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as
applicable, and which may be subject to such terms and conditions as apply generally to holders of common stock under the change in control documents. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT>
transactions with our stockholders, or an &#147;equity restructuring,&#148; the plan administrator will make equitable adjustments to the 2019 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of the 2019 Plan, a &#147;change in control&#148; means and includes each of the following: (i)&nbsp;a transaction or series of
transactions (other than an offering of our common stock to the general public through a registration statement filed with the SEC or a transaction or series of transactions that meets the requirements of clauses (x)&nbsp;and (y) of clause
(iii)&nbsp;below) whereby any &#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than us, any of our subsidiaries, an employee benefit plan
maintained by us or any of our subsidiaries or a &#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, us) directly or indirectly acquires beneficial ownership (within
the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of our securities possessing more than 50% of the total combined voting power of our securities outstanding immediately after such acquisition; or
(ii)&nbsp;during any period of two consecutive years, individuals who, at the beginning of such period, constitute the board of directors together with any new director(s) (other than a director designated by a person who shall have entered into an
agreement with us to effect a transaction described in clauses </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">165 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
(i)&nbsp;or (iii)) whose election by the board of directors or nomination for election by our stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of
the directors then still in office who either were directors at the beginning of the <FONT STYLE="white-space:nowrap">two-year</FONT> period or whose election or nomination for election was previously so approved, cease for any reason to constitute
a majority thereof; or (iii)&nbsp;the consummation by us (whether directly involving us or indirectly involving us through one or more intermediaries) of (a)&nbsp;a merger, consolidation, reorganization, or business combination or (b)&nbsp;a sale or
other disposition of all or substantially all of our assets in any single transaction or series of related transactions or (c)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: (x)&nbsp;which results
in our voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into our voting securities or the voting securities of a successor entity, directly or indirectly,
at least a majority of the combined voting power of our outstanding voting securities or the successor entity&#146;s outstanding voting securities immediately after the transaction, and (y)&nbsp;after which no person or group beneficially owns
voting securities representing 50% or more of the combined voting power of us or the successor entity (provided that no person will be treated as beneficially owning 50% or more of the combined voting power of us or the successor entity for purposes
of this clause (y)&nbsp;solely as a result of the voting power held in us prior to the consummation of the transaction). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Foreign Participants,
Claw-Back Provisions, Transferability and Participant Payments </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to foreign participants, the plan administrator may
modify award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above. All awards will be subject to the provisions of any claw-back policy implemented by our company to the extent set
forth in such claw-back policy or in the applicable award agreement. With limited exceptions for estate planning, domestic relations orders, certain beneficiary designations and the laws of descent and distribution, awards under the 2019 Plan are
generally <FONT STYLE="white-space:nowrap">non-transferable</FONT> prior to vesting and are exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2019 Plan and exercise price
obligations arising in connection with the exercise of stock options under the 2019 Plan, the plan administrator may, in its discretion, accept cash, wire transfer, or check, shares of our common stock that meet specified conditions, a &#147;market
sell order&#148; or such other consideration as it deems suitable or any combination of the foregoing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Plan Amendment and Termination
</I></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors may amend or terminate the 2019 Plan at any time; however, except in connection with certain changes in
our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2019 Plan. The plan administrator will have the authority, without the approval of our stockholders, to amend any
outstanding stock option or SAR to reduce its exercise price per share. No award may be granted pursuant to the 2019 Plan after the tenth anniversary of the date on which our board of directors adopted the 2019 Plan. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Securities Laws </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Plan is intended
to conform to all provisions of the Securities Act, and the Exchange Act and any and all regulations and rules promulgated by the SEC thereunder, including, without limitation, Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> The 2019 Plan will
be administered, and awards will be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Federal
Income Tax Consequences </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The material federal income tax consequences of the 2019 Plan under current federal income tax law are
summarized in the following discussion, which deals with the general tax principles applicable </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">166 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
to the 2019 Plan. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change. Foreign, state and local tax laws, and
employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and by locality. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Stock Options and SARs. A 2019 Plan participant generally will not recognize taxable income and we generally will not be entitled to a tax deduction upon the grant of a stock option or SAR. The tax consequences of
exercising a stock option and the subsequent disposition of the shares received upon exercise will depend upon whether the option qualifies as an ISO or an NSO. Upon exercising an NSO when the fair market value of our stock is higher than the
exercise price of the option, a 2019 Plan participant generally will recognize taxable income at ordinary income tax rates equal to the excess of the fair market value of the stock on the date of exercise over the purchase price, and we (or our
subsidiaries, if any) generally will be entitled to a corresponding tax deduction for compensation expense, in the amount equal to the amount by which the fair market value of the shares purchased exceeds the purchase price for the shares. Upon a
subsequent sale or other disposition of the option shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in
the shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon exercising an ISO, a 2019 Plan participant generally will not recognize taxable income, and we will not be entitled to
a tax deduction for compensation expense. However, upon exercise, the amount by which the fair market value of the shares purchased exceeds the purchase price will be an item of adjustment for alternative minimum tax purposes. The participant will
recognize taxable income upon a sale or other taxable disposition of the option shares. For federal income tax purposes, dispositions are divided into two categories: qualifying and disqualifying. A qualifying disposition generally occurs if the
sale or other disposition is made more than two years after the date the option was granted and more than one year after the date the shares are transferred upon exercise. If the sale or disposition occurs before these two periods are satisfied,
then a disqualifying disposition generally will result. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon a qualifying disposition of ISO shares, the participant will recognize
long-term capital gain in an amount equal to the excess of the amount realized upon the sale or other disposition of the shares over their purchase price. If there is a disqualifying disposition of the shares, then the excess of the fair market
value of the shares on the exercise date (or, if less, the price at which the shares are sold) over their purchase price will be taxable as ordinary income to the participant. If there is a disqualifying disposition in the same year of exercise, it
eliminates the item of adjustment for alternative minimum tax purposes. Any additional gain or loss recognized upon the disposition will be recognized as a capital gain or loss by the participant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We will not be entitled to any tax deduction if the participant makes a qualifying disposition of ISO shares. If the participant makes a
disqualifying disposition of the shares, we should be entitled to a tax deduction for compensation expense in the amount of the ordinary income recognized by the participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Upon exercising or settling a SAR, a 2019 Plan participant will recognize taxable income at ordinary income tax rates, and we should be entitled to a corresponding tax deduction for compensation expense, in the
amount paid or value of the shares issued upon exercise or settlement. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and upon the subsequent disposition of the shares the participant will
recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Restricted Stock and RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2019 Plan participant generally will not recognize taxable income at ordinary income tax
rates and we generally will not be entitled to a tax deduction upon the grant of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">167 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
restricted stock or RSUs. Upon the termination of restrictions on restricted stock or the payment of RSUs, the participant will recognize taxable income at ordinary income tax rates, and we
should be entitled to a corresponding tax deduction for compensation expense, in the amount paid to the participant or the amount by which the then fair market value of the shares received by the participant exceeds the amount, if any, paid for
them. Upon the subsequent disposition of any shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the
shares. However, a 2019 Plan participant granted restricted stock that is subject to forfeiture or repurchase through a vesting schedule such that it is subject to a &#147;risk of forfeiture&#148; (as defined in Section&nbsp;83 of the Code) may make
an election under Section&nbsp;83(b) of the Code to recognize taxable income at ordinary income tax rates, at the time of the grant, in an amount equal to the fair market value of the shares of common stock on the date of grant, less the amount
paid, if any, for such shares. We will be entitled to a corresponding tax deduction for compensation, in the amount recognized as taxable income by the participant. If a timely Section&nbsp;83(b) election is made, the participant will not recognize
any additional ordinary income on the termination of restrictions on restricted stock, and we will not be entitled to any additional tax deduction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Other Stock or Cash-Based Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2019 Plan participant will not recognize taxable income and we will not be entitled to a tax deduction upon the grant of other stock or cash-based
awards until cash or shares are paid or distributed to the participant. At that time, any cash payments or the fair market value of shares that the participant receives will be taxable to the participant at ordinary income tax rates and we should be
entitled to a corresponding tax deduction for compensation expense. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and upon the subsequent disposition of the shares, the participant will
recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Existing Equity Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;6, 2019, our board of directors and our
stockholders approved the adoption of the Existing Incentive Plan. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A total of 2,231,739 shares of our common stock are reserved for
issuance under the Existing Incentive Plan. As of June&nbsp;30, 2019, 16,260 shares of our common stock were subject to outstanding restricted stock awards under the Existing Incentive Plan and 2,215,479 shares of our common stock remained available
for future issuance under the Existing Incentive Plan. Since June&nbsp;30, 2019, options to purchase a total of 1,400,528 shares of our common stock have been granted under the Existing Incentive Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After the effective date of the 2019 Plan, no additional awards will be granted under the Existing Incentive Plan. However, the Existing Incentive
Plan will continue to govern the terms and conditions of the outstanding awards granted under it. Shares of our common stock subject to awards granted under the Existing Incentive Plan that expire, lapse or are terminated, exchanged for cash,
surrendered, repurchased or forfeited following the effective date of the Existing Incentive Plan will be available for issuance under the Existing Incentive Plan in accordance with its terms. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors administers the Existing Incentive Plan, unless it delegates authority for
administration of the plan. Subject to the terms and conditions of the Existing Incentive Plan, the administrator has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each
person, determine the number of awards to grant, determine the number of shares to be subject to such awards, and the terms and conditions of such awards, and make all other determinations and decisions and to take all other
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">168 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
actions necessary or advisable for the administration of the Existing Incentive Plan. The plan administrator is also authorized to establish, adopt, amend or revise rules relating to
administration of the Existing Incentive Plan, subject to certain restrictions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;Awards under
the Existing Incentive Plan may be granted to individuals who are then our employees, consultants and members of our board of directors and our subsidiaries. Only employees may be granted ISOs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Existing Incentive Plan provides that our administrator may grant or issue stock options (including NSOs
and ISOs), restricted stock, RSUs, other stock-based awards, or any combination thereof. The administrator considers each award grant subjectively, considering factors such as the individual performance of the recipient and the anticipated
contribution of the recipient to the attainment of our long-term goals. Each award is set forth in a separate agreement with the person receiving the award and indicates the type, terms and conditions of the award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Corporate Transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator has broad discretion to equitably adjust the provisions of the
Existing Incentive Plan and the terms and conditions of existing and future awards, including with respect to aggregate number and type of shares subject to the Existing Incentive Plan and awards granted pursuant to the Existing Incentive Plan, to
prevent the dilution or enlargement of intended benefits and/or facilitate necessary or desirable changes in the event of certain transactions and events affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions,
consolidations and other corporate transactions. The plan administrator may also provide for the acceleration, <FONT STYLE="white-space:nowrap">cash-out,</FONT> termination, assumption, substitution or conversion of awards in the event of a change
in control or certain other unusual or nonrecurring events or transactions. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders, or an &#147;equity restructuring,&#148; the
plan administrator will make equitable adjustments to the Existing Incentive Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In the event of a change of control where the acquirer does not assume awards granted under the Existing Incentive Plan, awards issued under the Existing Incentive Plan held by persons who have not experienced a
termination of service will be subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as applicable, immediately prior to the change in control. Under the Existing Incentive Plan, a change of
control is generally defined as: (i)&nbsp;a merger or consolidation of our company with or into any other corporation or other entity or person; (ii)&nbsp;a sale, lease, exchange or other transfer in one transaction or a series of related
transactions of all or substantially all of our company&#146;s assets; or (iii)&nbsp;any other transaction, including the sale by us of new shares of our capital stock or a transfer of existing shares of our capital stock, the result of which is
that a third party that is not an affiliate of us or our stockholders (or a group of third parties not affiliated with us or our stockholders) immediately prior to such transaction acquires or holds capital stock representing a majority of our
outstanding voting power immediately following such transaction; provided that the following events shall not constitute a &#147;change in control&#148; under the Existing Incentive Plan: (a)&nbsp;a transaction (other than a sale of all or
substantially all of our assets) in which the holders of our voting securities immediately prior to the merger or consolidation hold, directly or indirectly, at least a majority of the voting securities in the successor corporation or its parent
immediately after the merger or consolidation; (b)&nbsp;a sale, lease, exchange or other transaction in one transaction or a series of related transactions of all or substantially all of our assets to an affiliate of ours; (c)&nbsp;an initial public
offering of any of our securities or any other transaction principally for bona fide equity financing purposes; (d)&nbsp;a reincorporation solely to change our jurisdiction; or (e)&nbsp;a transaction undertaken for the primary purpose of creating a
holding company that will be owned in substantially the same proportion by the persons who held our securities immediately before such transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Amendment and Termination of the Existing Incentive Plan</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may terminate, amend or modify the Existing Incentive Plan. However, stockholder approval of any
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">169 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
amendment to the Existing Incentive Plan must be obtained to the extent necessary and desirable to comply with any applicable law, regulation or stock exchange rule, or for any amendment to the
Existing Incentive Plan that increases the number of shares available under the Existing Incentive Plan. If not terminated earlier by the compensation committee or the board of directors, the Existing Incentive Plan will terminate on May&nbsp;6,
2029. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Securities Laws and Federal Income Tax Consequences</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Existing Incentive Plan is designed to
comply with applicable securities laws in the same manner as described above in the description of the 2019 Plan under the heading &#147;&#151;2019 Incentive Award Plan&#151;Securities Laws.&#148; The general federal tax consequences of awards under
the Existing Incentive Plan are the same as those described above in the description of the 2019 Plan under the heading &#147;&#151;2019 Incentive Award Plan&#151;Federal Income Tax Consequences.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>2019 Employee Stock Purchase Plan </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors and our stockholders have approved the ESPP, which will become effective in connection with this offering. The material terms
of the ESPP are summarized below. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Shares Available; Administration.&nbsp;&nbsp;&nbsp;&nbsp;</I>A total of 270,000 shares of
our common stock are initially reserved for issuance under our ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January&nbsp;1 of each calendar year beginning in 2020 and ending in 2029, by
an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii)&nbsp;such smaller number of shares as is determined by our board of directors. In no event will more than
10,000,000 shares of our common stock be available for issuance under the ESPP. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors or its committee will have
authority to interpret the terms of the ESPP and determine eligibility of participants. We expect that the compensation committee will be the initial administrator of the ESPP. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Eligibility.&nbsp;&nbsp;&nbsp;&nbsp;</I>Our employees are eligible to participate in the ESPP if they meet the eligibility requirements under
the ESPP established from time to time by the plan administrator. However, an employee may not be granted rights to purchase stock under our ESPP if such employee, immediately after the grant, would own (directly or through attribution) stock
possessing 5% or more of the total combined voting power or value of all classes of our common or other class of stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Grant of
Rights.&nbsp;&nbsp;&nbsp;&nbsp;</I>The ESPP is intended to qualify under Section&nbsp;423 of the Code and stock will be offered under the ESPP during offering periods. The length of the offering periods under the ESPP will be determined by the plan
administrator and may be up to 27 months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The number of purchase periods within, and purchase dates during each offering period will be
established by the plan administrator prior to the commencement of each offering period. Offering periods under the ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of
future offering periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their
eligible compensation, which includes a participant&#146;s gross base compensation for services to us, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other
special payments. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period or purchase period, which, in the absence of a contrary designation, will be
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">170 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
100,000&nbsp;shares. In addition, no employee will be permitted to accrue the right to purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during
which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day of the offering period). </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of our common stock. The option will be exercised on the applicable purchase date(s)
during the offering period, to the extent of the payroll deductions accumulated during the applicable purchase period. The purchase price of the shares, in the absence of a contrary determination by the plan administrator, will be 85% of the lower
of the fair market value of our common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. Participants may voluntarily end their
participation in the ESPP at any time at least one week prior to the end of the applicable offering period (or such shorter or longer period specified by the plan administrator), and will be paid their accrued payroll deductions that have not yet
been used to purchase shares of common stock. Participation ends automatically upon a participant&#146;s termination of employment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A
participant may not transfer rights granted under the ESPP other than by will, the laws of descent and distribution or as otherwise provided under the ESPP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Certain Transactions.&nbsp;&nbsp;&nbsp;&nbsp;</I>In the event of certain transactions or events affecting our common stock, such as any stock dividend or other distribution, change in control, reorganization,
merger, consolidation or other corporate transaction, the plan administrator will make equitable adjustments to the ESPP and outstanding rights. In addition, in the event of the foregoing transactions or events or certain significant transactions,
including a change in control, the plan administrator may provide for (i)&nbsp;either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (ii)&nbsp;the assumption or
substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (iii)&nbsp;the adjustment in the number and type of shares of stock subject to outstanding rights, (iv)&nbsp;the use of
participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (v)&nbsp;the termination of all outstanding rights.
Under the ESPP, a change in control has the same definition as given to such term in the Existing Incentive Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Plan Amendment;
Termination.&nbsp;&nbsp;&nbsp;&nbsp;</I>The plan administrator may amend, suspend or terminate the ESPP at any time. However, stockholder approval of any amendment to the ESPP will be obtained for any amendment which increases the aggregate number
or changes the type of shares that may be sold pursuant to rights under the ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in the ESPP or changes the ESPP in any manner that would cause the ESPP
to no longer be an employee stock purchase plan within the meaning of Section&nbsp;423(b) of the Code. The ESPP will remain in effect until terminated by our board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Securities Laws.&nbsp;&nbsp;&nbsp;&nbsp;</I>The ESPP has been designed to comply with various securities laws in the same manner as described
above in the description of the 2019 Plan under the heading &#147;&#151;2019 Incentive Award Plan&#151;Securities Laws.&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Federal Income Taxes.&nbsp;&nbsp;&nbsp;&nbsp;</I>The material federal income tax consequences of the ESPP under current federal income tax law
are summarized in the following discussion, which deals with the general tax principles applicable to the ESPP. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change.
Foreign, state and local tax laws, and employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and from locality to locality. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">171 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The ESPP, and the right of participants to make purchases thereunder, is intended to qualify
under the provisions of Section&nbsp;423 of the Code. Under the applicable Code provisions, no income will be taxable to a participant until the sale or other disposition of the shares purchased under the ESPP. This means that an eligible employee
will not recognize taxable income on the date the employee is granted an option under the ESPP (i.e., the first day of the offering period). In addition, the employee will not recognize taxable income upon the purchase of shares. Upon such sale or
disposition, the participant will generally be subject to tax in an amount that depends upon the length of time such shares are held by the participant prior to disposing of them. If the shares are sold or disposed of more than two years from the
first day of the offering period during which the shares were purchased and more than one year from the date of purchase, or if the participant dies while holding the shares, the participant (or his or her estate) will recognize ordinary income
measured as the lesser of: (i)&nbsp;the excess of the fair market value of the shares at the time of such sale or disposition over the purchase price; or (ii)&nbsp;an amount equal to 15% of the fair market value of the shares as of the first day of
the offering period. Any additional gain will be treated as long-term capital gain. If the shares are held for the holding periods described above but are sold for a price that is less than the purchase price, there is no ordinary income and the
participating employee has a long-term capital loss for the difference between the sale price and the purchase price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If the shares are
sold or otherwise disposed of before the expiration of the holding periods described above, the participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares are purchased
over the purchase price and we will be entitled to a tax deduction for compensation expense in the amount of ordinary income recognized by the employee. Any additional gain or loss on such sale or disposition will be long-term or short-term capital
gain or loss, depending on how long the shares were held following the date they were purchased by the participant prior to disposing of them. If the shares are sold or otherwise disposed of before the expiration of the holding periods described
above but are sold for a price that is less than the purchase price, the participant will recognize ordinary income equal to the excess of the fair market value of the shares on the date of purchase over the purchase price (and we will be entitled
to a corresponding deduction), but the participant generally will be able to report a capital loss equal to the difference between the sales price of the shares and the fair market value of the shares on the date of purchase. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Director Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Historically, we have
not paid cash or stock-based compensation to directors for their service on our board of directors. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On January&nbsp;23, 2018,
YamadaCo IIA issued and sold to Dr.&nbsp;Yamada, 1,686,704 shares of common stock of YamadaCo IIA for a per share purchase price of $0.0002958. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">On March&nbsp;13, 2019, we entered into a stock restriction agreement with Dr.&nbsp;Yamada whereby Dr.&nbsp;Yamada&#146;s previously-acquired 1,686,704 shares of our common stock were subjected to new vesting
conditions, such that 421,676 shares were deemed vested as of March&nbsp;13, 2019 and the remaining 1,265,028 shares were converted into unvested shares of restricted stock that vest in equal monthly installments over the 48 months thereafter ending
on March&nbsp;13, 2023, subject, in each case, to continued employment or status as a service provider. Any unvested shares held by Dr.&nbsp;Yamada upon a termination of employment or service (after giving effect to any accelerated vesting
provisions described further below), will be subject to repurchase by us at the original purchase price. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under
Dr.&nbsp;Yamada&#146;s stock restriction agreement, 100% of any unvested shares will automatically accelerate and vest upon (i)&nbsp;a termination of service by us without cause or by him for good reason
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">172 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
following a change in control, or (ii)&nbsp;the refusal by us to enter into a consulting agreement with him in connection with his resignation, subject to his continued employment or service
through the date of such event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The defined terms &#147;change in control,&#148; &#147;cause&#148; and &#147;good reason&#148; have the
same meanings in Dr. Yamada&#146;s stock restriction agreement as given to such terms in Mr.&nbsp;Socks&#146; stock restriction agreement and described above under &#147;Executive and Director Compensation&#151;Equity-Based Incentive Awards.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, we entered into an offer letter with Dr.&nbsp;Yamada, our Chairman of the board of directors. Pursuant to
Dr.&nbsp;Yamada&#146;s offer letter, Dr.&nbsp;Yamada will be paid an annual cash fee of $100,000, paid quarterly, for his services as Chairman. Additionally, as a member of our board of directors, we will reimburse Dr.&nbsp;Yamada for reasonable
travel and other expenses to attend board meetings and other board-related functions. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Effective August&nbsp;29, 2019, we appointed
Terrie Curran to our board of directors. In connection with Ms. Curran&#146;s appointment to our board of directors, we granted to her stock options to purchase 867,200 shares of our common stock under the Existing Incentive Plan. For a description
of the stock options granted to Ms. Curran, see &#147;&#151;Employment Letter with Terrie Curran&#148; above. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Effective
September&nbsp;26, 2019, we entered into an offer letter with each of Heidi Kunz and Michael Cola in connection with their appointment to our board of directors. Pursuant to each offer letter, Ms.&nbsp;Kunz and Mr.&nbsp;Cola will be paid an annual
cash retainer of $40,000, paid quarterly, which retainer will commence immediately. Additionally, as a member of our board of directors, we will reimburse Ms.&nbsp;Kunz and Mr.&nbsp;Cola for reasonable travel and other expenses to attend board
meetings and other board-related functions. Pursuant to their offer letters, we also granted each of Ms.&nbsp;Kunz and Mr.&nbsp;Cola stock options to purchase 43,360 shares of our common stock. The stock options have a
<FONT STYLE="white-space:nowrap">ten-year</FONT> term and an exercise price of $13.04 per share, which our board of directors determined was equal to the fair market value per share of our common stock on the date of grant. The options will vest
over a three-year period, with <FONT STYLE="white-space:nowrap">one-third</FONT> vesting on the first anniversary of the date of grant and the remainder vesting quarterly over the 24 months thereafter, subject to continued service with us on each
vesting date. Such stock options will accelerate in full upon a change in control of our company. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with this
offering, our board of directors and our stockholders have approved a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program. The material terms of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation program are summarized below. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation
program will provide for annual retainer fees and/or long-term equity awards for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual retainer
of $40,000. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors serving as the chairs of the audit, compensation and nominating and corporate governance committees will receive additional annual retainers of $20,000, $15,000 and $10,000,
respectively. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors serving as members of the audit, compensation and nominating and corporate governance committees will receive additional annual retainers of $10,000, $7,500 and $5,000,
respectively. Additionally, the non-executive chairman of the board will receive an additional annual retainer of $40,000. The <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will also receive initial grants of options to purchase
20,000&nbsp;shares of our common stock upon election to the board of directors, one-third of which will vest on the first anniversary of the grant date and the remainder of which will vest in quarterly installments over the following 24&nbsp;months,
and thereafter annual grants of options to purchase 10,000&nbsp;shares of our common stock, vesting on the first to occur of (i)&nbsp;the first anniversary of the grant date or (ii)&nbsp;the next occurring annual meeting of our stockholders, in each
case, subject to the non-employee director continuing in service on our board of directors through such vesting date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">173 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Compensation under our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation
program will be subject to the annual limits on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2019 Plan, as described above. Our board of directors or its authorized committee may modify the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time,
subject to the annual limit on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2019 Plan. As provided in the 2019 Plan, our board of directors or its authorized committee may make exceptions to this limit
for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the board of directors or its authorized committee may determine in its discretion, provided that the
<FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such additional compensation may not participate in the decision to award such compensation or in other compensation decisions involving
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Limitations of Liability and Indemnification Matters </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our directors and officers
to the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any breach of the director&#146;s duty of loyalty to us or our stockholders; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any transaction from which the director derived an improper personal benefit. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that if Delaware law is amended to authorize
corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This limitation of liability
does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that we shall have the power to indemnify our employees and agents to the fullest extent permitted by law. Our
amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this capacity, regardless of whether our amended and restated bylaws
would permit indemnification. We have obtained directors&#146; and officers&#146; liability insurance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have entered into separate
indemnification agreements with our directors and executive officers, in addition to indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, provide
for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts incurred by this person in any action or proceeding arising out of this person&#146;s services as a director or executive officer or at
our request. We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and executive
officers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The above description of the indemnification provisions of our amended and restated certificate of incorporation, our amended
and restated bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">174 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The limitation of liability and indemnification provisions in our amended and restated
certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors
and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these
indemnification provisions. Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the
SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought,
nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">175 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_14"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following includes a summary of transactions since our inception to which we have been a party in which the amount involved exceeded or will
exceed the lesser of $120,000 and one percent of the average of our total assets at year-end for the last two completed fiscal years, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of
our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which
are described under &#147;Executive and Director Compensation.&#148; The transactions below also include transactions of YamadaCo IIA, Inc. prior to the Merger. We also describe below certain other transactions with our directors, executive officers
and stockholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Convertible Promissory Note Financings </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Prior Convertible Promissory Note Financings with Frazier Life Sciences IX, L.P. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In January
2018, YamadaCo IIA, Inc. entered into a convertible promissory note purchase agreement with Frazier Life Sciences IX, L.P., or FLS IX, pursuant to which from January 2018 to December 2018 YamadaCo IIA issued and sold to FLS IX three convertible
promissory notes, or the YamadaCo Notes, in the aggregate principal amount of $1.5&nbsp;million. The YamadaCo Notes accrued interest at the then applicable federal rate (1.68%, 2.38% and 2.55%, respectively) per annum, and were due and payable upon
demand by FLS IX nine months from the date of issuance, subject to earlier conversion or repayment in the event YamadaCo IIA completed an equity financing or a change of control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In January 2018, we entered into a convertible promissory note purchase agreement with FLS IX, pursuant to which from January 2018 to April 2019,
we issued and sold to FLS IX three convertible promissory notes, or the Phathom Notes, in the aggregate principal amount of $0.9&nbsp;million. The Phathom Notes accrued interest at the then applicable federal rate (1.68%, 2.42% and 2.52%,
respectively) per annum, and were due and payable upon demand by FLS IX nine months from the date of issuance, subject to earlier conversion or repayment in the event we completed an equity financing or a change of control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The YamadaCo Notes and Phathom Notes, in the aggregate amount of $2.4&nbsp;million, including accrued interest thereon, were cancelled and
exchanged for May 2019 Notes issued in the May 2019 convertible note financing described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The general partner of FLS IX is FHMLS
IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper, M.D., Ph.D., a member of our board of directors, is one of the managing members of FHMLS IX, L.L.C. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">176 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>May 2019 Convertible Promissory Note Financing </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019, we entered into a convertible promissory note purchase agreement with certain investors, or the 2019 Note Purchase Agreement, pursuant
to which in May 2019 we issued and sold to such investors convertible promissory notes, or the May 2019 Notes, in the aggregate principal amount of approximately $90.3&nbsp;million. The May 2019 Notes accrue interest at a rate of 6% per annum and
become payable upon demand of the holders of at least 60% of the outstanding principal amount of the May 2019 Notes one year from the date of issuance, subject to earlier conversion or repayment in the event we complete an equity financing or a
change of control. We have not paid any interest on the May 2019 Notes to date. The participants in this May 2019 Note financing included the following 5% or greater stockholders and or entities affiliated with members of our board of directors.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Participants</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Aggregate&nbsp;Principal<BR>Amount&nbsp;of&nbsp;May&nbsp;2019<BR>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Frazier Life Sciences IX, L.P.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">20,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Entities affiliated with Medicxi Growth</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">15,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of convertible promissory notes held by FLS IX, or the Frazier May 2019 Notes. Additional details regarding FLS&nbsp;IX and its equity holdings
are provided under the section titled &#147;Principal Stockholders.&#148; James Topper, M.D., Ph.D., a member of our board of directors, is one of the managing members of FHMLS IX, L.L.C, which is an affiliate of FLS IX.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of convertible promissory notes, or the Medicxi Notes, held by Medicxi Growth I LP and Medicxi Growth
<FONT STYLE="white-space:nowrap">Co-Invest</FONT> I LP, collectively Medicxi Growth. Jonathan Edwards, Ph.D., a member of our board of directors, is a Partner of Medicxi, an affiliate of Medicxi Growth. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The outstanding principal and unpaid accrued interested due on the Frazier May 2019 Notes and the Medicxi Notes will automatically convert into an
aggregate of 1,353,423&nbsp;shares and 1,015,067&nbsp;shares of our common stock, respectively, immediately prior to the closing of this offering, each based on an assumed initial public offering price of $19.00&nbsp;per share, the midpoint of the
price range set forth on the cover page of this prospectus, and assuming the conversion occurs on October&nbsp;28, 2019. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The May
2019 Notes are subordinated to borrowings under our Loan Agreement with Silicon Valley Bank and WestRiver Innovation Lending Fund VIII, L.P. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Investor Rights Under the 2019 Note Purchase Agreement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Registration Rights </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase
Agreement provides FLS IX, Takeda, and all holders of the May 2019 Notes with specified registration rights relating to the registration of shares of common stock held by such entities, including shares of our common stock issuable upon conversion
of the May 2019 Notes and shares of our common stock issuable upon the exercise or conversion of any securities exercisable or convertible into shares of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The registration rights terminate upon the earlier of: (i)&nbsp;five years after the closing of this offering or (ii)&nbsp;with respect to a particular holder, such time at which such holder can sell all shares
held by it in compliance with Rule 144 under the Securities Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">See the section titled &#147;Description of Capital
Stock&#151;Registration Rights&#148; for more information regarding these registration rights. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Voting Rights </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase Agreement provides for rights relating to the election of members to serve on our board of directors. Pursuant to the 2019
Note Purchase Agreement, as amended in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">177 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
September 2019, the following directors were each elected to serve as members on our board of directors and, as of the date of this prospectus, continue to so serve: David Socks, Tadataka Yamada,
M.D., Michael F. Cola, Terrie Curran, Jonathan Edwards, Ph.D., Heidi Kunz, Chris Slavinsky, and James Topper, M.D., Ph.D. Mr.&nbsp;Socks, our President and Chief Executive Officer, was initially selected to serve on our board of directors in his
role as Chief Executive Officer. Dr.&nbsp;Yamada was initially selected to serve on our board of directors as a representative of holders of our common stock, as designated by a majority of our common stockholders. Dr.&nbsp;Topper was initially
selected to serve on our board of directors as a representative of holders of our common stock, as designated by FLS IX. Dr.&nbsp;Edwards was initially selected to serve on our board of directors as a representative of the holders of the May 2019
Notes. Mr.&nbsp;Cola, Ms.&nbsp;Curran, Ms.&nbsp;Kunz, and Mr.&nbsp;Slavinsky were initially selected to serve on our board of directors as representatives of holders of our common stock, with Mr.&nbsp;Slavinsky being designated by Takeda.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase Agreement provides that Takeda may designate a member to serve on our board of directors as a representative of
holders of our common stock, provided that such right does not apply at any time the board of directors consists of fewer than five individuals that are not affiliated with Takeda. In connection with our appointment of Ms. Curran to our board of
directors in August 2019, at which time we had five directors serving on our board, we also appointed Mr.&nbsp;Slavinsky to our board pursuant this right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The voting rights provisions of the 2019 Note Purchase Agreement will terminate upon the closing of this offering, and members previously elected to our board of directors pursuant to this agreement will continue
to serve as directors until they resign, are removed or their successors are duly elected by holders of our common stock. The composition of our board of directors after this offering is described in more detail under &#147;Management&#151;Board
Composition and Election of Directors.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Other Rights </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase Agreement provides certain holders of our May 2019 Notes with various additional rights including, among others, information rights, <FONT STYLE="white-space:nowrap">pre-emptive</FONT>
rights, drag along rights, rights of first refusal, <FONT STYLE="white-space:nowrap">co-sale</FONT> rights, and certain additional covenants made by us. Except as set forth above, all rights under the 2019 Note Purchase Agreement will terminate upon
the closing of this offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Takeda Agreements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>License Agreement and Clinical Manufacturing and Supply Agreement </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, we and Takeda, one of our 5% stockholders, entered into the Takeda License and a clinical manufacturing and supply agreement. Such agreements are described in &#147;Business&#151;Intellectual
Property&#151;License Agreement with Takeda Pharmaceutical Company Limited.&#148; </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Takeda License, we
(i)&nbsp;entered into a Stock Issuance Agreement with Takeda, pursuant to which we issued Takeda 1,084,000 shares of our common stock, (ii)&nbsp;issued the Takeda Warrant to purchase 7,588,000 shares of common stock at an exercise price of
$0.00004613 per share and (iii)&nbsp;granted the Takeda Warrant Right, pursuant to which Takeda has a right to receive an additional common stock warrant upon the closing of this offering if Takeda&#146;s fully-diluted ownership represents less than
a specified percentage of our fully-diluted capitalization, including shares issuable upon conversion of outstanding convertible promissory notes, calculated immediately prior to the closing of this offering, each as partial consideration under the
Takeda License. The Takeda Warrant expires ten years from its date of issuance, subject to its earlier termination upon the completion of certain mergers, acquisitions and similar transactions. The Takeda Warrant Right will expire upon the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">178 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
closing of this offering based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover of this prospectus. See the section titled
&#147;Description of Capital Stock&#151;Warrants&#148; for more information regarding the Takeda Warrant and the Takeda Warrant Right. In connection with the Takeda License, we provided Takeda with various investor rights, including <FONT
STYLE="white-space:nowrap">pre-emptive</FONT> rights, drag along rights, voting rights and certain registration rights. See &#147;&#151;Investor Rights Under the 2019 Note Purchase Agreement&#148; above for more information regarding these voting
rights and registration rights. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Merger </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Initial Founder Equity Issuances </I></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On
January&nbsp;23, 2018, YamadaCo IIA issued and sold to Tadataka Yamada, M.D., our Chairman, 1,686,704 shares of YamadaCo IIA common stock at a purchase price of $0.0002958 per share, after giving effect to the merger described below. On
February&nbsp;14, 2018, YamadaCo IIA issued and sold to FLS IX 1,693,463 shares of YamadaCo IIA common stock at a purchase price of $0.0002958 per share, after giving effect to the merger described below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On February&nbsp;13, 2018, we issued and sold to David Socks, our President and Chief Executive Officer and a member of our board of directors,
1,686,704&nbsp;shares of our common stock at a purchase price of $0.0002958 per share. On February&nbsp;14, 2018, we issued and sold to FLS IX 1,693,463 shares of our common stock at a purchase price of $0.0002958 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On March&nbsp;13, 2019, we entered into stock restriction agreements with each of Mr.&nbsp;Socks and Dr.&nbsp;Yamada providing for vesting and a
company right to repurchase the unvested shares held by Mr.&nbsp;Socks and Dr.&nbsp;Yamada upon the occurrence of certain events. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For
more information regarding these stock issuances to Dr.&nbsp;Yamada and Mr.&nbsp;Socks, see the section in this prospectus entitled &#147;Executive and Director Compensation&#151;Equity-Based Incentive Awards&#148; and &#147;Executive and Director
Compensation&#151;Narrative Disclosure to Summary Compensation Table&#151;Director Compensation.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Merger Agreement </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On March&nbsp;13, 2019, YamadaCo IIA merged with and into our company, with our company surviving the merger, or the Merger. Immediately prior to
the Merger, we effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1,559.1183-for-1</FONT></FONT> forward stock split for each outstanding share of our common stock. Effective upon the closing of the Merger, each issued and
outstanding share of YamadaCo IIA was converted into 1,559.1183 shares of our common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Additional Equity Issuances </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the Merger, on March&nbsp;13, 2019, we issued and sold to FLS IX 1,491,072 shares of our common stock at a purchase price of $0.0002958
per share. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Additional Executive Officer Equity Issuances </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Following the Merger, on March&nbsp;13, 2019, we issued and sold to each of Azmi Nabulsi, M.D., M.P.H., our Chief Operating Officer, and Aditya Kohli, Ph.D., our Chief Business Officer, 867,200 and 843,352 shares
of our common stock, respectively, at a purchase price of $0.0002958 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">179 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Shared Operating Expenses </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Frazier is a principal stockholder of our company and is represented on our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For
the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019, we conducted our operations within office space controlled by Frazier and Frazier allocated a portion of the costs associated with this office to us. In addition,
Frazier paid for various goods and services, such as employee wages, insurance and expense reimbursements and various administrative services associated with our operations and charged us for those expenses. For the year ended December&nbsp;31, 2018
and the six months ended June&nbsp;30, 2018 and 2019, we incurred $0.3&nbsp;million, $0.1&nbsp;million and $0.1&nbsp;million, respectively, of shared operating expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Employment Arrangements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have entered into employment letter agreements with our executive
officers. For more information regarding these employment agreements, see the section in this prospectus entitled &#147;Executive and Director Compensation&#151;Employment Letters with our Executive Officers.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Director and Officer Indemnification </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We
have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds)
and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#146; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or
proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as a director or executive officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by the Delaware General
Corporation Law. Further, we have purchased a policy of directors&#146; and officers&#146; liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. For
further information, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Directed Share
Program </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">At our request, the underwriters have reserved up to 3.0% of the shares of common stock to be offered by this prospectus
for sale, at the initial public offering price, to certain of our directors, officers, employees, and their friends and family members through a directed share program. We do not currently know whether any of our directors, officers, or their
affiliates, or holders of more than 5% of our common stock will purchase more than $120,000 in value of such reserved shares of our common stock in this offering. See &#147;Underwriting&#151;Directed Share Program.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Policies and Procedures for Related Person Transactions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our board of directors has adopted a written related person transaction policy, to be effective upon the closing of this offering, setting forth the policies and procedures for the review and approval or
ratification of related-person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, any transaction, arrangement or relationship, or
any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000, and a related person had or will have a
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">180 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest,
indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to,
whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred
prior to the adoption of this policy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">181 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_15"></A>PRINCIPAL STOCKHOLDERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table sets forth information with respect to the beneficial ownership of our common stock as of September&nbsp;30, 2019, and as
adjusted to reflect the sale of shares of common stock in this offering, by: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our named executive officer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">each of our directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">all of our executive officers and directors as a group; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">each person<B> </B>or group of affiliated persons known by us to beneficially own more than 5% of our common stock. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership
includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership prior to this offering is based on 11,876,518 shares of common stock outstanding on September&nbsp;30, 2019, which includes
4,455,525&nbsp;shares subject to forfeiture or a right of repurchase. Applicable percentage ownership after this offering is based on the sale of 7,900,000 shares of common stock in this offering and gives effect to the automatic conversion of the
May 2019 Notes into an aggregate of 6,106,940 shares of our common stock immediately prior to the closing of this offering (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover
page of this prospectus, and assuming the conversion occurs on October 28, 2019). In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options, warrants or
other rights held by such person that are currently exercisable or will become exercisable within 60 days of September&nbsp;30, 2019 are considered outstanding, although these shares are not considered outstanding for purposes of computing the
percentage ownership of any other person. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Unless otherwise indicated, the address of each beneficial owner listed below is c/o
Phathom Pharmaceuticals, Inc., 2150 E. Lake Cook Road, Suite 800, Buffalo Grove, Illinois 60089. We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the
shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">182 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Beneficial&nbsp;Ownership<BR>Prior to this Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Beneficial&nbsp;Ownership<BR>After this Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>5% or Greater Stockholders</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Takeda Pharmaceutical Company Limited</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,084,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,672,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">25.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Frazier Life Sciences IX, L.P.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4,877,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,231,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Executive Officers and Directors</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">David
Socks</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,686,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">14.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,686,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Tadataka Yamada,
M.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,686,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">14.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,686,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Michael F. Cola</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Terrie Curran</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Azmi Nabulsi, M.D., M.P.H.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">867,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">867,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Aditya Kohli,
Ph.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">843,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">843,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">James Topper, M.D.,
Ph.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4,877,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,231,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Jonathan Edwards, Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Heidi Kunz</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Chris Slavinsky</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">All executive officers and directors as a group (10&nbsp;persons)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9,961,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">83.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">11,315,381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">43.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Less than 1%. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">The number of shares beneficially owned before the offering does not include 7,588,000 shares of common stock issuable upon exercise of the Takeda Warrant, which
becomes exerciseable upon the closing of this offering. The number of shares beneficially owned after the offering includes 7,588,000&nbsp;shares of common stock issuable upon the exercise of the Takeda Warrant. The address for Takeda Pharmaceutical
Company Limited is <FONT STYLE="white-space:nowrap">1-1,</FONT> <FONT STYLE="white-space:nowrap">Doshomachi&nbsp;4-chome,</FONT> <FONT STYLE="white-space:nowrap">Chuo-ku,</FONT> Osaka <FONT STYLE="white-space:nowrap">540-8645,</FONT> Japan.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">The shares are held directly by Frazier Life Sciences IX, L.P., or FLS IX. The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX,
L.P. is FHMLS IX, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr.&nbsp;Topper and Mr.&nbsp;Heron disclaim beneficial
ownership of such securities except to the extent of their pecuniary interest therein. The number of shares beneficially owned after the offering includes 1,353,423 shares of common stock issuable upon the conversion of May 2019 Notes in the
aggregate principal amount of $20,000,000 plus accrued interest held by Frazier Life Sciences IX, L.P. immediately prior to the closing of this offering (based on an assumed initial public offering price of $19.00 per share, the midpoint of the
price range set forth on the cover page of this prospectus, and assuming the conversion occurs on October 28, 2019). The address for FLS IX is 601 Union Street, Suite 3200, Seattle, WA 98101. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of 1,686,704 shares of common stock held by the David A. Socks 2013 Revocable Trust, 1,106,900 of which were subject to a right of repurchase
by us as of September&nbsp;30, 2019. David Socks is a trustee of the David A. Socks 2013 Revocable Trust and in such capacity has the sole power to vote and dispose of such shares. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of 1,686,704 shares of common stock held by Dr.&nbsp;Yamada, 1,106,900 of which were subject to a right of repurchase by us as of
September&nbsp;30, 2019. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of 867,200 shares of common stock held by Dr.&nbsp;Nabulsi, all of which were subject to a right of repurchase by us as of September&nbsp;30,
2019, </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of 843,352 shares of common stock held by Dr.&nbsp;Kohli, 553,450 of which were subject to a right of repurchase by us as of September&nbsp;30,
2019. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of the shares held by the executive officers and directors described in footnotes 2 through 6 above. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">183 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_16"></A>DESCRIPTION OF CAPITAL STOCK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following description
summarizes some of the terms of our amended and restated certificate of incorporation and amended and restated bylaws and of the Delaware General Corporation Law. Because it is only a summary, it does not contain all the information that may be
important to you. For a complete description you should refer to our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to the registration statement of which the prospectus
is a part. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the closing of this offering, our authorized capital stock will consist of 400,000,000&nbsp;shares of common
stock, $0.0001 par value per share, and 40,000,000&nbsp;shares of preferred stock, $0.0001 par value per share. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Common Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, there were 11,876,518 shares of our common stock outstanding, including 4,657,250 shares of restricted common stock which
are subject to forfeiture or our right of repurchase as of June&nbsp;30, 2019, and held of record by 20 stockholders. Based on the number of shares of common stock outstanding as of June&nbsp;30, 2019, and assuming (i)&nbsp;the automatic conversion
of the May 2019 Notes into an aggregate of 6,106,940 shares of our common stock immediately prior to the closing of this offering (based on an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on
the cover page of this prospectus, and assuming the conversion occurs on October 28, 2019) and (ii)&nbsp;the issuance by us of 7,900,000 shares of common stock in this offering, there will be 25,883,458 shares of common stock outstanding upon the
closing of this offering. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the
holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we
may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or
represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in
voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation. See
below under &#147;&#151;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws&#151;Amendment of Charter Provisions.&#148; </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors
out of legally available funds. In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or
provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or
sinking funds provisions applicable to the common stock. All outstanding shares of common stock are, and the common stock to be outstanding upon the closing of this offering will be, duly authorized, validly issued, fully paid and nonassessable. The
rights, preferences and privileges of holders of common stock are subject to and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">184 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Preferred Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of the date of this
prospectus, we do not have shares of preferred stock authorized or outstanding. Under the terms of our amended and restated certificate of incorporation, which will become effective immediately prior to the closing of this offering, our board of
directors has the authority, without further action by our stockholders, to issue up to 40,000,000&nbsp;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix
the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not
below the number of shares of such series then outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors may authorize the issuance of preferred stock with
voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate
purposes, could, among other things, have the effect of delaying, deterring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have
no current plans to issue any shares of preferred stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Warrants </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In May 2019, in connection with the Takeda License, we issued the Takeda Warrant to purchase 7,588,000 shares of our common stock with an exercise price of $0.00004613 per share. The Takeda Warrant contains a net
exercise provision under which Takeda may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares of our common stock based on the fair market value of our common stock at the time of the net
exercise of the warrant after deduction of the aggregate exercise price. The Takeda Warrant expires ten years from its date of issuance, subject to its earlier termination upon the completion of certain mergers, acquisitions and similar
transactions. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019, in connection with the Takeda License, we granted to Takeda the Takeda Warrant Right, pursuant to
which Takeda has a right to right to receive an additional common stock warrant should Takeda&#146;s fully-diluted ownership represent less than a certain specified percentage of our fully-diluted capitalization, including shares issuable upon
conversion of the outstanding May 2019 Notes in connection with this offering, calculated immediately prior to the closing of this offering. The Takeda Warrant Right will expire upon the closing of this offering (based on an assumed initial public
offering price of $19.00 per share, the midpoint of the price range set forth on the cover of this prospectus). </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019,
in connection with the entry into the Loan Agreement, we issued to the lenders the Lender Warrants to purchase an aggregate of 16,446 shares of our common stock with an exercise price equal to $15.20 per share (based on an assumed initial public
offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus). The Lender Warrants only become exercisable if and when we borrow Term Loan B under our Loan Agreement. The Lender Warrants expire
ten years from the date of issuance, subject to their earlier termination on September&nbsp;30, 2020 if we do not draw down on Term Loan&nbsp;B on or before March&nbsp;31, 2020. The Lender Warrants also include a put option pursuant to which, in the
event that we do not draw down on Term Loan&nbsp;B on or before March&nbsp;31, 2020, the lenders may require us to repurchase the Lender Warrants for a total aggregate repurchase price of $500,000. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">185 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Registration Rights </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, upon the closing of this offering holders of 12,068,938 shares of our common stock, which includes all of the shares of common stock issuable upon the automatic conversion of the May 2019
Notes, or their transferees, will be entitled to the following rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to the 2019 Note Purchase Agreement by and among us and certain investors. In
addition, upon the closing of this offering Takeda will be entitled to the same rights with respect to the registration of 7,588,000 shares of our common stock underlying the Takeda Warrant. The registration of shares of common stock as a result of
the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Demand Registration Rights </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Form <FONT
STYLE="white-space:nowrap">S-1.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></I> If at any time beginning six months following the effective date of the registration statement of which this prospectus forms a part, the holders of at least 25% of the registrable
securities request in writing that we effect a registration with respect to all or a part of the registrable securities then outstanding where the price to the public of the offering is $10.0&nbsp;million or more, we may be required to provide
notice to all holders of registrable securities and to use commercially reasonable efforts to effect such registration; provided, however, that we will not be required to effect such a registration if, within the preceding 12 months, we have already
effected two registrations for the holders of registrable securities in response to these demand registration rights, subject to certain exceptions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Form S-</I>3.&nbsp;&nbsp;&nbsp;&nbsp; If at any time we become entitled under the Securities Act to register our shares on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the holders of at least 20% of the
registrable securities request in writing that we effect a registration with respect to all or a part of the registrable securities then outstanding where the price to the public of the offering is $3.0&nbsp;million or more, we may be required to
provide notice to all holders of registrable securities and to use commercially reasonable efforts to effect such registration; provided, however, that we will not be required to effect such a registration if, within the preceding 12 months, we have
already effected two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If
the holders requesting registration intend to distribute their shares by means of an underwriting, the underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the
shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Piggyback Registration Rights </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">If at any time following the closing of this offering we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities will be
entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the
number of shares to be underwritten for reasons related to the marketing of the shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Indemnification </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase Agreement contains customary cross indemnification provisions, under which we are obligated to indemnify holders of
registrable securities in the event of material misstatements or omissions in a registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">186 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Expenses </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights.
These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders, blue sky fees and expenses and the expenses of any
special audits incident to the registration. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Termination of Registration Rights </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The registration rights terminate upon the earlier of: (i)&nbsp;five years after the closing of this offering or (ii)&nbsp;with respect to a
particular holder, such time at which such holder can sell all shares held by it in compliance with Rule 144 under the Securities Act. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Anti-Takeover
Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Some provisions of Delaware law, our amended and restated
certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or
otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or
in our best interests, including transactions which provide for payment of a premium over the market price for our shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">These
provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of
directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these
proposals because negotiation of these proposals could result in an improvement of their terms. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Undesignated Preferred Stock </I></B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The ability of our board of directors, without action by the stockholders, to issue up to 40,000,000 shares of undesignated preferred stock with
voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in
control or management of our company. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stockholder Meetings </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board of directors, chief executive officer or president, or by a resolution adopted by a
majority of our board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting
and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">187 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Elimination of Stockholder Action by Written Consent </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written consent
without a meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Staggered Board of Directors </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. For more information on the classified
board of directors, see &#147;Management&#151;Board Composition and Election of Directors.&#148; This system of electing and removing directors may tend to discourage a third party from attempting to obtain control of us, because it generally makes
it more difficult for stockholders to replace a majority of the directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Removal of Directors </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office except for cause
and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stockholders Not Entitled to Cumulative Voting </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our
common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Delaware Anti-Takeover Statute </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We
are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three
years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception
applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s
voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect
with respect to transactions not approved in advance by the board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Choice of Forum </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court
of Chancery of the State of Delaware will be the sole and exclusive forum under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary
duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents; (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General
Corporation Law of the State of Delaware or our amended and restated certificate of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">188 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
incorporation or amended and restated bylaws; (iv)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (v)&nbsp;any action
asserting a claim governed by the internal affairs doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts have
exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange
Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the
rules and regulations thereunder. In any case, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other
companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our amended and restated certificate of incorporation
also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Amendment of Charter Provisions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding
voting stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws
could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover
attempts. These provisions may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may
otherwise deem to be in their best interests. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is
250 Royall Street, Canton, Massachusetts 02021. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>The Nasdaq Global Market Listing </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have applied to have our common stock listed on the Nasdaq Global Market under the symbol &#147;PHAT.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Limitations of Liability and Indemnification Matters </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">For a discussion of liability and indemnification, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">189 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in the
public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Although we have applied to have our common stock listed on the Nasdaq Global Market, we cannot assure you that there will be an
active public market for our common stock. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Based on the number of shares of our common stock outstanding as of June&nbsp;30, 2019,
and assuming (i)&nbsp;the issuance of 7,900,000 shares in this offering, (ii)&nbsp;the automatic conversion of the May 2019 Notes into an aggregate of 6,106,940 shares of our common stock immediately prior to the closing of this offering (based on
an assumed initial public offering price of $19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on October 28, 2019), (iii) no exercise of the underwriters&#146; option
to purchase additional shares of common stock, and (iv)&nbsp;no exercise of outstanding options, warrants, or other rights we will have outstanding an aggregate of 25,883,458 shares of common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act,
except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. Shares purchased by our affiliates would be subject to the Rule 144 resale restrictions described below, other than the
holding period requirement. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The remaining 17,983,458 shares of common stock will be &#147;restricted securities,&#148; as that term
is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or 701 under the
Securities Act, each of which is summarized below. We expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, 7,588,000 shares of common stock issuable
to Takeda upon the exercise of the Takeda Warrant will become exercisable upon the closing of this offering. Upon exercise of the Takeda Warrant, these shares of common stock will be eligible for sale subject to the lock&#150;up agreements described
below and Rules 144 and 701 under the Securities Act. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days,
after the date of this prospectus, subject to specified exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock
or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See &#147;&#151;Registration Rights&#148; below and &#147;Description of Capital Stock&#151;Registration Rights.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC, and Evercore Group L.L.C. may, in their sole discretion and at any time or from time
to time before the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, in certain cases without public notice, release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements.
There are no existing agreements between the underwriters and any of our stockholders who will </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">190 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to such <FONT
STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the closing of this offering, certain of our officers, directors
and significant stockholders may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify
their assets and investments. Under these <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a broker may execute trades pursuant to parameters established by the officer, director or stockholder when entering into the plan, without
further direction from such officer, director or stockholder. Such sales would not commence until the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by such officer, director or stockholder in
connection with this offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Rule 144 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Affiliate Resales of Restricted Securities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days
before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of
shares within any three-month period that does not exceed the greater of: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">1% of the number of shares of our common stock then outstanding, which will equal approximately 258,834 shares immediately after this offering; or
</FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the average weekly trading volume in our common stock on the Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on Form 144
with respect to such sale. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Affiliate resales under Rule 144 are also subject to the availability of current public
information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form 144
with the SEC and the Nasdaq Global Market concurrently with either the placing of a sale order with the broker or the execution of a sale directly with a market maker. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an
affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell
such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the <FONT
STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT
STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Rule 701 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In general, under Rule 701, any of
an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">191 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
or other written agreement before the effective date of a registration statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule
144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule
144 without having to comply with the current public information and holding period requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Equity Plans </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all
shares of common stock subject to outstanding stock options and common stock issued or issuable under our equity incentive plans and employee stock purchase plan. We expect to file the registration statement covering shares offered pursuant to these
stock plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by affiliates in the
public market subject to compliance with the resale provisions of Rule 144. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Registration Rights </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, upon the closing of this offering holders of 12,068,938 shares of our common stock, which includes all of the shares of
common stock issuable upon the automatic conversion of the May 2019 Notes, or their transferees will be entitled to various rights with respect to the registration of these shares under the Securities Act. In addition, upon the closing of this
offering, Takeda will be entitled to the same rights with respect to the registration of 7,588,000 shares of our common stock underlying the Takeda Warrant. Registration of these shares under the Securities Act would result in these shares becoming
fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered by a registration
statement will be eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">192 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_18"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following discussion is a summary of the material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all
potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S.
Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect
as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This
discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This
discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the alternative minimum tax or the Medicare
contribution tax on net investment income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">U.S. expatriates and former citizens or long-term residents of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated
investment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">banks, insurance companies, and other financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">brokers, dealers or traders in securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that accumulate earnings to avoid U.S. federal
income tax; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">persons deemed to sell our common stock under the constructive sale provisions of the Code; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock being taken into account in an
&#147;applicable financial statement&#148; (as defined in the Code); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which are held by qualified
foreign pension funds. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If an entity treated as a partnership for U.S. federal income tax purposes holds our common
stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the
partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">193 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>THIS DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX
ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT
TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of this
discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A
U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a trust that (i)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning
of Section&nbsp;7701(a)(30) of the Code), or (ii)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Distributions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As described in the section entitled &#147;Dividend Policy,&#148; we do not
anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax
purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and
first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under
&#147;&#151;Sale or Other Taxable Disposition.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Subject to the discussion below on effectively connected income, dividends paid to
a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty,
provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other
applicable documentation) certifying qualification for the lower treaty rate). If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds the stock through a financial institution or other agent acting on the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide appropriate documentation to the agent, who then will be required to provide certification
to the applicable withholding agent, either directly or through other intermediaries. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate,
may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits
under any applicable income tax treaty. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively
connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">194 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such dividends are attributable), the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding
agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United
States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates.
A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends,
as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Sale or Other Taxable Disposition </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States
(and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is attributable); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States for 183 days or more during the
taxable year of the disposition and certain other requirements are met; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property holding corporation, or USRPHC, for U.S.
federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Gain described in the first bullet point above generally will be subject to U.S. federal
income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income
tax treaty) on such effectively connected gain, as adjusted for certain items. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Gain described in the second bullet point above will be
subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the
determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there
can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually or constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. If we are a USRPHC and either our common stock is not regularly traded on an established securities market or a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds,
or is treated as holding, more than 5% of our outstanding common stock, directly or indirectly, during the applicable testing period, such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will generally be taxed on any gain in the same manner
as gain that is effectively connected with the conduct of a U.S. trade </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">195 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
or business, except that the branch profits tax generally will not apply. If we are a USRPHC and our common stock is not regularly traded on an established securities market, a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s proceeds received on the disposition of shares will also generally be subject to withholding at a rate of 15%. Prospective investors are encouraged to consult their own tax advisors regarding
the possible consequences to them if we are, or were to become, a USRPHC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Information Reporting
and Backup Withholding </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable
withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns
are required to be filed with the IRS in connection with any dividends on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or
other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the
certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to
the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against
a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Withholding taxes may be
imposed under Sections 1471 to 1474 of the Code (such Sections are commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions
and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on, or subject to the proposed Treasury Regulations discussed below, gross proceeds from the sale or other
disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial
institution undertakes certain diligence and reporting obligations, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in
the Code) or furnishes identifying information regarding each substantial United States owner, or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an
exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in clause (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring,
among other things, that it undertake to identify accounts held by certain &#147;specified United States persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such
accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an
intergovernmental agreement with the United States governing FATCA may be subject to different rules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">196 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA
generally applies to payments of dividends on our common stock. While withholding under FATCA would also have applied to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019, recently proposed
Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our
common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">197 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_19"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain
conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC, and Evercore Group L.L.C. are the representatives of the underwriters. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Underwriters</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Number&nbsp;of</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Goldman Sachs&nbsp;&amp; Co. LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Jefferies LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Evercore Group L.L.C.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Needham &amp; Company, LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7,900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other
than the shares covered by the option described below unless and until this option is exercised. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters have an option to
buy up to an additional 1,185,000 shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise that option for 30 days. If any shares are purchased pursuant to
this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the
underwriters&#146; option to purchase 1,185,000 additional shares. </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>No&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Full&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Per Share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set
forth on the cover page of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public
offering price. After the initial offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the
underwriters&#146; right to reject any order in whole or in part. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We and our officers, directors, and holders of substantially all of
our securities have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this
prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of the representatives. This agreement does not apply to any existing employee benefit plans. See &#147;Shares Eligible for
Future Sale&#148; for a discussion of certain transfer restrictions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to the offering, there has been no public market for the
shares. The initial public offering price will be negotiated among our company and the representatives. Among the factors to be considered in determining the initial public offering price of the shares, in addition to prevailing market
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">198 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
conditions, will be our historical performance, estimates of our business potential and earnings prospects, an assessment of our management and the consideration of the above factors in relation
to market valuation of companies in related businesses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have applied to have our common stock listed on the Nasdaq Global Market
under the symbol &#147;PHAT.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the offering, the underwriters may purchase and sell shares of our common stock
in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required
to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that is not greater than the amount of additional
shares for which the underwriters&#146; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In
determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional
shares pursuant to the option described above. &#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must
cover any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open
market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the
offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a
portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have
the effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result, the price of the
common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the
Nasdaq Global Market, in the OTC market or otherwise. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We estimate that our share of the total expenses of the offering, excluding
underwriting discounts and commissions, will be approximately $2.8 million. We have also agreed to reimburse the underwriters for certain expenses incurred by them in connection with the offering in an amount up to $40,000. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">At our request, the underwriters have reserved up to 3.0% of the shares of common stock to be offered by this prospectus for sale, at the initial
public offering price, to certain of our directors, officers, employees, and their friends and family members through a directed share program. Goldman Sachs &amp; Co. LLC will administer our directed share program. The number of shares available
for sale to the general public in the offering will be reduced to the extent these persons purchase the reserved shares. Any reserved shares not so purchased will be offered by the underwriters to the general public
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">199 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
on the same terms as the other shares offered by this prospectus. The underwriters will receive the same discount from such reserved shares as they will from other shares of our common stock sold
to the public in this offering. We have agreed to indemnify the underwriters against certain liabilities and expenses, including liabilities under the Securities Act, in connection with sales of the reserved shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and
trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and
services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they received or
will receive customary fees and expenses.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the ordinary course of their various business activities, the underwriters and their
respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for
their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise)
and/or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent
research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>European Economic Area </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In relation to each
Member State of the European Economic Area (each a &#147;Member State&#148;), no shares of common stock (the &#147;Shares&#148;) have been offered or will be offered pursuant to the offering to the public in that Member State prior to the
publication of a prospectus in relation to the Shares which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all
in accordance with the Prospectus Regulation), except that offers of Shares may be made to the public in that Member State at any time under the following exemptions under the Prospectus Regulation: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior
consent of the representatives for any such offer; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">provided that no such offer of Shares shall require the company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to any Shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide
to purchase or subscribe for any Shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">200 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>United Kingdom </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Each Underwriter has represented and agreed that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in
investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (FSMA)) received by it in connection with the issue or sale of the Shares in circumstances in which Section 21(1) of the FSMA does not apply to the
company or the underwriter; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the Shares in, from or
otherwise involving the United Kingdom. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Canada </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument
<FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration
Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory of these rights or consult with a legal advisor. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Hong Kong </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The shares
may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of
the Laws of Hong Kong) (&#147;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#148;) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)
(&#147;Securities and Futures Ordinance&#148;), or (ii)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the
document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for
the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong)
other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made
thereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">201 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Singapore </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation
for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore
other than (i)&nbsp;to an institutional investor (as defined under Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;)) under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in
Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant
to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not
be transferable for 6 months after that corporation has acquired the shares under Section&nbsp;275 of the SFA except: (i)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2)
of the SFA), (ii) where such transfer arises from an offer in that corporation&#146;s securities pursuant to Section&nbsp;275(1A) of the SFA, (iii)&nbsp;where no consideration is or will be given for the transfer, (iv)&nbsp;where the transfer is by
operation of law, (v)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (vi)&nbsp;as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (&#147;Regulation
32&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where
the trustee is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#146; rights and interest (howsoever
described) in that trust shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (i)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as
defined in Section&nbsp;275(2) of the SFA), (ii) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for
each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (iii) where no consideration is or will be given for the transfer, (iv)&nbsp;where the transfer is by operation of law, (v)&nbsp;as
specified in Section&nbsp;276(7) of the SFA, or (vi)&nbsp;as specified in Regulation 32. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Japan </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as
amended), or the FIEA. The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws
of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any
relevant laws and regulations of Japan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Australia </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">This prospectus is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities&nbsp;&amp;
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">202 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">You confirm and warrant that you are either: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s certificate to
the Company which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a person associated with the Company under Section&nbsp;708(12) of the Corporations Act; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">You warrant and agree that
you will not offer any of the securities issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document
under section 708 of the Corporations Act. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Israel </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In Israel, this
prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law and (ii)&nbsp;investors listed in the first
addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange,
underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified
investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they
fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Switzerland </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock
exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards
for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the
securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Neither this prospectus nor
any other offering or marketing material relating to the offering, our company or the securities have been or will be filed with or approved by any Swiss regulatory authority. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">203 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities
has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to
acquirers of securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">204 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_20"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, San Diego, California. The
underwriters are being represented by Cooley LLP, San Diego, California. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_21"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our combined financial statements at December 31, 2018 and for
the year then ended, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about Phathom Pharmaceuticals, Inc.&#146;s ability to continue as a going concern as described in
Note&nbsp;1 to the combined financial statements). We have included our combined financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst &amp; Young LLP&#146;s report, given on their authority as
experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to
the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other
document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the
registration statement. Upon the closing of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. The SEC maintains an Internet website that contains reports,
proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is www.sec.gov. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Upon the closing of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, will file periodic reports, proxy statements and
other information with the SEC. Such periodic reports, proxy statements and other information will be available at the website of the SEC referred to above. We maintain a website at www.phathompharma.com. Upon the closing of this offering, you may
access our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those
reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The
reference to our website address does not constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">205 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_23"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>INDEX TO COMBINED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_2">Combined Balance Sheets</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-3</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_3">Combined Statements of&nbsp;Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_4">Combined Statements&nbsp;of&nbsp;Stockholders&#146; Deficit</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_5">Combined Statements of Cash Flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-6</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_6">Notes to Combined Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-7</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">To the Stockholders and the Board of Directors of </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">Phathom Pharmaceuticals, Inc. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Opinion on the Financial Statements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have audited the accompanying combined balance sheet of Phathom Pharmaceuticals, Inc. (the Company) as of December&nbsp;31, 2018, the related
combined statement of operations, stockholders&#146; deficit and cash flows for the year then ended, and the related notes (collectively referred to as the &#147;combined financial statements&#148;). In our opinion, the combined financial statements
present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2018, and the results of its operations and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The Company&#146;s Ability to Continue as a Going Concern </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The accompanying combined financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred net losses
and negative cash flows from operating activities since its inception, and has stated that substantial doubt exists about the Company&#146;s ability to continue as a going concern. Management&#146;s evaluation of the events and conditions and
management&#146;s plans regarding these matters are also described in Note 1. The combined financial statements do not include any adjustments that might result from the outcome of these uncertainties. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Basis for Opinion </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">These financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audit. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over
financial reporting. Accordingly, we express no such opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable
basis for our opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:55%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">/s/ Ernst&nbsp;&amp; Young LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">We have served as the Company&#146;s auditor since 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">San Diego, California
</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">July 26, 2019 </FONT></P>   <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
STYLE="font-family:ARIAL" SIZE="2">except for the last paragraph in Note&nbsp;8, as to which the date is </FONT></P>   <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">October&nbsp;15, 2019 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_2"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>COMBINED BALANCE SHEETS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>(in
thousands, except share and par value data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro&nbsp;Forma<BR>June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Prepaid expenses and other current assets (including related party amounts of $19 and $15, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Liabilities and Stockholders&#146; Deficit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accounts payable (including related party amounts of $45 and $31, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accrued expenses (including related party amounts of $2 and $19, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accrued interest (including related party amounts of $13 and $82, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes payable at fair value (including related party amounts of $1,950 and $20,552, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities (including related party amounts of ($0 and $49,171, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">144,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, net of discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">22,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">169,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Commitments and contingencies (Note 3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Stockholders&#146; deficit:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock, $0.0001 par value; authorized shares&#151;50,000,000 at June&nbsp;30, 2019 (unaudited); issued shares&#151;11,876,518 at
June&nbsp;30, 2019 (unaudited); outstanding shares&#151;7,219,268 at June&nbsp;30, 2019 (unaudited); 17,983,458 and 13,326,208&nbsp;shares issued and outstanding, respectively, pro forma (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">148,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">58,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total liabilities and stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See accompanying notes. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_3"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>COMBINED STATEMENTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(in thousands, except share and per share data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year&nbsp;Ended<BR>December<BR>31,&nbsp;2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative (includes related party amounts of $321, $124 and $18, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense (includes related party amounts of $(13), $(4) and $(82), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities (includes related party amounts of $0, $0 and $(1,277), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes (includes related party amounts of $(50), $(4) and $(502),
respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Weighted-average shares of common stock outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,051,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,331,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,640,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss per share, basic and diluted (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(9.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma weighted-average shares of common stock outstanding, basic and diluted (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,098,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,578,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See accompanying notes. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_4"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>COMBINED STATEMENTS OF STOCKHOLDERS&#146; DEFICIT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(in thousands, except share data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Common&nbsp;Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Accumulated<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Combined balance at January&nbsp;1, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock to founders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Combined balance at December&nbsp;31, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Merger of entities under common control into the Company (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,760,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Vesting restrictions placed on previously issued and outstanding common stock (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(3,373,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,491,072</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock in connection with license agreement (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,084,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Vesting of restricted shares (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,257,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at June&nbsp;30, 2019 (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7,219,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Common&nbsp;Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Accumulated</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Deficit&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Combined balance at January&nbsp;1, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock to founders (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Combined balance at June&nbsp;30, 2018 (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See accompanying notes. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_5"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>COMBINED STATEMENTS OF CASH FLOWS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(in thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year&nbsp;Ended<BR>December&nbsp;
31,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Cash flows from operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Amortization of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities (includes related party amounts of $0, $0 and $1,277, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes (includes related party amounts of $50, $4 and $502, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Prepaid expenses and other current assets (includes related party amounts of $(19), $(13) and $4, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accounts payable and accrued expenses (includes related party amounts of $47, $54 and $3, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">883</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accrued interest (includes related party amounts of $13, $4 and $82, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">981</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(6,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Cash flows from investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash paid for purchased <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(25,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(25,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Cash flows from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Proceeds from issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Proceeds from issuance of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">88,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Proceeds from issuance of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">113,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net increase in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents&#151;beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents&#151;end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Supplemental disclosure of cash flow information</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest paid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Supplemental disclosure of noncash investing and financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Exchange of accrued interest for convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of Takeda Warrants in connection with Takeda License</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">47,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock in connection with Takeda License</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock warrants in connection with long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Unpaid initial public offering costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Final interest payment fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See accompanying notes. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_6"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>1. Organization, Basis of Presentation and Summary of Significant Accounting Policies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Organization
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Phathom Pharmaceuticals, Inc. (the &#147;Company&#148; or &#147;Phathom&#148;) was incorporated in the state of Delaware in
January 2018 under the name North Bridge IV, Inc. On March&nbsp;13, 2019, the Company changed its name to Phathom Pharmaceuticals, Inc. and merged with YamadaCo IIA, Inc. (&#147;YamadaCo&#148;), a Delaware corporation formed in September 2017, with
Phathom being the surviving entity (the &#147;Merger&#148;). All activities of YamadaCo prior to 2018 related to formation and were insignificant. The Company is a late clinical-stage biopharmaceutical company focused on developing and
commercializing novel treatments for gastrointestinal diseases. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stock Split and Conversion </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">During 2018, without consideration of the forward stock split described in Note&nbsp;8, both the Company and YamadaCo issued 1,000 shares of common
stock at a purchase price of $1.00 per share, and had no other capital transactions prior to the Merger. Immediately prior to the Merger, the Company effected a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1,559.1183-for-1</FONT></FONT> forward stock split for each outstanding share of its common stock and, effective upon the closing of the Merger, each issued and outstanding share of
YamadaCo was converted into 1,559.1183 shares of the Company&#146;s common stock. Upon completion of the Merger, the Company had 6,760,334 shares of common stock outstanding, with the prior stockholders of each YamadaCo and Phathom holding an equal
number of shares. The accompanying combined financial statements and notes to the combined financial statements give retroactive effect to the forward stock split and conversion for all periods presented. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Basis of Presentation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
Company&#146;s combined financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;). The accompanying combined financial statements include the accounts of the Company (the receiving entity)
and YamadaCo, prior to the Merger. The Company and YamadaCo were entities under the common control of Frazier Life Sciences IX, L.P. (&#147;Frazier&#148;) as a result of, among others, Frazier&#146;s; (i)&nbsp;ownership of a majority of the
outstanding capital stock of both companies, (ii)&nbsp;financing of both companies, (iii)&nbsp;control of board of directors of both companies, and (iv)&nbsp;management of both companies. Both the Company and YamadaCo were formed for the purpose of
identifying potential assets around which to form an operating company. As the merged entities were under common control, the combined financial statements report the financial position, results of operations and cash flows of the Company and
YamadaCo as though the transfer of net assets and equity interests had occurred at the beginning of 2018. All intercompany accounts and transactions have been eliminated in combination. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Liquidity and Capital Resources </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From inception to June&nbsp;30, 2019, the Company has
devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> its initial product candidate, vonoprazan, meeting with regulatory authorities,
and preparing for the planned Phase 3 clinical trials of vonoprazan. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses
and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development and commercialization
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(CONTINUED) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
of vonoprazan. From inception to June&nbsp;30, 2019, the Company has funded its operations through the issuance of convertible promissory notes and commercial bank debt. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The accompanying combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the
realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of
liabilities that may result from the outcome of this uncertainty. Management is required to perform a <FONT STYLE="white-space:nowrap">two-step</FONT> analysis over the Company&#146;s ability to continue as a going concern. Management must first
evaluate whether there are conditions and events that raise substantial doubt about the Company&#146;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider
whether its plans alleviate that doubt (Step 2). Management has prepared cash flow forecasts which indicate that based on the Company&#146;s expected operating losses, negative cash flows and maturities of outstanding convertible promissory notes,
there is substantial doubt about the Company&#146;s ability to continue as a going concern for twelve months after the date the combined financial statements for the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019 are
issued. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company&#146;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management
plans to raise additional capital through equity offerings, the Company&#146;s existing loan and security agreement, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While
management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company may not be able to
secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may
have rights, preferences and privileges senior to those of the Company&#146;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable
rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or
other operations. If any of these events occur, the Company&#146;s ability to achieve the development and commercialization goals would be adversely affected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Use of Estimates </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The preparation of the Company&#146;s combined financial statements
requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#146;s combined financial statements and accompanying notes.
The most significant estimates in the Company&#146;s combined financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments.
Although these estimates are based on the Company&#146;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Unaudited Interim Financial Information </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The accompanying interim balance sheet as of June&nbsp;30, 2019, the combined statements of operations and cash flows for the six months ended June&nbsp;30, 2018 and 2019 and the combined
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(CONTINUED) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
statement of stockholders&#146; deficit for the six months ended June&nbsp;30, 2018 and 2019 and the related footnote disclosures are unaudited. In management&#146;s opinion, the unaudited
interim financial statements have been prepared on the same basis as the audited combined financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#146;s
financial position as of June&nbsp;30, 2019 and its results of operations and cash flows for the six months ended June&nbsp;30, 2018 and 2019 in accordance with GAAP. The results for the six months ended June&nbsp;30, 2019 are not necessarily
indicative of the results expected for the full fiscal year or any other interim period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Unaudited Pro Forma Balance Sheet Information
</I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The unaudited pro forma balance sheet information as of June&nbsp;30, 2019 in the accompanying combined balance sheet gives
effect to: (i)&nbsp;the automatic conversion of all outstanding convertible promissory notes and related accrued interest (see Note 4) into&nbsp;6,106,940 shares of common stock (assuming an initial public offering (&#147;IPO&#148;) price of $19.00
per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs on&nbsp;October 28, 2019), the expected closing date of the Company&#146;s IPO, and (ii)&nbsp;the reclassification
of the Takeda Warrant to stockholders&#146; equity. Shares of common stock issued in the IPO and any related net proceeds are excluded from the pro forma information. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Fair Value Option </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As permitted under Accounting Standards Codification
(&#147;ASC&#148;) 825, <I>Financial Instruments</I>, (&#147;ASC 825&#148;), the Company has elected the fair value option to account for its convertible promissory notes issued since inception. In accordance with ASC 825, the Company records these
convertible promissory notes at fair value with changes in fair value recorded in the combined statements of operations. As a result of applying the fair value option, direct costs and fees related to the convertible promissory notes were recognized
in earnings as incurred and not deferred. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Fair Value Measurements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset
and liability category measured at fair value on either a recurring or <FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a
basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Level&nbsp;1:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Observable inputs such as quoted prices in active markets. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Level&nbsp;2:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Level&nbsp;3:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The carrying amounts of the Company&#146;s financial instruments, including cash and cash equivalents classified
within the Level&nbsp;1 designation discussed above, prepaid and other current </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(CONTINUED) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Warrant liabilities and convertible promissory notes are recorded at fair value on a
recurring basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company has no financial assets measured at fair value on a recurring basis. None of the Company&#146;s <FONT
STYLE="white-space:nowrap">non-financial</FONT> assets or liabilities are recorded at fair value on a <FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. No transfers between levels have occurred during the periods presented. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Liabilities measured at fair value on a recurring basis are as follows (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at<BR>Reporting&nbsp;Date&nbsp;Using:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets<BR>for&nbsp;Identical<BR>Assets</B></FONT><br><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>(Level&nbsp;1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Significant<BR>Other<BR>Observable<BR>Inputs</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Level&nbsp;
2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Significant<BR>Unobservable<BR>Inputs</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Level&nbsp;
3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December&nbsp;31, 2018:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;142,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;142,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The warrant liabilities consist of an issued and outstanding common stock warrant (the &#147;Takeda Warrant&#148;)
and a right to receive an additional common stock warrant (the &#147;Takeda Warrant Right&#148;, and together with the Takeda Warrant, the &#147;Takeda Warrants&#148;) issued to Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;) in
connection with a May 2019 license agreement (see Note 3) and warrants (the &#147;Lender Warrants&#148;) issued in connection with a loan and security agreement for commercial bank debt (see Note 5). The Takeda Warrants are accounted for as
liabilities as they do not meet all the conditions for equity classification due to (i)&nbsp;insufficient authorized shares for the Takeda Warrant and (ii)&nbsp;the Takeda Warrant Right is not indexed to the Company&#146;s own stock. The Lender
Warrants are accounted for as liabilities as they contain a holder put right under which the lenders could require the Company to pay cash in exchange for the warrants. The fair value of the Takeda Warrants is derived from the model used to estimate
the fair value the Company&#146;s common stock (see Note 6). The fair value of the Lender Warrants is estimated using a probability-weighted model considering IPO and <FONT STYLE="white-space:nowrap">non-IPO</FONT> scenarios. The IPO scenarios
utilize a binomial lattice model to estimate a distribution of total equity values as of a projected IPO date. The <FONT STYLE="white-space:nowrap">non-IPO</FONT> scenario utilizes the repurchase price associated with the warrant put right
discounted to present value based on venture capital rates of return and the term associated with the put right. As of June&nbsp;30, 2019, the fair value of the Takeda Warrants was $49.2&nbsp;million and the fair value of the Lender Warrants was
$0.4&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As further described in Note 4, the Company issued convertible promissory notes to Frazier (the &#147;Frazier
Notes&#148;) from January 2018 to April 2019 and issued convertible promissory notes in May 2019 (the &#147;May 2019 Notes&#148;) to investors including Frazier. The Company has elected the fair value option for each of its convertible promissory
note issuances. The fair value of the Frazier Notes was estimated using a scenario-based analysis that estimated the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment
returns, considering possible </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-10 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
outcomes available to the noteholders, including conversions in subsequent equity financings, change of control transactions, settlement and dissolution. The fair value of the May 2019 Notes is
estimated using a scenario-based analysis that estimates the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to
the noteholders, including various IPO, settlement, equity financing, corporate transaction and dissolution scenarios. As of December&nbsp;31, 2018, the fair value of the Frazier Notes was $2.0&nbsp;million and the Frazier Notes were exchanged for
May 2019 Notes in May 2019. As of June&nbsp;30, 2019, the fair value of the May 2019 Notes was $92.7&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company adjusts
the carrying value of its warrant liabilities and convertible promissory notes to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as change in fair value of warrant liabilities
and change in fair value of convertible promissory notes, respectively, in the combined statements of operations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table
summarizes information about the significant unobservable inputs used in the fair value measurements for the Takeda Warrants and the May 2019 Notes: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Liability</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair&nbsp;value<BR>as&nbsp;of&nbsp;initial<BR>valuation
date</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair&nbsp;value<BR>as&nbsp;of<BR>June&nbsp;30,&nbsp;
2019</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair value method as
of<BR>initial&nbsp;valuation&nbsp;date</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(and relative weighting)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair&nbsp;value&nbsp;method</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>as&nbsp;of June&nbsp;30,&nbsp;2019</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>(and relative weighting)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Key&nbsp;unobservable&nbsp;inputs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Range</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">Takeda Warrants</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">47,894</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">49,171</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Financing&nbsp;transactions&nbsp;(40%)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Income
approach (60%)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Financing&nbsp;transactions&nbsp;(40%)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Income
approach (60%)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Transaction&nbsp;prices&nbsp;per&nbsp;share</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Estimated time to liquidity</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Discount rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"></P> <P STYLE="margin-bottom:1px; margin-top:0px"></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="white-space:nowrap">$9.33-$10.56</FONT></FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT
STYLE="white-space:nowrap">0.29-1.73&nbsp;years</FONT></FONT></P> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">13</FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT
STYLE="font-family:ARIAL" SIZE="1">%&nbsp;</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">May&nbsp;2019 Notes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">90,250</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">92,743</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Financing&nbsp;transactions&nbsp;(40%)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Income
approach (60%)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Financing transactions (40%)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Income approach
(60%)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Estimated&nbsp;time&nbsp;to liquidity</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Volatility</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Discount rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"></P> <P STYLE="margin-bottom:1px; margin-top:0px"></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="white-space:nowrap">0.29-1.73&nbsp;years</FONT></FONT><BR>
<P STYLE="margin-bottom:0px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">70</FONT></P>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="white-space:nowrap">22.6%-25</FONT></FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">%&nbsp;</FONT></P> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT
STYLE="font-family:ARIAL" SIZE="1">%&nbsp;</FONT></P></TD></TR>
</TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There are significant judgments, assumptions and estimates inherent in the determination of the fair value of
each of the instruments described above. These include determination of a valuation method and selection of the possible outcomes available to the Company, including the determination of timing and expected future investment returns for such
scenarios. The Company considered the equity value of an initial public offering using market transactions and have determined the expected value of various stay private and dissolution scenarios using the income approach, which is based on
assumptions regarding the Company&#146;s future operating performance. The related judgments, assumptions and estimates are highly interrelated and changes in any one assumption could necessitate changes in another. In particular, any changes in the
probability of a particular outcome would require a related change to the probability of another outcome. In addition, the fair value of the May 2019 Notes is derived using assumptions that are consistent with the assumptions used to value the
Company&#146;s common stock and the Takeda Warrants, and the concluded fair value of the May 2019 Notes is used in the determination of both the fair value of the Company&#146;s common stock and the Takeda Warrants. In the future, depending on the
valuation approaches used and the expected timing and weighting of each, the inputs described above, or other inputs, may have a greater or lesser impact on the Company&#146;s estimates of fair value. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-11 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table provides a reconciliation of all liabilities measured at fair value using
Level&nbsp;3 significant unobservable inputs (in thousands): </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Warrant<BR>Liabilities</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Convertible<BR>Promissory<BR>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at January&nbsp;1, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at December&nbsp;31, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">90,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Exchange of convertible promissory notes (Note 4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">48,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Cash and Cash Equivalents </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking
accounts and money market funds. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Concentrations of Credit Risk </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial
institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository
institutions in which those deposits are held. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Deferred Offering Costs </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company has deferred offering costs consisting of legal, accounting and other fees and costs directly attributable to its planned IPO. The
deferred offering costs will be offset against the proceeds received upon the completion of the planned IPO. In the event the planned IPO is terminated, all of the deferred offering costs will be expensed within the Company&#146;s statements of
operations. As of June&nbsp;30, 2019, $0.3&nbsp;million of deferred offering costs were recorded within other long-term assets on the balance sheet. No such costs were included on the combined balance sheet as of December&nbsp;31, 2018. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Research and Development Expenses and Accruals </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in
research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#146;s planned clinical trials of vonoprazan, and costs
related to manufacturing vonoprazan for clinical trials. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-12 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company has entered into various research and development contracts with clinical research
organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of
performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the
accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances
at the end of any reporting period. Actual results could differ from the Company&#146;s estimates. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use.
Intangible assets that do not have future alternative use are considered acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development. When the acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of
the awards (generally the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Income Taxes
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax
assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the
financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in
the statement of operations in the period that includes the enactment date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company recognizes net deferred tax assets to the
extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary
differences, projected future taxable income, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future
in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Company records uncertain tax positions on the basis of a <FONT STYLE="white-space:nowrap">two-step</FONT> process whereby (i)&nbsp;management determines whether it is more likely than not that the tax
positions will be sustained on </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-13 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
the basis of the technical merits of the position and (ii)&nbsp;for those tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold,
management recognizes the largest amount of tax benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax
benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Comprehensive Loss
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <FONT
STYLE="white-space:nowrap">non-owner</FONT> sources. The Company&#146;s comprehensive loss was the same as its reported net loss for all periods presented. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Segment Reporting </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating segments are identified as components of an enterprise
about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business
as one operating segment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Net Loss Per Share </I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 and 2019, the net loss per share was recast to include in the numerator the net losses of both the Company and YamadaCo and
include in the denominator the combined weighted-average outstanding shares of both the Company and YamadaCo. Basic net loss per share is computed by dividing the combined net loss by the weighted-average number of common shares outstanding for the
period, without consideration for potentially dilutive securities. The Company has excluded weighted-average unvested shares of 2,728,593 shares from the weighted-average number of common shares outstanding for the six months ended June&nbsp;30,
2019. No shares of common stock were unvested during the year ended December&nbsp;31, 2018. Diluted net loss per share is computed by dividing the combined net loss by the weighted-average number of common shares and dilutive common stock
equivalents outstanding for the period determined using the treasury-stock and <FONT STYLE="white-space:nowrap">if-converted</FONT> methods. Dilutive common stock equivalents are comprised of unvested common stock, warrants and convertible
promissory notes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The unaudited pro forma basic and diluted net loss per share reflects (i)&nbsp;the automatic conversion of all outstanding convertible promissory notes and related accrued interest into&nbsp;6,106,940&nbsp;shares
of common stock (assuming an IPO price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs on&nbsp;October 28, 2019, the expected closing date of the
Company&#146;s IPO), and (ii)&nbsp;the reclassification of the Takeda Warrant to stockholders&#146; equity, each as of the beginning of the period presented or the issuance date, if later. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The unaudited pro forma basic and diluted net loss per share amounts do not give effect to the issuance of common stock issued in the IPO nor do
they give effect to potential dilutive securities where the impact would be anti-dilutive. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-14 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table summarizes the Company&#146;s unaudited pro forma net loss per share (in
thousands, except share and per share data): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six&nbsp;Months</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Ended</B></FONT><br><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Numerator</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense on convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of Takeda Warrant</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,277</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Denominator</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Weighted-average shares of common stock outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,051,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,640,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma adjustments to reflect assumed weighted-average effect of conversion of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">46,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,937,902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma weighted-average shares of common stock outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,098,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,578,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(9.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Recently Adopted Accounting Pronouncements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In June 2018, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation (Topic</I><I></I><I>&nbsp;718): Improvements to Nonemployee Share-Based Payment Accounting</I>. This guidance expands the scope of Topic&nbsp;718,
<I>Compensation&#151;Stock Compensation</I>, which currently only includes share-based payments to employees, to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to
nonemployees and employees will be substantially aligned. This ASU supersedes <FONT STYLE="white-space:nowrap">Subtopic&nbsp;505-50,</FONT> <I>Equity&#151;Equity-Based Payments to <FONT STYLE="white-space:nowrap">Non-Employees</FONT></I> and is
effective for public companies for annual periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years, with early adoption permitted as long as ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09</FONT> has
been adopted by the Company. The Company adopted this guidance effective January&nbsp;1, 2018, and the adoption did not have a material impact on the Company&#146;s financial statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases (Topic 842)</I>, which requires a lessee
to recognize a lease liability and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for all leases with lease terms of more than 12 months. Additionally, certain qualitative and quantitative
disclosures will be required in the financial statements. This guidance is effective for annual reporting periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years, and early adoption is permitted. Companies
may adopt this guidance using a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company adopted this guidance effective January&nbsp;1,
2018, and the adoption did not have any impact on the Company&#146;s financial statements as the Company did not have any leases through June&nbsp;30, 2019. As </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-15 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
the Company enters into future, material lease agreements, the adoption of this guidance is expected to result in a significant increase in the total assets and liabilities reported on the
balance sheets. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Recently Issued Accounting Pronouncements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair Value Measurement (Topic 820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value
Measurement,</I> which eliminates, modifies and adds disclosure requirements on fair value measurements. The standard is effective for annual periods beginning after December&nbsp;15, 2019, including interim periods within those fiscal years, and
early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13</FONT> will have on the Company&#146;s financial statements. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>2. Related Party Transactions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Frazier is a
principal stockholder of the Company and is represented on the Company&#146;s board of directors. For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019, the Company conducted its operations within office space
controlled by Frazier and Frazier allocated a portion of the costs associated with this office to the Company. In addition, Frazier paid for various goods and services, such as employee wages, insurance and expense reimbursements and various
administrative services associated with the operations of the Company and charged the Company for those expenses. As of December&nbsp;31, 2018 and June&nbsp;30, 2019, the Company had outstanding accounts payable balances due to Frazier of $45,000
and $50,000, respectively, related to these shared operating expenses. For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 and 2019, the Company incurred $0.3&nbsp;million, $0.1&nbsp;million and $0.1&nbsp;million,
respectively, of shared operating expenses. In addition to the shared operating expenses, the Company issued convertible promissory notes to Frazier during 2018 and 2019 (see Note 4). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Mountain Field LLC (&#147;Mountain Field&#148;) is an entity owned by the chairman of the Company&#146;s board of directors. During the year ended
December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019, the Company charged Mountain Field for certain rent and payroll related expenses. These shared expenses were allocated based on usage of the related facilities and time incurred by
personnel. As of December&nbsp;31, 2018 and June&nbsp;30, 2019, the Company had an outstanding accounts receivable balance from Mountain Field of $19,000 and $15,000, respectively, related to shared operating expenses. For the year ended
December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 and 2019, the Company charged Mountain Field $4,000, $3,000 and $0.1&nbsp;million, respectively, for shared expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Takeda became a common stockholder of the Company as of May&nbsp;7, 2019 in connection with the May 2019 license agreement (see Note 3).
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>3. Commitments and Contingencies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>License
Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an
exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe (the &#147;Takeda License&#148;). The Company also has the right to sublicense its rights under the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-16 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
agreement, subject to certain conditions. The agreement will remain in effect, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, until the later of (i)&nbsp;the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at
least one other therapeutically active ingredient, (ii)&nbsp;the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License
upon six months&#146; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#146;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists
in challenging, licensed patents. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In consideration of the Takeda License, the Company (i)&nbsp;paid Takeda $25.0&nbsp;million in
cash, (ii)&nbsp;issued Takeda 1,084,000 shares of its common stock at a fair value of $5.9&nbsp;million, (iii)&nbsp;issued the Takeda Warrant to purchase 7,588,000 shares of its common stock at an exercise price of $0.00004613 per share at an
initial fair value of $47.9&nbsp;million, and (iv)&nbsp;issued the Takeda Warrant Right to receive an additional common stock warrant should Takeda&#146;s fully-diluted ownership of the Company represent less than a certain specified percentage of
the fully-diluted capitalization, including shares issuable upon conversion of outstanding convertible promissory notes, calculated immediately before the closing of the Company&#146;s IPO, with a nominal initial fair value due to the low
probability of issuance. In addition, the Company is obligated to pay Takeda up to an aggregate of $250.0&nbsp;million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate
net sales of licensed products, subject to certain adjustments. The Company incurred $0.1&nbsp;million of transaction costs in connection with the Takeda License. The Takeda Warrant has an exercise price of $0.00004613 per share, expires on
May&nbsp;7, 2029 and becomes exercisable upon (i)&nbsp;certain change of control transactions of the Company or (ii)&nbsp;the consummation of an IPO by the Company. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The transaction has been accounted for as an asset acquisition as substantially all of the fair value is concentrated in a group of similar assets. The $78.9&nbsp;million fair value of the consideration paid for
these research and development assets, which have no alternative future use, was recorded as <FONT STYLE="white-space:nowrap">in-process</FONT> research and development in the Company&#146;s combined statement of operations for the six months ended
June&nbsp;30, 2019. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Contingencies </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be
made and such expenditures can be reasonably estimated. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>4. Convertible Promissory Notes </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Frazier Convertible Note Financing </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From January 2018 to April 2019, the Company issued
the Frazier Notes for an aggregate of $2.4&nbsp;million and bearing interest at per annum rates ranging from 1.68% to 2.55%. Of the Frazier Notes, $1.9&nbsp;million were issued in 2018 and $0.5&nbsp;million were issued in April 2019. Due to certain
embedded features within the Frazier Notes, the Company elected to account for these notes and all their embedded features under the fair value option. The Company recorded changes in the fair value of the Frazier Notes in the combined statements of
operations until May 2019, when the Frazier Notes and related accrued interest were exchanged, at their then fair value of $2.4&nbsp;million, for the May 2019 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-17 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
Notes. For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018, the Company recognized $50,000 and $4,000, respectively, of change in fair value of convertible
promissory notes in the combined statements of operations related to increases in the fair value of the Frazier Notes. For the six months ended June&nbsp;30, 2019, the Company recognized $50,000 of other income in the combined statements of
operations related to decreases in the fair value of the Frazier Notes. For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 and 2019, the Company recognized $13,000, $4,000 and $15,000, respectively, of interest
expense in connection with the Frazier Notes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>May 2019 Convertible Note Financing </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, the Company entered into a note purchase agreement under which it issued the unsecured May 2019 Notes for an aggregate of
$90.3&nbsp;million, resulting in gross proceeds to the Company of $87.8&nbsp;million in cash and $2.4&nbsp;million related to the exchange of the Frazier Notes and related accrued interest for the May 2019 Notes. Including the conversion of the
Frazier Notes, Frazier purchased $20.0&nbsp;million of the May 2019 Notes. The May 2019 Notes bear interest at a rate of 6% per annum and are subordinated to borrowings under the Company&#146;s loan and security agreement (see Note 5). The May 2019
Notes become payable upon demand of the holders of at least 60% of the outstanding principal amount of the May 2019 Notes, including Frazier, on May&nbsp;7, 2020 (the &#147;Maturity Date&#148;), and become due and payable on May&nbsp;7, 2022,
subject to earlier conversion or repayment in the event the Company completes certain equity financings or a change of control. The May 2019 Notes can be converted/redeemed as follows (i)&nbsp;automatically converted upon a qualified equity
financing, with a conversion price of the lesser of 80% of the price paid per share in such financing or the conversion cap price per share, (ii)&nbsp;optionally converted upon a <FONT STYLE="white-space:nowrap">non-qualified</FONT> equity financing
with a conversion price of 80% of the price paid per share in such financing, (iii)&nbsp;optionally converted any time after the Maturity Date, with a conversion price per share of the conversion cap price per share, (iv)&nbsp;automatically upon an
IPO with a conversion price per share of the lesser of 80% of the IPO price per share, or the conversion cap price per share, and (v)&nbsp;upon certain corporate transactions, receive cash equal to the greater of (A)&nbsp;two times the then
outstanding principal and accrued interest and (B)&nbsp;an amount equal to the amount that would be received as if the May 2019 Notes were converted with a conversion price of the conversion cap price per share. The conversion cap price per share is
defined as $500.0&nbsp;million less the outstanding principal and accrued interest divided by the total of (1)&nbsp;the total number of common shares outstanding immediately prior to conversion, (2)&nbsp;the number of common shares issuable upon
exercise or conversion of exercisable or convertible securities, and (3)&nbsp;the number of shares of capital stock reserved for issuance under the Company&#146;s equity incentive plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The note purchase agreement includes, among others, covenants related to delivery of certain financial reports, certain registration rights, voting
provisions regarding the composition of the Company&#146;s board of directors, and limitations on the Company&#146;s ability to pay dividends, incur additional indebtedness or consummate certain changes of control. The note purchase agreement also
contains customary events of default, including bankruptcy, the failure to make payments when due, and certain material adverse changes. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the
Company may be declared immediately due and payable. As of June&nbsp;30, 2019, the Company was in compliance with all applicable covenants under the note purchase agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Due to certain embedded features within the May 2019 Notes, the Company elected to account for these notes and all their embedded features under the fair value option. For the six months ended
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-18 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
June&nbsp;30, 2019, the Company recognized $2.5&nbsp;million of other expense in the combined statements of operations related to increases in the fair value of the May 2019 Notes. For the six
months ended June&nbsp;30, 2019, the Company recognized $0.8&nbsp;million of interest expense in connection with the May 2019 Notes. As of June 30, 2019, the outstanding principal and accrued interest on the May 2019 Notes was $90.3 million and $0.8
million, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>5. Long-Term Debt </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Long-term debt consists of the following (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Unamortized debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, net of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;14, 2019, the Company entered into a loan and security agreement (the &#147;Loan Agreement&#148;, and
all amounts borrowed thereunder the &#147;Term Loans&#148;) with Silicon Valley Bank (&#147;SVB&#148;), as administrative and collateral agent, and lenders including SVB and WestRiver Innovation Lending Fund VIII, L.P. (&#147;WestRiver&#148;). The
Company borrowed $25.0&nbsp;million (&#147;Term Loan A&#148;) at the inception of the Loan Agreement and has the right to borrow an additional $25.0&nbsp;million (&#147;Term Loan B&#148;). Term Loan B is available through March&nbsp;31, 2020,
provided that (i)&nbsp;the Company has received at least $150.0&nbsp;million of net cash proceeds in connection with the issuance and sale, subsequent to April&nbsp;1 2019, of its equity securities and subordinated debt, (ii)&nbsp;the Company has
initiated Phase 3 clinical trials for vonoprazan, and (iii)&nbsp;no event of default has occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Term Loans bear interest at a
floating rate of the higher of the Wall Street Journal Prime rate plus 1.75% (7.25% at June&nbsp;30, 2019) or 7.25%. The monthly payments consist of interest-only through June&nbsp;1, 2021 or, in the event of positive data with respect to the
Company&#146;s Phase 3 clinical trial in both indications for Vonoprazan sufficient to file an NDA with the FDA, through June&nbsp;1, 2022. Subsequent to the interest-only period, the Term Loans will be payable in equal monthly installments of
principal, plus accrued and unpaid interest through the maturity date of May&nbsp;1, 2024. In addition, the Company is obligated to pay a final payment fee of 8.25% of the original principal amount of the Term Loans. As of June&nbsp;30, 2019, the
final payment fee of $2.1&nbsp;million has been recorded as an other long-term liability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company may elect to prepay all or a
portion of the Term Loans prior to maturity, subject to a prepayment fee of up to 2.0% of the then outstanding principal balance and payment of a pro rata portion of the final payment fee. After repayment, no Term Loan amounts may be borrowed again.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The borrowings under the Loan Agreement are collateralized by substantially all of the Company&#146;s assets, excluding intellectual
property and certain other assets. The Loan Agreement includes affirmative and negative covenants. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver
certain financial reports, maintain insurance coverage and satisfy certain requirements regarding its operating accounts. The negative covenants include, among others, limitations on the Company&#146;s
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-19 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain
investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions. The Loan Agreement also contains customary events of default, including bankruptcy, the failure to make
payments when due, and a material adverse change. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company would begin to bear interest at a rate that is 4.00% above the rate effective
immediately before the event of default and may be declared immediately due and payable by SVB, as collateral agent. As of June&nbsp;30, 2019, the Company was in compliance with all applicable covenants under the Loan Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Loan Agreement, the Company issued the Lender Warrants to purchase stock of the Company. The Lender Warrants become
exercisable only if the Company borrows Term Loan B, and the number, class and per share price of the shares subject to the warrants is dependent on the terms of certain future equity financing transactions of the Company, including an IPO. The
Lender Warrants expire ten years from the date of issuance, subject to earlier termination on September&nbsp;30, 2020 if the Company does not draw down Term Loan B on or before March&nbsp;31, 2020. The Lender Warrants include a put option pursuant
to which, in the event that the Company does not draw down Term Loan B on or before March&nbsp;31, 2020, the warrant holders may require that the Company repurchase the warrants for a total aggregate repurchase price of $0.5&nbsp;million. The put
right is exercisable through September&nbsp;30, 2020. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The initial $0.4&nbsp;million fair value of the Lender Warrants, the
$2.1&nbsp;million final payment fee and $0.2&nbsp;million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Term Loans. For the six months
ended June&nbsp;30, 2019, the Company recognized $0.3&nbsp;million of interest expense, including amortization of the debt discount, in connection with the Loan Agreement. As of June&nbsp;30, 2019, the Company had outstanding Term Loans of
$25.0&nbsp;million and accrued interest of $0.2&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Future minimum principal and interest payments under the Term Loans,
including the final payment fee, as of June&nbsp;30, 2019 are as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Year&nbsp;ending&nbsp;December&nbsp;31:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2021</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2023</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2024</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total principal and interest payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">33,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Less interest and final payment fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-20 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>6. Stockholders&#146; Deficit </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Common Stock </I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In March 2019, subsequent to the Merger, the Company sold 1,491,072
shares of the Company&#146;s common stock to Frazier. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In March 2019, the founders granted the Company a repurchase right for
the 3,373,408 shares of common stock originally purchased in 2018. The Company has the right, but not the obligation, to repurchase unvested shares in the event the founder&#146;s relationship with the Company is terminated, subject to certain
limitations, at the original purchase price of the stock. The repurchase right lapses for 843,352 shares in March 2019 and the repurchase right for the remaining 2,530,056 shares lapses in equal monthly amounts over the following <FONT
STYLE="white-space:nowrap">48-month</FONT> period ending in March 2023. The fair value of the founder shares at the date the repurchase right was granted is being recognized as stock-based compensation expense on a straight-line basis over the
vesting period. As of June&nbsp;30, 2019, 2,371,928 shares of common stock were subject to repurchase by the Company and the associated repurchase liability was not significant. The amount of recognized and unrecognized stock-based compensation
related to the founder stock was immaterial for all periods presented. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019, the Company issued Takeda 1,084,000 shares
of common stock in connection with the Takeda License. </FONT></P>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">For the period from January&nbsp;1, 2019 to
May&nbsp;6, 2019, the Company issued 2,524,852 shares of common stock to various employees and consultants of the Company for aggregate proceeds of approximately $1,000. Upon issuance, these shares were subject to a repurchase option by the Company
at the original purchase price of the shares. The repurchase rights generally lapse as to 25% of the shares on the first anniversary of the vesting commencement date, and the repurchase right lapses as to 1/48</FONT><FONT
STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"> of the shares each <FONT STYLE="white-space:nowrap">one-month</FONT> period thereafter,
subject to the purchaser remaining continuously an employee, consultant or director of the Company. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Equity Incentive Plan
</I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company&#146;s 2019 Equity Incentive Plan (the &#147;Existing Incentive Plan&#148;) provides for the grant of incentive
stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. As of
June&nbsp;30, 2019, the Company had 2,231,739 shares of common stock authorized for issuance under the Existing Incentive Plan, of which 2,215,479 shares remained available for grant. In May 2019, the Company issued 16,260 shares of common stock
under a restricted stock award, of which 10,840 were unvested as of June&nbsp;30, 2019. For the six months ended June&nbsp;30, 2019, the Company recognized $29,000 of stock-based compensation expense related to restricted stock awards under the
Existing Incentive Plan and the grant date fair value of the award was $5.43 per share, the grant date fair value of the Company&#146;s common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-21 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A summary of the Company&#146;s unvested shares is as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance&nbsp;at&nbsp;January&nbsp;1,&nbsp;2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Vesting restrictions placed on previously issued shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,373,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Sale of unvested common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,524,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of unvested restricted stock awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">16,260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Share vesting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,257,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4,657,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For accounting purposes, unvested shares of common stock are considered issued, but not outstanding until they
vest. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stock-Based Compensation Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the combined statements of operations as follows (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, the Company had $59,000 of unrecognized stock-based compensation expense, which is
expected to be recognized over a weighted-average period of 0.7 years. For the six months ended June&nbsp;30, 2019, the vested fair value of the restricted stock awards was $29,000. There was no stock-based compensation expense for the year ended
December&nbsp;31, 2018. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Valuation of Common Stock </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Prior to obtaining the Takeda License on May&nbsp;7, 2019, the fair value of the Company&#146;s common stock was nominal since the Company was not sufficiently capitalized and held no assets that could be used to
generate future revenues. Subsequent to obtaining the Takeda License and issuing the May 2019 Notes, the Company estimated the fair value of its common stock using methodologies, approaches and assumptions consistent with the American Institute of
Certified Public Accountants Accounting and Valuation Guide: <I>Valuation of Privately Held Company Equity Securities Issued as Compensation </I>(the &#147;Practice Aid&#148;). The Practice Aid prescribes several valuation approaches for setting the
value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. The Company&#146;s 2019 valuations utilized a scenario-based analysis that estimated the
fair value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the Company, including various IPO, stay private and dissolution scenarios, and
applying a discount for lack of marketability. The Company considered various stay private scenarios using the income approach and allocated the indicated equity value to each class of equity based on the current-value method. The Company also
considered various IPO scenarios </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-22 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
based on expected equity values in an IPO and allocated the indicated equity value to each class of equity on a fully-diluted basis considering the dilutive impacts of the May 2019 Notes and the
Lender Warrants. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Common Stock Reserved for Future Issuance </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Common stock reserved for future issuance consists of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7,588,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Shares available for issuance under the Existing Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,215,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9,803,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December&nbsp;31, 2018, no shares of common stock were reserved for future issuance. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>7. Income Taxes </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A reconciliation between
the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Tax computed at federal statutory rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(271</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Permanent differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Significant components of the Company&#146;s net deferred tax assets are as follows (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Deferred tax assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net operating loss carryforwards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accruals and reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net deferred taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Based upon the Company&#146;s history of operating losses, the Company is unable to conclude that it is more likely
than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December&nbsp;31, 2018. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-23 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December&nbsp;31, 2018, the Company had federal net operating loss carryforwards of
approximately $23,000, which do not expire, and no material federal or California research and development credits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to
Internal Revenue Code Sections 382 and 383, annual use of the Company&#146;s net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a
three-year period. The Company has not completed a Section&nbsp;382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#146;s formation. If eliminated, the related asset
would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the
Company&#146;s effective tax rate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December&nbsp;31, 2018, there were no material unrecognized tax benefits recorded in the
combined financial statements and the Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Company is subject to taxation in the United States federal and state jurisdictions. The Company has not yet filed federal income tax and state income tax returns, but upon filing will be subject to examination
by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits.&nbsp;The Company is not currently under examination by any tax authority. The Company&#146;s policy is to recognize
interest and penalties related to income tax matters as a component of income tax expense. The Company has not recognized interest or penalties in its combined statements of operations since inception. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>8. Subsequent Events </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of
the financial statements as of December&nbsp;31, 2018 and for the year then ended, and the interim financial statements as of June&nbsp;30, 2019 and for the six months then ended, the Company has completed an evaluation of all subsequent events
through July&nbsp;26, 2019 to ensure these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. The Company has
further evaluated subsequent events for disclosure purposes through October&nbsp;15, 2019. Except as described below, the Company has concluded that no subsequent event has occurred that requires disclosure. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>2019 Incentive Award Plan </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In October 2019, the board of directors adopted, and the Company&#146;s stockholders approved the 2019 Equity Incentive Plan (the &#147;2019
Plan&#148;), which will become effective in connection with this offering. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then
employees, officers, non-employee directors or consultants of the Company or its subsidiaries. An aggregate of 2,700,000 shares of the Company&#146;s common stock will initially be available for issuance under awards granted pursuant to the 2019
Plan. The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been
exercised in full after the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-24 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective
date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above equal to 1,416,788 shares, and (ii)&nbsp;an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029,
equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Approval of the Employee Stock Purchase Plan </I></B></FONT></P>   <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In October 2019, the board of directors adopted, and the Company&#146;s stockholders approved, the Employee Stock Purchase Plan (the &#147;ESPP&#148;), which will become effective in connection with this offering.
The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation, which includes a participant&#146;s gross base compensation for services to the Company, including overtime payments and
excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of 270,000 shares of common stock is initially reserved for issuance under the ESPP. In addition, the number of
shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the
immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. </FONT></P>   <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Forward Stock
Split </I></B></FONT></P>   <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On October 11, 2019, the Company effected a 2.168-for-1 forward stock split of its common stock (the
&#147;Forward Stock Split&#148;). The par value of the common stock was not adjusted as a result of the Forward Stock Split and the authorized shares were increased to 50,000,000 shares of common stock in connection with the Forward Stock Split. The
accompanying combined financial statements and notes to the combined financial statements give retroactive effect to the Forward Stock Split for all periods presented, unless otherwise indicated. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-25 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:0px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>  <P STYLE="margin-top:36px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4">7,900,000 Shares </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="5"><B>Phathom Pharmaceuticals, Inc. </B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4">Common Stock </FONT></P> <P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g81j47.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="4"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4"><B>Jefferies</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="4"><B>Evercore&nbsp;ISI</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>Needham &amp; Company </B></FONT></P>
<P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:36px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2019 (the 25th day after the date of this prospectus) all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146;
obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </B></FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Part II </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution.
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement,
other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq Global Market
listing fee. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Amount&nbsp;paid&nbsp;or<BR>to be paid</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">23,585</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">27,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Nasdaq Global Market listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accountants&#146; fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">425,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,550,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Transfer Agent&#146;s fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Printing and engraving expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Miscellaneous</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">170,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,800,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a
corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly
violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that no director of the Registrant shall
be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law of the State of
Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Section&nbsp;145 of the
General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation,
partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an
action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he
reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the
right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other
adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other
court shall deem proper. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation, which will become effective immediately
prior to the closing of this offering, provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of
us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with,
another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses
(including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he
or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of
incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a
director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or
by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with
such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect
to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such
expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred in
connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have entered into indemnification
agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement
amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our
request. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation
arising out of claims based on acts or omissions in their capacities as directors or officers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In any underwriting agreement we enter
into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act,
against certain liabilities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Set forth below is information regarding unregistered securities issued by us since January&nbsp;1, 2018. Also included is the consideration
received by us for such securities and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">(a) Issuances of Securities </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">1. From January 2018 to December 2018, YamadaCo IIA, Inc. issued convertible promissory notes, or the YamadaCo Notes, in an
aggregate principal amount of $1.5&nbsp;million to Frazier Life Sciences IX, L.P., or FLS IX. From January 2018 to April 2019, we (originally as North Bridge IV, Inc.) issued convertible promissory notes, or the Phathom Notes, in an aggregate
principal amount of $0.9&nbsp;million to FLS IX. On May&nbsp;7, 2019, the YamadaCo Notes and the Phathom Notes were cancelled in exchange for newly issued convertible promissory notes in the principal amount of approximately $2.4&nbsp;million, which
amount represented the principal and accrued interest on the YamadaCo Notes and the Phathom Notes as of such date. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">2. In February 2018, we issued 1,000 shares of common stock to our founders and entities affiliated with them at a purchase price of
$1.00 per share pursuant to stock purchase agreements. In March 2019, we effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1,559.1183-for-1</FONT></FONT> forward stock split for each outstanding share of our common stock,
resulting in 1,559,118 shares of our common stock held by such founders and entities affiliated with them. In October 2019, we effected a 2.168-for-1 forward stock split for each outstanding share of our common stock, resulting in 3,380,167 shares
of our common stock held by such founders and entities affiliated with them. </FONT></P>   <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">3. From January 2018 to February
2018, YamadaCo IIA, Inc. issued 1,000 shares of its common stock to its founders and entities affiliated with them at a purchase price of $1.00 per share pursuant to stock purchase agreements. In March 2019, effective upon the completion of the
merger of YamadaCo IIA, Inc. with and into us, each issued and outstanding share of YamadaCo IIA, Inc. was converted into 1559.1183 shares of our common stock, resulting in 1,559,118 shares of our common stock held by such founders and entities
affiliated with them. In October 2019, we effected a 2.168-for-1 forward stock split for each outstanding share of our common stock, resulting in 3,380,167 shares of our common stock held by such founders and entities affiliated with them.
</FONT></P>   <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">4. In March 2019, we issued 1,491,072 shares of common stock to FLS IX at a purchase price of $0.0002958 per
share pursuant to a stock purchase agreement. </FONT></P>   <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">5. In May 2019, we issued 1,084,000 shares of common stock to
Takeda pursuant to a stock issuance agreement and a warrant to purchase 7,588,000 shares of our common stock with an exercise price of $0.00004613 per share as partial consideration for the Takeda License. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">6. In May 2019, we issued convertible promissory notes in an aggregate principal amount of $90.3&nbsp;million to FLS IX and other
investors pursuant to a note purchase agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">7. In May 2019, we issued warrants to Silicon Valley Bank and WestRiver
Innovation Lending Fund VIII, L.P., the number, class and exercise price of which are dependent on the terms of certain future equity financing transactions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">No underwriters were involved in the foregoing issuances of securities. The securities described in this section (a)&nbsp;of Item 15 were issued to investors in reliance upon the exemption from the registration
requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such
registration was required. All holders of securities described above represented to us in connection with their purchase or issuance that they were accredited investors and were acquiring the securities for their own account for investment purposes
only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The holders received written disclosures that
the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">(b) Grants of Restricted Stock and Stock Options </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">1. In March 2019, we issued 1,743,072 shares of our restricted common stock to certain of our founders at a purchase price of
$0.0002958 per share pursuant to restricted stock purchase agreements. </FONT></P>   <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">2. From April 2019 to May 2019, we
issued 781,780 shares of our restricted common stock to certain of our employees and consultants at a purchase price of $0.0002958 per share pursuant to restricted stock purchase agreements. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">3. In May 2019, we granted 16,260 shares of our restricted common stock under our existing 2019 equity incentive plan to a
consultant in connection with services provided to us by such person. </FONT></P>   <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">4.<B> </B>In August 2019, we granted
stock options to purchase an aggregate of 906,224&nbsp;shares of our common stock at a price of $6.95 per share, to certain of our employees and directors in connection with services provided to us by such persons. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">5. In September 2019, we granted stock options to purchase an aggregate of 494,304&nbsp;shares of our common stock at a price of
$13.04 per share, to certain of our employees and directors in connection with services provided to us by such persons. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
restricted stock, stock options and the common stock issuable upon the exercise of such options as described in this section (b)&nbsp;of Item 15 were issued pursuant to written compensatory plans or arrangements with our employees and directors, in
reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the Securities Act or the exemption set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated
thereunder relative to transactions by an issuer not involving any public offering. All recipients either received adequate information about us or had access, through employment or other relationships, to such information. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">All of the foregoing securities are deemed restricted securities for purposes of the Securities Act. All certificates representing the issued
shares of capital stock described in this Item 15 included appropriate legends setting forth that the securities had not been registered and the applicable restrictions on transfer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">(a)
<B>Exhibits.</B>&nbsp;&nbsp;&nbsp;&nbsp;See Exhibit Index attached to this registration statement, which is incorporated by reference herein. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">(b) <B>Financial Statement Schedules.&nbsp;&nbsp;&nbsp;&nbsp;</B>Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the combined
financial statements or notes thereto. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;17. Undertakings. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the
underwriter to permit prompt delivery to each purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in
the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The undersigned hereby undertakes that: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a
form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The undersigned registrant hereby undertakes that, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of
and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any
statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The undersigned registrant hereby undertakes that, for the purpose of determining liability of the registrant under the Securities Act of 1933 to
any purchaser in the initial distribution of the securities in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the
purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such
purchaser: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">(1) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required
to be filed pursuant to Rule 424; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">(2) Any free writing prospectus relating to the offering prepared by or on behalf of
the undersigned registrant or used or referred to by the undersigned registrant; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">(3) The portion of any other free
writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">(4) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Exhibit Index </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Description of Exhibit</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;1.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex11.htm">Form of Underwriting Agreement </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;2.1**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex21.htm">Agreement of Merger, dated March&nbsp;
13, 2019, by and between YamadaCo IIA, Inc. and the Registrant </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;3.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex31.htm">Amended and Restated Certificate of Incorporation, as amended (currently in effect)</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;3.2**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex32.htm">Bylaws, as amended (currently in effect)
</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;3.3**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex33.htm">Form of Amended and Restated Certificate of
 Incorporation (to be effective immediately prior to the closing of this offering)</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;3.4**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex34.htm">Form of Amended and Restated Bylaws (to be effective
 immediately prior to the closing of this offering)</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;4.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex41.htm">Specimen stock certificate evidencing the shares of common stock </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;4.2**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex42.htm">Warrant to purchase shares of common stock issued
 to Takeda Pharmaceutical Company Limited, dated May&nbsp;7, 2019</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;4.3**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex43.htm">Warrant to purchase stock issued to Silicon
 Valley Bank, dated May&nbsp;14, 2019</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;4.4**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex44.htm">Warrant to purchase stock issued to WestRiver
 Innovation Lending Fund VIII, L.P., dated May&nbsp;14, 2019</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;4.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex45.htm">Note Purchase Agreement, dated May&nbsp;
7, 2019, by and among the Registrant and the other parties party thereto, as amended</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;5.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex51.htm">Opinion of Latham&nbsp;&amp; Watkins LLP </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.1#**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex101.htm">Phathom Pharmaceuticals, Inc. 2019 Equity Incentive
 Plan</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.2#**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex102.htm">Form of Stock Option Grant Notice and Stock
 Option Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.3#**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex103.htm">Form of Restricted Stock Grant Notice and Restricted
 Stock Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.4#</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex104.htm">Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan and form of stock option grant notice and stock option agreement
 thereunder </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.5#</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex105.htm">Phathom Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.6#</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex106.htm"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.7#**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex107.htm">Letter Agreement, dated May 7, 2019, by and
 between Tadataka Yamada, M.D. and the Registrant </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.8#**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex108.htm">Employment Letter Agreement, dated July&nbsp;21,
 2019, by and between David Socks and the Registrant </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.9#**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex109.htm">Amended and Restated Employment Letter Agreement,
 dated September&nbsp;25, 2019, by and between Azmi Nabulsi, M.D., M.P.H. and the Registrant </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.10#**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex1010.htm">Employment Letter Agreement, dated July&nbsp;23,
 2019, by and between Aditya Kohli, Ph.D. and the Registrant </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.11#**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex1011.htm">Form of Indemnification Agreement for Directors
 and Officers</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.12&#134;**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex1012.htm">License Agreement, dated May&nbsp;
7, 2019, by and between Takeda Pharmaceutical Company Limited and the Registrant</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.13**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex1013.htm">Loan and Security Agreement, dated May&nbsp;14,
 2019, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and the Registrant </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">10.14#**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001783183/000119312519258922/d63338dex1014.htm">Employment Letter Agreement, dated August&nbsp;29,
 2019, by and between Terrie Curran and the Registrant </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">23.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex231.htm">Consent of independent registered public accounting firm</A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">23.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="d63338dex51.htm">Consent of Latham&nbsp;&amp; Watkins LLP (included in Exhibit&nbsp;5.1) </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:0.50em"><FONT STYLE="font-family:ARIAL" SIZE="2">24.1**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338ds1.htm#exind63338_1">Power of Attorney (included on signature
 page)</A></FONT></P></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Previously filed. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">#</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Indicates management contract or compensatory plan. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#134;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Portions of this exhibit have been omitted for confidentiality purposes. </FONT></P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>SIGNATURES </B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego,
State of California, on this 15th&nbsp;day of October, 2019. </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:ARIAL" SIZE="2">PHATHOM PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="2">/s/ David Socks</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">David Socks</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">President, Chief Executive Officer and Director</FONT></TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="exind63338_1"></A>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
held on the dates indicated. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="2">/s/ David Socks</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">David Socks</FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">President, Chief Executive Officer and</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Director (principal executive officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">October 15,&nbsp;2019</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="2">/s/ Aditya Kohli, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Aditya Kohli, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Chief Business Officer</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">(principal&nbsp;financial&nbsp;and&nbsp;accounting&nbsp;officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">October 15, 2019</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" align="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Tadataka Yamada, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Chairman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">October 15, 2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" align="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Michael F. Cola</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">October 15,&nbsp;2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" align="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Terrie Curran</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">October 15, 2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" align="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Jonathan Edwards, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">October 15, 2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" align="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Heidi Kunz</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">October 15,&nbsp;2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" align="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Chris Slavinsky</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">October 15, 2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" align="left"><FONT STYLE="font-family:ARIAL" SIZE="2">James Topper, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">October 15, 2019</FONT></TD></TR>
</TABLE>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">*By:&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="2">/s/ David Socks</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">David Socks</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Attorney-in-Fact</FONT></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d63338dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phathom Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock, par value $0.0001 per share </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I><U>Underwriting Agreement </U></I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As representatives (the &#147;Representatives&#148;) of the several Underwriters </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">named in Schedule I hereto, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman
Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York
10282 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phathom Pharmaceuticals,
Inc., a Delaware corporation (the &#147;Company&#148;), proposes, subject to the terms and conditions stated in this agreement (this &#147;Agreement&#148;), to issue and sell to the several Underwriters named in Schedule I hereto (the
&#147;Underwriters&#148;) for whom you are acting as representatives (the &#147;Representatives&#148;) an aggregate of [&#9679;] shares (the &#147;Firm Shares&#148;) and, at the election of the Underwriters, up to [&#9679;] additional shares (the
&#147;Optional Shares&#148;) of common stock, par value $0.0001 per share (&#147;Stock&#148;), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section&nbsp;2 hereof being collectively
called the &#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC (the &#147;Directed Share Underwriter&#148;) has agreed to reserve up to
[&#9679;] Shares of the Firm Shares to be purchased by it under this Agreement for sale at the direction of the Company to certain parties related to the Company (collectively, &#147;Participants&#148;). The Shares to be sold by the Directed Share
Underwriter pursuant to the Directed Share Program, at the direction of the Company, are hereinafter called the &#147;Directed Shares.&#148; Any Directed Shares not confirmed for purchase by the deadline established therefor by the Directed Share
Underwriter in consultation with the Company will be offered to the public by the Underwriters as set forth in the Prospectus. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The Company represents and warrants to, and agrees with, each of
the Underwriters that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
No.&nbsp;333&#150;234020) (the &#147;Initial Registration Statement&#148;) in respect of the Shares has been filed with the Securities and Exchange Commission (the &#147;Commission&#148;); the Initial Registration Statement and any <FONT
STYLE="white-space:nowrap">post-effective</FONT> amendment thereto, each in the form heretofore delivered to you, have been declared effective by the Commission in such form; other than a registration statement, if any, increasing the size of the
offering (a &#147;Rule 462(b) Registration Statement&#148;), filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#147;Act&#148;), which became effective upon filing, no other document with respect to the Initial
Registration Statement has been filed with the Commission; and no stop order suspending the effectiveness of the Initial Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration Statement, if any, has been issued
and no proceeding for that purpose has been initiated or threatened by the Commission (any preliminary prospectus included in the Initial Registration Statement or filed with the Commission pursuant to Rule 424(a) of the rules and regulations of the
Commission under the Act is hereinafter called a &#147;Preliminary Prospectus&#148;; the various parts of the Initial Registration Statement and the Rule 462(b) Registration Statement, if any, including all exhibits thereto and including the
information contained in the form of final prospectus filed with the Commission pursuant to Rule 424(b) under the Act in accordance with Section&nbsp;5(a) hereof and deemed by virtue of Rule 430A under the Act to be part of the Initial Registration
Statement at the time it was declared effective, each as amended at the time such part of the Initial Registration Statement became effective or such part of the Rule 462(b) Registration Statement, if any, became or hereafter becomes effective, are
hereinafter collectively called the &#147;Registration Statement&#148;; the Preliminary Prospectus relating to the Shares that was included in the Registration Statement immediately prior to the Applicable Time (as defined in Section&nbsp;1(c)
hereof) is hereinafter called the &#147;Pricing Prospectus&#148;; such final prospectus, in the form first filed pursuant to Rule 424(b) under the Act, is hereinafter called the &#147;Prospectus&#148;; any oral or written communication with
potential investors undertaken in reliance on Section&nbsp;5(d) of the Act is hereinafter called a &#147;Section&nbsp;5(d) Communication&#148;; any Section&nbsp;5(d) Communication that is a written communication within the meaning of Rule 405 under
the Act is hereinafter called a &#147;Section&nbsp;5(d) Writing&#148;; and any &#147;issuer free writing prospectus&#148; as defined in Rule 433 under the Act relating to the Shares is hereinafter called an &#147;Issuer Free Writing
Prospectus&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;(A) No order preventing or suspending the use of any Preliminary Prospectus or any Issuer
Free Writing Prospectus has been issued by the Commission, and (B)&nbsp;each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the rules and regulations of the Commission
thereunder, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading; <I>provided</I>, <I>however</I>, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information (as defined in Section&nbsp;9(b) of this
Agreement); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of this Agreement, the &#147;Applicable Time&#148; is [&#9679;] p.m. (Eastern
time) on the date of this Agreement. The Pricing Prospectus, as supplemented by the information listed on Schedule II(c) hereto, taken together (collectively, the &#147;Pricing Disclosure Package&#148;), as of the Applicable Time, did not, and as of
each Time of Delivery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(as defined in Section&nbsp;4(a) of this Agreement) will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and each Issuer Free Writing Prospectus and each Section&nbsp;5(d) Writing does not conflict with the information contained in the Registration Statement, the Pricing
Prospectus or the Prospectus and each Issuer Free Writing Prospectus, and each Section&nbsp;5(d) Writing, as supplemented by and taken together with the Pricing Disclosure Package, as of the Applicable Time, did not, and as of each Time of Delivery
will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that
this representation and warranty shall not apply to statements or omissions made in reliance upon and in conformity with the Underwriter Information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Registration Statement conforms, and the Prospectus and any further amendments or supplements to the
Registration Statement and the Prospectus will conform, in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder and do not and will not, as of the applicable effective date as to each part
of the Registration Statement, as of the applicable filing date as to the Prospectus and any amendment or supplement thereto, and as of each Time of Delivery, contain an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter
Information; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company has not, since the date of the latest audited financial statements included in the
Pricing Disclosure Package and the Prospectus, (i)&nbsp;sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree or (ii)&nbsp;entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company or incurred any liability or obligation, direct or contingent, that is
material to the Company, in each case otherwise than as set forth or contemplated in the Pricing Disclosure Package and the Prospectus; and, since the respective dates as of which information is given in the Registration Statement and the Pricing
Disclosure Package and the Prospectus, there has not been (x)&nbsp;any change in the capital stock (other than as a result of (i)&nbsp;the exercise, if any, of stock options or the award, if any, of stock options or restricted stock in the ordinary
course of business pursuant to the Company&#146;s equity plans that are described in the Pricing Disclosure Package and the Prospectus or (ii)&nbsp;the issuance, if any, of stock upon conversion of Company securities as described in the Pricing
Disclosure Package and the Prospectus) or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or (y)&nbsp;any Material Adverse Effect (as defined below); as used in this Agreement, &#147;Material Adverse Effect&#148; shall mean any
material adverse change or effect, or any development involving a prospective material adverse change or effect, in or affecting (i)&nbsp;the business, properties, general affairs, management, financial position, stockholders&#146; equity, prospects
or results of operations of the Company, except as set forth or contemplated in the Pricing Disclosure Package or the Prospectus, or (ii)&nbsp;the ability of the Company to perform its obligations under this Agreement, including the issuance and
sale of the Shares, or to consummate the transactions contemplated in the Pricing Disclosure Package and the Prospectus; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Company does not own any real property and has good and
marketable title to all personal property owned by it, in each case free and clear of all liens, encumbrances and defects except such as are described in the Pricing Disclosure Package and the Prospectus or such as do not materially affect the value
of such property and do not interfere with the use made and proposed to be made of such property by the Company; and any real property and buildings held under lease by the Company are, to the Company&#146;s knowledge, held by the Company under
valid, subsisting and enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;The Company has been (i)&nbsp;duly incorporated and is validly existing and in good standing under the laws of the
State of Delaware, with power and authority (corporate and other) to own and/or lease its properties and conduct its business as described in the Pricing Disclosure Package and the Prospectus, and (ii)&nbsp;duly qualified as a foreign corporation
for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except, in the case of this clause (ii), where the
failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;The Company has no subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Company has an authorized capitalization as set forth in the Pricing Disclosure Package and the Prospectus and
all of the issued shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and conform to the description of the Stock contained in the
Pricing Disclosure Package and Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;The Shares to be issued and sold by the Company to the Underwriters
hereunder have been duly and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform to
the description of the Stock contained in the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been complied with or otherwise effectively waived; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;The issue and sale of the Shares and the compliance by the Company with this Agreement and the consummation by the
Company of the transactions contemplated in this Agreement and the Pricing Disclosure Package and the Prospectus will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under,
(A)&nbsp;any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any of the property or assets of the Company is subject, (B)&nbsp;the
certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document) of the Company, or (C)&nbsp;any statute or any judgment, order, rule or regulation of any court or governmental agency or
body having jurisdiction over the Company or any of its properties except, in the case of clauses (A)&nbsp;and (C), for such defaults, breaches, or violations that would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the issue and sale of the Shares or the consummation by the Company of
the transactions contemplated by this Agreement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
except (X)&nbsp;such as have been obtained under the Act, the approval by the Financial Industry Regulatory Authority (&#147;FINRA&#148;) of the underwriting terms and arrangements and such
consents, approvals, authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Shares by the Underwriters and (Y)&nbsp;such as have been
obtained under the laws and regulations of jurisdictions outside the United States in which the Directed Shares were offered; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;The Company is not (i)&nbsp;in violation of its certificate of incorporation or
<FONT STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the
Company or any of its properties, or (iii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or
instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii)&nbsp;and (iii), for such defaults as would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;The statements set forth in the Pricing Disclosure Package and Prospectus
under the captions &#147;Description of Capital Stock&#148; and &#147;Shares Eligible for Future Sale&#148;, insofar as they purport to constitute a summary of the terms of the Stock, and under the captions &#147;Material United States Federal
Income Tax Consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#148;, and &#147;Underwriting&#148;, insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and
fair in all material respects; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;Other than as set forth in the Pricing Disclosure Package and the Prospectus,
there are no legal or governmental proceedings pending to which the Company or, to the Company&#146;s knowledge, any officer or director of the Company, is a party or of which any property of the Company or, to the Company&#146;s knowledge, any
officer or director of the Company, is the subject which, if determined adversely to the Company, would individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and, to the Company&#146;s knowledge, no such
proceedings are threatened or contemplated by governmental authorities or others; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;The Company is not and,
after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Pricing Disclosure Package and the Prospectus, will not be an &#147;investment company&#148;, as such term is defined in the
Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;At the time of filing the
Initial Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Shares, and at
the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined under Rule 405 under the Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young LLP, who have certified certain financial statements of the Company, are independent public
accountants as required by the Act and the rules and regulations of the Commission thereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;The Company
maintains a system of internal control over financial reporting (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> under the Securities Exchange Act of 1934, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended (the &#147;Exchange Act&#148;)) that (i)&nbsp;complies with the requirements of the Exchange Act, (ii)&nbsp;has been designed by the Company&#146;s principal executive officer and
principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted
accounting principles (&#147;GAAP&#148;) and (iii)&nbsp;is sufficient to provide reasonable assurance that (A)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization, (B)&nbsp;transactions are recorded
as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets, (C)&nbsp;access to assets is permitted only in accordance with management&#146;s
general or specific authorization and (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and the Company&#146;s internal
control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting (it being understood that this subsection shall not require the Company to comply with
Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (&#147;Sarbanes-Oxley Act&#148;) as of an earlier date than it would otherwise be required to so comply under
applicable law); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;Since the date of the latest audited financial statements included in the Pricing Disclosure
Package and the Prospectus, there has been no change in the Company&#146;s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#146;s internal
control over financial reporting; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains disclosure controls and procedures (as such term is
defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> under the Exchange Act) that comply with the requirements of the Exchange Act applicable to the Company as of the date of this Agreement; such disclosure controls and procedures have
been designed to ensure that material information relating to the Company is made known to the Company&#146;s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures
are effective; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;This Agreement has been duly authorized, executed and delivered by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or
other person associated with or acting on behalf of the Company has (i)&nbsp;made, offered, promised or authorized any unlawful contribution, gift, entertainment or other unlawful expense or taken any act in furtherance thereof; (ii)&nbsp;made,
offered, promised or authorized any direct or indirect unlawful payment; or (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, the Bribery Act 2010 of the United Kingdom or any
other applicable anti-bribery or anti-corruption law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&nbsp;&nbsp;&nbsp;&nbsp;The operations of the Company are and have been
conducted at all times in compliance with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated
thereunder, and the anti-money laundering laws of the various jurisdictions in which the Company conducts business (collectively, the &#147;Money Laundering Laws&#148;) and no action, suit or proceeding by or before
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate
of the Company is currently the subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury , or the U.S.
Department of State and including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person,&#148; the European Union, Her Majesty&#146;s Treasury, the United Nations Security Council, or other
relevant sanctions authority (collectively, &#147;Sanctions&#148;), nor is the Company located, organized or resident in a country or territory that is the subject or target of Sanctions, and the Company will not directly or indirectly use the
proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any
person, or in any country or territory, that, at the time of such funding, is the subject or the target of Sanctions or (ii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the
transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&nbsp;&nbsp;&nbsp;&nbsp;The financial statements,
including the notes thereto, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, together with the related schedules and notes, present fairly in all material respects the financial position of the Company at
the dates indicated and the statement of operations, stockholders&#146; equity and cash flows of the Company for the periods specified; said financial statements have been prepared in conformity with GAAP applied on a consistent basis throughout the
periods involved. The supporting schedules, if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, present fairly in all material respects and in accordance with GAAP the information required to be stated
therein. The selected financial data and the summary financial information included in the Registration Statement, the Pricing Disclosure Package and the Prospectus present fairly in all material respects the information shown therein and have been
compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included in the Registration
Statement, the Pricing Disclosure Package or the Prospectus under the Act or the rules and regulations promulgated thereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&nbsp;&nbsp;&nbsp;&nbsp;From the time of initial confidential submission of a registration statement relating to the Shares with the
Commission (or, if earlier, the first date on which a Section&nbsp;5(d) Communication was made) through the date hereof, the Company has been and is an &#147;emerging growth company&#148; as defined in Section&nbsp;2(a)(19) of the Act (an
&#147;Emerging Growth Company&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&nbsp;&nbsp;&nbsp;&nbsp;There are no persons with registration rights or other similar rights
to have any securities registered under the Registration Statement or otherwise registered by the Company under the Act, except as have been validly waived or complied with in connection with the offering of the Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&nbsp;&nbsp;&nbsp;&nbsp;No material labor disturbance by or dispute with current or former employees or officers of the Company exists or,
to the Company&#146;s knowledge, is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated or threatened, and the Company is not are aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of the Company&#146;s principal suppliers,
manufacturers or contractors. The Company is not a party to any collective bargaining agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)&nbsp;&nbsp;&nbsp;&nbsp;Except as
set forth in the Pricing Disclosure Package and the Prospectus, the Company has insurance covering its properties, operations, personnel and business, including business interruption insurance, which insurance is in amounts and insures against such
losses and risks as are reasonable and is ordinary and customary for comparable companies in the same or similar business; and the Company has (i)&nbsp;not received notice from any insurer or agent of such insurer that capital improvements or other
expenditures are required or necessary to be made in order to continue such insurance nor (ii)&nbsp;no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage at reasonable cost from similar insurers as may be reasonably necessary to continue its business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd)&nbsp;&nbsp;&nbsp;&nbsp;Any studies, tests and preclinical studies and clinical trials conducted by the Company and, to the knowledge of
the Company, any studies, tests and preclinical studies and clinical trials conducted on behalf of the Company or in which the Company has participated, were, and if still pending are, being conducted in accordance all applicable laws, including the
U.S. Federal Food, Drug and Cosmetic Act and rules and regulations thereunder, except where the failure to be so conducted would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; the Company is not
aware of any studies, tests or trials, the results of which the Company believes reasonably and materially call into question the study, test, or trial results described or referred to in the Pricing Disclosure Package and the Prospectus when viewed
in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or correspondence
from the FDA or any other comparable federal, state, local or foreign governmental or regulatory authority requiring the termination or suspension of any studies, tests or preclinical studies or clinical trials conducted by or on behalf of the
Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&nbsp;&nbsp;&nbsp;&nbsp;Except as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect, the Company is, and at all times since the Company&#146;s inception on May&nbsp;15, 2019 has been, in compliance with all Health Care Laws (defined herein), including, but not limited to, the rules and regulations of the U.S.
Department of Health and Human Services Office of Inspector General, the Centers for Medicare&nbsp;&amp; Medicaid Services, the HHS Office for Civil Rights, the U.S. Department of Justice and any other governmental agency or body having jurisdiction
over the Company or any of its properties, and has not, since the Company&#146;s inception on May&nbsp;15, 2019, engaged in any activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive
exclusion from Medicare, Medicaid, or any other local, state or federal healthcare program. For purposes of this Agreement, &#147;Health Care Laws&#148; shall mean the U.S. Federal Food, Drug and Cosmetic Act (21 U.S.C. &#167;&nbsp;301 et seq.); the
federal Anti-kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7b(b)),</FONT> the Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7h),</FONT> the civil False Claims Act (31
U.S.C. &#167;&#167;&nbsp;3729 et seq.), the criminal False Claims Act (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7b(a)),</FONT> all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C.
&#167;&#167;&nbsp;286, 287, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167;&#167;&nbsp;1320d et seq.) (&#147;HIPAA&#148;), the exclusions law (42
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7),</FONT> the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7a),</FONT> Medicare (Title
XVIII of the Social Security Act), and Medicaid (Title XIX of the Social Security Act), each as amended, and the regulations promulgated thereunder. The Company and each of its directors, officers, and employees, and to the Company&#146;s knowledge,
its agents, affiliates and representatives, are not a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of
correction or similar agreement imposed by any governmental authority. The Company and its directors, officers, and employees, and to the Company&#146;s knowledge, its agents, affiliates and representatives, have not received any written
notification, correspondence or any other written communication, and the Company has not received any oral communication, from any governmental authority of potential or actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or liability
of, the Company under any Health Care Laws; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)&nbsp;&nbsp;&nbsp;&nbsp;The Company possesses, and is in compliance with the terms of,
all applications, certificates, approvals, clearances, registrations, exemptions, franchises, licenses, permits, consents and other authorizations necessary to conduct its business (collectively, &#147;Licenses&#148;), issued by the appropriate
federal, state, local or foreign governmental or regulatory authorities including, without limitation, from the FDA and equivalent foreign regulatory authorities (collectively, the &#147;Regulatory Agencies&#148;), except where the failure to
possess or comply with the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. All such Licenses are in full force and effect and the Company is not in material violation of any term or
conditions of any such License. The Company has fulfilled and performed all of its material obligations with respect to such Licenses and, to the Company&#146;s knowledge, no event has occurred which allows, or after notice or lapse of time would
allow, revocation or termination thereof or results in any other impairment of the rights of the holder of any such License. The Company has not received any written, and to the Company&#146;s knowledge, oral, notice of proceedings relating to the
revocation or material adverse modification of any such Licenses and, to the Company&#146;s knowledge, no Regulatory Agency has taken any action to materially limit, suspend or revoke any such License possessed by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company, nor, to the Company&#146;s knowledge, any of its officers, employees, directors, or agents,
have been excluded, suspended or debarred from participation in any U.S. federal health care program or, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in
debarment, suspension, or exclusion, or convicted of any crime or engaged in any conduct that would reasonably be expected to result in any suspension, exclusion, or debarment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)&nbsp;&nbsp;&nbsp;&nbsp;Except as described in the Pricing Disclosure Package, the Company owns or has valid and enforceable licenses or
other rights to use all patents and patent applications, copyrights, trademarks, trademark registrations, service marks, service mark registrations, trade names, service names and <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade
secrets and other unpatented and/or unpatentable proprietary or confidential information, inventions, systems or procedures) including the right to sue for past, present and future infringement, misappropriation or dilution of any of the foregoing,
to the extent the foregoing are necessary for the conduct of the business of the Company in the manner described in the Pricing Disclosure Package and the Prospectus (collectively, the &#147;Company Intellectual Property&#148;). Other than as
disclosed in the Pricing Disclosure Package, there are no rights of third parties to any of the material patents, trademarks and copyrights within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company Intellectual Property disclosed in the Pricing Disclosure Package as being owned by the Company, and such intellectual property is owned by the Company free and clear of all material
liens, security interests, or encumbrances. To the knowledge of the Company, the material patents, trademarks and copyrights held or licensed by the Company included within the Company&#146;s Intellectual Property are valid, enforceable and
subsisting. Other than as disclosed in the Pricing Disclosure Package and the Prospectus, (i)&nbsp;the Company is not obligated to pay a material royalty, grant a material license, or provide other material consideration to any third party in
connection with the Company Intellectual Property, (ii)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, alleging that the conduct of the business of the Company in the manner described
in the Pricing Disclosure Package is infringing, misappropriating, diluting or otherwise violating any intellectual property rights of others, or alleging that such conduct of the Company would, upon the commercialization of any product or service
proposed in the Pricing Disclosure Package and the Prospectus to be conducted, infringe, misappropriate, dilute, or otherwise violate, any rights of others with respect to any of the Company&#146;s product candidates, processes or intellectual
property, and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim, (iii)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is
threatened, challenging the validity, enforceability, scope, registration, ownership or use of any of the Company&#146;s Intellectual Property, and the Company is not aware of any facts which could form a reasonable basis for any such action, suit,
proceeding or claim, (iv)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, challenging the Company&#146;s rights in or to any Company Intellectual Property and the Company is unaware of
any facts which could form a reasonable basis for any such action, suit, proceeding or claim, (v)&nbsp;to the knowledge of the Company, the development, manufacture, sale, and any currently proposed use of any of the products, proposed products or
processes of the Company referred to in the Pricing Disclosure Package and the Prospectus, in the current or proposed conduct of the business of the Company do not currently, and will not upon commercialization, to the knowledge of the Company,
infringe any right or valid patent claim of any third party, (vi)&nbsp;to the knowledge of the Company, no employee, consultant or independent contractor of the Company is in violation in any material respect of any term of any employment contract,
patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement nondisclosure agreement or any restrictive covenant to
or with a former employer or independent contractor where the basis of such violation relates to the ownership by the Company of any Company Intellectual Property, (vii)&nbsp;the Company has taken reasonable measures to protect its material
confidential information and material trade secrets and to maintain and safeguard the Company&#146;s material Intellectual Property, including the execution of appropriate nondisclosure, confidentiality and invention assignment agreements, and
(viii)&nbsp;to the knowledge of the Company, the Company has complied with the material terms of each agreement pursuant to which Company Intellectual Property has been licensed to the Company, and all such agreements are in full force and effect,
except in each of (i)-(viii) such as would not, if determined adversely to the Company, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;(i) The Company&#146;s information technology assets and equipment, computers, systems, networks, hardware,
software, websites, applications, and databases (collectively, &#147;IT Systems&#148;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company as currently
conducted, free and clear of all material bugs, errors, defects, Trojan horses, time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bombs, malware and other corruptants; (ii)&nbsp;the Company has implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect its
material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&#147;Personal Data&#148;))
used in connection with its business, and to the Company&#146;s knowledge, there have been no material breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or
liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same; and (iii)&nbsp;the Company is presently in material compliance with all applicable laws or statutes and all judgments,
orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT
Systems and Personal Data from unauthorized use, access, misappropriation or modification; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)&nbsp;&nbsp;&nbsp;&nbsp;Except as would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, all patents and patent applications within the Company Intellectual Property disclosed in the Pricing Disclosure Package as owned by or licensed to the
Company have, to the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, there are no material defects in such patents; to the knowledge of the Company, the parties prosecuting such applications
have materially complied with their duty of candor and disclosure to the U.S. Patent and Trademark Office (&#147;USPTO&#148;) in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that
were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)&nbsp;&nbsp;&nbsp;&nbsp;Any statistical, industry-related and market-related data included in the Pricing Disclosure Package and the
Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects and, to the extent required by such sources, the Company has obtained the written consent to
the use of such data from such sources; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)&nbsp;&nbsp;&nbsp;&nbsp;There are no <FONT STYLE="white-space:nowrap">off-balance</FONT>
sheet arrangements (as defined in Item 303(a)(4)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Act) that may have a material current or future effect on the Company&#146;s financial condition, changes in financial condition,
results of operations, liquidity, capital expenditures or capital resources; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm)&nbsp;&nbsp;&nbsp;&nbsp;The Company has not sold or
issued any securities during the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of the Prospectus, including any sales pursuant to Rule 144A or Regulation D of the Act, other than (i)&nbsp;shares issued pursuant to
employee benefit plans disclosed in the Pricing Disclosure Package and the Prospectus, stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants, or (ii)&nbsp;as disclosed in the Pricing
Disclosure Package and the Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn)&nbsp;&nbsp;&nbsp;&nbsp;All United States federal income tax returns of the Company required
by law to be filed have been filed and all taxes shown as due on such returns or that otherwise have been assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to
which adequate reserves have been provided. The Company has filed all other tax returns that are required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect, and has paid all material taxes due pursuant to such returns or pursuant to any assessment received by the Company, except for such taxes, if any, as are being contested in good faith and as to which
adequate reserves have been provided. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or <FONT
STYLE="white-space:nowrap">re-assessments</FONT> for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. No tax deficiency has been determined adversely to the Company which has had (nor does the Company have any written notice or knowledge of any tax deficiency which could reasonably be expected to be determined adversely to the
Company and which would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo)&nbsp;&nbsp;&nbsp;&nbsp;The Company has not taken and will not take, directly or indirectly, without giving effect to activities by the
Underwriters, any action that is designed to or that has constituted or might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp)&nbsp;&nbsp;&nbsp;&nbsp;The Company is not a party to any contract, agreement or understanding with any person (other than this Agreement)
that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq)&nbsp;&nbsp;&nbsp;&nbsp;No relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors,
officers, stockholders, customers or suppliers of the Company, on the other, that is required by the Act to be described in the Pricing Disclosure Package and the Prospectus and that is not so described in such documents and in the Pricing
Disclosure Package and the Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)&nbsp;&nbsp;&nbsp;&nbsp;Solely to the extent that the Sarbanes-Oxley Act has been applicable
to the Company, the Company has taken all necessary actions to ensure that it is in compliance with all provisions of the Sarbanes-Oxley Act with which the Company is required to comply as of the Applicable Time, and the Company currently plans to
take reasonable steps to ensure that it will be in compliance with other provisions of the Sarbanes-Oxley Act not currently in effect, upon the effectiveness of such provisions, or which will become applicable to the Company at all times after the
effectiveness of the Registration Statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss)&nbsp;&nbsp;&nbsp;&nbsp;The Company does not have any debt securities or preferred stock
that are rated by any &#147;nationally recognized statistical rating agency&#148; (as defined in Section&nbsp;3(a)(62) of the Exchange Act); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt)&nbsp;&nbsp;&nbsp;&nbsp;The Registration Statement, the Pricing Disclosure Package and the Prospectus, any Preliminary Prospectus and any
Issuer Free Writing Prospectuses comply in all material respects, and any further amendments or supplements thereto will comply in all material respects, with any applicable laws or regulations of foreign jurisdictions in which the Pricing
Disclosure Package, the Prospectus, any Preliminary Prospectus and any Issuer Free Writing Prospectus, as amended or supplemented, if applicable, are distributed in connection with the Directed Share Program; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu)&nbsp;&nbsp;&nbsp;&nbsp;No authorization, approval, consent, license, order,
registration or qualification of or with any government, governmental instrumentality or court, other than such as have been obtained, is necessary under the securities laws and regulations of foreign jurisdictions in which the Directed Shares are
offered outside the United States; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv)&nbsp;&nbsp;&nbsp;&nbsp;The Company has specifically directed in writing the allocation of Shares
to each Participant in the Directed Share Program, and neither the Directed Share Underwriter nor any other Underwriter has had any involvement or influence, directly or indirectly, in such allocation decision; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww)&nbsp;&nbsp;&nbsp;&nbsp;The Company has not offered, or caused the Directed Share Underwriter or such Directed Share Underwriter&#146;s
affiliates to offer, Shares to any person pursuant to the Directed Share Program (i)&nbsp;for any consideration other than the cash payment of the initial public offering price per share set forth in Schedule II hereof or (ii)&nbsp;with the specific
intent to unlawfully influence (x)&nbsp;a customer or supplier of the Company to alter the customer or supplier&#146;s terms, level or type of business with the Company or (y)&nbsp;a trade journalist or publication to write or publish favorable
information about the Company or its products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions herein set forth,
(a)&nbsp;the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at a purchase price per share of $[&#9679;], the number of Firm Shares set forth
opposite the name of such Underwriter in Schedule I hereto and (b)&nbsp;in the event and to the extent that the Underwriters shall exercise the election to purchase Optional Shares as provided below, the Company agrees to issue and sell to each of
the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the purchase price per share set forth in clause (a)&nbsp;of this Section&nbsp;2 (provided that the purchase price per Optional Share
shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares), that portion of the number of Optional Shares as to which such election
shall have been exercised (to be adjusted by you so as to eliminate fractional shares) determined by multiplying such number of Optional Shares by a fraction, the numerator of which is the maximum number of Optional Shares which such Underwriter is
entitled to purchase as set forth opposite the name of such Underwriter in Schedule I hereto and the denominator of which is the maximum number of Optional Shares that all of the Underwriters are entitled to purchase hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the Underwriters the right to purchase at their election up to [&#9679;] Optional Shares, at the purchase price
per share set forth in the paragraph above, for the sole purpose of covering sales of shares in excess of the number of Firm Shares, provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends
or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares. Any such election to purchase Optional Shares may be exercised only by written notice from the Representatives to the Company, given
within a period of 30 calendar days after the date of this Agreement, setting forth the aggregate number of Optional Shares to be purchased and the date on which such Optional Shares are to be delivered, as determined by the Representatives but in
no event earlier than the First Time of Delivery (as defined in Section&nbsp;4 hereof) or, unless the Representatives and the Company otherwise agree in writing, earlier than two or later than ten business days after the date of such notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;Upon the authorization by you of the release of the Firm Shares,
the several Underwriters propose to offer the Firm Shares for sale upon the terms and conditions set forth in the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;(a) The Shares to be purchased by each Underwriter hereunder, in book-entry form, and in such authorized
denominations and registered in such names as the Representatives may request upon at least forty-eight hours&#146; prior notice to the Company shall be delivered by or on behalf of the Company to the Representatives, through the facilities of the
Depository Trust Company (&#147;DTC&#148;), for the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal <FONT STYLE="white-space:nowrap">(same-day)</FONT> funds
to the account specified by the Company to the Representatives at least forty-eight hours in advance. The time and date of such delivery and payment shall be, with respect to the Firm Shares, 9:30 a.m., New York City time, on [&#9679;], 2019 or such
other time and date as the Representatives and the Company may agree upon in writing, and, with respect to the Optional Shares, 9:30 a.m., New York time, on the date specified by the Representatives in the written notice given by the Representatives
of the Underwriters&#146; election to purchase such Optional Shares, or such other time and date as the Representatives and the Company may agree upon in writing. Such time and date for delivery of the Firm Shares is herein called the &#147;First
Time of Delivery&#148;, such time and date for delivery of the Optional Shares, if not the First Time of Delivery, is herein called the &#147;Second Time of Delivery&#148;, and each such time and date for delivery is herein called a &#147;Time of
Delivery&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The documents to be delivered at each Time of Delivery by or on behalf of the parties hereto
pursuant to Section&nbsp;8 hereof, including the cross receipt for the Shares and any additional documents requested by the Underwriters pursuant to Section&nbsp;8(i) hereof, will be delivered at the offices of Cooley LLP, 4401 Eastgate Mall, San
Diego, California 92121 (the &#147;Closing Location&#148;), and the Shares will be delivered, all at such Time of Delivery. A meeting will be held at the Closing Location at [&#9679;] p.m., New York City time, on the New York Business Day next
preceding such Time of Delivery, at which meeting the final drafts of the documents to be delivered pursuant to the preceding sentence will be available for review by the parties hereto. For the purposes of this Section&nbsp;4, &#147;New York
Business Day&#148; shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York City are generally authorized or obligated by law or executive order to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees with each of the Underwriters: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant to Rule 424(b) under the
Act not later than the Commission&#146;s close of business on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier time as may be required by Rule 430A(a)(3) under the Act; to make no
further amendment or any supplement to the Registration Statement or the Prospectus prior to the last Time of Delivery which shall be disapproved by you promptly after reasonable notice thereof; to advise you, promptly after it receives notice
thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and to furnish you with copies thereof; to file promptly all material required
to be filed by the Company with the Commission pursuant to Rule 433(d) under the Act; to advise you, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use of
any Preliminary Prospectus or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other prospectus in respect of the Shares, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for
any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing or
suspending the use of any Preliminary Prospectus or other prospectus or suspending any such qualification, to promptly use its best efforts to obtain the withdrawal of such order; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Promptly from time to time to take such action as you may reasonably request to qualify the Shares for offering and
sale under the securities laws of such jurisdictions as you may request and to comply with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to complete the distribution of
the Shares, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation (where not otherwise required) or to file a general consent to service of process in any jurisdiction (where not otherwise
required); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Prior to 10:00 a.m., New York City time, on the New York Business Day next succeeding the date of
this Agreement (or such other time as may be agreed to by the Representatives and the Company) and from time to time, to furnish the Underwriters with written and electronic copies of the Prospectus in New York City in such quantities as you may
reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to the expiration of nine months after the time of issue of the Prospectus in connection
with the offering or sale of the Shares and if at such time any event shall have occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act)<B> </B>is delivered, not misleading, or,
if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus in order to comply with the Act, to notify you and upon your request to prepare and furnish without charge to each Underwriter and to any
dealer in securities as many written and electronic copies as you may from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance; and in
case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act)<B> </B>in connection with sales of any of the Shares at any time nine months or more after the time of issue of the
Prospectus, upon your request but at the expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as you may request of an amended or supplemented Prospectus complying with Section&nbsp;10(a)(3)
of the Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;To make generally available to its securityholders as soon as practicable (which may be satisfied
by filing with the Commission&#146;s Electronic Data Gathering Analysis and Retrieval System (&#147;EDGAR&#148;)), but in any event not later than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under
the Act), an earnings statement of the Company (which need not be audited) complying with Section&nbsp;11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;(i) During the period beginning from the date hereof and
continuing to and including the date 180 days after the date of the Prospectus (the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), not to (1)&nbsp;offer, sell, contract to sell, pledge, grant any option to purchase, make any
short sale or otherwise transfer or dispose of, directly or indirectly, or file with or confidentially submit to the Commission a registration statement under the Act relating to, any securities of the Company that are substantially similar to the
Shares, including but not limited to any options or warrants to purchase shares of Stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, Stock or any such substantially similar securities,
(2)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clauses (1)&nbsp;or (2) above is
to be settled by delivery of Stock or such other securities, in cash or otherwise or (3)&nbsp;publicly disclose the intention to do any of the foregoing, in each case, without the prior written consent of the Representatives; provided, however, that
the foregoing restrictions shall not apply to: (A)&nbsp;the Shares to be sold hereunder, (B)&nbsp;any shares of Stock or any securities or other awards convertible into, exercisable for, or that represent the right to receive, shares of Stock
pursuant to any stock option plan, incentive plan or stock purchase plan of the Company (collectively, &#147;Company Stock Plans&#148;) or otherwise in equity compensation arrangements described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, (C)&nbsp;any shares of Stock issued upon the conversion, exercise or exchange of convertible, exercisable or exchangeable securities outstanding on the date of this Agreement and described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, (D)&nbsp;the filing by the Company of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to any Company Stock Plan described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, and (E)&nbsp;any shares of Stock or any securities convertible into or exchangeable for, or that represent the right to receive, shares of Stock issued in connection with any
bona fide licensing, commercialization, joint venture, technology transfer or development collaboration agreement with an unaffiliated third party, provided that in the case of clause (E), the aggregate number of shares that the Company may sell or
issue or agree to sell or issue pursuant to clause (E)&nbsp;shall not exceed 5.0% of the total number of shares of Stock issued and outstanding immediately following the completion of the transactions contemplated by this Agreement, and provided,
further, that the Company shall cause each recipient of such securities pursuant to clauses (B), (C) and (E)&nbsp;during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period to execute and deliver to the Representatives, on or prior to the
issuance of such securities, a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in substantially the form attached as Annex II hereto for the remainder of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined therein) and
enter stop transfer instructions with the Company&#146;s transfer agent and registrar on such securities, which the Company agrees it will not waive or amend without the prior written consent of the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If the Representatives, in their sole discretion, agree to release or waive the restrictions set forth in a <FONT
STYLE="white-space:nowrap">lock-up</FONT> letter described in Section&nbsp;8(i) hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver at least three business days before the effective
date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Annex I hereto through a major news service at least two business days before the effective date of the
release or waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;To enforce all existing agreements between the Company and any of its securityholders
that prohibit the sale, transfer, assignment, pledge or hypothecation of any of the Company&#146;s securities in connection with the Company&#146;s initial public offering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
until, in respect of any particular securityholder, the earlier to occur of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period or (ii)&nbsp;the expiration of
any similar arrangement entered into by such securityholder with the Representatives; to direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such existing <FONT
STYLE="white-space:nowrap">&#147;lock-up,&#148;</FONT> &#147;market <FONT STYLE="white-space:nowrap">stand-off,&#148;</FONT> &#147;holdback&#148; or similar provisions of such agreements for the duration of the periods contemplated in the preceding
clause; and not to release or otherwise grant any waiver of such provisions in such agreements during such periods without the prior written consent of the Representatives, on behalf of the Underwriters; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;During the period of three years from the effective date of the Registration Statement, so long as the Company is
subject to the reporting requirements of either Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act, to furnish to its stockholders as soon as practicable after the end of each fiscal year an annual report (including a balance sheet and
statements of income, stockholders&#146; equity and cash flows of the Company certified by independent public accountants) and, as soon as practicable after the end of each of the first three quarters of each fiscal year (beginning with the fiscal
quarter ending after the effective date of the Registration Statement), to make available to its stockholders consolidated summary financial information of the Company for such quarter in reasonable detail; provided, that no reports, documents or
other information needs to be furnished pursuant to this Section&nbsp;5(f) to the extent they are available on EDGAR; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;During a period of three years from the effective date of the Registration Statement, to furnish to you copies of
all reports or other communications (financial or other) furnished to stockholders, and to deliver to you (i)&nbsp;as soon as they are available, copies of any reports and financial statements furnished to or filed with the Commission or any
national securities exchange on which any class of securities of the Company is listed; and (ii)&nbsp;such additional information concerning the business and financial condition of the Company as you may from time to time reasonably request (such
financial statements to be on a consolidated basis to the extent the accounts of the Company are consolidated in reports furnished to its stockholders generally or to the Commission); provided, that no reports or documents or other information needs
to be furnished pursuant to this Section&nbsp;5(g) to the extent they are available on EDGAR; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;To use the net
proceeds received by it from the sale of the Shares pursuant to this Agreement in the manner specified in the Pricing Disclosure Package and the Prospectus under the caption &#147;Use of Proceeds&#148;; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;To use its best efforts to list for quotation the Shares on the Nasdaq Global Market (&#147;Nasdaq&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;To file with the Commission such information on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT
STYLE="white-space:nowrap">10-K</FONT> as may be required by Rule 463 under the Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;If the Company elects to
rely upon Rule 462(b), the Company shall file a Rule 462(b) Registration Statement with the Commission in compliance with Rule 462(b) by 10:00 p.m., Washington, D.C. time, on the date of this Agreement, and the Company shall at the time of filing
either pay to the Commission the filing fee for the Rule 462(b) Registration Statement or give irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under the Act; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;Upon request of any Underwriter, to furnish, or cause to be
furnished, to such Underwriter an electronic version of the Company&#146;s trademarks, servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the
<FONT STYLE="white-space:nowrap">on-line</FONT> offering of the Shares (the &#147;License&#148;); provided, however, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or
transferred; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;To comply with all applicable securities and other laws, rules and regulations in each
jurisdiction in which the Directed Shares are offered in connection with the Directed Share Program; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;To
promptly notify you if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of the Shares within the meaning of the Act and (ii)&nbsp;the last Time of Delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company represents and agrees that, without the prior consent of the Representatives, it has not made and
will not make any offer relating to the Shares that would constitute a &#147;free writing prospectus&#148; as defined in Rule 405 under the Act; each Underwriter represents and agrees that, without the prior consent of the Company and the
Representatives, it has not made and will not make any offer relating to the Shares that would constitute a free writing prospectus required to be filed with the Commission; any such free writing prospectus the use of which has been consented to by
the Company and the Representatives is listed on Schedule II(a) hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company has complied and will
comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the Commission or retention where required and legending; and the Company represents that it has satisfied and
agrees that it will satisfy the conditions under Rule 433 under the Act to avoid a requirement to file with the Commission any electronic road show; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees that if at any time following issuance of an Issuer Free Writing Prospectus or any
Section&nbsp;5(d) Writing prepared or authorized by it any event occurred or occurs as a result of which such Issuer Free Writing Prospectus or Section&nbsp;5(d) Writing prepared by or authorized by it would conflict with the information in the
Registration Statement, the Pricing Disclosure Package or the Prospectus or would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances
then prevailing, not misleading, the Company will give prompt notice thereof to the Representatives and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus,
Section&nbsp;5(d) Writing or other document which will correct such conflict, statement or omission; provided, however, that this representation and warranty shall not apply to any statements or omissions in an Issuer Free Writing Prospectus or
Section&nbsp;5(d) Writing prepared or authorized by it made in reliance upon and in conformity with the Underwriter Information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Company represents and agrees that (i)&nbsp;it has not engaged in, or authorized any other person to engage in,
any Section&nbsp;5(d) Communications, other than Section&nbsp;5(d) Communications with the prior consent of the Representatives with entities that are qualified institutional buyers as defined in Rule 144A under the Act or institutions that are
accredited investors as defined in Rule 501(a) under the Act; and (ii)&nbsp;it has not distributed, or authorized any other person to distribute, any Section&nbsp;5(d) Writings, other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than those distributed with the prior consent of the Representatives that are listed on Schedule II(d) hereto; and the Company reconfirms that the Underwriters have been authorized to act on its
behalf in engaging in Section&nbsp;5(d) Communications; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Each Underwriter represents and agrees that any
Section&nbsp;5(d) Communications undertaken by it were with entities that are qualified institutional buyers as defined in Rule 144A under the Act or institutions that are accredited investors as defined in Rule 501(a) under the Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;The Company covenants and agrees with the several Underwriters that the Company will pay or cause to be paid the
following: (i)&nbsp;the fees, disbursements and expenses of the Company&#146;s counsel and accountants in connection with the registration of the Shares under the Act and all other expenses in connection with the preparation, printing, reproduction
and filing of the Registration Statement, any Preliminary Prospectus, any Section&nbsp;5(d) Writing, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering of copies thereof to the
Underwriters and dealers; (ii)&nbsp;the cost of printing or producing any Agreement among Underwriters, this Agreement, the Blue Sky Memorandum, closing documents (including any compilations thereof) and any other documents in connection with the
offering, purchase, sale and delivery of the Shares; (iii)&nbsp;all expenses in connection with the qualification of the Shares for offering and sale under state securities laws as provided in Section&nbsp;5(b) hereof, including the fees and
disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky survey; (iv)&nbsp;all fees and expenses in connection with listing the Shares on Nasdaq; (v)&nbsp;the filing fees incident to,
and the fees and disbursements of counsel for the Underwriters in connection with, any required review by FINRA of the terms of the sale of the Shares; (vi)&nbsp;the cost of preparing stock certificates; (vii)&nbsp;the cost and charges of any
transfer agent or registrar; (viii)&nbsp;all fees and disbursements of counsel incurred by the Underwriters in connection with the Directed Share Program and stamp duties, similar taxes or duties or other taxes, if any, incurred by the Underwriters
in connection with the Directed Share Program; and (ix)&nbsp;all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in this Section; provided, however, that the amounts
payable by the Company pursuant to clauses (iii)&nbsp;and (v) for the fees and disbursements of counsel to the Underwriters described in clauses (iii)&nbsp;and (v) shall not exceed $40,000 in the aggregate. It is understood, however, that, except as
provided in this Section, and Sections 9, 10 and 13 hereof, the Underwriters will pay all of their own costs and expenses, including the fees of their counsel, stock transfer taxes on resale of any of the Shares by them, and any advertising expenses
connected with any offers they may make and all travel and lodging expenses of the Underwriters and their representatives and counsel; provided, however, that, the cost of any aircraft chartered in connection with any roadshow shall be paid 50% by
the Company and 50% by the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Underwriters hereunder, as to the Shares to be
delivered at each Time of Delivery, shall be subject, in their discretion, to the condition that all representations and warranties and other statements of the Company herein are, at and as of the Applicable Time and such Time of Delivery, true and
correct, the condition that the Company shall have performed all of its obligations hereunder theretofore to be performed, and the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Act within the
applicable time period prescribed for such filing by the rules </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and regulations under the Act and in accordance with Section&nbsp;5(a) hereof; all material required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been filed with
the Commission within the applicable time period prescribed for such filing by Rule 433; if the Company has elected to rely upon Rule 462(b) under the Act, the Rule 462(b) Registration Statement shall have become effective by 10:00 p.m., Washington,
D.C. time, on the date of this Agreement; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the
Commission; no stop order suspending or preventing the use of the Pricing Disclosure Package, Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and all requests for additional information on
the part of the Commission shall have been complied with to your reasonable satisfaction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Cooley LLP, counsel
for the Underwriters, shall have furnished to you such written opinion or opinions, dated such Time of Delivery, in form and substance satisfactory to the Representatives, with respect to such matters as the Representatives may reasonably request,
and such counsel shall have received such papers and information as they may reasonably request to enable them to pass upon such matters; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Latham&nbsp;&amp; Watkins LLP, counsel for the Company, shall have furnished to the Representatives their written
opinion and negative assurance letter, dated such Time of Delivery, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Wilson Sonsini Goodrich&nbsp;&amp; Rosati, intellectual property counsel for the Company, shall have furnished to
the Representatives their written opinion with respect to certain intellectual property matters, dated such Time of Delivery, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;On the date of the Prospectus at a time prior to the execution of this Agreement, at 9:30 a.m., New York City time,
on the effective date of any <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment to the Registration Statement filed subsequent to the date of this Agreement and also at each Time of Delivery, Ernst&nbsp;&amp; Young LLP shall have
furnished to the Representatives a letter or letters, dated the respective dates of delivery thereof, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;(i) The Company shall not have sustained since the date of the latest audited financial statements included in the
Pricing Disclosure Package and the Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree,
otherwise than as set forth or contemplated in the Pricing Disclosure Package and the Prospectus, and (ii)&nbsp;since the respective dates as of which information is given in the Pricing Disclosure Package and the Prospectus there shall not have
been any change in the capital stock (other than as a result of the exercise of stock options or the award of stock options or restricted stock in the ordinary course of business pursuant to the Company&#146;s equity plans that are described in the
Pricing Disclosure Package) or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any change or effect, or any development involving a prospective change or effect, in or affecting (x)&nbsp;the business, properties, general
affairs, management, financial position, stockholders&#146; equity or results of operations of the Company, except as set forth or contemplated in the Pricing Disclosure Package and the Prospectus, or (y)&nbsp;the ability of the Company to perform
its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transactions contemplated in the Pricing Disclosure Package and the Prospectus, the effect of which, in any such case described in clause (i)&nbsp;or (ii), is in your judgment so material and
adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Disclosure Package and the
Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;On or after the Applicable Time there shall not have occurred any of the following: (i)&nbsp;a
suspension or material limitation in trading in securities generally on the New York Stock Exchange or on Nasdaq; (ii)&nbsp;a suspension or material limitation in trading in the Company&#146;s securities on Nasdaq; (iii)&nbsp;a general moratorium on
commercial banking activities declared by either Federal, California State or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; (iv)&nbsp;the outbreak or
escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war; or (v)&nbsp;the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in
the United States or elsewhere, if the effect of any such event specified in clause (iv)&nbsp;or (v) in your judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such
Time of Delivery on the terms and in the manner contemplated in the Pricing Disclosure Package and the Prospectus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;The Shares to be sold at such Time of Delivery shall have been duly listed for quotation on Nasdaq; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have obtained and delivered to the Underwriters executed copies of an agreement from each
director, officer and other security holder of the Company representing all of the shares of capital stock of the Company, substantially to the effect set forth in Annex II hereof in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have delivered to the Representatives on the date of the Prospectus at a time prior to the
execution of this Agreement and at such Time of Delivery a certificate of the Chief Financial Officer of the Company, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have complied with the provisions of Section&nbsp;5(c) hereof with respect to the furnishing of
prospectuses on the New York Business Day next succeeding the date of this Agreement (or such other time as may be agreed to by the Representatives and the Company); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have furnished or caused to be furnished to you at such Time of Delivery certificates of officers
of the Company satisfactory to you as to the accuracy of the representations and warranties of the Company herein at and as of such Time of Delivery, as to the performance by the Company of all of its obligations hereunder to be performed at or
prior to such Time of Delivery, as to the matters set forth in subsections (a)&nbsp;and (e) of this Section and as to such other matters as you may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company will indemnify and hold harmless each Underwriter against any losses, claims, damages or
liabilities, joint or several, to which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement, any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any &#147;roadshow&#148; as defined in Rule 433(h) under the Act (a
&#147;roadshow&#148;), or any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Act, or any Section&nbsp;5(d) Writing, or arise out of or are based upon the omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by such Underwriter in connection with investigating or
defending any such action or claim as such expenses are incurred; <I>provided</I>, <I>however</I>, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an
untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus, or any amendment or supplement thereto, or any Issuer Free
Writing Prospectus, or any Section&nbsp;5(d) Writing, in reliance upon and in conformity with the Underwriter Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Underwriter will indemnify and hold harmless the Company against any losses, claims, damages or liabilities to
which the Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any Section&nbsp;5(d)
Writing, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the
extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus, or any amendment or supplement
thereto, or any Issuer Free Writing Prospectus, or any roadshow or any Section&nbsp;5(d) Writing, in reliance upon and in conformity with the Underwriter Information; and will reimburse the Company for any legal or other expenses reasonably incurred
by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. As used in this Agreement with respect to an Underwriter and an applicable document, &#147;Underwriter Information&#148; shall mean
the written information furnished to the Company by such Underwriter through the Representatives expressly for use therein; it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following
information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the fifth paragraph under the caption &#147;Underwriting&#148;, and the information contained in the ninth, tenth and eleventh
paragraphs under the caption &#147;Underwriting&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Promptly after receipt by an indemnified party under
subsection (a)&nbsp;or (b) of this Section&nbsp;9 of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying
party in writing of the commencement thereof; provided that the failure to notify the indemnifying party shall not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;9 except to the extent that it has
been materially prejudiced (through the forfeiture of substantive rights or defenses) by such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
failure; and provided further that the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise than under the preceding
paragraphs of this Section&nbsp;9. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to
the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be
counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection
for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of investigation. No indemnifying party shall, without
the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be
sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i)&nbsp;includes an unconditional release of the indemnified party from all liability
arising out of such action or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;If the indemnification provided for in this Section&nbsp;9 is unavailable to or insufficient to hold harmless an
indemnified party under subsection (a)&nbsp;or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on
the other from the offering of the Shares. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such
indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions which
resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be
deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in
the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company on the one hand or the Underwriters on the other and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and
the Underwriters agree that it would not be just and equitable if contribution pursuant to this subsection (d)&nbsp;were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other
method of allocation which does not take account of the equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
actions in respect thereof) referred to above in this subsection (d)&nbsp;shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten
by it and distributed to the public were offered to the public exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No
person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations in this
subsection (d)&nbsp;to contribute are several in proportion to their respective underwriting obligations and not joint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Company under this Section&nbsp;9 shall be in addition to any liability which the Company
may otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of each Underwriter and each person, if any, who controls any Underwriter within the meaning of the Act and each broker-dealer or other
affiliate of any Underwriter; and the obligations of the Underwriters under this Section&nbsp;9 shall be in addition to any liability which the respective Underwriters may otherwise have and shall extend, upon the same terms and conditions, to each
officer and director of the Company and to each person, if any, who controls the Company within the meaning of the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company will indemnify and hold harmless the Directed Share Underwriter against any losses, claims, damages
and liabilities to which the Directed Share Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims damages or liabilities (or actions in respect thereof)&nbsp;(i) arise out of or are based upon an untrue statement
or alleged untrue statement of a material fact contained in any material prepared by or with the consent of the Company for distribution to Participants in connection with the Directed Share Program or arise out of or are based upon the omission or
alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;arise out of or are based upon the failure of any Participant to pay for and accept delivery of
Directed Shares that the Participant agreed to purchase, or (iii)&nbsp;are related to, arise out of or are in connection with the Directed Share Program, and will reimburse the Directed Share Underwriter for any legal or other expenses reasonably
incurred by the Directed Share Underwriter in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable to the extent that any such loss, claim, damage
or liability with respect to clause (i)&nbsp;above, arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus
or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus or any Section&nbsp;5(d) Writing, or any material prepared by or with the consent of the Company for distribution to Participants in connection with the
Directed Share Program, in reliance upon and in conformity with the Underwriter Information; provided, further, the Company shall not be liable to the extent that any such loss, claim, damage or liability with respect to clauses (ii)&nbsp;and (iii)
above, is finally judicially determined to have resulted from the bad faith or gross negligence of the Directed Share Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Promptly after receipt by the Directed Share Underwriter of notice of the commencement of any action, the Directed
Share Underwriter shall, if a claim in respect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof is to be made against the Company, notify the Company in writing of the commencement thereof; provided that the failure to notify the Company shall not relieve the Company from any
liability that it may have under the preceding paragraph of this Section&nbsp;10 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that the
failure to notify the Company shall not relieve it from any liability that it may have to the Directed Share Underwriter otherwise than under the preceding paragraph of this Section&nbsp;10. In case any such action shall be brought against the
Directed Share Underwriter and it shall notify the Company of the commencement thereof, the Company shall be entitled to participate therein and, to the extent that it shall wish, to assume the defense thereof, with counsel satisfactory to the
Directed Share Underwriter (who shall not, except with the consent of the Directed Share Underwriter, be counsel to the Company), and, after notice from the Company to the Directed Share Underwriter of its election so to assume the defense thereof,
the Company shall not be liable to the Directed Share Underwriter under this subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by the Directed Share Underwriter, in connection with the
defense thereof other than reasonable costs of investigation. The Company shall not, without the written consent of the Directed Share Underwriter, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any
pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the Directed Share Underwriter is an actual or potential party to such action or claim) unless such settlement,
compromise or judgment (i)&nbsp;includes an unconditional release of the Directed Share Underwriter from all liability arising out of such action or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a
failure to act, by or on behalf of the Directed Share Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If the indemnification provided for in this
Section&nbsp;10 is unavailable to or insufficient to hold harmless the Directed Share Underwriter under subsection (a)&nbsp;above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then the
Company shall contribute to the amount paid or payable by the Directed Share Underwriter as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits
received by the Company on the one hand and the Directed Share Underwriter on the other from the offering of the Directed Shares. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then the
Company shall contribute to such amount paid or payable by the Directed Share Underwriter in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Directed
Share Underwriter on the other in connection with any statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative
benefits received by the Company on the one hand and the Directed Share Underwriter on the other shall be deemed to be in the same proportion as the total net proceeds from the offering of the Directed Shares (before deducting expenses) received by
the Company bear to the total underwriting discounts and commissions received by the Directed Share Underwriter for the Directed Shares. If the loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue
statement of a material fact or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, the relative fault shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the Company on the one hand or the Directed Share Underwriter on the other and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission. The Company and the Directed Share Underwriter agree that it would not be just and equitable if contribution pursuant to this subsection (c)&nbsp;were determined by pro rata allocation or by any other method of allocation
which does not take account of the equitable considerations referred to above in this subsection (c). The amount paid or payable by the Directed Share Underwriter as a result of the losses, claims, damages or liabilities (or actions in respect
thereof) referred to above in this subsection (c)&nbsp;shall be deemed to include any legal or other expenses reasonably incurred by the Directed Share Underwriter in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this subsection (c), the Directed Share Underwriter shall not be required to contribute any amount in excess of the amount by which the total price at which the Directed Shares sold by it and distributed to the
Participants exceeds the amount of any damages which the Directed Share Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Company under this Section&nbsp;10 shall be in addition to any liability which the Company
may otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of the Directed Share Underwriter and each person, if any, who controls the Directed Share Underwriter within the meaning of the Act and
each broker-dealer or other affiliate of the Directed Share Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;(a) If any Underwriter shall default
in its obligation to purchase the Shares which it has agreed to purchase hereunder at a Time of Delivery, you may in your discretion arrange for you or another party or other parties to purchase such Shares on the terms contained herein. If within <FONT
STYLE="white-space:nowrap">thirty-six</FONT> hours after such default by any Underwriter you do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of <FONT STYLE="white-space:nowrap">thirty-six</FONT>
hours within which to procure another party or other parties satisfactory to you to purchase such Shares on such terms. In the event that, within the respective prescribed periods, you notify the Company that you have so arranged for the purchase of
such Shares, or the Company notifies you that it has so arranged for the purchase of such Shares, you or the Company shall have the right to postpone such Time of Delivery for a period of not more than seven days, in order to effect whatever changes
may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees to file promptly any amendments or supplements to the Registration Statement or the Prospectus which in
your opinion may thereby be made necessary. The term &#147;Underwriter&#148; as used in this Agreement shall include any person substituted under this Section with like effect as if such person had originally been a party to this Agreement with
respect to such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any arrangements for the purchase of the Shares of a
defaulting Underwriter or Underwriters by you and the Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the
aggregate number of all the Shares to be purchased at such Time of Delivery, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the number of Shares which such
Underwriter agreed to purchase hereunder at such Time of Delivery and, in addition, to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase its pro rata share (based on the number of Shares
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which such Underwriter agreed to purchase hereunder) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve
a defaulting Underwriter from liability for its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any arrangements for the
purchase of the Shares of a defaulting Underwriter or Underwriters by you and the Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased exceeds
<FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of all the Shares to be purchased at such Time of Delivery, or if the Company shall not exercise the right described in subsection (b)&nbsp;above to require <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase Shares of a defaulting Underwriter or Underwriters, then this Agreement (or, with respect to the Second Time of Delivery, the obligations of the Underwriters to purchase and
of the Company to sell the Optional Shares) shall thereupon terminate, without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company, except for the expenses to be borne by the Company and the
Underwriters as provided in Section&nbsp;7 hereof and the indemnity and contribution agreements in Sections 9 and 10 hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;The respective indemnities, agreements, representations, warranties and other statements of the Company and the
several Underwriters, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made
by or on behalf of any Underwriter or any controlling person of any Underwriter, or the Company, or any officer or director or controlling person of the Company, and shall survive delivery of and payment for the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement shall be terminated pursuant to Section&nbsp;11 hereof, the Company shall not then be under any
liability to any Underwriter except as provided in Sections&nbsp;7 and 9 hereof; but, if for any other reason, any Shares are not delivered by or on behalf of the Company as provided herein, the Company will reimburse the Underwriters through you
for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses approved in writing by you, including fees and disbursements of counsel, reasonably incurred by the Underwriters in making preparations
for the purchase, sale and delivery of the Shares not so delivered, but the Company shall then be under no further liability to any Underwriter except as provided in Sections 7 and 9 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;In all dealings hereunder, you shall act on behalf of each of the Underwriters, and the parties hereto shall be
entitled to act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you jointly or by the Representatives on behalf of the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All statements, requests, notices and agreements hereunder shall be in writing, and (A)&nbsp;if to the Underwriters shall be delivered or sent
by mail or <FONT STYLE="white-space:nowrap">e-mail</FONT> transmission to you as the representatives (i)&nbsp;in care of Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Registration Department;
(ii)&nbsp;in care of Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by <FONT STYLE="white-space:nowrap">e-mail</FONT> at Prospectus_Department@Jefferies.com; and (iii)&nbsp;in
care of Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by <FONT STYLE="white-space:nowrap">e-mail</FONT> at ecm.prospectus@evercore.com and (B)&nbsp;if to the Company shall be
delivered or sent by mail to the address of the Company set forth on the cover of the Registration Statement, Attention: Chief Executive Officer; provided, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
however, that any notice to an Underwriter pursuant to Section&nbsp;9(c) hereof shall be delivered or sent by mail to such Underwriter at its address to be supplied to the Company by the
Representatives upon request; provided, however, that notices under subsection 5(e) shall be in writing, and if to the Underwriters shall be delivered or sent by mail to you as the Representatives at Goldman Sachs&nbsp;&amp; Co. LLC, 200 West
Street, New York, New York 10282-2198, Attention: Control Room; and at Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY 10022, Attention: General Counsel; and at Evercore Group L.L.C., 55 East 52nd Street, 36th Floor, New York, New York
10055, Attention: [&#9679;]. Any such statements, requests, notices or agreements shall take effect upon receipt thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance
with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their
respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be binding upon, and inure solely to the benefit of, the Underwriters, the Company and, to the
extent provided in Sections 9 and 12 hereof, the officers and directors of the Company and each person who controls the Company or any Underwriter, and their respective heirs, executors, administrators, successors and assigns, and no other person
shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Shares from any Underwriter shall be deemed a successor or assign by reason merely of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;Time shall be of the essence of this Agreement. As used herein, the term &#147;business day&#148; shall mean any
day when the Commission&#146;s office in Washington, D.C. is open for business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges and
agrees that (i)&nbsp;the purchase and sale of the Shares pursuant to this Agreement is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the
other, (ii)&nbsp;in connection therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the Company, (iii)&nbsp;no Underwriter has assumed an advisory or fiduciary
responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) or any other
obligation to the Company except the obligations expressly set forth in this Agreement and (iv)&nbsp;the Company has consulted its own legal and financial advisors to the extent it deemed appropriate. The Company agrees that it will not claim that
the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and
the Underwriters, or any of them, with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;This Agreement, any claim,
controversy or disputes arising under or related to this Agreement and any transaction contemplated by this Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of
laws that would results in the application of any other law than the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
laws of the State of New York. The Company agrees that any suit or proceeding arising in respect of this Agreement or any transaction contemplated by this Agreement will be tried exclusively in
the U.S. District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in The City and County of New York and the Company agrees to submit to the jurisdiction of, and to
venue in, such courts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;The Company and each of the Underwriters hereby irrevocably waives, to the fullest
extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of
which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the Company is authorized to disclose to any persons the U.S.
federal and state income tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and other tax analyses) provided to the Company relating to that treatment and structure, without the
Underwriters imposing any limitation of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall not apply) to the extent necessary to enable any person to comply
with securities laws. For this purpose, &#147;tax structure&#148; is limited to any facts that may be relevant to that treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.&nbsp;&nbsp;&nbsp;&nbsp;Recognition of the U.S. Special Resolution Regimes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special
Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if
this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes
subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under
the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;As used in this section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12
U.S.C. &#167;&nbsp;1841(k). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;252.82(b); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance
with, 12 C.F.R. &#167; 47.3(b); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &#167; 382.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with,
12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the
Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please sign and return to us a
counterpart signature page, and upon the acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof shall constitute a binding agreement between each of the Underwriters and the Company. It is understood
that your acceptance of this letter on behalf of each of the Underwriters is pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without
warranty on your part as to the authority of the signers thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Phathom Pharmaceuticals, Inc.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted as of the date hereof:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Jefferies LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Evercore Group L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of each of the Underwriters </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Number&nbsp;of<BR>Firm<BR>Shares&nbsp;to&nbsp;be<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Optional<BR>Shares to be<BR>Purchased<BR>if&nbsp;Maximum<BR>Option<BR>Exercised</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Needham&nbsp;&amp; Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Issuer Free Writing Prospectuses not included in the Pricing Disclosure Package: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[Electronic roadshow dated [&#149;]] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)
Additional Documents Incorporated by Reference: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[None] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Information other than the Pricing Prospectus that comprise the Pricing Disclosure Package: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The initial public offering price per share for the Shares is $[&#9679;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The number of Shares purchased by the Underwriters is [&#9679;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[Add any other pricing disclosure.] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section 5(d) Writings: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[Phathom Pharmaceuticals, Inc. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Presentation
dated [&#9679;], 2019.] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Press Release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phathom
Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[Date] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phathom
Pharmaceuticals, Inc. (the &#147;Company&#148;) announced today that Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C., the lead book-running managers in the Company&#146;s recent public sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, are [waiving] [releasing] a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction with respect
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of the Company&#146;s common stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;, and the shares may be sold on or after such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such
securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phathom Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As representatives of the several Underwriters </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">named in Schedule I to the Underwriting Agreement, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10055 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Re: <U>Phathom
Pharmaceuticals, Inc. &#150; <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that you, as representatives (the &#147;Representatives&#148;), propose to enter into an underwriting agreement
(the &#147;Underwriting Agreement&#148;) on behalf of the several Underwriters named in Schedule I to such agreement (collectively, the &#147;Underwriters&#148;), with Phathom Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;),
providing for a public offering (the &#147;Public Offering&#148;) of the Common Stock of the Company (the &#147;Shares&#148;) pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be filed with the Securities
and Exchange Commission (the &#147;SEC&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the agreement by the Underwriters to offer and sell the Shares, and of
other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning from the date of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and
continuing to and including the date 180 days after the date set forth on the final prospectus (the &#147;Prospectus&#148;) used to sell the Shares (the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), the undersigned shall not,
and shall not cause or direct any of its affiliates to, without the consent of the Representatives, (i)&nbsp;offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise dispose of any shares of Common Stock of the Company,
or any options or warrants to purchase any shares of Common Stock of the Company, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock of the Company (such options, warrants or other
securities, collectively, &#147;Derivative Instruments&#148;), including without limitation any such shares or Derivative Instruments now owned or hereafter acquired by the undersigned, (ii)&nbsp;engage in any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap
or any other derivative transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the undersigned or someone
other than the undersigned), or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any shares of Common Stock of the Company or Derivative Instruments, whether any such transaction or
arrangement (or instrument provided for thereunder) would be settled by delivery of Common Stock or other securities, in cash or otherwise (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a
&#147;Transfer&#148;) or (iii)&nbsp;otherwise publicly announce any intention to engage in or cause any action or activity described in clause (i)&nbsp;above or transaction or arrangement described in clause (ii)&nbsp;above. The undersigned
represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement that provides for, is designed to or which reasonably could be expected to
lead to or result in any Transfer during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. If the undersigned is a director or officer of the Company, the undersigned agrees that the foregoing provisions shall be equally applicable to any
issuer-directed or other Shares the undersigned may purchase in the Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is not a natural person, the
undersigned represents and warrants that no single natural person or entity beneficially owns, directly or indirectly, 50% or more of the equity interests (excluding any <FONT STYLE="white-space:nowrap">non-economic</FONT> interests) in the
undersigned, except for a natural person or entity that has executed a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in substantially the same form as this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. For purposes of this
paragraph, &#147;beneficially owns&#148; shall mean solely a pecuniary interest under Rule <FONT STYLE="white-space:nowrap">16a-1(a)(2)</FONT> of the rules promulgated under the Securities Exchange Act of 1934, as amended (the &#147;Exchange
Act&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, (i)&nbsp;the Representatives agree that, at least three business
days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock, the Representatives will notify the Company of the impending release or waiver, and (ii)&nbsp;the Company
has agreed or will agree in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any release or waiver
granted by the Representatives hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if (a)&nbsp;the release or waiver is
effected solely to permit a transfer not for consideration and (b)&nbsp;the transferee has agreed in writing to be bound by the same terms described in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement to the extent and for the duration
that such terms remain in effect at the time of the transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may, without the consent of
the Representatives, Transfer the undersigned&#146;s shares of Common Stock of the Company and Derivative Instruments: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) as a <I>bona
fide</I> gift or gifts; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the
undersigned; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iii) if the undersigned is a trust, to the trustor or beneficiary of such trust or to the estate of a beneficiary of such
trust; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iv) by will or intestate succession to the legal representative, heir or beneficiary of the
undersigned; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(v) as a distribution to limited partners, members or stockholders of the undersigned; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;to the undersigned&#146;s affiliates or to any investment fund or other entity controlled or managed by the undersigned; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(vii) pursuant to a court or regulatory agency order, a qualified domestic order or in connection with a divorce settlement, <U>provided</U>,
(1)&nbsp;the Representatives receive a signed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in the same form as this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement for the balance of the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each transferee, (2)&nbsp;no public disclosure or filing shall be made voluntarily during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and (3)&nbsp;any required filing under
Section&nbsp;16 of the Exchange Act, during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that such Transfer relates to the circumstances described in this clause (vii); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(viii) to the Company as forfeitures to satisfy tax withholding and remittance obligations of the undersigned in connection with the vesting or
exercise of equity awards granted pursuant to the Company&#146;s equity incentive plans or Derivative Instruments described in the Prospectus or Transfers to the Company pursuant to a net exercise or cashless exercise by the stockholder of
outstanding equity awards pursuant to the Company&#146;s equity incentive plans or Derivative Instruments described in the Prospectus, <U>provided</U> any Common Stock of the Company issued upon vesting or exercise shall remain subject to the
restrictions on transfer set forth in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, and <U>provided</U>, <U>further</U>, no public disclosure or filing shall be made voluntarily during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period nor shall be required within 30 days after the date of the Prospectus, and after such 30th day, any required filing under Section&nbsp;16 of the Exchange Act during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that such Transfer is pursuant to the circumstances described in this clause (viii); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ix) to the Company pursuant to any contractual arrangement disclosed in the Prospectus and in effect on the date of the Prospectus that
provides for the repurchase by the Company or forfeiture of the undersigned&#146;s Common Stock of the Company or Derivative Instruments in connection with the termination of the undersigned&#146;s service to the Company, <U>provided</U> that
(1)&nbsp;no public disclosure or filing shall be made voluntarily during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and (2)&nbsp;any required filing under Section&nbsp;16 of the Exchange Act made during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (ix); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(x) in connection with the conversion of the outstanding convertible notes into shares of Common Stock in connection with the consummation of
the Public Offering as described in the Prospectus, <U>provided</U>, that, any such shares of Common Stock received upon such conversion shall remain subject to the provisions of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(xi) upon the completion of a <I>bona fide</I> third-party tender offer, merger, consolidation or other similar transaction that is approved by
the Board of Directors of the Company and made to all holders of the Company&#146;s securities involving a change of control of the Company, <U>provided</U> that, in the event that such tender offer, merger, consolidation or other similar
transaction is not completed, any Common Stock of the Company or Derivative Instruments held by the undersigned shall remain subject to the restrictions on transfer set forth in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (for
purposes hereof, &#147;change of control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would
hold more than 50% of the outstanding voting securities of the Company (or the surviving entity)); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(xii) with the prior written consent
of the Representatives on behalf of the Underwriters. In addition, with respect to clauses (i)&nbsp;through (vi) above, it shall be a condition to such transfer that (1)&nbsp;the Representatives receive a signed
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in the same form as this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each donee, trustee,
distributee or transferee, as the case may be, (2)&nbsp;any such transfer shall not involve a disposition for value and (3)&nbsp;no public filing or disclosure shall be required or voluntarily made during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period in connection with such transfer. For purposes of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, &#147;immediate family&#148; shall mean any relationship by blood, marriage or
adoption, not more remote than first cousin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding the foregoing, if the undersigned is a corporation,
partnership, limited liability company, or similar entity, the undersigned may, without the consent of the Representatives, transfer shares of Common Stock of the Company to any wholly-owned subsidiary of such corporation, partnership, limited
liability company or similar entity; <U>provided</U>, <U>however</U>, that in any such case, it shall be a condition to the transfer that the transferee execute an agreement stating that the transferee is receiving and holding such shares of Common
Stock of the Company subject to the provisions of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and there shall be no further transfer of such capital stock except in accordance with this
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, and <U>provided</U>, <U>further</U> that any such transfer shall not involve a disposition for value and no public filing or disclosure shall be required or voluntarily made during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period in connection with such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding anything herein to the
contrary, the undersigned may, without the consent of the Representatives, establish a trading plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (a <FONT STYLE="white-space:nowrap">&#147;10b5-1</FONT>
Trading Plan&#148;) or amend an existing <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan so long as there are no sales of Common Stock of the Company or Derivative Instruments under such plan during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; <U>provided</U> that, the establishment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan or the amendment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan, in
either case, providing for sales of Common Stock of the Company or Derivative Instruments shall only be permitted if (i)&nbsp;the establishment or amendment of such plan is not required to be reported in any public report or filing with the SEC, or
otherwise, and (ii)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the undersigned may, without the consent of the Representatives, sell shares of Common Stock of the Company purchased by the
undersigned in the Public Offering or on the open market following the Public Offering if and only if (i)&nbsp;such sales are not required to be reported in any public report or filing with the SEC, or otherwise, during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period and (ii)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such sales during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned now has, and, except as contemplated by any of clauses (i)&nbsp;through (xii) above, for the duration of this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will have, good and marketable title to the undersigned&#146;s shares of Common Stock of the Company, free and clear of all liens, encumbrances, and claims whatsoever, other than (i)&nbsp;rights of
repurchase or vesting conditions in favor of the Company or (ii)&nbsp;any charitable pledge of the undersigned&#146;s Common Stock of the Company that by its terms could not result in any transfer, disposition or distribution of such shares during
the term of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company&#146;s transfer agent and registrar against the transfer of the undersigned&#146;s shares of Common Stock of the Company except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the Underwriters are relying upon this <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal
representatives, successors, and assigns. The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall terminate and the understand shall be released from all obligations under
this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, (i)&nbsp;if the Underwriting Agreement does not become effective by December&nbsp;31, 2019, (ii) if the Underwriting Agreement (other than the provisions thereof which survive
termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, (iii)&nbsp;if the Company files an application to withdraw the Registration Statement or (iv)&nbsp;if the Representatives, on
behalf of the underwriters, advise the Company, or the Company advises the Representatives, in writing, prior to the execution of the Underwriting Agreement, that they have determined not to proceed with the Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and any claim, controversy or dispute arising under or related to this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflict of laws principles thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Security Holder <I>(Print exact name</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d63338dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHATHOM
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Pursuant to Sections 242 and 245 of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Corporation Law of the State of Delaware) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phathom Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of
the State of Delaware (the &#147;<B><I>General Corporation Law</I></B>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY</B>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;That the name of this corporation is Phathom Pharmaceuticals, Inc., and that this corporation was originally
incorporated pursuant to the General Corporation Law on January&nbsp;9, 2018 under the name North Bridge IV, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;That the Board of Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation
of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders
therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>RESOLVED</B>, that the
Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The name of this corporation is Phathom Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>II. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
address of the registered office of the corporation in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, City of Wilmington, County of New Castle, State of Delaware 19808, and the name of the registered agent of the
corporation in the State of Delaware at such address is Corporation Service Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>III. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The purpose of this corporation is to engage in any lawful act or activity for which a corporation may be organized under the
General Corporation Law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IV. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;This corporation is authorized to issue
only one class of stock, to be designated Common Stock. The total number of shares of Common Stock presently authorized is Ten Million (10,000,000), each having a par value of $0.0001. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;The management of the business and the conduct of the affairs of the corporation shall be
vested in its Board of Directors. The number of directors which shall constitute, the whole Board of Directors shall be fixed by the Board of Directors in the manner provided in the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the
corporation. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the corporation required by law or by
this Amended and Restated Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of the capital stock of the
corporation entitled to vote generally in the election of directors, voting together as a single class. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VI. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;The corporation renounces, to the fullest extent permitted by law, any interest or expectancy
of the corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An &#147;<B><I>Excluded Opportunity</I></B>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed
by, or which otherwise comes into the possession of (i)&nbsp;any director of the corporation who is not an employee of the corporation or any of its subsidiaries, or (ii)&nbsp;any holder of securities convertible into or exercisable for the capital
stock of the corporation (including any shares of capital stock of the corporation issued upon the conversion or exercise thereof), or any partner, member, director, stockholder, employee, affiliate or agent of any such holder, other than someone
who is an employee or consultant of the corporation or any of its subsidiaries (collectively, the persons referred to in clauses (i)&nbsp;and (ii) are &#147;<B><I>Covered Persons</I></B>&#148;), unless such matter, transaction or interest is
presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of the corporation while such Covered Person is performing
services in such capacity. Any repeal or modification of this Article VI will only be prospective and will not affect the rights under this Article VI in effect at the time of the occurrence of any actions or omissions to act giving rise to
liability. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VII. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The corporation elects not to be governed by Section&nbsp;203 of the General Corporation Law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VIII. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by law, a director of the corporation shall not be personally
liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article
VIII to authorize corporate </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
action further eliminating or limiting the personal liability of directors, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by
the General Corporation Law as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;Any repeal or modification of the foregoing
provisions of this Article VIII by the stockholders of the corporation shall not adversely affect any right or protection of a director of the corporation existing at the time of, or increase the liability of any director of the corporation with
respect to any acts or omissions of such director occurring prior to, such repeal or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IX. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by applicable law, the corporation is authorized to provide
indemnification of (and advancement of expenses to) directors, officers and agents of the corporation (and any other persons to which General Corporation Law permits the corporation to provide indemnification) through Bylaw provisions, agreements
with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;Any amendment, repeal or modification of the foregoing provisions of this Article IX shall
not (i)&nbsp;adversely affect any right or protection of any director, officer or other agent of the corporation existing at the time of such amendment, repeal or modification or (ii)&nbsp;increase the liability of any director of the corporation
with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>X.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The corporation reserves the right to amend, alter, change or repeal any provision contained in this Amended and
Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this reservation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;That the foregoing amendment and restatement was approved by the holders of the requisite number of
shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.&nbsp;&nbsp;&nbsp;&nbsp;That this Certificate of Incorporation, which restates and integrates and further amends the
provisions of this corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, this Amended and Restated Certificate of
Incorporation has been executed by a duly authorized officer of this corporation on this 6th day of May, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ David&nbsp;Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Phathom Pharmaceuticals, Inc. (the &#147;<B><I>Corporation</I></B>&#148;) originally
filed its Certificate of Incorporation with the Secretary of State of Delaware on January&nbsp;9, 2018 under the name North Bridge IV, Inc., and is organized and existing under the General Corporation Law of the State of Delaware, hereby certifies
as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;That the Board of Directors of said Corporation duly adopted resolutions proposing
and declaring advisable the following amendments of the Amended and Restated Certificate of Incorporation (as amended, the &#147;<B><I>Certificate</I></B>&#148;) of said Corporation. The resolutions setting forth the proposed amendments are as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>RESOLVED</B>, that Article Fourth of the Certificate is hereby amended and restated in their entirety as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;This corporation is authorized to issue only one class of
stock, to be designated Common Stock. The total number of shares of Common Stock presently authorized is 50&nbsp;million (50,000,000), each having a par value of $0.0001. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective upon the filing of this Certificate of Amendment with the Secretary of State of the State of Delaware, a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2.168-for-1</FONT></FONT> forward stock split for each share of Common Stock outstanding or held in treasury immediately prior to such time shall automatically and without any action on the
part of the holders thereof occur (the &#147;<B><I>Forward Stock Split</I></B>&#148;). The par value of the Common Stock shall remain $0.0001 per share. This conversion shall apply to all shares of Common Stock. No fractional shares of Common Stock
shall be issued upon the Forward Stock Split or otherwise. In lieu of any fractional shares of Common Stock to which the stockholder would otherwise be entitled upon the Forward Stock Split, the Company shall pay cash equal to such fraction
multiplied by the then fair market value of the Common Stock as determined by the Company&#146;s Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All certificates representing shares of Common Stock outstanding immediately prior to the filing of this
Certificate of Amendment shall immediately after the filing of this Certificate of Amendment represent instead the number of shares of Common Stock as provided above. Notwithstanding the foregoing, any holder of Common Stock may (but shall not be
required to) surrender his, her or its stock certificate or certificates to the Company, and upon such surrender the holder may request that the Company issue a certificate for the correct number of shares of Common Stock to which the holder is
entitled under the provisions of this Certificate of Amendment. Shares of Common Stock that were outstanding prior to the filing of this Certificate of Amendment, and that are not outstanding after and as a result of the filing of this Certificate
of Amendment, shall resume the status of authorized but unissued shares of Common Stock.&#148; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;That thereafter, pursuant to a resolution of the
Board of Directors and in lieu of a meeting of stockholders, the stockholders gave their approval of said amendment by written consent in accordance with the provisions of Section&nbsp;228 of the General Corporation Law of the State of Delaware.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;That said amendment was duly adopted in accordance with the provisions of Sections 242 and 228
of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.&nbsp;&nbsp;&nbsp;&nbsp;That said amendment shall be executed,
filed and recorded in accordance with Section&nbsp;103 of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page
Intentionally Left Blank</I>] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, this Certificate of Amendment has been executed
by a duly authorized officer of the Corporation on this 11th day of October, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>d63338dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g63338g18f70.jpg" ALT="LOGO">

 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">THIS CERTIFIES THATis the owner ofCUSIPDATEDCOUNTERSIGNED AND REGISTERED:COMPUTERSHARE TRUST COMPANY,
N.A.TRANSFER AGENT AND REGISTRAR,FULLY-PAID AND <FONT STYLE="white-space:nowrap">NON-ASSESSABLE</FONT> SHARES OF COMMON STOCK OFPhathom Pharmaceuticals, Inc. (hereinafter called the &#147;Company&#148;), transferable on the books of theCompany in
person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. ThisCertificate and the shares represented hereby, are issued and shall be held subject to all of the provisions of theCertificate of Incorporation, as
amended, and the <FONT STYLE="white-space:nowrap">By-Laws,</FONT> as amended, of the Company (copies of which are onfile with the Company and with the Transfer Agent), to all of which each holder, by acceptance hereof, assents.This Certificate is
not valid unless countersigned and registered by the Transfer Agent and Registrar.Witness the facsimile seal of the Company and the facsimile signatures of its duly authorized officers.COMMON STOCKPAR VALUE $0.0001COMMON STOCKSEE REVERSE FOR CERTAIN
DEFINITIONSCertificateNumberShares.PHATHOM PHARMACEUTICALS, INC.INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWAREPresident and Chief Executive OfficerChief Business OfficerByAUTHORIZED SIGNATURE1/9/2018DEL AWAR EC O R PO R ATEP HATHOM
PHARMACEUTICALS, INC.ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS#XXXXXX XX <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">XDD-MMM-YYYY*</FONT></FONT> * 000000* * * * * * * * * * * * * * * * * ** * * 000000* * * * * * * * *
* * * * * * * ** * * * 000000* * * * * * * * * * * * * * * ** * * * * 000000* * * * * * * * * * * * * * ** * * * * * 000000* * * * * * * * * * * * * *** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander
David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample**** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample ****
Mr.&nbsp;Alexander DavidSample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;AlexanderDavid Sample **** Mr.&nbsp;Alexander David
Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander
David Sample **** Mr.&nbsp;Alexander David Sample ****Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample****
Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander DavidSample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David
Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;AlexanderDavid Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample ****
Mr.&nbsp;Alexander David Sample **** Mr.Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample ****Mr.&nbsp;Alexander David Sample
**** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Sample ****
Mr.&nbsp;
Sample**000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**S***ZERO
 HUNDRED THOUSANDZERO HUNDRED AND ZERO***MR. SAMPLE&nbsp;&amp; MRS. SAMPLE&nbsp;&amp;MR. SAMPLE&nbsp;&amp; MRS. SAMPLEZQ00000000Certificate
Numbers1234567890/12345678901234567890/12345678901234567890/12345678901234567890/12345678901234567890/12345678901234567890/1234567890Total TransactionNum/No.123456Denom.123456Total1234567MR A SAMPLEDESIGNATION (IF ANY)ADD 1ADD 2ADD 3ADD 4PO BOX
505006, Louisville, KY 40233-5006CUSIP/IDENTIFIER XXXXXX XX XHolder ID XXXXXXXXXXInsurance Value 1,000,000.00Number of Shares 123456DTC 12345678 123456789012345THIS CERTIFICATE IS TRANSFERABLE INCITIES DESIGNATED BY THE TRANSFERAGENT, AVAILABLE
ONLINE ATwww.computershare.comThe IRS requires that the named transfer agent (&#147;we&#148;) report the costbasis of certain shares or units acquired after January&nbsp;1, 2011. If yourshares or units are covered by the legislation, and you
requested to sellor transfer the shares or units using a specific cost basis calculationmethod, then we have processed as you requested. If you did notspecify a cost basis calculation method, then we have defaulted to thefirst in, first out (FIFO)
method. Please consult your tax advisor if youneed additional information about cost basis.If you do not keep in contact with the issuer or do not have anyactivity in your account for the time period specified by state law,your property may become
subject to state unclaimed propertylaws and transferred to the appropriate state.For value received,_ hereby sell, assign and transfer unto Shares AttorneyDated: 20Signature: Signature:Notice: The signature to this assignment must correspond with
the nameas written upon the face of the certificate, in every particular,without alteration or enlargement, or any change whatever.PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS,
INCLUDING POSTAL ZIP CODE, OF ASSIGNEE)of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appointto transfer the said stock on the books of the within-named Company with full power of substitution in
the premises.. </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g63338g49l94.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">PHATHOM PHARMACEUTICALS, INC.THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS,
DESIGNATIONS,PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THEQUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS, PREFERENCES
ANDLIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, ANDTHE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO
DETERMINEVARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFERAGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS
LEGALREPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THATMAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE.Signature(s) Guaranteed:
Medallion Guarantee StampTHE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks,Stockbrokers, Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVEDSIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT
TO S.E.C. RULE <FONT STYLE="white-space:nowrap">17Ad-15.The</FONT> following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in fullaccording to applicable laws or
regulations:TEN COM&#151;as tenants in common UNIF GIFT MIN ACT -.. Custodian.(Cust) (Minor)TEN ENT&#151;as tenants by the entireties under Uniform Gifts to Minors Act.(State)JT TEN&#151;as joint tenants with right of survivorship UNIF TRF MIN ACT
-.. Custodian (until age. )and not as tenants in common (Cust). under Uniform Transfers to Minors Act. (Minor) (State)Additional abbreviations may also be used though not in the above list. </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>5
<FILENAME>d63338dex45.htm
<DESCRIPTION>EX-4.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHATHOM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTE PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May&nbsp;7, 2019 </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terms of the Convertible Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Issuance of Convertible Notes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">6</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Right to Convert Notes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">7</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Mechanics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Initial Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">9</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Second Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">9</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conditions of Lenders&#146; Obligations at Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">9</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conditions of the Company&#146;s Obligations at Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">10</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations and Warranties of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Organization, Good Standing and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">10</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">10</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">11</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Authorization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">11</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Compliance with Other Instruments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">12</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Governmental Consents and Filings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">12</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">12</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">13</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">14</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Absence of Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">14</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Valid Issuance of Conversion Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">14</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Committee on Foreign Investment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">14</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">14</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations, Warranties and Additional Agreements of the Lenders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Representations and Warranties of the Lenders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">15</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Further Limitations on Disposition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">16</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Legends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">16</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Bad Actor Representations and Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">16</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exculpation Among Lenders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">16</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defaults and Remedies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Events of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">17</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">18</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Covenants of the Company; Rights of the Holders of the Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delivery of Financial Statements; Inspection Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">18</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Right of First Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">19</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Rights of Refusal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">21</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Drag Along Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">24</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Registration&nbsp;Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">27</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Voting&nbsp;Provisions&nbsp;Regarding&nbsp;the&nbsp;Board&nbsp;Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">37</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Protective Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">40</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Directors&#146; and Officers&#146; Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">41</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Observer Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">41</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">42</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Successors and Assigns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">43</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">43</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Counterparts; Delivery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">43</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Titles and Subtitles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">43</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">43</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Finder&#146;s Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">44</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">44</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entire Agreement; Amendments and Waivers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">44</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Effect of Amendment or Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">45</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">45</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;Market <FONT STYLE="white-space:nowrap">Stand-Off&#148;</FONT> Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">45</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Financing Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">46</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">MFN Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">46</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exculpation Among Lenders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">46</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Acknowledgement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">47</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnity; Costs, Expenses and Attorneys&#146; Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">47</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Further Assurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">47</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dispute Resolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">47</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Waiver of Jury Trial</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">47</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">48</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Spousal Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">48</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Limitation of Liability; Freedom to Operate Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">48</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibits </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#150;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form&nbsp;of&nbsp;Note</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#150;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rule 506(D) Bad Actor Representations</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#150;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">List of Common Holders</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#150;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Management Rights Letter</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#150;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Indemnification Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#150;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure Schedule</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit G</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#150;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Adoption Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit H</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#150;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Spousal Consent</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTE PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THIS NOTE PURCHASE AGREEMENT</B> (&#147;<U>Agreement</U>&#148;) is made as of May&nbsp;7, 2019, by and among Phathom
Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and the lenders (each, a &#147;Lender&#148; and collectively, the &#147;<U>Lenders</U>&#148;) named on the Schedule of Lenders attached hereto (the &#147;<U>Schedule of
Lenders</U>&#148;), and the Common Holders (as defined herein) (collectively, the &#147;<U>Parties</U>&#148;). Capitalized terms not otherwise defined in this Agreement shall have the meanings ascribed to them in Section&nbsp;1 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, each of the Lenders intends to provide certain Consideration to the Company as described for each Lender on
the Schedule of Lenders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, the parties wish to provide for the sale and issuance of certain Notes in return
for the provision by the Lenders of the Consideration to the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, the parties intend for the
Company to issue in return for the Consideration one or more Notes that are convertible into shares of the Company&#146;s Equity Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS: </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Affiliate</U>&#148; shall mean, with respect to any Person, any other Person who, directly
or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital fund or other investment fund now
or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management or advisory company with, such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Board</U>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Common Holder</U>&#148; shall mean the holders of Common Stock listed on <U>Exhibit C</U>
attached hereto (collectively, the &#147;<U>Common Holders</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Common
Stock</U>&#148; means shares of common stock, par value $0.0001, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Intellectual Property</U>&#148; means all patents, patent applications, registered
and unregistered trademarks, trademark applications, registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, mask works, information and proprietary rights and processes, similar or
other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases that are owned or used by or are necessary to the
Company in the conduct of the Company&#146;s business as now conducted and as presently proposed to be conducted. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Consideration</U>&#148; shall mean the
amount of money paid by each Lender pursuant to this Agreement as shown on the Schedule of Lenders in the form of a check, wire transfer, cancellation or exchange of indebtedness, or any combination thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Conversion Cap Price Per Share</U>&#148; shall mean the quotient obtained by dividing the
following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Valuation Cap less the aggregate principal amount and accrued interest under
the Notes, by </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the <FONT STYLE="white-space:nowrap">Pre-closing</FONT> Capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Conversion Price</U>&#148; shall mean: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;with respect to a conversion pursuant to Section&nbsp;2.2(a) below, the lesser of (A)&nbsp;the
Discounted Conversion Price or (B)&nbsp;the Conversion Cap Price Per Share; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;with respect to
a conversion pursuant to Section&nbsp;2.2(b) below, the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Discounted Conversion Price; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;with respect to a conversion pursuant to Section&nbsp;2.2(c) below, the Conversion Cap Price Per
Share; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;with respect to a conversion pursuant to Section&nbsp;2.2(d) below, the lesser of
(A)&nbsp;the Discounted Conversion Price or (B)&nbsp;the Conversion Cap Price Per Share; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;with respect to a conversion pursuant to Section&nbsp;2.2(e) below, the Conversion Cap Price Per
Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Conversion Shares</U>&#148; shall, for purposes of determining the type of
Equity Securities issuable upon conversion of the Notes, mean: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;if the Notes are converted to
equity pursuant to Section&nbsp;2.2(a) below, the Equity Securities issued in the Next Equity Financing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;if the Notes are converted to equity pursuant to Section&nbsp;2.2(b) below, the Equity Securities
issued in the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;if the Notes are converted to equity pursuant to Section&nbsp;2.2(c) below, shares of Common
Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;if the Notes are converted to equity pursuant to Section&nbsp;2.2(d) below, shares of
Common Stock; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;if the Notes are converted to equity pursuant to Section&nbsp;2.2(e) below,
shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Corporate Transaction</U>&#148; shall mean (A)&nbsp;the
closing of the sale, transfer or other disposition of all or substantially all of this Company&#146;s assets, (B)&nbsp;the consummation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
merger or consolidation of this Company with or into another entity (except a merger or consolidation in which the holders of capital stock of this Company immediately prior to such merger or
consolidation continue to hold at least 50% of the voting power of the capital stock of this Company or the surviving or acquiring entity in substantially identical proportions and with substantially identical rights, preferences, privileges and
restrictions as existed immediately prior to such transaction), (C)&nbsp;the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a person or group of affiliated persons
(other than an underwriter of this corporation&#146;s securities), of this Company&#146;s securities if, after such closing, such person or group of affiliated persons would hold 50% or more of the outstanding voting stock of this Company (or the
surviving or acquiring entity) or (D)&nbsp;a liquidation, dissolution or winding up of this Company; <U>provided</U>, <U>however</U>, that a transaction shall not constitute a Corporate Transaction if its sole purpose is to change the state of this
Company&#146;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held this Company&#146;s securities immediately prior to such transaction. Notwithstanding the prior sentence,
the sale of shares of Preferred Stock in a bona fide financing transaction for the purposes of raising operating capital to bona fide institutional, venture capital, private equity and similar investors shall not be deemed a &#147;Corporate
Transaction.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Discounted Conversion Price</U>&#148; shall equal 80% of the New
Purchase Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Equity Securities</U>&#148; shall mean the Company&#146;s Common
Stock or Preferred Stock or any securities conferring the right to purchase the Company&#146;s Common Stock or Preferred Stock or securities directly or indirectly convertible into, or exchangeable for (with or without additional consideration), the
Company&#146;s Common Stock or Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Exchange Act</U>&#148; shall mean the
Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Form</U><U></U><U><FONT
STYLE="white-space:nowrap">&nbsp;S-3</FONT></U>&#148; shall mean such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits inclusion or
incorporation of substantial information by reference to other documents filed by the Company with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(o)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Frazier</U>&#148; shall mean Frazier Life Sciences IX, L.P. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(p)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Free Writing Prospectus</U>&#148; shall mean a free-writing prospectus, as defined in Rule
405. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(q)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Fully Diluted Capital Stock</U>&#148; shall mean the filly-diluted outstanding
capital stock of the Company, including (i)&nbsp;outstanding shares of Common Stock (i)&nbsp;outstanding shares of Preferred Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis), (ii) outstanding vested and unvested stock options
and all shares of Common Stock held in reserve in any of the Company&#146;s equity incentive plans that are not then yet allocated for outstanding and unexercised stock options, (iii)&nbsp;outstanding warrants (on an
<FONT STYLE="white-space:nowrap">as-exercised</FONT> basis), and (iv)&nbsp;other outstanding convertible securities (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis), including the Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(r)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Holder</U>&#148; shall mean any Person
owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section&nbsp;7.5(j) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(s)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Initial Public Offering</U>&#148; shall mean the closing of the issuance and sale of
shares of Equity Securities of the Company in the Company&#146;s first firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act in which the gross cash proceeds to the Company (before
underwriting discounts, commissions and fees) are at least $75,000,000 (excluding the aggregate amount of debt securities converted into Equity Securities upon conversion of convertible indebtedness, including, without limitation, the Notes
converted pursuant to Section&nbsp;2.2 below) or such lesser amount as may be approved by the Requisite Noteholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(t)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Key Employee</U>&#148; means any executive-level employee (including division director and
vice president-level positions) as well as any employee or consultant who either alone or in concert with others develops, invents, programs or designs any Company Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(u)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Material Adverse Effect</U>&#148; means a material adverse effect on the business, assets
(including intangible assets), liabilities, financial condition, property, prospects or results of operations of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Maturity Date</U>&#148; shall mean May&nbsp;7, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(w)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>New Purchase Price</U>&#148; shall mean the price paid per share in cash for Equity
Securities by the investors in the Initial Public Offering, Next Equity Financing or the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing, as applicable, other than as a result of conversion of indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Next Equity Financing</U>&#148; shall mean the next sale (or series of related sales) by
the Company of its Equity Securities following the date of this Agreement primarily for bona fide equity financing purposes from which the Company receives gross proceeds of not less than $75,000,000 (excluding the aggregate amount of debt
securities converted into Equity Securities upon conversion of convertible indebtedness, including, without limitation, the Notes converted pursuant to Section&nbsp;2.2 below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(y)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Discounted Conversion
Price</U>&#148; shall equal the Discounted Conversion Price unless otherwise agreed between the Company and Requisite Noteholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(z)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing</U>&#148;
shall mean the next sale (or series of related sales) by the Company of its Equity Securities following the date of this Agreement primarily for bona fide equity financing purposes from which the Company receives gross proceeds of less than
$75,000,000 (excluding the aggregate amount of debt securities converted into Equity Securities upon conversion of convertible indebtedness, including, without limitation, the Notes converted pursuant to Section&nbsp;2.2 below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Notes</U>&#148; shall mean the one or more promissory notes issued to each Lender
pursuant to Section&nbsp;2.1 below, the form of which is attached hereto as <U>Exhibit A</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Person</U>&#148; shall mean any
individual, corporation, partnership, trust, limited liability company, association or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U><FONT STYLE="white-space:nowrap">Pre-closing</FONT> Capitalization</U>&#148; shall mean
the sum determined immediately prior to the applicable conversion of the Notes of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;the number
of shares of Common Stock of the Company then outstanding immediately prior to the closing of the applicable conversion event, plus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the number of shares of Common Stock issuable, directly or indirectly, upon the exercise or
conversion of exercisable or convertible securities then outstanding immediately prior to the closing of the applicable conversion event, plus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the number of shares of capital stock (determined on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) reserved for issuance under the Company&#146;s equity incentive plans (net of any such shares underlying securities included in clause (ii)&nbsp;of this definition)
including, in the event of a conversion of the Notes in the Next Equity Financing, any increase in the number of such reserved shares expressly required by the terms and conditions of such Next Equity Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Preferred Stock</U>&#148; means shares of preferred stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>register</U>,&#148; &#147;<U>registered</U>,&#148; and &#147;<U>registration</U>&#148;
shall refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Registrable Securities</U>&#148; shall mean (i)&nbsp;the Equity Securities issued or
issuable, directly or indirectly, upon conversion of the Notes in accordance with the terms of this Agreement, excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which his, her or its rights under
Section&nbsp;7.5 of this Agreement are not assigned, (ii)&nbsp;any shares of Common Stock held by Frazier and (iii)&nbsp;any shares of Common Stock (including shares of Common Stock issuable upon the exercise or conversion of any securities
exercisable or convertible into shares of Common Stock) held by Takeda. In addition, the number of shares of Registrable Securities outstanding shall equal the aggregate of the number of shares of Common Stock outstanding that are, and the number of
shares of Common Stock issuable, directly or indirectly, pursuant to then exercisable or convertible securities that are, Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Requisite Noteholders</U>&#148; shall mean the holders of not less than sixty percent
(60%) in interest of the aggregate outstanding principal amount of the Notes, including Frazier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Rule 144</U>&#148; shall mean Rule 144 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Rule 144(b)(1)(i)</U>&#148; shall mean subsection (b)(1)(i) of Rule 144 under the
Securities Act as it applies to Persons who have held shares for more than one (1)&nbsp;year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Rule 405</U>&#148; shall mean Rule 405
under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Sale of the Company</U>&#148; shall mean either:
(a)&nbsp;a transaction or series of related transactions in which a person, or a group of related persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a
&#147;<U>Stock Sale</U>&#148;) or (b)&nbsp;a Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>SEC</U>&#148;
shall mean the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Securities Act</U>&#148; shall
mean the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(nn)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Shares</U>&#148; shall mean and include
any securities of the Company the holders of which are entitled to vote for one or more members of the Board, including without limitation, all shares of Common Stock, by whatever name called, now owned or subsequently acquired by a stockholder,
however acquired, whether through stock splits, stock dividends, reclassifications, recapitalizations, similar events or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Takeda&#148; shall mean Takeda Pharmaceutical Company Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(pp)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Takeda Agreements</U>&#148; shall mean the Takeda License, Takeda Supply Agreement and
Takeda Equity Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(qq)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Takeda License</U>&#148; shall mean that certain License
Agreement by and between the Company and Takeda dated May&nbsp;7, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(rr)&nbsp;&nbsp;&nbsp;&nbsp; &#147;<U>Takeda
Equity Documents</U>&#148; shall mean that certain Stock Issuance Agreement and Warrant to Purchase Shares of Common Stock by and between the Company and Takeda and the other requisite parties thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Takeda Supply Agreement</U>&#148; shall mean that certain Clinical Supply Agreement by
and between the Company and Takeda dated May&nbsp;7, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(tt)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transfer</U>&#148; shall
mean any sale, assignment, encumbrance, hypothecation, pledge, conveyance in trust, gift, transfer by bequest, devise or descent, or other transfer or disposition of any kind, including, without limitation, transfers pursuant to divorce or legal
separation, transfers to receivers, levying creditors, trustees or receivers in bankruptcy proceedings or general assignees for the benefit of creditors, whether voluntary, involuntarily or by operation of law, directly or indirectly, of any of the
Equity Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(uu)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Valuation Cap</U>&#148; shall mean $500,000,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms of the Convertible Notes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance of Convertible Notes</U>. In return for the Consideration paid by each Lender, the
Company shall sell and issue to such Lender one or more Notes. Each Note shall have a principal balance equal to the Consideration paid by such Lender for the Note, as set forth in the Schedule of Lenders. Each Note shall be convertible into
Conversion Shares pursuant to Section&nbsp;2.2 below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Right to Convert Notes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Next Equity Financing</U>. The then outstanding principal and unpaid accrued interest of each
Note shall be automatically converted into Conversion Shares upon the closing of the Next Equity Financing. Notwithstanding the foregoing, accrued interest on each Note may be paid in cash upon mutual agreement of the Company and the applicable
Lender. The number of Conversion Shares to be issued upon such conversion shall be equal to the quotient obtained by dividing (i)&nbsp;the outstanding principal and unpaid accrued interest on a Note to be converted on the date of conversion by
(ii)&nbsp;the Conversion Price. At least twenty (20)&nbsp;calendar days prior to the closing of the Next Equity Financing, the Company shall notify the holder of each Note in writing of the terms (in reasonable summary detail) under which the Equity
Securities will be sold in such financing. Subject to Section&nbsp;8.12 below, the issuance of Conversion Shares pursuant to the conversion of each Note shall otherwise be upon and subject to the same terms and conditions applicable to the Equity
Securities sold in the Next Equity Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing</U>. The then
outstanding principal and unpaid accrued interest of each Note may be converted, at the option of the holder thereof into Conversion Shares upon the closing of the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing.
Notwithstanding the foregoing, accrued interest on each Note may be paid in cash upon mutual agreement of the Company and the applicable Lender. The number of Conversion Shares to be issued upon such conversion shall be equal to the quotient
obtained by dividing (i)&nbsp;the outstanding principal and unpaid accrued interest on a Note to be converted on the date of conversion by (ii)&nbsp;the Conversion Price. At least twenty (20)&nbsp;calendar days prior to the closing of the <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing, the Company shall notify the holder of each Note in writing of the terms (in reasonable summary detail) under which the Equity Securities will be sold in such financing. Subject
to Section&nbsp;8.12 below, the issuance of Conversion Shares pursuant to the conversion of each Note shall otherwise be upon and subject to the same terms and conditions applicable to the Equity Securities sold in the
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing. If a holder elects to convert its Note into Conversion Shares in connection with the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing, such
holder shall inform the Company of its election within twenty (20)&nbsp;calendar days after such notice is effectively given by the Company pursuant to Section&nbsp;8.5 hereof. In the event that a holder fails to inform the Company of its election
within such twenty (20)&nbsp;calendar day period, such holder&#146;s Note shall thereafter cease to be convertible into Conversion Shares to be issued pursuant to the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing;
<U>provided</U>,<I> </I><U>however</U>, such Note shall continue to accrue interest at the interest rate applicable to such Note until the redemption thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Treatment upon Maturity</U>. If the Next Equity Financing,
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing pursuant to which such Note has converted, Corporate Transaction or Initial Public Offering has not occurred on or before the Maturity Date, the principal and unpaid accrued
interest of each Note may be converted, at any time following the Maturity Date, at the option of the holder thereof, into Conversion Shares; provided that each Note, to the extent such Note has not already been converted into Conversion Shares at
the option of the holder thereof, shall be due and payable in cash following the Maturity Date solely upon demand of the Requisite Noteholders. The number of Conversion Shares to be issued upon conversion shall be equal to the quotient obtained by
dividing (i)&nbsp;the outstanding principal and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
unpaid accrued interest due on a Note to be converted on the date of the conversion by (ii)&nbsp;the Conversion Price. Notwithstanding anything to contrary in this Section&nbsp;2.2(c), in the
event that a Note is not converted pursuant to this Section&nbsp;2.2(c) and a Next Equity Financing, <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing pursuant to which such Note has converted, Corporate Transaction or
Initial Public Offering has not occurred on or before the third anniversary of the Initial Closing, then on such third anniversary, the outstanding principal and accrued interest shall become immediately due and payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Initial Public Offering</U>. Notwithstanding subsections (a), (b) or (c)&nbsp;above, in the
event of an Initial Public Offering prior to full payment of a Note or the prior conversion of a Note (as provided herein), all outstanding principal and unpaid accrued interest due on such Note shall be converted into Conversion Shares immediately
prior to the closing of the Initial Public Offering. The number of Conversion Shares to be issued upon conversion shall be equal to the quotient, obtained by dividing (x)&nbsp;the outstanding principal and unpaid accrued interest due on a Note to be
converted on the date of the conversion by (y)&nbsp;the Conversion Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate
Transaction</U>. In the event of a Corporate Transaction prior to full payment of a Note or the prior conversion of a Note (as provided herein), the greater of (i)&nbsp;an amount equal to two times (2x) the then outstanding principal and accrued
interest due on such Note or (ii)&nbsp;an amount equal to the proceeds (including, for the avoidance of doubt, any escrowed or contingent consideration payable to stockholders in such Corporate Transaction) which would be payable assuming all
outstanding principal and unpaid accrued interest due on such Note were converted into Conversion Shares immediately prior to the closing of the Corporate Transaction shall be due and payable in full prior to the closing of the Corporate
Transaction. The number of Conversion Shares which would be issued upon conversion shall be equal to the quotient, obtained by dividing (x)&nbsp;the outstanding principal and unpaid accrued interest due on a Note to be converted on the date of the
conversion by (y)&nbsp;the Conversion Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Fractional Shares</U>. Upon the conversion
of a Note into Conversion Shares, in lieu of any fractional shares to which the holder of the Note would otherwise be entitled, the Company shall pay the Note holder cash equal to such fraction multiplied by the Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics of Conversion</U>. The Company shall not be required to issue or deliver the
Conversion Shares with respect to any Note until (i)&nbsp;the holder of such Note has (A)&nbsp;surrendered such Note to the Company or (B)&nbsp;provided the Company evidence reasonably satisfactory to the Company of the ownership of and the loss,
theft, destruction or mutilation of such Note, including but not limited to an indemnity agreement reasonably satisfactory in form and amount to the Company, and (ii)&nbsp;(A) the closing of the applicable Next Equity Financing, <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing pursuant to which such Note is converted, Initial Public Offering or Corporate Transaction, or (B)&nbsp;the Maturity Date in the event such Note converts pursuant to
Section&nbsp;2.2(c). Additionally, before any Note holder shall be entitled to convert such holder&#146;s Note into Conversion Shares pursuant to Section&nbsp;2.2(b), such holder shall give written notice to the Company of the election to convert
such Note into Conversion Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing Mechanics</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Initial Closing</U>. The closing (the &#147;<U>Initial Closing</U>&#148;) of the purchase of the
Notes in return for the Consideration paid by each Lender (as set forth on the Schedule of Lenders) shall take place remotely via teleconference, <FONT STYLE="white-space:nowrap">e-mail</FONT> or likewise at 10 a.m., on May&nbsp;7, 2019, or at such
other time and place as the Company and Lenders purchasing a majority in interest of the aggregate principal amount of the Notes to be sold at the Initial Closing agree upon orally or in writing. At the Initial Closing, each Lender shall deliver the
Consideration to the Company set forth opposite such Lender&#146;s name on the Schedule of Lenders and the Company shall deliver to each Lender one or more executed Notes in return for the respective Consideration provided to the Company. In the
event that payment by a Lender is made, in whole or in part, by cancellation or exchange of indebtedness, then such Lender shall surrender to the Company for cancellation or exchange at the Initial Closing any evidence of such indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.2&nbsp;&nbsp;&nbsp;&nbsp; <U>Second Closing</U>. The second closing (the &#147;<U>Second Closing</U>&#148;) of the purchase
of the Notes in return for the Consideration paid by each Lender (as set forth on the Schedule of Lenders) shall take place remotely via teleconference, <FONT STYLE="white-space:nowrap">e-mail</FONT> or likewise at any time on or before the 20<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day following the Initial Closing, or at such other time and place as the Company and Lenders purchasing a majority in interest of the aggregate principal amount of the Notes to be sold at the
Second Closing agree upon orally or in writing; provided, that such sale shall not take place later than the earlier to occur of the date of a Next Equity Financing, <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing,
Initial Public Officer or Corporate Transaction (whichever occurs earliest) is consummated. At the Second Closing, each Lender shall deliver the Consideration to the Company set forth opposite such Lender&#146;s name on the Schedule of Lenders and
the Company shall deliver to each Lender one or more executed Notes in return for the respective Consideration provided to the Company. Each of the Initial Closing and the Second Closing shall be referred to herein as the &#147;<U>Closing</U>.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions of Lenders</U><U>&#146;</U><U> Obligations at Closing</U>. The obligations of
each Lender under Section&nbsp;3.1 or Section&nbsp;3.2 of this Agreement are subject to the fulfillment on or before such Closing of each of the following conditions, the waiver of which shall not be effective against any Lender who does not consent
thereto: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties</U>. The representations and warranties of the
Company contained in Section&nbsp;4 shall be true on and as of the Initial Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Proceedings and Documents</U>. All corporate and other proceedings in connection with the
transactions contemplated at the Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to the special counsel for the Lenders, and they shall have received all such counterpart original and certified or
other copies of such documents as they may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Board of Directors</U>. On
or prior to the Initial Closing, the directors of the Company shall be Messrs. David Socks, James Topper, Tadataka Yamada, M.D. and Jon Edwards and there shall be three vacancies on the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Management Rights Letter</U>. On or prior to
the Initial Closing, the Company and each Lender that has requested one shall have entered into a Management Rights Letter in the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;D</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification Agreement</U>. The Company and each member of the Board shall have entered into
an Indemnification Agreement in the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;E</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence of Defaults</U>. No Event of Default shall have occurred and be continuing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance of Notes</U>. Such Lender shall have received from the Company a duly executed Note as
required by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Takeda License</U>. The Takeda License (and related Takeda
Equity Documents and the Takeda Supply Agreement) in form reasonably acceptable to Frazier shall have been executed, and an executed copy shall have been delivered to each Lender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions of the Company</U><U>&#146;</U><U>s Obligations at Closing</U>. The obligations of
the Company to each Lender under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions by that Lender: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties</U>. The representations and warranties of the Lenders contained
in Section&nbsp;5 shall be true on and as of the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of
</U><U>Consideration</U>. The Lender shall have delivered the Consideration specified in Section&nbsp;3.1 or Section&nbsp;3.2, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties of the Company</U>. The Company hereby represents and warrants to
each Lender that, except as set forth on the Disclosure Schedule attached as <U>Exhibit F</U> to this Agreement, which exceptions shall be deemed to be part of the representations and warranties made hereunder, the following representations are true
and complete as of the date of the Initial Closing, except as otherwise indicated. The Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections and subsections contained in this Section&nbsp;4, and the
disclosures in any section or subsection of the Disclosure Schedule shall qualify other sections and subsections in this Section&nbsp;4 only to the extent it is readily apparent from a reading of the disclosure that such disclosure is applicable to
such other sections and subsections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization, Good Standing and Qualification</U>.
The Company is a corporation duly incorporated and organized, validly existing, and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to own and operate its properties and assets and to
carry on its business as now conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;The authorized capital of the Company consists,
immediately prior to the Initial Closing, of 10,000,000 shares of Common Stock, 5,470,600 of which are issued and outstanding immediately prior to the Initial Closing. All of the outstanding shares of Common Stock have been duly authorized, are
fully paid and nonassessable and were issued in compliance with all applicable federal and state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company has not authorized any shares of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;1,029,400 shares of Common Stock are authorized for issuance to employees, consultants and
directors pursuant to the Company&#146;s 2019 Equity Incentive Plan, none of which are subject to outstanding option awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;Section 4.2(d) of the Disclosure Schedule sets forth the capitalization of the Company immediately
following the Initial Closing including the number of shares of the following: (i)&nbsp;issued and outstanding Common Stock, including, with respect to restricted Common Stock, vesting schedule and repurchase price; and (ii)&nbsp;warrants or stock
purchase rights, if any. Except for (A)&nbsp;the conversion privileges of the Notes to be issued under this Agreement, (B)&nbsp;the rights provided in Section&nbsp;7.2 of this Agreement, and (C)&nbsp;the securities and rights described in
Section&nbsp;4.2(d) of the Disclosure Schedule, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire
from the Company any shares of Common Stock, or any securities convertible into or exchangeable for shares of Common Stock. All outstanding shares of the Company&#146;s Common Stock and all shares of the Company&#146;s Common Stock underlying
outstanding options are subject to (i)&nbsp;a right of first refusal in favor of the Company upon any proposed transfer (other than transfers for estate planning purposes); and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">lock-up</FONT> or market
standoff agreement of not less than one hundred eighty (180)&nbsp;days following the Initial Public Offering pursuant to a registration statement filed with the SEC under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise set forth in Section&nbsp;4.2(d) of the Disclosure Schedule, none of the
Company&#146;s stock purchase agreements contains a provision for acceleration of vesting (or lapse of a repurchase right) or other changes in the vesting provisions or other terms of such agreement or understanding upon the occurrence of any event
or combination of events. The Company has never adjusted or amended the exercise price of any stock options previously awarded, whether through amendment, cancellation, replacement grant, repricing, or any other means. The Company has no obligation
(contingent or otherwise) to purchase or redeem any of its capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>. The Company does not currently own or control, directly or indirectly, any
interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant in any joint venture, partnership or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization</U>. Except for the authorization and issuance of the shares issuable, directly
or indirectly, in connection with the conversion of the Notes, all corporate action has been taken on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution, delivery and performance of this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Agreement and the Notes. Except as may be limited by applicable bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors&#146; rights, the
Company has taken all corporate action required to make all of the obligations of the Company reflected in the provisions of this Agreement and the Notes, the valid and enforceable obligations they purport to be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Other Instruments</U>. The Company is not in violation or default (i)&nbsp;of
any provisions of its Certificate of Incorporation or Bylaws, (ii)&nbsp;of any instrument, judgment, order, writ or decree, (iii)&nbsp;under any note, indenture or mortgage, or (iv)&nbsp;under any lease, agreement, contract or purchase order to
which it is a party or by which it is bound that is required to be listed on the Disclosure Schedule,<I> </I>or (v)&nbsp;to its knowledge, of any provision of federal or state statute, rule or regulation applicable to the Company, the violation of
which would have a Material Adverse Effect. The execution, delivery and performance of this Agreement and the issuance and delivery of the Notes and the Conversion Shares, and any shares of Common Stock directly or indirectly issued in respect
thereof, and the consummation of the transactions contemplated hereby and thereby will not result in any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either (i)&nbsp;a default under
any such provision, instrument, judgment, order, writ, decree, contract or agreement; or (ii)&nbsp;an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or
nonrenewal of any material permit or license applicable to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Governmental
Consents and Filings</U>. Assuming the accuracy of the representations made by the Lenders in Section&nbsp;5 of this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with,
any federal, state or local governmental authority is required on the part of the Company in connection with the consummation of the transactions contemplated by this Agreement, other than a Form D or other qualifications or filings under applicable
federal and state securities laws, which qualification or filings will be made on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>. There is no claim, action, suit, proceeding, arbitration, complaint, charge or
investigation pending or to the Company&#146;s knowledge, currently threatened in writing (i)&nbsp;against the Company or any officer, director or Key Employee of the Company arising out of their employment or board relationship with the Company;
(ii)&nbsp;that questions the validity of this Agreement or the Notes or the right of the Company to enter into them, or to consummate the transactions contemplated hereby or thereby; or (iii)&nbsp;to the Company&#146;s knowledge, that would
reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. Neither the Company nor, to the Company&#146;s knowledge, any of its officers, directors or Key Employees is a party or is named as subject to the
provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers, directors or Key Employees, such as would affect the Company). There is no action, suit, proceeding or
investigation by the Company pending or which the Company intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any basis therefor known to the Company)
involving the prior employment of any of the Company&#146;s employees, their services provided in connection with the Company&#146;s business, any information or techniques allegedly proprietary to any of their former employers or their obligations
under any agreements with prior employers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual Property</U>. The Company owns
or possesses or can acquire on commercially reasonable terms sufficient legal rights to all Company Intellectual Property without any known conflict with, or infringement of, the rights of others, including prior employees or consultants, or
academic or medical institutions with which any of them may be affiliated now or may have been affiliated in the past. To the Company&#146;s knowledge, no product or service marketed or sold (or proposed to be marketed or sold) by the Company
violates or will violate any license or infringes or will infringe any intellectual property rights of any other party in the absence of a license to such intellectual property rights. Other than with respect to the Takeda Agreements or commercially
available software products under standard <FONT STYLE="white-space:nowrap">end-user</FONT> object code license agreements, there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind
relating to the Company Intellectual Property, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses,
information, proprietary rights and processes of any other Person. The Company has not received any communications alleging that the Company has infringed, or by conducting its business, would infringe any of the patents, trademarks, service marks,
tradenames, copyrights, trade secrets, mask works or other proprietary rights or processes of any other Person. To the Company&#146;s knowledge, no third party is infringing any of the Company Intellectual Property. The Company has obtained and
possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices that it owns or leases or that it has otherwise provided to its employees for their use in connection with the
Company&#146;s business. To the Company&#146;s knowledge, it will not be necessary to use any inventions of any of its employees or consultants (or Persons it currently intends to hire) made prior to their employment by the Company that are not
otherwise the subject of the Takeda Agreements, including prior employees or consultants, or academic or medical institutions with which any of them may be affiliated now or may have been affiliated in the past. Each employee and consultant has
assigned to the Company all intellectual property rights that he, she or it solely or jointly conceived, reduced to practice, developed or made during the period of his, her or its employment or consulting relationship with the Company that
(a)&nbsp;relate, at the time of conception, reduction to practice, development, or making of such intellectual property right, to the Company&#146;s business as then conducted or as then proposed to be conducted, (b)&nbsp;were developed on any
amount of the Company&#146;s time or with the use of any of the Company&#146;s equipment, supplies, facilities or information or (c)&nbsp;resulted from the performance of services for the Company. Section&nbsp;4.8 of the Disclosure Schedule lists
all patents, patent applications, registered trademarks, trademark applications, service marks, service mark applications, tradenames, registered copyrights, and licenses to and under any of the foregoing, in each case owned by the Company. The
Company has not embedded any open source, copyleft or community source code in any of its products generally available or in development, including but not limited to any libraries or code licensed under any General Public License, Lesser General
Public License or similar license arrangement. For purposes of this Section&nbsp;4.8, the Company shall be deemed to have knowledge of a patent right if the Company has actual knowledge of the patent right or would be found to be on notice of such
patent right as determined by reference to United States patent laws. No government funding, facilities of a university, college, other educational institution or research center, was used in the development
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of any Company Intellectual Property that is owned by the Company. To the Company&#146;s knowledge, no Person who was involved in, or who contributed to, the creation or development of any
Company Intellectual Property, has performed services for the government, university, college, or other educational institution or research center in a manner that would adversely affect the Company&#146;s rights in the Company Intellectual
Property.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Property</U>. The property
and assets that the Company owns are free and clear of all mortgages, deeds of trust, liens, loans and encumbrances, except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the
ordinary course of business and do not materially impair the&nbsp;Company&#146;s ownership or use of such property or assets. With respect to the property and assets it leases, the Company is in compliance with such leases and holds a valid
leasehold interest free of any liens, claims or encumbrances other than those of the lessors of such property or assets. The Company does not own any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence of Undisclosed Liabilities</U>. The Company does not have any liability or obligation
of any nature, whether accrued, absolute, contingent or otherwise, asserted or unasserted, known or unknown, in any case which has, or is reasonably likely to have, a Material Adverse Effect. The Company has not assumed, guaranteed, endorsed or
otherwise become directly or contingently liable on or for any indebtedness of any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Valid Issuance of Conversion Shares</U>. The Conversion Shares to be issued, sold and
delivered upon conversion of the Notes and any shares of Common Stock issued or issuable in respect thereof, will be duly and validly issued, fully paid and nonassessable and, based in part upon the representations and warranties of the Lenders in
this Agreement, will be issued in compliance with all applicable federal and state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Committee on Foreign Investment</U>. The Company is not currently a U.S. business that
produces, designs, tests, manufactures, fabricates, or develops a critical technology that is (a)&nbsp;utilized in connection with the U.S. business&#146;s activity in one or more pilot program industries, or (b)&nbsp;designed by the U.S. business
specifically for use in one or more pilot program industries, as these terms are defined at 31 C.F.R. Parts 800 and 801. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>. The Company has made available to the Lenders all the information reasonably
available to the Company that the Lenders have requested for deciding whether to purchase the Notes. No representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure Schedule, and no certificate furnished or
to be furnished to the Lenders at the Initial Closing contains any untrue statement of a material fact or, to the Company&#146;s knowledge, omits to state a material fact necessary in order to make the statements contained herein or therein not
misleading in light of the circumstances under which they were made. It is understood that this representation is qualified by the fact that the Company has not delivered to the Lenders, and has not been requested to deliver, a private placement or
similar memorandum or any written disclosure of the types of information customarily furnished to purchasers of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations, Warranties and Additional
Agreements of the Lenders</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties of the Lenders</U>. In
connection with the transactions provided for herein, each Lender hereby represents and warrants to the Company that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization</U>. This Agreement constitutes such Lender&#146;s valid and legally binding
obligation, enforceable in accordance with its terms, except as may be limited by (i)&nbsp;applicable bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors&#146; rights and (ii)&nbsp;laws
relating to the availability of specific performance, injunctive relief or other equitable remedies. Each Lender represents that it has full power and authority to enter into this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase Entirely for Own Account</U>. Each Lender acknowledges that this Agreement is made
with Lender in reliance upon such Lender&#146;s representation to the Company that the Notes, the Conversion Shares, and any Common Stock issuable, directly or indirectly, upon conversion of the Conversion Shares (collectively, the
&#147;<U>Securities</U>&#148;) will be acquired for investment for Lender&#146;s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that such Lender has no present intention of selling,
granting any participation in, or otherwise distributing the same. By executing this Agreement, each Lender further represents that such Lender does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or
grant participations to such person or to any third person, with respect to the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure of Information</U>. Each Lender acknowledges that it has received all the
information it considers necessary or appropriate for deciding whether to acquire the Securities. Each Lender further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions
of the offering of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment Experience</U>. Each Lender is an investor
in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of
evaluating the merits and risks of the investment in the Securities. If other than an individual, each Lender also represents it has not been organized solely for the purpose of acquiring the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accredited Investor</U>. Each Lender is an &#147;accredited investor&#148; within the meaning
of Rule 501 of Regulation D promulgated under the Securities Act, as presently in effect (&#147;<U>Rule 501</U>&#148;). If such Lender has been organized for the purpose of acquiring the Securities, each holder of securities of such Lender, or
holder of any right to acquire such securities or any of the Securities, is an &#147;accredited investor&#148; pursuant to Rule&nbsp;501. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Restricted Securities</U>. Each Lender understands that the Securities are characterized as
&#147;restricted securities&#148; under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be
resold without registration under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Securities Act only in certain limited circumstances. Each Lender represents that it is familiar with Rule 144 and understands the resale limitations imposed thereby and by the Securities Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Further Limitations on Disposition</U>. Without in any way limiting the representations
and warranties set forth above, each Lender further agrees not to make any disposition of all or any portion of the Securities unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this Section&nbsp;5
and Section&nbsp;8.11 and the transferring Lender has notified the Company of the proposed disposition and has furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition. It is agreed that the Company
will not require opinions of counsel for transactions made pursuant to Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lender shall not make any disposition of
any of the Securities to any person that would result in the Company being ineligible to rely on Rule 506 of Regulation D in regards to the issuance of the Securities or any subsequent issuance of securities of the Company, as such in either case is
in good faith determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding anything herein to the contrary, each Lender may freely transfer
the Securities to its Affiliates without restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Legends</U>. It is understood that
the Securities may bear the following legend: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OF 1933 OR SUCH TRANSFER IS EXEMPT
FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Bad Actor
Representations and Covenants</U>. Each Lender that is among the Persons identified in Rule 506(d)(1) of Regulation D (a &#147;<B>Covered Person</B>&#148;) hereby represents and warrants to the Company that such Lender has not been convicted of any
of the felonies or misdemeanors or has been subject to any of the orders, judgments, decrees or other conditions set forth in Rule 506(d) of Regulation D promulgated by the SEC, which are excerpted in their current form on <U>Exhibit B</U>. Each
Lender covenants that if it is then a Covered Person to provide immediate written notice to the Company in the event such Lender is convicted of any felony or misdemeanor or becomes subject to any order, judgment, decree or other condition set forth
in Rule 506(d) of Regulation D promulgated by the SEC, as may be amended from time to time. Each Lender covenants to provide such information to the Company as the Company may reasonably request in order to comply with the disclosure obligations set
forth in Rule 506(e) of Regulation D promulgated by the SEC, as may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Exculpation Among Lenders</U>. Each Lender acknowledges that it is not relying upon any person,
firm or corporation, other than the Company, in making its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
investment or decision to invest in the Company. Each Lender agrees that no Lender nor the respective controlling persons, officers, directors, partners, agents, or employees of any Lender shall
be liable to any other Lender for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Defaults and Remedies</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Events of Default</U>. Any of the following events shall be considered an &#147;<U>Event of
Default</U>&#148; with respect to each Note: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall default in the payment of any
part of the principal or unpaid accrued interest on the Note, (i)&nbsp;for more than two (2)&nbsp;days after demand for payment therefor by the Requisite Noteholders following the Note becoming due and payable pursuant to the terms and conditions of
the Notes, or (ii)&nbsp;after a date fixed by acceleration or otherwise; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall
make an assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts as they become due, or shall file a voluntary petition for bankruptcy, or shall file any petition or answer seeking for itself any
reorganization, arrangement, composition, readjustment, dissolution or similar relief under any present or future statute, law or regulation, or shall file any answer admitting the material allegations of a petition filed against the Company in any
such proceeding, or shall seek or consent to or acquiesce in the appointment of any trustee, receiver or liquidator of the Company, or of all or any substantial part of the properties of the Company, or the Company or its respective directors or
majority stockholders shall take any action looking to the dissolution or liquidation of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;Within thirty (30)&nbsp;days after the commencement of any proceeding against the Company seeking
any bankruptcy reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, such proceeding shall not have been dismissed, or within thirty (30)&nbsp;days
after the appointment without the consent or acquiescence of the Company of any trustee, receiver or liquidator of the Company or of all or any substantial part of the properties of the Company, such appointment shall not have been vacated; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;Within thirty (30)&nbsp;days after the Company becomes involved in litigation that threatens to
materially and adversely affect the Company&#146;s business, operations, assets, results of operations or prospects, if the Company&#146;s involvement has not terminated by such date in a manner that does not and could not reasonably be expected to
materially and adversely affect the Company&#146;s business, operations, assets, results of operations or prospects; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;Any default or defined event of default that has not otherwise been cured or forgiven within
fifteen (15)&nbsp;days after written notice to the Company from the applicable lender of such default or defined event of default shall occur under any agreement to which the Company is a party that evidences indebtedness for borrowed money by the
Company (excluding trade payables) of $50,000 or more; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall fail to observe or perform any
other obligation to be observed or performed by it under this Agreement or the Notes within fifteen (15)&nbsp;days after written notice from the Requisite Noteholders to perform or observe such obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>. Upon the occurrence of an Event of Default under Section&nbsp;6.1 hereof, at the
option and upon the declaration of the majority in interest of the aggregate outstanding principal amount of the Notes, the entire unpaid principal and accrued and unpaid interest on the Notes shall, without presentment, demand, protest, or notice
of any kind, all of which are hereby expressly waived, be forthwith due and payable, and such Requisite Noteholders may, immediately and without expiration of any period of grace, enforce payment of all amounts due and owing under such Notes and
exercise any and all other remedies granted to them at law, in equity or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Covenants of the Company</U><U>; Rights of the Holders of the Notes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery of Financial Statements</U><U>; Inspection Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall deliver to each Lender: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;as soon as practicable, but in any event within one hundred twenty (120)&nbsp;days after the end
of each fiscal year of the Company, an income statement for such fiscal year and a balance sheet of the Company, and a statement of cash flows for such year, such <FONT STYLE="white-space:nowrap">year-end</FONT> financial reports to be in reasonable
detail, prepared in accordance with generally accepted accounting principles (&#147;<U>GAAP</U>&#148;), and audited and certified by independent public accountants of nationally recognized standing selected by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;as soon as practicable, but in any event within forty-five (45)&nbsp;days after the end of each
of the first three (3)&nbsp;quarters of each fiscal year of the Company, an unaudited income statement and statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in
accordance with GAAP (except that such financial statements may (A)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments and (B)&nbsp;not contain all notes thereto that may be required in accordance with
GAAP); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;as soon as practicable, but in any event at least thirty (30)&nbsp;days prior to the
end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements and statements of cash flows for such months and, as soon as prepared, any other budgets or
revised budgets prepared by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;as soon as practicable, but in any event within
thirty (30)&nbsp;days after the end of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the
end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock
options and stock options not yet issued but reserved for issuance, if any, all in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
sufficient detail as to permit the Lenders to calculate their respective percentage ownership in the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;such other information relating to the financial condition, business or corporate affairs of the
Company as the Requisite Noteholders may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall not be obligated under this subsection&nbsp;(iv) or any other subsection of Section&nbsp;7.1 to provide
information that (A)&nbsp;it deems in good faith to be a trade secret or similar highly sensitive confidential information or (B)&nbsp;the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything else in this Section&nbsp;7.1 to the contrary, the Company may
cease providing the information set forth in this Section&nbsp;7.1 during the period starting with the date thirty (30)&nbsp;days before the Company&#146;s good-faith estimate of the date of filing of a registration statement if it reasonably
concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company&#146;s covenants under this Section&nbsp;7.1 shall be reinstated at such time as the Company is no longer
actively employing its commercially reasonable efforts to cause such registration statement to become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Inspection</U>. The Company shall permit each Lender, at such Lender&#146;s expense, to visit
and inspect the Company&#146;s properties, to examine its books of account and records and to discuss the Company&#146;s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Lender;
<U>provided</U>, <U>however</U>, that the Company shall not be obligated pursuant to this Section&nbsp;7.1 to provide access to any information that (A)&nbsp;it deems in good faith to be a trade secret or similar confidential information or
(B)&nbsp;the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Information and Inspection Covenants</U>. The covenants set forth in
Sections&nbsp;7.1(a) and 7.1(c) shall terminate and be of no further force or effect upon the earlier to occur of (i)&nbsp;the consummation of the Initial Public Offering, (ii)&nbsp;when the Company first becomes subject to the periodic reporting
requirements of Sections&nbsp;12(g) or 15(d) of the Exchange Act, whichever event shall first occur, (iii)&nbsp;the Next Equity Financing, (iv)&nbsp;a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing into which such
Lender&#146;s Note converts and (v)&nbsp;the consummation of a Corporate Transaction; provided in the case of (iii)&nbsp;or (iv), the Lender receives similar rights under the applicable financing documents for such transaction, and in the case of
(v), that the consideration received is either (A)&nbsp;cash or (B)&nbsp;securities of a company registered under, and in compliance with its obligations under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Right of First Offer</U>. Subject to the terms and conditions specified in this
Section&nbsp;7.2, the Company hereby grants to Takeda and each Lender a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). For purposes of this Section&nbsp;7.2, the term
&#147;<U>Lender</U>&#148; includes any general partners and Affiliates of a Lender. Takeda and each Lender shall be entitled to apportion the right of first offer hereby granted it among itself and its partners and Affiliates in such proportions as
it deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each time the Company proposes to offer any shares of, or securities
convertible into or exchangeable or exercisable for any shares of, its capital stock (including, without limitation, any such shares or securities issued in connection with debt securities) (&#147;<U>Shares</U>&#148;), the Company shall first make
an offering of such Shares to Takeda and each Lender in accordance with the following provisions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall deliver a notice in accordance with Section&nbsp;8.5 (&#147;<U>Notice</U>&#148;)
to Takeda and the Lenders stating (i)&nbsp;its bona fide intention to offer such Shares, (ii)&nbsp;the number of such Shares to be offered and (iii)&nbsp;the price and terms upon which it proposes to offer such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;By written notification received by the Company within ten (10)&nbsp;calendar days after the
giving of Notice, Takeda and each Lender may elect to purchase, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the following: (i)&nbsp;with respect to Takeda, fifteen percent (15%) of such
Shares; and (ii)&nbsp;with respect to each Lender, such Lender&#146;s respective pro rata portion of eighty five (85%) of such Shares determined in the proportion that the principal outstanding under the Note(s) held by such Lender bears to the
total principal outstanding under the Notes held by all the Lenders; <U>provided</U>, that if Takeda does not elect to purchase the full amount of Shares to which it is entitled to purchase under this Section&nbsp;7.2(b)(i), then each Lender shall
have a right to elect to purchase its pro rata portion of any such remaining Shares not purchased by Takeda pursuant to the provisions of this Section&nbsp;7.2(b)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;If all Shares that Takeda and the Lenders are entitled to obtain pursuant to Section&nbsp;7.2(b)
of this Agreement are not elected to be obtained as provided in Section&nbsp;7.2(b) of this Agreement, the Company may, during the ninety (90)&nbsp;day period following the expiration of the period provided in Section&nbsp;7.2(b) of this Agreement,
offer the remaining unsubscribed portion of such Shares to any Person or Persons at a price not less than that, and upon terms no more favorable to the offeree than those, specified in the Notice. If the Company does not enter into an agreement for
the sale of the Shares within such period, or if such agreement is not consummated within sixty (60)&nbsp;days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first
reoffered to Takeda and the Lenders in accordance herewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;The right of first offer in this
Section&nbsp;7.2 shall not be applicable to (i)&nbsp;the issuance or sale of shares of Common Stock (or options therefor) (appropriately adjusted for any stock split, dividend, combination or other recapitalization) to employees, directors,
consultants and other service providers for the primary purpose of soliciting or retaining their services pursuant to plans or agreements approved by the Board; (ii)&nbsp;the issuance of securities in the Initial Public Offering; (iii)&nbsp;the
issuance of securities pursuant to the conversion or exercise of convertible or exercisable securities; (iv)&nbsp;the issuance of securities in connection with a bona fide business acquisition by the Company, whether by merger, consolidation, sale
of assets, sale or exchange of stock or otherwise; (v)&nbsp;the issuance and sale of Conversion Shares; or (vi)&nbsp;the issuance of stock, warrants or other securities or rights pursuant to any equipment leasing arrangement or debt financing
arrangement; <U>provided</U> such issuances are approved by the Board and (except for the Initial Public Offering) are primarily for <FONT STYLE="white-space:nowrap">non-equity</FONT> financing purposes. In addition to the foregoing, the right of
first offer in this Section&nbsp;7.2 shall not be applicable with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
respect to any Lender in any subsequent offering of Shares if (i)&nbsp;at the time of such offering, the Lender is not an &#147;accredited investor,&#148; as that term is then defined in Rule
501(a) of the Securities Act and (ii)&nbsp;such offering of Shares is otherwise being offered only to accredited investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;The rights provided in this Section&nbsp;7.2 may not be assigned or transferred by any Lender;
<U>provided</U>, <U>however</U>, that a Lender that is a venture capital fund, private equity investor or investment advisor may assign or transfer such rights to its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;The right of first offer in this Section&nbsp;7.2, including notice with respect thereto, may be
waived by Takeda with the written consent of Takeda. The right of first offer in this Section&nbsp;7.2, including notice with respect thereto, may be waived by all Lenders with the written consent of the Requisite Noteholders. Takeda&#146;s and the
Requisite Noteholders&#146; right to waive the provisions of this Section&nbsp;7.2 shall be independent of one another. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;The covenants set forth in this Section&nbsp;7.2 shall terminate and be of no further force or
effect upon (i)&nbsp;the consummation of the Initial Public Offering, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Sections&nbsp;12(g) or 15(d) of the Exchange Act and (iii)&nbsp;upon the consummation of
a Corporate Transaction, whichever event shall first occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Rights of Refusal</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer Notice</U>. If at any time a Common Holder proposes to Transfer Equity Securities (a
&#147;<U>Selling Common Holder</U>&#148;), then the Selling Common Holder shall promptly give the Company and each Lender written notice of the Selling Common Holder&#146;s intention to make the Transfer (the &#147;<U>Transfer Notice</U>&#148;). The
Transfer Notice shall include (i)&nbsp;a description of the Equity Securities to be transferred (the &#147;<U>Offered Shares</U>&#148;), (ii)&nbsp;the name(s) and address(es) of the prospective transferee(s), (iii)&nbsp;the purchase price and form
of consideration proposed to be paid for the Offered Shares and (iv)&nbsp;the other material terms and conditions upon which the proposed Transfer is to be made. The Transfer Notice shall certify that the Selling Common Holder has received a firm
offer from the prospective transferee(s) and in good faith believes a binding agreement for the Transfer is obtainable on the terms set forth in the Transfer Notice. The Transfer Notice shall also include a copy of any written proposal, term sheet
or letter of intent or other agreement relating to the proposed Transfer. In the event that the transfer is being made pursuant to the provisions of Section&nbsp;7.3, the Transfer Notice shall state under which specific clause of Section&nbsp;7.3
the Transfer is being made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Company&#146;s Right of First Refusal</U>. The Company shall
have an option for a period of ten (10)&nbsp;days from delivery of the Transfer Notice in accordance with Section&nbsp;8.5 to elect to purchase the Offered Shares at the same price and subject to the same material terms and conditions as described
in the Transfer Notice. The Company may exercise such purchase option and purchase all or any portion of the Offered Shares by notifying the Selling Common Holder in writing before expiration of such ten&nbsp;(10) day period as to the number of such
shares that it wishes to purchase. If the Company gives the Selling Common Holder notice that it desires to purchase such shares, then payment for the Offered Shares shall be made by check or wire transfer against delivery of the Offered Shares to
be purchased at a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
time and place agreed upon between the parties, which time shall be no later than forty-five (45)&nbsp;days after delivery to the Company of the Transfer Notice in accordance with
Section&nbsp;8.5, unless the Transfer Notice contemplated a later closing with the prospective <FONT STYLE="white-space:nowrap">third-party</FONT> transferee(s) or unless the value of the consideration to be paid for the Offered Shares has not yet
been established pursuant to Section&nbsp;7.3(e)(ii). If the Company fails to purchase any or all of the Offered Shares by exercising the option granted in this Section&nbsp;7.3(b) within the period provided, the remaining Offered Shares shall be
subject to the options granted to the Lenders pursuant to Section&nbsp;7.3(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Transfer Notice</U>. Subject to the Company&#146;s option set forth in Section&nbsp;7.3(b), if at any time the Selling Common Holder proposes a Transfer, then, within five (5)&nbsp;days after the Company has declined to purchase all, or a portion,
of the Offered Shares or the Company&#146;s option to so purchase the Offered Shares has expired, the Selling Common Holder shall give each Lender an &#147;<U>Additional Transfer Notice</U>&#148; that shall include all of the information and
certifications required in a Transfer Notice and shall additionally identify the Offered Shares that the Company has declined to purchase (the &#147;<U>Remaining Shares</U>&#148;) and reference the Lenders&#146; rights of first refusal with respect
to the proposed Transfer contained in this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Lenders&#146; Right of First
Refusal</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;Each Lender shall have an option for a period of fifteen (15)&nbsp;days from the
delivery of the Additional Transfer Notice in accordance with Section&nbsp;8.5 from the Selling Common Holder set forth in Section&nbsp;7.3(c) to elect to purchase its respective pro rata share of the Remaining Shares at the same price and subject
to the same material terms and conditions as described in the Additional Transfer Notice. Each Lender may exercise such purchase option and purchase all or any portion of its pro rata share of the Remaining Shares (a &#147;<U>Participating
Lender</U>&#148; for the purposes of this Section&nbsp;7.3(d) and Section&nbsp;7.3(e)), by notifying the Selling Common Holder and the Company in writing, before expiration of the fifteen <FONT STYLE="white-space:nowrap">(15)-day</FONT> period as to
the number of such shares that it wishes to purchase (the &#147;<U>Participating Lender Notice</U>&#148;). Each Lender&#146;s pro rata share of the Remaining Shares shall be a fraction of the Remaining Shares, the numerator of which shall
be&nbsp;the number of shares of Common Stock either already issued or issuable, directly or indirectly, upon conversion of the Notes owned by such Lender on the date of the Transfer Notice&nbsp;and denominator of which shall be the total number of
shares of Common Stock either already issued or issuable, directly or indirectly, upon conversion of the Notes held by all Lenders on the date of the Transfer Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;In the event any Lender elects not to purchase its pro rata<I> </I>share of the Remaining Shares
available pursuant to its option under Section&nbsp;7.3(d)(i) within the time period set forth therein, then the Selling Common Holder shall promptly give written notice (the &#147;<U>Overallotment Notice</U>&#148;) to each Participating Lender that
has elected to purchase all of its pro rata share of the Remaining Shares (each a &#147;<U>Fully Participating Lender</U>&#148;), which notice shall set forth the number of Remaining Shares not purchased by the other Lenders (&#147;<U>Unsubscribed
Shares</U>&#148;), and shall offer the Fully Participating Lenders the right to acquire the Unsubscribed Shares. Each Fully Participating Lender shall have five (5)&nbsp;days after delivery of the Overallotment Notice in accordance with
Section&nbsp;8.5 to deliver a written notice to the Selling Common Holder (the &#147;<U>Participating Lenders Overallotment Notice</U>&#148;) of its election to purchase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
its pro rata share of the Unsubscribed Shares on the same terms and conditions as set forth in the Additional Transfer Notice, which such Participating Lenders Overallotment Notice shall also
indicate the maximum number of the Unsubscribed Shares that such Fully Participating Lender will purchase in the event that any other Fully Participating Lender elects not to purchase its pro rata share of the Unsubscribed Shares. For the purposes
of determining a Fully Participating Lender&#146;s pro rata share of the unsubscribed shares under this Section&nbsp;7.3(d)(ii), the numerator shall be the same as that used in Section&nbsp;7.3(d)(i) above and the denominator shall be the total
number of shares of Common Stock (including shares of Common Stock issuable, directly or indirectly, upon conversion of the Notes) owned by all Fully Participating Lenders on the date of the Transfer Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Each Participating Lender shall be entitled to apportion Remaining Shares to be purchased among
its partners and Affiliates, <U>provided</U> that such Participating Lender notifies the Selling Common Holder of such allocation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Participating Lenders shall effect the purchase of the Remaining Shares with payment by check
or wire transfer against delivery of the Remaining Shares to be purchased at a time and place agreed upon between the parties, which time shall be no later than sixty (60)&nbsp;days after delivery to the Company of the Transfer Notice in accordance
with Section&nbsp;8.5, unless the Transfer Notice contemplated a later closing with the prospective third-party transferee(s) or unless the value of the consideration to be paid for the Offered Shares has not yet been established pursuant to
Section&nbsp;7.3(e)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Should the purchase price specified in the Transfer Notice or
Additional Transfer Notice be payable in a form of consideration other than cash or evidences of indebtedness, the Company (and the Participating Lenders) shall have the right to pay such purchase price in an amount of cash equal to the fair market
value of such consideration. If the Selling Common Holder and the Company (or the Participating Lenders) cannot agree on such fair market value within ten (10)&nbsp;days after delivery to the Company of the Transfer Notice (or the delivery of the
Additional Transfer Notice to the Lenders), the valuation shall be made by an appraiser of recognized standing selected by the Selling Common Holder and the Company (or a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Participating Lenders) or, if they cannot agree on an appraiser within twenty (20)&nbsp;days after delivery to the Company of the Transfer
Notice (or the delivery of the Additional Transfer Notice to the Lenders), each shall select an appraiser of recognized standing and those appraisers shall designate a third appraiser of recognized standing, whose appraisal shall be determinative of
such value. The cost of such appraisal shall be shared equally by the Selling Common Holder, on the one hand, and the Company (and, to the extent there are any, the Participating Lenders, on the other hand, with that half of the cost to be borne by
the Company and the Participating Lenders to be apportioned on a pro rata basis based on the number of shares each such party has expressed an interest in purchasing pursuant to this Section&nbsp;7.3). If the time for the closing of the
Company&#146;s purchase or the Participating Lenders&#146; purchase has expired but the determination of the value of the purchase price offered by the prospective transferee(s) has not been finalized, then such closing shall be held on or prior to
the fifth business day after such valuation shall have been made pursuant to this Section&nbsp;7.3(e)(ii). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Drag Along Right</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Actions to be Taken</U>. In the event that the Board, the holders of a majority of the
outstanding shares of Common Stock, including the affirmative approval of Frazier, and the Requisite Noteholders (the &#147;<U>Requisite Parties</U>&#148;), approve a Sale of the Company, then each Common Holder, Takeda and Frazier hereby agrees
with respect to all Shares which it own(s) or over which it otherwise exercises voting or dispositive authority: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;in the event such transaction is to be brought to a vote at a stockholder meeting, after receiving
proper notice of any meeting of stockholders of the Company, to vote on the approval of a Sale of the Company, to be present, in person or by proxy, as a holder of shares of voting securities, at all such meetings and be counted for the purposes of
determining the presence of a quorum at such meetings; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;to vote (in person, by proxy or by
action by written consent, as applicable) all Shares in favor of such Sale of the Company and in opposition to any and all other proposals that could reasonably be expected to delay or impair the ability of the Company to consummate such Sale of the
Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;to refrain from exercising any dissenters&#146; rights or rights of appraisal
under applicable law at any time with respect to such Sale of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;to execute and
deliver all related documentation and take such other action in support of the Sale of the Company as shall reasonably be requested by the Company or the Requisite Parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;if the Sale of the Company is structured as a Stock Sale, to sell the same proportion of his, her
or its Shares as is being sold by the Requisite Parties, and, except as permitted in Section&nbsp;7.4(b) below, on the same terms and conditions as the Requisite Parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;not to deposit, and to cause their affiliates not to deposit, except as provided in this
Agreement, any Shares owned by such Common Holder, Takeda and Frazier or any of their Affiliates in a voting trust or subject any such Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to
do so by the acquirer in connection with the Sale of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;if the consideration
to be paid in exchange for the Shares pursuant to this Section&nbsp;7.4 includes any securities and due receipt thereof by any stockholder would require under applicable law (i)&nbsp;the registration or qualification of such securities or of any
person as a broker or dealer or agent with respect to such securities or (ii)&nbsp;the provision to any Common Holder, Takeda and Frazier of any information other than such information as a prudent issuer would generally furnish in an offering made
solely to &#147;accredited investors&#148; as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to any such Common Holder, Takeda and Frazier in lieu thereof, against surrender of the Shares which would
have otherwise been sold by such stockholder, an amount in cash equal to the fair value (as determined in good faith by the Company) of the securities which such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Common Holder, Takeda and Frazier would otherwise receive as of the date of the issuance of such securities in exchange for the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Exceptions</U>. Notwithstanding the foregoing, each Common Holder, Takeda, Frazier and any
holder of Common Stock issued upon the conversion of the Notes in accordance with the provisions of this Agreement will not be required to comply with Section&nbsp;7.4(a) above in connection with any proposed Sale of the Company (the
&#147;<U>Proposed Sale</U>&#148;) unless: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;any representations and warranties to be made by
such Common Holder, Takeda and Frazier in connection with the Proposed Sale are limited to representations and warranties related to authority, ownership and the ability to convey title to such Common Holder&#146;s, Takeda&#146;s and Frazier&#146;s
Shares, including, without limitation, representations and warranties that (i)&nbsp;the Common Holder, Takeda and Frazier holds all right, title and interest in and to the Shares such stockholder purports to hold, free and clear of all liens and
encumbrances, (ii)&nbsp;the obligations of the Common Holder, Takeda and Frazier in connection with the transaction have been duly authorized, if applicable, (iii)&nbsp;the documents to be entered into by the stockholder have been duly executed by
the Common Holder, Takeda and Frazier and delivered to the acquiror and are enforceable against the stockholder in accordance with their respective terms and (iv)&nbsp;neither the execution and delivery of documents to be entered into in connection
with the transaction, nor the performance of the Common Holder&#146;s, Takeda&#146;s and Frazier&#146;s obligations thereunder, will cause a breach or violation of the terms of any agreement, law or judgment, order or decree of any court or
governmental agency by which such stockholder is subject or bound; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Common Holder, Takeda
and Frazier shall not be liable for the inaccuracy of any representation or warranty made by any other person in connection with the Proposed Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to
cover breach of representations, warranties and covenants of the Company as well as breach by any stockholder of any identical representations, warranties and covenants provided by all stockholders); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the liability for indemnification, if any, of such Common Holder, Takeda and Frazier in the
Proposed Sale and for the inaccuracy of any representations and warranties made by the Company in connection with such Proposed Sale, is several and not joint with any other person (except to the extent that funds may be paid out of an escrow
established to cover breach of representations, warranties and covenants of the Company as well as breach by any stockholder of any identical representations, warranties and covenants provided by all stockholders), and is pro rata in proportion to
the amount of consideration paid to such Common Holder, Takeda and Frazier in connection with such Proposed Sale (in accordance with the provisions of the Company&#146;s Certificate of Incorporation); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;liability shall be limited to such Common Holder&#146;s, Takeda&#146;s and Frazier&#146;s
applicable share (determined based on the respective proceeds payable to each stockholder in connection with such Proposed Sale in accordance with the provisions of the Company&#146;s Certificate of Incorporation) of a negotiated aggregate
indemnification amount that applies equally to all Common Holder, Takeda and Frazier but that in no event exceeds the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
amount of consideration otherwise payable to such Common Holder, Takeda and Frazier in connection with such Proposed Sale, except with respect to claims related to fraud by such Common Holder,
Takeda and Frazier, the liability for which need not be limited as to such Common Holder, Takeda and Frazier; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;upon the consummation of the Proposed Sale, (A)&nbsp;each holder of each class or series of the
Company&#146;s stock will receive the same form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same class or series of stock, (B)&nbsp;each holder of a series of Preferred
Stock will receive the same amount of consideration per share of such series of Preferred Stock as is received by other holders in respect of their shares of such same series, (C)&nbsp;each holder of Common Stock will receive the same amount of
consideration per share of Common Stock as is received by other holders in respect of their shares of Common Stock, and (D)&nbsp;the aggregate consideration receivable by all holders of the Preferred Stock and Common Stock shall be allocated among
the holders of Preferred Stock and Common Stock on the basis of the relative liquidation preferences to which the holders of each respective series of Preferred Stock and the holders of Common Stock are entitled in a Corporate Transaction (assuming
for this purpose that the Proposed Sale is a Corporate Transaction) in accordance with the Company&#146;s Certificate of Incorporation in effect immediately prior to the Proposed Sale; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;subject to subsection 7.4(b)(v) above, requiring the same form of consideration to be available
to the holders of any single class or series of capital stock, if any holders of a series or class of capital stock of the Company are given an option as to the form and amount of consideration to be received as a result of the Proposed Sale, all
holders of such series or class of capital stock will be given the same option; <U>provided</U>, <U>however</U>, that nothing in this subsection 7.4(b)(vi) shall entitle any holder to receive any form of consideration that such holder would be
ineligible to receive as a result of such holder&#146;s failure to satisfy any condition, requirement or limitation that is generally applicable to the Company&#146;s stockholders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;no Common Holder that previously was a Lender shall be required to agree to any covenant not to
compete or covenant not to solicit customers, employees or suppliers of any party to the Proposed Sale, or any obligation to provide services to the Company, the Person or group of related Persons participating in the Proposed Sale, or any other
Person; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(viii)&nbsp;&nbsp;&nbsp;&nbsp;such Common Holder (unless such Common Holder is a Company officer or employee),
Takeda and Frazier are not required to agree to any restrictive covenant in connection with the Proposed Sale (including without limitation any covenant not to compete or covenant not to solicit customers, employees or suppliers of any party to the
Proposed Sale); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ix)&nbsp;&nbsp;&nbsp;&nbsp;such Common Holder, Takeda and Frazier and their Affiliates are not
required to amend, extend or terminate any contractual or other relationship with the Company, the acquirer or their respective Affiliates, except that such Common Holder, Takeda and Frazier may be required to agree to terminate the
investment-related documents between or among such Common Holder, Takeda or Frazier, the Company and/or other stockholders of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Rights</U>. The Company
covenants and agrees as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Request for Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the conditions of this Section&nbsp;7.5(a), if the Company shall receive at any time, a
written request from the Holders of at least twenty-five percent (25%) of the holders of Registrable Securities then outstanding (for purposes of this Section&nbsp;7.5(a), the &#147;<U>Initiating Holders</U>&#148;) that the Company file a
registration statement under the Securities Act covering the registration of Registrable Securities with an anticipated aggregate offering price of at least $10,000,000, then the Company shall, within twenty (20)&nbsp;days of the receipt thereof,
give written notice of such request to all Lenders, and subject to the limitations of this Section&nbsp;7.5(a), use its commercially reasonable efforts to effect, as soon as practicable, the registration under the Securities Act of all Registrable
Securities that the Holders request to be registered in a written request received by the Company within twenty (20)&nbsp;days of the mailing of the Company&#146;s notice pursuant to this Section&nbsp;7.5(a)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section&nbsp;7.5(a), and the Company shall include such information in the written notice referred to in Section&nbsp;7.5(a)(i).
In such event the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the
underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an
underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company (which underwriter or underwriters shall be reasonably acceptable to those Initiating Holders holding a majority of the
Registrable Securities then held by all Initiating Holders). Notwithstanding any other provision of this Section&nbsp;7.5(a), if the underwriter advises the Company that marketing factors require a limitation on the number of securities underwritten
(including Registrable Securities), then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to
the Holders of such Registrable Securities pro rata based on the number of Registrable Securities held by all such Holders (including the Initiating Holders). In no event shall any Registrable Securities be excluded from such underwriting unless all
other securities are first excluded. Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, the Company shall not be required to effect a registration
pursuant to this Section&nbsp;7.5(a): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(A)&nbsp;&nbsp;&nbsp;&nbsp;in any particular jurisdiction in which the Company
would be required to execute a general consent to service of process in effecting such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the Securities Act; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(B)&nbsp;&nbsp;&nbsp;&nbsp;after the Company, within the twelve
(12)&nbsp;month period preceding the date of such request, has effected two&nbsp;(2) registrations pursuant to this Section&nbsp;7.5(a), and such registrations have been declared or ordered effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(C)&nbsp;&nbsp;&nbsp;&nbsp;during the period starting with the date sixty&nbsp;(60) days prior to the Company&#146;s good
faith estimate of the date of the filing of and ending on a date one hundred eighty&nbsp;(180) days following the effective date of a Company-initiated registration subject to Section&nbsp;7.5(b) below, <U>provided</U> that the Company is actively
employing in good faith its commercially reasonable efforts to cause such registration statement to become effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(D)&nbsp;&nbsp;&nbsp;&nbsp;if the Initiating Holders propose to dispose of Registrable Securities that may be registered on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> pursuant to Section&nbsp;7.5(c) hereof; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(E)&nbsp;&nbsp;&nbsp;&nbsp;if
the Company shall furnish to Holders requesting a registration statement pursuant to this Section&nbsp;7.5(a) a certificate signed by the Company&#146;s Chief Executive Officer or Chairman of the Board stating that in the good faith judgment of the
Board, it would be seriously detrimental to the Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety
(90)&nbsp;days after receipt of the request of the Initiating Holders; <U>provided</U> that such right shall be exercised by the Company not more than once in any twelve&nbsp;(12) month period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Company Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;If (but without any obligation to do so) the Company proposes to register (including for this
purpose a registration effected by the Company for stockholders other than the Holders) any of its stock or other securities under the Securities Act in connection with the public offering of such securities (other than (i)&nbsp;a registration
relating to a demand pursuant to Section&nbsp;7.5(a) of this Agreement or (ii)&nbsp;a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or
transaction under Rule&nbsp;145 of the Securities Act, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable
Securities, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered), the Company shall, at such time, promptly give each Holder written notice of
such registration. Upon the written request of each Holder given within twenty (20)&nbsp;days after mailing of such notice by the Company in accordance with Section&nbsp;8.5 of this Agreement, the Company shall, subject to the provisions of
Section&nbsp;7.5(b)(iii) of this Agreement, use its commercially reasonable efforts to cause to be registered under the Securities Act all of the Registrable Securities that each such Holder requests to be registered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Right to Terminate Registration</U>. The Company shall have the right to terminate or withdraw
any registration initiated by it under this Section&nbsp;7.5(b) prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The expenses of such withdrawn registration shall be
borne by the Company in accordance with Section&nbsp;7.5(f) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriting Requirements</U>. In
connection with any offering involving an underwriting of shares of the Company&#146;s capital stock, the Company shall not be required under this Section&nbsp;7.5(b) to include any of the Holders&#146; securities in such underwriting unless they
accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by the Company (or by other Persons entitled to select the underwriters) and enter into an underwriting agreement in customary form with such
underwriters, and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required
to include in the offering only that number of such securities, including Registrable Securities, that the underwriters determine in their sole discretion will not jeopardize the success of the offering. In the event that the underwriters determine
that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be apportioned pro rata among the selling Holders based on the
number of Registrable Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (A)&nbsp;any Registrable Securities be excluded
from such offering unless all other stockholders&#146; securities have been first excluded from the offering and (B)&nbsp;the amount of securities of the selling Holders included in the offering be reduced below twenty percent (20%) of the total
amount of securities included in such offering, unless such offering is the Initial Public Offering, in which case the selling Holders may be excluded if the underwriters make the determination described above and no other stockholder&#146;s
securities are included in such offering. For purposes of the preceding sentence concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a venture capital fund, partnership or corporation, the
affiliated venture capital funds, partners, members, retired partners and stockholders of such Holder, or the estates and family members of any such partners, members and retired partners and any trusts for the benefit of any of the foregoing
Persons shall be deemed to be a single &#147;selling Holder,&#148; and any pro rata reduction with respect to such &#147;selling Holder&#148; shall be based upon the aggregate amount of Registrable Securities owned by all such related entities and
individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration</U>. In case
the Company shall receive from the Holders of at least twenty percent (20%) of the Registrable Securities (for purposes of this Section&nbsp;7.5(c), the &#147;<U><FONT STYLE="white-space:nowrap">S-3</FONT> Initiating Holders</U>&#148;) a written
request or requests that the Company effect a registration on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or
Holders, the Company shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;promptly give written notice of the proposed registration, and
any related qualification or compliance, to all other Holders; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;use its commercially
reasonable efforts to effect, as soon as practicable, such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders&#146;
Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holders joining in such request as are specified in a written </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
request given within fifteen (15)&nbsp;days after receipt of such written notice from the Company; <U>provided</U>, <U>however</U>, that the Company shall not be obligated to effect any such
registration, qualification or compliance, pursuant to this Section&nbsp;7.5(c): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(A)&nbsp;&nbsp;&nbsp;&nbsp;if <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is not available for such offering by the Holders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(B)&nbsp;&nbsp;&nbsp;&nbsp;if the Holders, together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters&#146; discounts or commissions) of less than $3,000,000; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(C)&nbsp;&nbsp;&nbsp;&nbsp;if the Company shall furnish to all Holders requesting a registration statement pursuant to this
Section&nbsp;7.5(c) a certificate signed by the Company&#146;s Chief Executive Officer or Chairman of the Board stating that in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such
registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90)&nbsp;days after receipt of the request of the
<FONT STYLE="white-space:nowrap">S-3</FONT> Initiating Holders; <U>provided</U> that such right shall be exercised by the Company not more than once in any twelve&nbsp;(12) month period; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(D)&nbsp;&nbsp;&nbsp;&nbsp;if the Company has, within the twelve (12)&nbsp;month period preceding the date of such request,
already effected two (2)&nbsp;registrations on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> pursuant to this Section&nbsp;7.5(c); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(E)&nbsp;&nbsp;&nbsp;&nbsp;in any particular jurisdiction in which the Company would be required to qualify to do business or
to execute a general consent to service of process in effecting such registration, qualification or compliance; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(F)&nbsp;&nbsp;&nbsp;&nbsp;if the Company, within thirty (30)&nbsp;days of receipt of the request of such <FONT
STYLE="white-space:nowrap">S-3</FONT> Initiating Holders, gives notice of its bona fide intention to effect the filing of a registration statement with the SEC within one hundred twenty (120)&nbsp;days of receipt of such request (other than a
registration effected solely to qualify an employee benefit plan or to effect a business combination pursuant to Rule 145), <U>provided</U> that the Company is actively employing in good faith its commercially reasonable efforts to cause such
registration statement to become effective; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(G)&nbsp;&nbsp;&nbsp;&nbsp;during the period starting with the date
thirty&nbsp;(30) days prior to the Company&#146;s good faith estimate of the date of the filing of and ending on a date ninety (90)&nbsp;days following the effective date of a Company-initiated registration subject to Section&nbsp;7.5(b) of this
Agreement, <U>provided</U> that the Company is actively employing in good faith its commercially reasonable efforts to cause such registration statement to become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If the <FONT STYLE="white-space:nowrap">S-3</FONT> Initiating Holders intend to distribute the
Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section&nbsp;7.5(c) and the Company shall include such information in the written notice
referred to in Section&nbsp;7.5(c)(i). The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
provisions of Section&nbsp;7.5(a)(ii) of this Agreement shall be applicable to such request (with the substitution of Section&nbsp;7.5(c) for references to Section 7.5(a)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the foregoing, the Company shall file a registration statement covering the
Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the <FONT STYLE="white-space:nowrap">S-3</FONT> Initiating Holders. Registrations effected pursuant to this
Section&nbsp;7.5(c) shall not be counted as requests for registration effected pursuant to Section&nbsp;7.5(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Obligations of the Company</U>. Whenever required under this Section&nbsp;7.5 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;prepare and file with the SEC a registration statement with respect to such Registrable Securities
and use its commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective
for a period of up to one hundred twenty (120)&nbsp;days or, if earlier, until the distribution contemplated in the Registration Statement has been completed; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;prepare and file with the SEC such amendments and supplements to such registration statement and
the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus
and any Free Writing Prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;use its commercially reasonable efforts to register and qualify the securities covered by such
registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, <U>provided</U> that the Company shall not be required in connection therewith or as a condition thereto to
qualify to do business or to file a general consent to service of process in any such states or jurisdictions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;in the event of any underwritten public offering, enter into and perform its obligations under an
underwriting agreement, in usual and customary form, with the managing underwriter of such offering; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;notify each Holder of Registrable Securities covered by such registration statement at any time
when a prospectus or Free Writing Prospectus (to the extent prepared by or on behalf of the Company) relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in
such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the
circumstances then existing, and, at the request of any such Holder, the Company will, as soon as reasonably practicable, file and furnish </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to all such Holders a supplement or amendment to such prospectus or Free Writing Prospectus (to the extent prepared by or on behalf of the Company) so that, as thereafter delivered to the
purchasers of such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to state any fact necessary to make the statements therein not misleading in light of the circumstances under which they were
made; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;cause all such Registrable Securities registered pursuant to this Section&nbsp;7.5 to
be listed on a national exchange or trading system and on each securities exchange and trading system on which similar securities issued by the Company are then listed; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(viii)&nbsp;&nbsp;&nbsp;&nbsp;provide a transfer agent and registrar for all Registrable Securities registered pursuant to
this Agreement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the provisions of this Section&nbsp;7.5, the Company shall be entitled to postpone or suspend, for a
reasonable period of time, the filing, effectiveness or use of, or trading under, any registration statement if the Company shall determine that any such filing or the sale of any securities pursuant to such registration statement would in the good
faith judgment of the Board: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(A)&nbsp;&nbsp;&nbsp;&nbsp;materially impede, delay or interfere with any material pending
or proposed financing, acquisition, corporate reorganization or other similar transaction involving the Company for which the Board has authorized negotiations; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(B)&nbsp;&nbsp;&nbsp;&nbsp;materially and adversely impair the consummation of any pending or proposed material offering or
sale of any class of securities by the Company; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(C)&nbsp;&nbsp;&nbsp;&nbsp;require disclosure of material nonpublic
information that, if disclosed at such time, would be materially harmful to the interests of the Company and its stockholders; <U>provided</U>, <U>however</U>, that during any such period all executive officers and directors of the Company are also
prohibited from selling securities of the Company (or any security of any of the Company&#146;s subsidiaries or affiliates). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of the suspension of effectiveness of any registration statement pursuant to this Section&nbsp;7.5(d), the
applicable time period during which such registration statement is to remain effective shall be extended by that number of days equal to the number of days the effectiveness of such registration statement was suspended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Information from Holder</U>. It shall be a condition precedent to the obligations of the
Company to take any action pursuant to this Section&nbsp;7.5 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and
the intended method of disposition of such securities as shall be reasonably required to effect the registration of such Holder&#146;s Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses of Registration</U>. All expenses
other than underwriting discounts and commissions incurred in connection with registrations, filings or qualifications pursuant to Sections&nbsp;7.5(a) and 7.5(b) of this Agreement, including, without limitation, all registration, filing and
qualification fees, printers&#146; and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders (not to exceed $50,000) shall be borne by the Company.
Notwithstanding the foregoing, the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section&nbsp;7.5(a) of this Agreement if the registration request is subsequently withdrawn at the request of
the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn
registration) unless, in the case of a registration requested under Section&nbsp;7.5(a) of this Agreement, the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to
Section&nbsp;7.5(a) of this Agreement; <U>provided</U>, <U>however</U>, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business or prospects of the Company from that known to the
Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain
their rights pursuant to Section&nbsp;7.5(a) of this Agreement. All expenses incurred in connection with a registration requested pursuant to Section&nbsp;7.5(c) of this Agreement, including, without limitation, all registration, filing,
qualification, printer&#146;s and accounting fees and the reasonable fees and disbursements of counsel for the selling Holder or Holders and counsel for the Company, shall be borne pro rata by the Holder or Holders participating in such registration
effected pursuant to Section&nbsp;7.5(c) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Delay of Registration</U>. No
Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section&nbsp;7.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. In the event any Registrable Securities are included in a registration
statement under this Section&nbsp;7.5: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;To the extent permitted by law, the Company will
indemnify and hold harmless each Holder, the partners, members, officers, directors and stockholders of each Holder, legal counsel and accountants for each Holder, any underwriter (as defined in the Securities Act) for such Holder and each Person,
if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Securities Act, the
Exchange Act, any state securities laws or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities laws, insofar as such losses, claims, damages, or liabilities (or actions or proceedings, whether
commenced or threatened, in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively, a &#147;<U>Violation</U>&#148;): (i)&nbsp;any untrue or alleged untrue statement of a material fact
contained in such registration statement, including any preliminary prospectus, final prospectus, or Free Writing Prospectus contained therein or any amendments or supplements thereto, any issuer information (as defined in Rule 433 of the Securities
Act) filed or required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
be filed pursuant to Rule 433(d) under the Securities Act or any other document incident to such registration prepared by or on behalf of the Company or used or referred to by the Company,
(ii)&nbsp;the omission or alleged omission of a material fact required to be stated in such registration statement, or necessary to make the statements therein not misleading or (iii)&nbsp;any violation or alleged violation by the Company of the
Securities Act, the Exchange Act, any state securities laws or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities laws, and the Company will reimburse each such Holder, underwriter, controlling
Person or other aforementioned Person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, action or proceeding as such expenses are incurred;
<U>provided</U>, <U>however</U>, that the indemnity agreement contained in this Section&nbsp;7.5(h)(i) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, action or proceeding if such settlement is effected
without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, action or proceeding to the extent that it arises out of or is based
upon a Violation that occurs in reliance upon, and in conformity with, written information furnished expressly for use in connection with such registration by any such Holder, underwriter, controlling Person or other aforementioned Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify
and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each Person, if any, who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the
Company, any underwriter, any other Holder selling securities in such registration statement and any controlling Person of any such underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of
the foregoing Persons may become subject, under the Securities Act, the Exchange Act, any state securities laws or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities laws, insofar as such losses,
claims, damages or liabilities (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance
upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any Person intended to be indemnified pursuant to this Section&nbsp;7.5(h)(ii) for
any legal or other expenses reasonably incurred by such Person in connection with investigating or defending any such loss, claim, damage, liability, action or proceeding as such expenses are incurred; <U>provided</U>, <U>however</U>, that the
indemnity agreement contained in this Section&nbsp;7.5(h)(ii) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, action or proceeding if such settlement is effected without the consent of the Holder (which
consent shall not be unreasonably withheld), and <U>provided</U> that in no event shall any indemnity under this Section&nbsp;7.5(h)(ii) exceed the gross proceeds from the offering received by such Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Promptly after receipt by an indemnified party under this Section&nbsp;7.5(h) of notice of the
commencement of any action or proceeding (including any governmental action or proceeding) for which a party may be entitled to indemnification, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party
under this Section&nbsp;7.5(h), deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in and, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties;
<U>provided</U>, <U>however</U>, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one (1)&nbsp;separate counsel, with the fees and expenses
to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other
party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action or proceeding, if prejudicial to its ability to defend such action
or proceeding, shall relieve such indemnifying party of any liability to the indemnified party under this Section&nbsp;7.5(h) to the extent of such prejudice, but the omission to so deliver written notice to the indemnifying party will not relieve
such indemnifying party of any liability that it may have to any indemnified party otherwise than under this Section&nbsp;7.5(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;If the indemnification provided for in this Section&nbsp;7.5(h) is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the
amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on
the other hand in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations; <U>provided</U>, <U>however</U>, that (A)&nbsp;no contribution by
any Holder, when combined with any amounts paid by such Holder pursuant to Section&nbsp;7.5(h)(ii), shall exceed the gross proceeds from the offering received by such Holder and (B)&nbsp;no Person guilty of fraudulent misrepresentation (within the
meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and <U>provided</U> <U>further</U> that in no event shall a Holder&#146;s liability
pursuant to this Section&nbsp;7.5(h)(iv), when combined with the amounts paid or payable by such Holder pursuant to Section&nbsp;7.5(h)(ii), exceed the proceeds from the offering received by such Holder (net of any expenses paid by such Holder). The
relative fault of the indemnifying party and the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material
fact relates to information supplied by the indemnifying party or by the indemnified party and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Company and Holders under this Section&nbsp;7.5(h)(ii) shall survive the
completion of any offering of Registrable Securities in a registration statement under this Section&nbsp;7.5 and otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Reports Under the Exchange Act</U>. With a
view to making available to the Holders the benefits of Rule&nbsp;144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration
on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the Company agrees to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;make and keep
public information available, as those terms are understood and defined in Rule&nbsp;144, at all times after the effective date of the Initial Public Offering; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;furnish to any Holder, so long as the
Holder owns any Registrable Securities, forthwith upon request (A)&nbsp;a written statement by the Company that it has complied with the reporting requirements of Rule&nbsp;144 (at any time after ninety (90)&nbsp;days after the effective date of the
first registration statement filed by the Company), the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (at any time after it so qualifies), (B)&nbsp;a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company and (C)&nbsp;such other
information as may be reasonably requested to avail any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to such form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment of Registration Rights</U>. The rights to cause the Company to register Registrable
Securities pursuant to this Section&nbsp;7.5 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities that (i)&nbsp;is an Affiliate, subsidiary, parent, partner, limited partner, retired
partner, member or stockholder of a Holder or (ii)&nbsp;is a Holder&#146;s family member or trust for the benefit of an individual Holder; <U>provided</U>: (A)&nbsp;the Company is, within a reasonable time after such transfer, furnished with written
notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (B)&nbsp;such transferee or assignee agrees in writing to be bound by and subject to the terms and
conditions of this Agreement, including, without limitation, the provisions of Section&nbsp;8.11 of this Agreement; and (C)&nbsp;such assignment shall be effective only if immediately following such transfer the further disposition of such
securities by the transferee or assignee is restricted under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitations on Subsequent Registration Rights</U>. From and after the date of this Agreement,
the Company shall not, without the prior written consent of the Requisite Noteholders, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder (i)&nbsp;to
include any of such securities in any registration filed under Section&nbsp;7.5(a), Section&nbsp;7.5(b) or Section&nbsp;7.5(c) of this Agreement, unless under the terms of such agreement, such holder or prospective holder may include such securities
in any such registration only to the extent that the inclusion of such securities will not reduce the amount of the Registrable Securities of the Holders that are included or (ii)&nbsp;to demand registration of their securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Registration Rights</U>. No
Holder shall be entitled to exercise any right provided for in this Section&nbsp;7.5 upon the earlier of (i)&nbsp;such time after the Initial Public Offering at which such Holder can sell all shares held by it in compliance with
Rule&nbsp;144(b)(1)(i) and (ii)&nbsp;the fifth anniversary of the Initial Public Offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting Provisions Regarding the Board Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Common Holder, Takeda and Frazier agrees to vote, or cause to be voted, all Shares owned by
such Common Holder, Takeda and Frazier, or over which such Common Holder, Takeda and Frazier has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that the size of the Board shall be set and
remain at seven (7)&nbsp;directors. Three of the seven director seats will be vacant as of the Initial Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Common Holder, Takeda and Frazier agrees to vote, or cause to be voted, all Shares owned by such Common
Holder, Takeda and Frazier, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of stockholders at which an election of
directors is held or pursuant to any written consent of the stockholders, the following persons shall be elected to the Board: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;One (1)&nbsp;person designated from time to time by Frazier, who shall initially be James Topper;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;One (1)&nbsp;person designated from time to time by the Lenders other than Frazier, which
individual shall initially be Jon Edwards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;One (1)&nbsp;person designated from time to time
by Takeda or its affiliates, which seat shall initially be vacant; <U>provided</U>, <U>however</U>, that if such seat is vacant, Takeda or its affiliates shall not have the right to designate a member to the Board to fill such vacant seat pursuant
to this Section&nbsp;7.6(b)(iii) at any time that the Board consists of fewer than five (5)&nbsp;individuals that are not affiliated with Takeda; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;One (1)&nbsp;person designated from time to time by the holders of a majority of the Common
Stock, which individual shall initially be Tadataka Yamada, M.D. (who shall initially be the Chairman of the Board); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s Chief Executive Officer, who shall initially be David Socks (the &#147;<U>CEO
Director</U>&#148;), <U>provided</U> that if for any reason the CEO Director shall cease to serve as the Chief Executive Officer of the Company, each of the Common Holders shall promptly vote their respective Shares (A)&nbsp;to remove the former
Chief Executive Officer of the Company from the Board if such person has not resigned as a member of the Board; and (B)&nbsp;to elect such person&#146;s replacement as Chief Executive Officer of the Company as the new CEO Director; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Two (2)&nbsp;individuals not otherwise an Affiliate of the Company or of any Lender who is
mutually acceptable to the other members of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;In the absence of any designation from the
Persons or groups with the right to designate a director as specified above, the director previously designated by them and then serving shall be reelected if still eligible and willing to serve as provided herein and otherwise, such Board seat
shall remain vacant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Each Common Holder, Takeda and Frazier also agrees to vote, or cause to be voted, all
Shares owned by such Common Holder, Takeda and Frazier, or over which such Common Holder, Takeda and Frazier has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;no director elected pursuant to Sections 7.6(b) or 7.6(c) of this Agreement may be removed from
office other than for cause unless (A)&nbsp;such removal is directed or approved by the Person(s) originally entitled to designate or approve such director pursuant to Section&nbsp;7.6(b); or (B)&nbsp;the Person(s) originally entitled to designate
or approve such director pursuant to Section&nbsp;7.6(b) is no longer so entitled to designate or approve such director; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;any vacancies created by the resignation, removal or death of a director elected pursuant to
Sections 7.6(b) or 7.6(c) shall be filled pursuant to the provisions of this Section&nbsp;7.6; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;upon the request of any party entitled to designate a director as provided in
Section&nbsp;7.6(b) to remove such director, such director shall be removed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All Common Holders, Takeda and Frazier agree to execute any
written consents required to perform the obligations of this Section&nbsp;7.6, and the Company agrees at the request of any Person or group entitled to designate directors to call a special meeting of stockholders for the purpose of electing
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;No Common Holder, nor any Affiliate of any Common Holder, nor Takeda, nor Frazier
shall have any liability as a result of designating a person for election as a director for any act or omission by such designated person in his or her capacity as a director of the Company, nor shall any Common Holder, Takeda or Frazier have any
liability as a result of voting for any such designee in accordance with the provisions of this Section&nbsp;7.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to use its best efforts, within the requirements of applicable law, to ensure
that the rights granted under this Section&nbsp;7.6 are effective and that the parties enjoy the benefits of this Section&nbsp;7.6. Such actions include, without limitation, the use of the Company&#146;s best efforts to cause the nomination and
election of the directors as provided in this Section&nbsp;7.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;Each party acknowledges and
agrees that each party hereto will be irreparably damaged in the event any of the provisions of this Section&nbsp;7.6 are not performed by the parties in accordance with their specific terms or are otherwise breached. Accordingly, it is agreed that
each of the Company, the Common Holders, Takeda and Frazier shall be entitled to an injunction to prevent breaches of this Section&nbsp;7.6, and to specific enforcement of this Section&nbsp;7.6 and its terms and provisions in any action instituted
in any court of the United States or any state having subject matter jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;All remedies, either under this Section&nbsp;7.6
or by law or otherwise afforded to any party, shall be cumulative and not alternative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;This
Section&nbsp;7.6 shall be effective as of the date hereof and shall continue in effect until and shall terminate upon the earliest to occur of (a)&nbsp;the consummation of the Initial Public Offering (other than a registration statement relating
either to the sale of securities to employees of the Company pursuant to its stock option, stock purchase or similar plan or an SEC Rule 145 transaction) and (b)&nbsp;the consummation of any other Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j)&nbsp;&nbsp;&nbsp;&nbsp;In the event that after the date of this Agreement, the Company enters into an agreement with any
Person to issue shares of capital stock to such Person, then, the Company shall cause such Person, as a condition precedent to entering into such agreement, to become a party to this Agreement by executing an Adoption Agreement in the form attached
hereto as <U>Exhibit G</U>, agreeing to be bound by and subject to the terms of this Agreement as a Common Holder and thereafter such person shall be deemed a Stockholder for all purposes under this Agreement.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;Each transferee or assignee of any Shares subject to this
Agreement shall continue to be subject to the terms hereof, and, as a condition precedent to the Company&#146;s recognition of such transfer, each transferee or assignee shall agree in writing to be subject to each of the terms of this Agreement by
executing and delivering an Adoption Agreement substantially in the form attached hereto as <U>Exhibit G</U>. Upon the execution and delivery of an Adoption Agreement by any transferee, such transferee shall be deemed to be a party hereto as if such
transferee were the transferor and such transferee&#146;s signature appeared on the signature pages of this Agreement and shall be deemed to be a Common Holder, as applicable. The Company shall not permit the transfer of the Shares subject to this
Agreement on its books or issue a new certificate representing any such Shares unless and until such transferee shall have complied with the terms of this Section&nbsp;7.6(k). Each certificate instrument, or book entry representing the Shares
subject to this Section&nbsp;7.6 if issued on or after the date of this Agreement shall be notated by the Company with a legend reading substantially as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;THE SHARES REPRESENTED HEREBY ARE SUBJECT TO A NOTE PURCHASE AGREEMENT, AS MAY BE AMENDED FROM TIME TO
TIME, (A COPY OF WHICH MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF THAT NOTE
PURCHASE AGREEMENT, INCLUDING CERTAIN RESTRICTIONS ON VOTING, TRANSFER AND OWNERSHIP SET FORTH THEREIN.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company, by its
execution of this Agreement, agrees that it will cause the certificates instruments, or book entry evidencing the Shares issued after the date hereof to be notated with the legend required by this Section&nbsp;7.6(k), and it shall supply, free of
charge, a copy of this Agreement to any holder of such Shares upon written request from such holder to the Company at its principal office. The parties to this Agreement do hereby agree that the failure to cause the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
certificates, instruments, or book entry evidencing the Shares to be notated with the legend required by this Section&nbsp;7.6(k) herein and/or the failure of the Company to supply, free of
charge, a copy of this Agreement as provided hereunder shall not affect the validity or enforcement of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l)&nbsp;&nbsp;&nbsp;&nbsp;In the event of any issuance of Shares or the voting securities of the Company hereafter to any of
the Common Holders (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like), such Shares shall become subject to this Agreement and shall be notated with the legend set forth
in Section&nbsp;7.6(k). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m)&nbsp;&nbsp;&nbsp;&nbsp;The voting of Shares pursuant to this Agreement may be effected in
person, by proxy, by written consent or in any other manner permitted by applicable law. For the avoidance of doubt, voting of the Shares pursuant to the Agreement need not make explicit reference to the terms of this Agreement.<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n)&nbsp;&nbsp;&nbsp;&nbsp;The Company will promptly pay or reimburse the directors for all reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with attending Board or committee meetings of the Company or in performing their duties as directors of the Company (including
expenses incurred in performing their duties as members of committees of the Board).<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Protective Provisions</U>. So long as a majority of the principal amount of the Notes
originally issued pursuant to this Agreement remains outstanding, the Company shall not (by amendment, merger, consolidation or otherwise) without (in addition to any other vote required by law or the Certificate of Incorporation) first obtaining
the written consent of the Requisite Noteholders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;consummate a Corporate Transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;authorize or issue any debt security (other than the Notes) in excess of $250,000 in the
aggregate; <U>provided</U>, <U>however</U>, that such Requisite Noteholder approval shall not be required for the contemplated debt facility (in an amount not to exceed $50,000,000 in principal amount) with Silicon Valley Bank as long as the final
terms and conditions of such proposed debt facility are unanimously approved by the Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;redeem, purchase or otherwise acquire (or pay into or set aside for a sinking fund for such
purpose) any share or shares of Preferred Stock or Common Stock; <U>provided</U>, <U>however</U>, that this restriction shall not apply to the repurchase of shares of Common Stock from employees, officers, directors, consultants or other persons
performing services for the Company or any subsidiary pursuant to agreements under which the Company has the option to repurchase such shares upon the occurrence of certain events, such as the termination of employment or service, or pursuant to a
right of first refusal; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;issue, create or authorize the creation of any security that is
senior to the Notes or otherwise more favorable to the purchasers thereof than the terms of the Notes; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<U>provided</U>, <U>however</U>, that such Requisite Noteholder approval shall not be required for the contemplated debt facility (in an amount not to exceed $50,000,000 in principal amount) with
Silicon Valley Bank as long as the final terms and conditions of such proposed debt facility are unanimously approved by the Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;change the authorized number of directors of the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;pay or declare any dividend on any shares of capital stock of the Company prior to the repayment
or conversion of the Notes in accordance with the terms of this Agreement other than dividends payable on the Common Stock solely in the form of additional shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Directors</U><U>&#146;</U><U> and Officers</U><U>&#146;</U><U> Insurance</U>. The Company has
as of the date hereof or shall within thirty (30)&nbsp;days of the date hereof use its commercially reasonable efforts to obtain from financially sound and reputable insurers directors and officers liability insurance in an amount and on terms and
conditions satisfactory to the Board, and will use its commercially reasonable efforts to cause such insurance policy to be maintained until such time as the Board determines that such insurance should be discontinued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Observer Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Abingworth Observer Right</U>. As long as Abingworth Bioventures VII LP
(&#147;<U>Abingworth</U>&#148;) holds a Note (or securities issued upon the conversion thereof), the Company shall invite a representative of Abingworth, who shall initially be Shelley Chu, to attend all meetings of its Board in a nonvoting observer
capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; <U>provided</U>, <U>however</U>, that such representative shall agree to hold in confidence
and trust with respect to all information so provided; and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or
attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>RA Capital Observer Right</U>. As long as RA Capital Healthcare Fund, L.P. (&#147;<U>RA
Capital</U>&#148;) holds a Note (or securities issued upon the conversion thereof), the Company shall invite a representative of RA Capital, who shall initially be Jake Simson, to attend all meetings of its Board in a nonvoting observer capacity
and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; <U>provided</U>, <U>however</U>, that such representative shall agree to hold in confidence and
trust with respect to all information so provided; and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or
attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Medicxi Observer Right</U>. In the event Affiliates of Medicxi Ventures Management (Jersey)
Limited (&#147;<U>Medicxi</U>&#148;) are not entitled to designate a member of the Board, the Company shall invite a representative of Medicxi to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such
representative copies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of all notices, minutes, consents and other materials that it provides to its directors; <U>provided</U>, <U>however</U>, that such representative shall agree to hold in confidence and trust with
respect to all information so provided; and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such
meeting could adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>. Each Lender agrees, severally and not jointly, to use the same degree of
care as such Lender uses to protect its own confidential information for any information obtained pursuant to this Agreement which the Company identifies in writing as being proprietary or confidential and such Lender acknowledges that it will not,
unless otherwise required by law or the rules of any national securities exchange, association or marketplace, disclose such information without the prior written consent of the Company except such information that (a)&nbsp;was in the public domain
prior to the time it was furnished to such Lender, (b)&nbsp;is or becomes (through no willful improper action or inaction by such Lender) generally available to the public, (c)&nbsp;was in its possession or known by such Lender without restriction
prior to receipt from the Company, (d)&nbsp;was rightfully disclosed to such Lender by a third party without restriction or (e)&nbsp;was independently developed without any use of the Company&#146;s confidential information. Notwithstanding the
foregoing, each Lender that is a limited partnership or limited liability company may disclose such proprietary or confidential information to any former partners or members who retained an economic interest in such Lender, current or prospective
partner of the partnership or any subsequent partnership under common investment management, investment advisor, limited partner, general partner, member or management company of such Lender (or any employee or representative of any of the
foregoing) (each of the foregoing Persons, a &#147;<U>Permitted Disclosee</U>&#148;) or legal counsel, accountants, consultant or representatives for such Lender. Furthermore, nothing contained herein shall prevent any Lender or any Permitted
Disclosee from (i)&nbsp;entering into any business, entering into any agreement with a third party, or investing in or engaging in investment discussions with any other company (whether or not competitive with the Company), provided that such Lender
or Permitted Disclosee does not, except as permitted in accordance with this Section&nbsp;7.10, disclose or otherwise make use of any proprietary or confidential information of the Company in connection with such activities, or (ii)&nbsp;making any
disclosures required by law, rule, regulation or court or other governmental order. The Company shall use the same degree of care as it uses to protect its own confidential information for any information obtained pursuant to this Agreement which
any such Lender identifies in writing as being proprietary or confidential and the Company acknowledges that it will not, unless otherwise required by law or the rules of any national securities exchange, association or marketplace, disclose such
information without the prior written consent of such Lender except such information that (a)&nbsp;was in the public domain prior to the time it was furnished to the Company, (b)&nbsp;is or becomes (through no willful improper action or inaction by
the Company) generally available to the public, (c)&nbsp;was in its possession or known by the Company without restriction prior to receipt from such Lender, (d)&nbsp;was rightfully disclosed to the Company by a third party without restriction or
(e)&nbsp;was independently developed without any use of such Lender confidential information. The confidentiality obligations set forth in this Section&nbsp;7.10 will survive for a period of five (5)&nbsp;years following the termination of this
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. Except as otherwise provided herein, the terms and conditions of
this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties; <U>provided</U>, <U>however</U>, the Company may not assign its obligations under this Agreement without the written consent of
the Requisite Noteholders. For the avoidance of doubt, a Lender that is a venture capital fund or private equity investor may assign or transfer its rights and obligations under this Agreement to its Affiliates. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This Agreement and the Notes shall be governed by and
construed under the laws of the State of Delaware as applied to agreements among Delaware residents, made and to be performed entirely within the State of Delaware, without regard to any choice of laws rules that may result in the application of the
laws of any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U><U>; Delivery</U>. This Agreement may be
executed by electronic signature and in two (2)&nbsp;or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1)&nbsp;and the same instrument. Counterparts may be delivered by facsimile,
electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. All notices and other communications given or made pursuant hereto shall be in
writing and shall be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, if not so confirmed, then
on the next business day, (c)&nbsp;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one (1) day after deposit with a nationally recognized overnight courier, specifying next
day delivery, with written verification of receipt. All communications shall be sent to the respective parties at the following addresses (or at such other addresses as shall be specified by notice given in accordance with this Section&nbsp;8.5):
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If to the Company: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Phathom Pharmaceuticals, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With a copy to (which alone shall not constitute sufficient notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12670 High Bluff Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">San Diego, CA 92103 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention: Cheston J. Larson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Email: <U>cheston.larson@lw.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Facsimile No.: (858) <FONT STYLE="white-space:nowrap">523-5450</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If to Lenders: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the respective addresses shown on the signature pages hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With a copy to (which alone shall not constitute sufficient notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One Marina Park Drive,&nbsp;Suite 900 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Boston, MA&nbsp;02210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention: Timothy H. Ehrlich and Albert W. Vanderlaan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Email: <U>tehrlich@gunder.com;</U> avanderlaan@gunder.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Facsimile No.: (617) <FONT STYLE="white-space:nowrap">648-9199</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Finder</U><U>&#146;</U><U>s Fee</U>. Each party represents that it neither is nor will be
obligated for any finder&#146;s fee or commission in connection with this transaction. Each Lender agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder&#146;s fee (and
the costs and expenses of defending against such liability or asserted liability) for which such Lender or any of its officers, partners, employees or representatives is responsible. The Company agrees to indemnify and hold harmless each Lender from
any liability for any commission or compensation in the nature of a finder&#146;s fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives
is responsible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>. If any action at law or in equity is necessary to enforce or
interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys&#146; fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. Each party hereto shall pay all
costs and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement. At the Initial Closing, the Company shall reimburse the reasonable fees and expenses of Gunderson Dettmer Stough Villeneuve
Franklin&nbsp;&amp; Hachigian, LLP, counsel for the Lenders, not to exceed $70,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement; Amendments and Waivers</U>. This Agreement, the Notes and the other documents expressly delivered pursuant hereto or in connection with the Closing hereunder constitute the full and entire understanding and agreement between the parties
with regard to the subjects hereof and thereof. The Company&#146;s agreements with each of the Lenders are separate agreements, and the sales of the Notes to each of the Lenders are separate sales. Nonetheless, any term of this Agreement or the
Notes may be amended and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
observance of any term of this Agreement or the Notes may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the
Company and the Requisite Noteholders. In addition, (i)&nbsp;no term of this Agreement or the Notes may be amended or waived without the written consent of each Lender if such amendment or waiver materially, adversely and disproportionately affects
such Lender in a manner different than all other Lenders, (ii)&nbsp;Section&nbsp;1 of the Note held by each Lender shall not be amended or waived with respect to such Lender without the written consent of such Lender, (iii)&nbsp;the outstanding
principal and interest amount of the Note held by each Lender shall not be amended or waived with respect to such Lender without the written consent of such Lender, and (iv)&nbsp;Section&nbsp;1(ff), Section&nbsp;7.2, Section&nbsp;7.4 and
Section&nbsp;7.6(b)(iii) of this Agreement shall not be amended or waived with respect to Takeda without the written consent of Takeda. Any waiver or amendment effected in accordance with this Section&nbsp;8.8 shall be binding upon each party to
this Agreement and any holder of any Note purchased under this Agreement at the time outstanding and each future holder of all such Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Amendment or Waiver</U>. Each Lender acknowledges that by the operation of
Section&nbsp;8.8 hereof, and subject to the limitations set forth therein, the Requisite Noteholders will have the right and power to diminish or eliminate all rights of such Lender under this Agreement and each Note issued to such Lender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If one or more provisions of this Agreement are held to be unenforceable
under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.11&nbsp;&nbsp;&nbsp;&nbsp;<U>&#147;</U><U>Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT></U><U>&#148;</U><U>
Agreement</U>. Each Lender hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Initial Public Offering and ending on the date
specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180)&nbsp;days) (a)&nbsp;lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock held immediately prior
to the effectiveness of the registration statement for such offering, or (b)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any
such transaction described in clause&nbsp;(a) or (b)&nbsp;above is to be settled by delivery of Common Stock or other securities, in cash or otherwise. The foregoing provisions of this Section&nbsp;8.11 shall apply only to the Company&#146;s Initial
Public Offering, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Lenders if all officers, directors and greater than one percent (1%) stockholders of the Company
enter into similar agreements. The underwriters in connection with the Company&#146;s Initial Public Offering are intended third-party beneficiaries of this Section&nbsp;8.11 and shall have the right, power and authority to enforce the provisions
hereof as though they were a party hereto. Each Lender further agrees to execute such agreements as may be reasonably requested by the underwriters in the Company&#146;s Initial Public Offering that are consistent with this Section&nbsp;8.11 or that
are necessary to give further effect thereto. Notwithstanding the foregoing, the Company and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
managing underwriter may extend the market <FONT STYLE="white-space:nowrap">stand-off</FONT> period specified above solely to the extent necessary to accommodate regulatory restrictions on
(1)&nbsp;the publication or other distribution of research reports, and (2)&nbsp;analyst recommendations and opinions, including, without limitation, the restrictions, if any, contained in FINRA Rule 2241 or any successor provisions or amendments
thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply to all Lenders subject to such agreements pro rata based on the number of shares subject to such
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to
the capital stock of the Company of each Lender (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Lender agrees that a legend reading substantially as follows shall be placed on all certificates representing all capital
stock of the Company of each Lender (and the shares or securities of every other person subject to the restriction contained in this Section&nbsp;8.11): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A
<FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD AFTER THE EFFECTIVE DATE OF THE ISSUER&#146;S REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE
SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER&#146;S PRINCIPAL OFFICE. SUCH <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Financing Documents</U>. Each Lender understands and agrees that the conversion of the Notes
into Conversion Shares may require such Lender&#146;s execution of certain agreements in the form agreed to by investors in the Next Equity Financing or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Next Equity Financing relating to the
purchase and sale of such securities as well as registration, <FONT STYLE="white-space:nowrap">co-sale,</FONT> rights of first refusal, rights of first offer and voting rights, if any, relating to such securities; <U>provided</U>, <U>however</U>,
that in no event shall conversion be conditioned upon any Lender be required to agree to undertake liability under any compelled voting (i.e., drag along provisions) for any third party (other than the Company) or that exceeds the consideration
received or to be received by such party or to grant any proxy with respect to voting of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.13&nbsp;&nbsp;&nbsp;&nbsp;<U>MFN Right</U>. In the event that the Company issues convertible notes (or similar convertible
instruments) at any time after the date hereof which have terms that are more favorable to the Lenders than the terms of the Notes, such as, but not limited to, a higher interest rate, lower capped valuation or larger discount to the applicable
conversion price, but which shall not include any Board representation or observer rights afforded to a specific Lender by reason of the magnitude of their investment (the &#147;<U>MFN Notes</U>&#148;), the Company shall promptly amend the terms of
the Notes to provide substantially equivalent terms to the Lender as the MFN Notes without further consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.14&nbsp;&nbsp;&nbsp;&nbsp;<U>Exculpation Among Lenders</U>. Each Lender acknowledges that it is not relying upon any
person, firm, corporation or stockholder, other than the Company and its officers and directors in their capacities as such, in making its investment or decision to invest in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Company. Each Lender agrees that no other Lender nor the respective controlling persons, officers, directors, partners, agents, stockholders or employees of any other Lender shall be liable
for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase and sale of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgement</U>. In order to avoid doubt, it is acknowledged that each Lender shall be
entitled to the benefit of all adjustments in the number of shares of Common Stock of the Company directly or indirectly issuable upon conversion of the Notes or as a result of any splits, recapitalizations, combinations or other similar transaction
affecting the Common Stock or the Conversion Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.16&nbsp;&nbsp;&nbsp;&nbsp; <U>Indemnity; Costs, Expenses and
Attorneys</U><U>&#146;</U><U> Fees</U>. The Company shall indemnify and hold each Lender harmless from any loss, cost, liability and legal or other expense, including attorneys&#146; fees of such Lender&#146;s counsel, which a Lender may directly or
indirectly suffer or incur by reason of the failure of the Company to perform any of its obligations under this Agreement, any Note, any agreement executed in connection herewith or therewith, any grant of or exercise of remedies with respect to any
collateral at any time securing any obligations evidenced by this Agreement or the Notes, or any Lender&#146;s execution or performance of this Agreement or any agreement executed in connection herewith; <U>provided</U>, <U>however</U>, the
indemnity agreement contained in this section shall not apply to liabilities which a Lender may directly or indirectly suffer or incur by reason of Lender&#146;s own gross negligence or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.17&nbsp;&nbsp;&nbsp;&nbsp;<U>Further Assurance</U>. From time to time, the Company shall use its commercially reasonable
efforts to execute and deliver to the Lenders such additional documents to the Lenders as the Requisite Noteholders may reasonably require to carry out the terms of this Agreement and the Notes and any agreements executed in connection herewith or
therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.18&nbsp;&nbsp;&nbsp;&nbsp;<U>Dispute Resolution</U>. The parties (a)&nbsp;hereby irrevocably and
unconditionally submit to the jurisdiction of the state courts of State of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or
based upon this Agreement, (b)&nbsp;agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of or the United States District Court for the District of Delaware, and
(c)&nbsp;hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the foregoing courts, that its property is
exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be
enforced in or by such court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.19&nbsp;&nbsp;&nbsp;&nbsp; <U>Waiver of Jury Trial</U>. TO THE EXTENT EACH MAY LEGALLY
DO SO, EACH PARTY HERETO HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, CAUSE OF ACTION, OR PROCEEDING ARISING UNDER OR WITH RESPECT TO THIS AGREEMENT, OR IN ANY WAY CONNECTED WITH, OR RELATED TO, OR INCIDENTAL TO,
THE DEALING OF THE PARTIES HERETO WITH RESPECT TO THIS AGREEMENT, OR THE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND IRRESPECTIVE OF WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. TO THE EXTENT EACH MAY LEGALLY DO SO,
EACH PARTY HERETO HEREBY AGREES THAT ANY SUCH CLAIM, DEMAND, ACTION, OR PROCEEDING SHALL BE DECIDED BY A COURT TRIAL WITHOUT A JURY AND THAT EITHER PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN
EVIDENCE OF THE CONSENT OF ANY OTHER PARTY HERETO TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.20&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The representations, warranties, covenants and agreements made herein shall
survive the closing of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.21&nbsp;&nbsp;&nbsp;&nbsp;<U>Spousal Consent</U>. If any
individual Common Holder is married on the date of this Agreement, such Common Holder&#146;s spouse shall execute and deliver to the Company a consent of spouse in the form of Exhibit H hereto (&#147;Consent of Spouse&#148;), effective on the date
hereof. Notwithstanding the execution and delivery thereof, such consent shall not be deemed to confer or convey to the spouse any rights in such Common Holder&#146;s Shares that do not otherwise exist by operation of law or the agreement of the
parties. If any individual Common Holder should marry or remarry subsequent to the date of this Agreement, such Common Holder shall within thirty (30)&nbsp;days thereafter obtain his/her new spouse&#146;s acknowledgement of and consent to the
existence and binding effect of all restrictions contained in this Agreement by causing such spouse to execute and deliver a Consent of Spouse acknowledging the restrictions and obligations contained in this Agreement and agreeing and consenting to
the same. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.22&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation of Liability; Freedom to Operate Affiliates</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;Other than as set forth below Section&nbsp;8.22(b), the total liability, in the aggregate, of each
Lender, and their respective Affiliates and their respective officers, directors, employees, consultants and agents, for any and all monetary claims, losses, costs or damages, including attorneys&#146; and accountants&#146; fees and expenses and
costs of any nature whatsoever or claims or expenses resulting from or in any way related to this Agreement or the Notes from any cause or causes shall be several and not joint with the other Lenders and shall not exceed the total Consideration paid
to the Company by such Lender for the Notes under this Agreement; <U>provided</U>, <U>however</U>, that this Section&nbsp;8.22 shall (i)&nbsp;in no way limit the Company&#146;s right to equitable relief, including injunctive relief and specific
performance from a Lender, (ii)&nbsp;apply to breaches of a Lender&#146;s confidentiality obligation, or (iii)&nbsp;limit liability for a Lender&#146;s conduct that is judicially determined to be bad faith, fraud or willful misconduct. Nothing in
this Agreement or the Notes shall restrict a Lender&#146;s freedom to operate any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;Nothing in Section&nbsp;8.22(a) shall modify any Lender&#146;s confidentiality obligations or the
fiduciary duties of any director designated by Lender or the contractual restrictions on any Lender-designated Board observer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature
pages follow.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>PHATHOM&nbsp;PHARMACEUTICALS,&nbsp;INC.</B></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>LENDERS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>FRAZIER LIFE SCIENCES IX, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: FHMLS IX, L.P.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: FHMLS IX, L.L.C.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ James Topper</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James Topper</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Managing Director</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">c/o Frazier Healthcare Partners</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">70 Willow Road, Suite 200</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Menlo Park, CA 94025</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: James Topper</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>LENDERS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>MEDICXI GROWTH <FONT STYLE="white-space:nowrap">CO-INVEST</FONT> I LP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: its manager Medicxi Ventures Management (Jersey) Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alex Di Santo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Director</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDICXI GROWTH I LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: its manager Medicxi Ventures Management (Jersey) Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alex Di Santo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Director</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address: Medicxi Ventures Management (Jersey) Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">44 Esplanade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">St Helier</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Jersey JE4 9WG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Channel Islands</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attention: Giles Johnstone-Scott</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Tel: </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U></U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">with mandatory copy to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Medicxi Ventures (UK) LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">25 Great Pulteney Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">London</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W1F 9LT</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attention: </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: <U></U></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>LENDERS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>RA CAPITAL HEALTHCARE FUND, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">RA Capital Management, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Natasha Kassian</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Natasha Kassian</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Authorized Signatory</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">RA Capital Management, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20 Park Plaza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Suite 1200</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Boston, MA 02116</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: General Counsel</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>LENDERS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>BLACKWELL PARTNERS LLC &#150; SERIES A</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Adrienne C. Clough</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adrienne C. Clough</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investment Manager</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DUMAC, Inc., Authorized Agent</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Head of Finance&nbsp;&amp; Controller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DUMAC, Inc., Authorized Agent</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Blackwell Partners LLC &#150; Series A</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">280 S. Mangum Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Suite 210</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Durham, NC 27701</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: Jannine Lall</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABINGWORTH BIOVENTURES VII LP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>acting by its Manager Abingworth LLP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ James
Abell&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James Abell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">c/o Abingworth LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38 Jermyn Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">London SW1Y 6DN</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">United Kingdom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: General Counsel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email: </P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JANUS HENDERSON GLOBAL LIFE SCIENCES FUND</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Andrew
Acker&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Andrew Acker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Portfolio Manager and Authorized Signatory</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JANUS HENDERSON CAPITAL FUNDS PLC ON BEHALF OF ITS SERIES</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>JANUS HENDERSON GLOBAL LIFE SCIENCES FUND</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Andrew Acker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Andrew Acker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Portfolio Manager and Authorized Signatory</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JANUS HENDERSON HORIZON FUND &#150; BIOTECHNOLOGY FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Andrew Acker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Andrew Acker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Portfolio Manager and Authorized Signatory</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">c/o Janus Capital Management LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">151 Detroit Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Denver, CO 80206</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Boston, MA 02116</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: Andy Acker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: Angela Morton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE FUND, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Mark
Lampert&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President BVF Inc., General Partner of BVF Partners L.P., itself GP of Biotechnology Value Fund, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">44 Montgomery Street, 40th</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Floor San Francisco, CA 94104</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With a copy to (which shall not constitute notice): </P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gibson, Dunn &amp; Crutcher LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">555 Mission Street, Suite 3000</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">San Francisco, CA 94105</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention: Ryan A. Murr</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE FUND II, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Mark
Lampert&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President BVF Inc., General Partner of BVF Partners L.P., itself GP of Biotechnology Value Fund II, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">44 Montgomery Street, 40th</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Floor San Francisco, CA 94104</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With a copy to (which shall not constitute notice): </P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gibson, Dunn &amp; Crutcher LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">555 Mission Street, Suite 3000</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">San Francisco, CA 94105</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention: Ryan A. Murr</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Trading Fund OS, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">PO Box 309 Ugland House, Grand Cayman,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">KY1-</FONT> 1104, Cayman Islands</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With a copy to (which shall not constitute notice): </P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gibson, Dunn &amp; Crutcher LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">555 Mission Street, Suite 3000</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">San Francisco, CA 94105</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention: Ryan A. Murr</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MSI BVF SPV, L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">c/o Magnitude Capital</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Mark
Lampert&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President BVF Inc., itself General Partner of </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BVF Partners L.P., itself
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MSI BVF SPV, L.L.C.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">200 Park Avenue, 56<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, NY 10166</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With a copy to (which shall not constitute notice): </P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gibson, Dunn&nbsp;&amp; Crutcher LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">555 Mission Street, Suite 3000</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">San Francisco, CA 94105</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention: Ryan A. Murr</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RICHARD KING MELLON FOUNDATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Douglas L. Sisson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Douglas L. Sisson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vice President and Treasurer</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MELLON FAMILY INVESTMENT COMPANY V</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its General Partner, MFIC V, LLC</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Lawrence S. Busch</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lawrence S. Busch</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Member</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GREENSPRING EARLY STAGE I, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Greenspring Early Stage General Partner I, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Greenspring Early Stage GP I, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Greenspring Associates, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">its sole member</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Eric Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Eric Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief&nbsp;Operating&nbsp;Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN&nbsp;WITNESS&nbsp;WHEREOF,&nbsp;the&nbsp;parties&nbsp;have&nbsp;executed&nbsp;this&nbsp;Agreement&nbsp;as&nbsp;of&nbsp;
the&nbsp;date&nbsp;first above&nbsp;written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GREENSPRING EARLY STAGE <FONT STYLE="white-space:nowrap">I-G,</FONT> L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Greenspring Early Stage General Partner I, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Greenspring Early Stage GP I, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Greenspring Associates, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">its sole member</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Eric Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Eric Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Operating Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MARSHFIELD ADVISERS, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Scott Carman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Scott Carman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Head of Private Equity</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marshfield Advisers, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">60 East South Temple Street, Suite 400</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Salt Lake City, UT 84111</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: Scott Carman, Head of Private Equity</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>LENDERS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>CATALYS PACIFIC FUND, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>General Partner:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Catalys Pacific Fund GP, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Catalys Pacific, LLC, its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Brian Taylor Slingsby</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Brian Taylor Slingsby, MD, PhD, MPH</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Managing Director</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>LENDERS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>SAHSEN VENTURES, LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Bryan White</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bryan White</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Managing Member</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Emails&nbsp;to:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With&nbsp;copies&nbsp;to:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>COMMON&nbsp;HOLDERS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David A. Socks 2013 Revocable Trust</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ David
Socks&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Tadataka Yamada</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tadataka Yamada</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Azmi Nabulsi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Azmi Nabulsi</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Roger Ulrich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roger Ulrich</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Aditya Kohli</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aditya Kohli</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Executed as of the date first above written, solely with respect to
Section&nbsp;1(ff), Section&nbsp;7.2, Section&nbsp;7.4, Section&nbsp;7.6 and Section&nbsp;8.8 of this Agreement and not as a &#147;Party&#148; to this Agreement for any other reason: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>TAKEDA:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Takeda Pharmaceutical Company Limited</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Fumihiko Sato</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fumihiko Sato</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Head of Portfolio Strategic Relations</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTE</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE OF LENDERS </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INITIAL CLOSING </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B></B>Lender<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>Total&nbsp;Consideration<BR>(Principal&nbsp;Balance&nbsp;of<BR>Promissory&nbsp;Note)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frazier Life Sciences IX, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,427,747.62</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frazier Life Sciences IX, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,572,252.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicxi Growth <FONT STYLE="white-space:nowrap">Co-Invest</FONT> I LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348,076.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicxi Growth I LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,651,923.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,756,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackwell Partners LLC &#150; Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,244,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abingworth Bioventures VII LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Global Life Sciences Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,278,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Capital Funds plc on behalf of its series Janus Henderson Global Life Sciences
Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,634,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Horizon Fund &#150; Biotechnology Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,708,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund II, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,996,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Trading Fund OS, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">536,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MSI BVF SPV L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">260,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard King Mellon Foundation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mellon Family Investment Company V</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greenspring Early Stage I, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,474,051.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greenspring Early Stage <FONT STYLE="white-space:nowrap">I-G,</FONT> L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">525,949.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marshfield Advisers, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sahsen Ventures, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INITIAL CLOSING TOTAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>86,750,000.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1) The Consideration for this Note is an exchange for the existing convertible notes issued
by the Company to Frazier as of the Initial Closing, which shall be null and void upon the issuance of the Note in the amount of $2,427,747.62, representing the principal and accrued interest on such convertible notes as of the Initial Closing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND CLOSING </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Lender</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total&nbsp;Consideration<BR>(Principal&nbsp;Balance&nbsp;of<BR>Promissory&nbsp;Note)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Catalys Pacific Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECOND CLOSING TOTAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,500,000.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL FOR ALL CLOSINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>90,250,000.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHATHOM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO NOTE PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Amendment (this &#147;<U>Amendment</U>&#148;) to the Note Purchase Agreement, dated as of May&nbsp;7, 2019 (the
&#147;<U>Purchase Agreement</U>&#148;), by and between Phathom Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and the Lenders named on the Schedule of Lenders attached thereto, and the Common Holders, is made as of
July&nbsp;26, 2019 (the &#147;<U>Effective Date</U>&#148;). The Company, the Lenders and the Common Holders are sometimes referred to in this Amendment collectively as the &#147;<U>Parties</U>&#148; and individually as a &#147;<U>Party</U>&#148;.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, pursuant to Section&nbsp;8.8 of the Purchase Agreement any term of the Purchase Agreement may be amended
and the observance of any term of the Purchase Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the Requisite Noteholders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, Section&nbsp;7.4 of the Purchase Agreement shall not be amended or waived with respect to Takeda without the
written consent of Takeda; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, Takeda and the undersigned Lenders representing the Requisite Noteholders
desire to amend the Purchase Agreement to provide for the termination of certain covenants contained in the Purchase Agreement upon the consummation of certain events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOW, THEREFORE</B>, in consideration of the mutual covenants contained herein, and for other good and valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. Capitalized terms used but not defined in this Amendment shall have the meanings
ascribed to them in the Purchase Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;The following Section&nbsp;7.3(f) is hereby added to the end of Section&nbsp;7.3 of the Purchase
Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;(f) <U>Termination</U>. The covenants set forth in this Section&nbsp;7.3 shall terminate and be of no
further force or effect upon (i)&nbsp;the consummation of the Initial Public Offering, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the Exchange Act and (iii)&nbsp;upon the
consummation of a Corporate Transaction, whichever event shall first occur.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;The
following Section&nbsp;7.4(c) is hereby added to the end of Section&nbsp;7.4 of the Purchase Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;(c)
<U>Termination</U>. This Section&nbsp;7.4 shall be effective as of the date of this Agreement and shall continue in effect until and shall </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
terminate upon the earliest to occur of (i)&nbsp;the consummation of the Initial Public Offering, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of
Sections 12(g) or 15(d) of the Exchange Act and (iii)&nbsp;upon the consummation of a Corporate Transaction; <U>provided</U> that the provisions of <U>Section</U><U></U><U>&nbsp;7.4</U> hereof will continue after the closing of any Sale of the
Company to the extent necessary to enforce the provisions of <U>Section</U><U></U><U>&nbsp;7.4</U> with respect to such Sale of the Company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;The following Section&nbsp;7.9(d) is hereby added to the end of Section&nbsp;7.9 of the Purchase
Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;(d) <U>Termination of Observer Rights</U>. The rights described in this Section&nbsp;7.9 shall terminate
and be of no further force or effect upon (i)&nbsp;such time as Abingworth, RA Capital or Medicxi, as applicable, no longer hold a Note (or securities issued upon the conversion thereof)&nbsp;(ii) the consummation of the Initial Public Offering,
(iii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the Exchange Act and (iv)&nbsp;upon the consummation of a Corporate Transaction, whichever event shall first occur. The
confidentiality obligations referenced in this Section&nbsp;7.9 will survive for a period of five (5)&nbsp;years following any such termination.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as specifically provided for in this Amendment, all of the terms and conditions of the
Purchase Agreement shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;This Amendment shall be governed by
and construed under the laws of the State of Delaware as applied to agreements among Delaware residents, made and to be performed entirely within the State of Delaware, without regard to any choice of laws rules that may result in the application of
the laws of any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;This Amendment may be executed by electronic signature and
in two (2)&nbsp;or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1)&nbsp;and the same instrument. Counterparts may be delivered by facsimile, electronic mail (including pdf) or other
transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature pages follow] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PHATHOM PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FRAZIER LIFE SCIENCES IX, L.P.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FHMLS IX, L.P.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its general partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FHMLS IX, L.L.C.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Its general partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:<U></U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ James Topper</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James Topper</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Managing Director</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;c/o Frazier Healthcare Partners</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;70 Willow Road, Suite 200</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;Menlo Park, CA 94025</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;Attn: James Topper</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDICXI GROWTH <FONT STYLE="white-space:nowrap">CO-INVEST</FONT> I LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: its manager Medicxi Ventures Management</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Jersey) Limited</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Nick McHardy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Director</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDICXI GROWTH I LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: its manager Medicxi Ventures Management</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Jersey) Limited</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Nick McHardy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Director</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address: Medicxi Ventures Management</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Jersey) Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">44 Esplanade</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">St Helier</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jersey JE4 9WG</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Channel Islands</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention: Giles Johnstone-Scott</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tel: </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U></U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with mandatory copy to:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Medicxi Ventures (UK) LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">25 Great Pulteney Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">London</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">W1F 9LT</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention: </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email: </P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL HEALTHCARE FUND, L.P.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">RA Capital Management, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">General Partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Peter Kolchinsky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Peter Kolchinsky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Authorized Signatory</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">RA Capital Management, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20 Park Plaza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Suite 1200</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Boston, MA 02116</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: General Counsel</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLACKWELL PARTNERS LLC &#150; SERIES A</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Abayomi A. Adigun</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Abayomi A. Adigun</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investment Manager</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DUMAC, Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Authorized Agent</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Head of Finance &amp; Controller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DUMAC, Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Authorized Agent</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Blackwell Partners LLC &#150; Series A</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">280 S. Mangum Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Suite 210</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Durham, NC 27701</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: Jannine Lall</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABINGWORTH BIOVENTURES VII LP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>acting by its Manager Abingworth LLP</B></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ John Heard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">John Heard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">General Counsel</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">c/o Abingworth LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38 Jermyn Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">London SW1Y 6DN</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">United Kingdom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: General Counsel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email: </P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMMON HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David A. Socks 2013 Revocable Trust</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Trustee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Tadataka Yamada</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tadataka Yamada</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Azmi Nabulsi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Azmi Nabulsi</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Roger Ulrich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roger Ulrich</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Aditya Kohli</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aditya Kohli</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Executed as of the date first above written, solely with respect to
Section&nbsp;7.4 and Section&nbsp;8.8 of the Purchase Agreement and not as a &#147;Party&#148;&nbsp;to&nbsp;this&nbsp;Amendment&nbsp;for&nbsp;any&nbsp;other&nbsp;reason: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TAKEDA PHARMACEUTICAL COMPANY LIMITED:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Takeda Pharmaceutical Company Limited</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Fumihiko Sato</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fumihiko Sato</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Head of Portfolio Strategic Relations</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHATHOM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT #2 TO NOTE PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Amendment #2 (this &#147;<U>Amendment</U>&#148;) to the Note Purchase Agreement, dated as of May&nbsp;7, 2019 (as amended
by the Amendment to Note Purchase Agreement, dated as of July&nbsp;26, 2019, the &#147;<U>Purchase Agreement</U>&#148;), by and between Phathom Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and the Lenders named on
the Schedule of Lenders attached thereto, and the Common Holders, is made as of September&nbsp;26, 2019 (the &#147;<U>Effective Date</U>&#148;). The Company, the Lenders and the Common Holders are sometimes referred to in this Amendment collectively
as the &#147;<U>Parties</U>&#148; and individually as a &#147;<U>Party</U>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, pursuant to
Section&nbsp;8.8 of the Purchase Agreement any term of the Purchase Agreement may be amended and the observance of any term of the Purchase Agreement may be waived (either generally or in a particular instance and either retroactively or
prospectively), with the written consent of the Company and the Requisite Noteholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>,
Section&nbsp;7.6(b)(iii) of the Purchase Agreement shall not be amended or waived with respect to Takeda without the written consent of Takeda; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, Takeda and the undersigned Lenders representing the Requisite Noteholders desire to amend the Purchase
Agreement to provide for an increase in the authorized size of the Board and to amend the composition of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOW, THEREFORE</B>, in consideration of the mutual covenants contained herein, and for other good and valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. Capitalized terms used but not defined in this Amendment shall have the meanings
ascribed to them in the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;Section 7.6(a) and Section&nbsp;7.6(b) are hereby amended and restated in their entirety as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;7.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting Provisions Regarding the Board Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Common Holder, Takeda and Frazier agrees to vote, or cause to be voted, all Shares owned by
such Common Holder, Takeda and Frazier, or over which such Common Holder, Takeda and Frazier has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that the size of the Board shall be set and
remain at eight (8)&nbsp;directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Common Holder, Takeda and Frazier agrees to vote, or
cause to be voted, all Shares owned by such Common Holder, Takeda and Frazier, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special
meeting of stockholders at which an election of directors is held or pursuant to </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
any written consent of the stockholders, the following persons shall be elected to the Board: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;One (1)&nbsp;person designated from time to time by Frazier, who shall initially be
James Topper; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;One (1)&nbsp;person designated from time to time by the Lenders
other than Frazier, which individual shall initially be Jon Edwards; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;One
(1)&nbsp;person designated from time to time by Takeda or its affiliates, which individual shall initially be Chris Slavinsky; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;One (1)&nbsp;person designated from time to time by the holders of a majority of
the Common Stock, which individual shall initially be Tadataka Yamada, M.D. (who shall initially be the Chairman of the Board); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s Chief Executive Officer, who shall initially be David Socks (the
&#147;CEO Director&#148;), provided that if for any reason the CEO Director shall cease to serve as the Chief Executive Officer of the Company, each of the Common Holders shall promptly vote their respective Shares (A)&nbsp;to remove the former
Chief Executive Officer of the Company from the Board if such person has not resigned as a member of the Board; and (B)&nbsp;to elect such person&#146;s replacement as Chief Executive Officer of the Company as the new CEO Director; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Three (3)&nbsp;individuals not otherwise an Affiliate of the Company or of any
Lender who is mutually acceptable to the other members of the Board, which individuals shall initially be Michael Cola, Terrie Curran and Heidi Kuntz.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;Section 1(cc)(iii) is hereby amended and restated in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;(iii) &nbsp;&nbsp;&nbsp;&nbsp;the number of shares of capital stock (determined on an as converted to
Common Stock basis) reserved for issuance under the Company&#146;s equity incentive plans (net of any such shares underlying securities included in clause (ii)&nbsp;of this definition) including, in the event of a conversion of the Notes in the Next
Equity Financing, any increase in the number of such reserved shares expressly required by the terms and conditions of such Next Equity Financing; provided that, for clarity, any shares reserved as part of an equity incentive plan or employee stock
purchase plan adopted in connection with an Initial Public Offering shall not be included in this clause (iii).&#148;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as specifically provided for in this Amendment, all of the terms and conditions of the
Purchase Agreement shall remain in full force and effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;This Amendment shall be governed by
and construed under the laws of the State of Delaware as applied to agreements among Delaware residents, made and to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
performed entirely within the State of Delaware, without regard to any choice of laws rules that may result in the application of the laws of any other jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;This Amendment may be executed by electronic signature and in two (2)&nbsp;or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one (1)&nbsp;and the same instrument. Counterparts may be delivered by facsimile, electronic mail (including pdf) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature pages follow]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PHATHOM PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page to the Amendment to the Note Purchase Agreement) </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FRAZIER LIFE SCIENCES IX, L.P.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FHMLS IX, L.P.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its general partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FHMLS IX, L.L.C.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its general partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:<U></U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ James Topper</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James Topper</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Managing Director</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;c/o Frazier Healthcare Partners</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;70 Willow Road, Suite 200</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;Menlo Park, CA 94025</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;Attn: James Topper</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page to the Amendment to the Note Purchase Agreement) </I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDICXI GROWTH <FONT STYLE="white-space:nowrap">CO-INVEST</FONT> I LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: its manager Medicxi Ventures Management</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Jersey) Limited</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Alex Di Santo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Alex Di Santo</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Director</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDICXI GROWTH I LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: its manager Medicxi Ventures Management</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Jersey) Limited</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Alex Di Santo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Alex Di Santo</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Director</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address: Medicxi Ventures Management</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Jersey) Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">44 Esplanade</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">St Helier</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jersey JE4 9WG</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Channel Islands</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention: Giles Johnstone-Scott</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tel: </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">E-mail:</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with mandatory copy to:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Medicxi Ventures (UK) LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">25 Great Pulteney Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">London</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">W1F 9LT</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention: Richard Lee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page to the Amendment to the Note Purchase Agreement) </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL HEALTHCARE FUND, L.P.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">RA Capital Management, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">General Partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Peter Kolchinsky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Peter Kolchinsky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Authorized Signatory</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">RA Capital Management, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20 Park Plaza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Suite 1200</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Boston, MA 02116</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: General Counsel</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page to the Amendment to the Note Purchase Agreement) </I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLACKWELL PARTNERS LLC &#150; SERIES A</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Abayomi A. Adigun</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Abayomi A. Adigun</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investment Manager</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DUMAC, Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Authorized Agent</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Head of Finance &amp; Controller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DUMAC, Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Authorized Agent</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Blackwell Partners LLC &#150; Series A</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">280 S. Mangum Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Suite 210</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Durham, NC 27701</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: Jannine Lall</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page to the Amendment to the Note Purchase Agreement) </I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABINGWORTH BIOVENTURES VII LP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>acting by its Manager Abingworth LLP</B></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ James Abell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James Abell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">c/o Abingworth LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38 Jermyn Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">London SW1Y 6DN</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">United Kingdom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn: General Counsel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page to the Amendment to the Note Purchase Agreement) </I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMMON HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David A. Socks 2013 Revocable Trust</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David Socks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Trustee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Tadataka Yamada</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tadataka Yamada</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Azmi Nabulsi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Azmi Nabulsi</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Roger Ulrich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roger Ulrich</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Aditya Kohli</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aditya Kohli</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page to the Amendment to the Note Purchase Agreement) </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Executed as of the date first above written, solely with respect to
Section&nbsp;7.6(b)(iii) and Section&nbsp;8.8 of the Purchase Agreement and not as a &#147;Party&#148; to this Amendment for any other reason: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TAKEDA:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Takeda Pharmaceutical Company Limited</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Chris Slavinsky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chris Slavinsky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VP, Center for External Innovation</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page to the Amendment to the Note Purchase Agreement) </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>d63338dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g63338snap003.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;15, 2019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phathom Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2150 E. Lake Cook Road, Suite 800
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Buffalo Grove, Illinois 60089 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Registration Statement No.</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;333-234020;</FONT> 9,085,000
shares of Common Stock, par value</U> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>$0.0001 per share</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as special
counsel to Phathom Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), in connection with the proposed issuance of up to 9,085,000 shares (including up to 1,185,000 shares subject to the underwriters&#146; option to purchase
additional shares) of common stock, $0.0001 par value per share (the &#147;Shares&#148;). The Shares are included in a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act of 1933, as amended (the
&#147;Act&#148;), filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on September&nbsp;30, 2019 (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-234020)</FONT> (as amended, the &#147;Registration Statement&#148;). The
term &#147;Shares&#148; shall include any additional shares of common stock registered by the Company pursuant to Rule 462(b) under the Act in connection with the offering contemplated by the Registration Statement. This opinion is being furnished
in connection with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related
Prospectus, other than as expressly stated herein with respect to the issue of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such matters
of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having
independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware and we express no opinion with respect to any other laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have
been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor in the circumstances contemplated by the form of underwriting
agreement most recently filed as an exhibit to the Registration Statement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and
nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
October&nbsp;15, 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g63338snap004.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be
relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus under
the heading &#147;Legal Matters.&#148; We further consent to the incorporation by reference of this letter and consent into any registration statement filed pursuant to Rule 462(b) with respect to the Shares. In giving such consent, we do not
thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Latham&nbsp;&amp; Watkins LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>7
<FILENAME>d63338dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHATHOM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019 INCENTIVE AWARD PLAN </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan&#146;s purpose is to enhance the Company&#146;s ability to attract, retain and motivate persons who make (or
are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article&nbsp;XI. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATION AND DELEGATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.1 <U>Administration</U>. The Plan is administered by the Administrator. The Administrator has authority to determine which
Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under the Plan, to
interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies
in the Plan or any Award as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator&#146;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming
any interest in the Plan or any Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.2 <U>Appointment of Committees</U>. To the extent Applicable Laws permit, the
Board may delegate any or all of its powers under the Plan to one or more Committees or officers of the Company or any of its Subsidiaries. The Board may abolish any Committee or <FONT STYLE="white-space:nowrap">re-vest</FONT> in itself any
previously delegated authority at any time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK AVAILABLE FOR AWARDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.1 <U>Number of Shares</U>. Subject to adjustment under Article&nbsp;VIII and the terms of this Article IV, Awards may be
made under the Plan covering up to the Overall Share Limit. As of the Plan&#146;s effective date under Section&nbsp;10.3, the Company will cease granting awards under the Prior Plan; however, Prior Plan Awards will remain subject to the terms of the
applicable Prior Plan. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.2 <U>Share Recycling</U>. If all or any part of an Award or Prior Plan Award expires, lapses or is terminated, exchanged for
cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award or </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Prior Plan Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award or
Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. Further, Shares delivered (either by actual delivery or attestation) to the Company by a
Participant to satisfy the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation (including Shares retained by the Company from the Award or Prior Plan Award being exercised
or purchased and/or creating the tax obligation) will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards or Prior Plan Awards shall not
count against the Overall Share Limit.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.3 <U>Incentive Stock Option Limitations</U>.
Notwithstanding anything to the contrary herein, no more than 40,000,000&nbsp;Shares may be issued pursuant to the exercise of Incentive Stock Options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.4 <U>Substitute Awards</U>. In connection with an entity&#146;s merger or consolidation with the Company or the
Company&#146;s acquisition of an entity&#146;s property or stock, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted before such merger or consolidation by such entity or its affiliate.
Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Overall Share Limit (nor shall Shares subject to a Substitute
Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of Shares that may be issued pursuant to the
exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a
<FONT STYLE="white-space:nowrap">pre-existing</FONT> plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such
<FONT STYLE="white-space:nowrap">pre-existing</FONT> plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration
payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not
be added to the Shares available for Awards under the Plan as provided above); provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the <FONT
STYLE="white-space:nowrap">pre-existing</FONT> plan, absent the acquisition or combination, and shall only be made to individuals who were not Employees or Directors prior to such acquisition or combination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.5 <U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation</U>. Notwithstanding any provision to the
contrary in the Plan, the Administrator may establish compensation for <FONT STYLE="white-space:nowrap">non-employee</FONT> Directors from time to time, subject to the limitations in the Plan. The Administrator will from time to time determine the
terms, conditions and amounts of all such <FONT STYLE="white-space:nowrap">non-employee</FONT> Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and
considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting
Standards Codification Topic 718, or any successor thereto) of Awards granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director during
any fiscal year of the Company may not exceed $750,000 increased to $1,000,000 in the fiscal year of a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director&#146;s initial service as a <FONT STYLE="white-space:nowrap">non-employee</FONT>
Director. The Administrator may make exceptions to this limit for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> Directors in extraordinary circumstances, as the Administrator may determine in its discretion, provided that the <FONT
STYLE="white-space:nowrap">non-employee</FONT> Director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving
<FONT STYLE="white-space:nowrap">non-employee</FONT> Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTIONS AND STOCK APPRECIATION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.1 <U>General</U>. The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to the
limitations in the Plan, including any limitations in the Plan that apply to Incentive Stock Options. The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the exercise price of each Option and
Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation
Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price
per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair
Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.2
<U>Exercise Price</U>. The Administrator will establish each Option&#146;s and Stock Appreciation Right&#146;s exercise price and specify the exercise price in the Award Agreement. The exercise price will not be less than 100% of the Fair Market
Value on the grant date of the Option or Stock Appreciation Right. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.3 <U>Duration</U>. Each Option or Stock Appreciation
Right will be exercisable at such times and as specified in the Award Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten years. Notwithstanding the foregoing and unless determined otherwise by the Company,
in the event that on the last business day of the term of an Option or Stock Appreciation Right (other than an Incentive Stock Option)&nbsp;(i) the exercise of the Option or Stock Appreciation Right is prohibited by Applicable Law, as determined by
the Company, or (ii)&nbsp;Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including blackout periods) or a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement undertaken
in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be extended until the date that is thirty (30)&nbsp;days after the end of the legal prohibition,
<FONT STYLE="white-space:nowrap">black-out</FONT> period or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, as determined by the Company; provided, however, in no event shall the extension last beyond the ten year term of the applicable
Option or Stock Appreciation Right. Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT
STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company
or any of its Subsidiaries, the right of the Participant and the Participant&#146;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company
otherwise determines. In addition, if, prior to the end of the term of an Option or Stock Appreciation Right, the Participant is given notice by the Company or any of its Subsidiaries of the Participant&#146;s Termination of Service by the Company
or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the date of the delivery of such notice, the right of the Participant and the Participant&#146;s transferees to exercise any Option or Stock
Appreciation Right issued to the Participant shall be suspended from the time of the delivery of such notice until the earlier of (i)&nbsp;such time as it is determined or otherwise agreed that the Participant&#146;s service as a Service Provider
will not be terminated for Cause as provided in such notice or (ii)&nbsp;the effective date of the Participant&#146;s Termination of Service by the Company or any of its Subsidiaries for Cause (in which case the right of the Participant and the
Participant&#146;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant will terminate immediately upon the effective date of such termination of Service). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.4 <U>Exercise</U>. Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of
exercise, in a form the Administrator approves (which may be electronic), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i)&nbsp;as specified in Section&nbsp;5.5 for the number of
Shares for which the Award is exercised and (ii)&nbsp;as specified in Section&nbsp;9.5 for any applicable taxes. Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.5 <U>Payment Upon Exercise</U>. Subject to Section&nbsp;10.8, any Company insider trading policy (including blackout
periods) and Applicable Laws, the exercise price of an Option must be paid by: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) cash, wire transfer of immediately
available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A)&nbsp;delivery
(including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price,
or (B)&nbsp;the Participant&#146;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price;
provided that such amount is paid to the Company at such time as may be required by the Administrator; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) to the extent
permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#146;s exercise valued at
their Fair Market Value on the exercise date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) to the extent permitted by the Administrator, delivery of a promissory
note or any other property that the Administrator determines is good and valuable consideration; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) to the extent
permitted by the Company, any combination of the above payment forms approved by the Administrator. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK; RESTRICTED STOCK UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.1 <U>General</U>. The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service
Provider, subject to the Company&#146;s right to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such shares) if conditions the Administrator specifies in
the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant to Service Providers Restricted Stock Units, which may
be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement. The Administrator will determine and set forth in the Award Agreement the terms and conditions for each
Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.2
<U>Restricted Stock</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Dividends</U>. Participants holding shares of Restricted Stock will be entitled to all
ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be
subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Stock Certificates</U>. The Company may require that the Participant deposit in escrow with the Company (or its
designee) any stock certificates issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.3 <U>Restricted Stock Units.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Settlement</U>. The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as
reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#146;s election, in a manner intended to comply with Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Stockholder Rights</U>. A Participant will have no rights of a stockholder with respect to Shares subject to any
Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)
<U>Dividend Equivalents</U>. If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the
Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as
set forth in the Award Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER STOCK OR CASH BASED AWARDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to
be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or
Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock or Cash Based Awards may be paid in
Shares, cash or other property, as the Administrator determines. Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal
(which may be based on the Performance Criteria), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADJUSTMENTS FOR CHANGES IN COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND CERTAIN OTHER EVENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.1 <U>Equity Restructuring</U><U>(a)</U>. In connection with any Equity Restructuring, notwithstanding anything to the
contrary in this Article&nbsp;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding
Award and/or the Award&#146;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments provided under this Section&nbsp;8.1 will be nondiscretionary and final and
binding on the affected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.2 <U>Corporate Transactions</U>. In the event of any dividend or other distribution (whether in the form of cash, Common
Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of
the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate
transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems
appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of
time after such change) and either automatically or upon the Participant&#146;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to
(x)&nbsp;prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y)&nbsp;to facilitate such transaction or
event or (z)&nbsp;give effect to such changes in Applicable Laws or accounting principles: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) To provide for the
cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the
Participant&#146;s rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#146;s
rights, in any case, is equal to or less than zero, then the Award may be terminated without payment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) To provide that
such Award shall vest and, to the extent applicable, be exercisable as to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall
be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and/or applicable exercise or purchase price, in all cases,
as determined by the Administrator; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) To make adjustments in the number and type of shares of Common Stock (or other
securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&nbsp;IV hereof on the maximum number and kind of shares
which may be issued) and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) To replace such Award with other rights or property selected by the Administrator; and/or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.3 <U>Effect of <FONT STYLE="white-space:nowrap">Non-Assumption</FONT> in a Change in Control</U>. Notwithstanding the
provisions of Section&nbsp;8.2, if a Change in Control occurs and a Participant&#146;s Awards are not continued, converted, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
assumed, or replaced with a substantially similar award by (a)&nbsp;the Company, or (b)&nbsp;a successor entity or its parent or subsidiary (an &#147;<B><I>Assumption</I></B>&#148;), and provided
that the Participant has not had a Termination of Service, then, immediately prior to the Change in Control, such Awards shall become fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on
such Awards shall lapse, in which case, such Awards shall be canceled upon the consummation of the Change in Control in exchange for the right to receive the Change in Control consideration payable to other holders of Common Stock (i)&nbsp;which may
be on such terms and conditions as apply generally to holders of Common Stock under the Change in Control documents (including, without limitation, any escrow, <FONT STYLE="white-space:nowrap">earn-out</FONT> or other deferred consideration
provisions) or such other terms and conditions as the Administrator may provide, and (ii)&nbsp;determined by reference to the number of shares subject to such Awards and net of any applicable exercise price; provided that to the extent that any
Awards constitute &#147;nonqualified deferred compensation&#148; that may not be paid upon the Change in Control under Section&nbsp;409A without the imposition of taxes thereon under Section&nbsp;409A, the timing of such payments shall be governed
by the applicable Award Agreement (subject to any deferred consideration provisions applicable under the Change in Control documents); and provided, further, that if the amount to which a Participant would be entitled upon the settlement or exercise
of such Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated without payment. The Administrator shall determine whether an Assumption of an Award has occurred in connection with a Change in
Control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.4 <U>Administrative Stand Still</U>. In the event of any pending stock dividend, stock split, combination or
exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including
any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty days before or after such transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.5 <U>General</U>. Except as expressly provided in the Plan or the Administrator&#146;s action under the Plan, no Participant
will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other
corporation. Except as expressly provided with respect to an Equity Restructuring under Section&nbsp;8.1 or the Administrator&#146;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of
any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#146;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect
or restrict in any way the Company&#146;s right or power to make or authorize (i)&nbsp;any adjustment, recapitalization, reorganization or other change in the Company&#146;s capital structure or its business, (ii)&nbsp;any merger, consolidation
dissolution or liquidation of the Company or sale of Company assets or (iii)&nbsp;any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. The
Administrator may treat Participants and Awards (or portions thereof) differently under this Article&nbsp;VIII. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS APPLICABLE TO AWARDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.1 <U>Transferability</U>. Except as the Administrator may determine or provide in an Award Agreement or otherwise for Awards
other than Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution, or, subject to the
Administrator&#146;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, will include references
to a Participant&#146;s authorized transferee that the Administrator specifically approves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.2 <U>Documentation</U>. Each Award will be evidenced in an Award
Agreement, which may be written or electronic, as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.3 <U>Discretion</U>. Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any
other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.4 <U>Termination of Status</U>. The Administrator will determine how the disability, death, retirement, authorized leave of
absence or any other change or purported change in a Participant&#146;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#146;s legal representative, conservator,
guardian or Designated Beneficiary may exercise rights under the Award, if applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.5 <U>Withholding</U>. Each
Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#146;s Awards by the date of the event creating the tax liability. The
Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any
payment of any kind otherwise due to a Participant. In the absence of a contrary determination by the Company (or, with respect to withholding pursuant to clause (ii)&nbsp;below with respect to Awards held by individuals subject to Section&nbsp;16
of the Exchange Act, a contrary determination by the Administrator), all tax withholding obligations will be calculated based on the minimum applicable statutory withholding rates. Subject to Section&nbsp;10.8 and any Company insider trading policy
(including blackout periods), Participants may satisfy such tax obligations (i)&nbsp;in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the
foregoing payment forms if one or more of the payment forms below is permitted, (ii)&nbsp;to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares delivered by attestation and Shares retained from the
Award creating the tax obligation, valued at their Fair Market Value on the date of delivery, (iii)&nbsp;if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A)&nbsp;delivery
(including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax
obligations, or (B)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax
withholding; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv)&nbsp;to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator.
Notwithstanding any other provision of the Plan, the number of Shares which may be so delivered or retained pursuant to clause (ii)&nbsp;of the immediately preceding sentence shall be limited to the number of Shares which have a Fair Market Value on
the date of delivery or retention no greater than the aggregate amount of such liabilities based on the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to
avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America)); provided, however, to the extent such Shares were acquired by Participant from the Company as compensation,
the Shares must have been held for the minimum period required by applicable accounting rules to avoid a charge to the Company&#146;s earnings for financial reporting purposes; provided, further, that, any such Shares delivered or retained shall be
rounded up to the nearest whole Share to the extent rounding up to the nearest whole Share does not result in the liability classification of the applicable Award under generally accepted accounting principles in the United States of America. If any
tax withholding obligation will be satisfied under clause (ii)&nbsp;above by the Company&#146;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#146;s behalf some or all
of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#146;s acceptance of an Award under the Plan will constitute the Participant&#146;s authorization to the Company and instruction and
authorization to such brokerage firm to complete the transactions described in this sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.6 <U>Amendment of Award;
Repricing</U>. The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. The Participant&#146;s consent to such action will be required unless (i)&nbsp;the action, taking into account any related action, does not materially and adversely affect the
Participant&#146;s rights under the Award, or (ii)&nbsp;the change is permitted under Article&nbsp;VIII or pursuant to Section&nbsp;10.6. Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may, without the
approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock
Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.7 <U>Conditions on Delivery of Stock</U>. The Company will not be obligated to deliver any Shares under the Plan or remove
restrictions from Shares previously delivered under the Plan until (i)&nbsp;all Award conditions have been met or removed to the Company&#146;s satisfaction, (ii)&nbsp;as determined by the Company, all other legal matters regarding the issuance and
delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed and delivered to the Company such representations or
agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#146;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the
lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.8 <U>Acceleration</U>. The Administrator may at any time provide that any Award will become immediately vested and fully or
partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.9
<U>Additional Terms of Incentive Stock Options</U>. The Administrator may grant Incentive Stock Options only to employees of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections&nbsp;424(e) or
(f)&nbsp;of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not
be less than 110% of the Fair Market Value on the Option&#146;s grant date, and the term of the Option will not exceed five years. All Incentive Stock Options will be subject to and construed consistently with Section&nbsp;422 of the Code. By
accepting an Incentive Stock Option, the Participant agrees to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i)&nbsp;two
years from the grant date of the Option or (ii)&nbsp;one year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption
of indebtedness or other consideration, in such disposition or other transfer. Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an
&#147;incentive stock option&#148; under Section&nbsp;422 of the Code. Any Incentive Stock Option or portion thereof that fails to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code for any reason, including becoming
exercisable with respect to Shares having a fair market value exceeding the $100,000 limitation under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.422-4,</FONT> will be a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT>
Stock Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.1 <U>No Right to Employment or Other Status</U>. No person will have any claim or right to be granted an Award, and the
grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship
with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.2 <U>No Rights as Stockholder; Certificates</U>. Subject to the Award Agreement, no Participant or Designated Beneficiary
will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or
Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its
transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.3 <U>Effective Date and Term of Plan</U>. Unless earlier terminated by the Board, the Plan will become effective on the day
prior to the Public Trading Date and will remain in effect until the tenth anniversary of the earlier of (i)&nbsp;the date the Board adopted the Plan or (ii)&nbsp;the date the Company&#146;s stockholders approved the Plan, but Awards previously
granted may extend beyond that date in accordance with the Plan. If the Plan is not approved by the Company&#146;s stockholders, the Plan will not become effective, no Awards will be granted under the Plan and the Prior Plan will continue in full
force and effect in accordance with its terms. The Plan will be submitted for the approval of the Company&#146;s stockholders within twelve (12)&nbsp;months after the date of the Board&#146;s adoption of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.4 <U>Amendment of Plan</U>. The Administrator may amend, suspend or terminate the Plan at any time; provided that no
amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#146;s consent. No Awards may be granted under the Plan during any
suspension period or after the Plan&#146;s termination. Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The
Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.5
<U>Provisions for Foreign Participants</U>. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in
laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.6 <U>Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>General</U>. The Company intends that all Awards be structured to comply with, or be exempt from, Section&nbsp;409A,
such that no adverse tax consequences, interest, or penalties under Section&nbsp;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#146;s consent, amend this Plan or
Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions
intended to (A)&nbsp;exempt this Plan or any Award from Section&nbsp;409A, or (B)&nbsp;comply with Section&nbsp;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
after an Award&#146;s grant date. The Company makes no representations or warranties as to an Award&#146;s tax treatment under Section&nbsp;409A or otherwise. The Company will have no obligation
under this Section&nbsp;10.6 or otherwise to avoid the taxes, penalties or interest under Section&nbsp;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits
under the Plan are determined to constitute noncompliant &#147;nonqualified deferred compensation&#148; subject to taxes, penalties or interest under Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Separation from Service</U>. If an Award constitutes &#147;nonqualified deferred compensation&#148; under
Section&nbsp;409A, any payment or settlement of such Award upon a termination of a Participant&#146;s Service Provider relationship will, to the extent necessary to avoid taxes under Section&nbsp;409A, be made only upon the Participant&#146;s
&#147;separation from service&#148; (within the meaning of Section&nbsp;409A), whether such &#147;separation from service&#148; occurs upon or after the termination of the Participant&#146;s Service Provider relationship. For purposes of this Plan
or any Award Agreement relating to any such payments or benefits, references to a &#147;termination,&#148; &#147;termination of employment&#148; or like terms means a &#147;separation from service.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Payments to Specified Employees</U>. Notwithstanding any contrary provision in the Plan or any Award Agreement, any
payment(s) of &#147;nonqualified deferred compensation&#148; required to be made under an Award to a &#147;specified employee&#148; (as defined under Section&nbsp;409A and as the Administrator determines) due to his or her &#147;separation from
service&#148; will, to the extent necessary to avoid taxes under Section&nbsp;409A(a)(2)(B)(i) of the Code, be delayed for the <FONT STYLE="white-space:nowrap">six-month</FONT> period immediately following such &#147;separation from service&#148;
(or, if earlier, until the specified employee&#146;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such <FONT STYLE="white-space:nowrap">six-month</FONT> period or as soon as administratively
practicable thereafter (without interest). Any payments of &#147;nonqualified deferred compensation&#148; under such Award payable more than six months following the Participant&#146;s &#147;separation from service&#148; will be paid at the time or
times the payments are otherwise scheduled to be made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.7 <U>Limitations on Liability</U>. Notwithstanding any other
provisions of the Plan, no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss,
liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator,
director, officer, other employee or agent of the Company or any Subsidiary. The Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated
any duty or power relating to the Plan&#146;s administration or interpretation, against any cost or expense (including attorneys&#146; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#146;s approval)
arising from any act or omission concerning this Plan unless arising from such person&#146;s own fraud or bad faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.8
<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>. The Company may, at the request of any underwriter representative or otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit
Participants from, directly or indirectly, selling or otherwise transferring any Shares or other Company securities during a period of up to one hundred eighty days following the effective date of a Company registration statement filed under the
Securities Act, or such longer period as determined by the underwriter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.9 <U>Data Privacy</U>. As a condition for
receiving any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates
exclusively for implementing, administering and managing the Participant&#146;s participation in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Participant&#146;s name, address and telephone number; birthdate; social security, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the
Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the &#147;<B><I>Data</I></B>&#148;). The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as
necessary to implement, administer and manage a Participant&#146;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration
and management. These recipients may be located in the Participant&#146;s country, or elsewhere, and the Participant&#146;s country may have different data privacy laws and protections than the recipients&#146; country. By accepting an Award, each
Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and manage the Participant&#146;s participation in the Plan, including any required Data transfer to
a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#146;s
participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any
necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section&nbsp;10.9 in writing, without cost, by contacting the local human resources representative. The Company may cancel Participant&#146;s
ability to participate in the Plan and, in the Administrator&#146;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the consents in this Section&nbsp;10.9. For more information on the
consequences of refusing or withdrawing consent, Participants may contact their local human resources representative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.10 <U>Severability</U>. If any portion of the Plan or any action taken under it is held illegal or invalid for any reason,
the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.11 <U>Governing Documents</U>. If any contradiction occurs between the Plan and any Award Agreement or other written
agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan
will not apply. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.12 <U>Governing Law</U>. The Plan and all Awards will be governed by and interpreted in accordance with
the laws of the State of Delaware, disregarding any state&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles requiring the application of a jurisdiction&#146;s laws other than the State of
Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.13 <U>Claw-back Provisions</U>. All Awards (including, without limitation, any proceeds, gains or other
economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or resale of any shares of Common Stock underlying the Award) shall be subject to the provisions of any claw-back
policy implemented by the Company, including, without limitation, any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated
thereunder) as and to the extent set forth in such claw-back policy or the Award Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.14 <U>Titles and
Headings</U>. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#146;s text, rather than such titles or headings, will control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.15 <U>Conformity to Securities Laws</U>. Participant acknowledges that the Plan is intended to conform to the extent
necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.16 <U>Relationship to Other Benefits</U>. No payment under the Plan will be taken into account in determining any benefits
under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.17 <U>Broker-Assisted Sales</U>. In the event of a broker-assisted sale of Shares in connection with the payment of amounts
owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&nbsp;9.5: (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first
becomes due, or as soon thereafter as practicable; (b)&nbsp;such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price; (c)&nbsp;the applicable Participant will be
responsible for all broker&#146;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d)&nbsp;to the
extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (e)&nbsp;the Company and its designees are under
no obligation to arrange for such sale at any particular price; and (f)&nbsp;in the event the proceeds of such sale are insufficient to satisfy the Participant&#146;s applicable obligation, the Participant may be required to pay immediately upon
demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#146;s obligation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As used in the Plan, the following words and phrases will have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.1 &#147;<B><I>Administrator</I></B>&#148; means the Board or a Committee to the extent that the Board&#146;s powers or
authority under the Plan have been delegated to such Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.2 &#147;<B><I>Applicable Laws</I></B>&#148; means the
requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common
Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.3 &#147;<B><I>Award</I></B>&#148; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation
Rights, Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.4 &#147;<B><I>Award
Agreement</I></B>&#148; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.5 &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.6 &#147;<B><I>Cause</I></B>&#148; with respect to a Participant, means &#147;Cause&#148; (or any term of similar effect) as
defined in such Participant&#146;s employment agreement with the Company if such an agreement exists and contains a definition of Cause (or term of similar effect), or, if no such agreement exists or such agreement does not contain a definition of
Cause (or term of similar effect), then Cause shall include, but not be limited to: (i)&nbsp;the Participant&#146;s unauthorized use or disclosure of confidential information or trade secrets of the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Company or any material breach of a written agreement between the Participant and the Company, including without limitation a material breach of any employment, confidentiality, <FONT
STYLE="white-space:nowrap">non-compete,</FONT> <FONT STYLE="white-space:nowrap">non-solicit</FONT> or similar agreement; (ii)&nbsp;the Participant&#146;s commission of, indictment for or the entry of a plea of guilty or <I>nolo contendere</I> by the
Participant to, a felony under the laws of the United States or any state thereof or any crime involving dishonesty or moral turpitude (or any similar crime in any jurisdiction outside the United States); (iii) the Participant&#146;s gross
negligence or willful misconduct or the Participant&#146;s willful or repeated failure or refusal to substantially perform assigned duties; (iv)&nbsp;any act of fraud, embezzlement, material misappropriation or dishonesty committed by the
Participant against the Company; or (v)&nbsp;any acts, omissions or statements by a Participant which the Company reasonably determines to be materially detrimental or damaging to the reputation, operations, prospects or business relations of the
Company.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.7 &#147;<B><I>Change in Control</I></B>&#148; means and
includes each of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) A transaction or series of transactions (other than an offering of Common Stock to the
general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i)&nbsp;and (ii) of subsection&nbsp;(c) below) whereby any
&#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections&nbsp;13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the
Company or any of its Subsidiaries or a &#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within
the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#146;s securities outstanding immediately after such
acquisition; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) During any period of two consecutive years, individuals who, at the beginning of such period,
constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a)&nbsp;or (c)) whose election by the
Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the Directors then still in office who either were Directors at the beginning of the <FONT
STYLE="white-space:nowrap">two-year</FONT> period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or
more intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related
transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)
which results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result
of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the
&#147;<B><I>Successor Entity</I></B>&#148;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power
of the Successor Entity; <U>provided</U>, <U>however</U>, that no person or group shall be treated for purposes of this clause (ii)&nbsp;as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of
the voting power held in the Company prior to the consummation of the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, if a Change in Control constitutes a payment
event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section&nbsp;409A, to the extent required to avoid the imposition of additional taxes under Section&nbsp;409A, the
transaction or event described in subsection&nbsp;(a), (b) or (c)&nbsp;with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a
&#147;change in control event,&#148; as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively
whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination
of whether a Change in Control is a &#147;change in control event&#148; as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> shall be consistent with such regulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.8 &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.9 &#147;<B><I>Committee</I></B>&#148; means one or more committees or subcommittees of the Board, which may include one
or more Company directors or executive officers, to the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> it is intended that each member of the Committee will
be, at the time the Committee takes any action with respect to an Award that is subject to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; within the meaning of Rule <FONT
STYLE="white-space:nowrap">16b-3;</FONT> however, a Committee member&#146;s failure to qualify as a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.10
&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.11 &#147;<B><I>Company</I></B>&#148;
means Phathom Pharmaceuticals, Inc., a Delaware corporation, or any successor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.12 &#147;<B><I>Consultant</I></B>&#148;
means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant or adviser: (a)&nbsp;renders bona fide services to the Company; (b)&nbsp;renders services not in
connection with the offer or sale of securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&#146;s securities; and (c)&nbsp;is a natural person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.13 &#147;<B><I>Designated Beneficiary</I></B>&#148; means the beneficiary or beneficiaries the Participant designates, in a
manner the Administrator determines, to receive amounts due or exercise the Participant&#146;s rights if the Participant dies or becomes incapacitated. Without a Participant&#146;s effective designation, &#147;Designated Beneficiary&#148; will mean
the Participant&#146;s estate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.14 &#147;<B><I>Director</I></B>&#148; means a Board member. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.15 &#147;<B><I>Disability</I></B>&#148; means a permanent and total disability under Section&nbsp;22(e)(3) of the Code, as
amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.16 &#147;<B><I>Dividend Equivalents</I></B>&#148; means a right granted to a Participant under the Plan to
receive the equivalent value (in cash or Shares) of dividends paid on Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.17 &#147;<B><I>Employee</I></B>&#148;
means any employee of the Company or its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.18 &#147;<B><I>Equity Restructuring</I></B>&#148; means, as determined by
the Administrator, a <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transaction between the Company and its stockholders, such as a stock dividend, stock split, <FONT STYLE="white-space:nowrap">spin-off</FONT> or recapitalization through a
large, nonrecurring cash dividend, that affects the number or kind of shares of Common Stock (or other securities of the Company) or the share price of Common Stock (or other securities of the Company) and causes a change in the per share value of
the Common Stock underlying outstanding Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.19 &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange
Act of 1934, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.20 &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a share of
Common Stock determined as follows: (a)&nbsp;if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale
occurred on such date, the last day preceding such date during which a sale occurred, as reported in <I>The Wall Street Journal</I> or another source the Administrator deems reliable; (b)&nbsp;if the Common Stock is not traded on a stock exchange
but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in <I>The Wall Street
Journal </I>or another source the Administrator deems reliable; or (c)&nbsp;without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion. Notwithstanding the foregoing, with respect to
any Award granted on the pricing date of the Company&#146;s initial public offering, the Fair Market Value shall mean the initial public offering price of a Share as set forth in the Company&#146;s final prospectus relating to its initial public
offering filed with the Securities and Exchange Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.21 &#147;<B><I>Good Reason</I></B>&#148; means (a)&nbsp;if
a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#147;good reason&#148; is defined, &#147;Good Reason&#148; as defined in such agreement,
and (b)&nbsp;if no such agreement exists, (i)&nbsp;a change in the Participant&#146;s position with the Company (or its Subsidiary employing the Participant) that materially reduces the Participant&#146;s authority, duties or responsibilities or the
level of management to which he or she reports, (ii)&nbsp;a material diminution in the Participant&#146;s level of compensation (including base salary, fringe benefits and target bonuses under any corporate performance-based incentive programs) or
(iii)&nbsp;a relocation of the Participant&#146;s place of employment by more than 50 miles, provided that such change, reduction or relocation is effected by the Company (or its Subsidiary employing the Participant) without the Participant&#146;s
consent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.22 &#147;<B><I>Greater Than 10% Stockholder</I></B>&#148; means an individual then owning (within the meaning
of Section&nbsp;424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary corporation, as defined in Section&nbsp;424(e) and (f)&nbsp;of the Code, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.23 &#147;<B><I>Incentive Stock Option</I></B>&#148; means an Option intended to qualify as an &#147;incentive stock
option&#148; as defined in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.24
&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</I></B>&#148; means an Option not intended or not qualifying as an Incentive Stock Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.25 &#147;<B><I>Option</I></B>&#148; means an option to purchase Shares, which will either be an Incentive Stock option or a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.26 &#147;<B><I>Other Stock or Cash Based
Awards</I></B>&#148; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property awarded to a Participant under Article&nbsp;VII. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.27 &#147;<B><I>Overall Share Limit</I></B>&#148; means the sum of (a)
2,700,000&nbsp;Shares; (b)&nbsp;any shares of Common Stock which are subject to Prior Plan Awards which become available for issuance under the Plan pursuant to Article IV (which number added to the Overall Share Limit pursuant to clause
(b)&nbsp;shall not exceed 1,416,788&nbsp;shares of Common Stock); and (c)&nbsp;an annual increase on the first day of each calendar year beginning January&nbsp;1, 2020 and ending on and including January&nbsp;1, 2029, equal to the lesser of
(i)&nbsp;5% of the aggregate number of shares of Common Stock outstanding on the final day of the immediately preceding calendar year and (ii)&nbsp;such smaller number of Shares as is determined by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.28 &#147;<B><I>Participant</I></B>&#148; means a Service Provider who has been granted an Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.29 &#147;<B><I>Performance Criteria</I></B>&#148; mean the criteria (and adjustments) that the Administrator may select for
an Award to establish performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and
<FONT STYLE="white-space:nowrap">non-cash</FONT> equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to
gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus);
cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales;
costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends);
regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added
models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters;
strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand;
acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the
Company&#146;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the
indicators of performance relative to performance of other companies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.30 &#147;<B><I>Plan</I></B>&#148; means this 2019
Incentive Award Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.31 &#147;<B><I>Prior Plan</I></B>&#148; means the Phathom Pharmaceuticals, Inc. 2019 Equity
Incentive Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.32 &#147;<B><I>Prior Plan Award</I></B>&#148; means an award outstanding under the Prior Plan as of the
Plan&#146;s effective date under Section&nbsp;10.3. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.33 &#147;<B><I>Public Trading Date</I></B>&#148; means the first
date upon which the Common Stock is listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation
system, or, if earlier, the date on which the Company becomes a &#147;publicly held corporation&#148; for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.162-27(c)(1).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.34 &#147;<B><I>Restricted Stock</I></B>&#148; means Shares awarded to a Participant under Article&nbsp;VI subject to certain
vesting conditions and other restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.35 &#147;<B><I>Restricted Stock Unit</I></B>&#148; means an unfunded,
unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date awarded to a Participant under Article&nbsp;VI
subject to certain vesting conditions and other restrictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.36 &#147;<B><I>Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.37 &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148; means Section&nbsp;409A of the Code and all
regulations, guidance, compliance programs and other interpretative authority thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.38 &#147;<B><I>Securities
Act</I></B>&#148; means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.39 &#147;<B><I>Service Provider</I></B>&#148; means an
Employee, Consultant or Director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.40 &#147;<B><I>Shares</I></B>&#148; means shares of Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.41 &#147;<B><I>Stock Appreciation Right</I></B>&#148; means a stock appreciation right granted under Article&nbsp;V. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.42 &#147;<B><I>Subsidiary</I></B>&#148; means any entity (other than the Company), whether domestic or foreign, in an
unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total
combined voting power of all classes of securities or interests in one of the other entities in such chain. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.43
&#147;<B><I>Substitute Awards</I></B>&#148; shall mean Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by
a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.44
&#147;<B><I>Termination of Service</I></B>&#148; means the date the Participant ceases to be a Service Provider. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHATHOM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019 INCENTIVE AWARD PLAN </B></P></div>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION GRANT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Capitalized terms not specifically defined in this Stock Option Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;) have
the meanings given to them in the 2019 Incentive Award Plan (as amended from time to time, the &#147;<B><I>Plan</I></B>&#148;) of Phathom Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company hereby grants to the participant listed below (&#147;<B><I>Participant</I></B>&#148;) the stock option described
in this Grant Notice (the &#147;<B><I>Option</I></B>&#148;), subject to the terms and conditions of the Plan and the Stock Option Agreement attached hereto as <B>Exhibit A</B> (the &#147;<B><I>Agreement</I></B>&#148;), both of which are incorporated
into this Grant Notice by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Participant:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Grant Date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Exercise Price per Share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Shares Subject to the Option:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Final Expiration Date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Vesting Commencement Date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Vesting Schedule:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[To be specified in individual award agreements]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Type of Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#9744; Incentive Stock Option &#9744; <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By Participant&#146;s signature below, Participant agrees to be bound by the terms of this
Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all
provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or
the Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>PHATHOM PHARMACEUTICALS, INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>PARTICIPANT</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Print&nbsp;Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Print&nbsp;Name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not
defined in the Grant Notice, in the Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.1 <U>Grant of Option</U>. The Company has granted to Participant the Option effective as of the grant date set forth in the
Grant Notice (the &#147;<B><I>Grant Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.2 <U>Incorporation of Terms of Plan</U>. The Option is
subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIII. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERIOD OF
EXERCISABILITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13.1 <U>Commencement of Exercisability</U>. The Option will vest and become exercisable according to
the vesting schedule in the Grant Notice (the &#147;<B><I>Vesting Schedule</I></B>&#148;), except that any fraction of a Share as to which the Option would be vested or exercisable will be accumulated and will vest and become exercisable only when a
whole Share has accumulated. The Option shall not be exercisable with respect to fractional Shares. Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, unless the Administrator otherwise determines, the Option
will immediately expire and be forfeited as to any portion that is not vested and exercisable as of Participant&#146;s Termination of Service for any reason. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13.2 <U>Duration of Exercisability</U>. The Vesting Schedule is cumulative. Any portion of the Option which vests and becomes
exercisable will remain vested and exercisable until the Option expires. The Option will be forfeited immediately upon its expiration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13.3 <U>Expiration of Option</U>. Subject to Section&nbsp;5.3 of the Plan, the Option may not be exercised to any extent by
anyone after, and will expire on, the first of the following to occur: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The final expiration date in the Grant Notice;
which shall in no event be more than ten (10)&nbsp;years from the Grant Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) If this Option is designated as an
Incentive Stock Option and the Participant, at the time the Option was granted, was a Greater Than 10% Stockholder, the expiration of five (5)&nbsp;years from the Grant Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Except as the Administrator may otherwise approve, the expiration of three (3)&nbsp;months from the date of
Participant&#146;s Termination of Service, unless Participant&#146;s Termination of Service is for Cause or by reason of Participant&#146;s death or Disability; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Except as the Administrator may otherwise approve, the expiration of one (1)&nbsp;year from the date of Participant&#146;s
Termination of Service by reason of Participant&#146;s death or Disability; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) Except as the Administrator may
otherwise approve, the date of Participant&#146;s Termination of Service for Cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE OF OPTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14.1 <U>Person Eligible to Exercise</U>. During Participant&#146;s lifetime, only Participant may exercise the Option, unless
it has been disposed of, with the consent of the Administrator, pursuant to a domestic relations order. After Participant&#146;s death, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under
Section&nbsp;2.3 hereof, be exercised by the Participant&#146;s Designated Beneficiary or by any person empowered to do so under the deceased Participant&#146;s will or under the then applicable laws of descent and distribution. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14.2 <U>Partial Exercise</U>. Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be
exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14.3 <U>Tax Withholding</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Company has the right and option, but not the obligation, to treat Participant&#146;s failure to provide timely payment
in accordance with the Plan of any withholding tax arising in connection with the Option as Participant&#146;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Option.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with
the Option, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Option. Neither the Company nor any Subsidiary makes any representation or undertaking
regarding the treatment of any tax withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the Option to
reduce or eliminate Participant&#146;s tax liability. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.1 <U>Adjustments</U>. Participant acknowledges that the Option is subject to adjustment, modification and termination in
certain events as provided in this Agreement and the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.2 <U>Notices</U>. Any notice to be given under the terms of
this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#146;s Secretary at the Company&#146;s principal office or the Secretary&#146;s then-current email address or facsimile number. Any notice to be
given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#146;s last known mailing address, email
address or facsimile number in the Company&#146;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually
received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally
recognized express shipping company or upon receipt of a facsimile transmission confirmation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.3 <U>Titles</U>. Titles
are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.4 <U>Conformity to Securities Laws</U>. The Participant acknowledges that
the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended to the extent necessary to conform to such Applicable Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.5 <U>Successors and Assigns</U>. The Company may assign any of its rights under this Agreement to single or multiple
assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in the Plan, this Agreement shall be binding upon and inure to the benefit of the heirs,
legatees, legal representatives, successors and assigns of the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.6 <U>Limitations Applicable to
Section</U><U></U><U>&nbsp;16 Persons</U>. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&nbsp;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject
to any additional limitations set forth in any applicable exemptive rule under Section&nbsp;16 of the Exchange Act (including any amendment to <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3)</FONT> that are requirements for the application of such
exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.7 <U>Entire Agreement</U>. The Plan, the Grant Notice and this Agreement constitute the entire agreement of the parties and
supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.8 <U>Agreement Severable</U>. In the event that any provision of the Grant Notice or this Agreement is held illegal or
invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.9 <U>Limitation on Participant&#146;s Rights</U>. Participation in the Plan confers no rights or interests other than as
herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets.
Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a general
unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.10 <U>Not a Contract
of Employment</U>. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company
and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written
agreement between the Company or a Subsidiary and Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.11 <U>Counterparts</U>. The Grant Notice may be executed
in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.12 <U>Incentive Stock Options</U>. If the Option is designated as an Incentive Stock Option: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Participant acknowledges that to the extent the aggregate fair market value of shares (determined as of the time the option
with respect to the shares is granted) with respect to which stock options intended to qualify as &#147;incentive stock options&#148; under Section&nbsp;422 of the Code, including the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Option, are exercisable for the first time by Participant during any calendar year exceeds $100,000 or if for any other reason such stock options do not qualify or cease to qualify for treatment
as &#147;incentive stock options&#148; under Section&nbsp;422 of the Code, such stock options (including the Option) will be treated as <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options. Participant further acknowledges that the
rule set forth in the preceding sentence will be applied by taking the Option and other stock options into account in the order in which they were granted, as determined under Section&nbsp;422(d) of the Code. Participant acknowledges that amendments
or modifications made to the Option pursuant to the Plan that would cause the Option to become a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option will not materially or adversely affect Participant&#146;s rights under the Option,
and that any such amendment or modification shall not require Participant&#146;s consent. Participant also acknowledges that if the Option is exercised more than three (3)&nbsp;months after Participant&#146;s Termination of Service as an Employee,
other than by reason of death or disability, the Option will be taxed as a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Participant will give prompt written notice to the Company of any disposition or other transfer of any Shares acquired
under this Agreement if such disposition or other transfer is made (a)&nbsp;within two (2)&nbsp;years from the Grant Date or (b)&nbsp;within one (1)&nbsp;year after the transfer of such Shares to Participant. Such notice will specify the date of
such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>8
<FILENAME>d63338dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHATHOM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019 EMPLOYEE STOCK PURCHASE PLAN </B></P></div>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The purposes of this Phathom Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan (as it may be amended or
restated from time to time, the &#147;<B><I>Plan</I></B>&#148;) are to assist Eligible Employees of Phathom Pharmaceuticals, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and its Designated Subsidiaries in acquiring a stock
ownership interest in the Company pursuant to a plan which is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423(b) of the Code, and to help Eligible Employees provide for their future security
and to encourage them to remain in the employment of the Company and its Designated Subsidiaries. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS AND CONSTRUCTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly
indicates otherwise. The singular pronoun shall include the plural where the context so indicates. Masculine, feminine and neuter pronouns are used interchangeably and each comprehends the others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.1 &#147;<B><I>Administrator</I></B>&#148; means the entity that conducts the general administration of the Plan as provided
in Article&nbsp;XI. The term &#147;Administrator&#148; shall refer to the Committee unless the Board has assumed the authority for administration of the Plan as provided in Article&nbsp;XI. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.2 &#147;<B><I>Applicable Law</I></B>&#148; means the requirements relating to the administration of equity incentive plans
under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any
foreign country or other jurisdiction where rights under this Plan are granted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.3 &#147;<B><I>Board</I></B>&#148; means
the Board of Directors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.4 &#147;<B><I>Change in Control</I></B>&#148; means and include each of the
following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) A transaction or series of transactions (other than an offering of Common Stock to the general public
through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i)&nbsp;and (ii) of subsection&nbsp;(c) below) whereby any &#147;person&#148; or
related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections&nbsp;13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its
Subsidiaries or a &#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of securities of </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Company possessing more than 50% of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together
with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a)&nbsp;or (c)) whose election by the Board or nomination for election
by the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the Directors then still in office who either were Directors at the beginning of the
<FONT STYLE="white-space:nowrap">two-year</FONT> period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or
more intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related
transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)
which results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result
of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the
&#147;<B><I>Successor Entity</I></B>&#148;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power
of the Successor Entity; <U>provided</U>, <U>however</U>, that no person or group shall be treated for purposes of this clause (ii)&nbsp;as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of
the voting power held in the Company prior to the consummation of the transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Administrator shall have full and
final authority, which shall be exercised in its sole discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of such Change in Control and any incidental matters relating thereto.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.5 &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended and the regulations issued
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.6 &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company and such other securities of
the Company that may be substituted therefor pursuant to Article&nbsp;VIII. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.7 &#147;<B><I>Company</I></B>&#148; means
Phathom Pharmaceuticals, Inc., a Delaware corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.8 &#147;<B><I>Compensation</I></B>&#148; of an Eligible Employee
means the gross base compensation received by such Eligible Employee as compensation for services to the Company or any Designated Subsidiary, including prior week adjustment and overtime payments but excluding vacation pay, holiday pay, jury duty
pay, funeral leave pay, military leave pay, commissions, incentive compensation, <FONT STYLE="white-space:nowrap">one-time</FONT> bonuses (e.g., retention or sign on bonuses), education or tuition reimbursements, travel expenses, business and moving
reimbursements, income received in connection with any stock options, stock appreciation rights, restricted stock, restricted stock units or other compensatory equity awards, fringe benefits, other special payments
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and all contributions made by the Company or any Designated Subsidiary for the Employee&#146;s benefit under any employee benefit plan now or hereafter established. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.9 &#147;<B><I>Designated Subsidiary</I></B>&#148; means any Subsidiary designated by the Administrator in accordance with
Section&nbsp;11.3(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.10 &#147;<B><I>Director</I></B>&#148; means a Board member. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.11 &#147;<B><I>Effectiv</I></B>e <B><I>Date</I></B>&#148; means the day prior to the Public Trading Date, provided that the
Board has adopted the Plan prior to or on such date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.12 &#147;<B><I>Eligible Employee</I></B>&#148; means an Employee
who does not, immediately after any rights under this Plan are granted, own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of Common Stock and other stock of the Company, a
Parent or a Subsidiary (as determined under Section&nbsp;423(b)(3) of the Code). For purposes of the foregoing sentence, the rules of Section&nbsp;424(d) of the Code with regard to the attribution of stock ownership shall apply in determining the
stock ownership of an individual, and stock that an Employee may purchase under outstanding options shall be treated as stock owned by the Employee; <U>provided</U>, <U>however</U>, that the Administrator may provide in an Offering Document that an
Employee shall not be eligible to participate in an Offering Period if: (a)&nbsp;such Employee is a highly compensated employee within the meaning of Section&nbsp;423(b)(4)(D) of the Code, (b)&nbsp;such Employee has not met a service requirement
designated by the Administrator pursuant to Section&nbsp;423(b)(4)(A) of the Code (which service requirement may not exceed two years), (c) such Employee&#146;s customary employment is for twenty hours or less per week, (d)&nbsp;such Employee&#146;s
customary employment is for less than five months in any calendar year and/or (e)&nbsp;such Employee is a citizen or resident of a foreign jurisdiction and the grant of a right to purchase Common Stock under the Plan to such Employee would be
prohibited under the laws of such foreign jurisdiction or the grant of a right to purchase Common Stock under the Plan to such Employee in compliance with the laws of such foreign jurisdiction would cause the Plan to violate the requirements of
Section&nbsp;423 of the Code, as determined by the Administrator in its sole discretion; <U>provided</U>, <U>further</U>, that any exclusion in clauses (a), (b), (c), (d) or (e)&nbsp;shall be applied in an identical manner under each Offering Period
to all Employees, in accordance with Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.423-2(e).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.13 &#147;<B><I>Employee</I></B>&#148; means any officer or other employee (as defined in accordance with Section&nbsp;3401(c)
of the Code) of the Company or any Designated Subsidiary. &#147;Employee&#148; shall not include any director of the Company or a Designated Subsidiary who does not render services to the Company or a Designated Subsidiary as an employee within the
meaning of Section&nbsp;3401(c) of the Code. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company or Designated Subsidiary
and meeting the requirements of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(h)(2).</FONT> Where the period of leave exceeds three months and the individual&#146;s right to reemployment is not guaranteed either by
statute or by contract, the employment relationship shall be deemed to have terminated on the first day immediately following such three-month period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.14 &#147;<B><I>Enrollment Date</I></B>&#148; means the first day of each Offering Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.15 &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.16 &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a share of Common Stock determined as
follows: (a)&nbsp;if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in <I>The Wall Street Journal</I> or another source the Administrator deems reliable;
(b)&nbsp;if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during
which a sale occurred, as reported in <I>The Wall Street Journal</I> or another source the Administrator deems reliable; or (c)&nbsp;without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its
discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.17 &#147;<B><I>Grant Date</I></B>&#148; means the first Trading Day of an Offering Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.18 &#147;<B><I>Offering Document</I></B>&#148; shall have the meaning given to such term in Section&nbsp;4.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.19 &#147;<B><I>Offering Period</I></B>&#148; shall have the meaning given to such term in Section&nbsp;4.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.20 &#147;<B><I>Parent</I></B>&#148; means any corporation, other than the Company, in an unbroken chain of corporations
ending with the Company if, at the time of the determination, each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such
chain. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.21 &#147;<B><I>Participant</I></B>&#148; means any Eligible Employee who has executed a subscription agreement
and been granted rights to purchase Common Stock pursuant to the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.22 &#147;<B><I>Plan</I></B>&#148; means this
Phathom Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan, as it may be amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.23
&#147;<B><I>Public Trading Date</I></B>&#148;<I> </I>means the first date upon which the Common Stock is listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of
issuance as a national market security on an interdealer quotation system, or, if earlier, the date on which the Company becomes a &#147;publicly held corporation&#148; for purposes of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.162-27(c)(1).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.24 &#147;<B><I>Purchase Date</I></B>&#148; means
the last Trading Day of each Purchase Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.25 &#147;<B><I>Purchase Period</I></B>&#148; shall refer to one or more
periods within an Offering Period, as designated in the applicable Offering Document; <U>provided</U>, <U>however</U>, that, in the event no Purchase Period is designated by the Administrator in the applicable Offering Document, the Purchase Period
for each Offering Period covered by such Offering Document shall be the same as the applicable Offering Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.26
&#147;<B><I>Purchase Price</I></B>&#148; means the purchase price designated by the Administrator in the applicable Offering Document (which purchase price shall not be less than 85% of the Fair Market Value of a Share on the Grant Date or on the
Purchase Date, whichever is lower); <U>provided</U>, <U>however</U>, that, in the event no purchase price is designated by the Administrator in the applicable Offering Document, the purchase price for the Offering Periods covered by such Offering
Document shall be 85% of the Fair Market Value of a Share on the Grant Date or on the Purchase Date, whichever is lower; <U>provided</U>, <U>further</U>, that the Purchase Price may be adjusted by the Administrator pursuant to Article&nbsp;VIII and
shall not be less than the par value of a Share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.27 &#147;<B><I>Securities</I></B> <B><I>Act</I></B>&#148; means the
Securities Act of 1933, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.28 &#147;<B><I>Share</I></B>&#148; means a share of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.29 &#147;<B><I>Subsidiary</I></B>&#148; means any corporation, other than
the Company, in an unbroken chain of corporations beginning with the Company if, at the time of the determination, each of the corporations other than the last corporation in an unbroken chain owns stock possessing 50% or more of the total combined
voting power of all classes of stock in one of the other corporations in such chain; <U>provided</U>, however, that a limited liability company or partnership may be treated as a Subsidiary to the extent either (a)&nbsp;such entity is treated as a
disregarded entity under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;301.7701-3(a)</FONT> by reason of the Company or any other Subsidiary that is a corporation being the sole owner of such entity, or (b)&nbsp;such entity
elects to be classified as a corporation under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;301.7701-3(a)</FONT> and such entity would otherwise qualify as a Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.30 &#147;<B><I>Trading</I></B> <B><I>Day</I></B>&#148; means a day on which national stock exchanges in the United States are
open for trading. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES SUBJECT TO THE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.1 <U>Number of Shares</U>. Subject to Article&nbsp;VIII, the aggregate number of Shares that may be issued pursuant to
rights granted under the Plan shall be 270,000 Shares. In addition to the foregoing, subject to Article&nbsp;VIII, on the first day of each calendar year beginning on January&nbsp;1, 2020 and ending on and including January&nbsp;1, 2029, the number
of Shares available for issuance under the Plan shall be increased by that number of Shares equal to the lesser of (a) 1% of the Shares outstanding on the final day of the immediately preceding calendar year, and (b)&nbsp;such smaller number of
Shares as determined by the Board. If any right granted under the Plan shall for any reason terminate without having been exercised, the Common Stock not purchased under such right shall again become available for issuance under the Plan.
Notwithstanding anything in this Section&nbsp;3.1 to the contrary, the number of Shares that may be issued or transferred pursuant to the rights granted under the Plan shall not exceed an aggregate of 10,000,000 Shares, subject to Article 8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.2 <U>Stock Distributed</U>. Any Common Stock distributed pursuant to the Plan may consist, in whole or in part, of authorized
and unissued Common Stock, treasury stock or Common Stock purchased on the open market. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING PERIODS; OFFERING DOCUMENTS; PURCHASE DATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.1 <U>Offering Periods</U>. The Administrator may from time to time grant or provide for the grant of rights to purchase
Common Stock under the Plan to Eligible Employees during one or more periods (each, an &#147;<B><I>Offering Period</I></B>&#148;) selected by the Administrator. The terms and conditions applicable to each Offering Period shall be set forth in an
&#147;<B><I>Offering Document</I></B>&#148; adopted by the Administrator, which Offering Document shall be in such form and shall contain such terms and conditions as the Administrator shall deem appropriate and shall be incorporated by reference
into and made part of the Plan and shall be attached hereto as part of the Plan. The Administrator shall establish in each Offering Document one or more Purchase Periods during such Offering Period during which rights granted under the Plan shall be
exercised and purchases of Shares carried out during such Offering Period in accordance with such Offering Document and the Plan. The provisions of separate Offering Periods under the Plan need not be identical. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.2 <U>Offering Documents</U>. Each Offering Document with respect to an Offering Period shall specify (through incorporation
of the provisions of this Plan by reference or otherwise): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) the length of the Offering Period, which period shall not
exceed twenty-seven months; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) the length of the Purchase Period(s) within the Offering Period; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) the maximum number of Shares that may be purchased by any Eligible Employee during such Offering Period, which, in the
absence of a contrary designation by the Administrator, shall be 100,000 Shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) in connection with each Offering
Period that contains more than one Purchase Period, the maximum aggregate number of shares which may be purchased by any Eligible Employee during each Purchaser Period, which, in the absence of a contrary designation by the Administrator, shall be
100,000 Shares; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) such other provisions as the Administrator determines are appropriate, subject to the Plan. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY
AND PARTICIPATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.1 <U>Eligibility</U>. Any Eligible Employee who shall be employed by the Company or a Designated
Subsidiary on a given Enrollment Date for an Offering Period shall be eligible to participate in the Plan during such Offering Period, subject to the requirements of this Article&nbsp;V and the limitations imposed by Section&nbsp;423(b) of the Code.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.2 <U>Enrollment in Plan</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Except as otherwise set forth in an Offering Document or determined by the Administrator, an Eligible Employee may become a
Participant in the Plan for an Offering Period by delivering a subscription agreement to the Company by such time prior to the Enrollment Date for such Offering Period (or such other date specified in the Offering Document) designated by the
Administrator and in such form as the Company provides. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Each subscription agreement shall designate a whole percentage
of such Eligible Employee&#146;s Compensation to be withheld by the Company or the Designated Subsidiary employing such Eligible Employee on each payday during the Offering Period as payroll deductions under the Plan or, if permitted by the
Administrator, contributions to be made by such Eligible Employee. The designated percentage may not be less than 1% and may not be more than the maximum percentage specified by the Administrator in the applicable Offering Document (which percentage
shall be 20% in the absence of any such designation). The payroll deductions or, if permitted by the Administrator, contributions made for each Participant shall be credited to an account for such Participant under the Plan and shall be deposited
with the general funds of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) A Participant may increase or decrease the percentage of Compensation
designated in his or her subscription agreement, subject to the limits of this Section&nbsp;5.2, or may suspend his or her payroll deductions, or, if permitted by the Administrator, contributions, at any time during an Offering Period;
<U>provided</U>, <U>however</U>, that the Administrator may limit the number of changes a Participant may make to his or her payroll deduction elections or, if permitted by the Administrator, contributions, during each Offering Period in the
applicable Offering Document (and in the absence of any specific designation by the Administrator, a Participant shall be allowed one change to his or her payroll deduction elections or, if permitted by the Administrator, contributions, during each
Offering Period). Any such change or suspension of payroll deductions, or, if permitted by the Administrator, contributions, shall be effective with the first full payroll period that is at least five business days after the Company&#146;s receipt
of the new subscription agreement (or such shorter or longer period as may be specified by the Administrator in the applicable Offering Document). In the event a Participant suspends his or her payroll deductions or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
contributions, such Participant&#146;s cumulative payroll deductions or contributions prior to the suspension shall remain in his or her account and shall be applied to the purchase of Shares on
the next occurring Purchase Date and shall not be paid to such Participant unless he or she withdraws from participation in the Plan pursuant to Article&nbsp;VII. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Except as set forth in Section&nbsp;5.8, as otherwise set forth in an Offering Document or determined by the Administrator,
a Participant may participate in the Plan only by means of payroll deduction and may not make contributions by lump sum payment for any Offering Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.3 <U>Payroll Deductions</U>. Except as otherwise provided in the applicable Offering Document or Section&nbsp;5.8, payroll
deductions for a Participant shall commence on the first payroll following the Enrollment Date and shall end on the last payroll in the Offering Period to which the Participant&#146;s authorization is applicable, unless sooner terminated by the
Participant as provided in Article&nbsp;VII or suspended by the Participant or the Administrator as provided in Section&nbsp;5.2 and Section&nbsp;5.6, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.4 <U>Effect of Enrollment</U>. A Participant&#146;s completion of a subscription agreement will enroll such Participant in
the Plan for each subsequent Offering Period on the terms contained therein until the Participant either submits a new subscription agreement, withdraws from participation under the Plan as provided in Article&nbsp;VII or otherwise becomes
ineligible to participate in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.5 <U>Limitation on Purchase of Common Stock</U>. An Eligible Employee may be
granted rights under the Plan only if such rights, together with any other rights granted to such Eligible Employee under &#147;employee stock purchase plans&#148; of the Company, any Parent or any Subsidiary, as specified by Section&nbsp;423(b)(8)
of the Code, do not permit such employee&#146;s rights to purchase stock of the Company or any Parent or Subsidiary to accrue at a rate that exceeds $25,000 of the fair market value of such stock (determined as of the time which such rights are
granted) for each calendar year in which such rights are outstanding at any time. This limitation shall be applied in accordance with Section&nbsp;423(b)(8) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.6 <U>Decrease or Suspension of Payroll Deductions</U><U> </U><U>or</U><U> Contributions</U>. Notwithstanding the foregoing,
to the extent necessary to comply with Section&nbsp;423(b)(8) of the Code and Section&nbsp;5.5 or the other limitations set forth in this Plan, a Participant&#146;s payroll deductions or contributions may be suspended or discontinued by the
Administrator at any time during an Offering Period. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares by reason of Section&nbsp;423(b)(8) of the Code, Section&nbsp;5.5 or the
other limitations set forth in this Plan shall be paid to such Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.7 <U>Foreign Employees</U>. In order to facilitate participation in the Plan, the Administrator may provide for such special
terms applicable to Participants who are citizens or residents of a foreign jurisdiction, or who are employed by a Designated Subsidiary outside of the United States, as the Administrator may consider necessary or appropriate to accommodate
differences in local law, tax policy or custom. Such special terms may not be more favorable than the terms of rights granted under the Plan to Eligible Employees who are residents of the United States. Moreover, the Administrator may approve such
supplements to, or amendments, restatements or alternative versions of, this Plan as it may consider necessary or appropriate for such purposes without thereby affecting the terms of this Plan as in effect for any other purpose. No such special
terms, supplements, amendments or restatements shall include any provisions that are inconsistent with the terms of this Plan as then in effect unless this Plan could have been amended to eliminate such inconsistency without further approval by the
stockholders of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.8 <U>Leave of Absence</U>. During leaves of absence approved by the Company meeting the
requirements of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(h)(2)</FONT> under the Code, a Participant may continue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
participation in the Plan by making cash payments to the Company on his or her normal payday equal to his or her authorized payroll deduction. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRANT AND
EXERCISE OF RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.1 <U>Grant of Rights</U>. On the Grant Date of each Offering Period, each Eligible Employee
participating in such Offering Period shall be granted a right to purchase the maximum number of Shares specified under Section&nbsp;4.2, subject to the limits in Section&nbsp;5.5, and shall have the right to buy, on each Purchase Date during such
Offering Period (at the applicable Purchase Price), such number of whole Shares as is determined by dividing (a)&nbsp;such Participant&#146;s payroll deductions or permitted contributions accumulated prior to such Purchase Date and retained in the
Participant&#146;s account as of the Purchase Date, by (b)&nbsp;the applicable Purchase Price (rounded down to the nearest Share). The right shall expire on the earlier of: (x)&nbsp;the last Purchase Date of the Offering Period, (y)&nbsp;last day of
the Offering Period and (z)&nbsp;the date on which the Participant withdraws in accordance with Section&nbsp;7.1 or Section&nbsp;7.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.2 <U>Exercise of Rights</U>. On each Purchase Date, each Participant&#146;s accumulated payroll deductions or permitted
contributions and any other additional payments specifically provided for in the applicable Offering Document will be applied to the purchase of whole Shares, up to the maximum number of Shares permitted pursuant to the terms of the Plan and the
applicable Offering Document, at the Purchase Price. No fractional Shares shall be issued upon the exercise of rights granted under the Plan, unless the Offering Document specifically provides otherwise. Any cash in lieu of fractional Shares
remaining after the purchase of whole Shares upon exercise of a purchase right will be credited to a Participant&#146;s account and returned to the Participant in one lump sum payment in a subsequent payroll check as soon as practicable after the
Exercise Date, unless the Administrator provides that such amounts should be rolled over to the next occurring Offering Period in the applicable Offering Document. Shares issued pursuant to the Plan may be evidenced in such manner as the
Administrator may determine and may be issued in certificated form or issued pursuant to book-entry procedures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.3 <U>Pro
Rata Allocation of Shares</U>. If the Administrator determines that, on a given Purchase Date, the number of Shares with respect to which rights are to be exercised may exceed (a)&nbsp;the number of Shares that were available for issuance under the
Plan on the Enrollment Date of the applicable Offering Period, or (b)&nbsp;the number of Shares available for issuance under the Plan on such Purchase Date, the Administrator may in its sole discretion provide that the Company shall make a pro rata
allocation of the Shares available for purchase on such Enrollment Date or Purchase Date, as applicable, in as uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all Participants for whom
rights to purchase Common Stock are to be exercised pursuant to this Article&nbsp;VI on such Purchase Date, and shall either (i)&nbsp;continue all Offering Periods then in effect, or (ii)&nbsp;terminate any or all Offering Periods then in effect
pursuant to Article&nbsp;IX. The Company may make pro rata allocation of the Shares available on the Enrollment Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional Shares for
issuance under the Plan by the Company&#146;s stockholders subsequent to such Enrollment Date. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares shall be paid to such
Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.4 <U>Withholding</U>. At
the time a Participant&#146;s rights under the Plan are exercised, in whole or in part, or at the time some or all of the Common Stock issued under the Plan is disposed of, the Participant must make adequate provision for the Company&#146;s federal,
state, or other tax withholding obligations, if any, that arise upon the exercise of the right or the disposition of the Common Stock. At any time, the Company may, but shall not be obligated to, withhold from the Participant&#146;s compensation the
amount necessary for the Company to meet applicable withholding obligations, including any withholding required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to make available to the Company any tax deductions or benefits attributable to sale or early disposition of Common Stock by the Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.5 <U>Conditions to Issuance of Common Stock</U>. The Company shall not be required to issue or deliver any certificate or
certificates for, or make any book entries evidencing, Shares purchased upon the exercise of rights under the Plan prior to fulfillment of all of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The admission of such Shares to listing on all stock exchanges, if any, on which the Common Stock is then listed; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) The completion of any registration or other qualification of such Shares under any state or federal law or under the
rulings or regulations of the Securities and Exchange Commission or any other governmental regulatory body, that the Administrator shall, in its absolute discretion, deem necessary or advisable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The obtaining of any approval or other clearance from any state or federal governmental agency that the Administrator
shall, in its absolute discretion, determine to be necessary or advisable; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) The payment to the Company of all amounts
that it is required to withhold under federal, state or local law upon exercise of the rights, if any; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) The lapse
of such reasonable period of time following the exercise of the rights as the Administrator may from time to time establish for reasons of administrative convenience. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITHDRAWAL; CESSATION OF ELIGIBILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.1 <U>Withdrawal</U>. A Participant may withdraw all but not less than all of the payroll deductions or contributions
credited to his or her account and not yet used to exercise his or her rights under the Plan at any time by giving written notice to the Company in a form acceptable to the Company no later than one week prior to the end of the Offering Period (or
such shorter or longer period specified by the Administrator in the Offering Document). All of the Participant&#146;s payroll deductions credited to his or her account or contributions made by the Participant during an Offering Period shall be paid
to such Participant as soon as reasonably practicable after receipt of notice of withdrawal and such Participant&#146;s rights for the Offering Period shall be automatically terminated, and no further payroll deductions for the purchase of Shares
shall be made or contributions accepted for such Offering Period. If a Participant withdraws from an Offering Period, payroll deductions shall not resume at the beginning of the next Offering Period unless the Participant timely delivers to the
Company a new subscription agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.2 <U>Future Participation</U>. A Participant&#146;s withdrawal from an Offering
Period shall not have any effect upon his or her eligibility to participate in any similar plan that may hereafter be adopted by the Company or a Designated Subsidiary or in subsequent Offering Periods that commence after the termination of the
Offering Period from which the Participant withdraws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.3 <U>Cessation of Eligibility</U>. Upon a Participant&#146;s
ceasing to be an Eligible Employee for any reason, he or she shall be deemed to have elected to withdraw from the Plan pursuant to this Article&nbsp;VII and the payroll deductions credited to such Participant&#146;s account or contributions made by
such Participant during the Offering Period shall be paid to such Participant or, in the case of his or her death, to the person or persons entitled thereto under Section&nbsp;12.4, as soon as reasonably practicable, and such Participant&#146;s
rights for the Offering Period shall be automatically terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADJUSTMENTS UPON CHANGES IN STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.1 <U>Changes in Capitalization</U>. Subject to Section&nbsp;8.3, in the event that the Administrator determines that any
dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), Change in Control, reorganization, merger, amalgamation, consolidation, combination, repurchase, recapitalization, liquidation,
dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, issuance of warrants or other rights to purchase Common
Stock or other securities of the Company, or other similar corporate transaction or event, as determined by the Administrator, affects the Common Stock such that an adjustment is determined by the Administrator to be appropriate in order to prevent
dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any outstanding purchase rights under the Plan, the Administrator shall make equitable adjustments, if any,
to reflect such change with respect to (a)&nbsp;the aggregate number and type of Shares (or other securities or property) that may be issued under the Plan (including, but not limited to, adjustments of the limitations in Section&nbsp;3.1 and the
limitations established in each Offering Document pursuant to Section&nbsp;4.2 on the maximum number of Shares that may be purchased); (b) the class(es) and number of Shares and price per Share subject to outstanding rights; and (c)&nbsp;the
Purchase Price with respect to any outstanding rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.2 <U>Other Adjustments</U>. Subject to Section&nbsp;8.3, in the
event of any transaction or event described in Section&nbsp;8.1 or any unusual or nonrecurring transactions or events affecting the Company, any affiliate of the Company, or the financial statements of the Company or any affiliate (including without
limitation any Change in Control), or of changes in Applicable Law or accounting principles, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the
following actions whenever the Administrator determines that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right
under the Plan, to facilitate such transactions or events or to give effect to such changes in laws, regulations or principles: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) To provide for either (i)&nbsp;termination of any outstanding right in exchange for an amount of cash, if any, equal to the
amount that would have been obtained upon the exercise of such right had such right been currently exercisable or (ii)&nbsp;the replacement of such outstanding right with other rights or property selected by the Administrator in its sole discretion;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) To provide that the outstanding rights under the Plan shall be assumed by the successor or survivor corporation, or a
parent or subsidiary thereof, or shall be substituted for by similar rights covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) To make adjustments in the number and type of Shares (or other securities or property) subject to outstanding rights
under the Plan and/or in the terms and conditions of outstanding rights and rights that may be granted in the future; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)
To provide that Participants&#146; accumulated payroll deductions or contributions may be used to purchase Common Stock prior to the next occurring Purchase Date on such date as the Administrator determines in its sole discretion and the
Participants&#146; rights under the ongoing Offering Period(s) shall be terminated; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) To provide that all
outstanding rights shall terminate without being exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.3 <U>No Adjustment </U><U>Under</U><U> Certain Circumstances</U>. No
adjustment or action described in this Article&nbsp;VIII or in any other provision of the Plan shall be authorized to the extent that such adjustment or action would cause the Plan to fail to satisfy the requirements of Section&nbsp;423 of the Code.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.4 <U>No Other Rights</U>. Except as expressly provided in the Plan, no Participant shall have any rights by reason of
any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of shares of stock of any class or any dissolution, liquidation, merger, or consolidation of the Company or any
other corporation. Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall
affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares subject to outstanding rights under the Plan or the Purchase Price with respect to any outstanding rights. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT,
MODIFICATION AND TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.1 <U>Amendment, Modification and Termination</U>. The Administrator may amend, suspend
or terminate the Plan at any time and from time to time; <U>provided</U><I>, </I><U>however</U>, that approval of the Company&#146;s stockholders shall be required to amend the Plan to: (a)&nbsp;increase the aggregate number, or change the type, of
shares that may be sold pursuant to rights under the Plan under Section&nbsp;3.1 (other than an adjustment as provided by Article&nbsp;VIII); (b) change the corporations or classes of corporations whose employees may be granted rights under the
Plan; or (c)&nbsp;change the Plan in any manner that would cause the Plan to no longer be an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.2 <U>Certain Changes to Plan</U>. Without stockholder consent and without regard to whether any Participant rights may be
considered to have been adversely affected, to the extent permitted by Section&nbsp;423 of the Code, the Administrator shall be entitled to change or terminate the Offering Periods, limit the frequency and/or number of changes in the amount withheld
from Compensation during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for
delays or mistakes in the Company&#146;s processing of payroll withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock
for each Participant properly correspond with amounts withheld from the Participant&#146;s Compensation, and establish such other limitations or procedures as the Administrator determines in its sole discretion to be advisable that are consistent
with the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.3 <U>Actions In the Event of Unfavorable Financial Accounting Consequences</U>. In the event the
Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion and, to the extent necessary or desirable, modify or amend the Plan to reduce or
eliminate such accounting consequence including, but not limited to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) altering the Purchase Price for any Offering
Period including an Offering Period underway at the time of the change in Purchase Price; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) shortening any Offering
Period so that the Offering Period ends on a new Purchase Date, including an Offering Period underway at the time of the Administrator action; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) allocating Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such modifications or amendments shall not require stockholder approval or
the consent of any Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.4 <U>Payments Upon Termination of Plan</U>. Upon termination of the Plan, the balance
in each Participant&#146;s Plan account shall be refunded as soon as practicable after such termination, without any interest thereon. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM OF PLAN
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan shall be effective on the Effective Date. The effectiveness of the Plan shall be subject to approval of the
Plan by the stockholders of the Company within twelve months following the date the Plan is first approved by the Board. No right may be granted under the Plan prior to such stockholder approval. The Plan shall be in effect until terminated under
Section&nbsp;9.1 hereof. No rights may be granted under the Plan during any period of suspension of the Plan or after termination of the Plan. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.1 <U>Administrator</U>. Unless otherwise determined by the Board, the Administrator of the Plan shall be the Compensation
Committee of the Board (or another committee or a subcommittee of the Board to which the Board delegates administration of the Plan) (such committee, the &#147;<B><I>Committee</I></B>&#148;). The Board may at any time vest in the Board any authority
or duties for administration of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.2 <U>Action by the Administrator</U>. Unless otherwise established by the
Board or in any charter of the Administrator, a majority of the Administrator shall constitute a quorum. The acts of a majority of the members present at any meeting at which a quorum is present and, subject to Applicable Law and the Bylaws of the
Company, acts approved in writing by a majority of the Administrator in lieu of a meeting, shall be deemed the acts of the Administrator. Each member of the Administrator is entitled to, in good faith, rely or act upon any report or other
information furnished to that member by any officer or other employee of the Company or any Designated Subsidiary, the Company&#146;s independent certified public accountants, or any executive compensation consultant or other professional retained
by the Company to assist in the administration of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.3 <U>Authority of Administrator</U><U>. The Administrator
shall have the power, subject to,</U> and within the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) To determine
when and how rights to purchase Common Stock shall be granted and the provisions of each offering of such rights (which need not be identical). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) To designate from time to time which Subsidiaries of the Company shall be Designated Subsidiaries, which designation may be
made without the approval of the stockholders of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) To construe and interpret the Plan and rights granted
under it, and to establish, amend and revoke rules and regulations for its administration. The Administrator, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it shall deem
necessary or expedient to make the Plan fully effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) To amend, suspend or terminate the Plan as provided in
Article&nbsp;IX. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) Generally, to exercise such powers and to perform such acts as the
Administrator deems necessary or expedient to promote the best interests of the Company and its Subsidiaries and to carry out the intent that the Plan be treated as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423
of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.4 <U>Decisions Binding</U>. The Administrator&#146;s interpretation of the Plan, any rights granted
pursuant to the Plan, any subscription agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding, and conclusive on all parties. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.1 <U>Restriction upon Assignment</U>. A right granted under the Plan shall not be transferable other than by will or the
applicable laws of descent and distribution, and is exercisable during the Participant&#146;s lifetime only by the Participant. Except as provided in Section&nbsp;12.4 hereof, a right under the Plan may not be exercised to any extent except by the
Participant. The Company shall not recognize and shall be under no duty to recognize any assignment or alienation of the Participant&#146;s interest in the Plan, the Participant&#146;s rights under the Plan or any rights thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.2 <U>Rights as a Stockholder</U>.<B> </B>With respect to Shares subject to a right granted under the Plan, a Participant
shall not be deemed to be a stockholder of the Company, and the Participant shall not have any of the rights or privileges of a stockholder, until such Shares have been issued to the Participant or his or her nominee following exercise of the
Participant&#146;s rights under the Plan. No adjustments shall be made for dividends (ordinary or extraordinary, whether in cash securities, or other property) or distribution or other rights for which the record date occurs prior to the date of
such issuance, except as otherwise expressly provided herein or as determined by the Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.3
<U>Interest</U>.<B> </B>No interest shall accrue on the payroll deductions or contributions of a Participant under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.4 <U>Designation of Beneficiary</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) A Participant may, in the manner determined by the Administrator, file a written designation of a beneficiary who is to
receive any Shares and/or cash, if any, from the Participant&#146;s account under the Plan in the event of such Participant&#146;s death subsequent to a Purchase Date on which the Participant&#146;s rights are exercised but prior to delivery to such
Participant of such Shares and cash. In addition, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant&#146;s account under the Plan in the event of such Participant&#146;s death prior to
exercise of the Participant&#146;s rights under the Plan. If the Participant is married and resides in a community property state, a designation of a person other than the Participant&#146;s spouse as his or her beneficiary shall not be effective
without the prior written consent of the Participant&#146;s spouse. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Such designation of beneficiary may be changed by
the Participant at any time by written notice to the Company. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant&#146;s death, the Company
shall deliver such Shares and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such
Shares and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.5 <U>Notices</U>. All notices or other communications by a Participant to
the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.6 <U>Equal Rights and Privileges</U>. Subject to Section&nbsp;5.7, all Eligible Employees will have equal rights and
privileges under this Plan so that this Plan qualifies as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code. Subject to Section&nbsp;5.7, any provision of this Plan that is inconsistent with
Section&nbsp;423 of the Code will, without further act or amendment by the Company, the Board or the Administrator, be reformed to comply with the equal rights and privileges requirement of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.7 <U>Use of Funds</U>. All payroll deductions or contributions received or held by the Company under the Plan may be used by
the Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions or contributions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.8 <U>Reports</U>. Statements of account shall be given to Participants at least annually, which statements shall set forth
the amounts of payroll deductions or contributions, the Purchase Price, the number of Shares purchased and the remaining cash balance, if any. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.9 <U>No Employment Rights</U>. Nothing in the Plan shall be construed to give any person (including any Eligible Employee or
Participant) the right to remain in the employ of the Company or any Parent or Subsidiary or affect the right of the Company or any Parent or Subsidiary to terminate the employment of any person (including any Eligible Employee or Participant) at
any time, with or without cause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.10 <U>Notice of Disposition of Shares</U>. Each Participant shall give prompt notice
to the Company of any disposition or other transfer of any Shares purchased upon exercise of a right under the Plan if such disposition or transfer is made: (a)&nbsp;within two years from the Grant Date of the Offering Period in which the Shares
were purchased or (b)&nbsp;within one year after the Purchase Date on which such Shares were purchased. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of
indebtedness or other consideration, by the Participant in such disposition or other transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.11 <U>Governing Law</U>.
The Plan and any agreements hereunder shall be administered, interpreted and enforced under the internal laws of the State of Delaware without regard to conflicts of laws thereof or of any other jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.12 <U>Electronic Forms</U>. To the extent permitted by Applicable Law and in the discretion of the Administrator, an
Eligible Employee may submit any form or notice as set forth herein by means of an electronic form approved by the Administrator. Before the commencement of an Offering Period, the Administrator shall prescribe the time limits within which any such
electronic form shall be submitted to the Administrator with respect to such Offering Period in order to be a valid election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>9
<FILENAME>d63338dex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHATHOM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR COMPENSATION PROGRAM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-employee</FONT> members of the board of directors (the &#147;<B><I>Board</I></B>&#148;)
of Phathom Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;) shall receive cash and equity compensation as set forth in this <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program (this
&#147;<B><I>Program</I></B>&#148;). This Program has been adopted under the Company&#146;s 2019 Incentive Award Plan (the &#147;<B><I>Equity Plan</I></B>&#148;) and shall be effective on the Effective Date. The cash and equity compensation described
in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148;) who is entitled to receive such cash or equity compensation, unless such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director declines the receipt of such cash or equity
compensation by written notice to the Company. This Program shall remain in effect until it is revised or rescinded by further action of the Board. This Program may be amended, modified or terminated by the Board at any time in its sole discretion.
The terms and conditions of this Program shall supersede any prior cash and/or equity compensation arrangements for service as a member of the Board between the Company and any of its <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors.
No <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall have any rights hereunder, except with respect to stock options granted pursuant to the Program. Capitalized terms not otherwise defined herein shall have the meanings ascribed
in the Equity Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <U>Cash Compensation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Annual Retainers</U>. Each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall receive an annual
retainer of $40,000 for service on the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Additional Annual Retainers</U>. In addition, each <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director shall receive the following additional annual retainers, as applicable: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Chairperson of the Board</U>. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as Chairperson of
the Board shall receive an additional annual retainer of $40,000 for such service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>Audit Committee</U>. A <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $20,000 for such service. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as
a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $10,000 for such service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) <U>Compensation Committee</U>. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as Chairperson of
the Compensation Committee shall receive an additional annual retainer of $15,000 for such service. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as a member of the Compensation Committee (other than the Chairperson) shall
receive an additional annual retainer of $7,500 for such service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) <U>Nominating and Corporate Governance
Committee</U>. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $10,000 for such service. A <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as a member of </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Payment of Retainers</U>. The annual retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis
based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director does not serve as a <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director, or in the applicable positions described in Section&nbsp;1(b), for an entire calendar quarter, the retainer paid to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall be
prorated for the portion of such calendar quarter actually served as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, or in such position, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Equity Compensation</U>. <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors shall be granted the equity
awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Equity Plan, or any other applicable Company equity incentive plan then-maintained by the Company, and shall be granted
subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms previously approved by the Board. All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all
grants of stock options hereby are subject in all respects to the terms of the Equity Plan and the applicable award agreement. For the avoidance of doubt, the share numbers in this Program already give effect to the forward stock split of the
Company&#146;s common stock to be effected by the Company in connection with its initial public offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Initial
Awards</U>. Each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who is initially elected or appointed to the Board after the Effective Date shall receive an option under the Equity Plan, or any other applicable Company equity
incentive plan then-maintained by the Company, to purchase 20,000&nbsp;shares of the Company&#146;s common stock on the date of such initial election or appointment. The awards described in this Section&nbsp;2(a) shall be referred to as
&#147;<B><I>Initial Awards</I></B>.&#148; No <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall be granted more than one Initial Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Subsequent Awards</U>. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who (i)&nbsp;is serving on the
Board as of the date of any annual meeting of the Company&#146;s stockholders after the Effective Date and has been serving as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for at least six months as of the date of such meeting,
and (ii)&nbsp;will continue to serve as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director immediately following such meeting, shall be automatically granted an option under the Equity Plan, or any other applicable Company equity
incentive plan then-maintained by the Company, to purchase 10,000 of the Company&#146;s common stock on the date of such annual meeting. The awards described in this Section&nbsp;2(b) shall be referred to as &#147;<B><I>Subsequent
Awards</I></B>.&#148; For the avoidance of doubt, a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director elected for the first time to the Board at an annual meeting of the Company&#146;s stockholders shall only receive an Initial Award in
connection with such election, and shall not receive any Subsequent Award on the date of such meeting as well. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)
<U>Termination of Employment of Employee Directors</U>. Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the
Company and remain on the Board will not receive an Initial Award pursuant to Section&nbsp;2(a) above, but to the extent that they are otherwise entitled, will receive, after termination from employment with the Company and any parent or subsidiary
of the Company, Subsequent Awards as described in Section&nbsp;2(b) above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Terms of Awards Granted to <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Purchase Price</U>. The per share exercise price of
each option granted to a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall equal the Fair Market Value of a share of common stock on the date the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
option is granted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>Vesting</U>. <FONT
STYLE="white-space:nowrap">One-third</FONT> of each Initial Award shall vest and become exercisable on the one (1)-year anniversary of the date of grant, and the remainder will vest in substantially equal quarterly installments over the twenty-four
(24)&nbsp;months following the date of grant, subject to the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director continuing in service on the Board through each such vesting date. Each Subsequent Award shall vest and/or become exercisable
on the first to occur of (A)&nbsp;the first anniversary of the date of grant or (B)&nbsp;the next occurring annual meeting of the Company&#146;s stockholders, subject to the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director continuing in
service on the Board through such vesting date. Unless the Board otherwise determines, no portion of an Initial Award or Subsequent Award which is unvested and/or exercisable at the time of a <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director&#146;s termination of service on the Board shall become vested and/or exercisable thereafter. Upon a Change in Control, all outstanding equity awards granted under the Equity Plan, and any other equity incentive plan maintained by the
Company, that are held by a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall become fully vested and/or exercisable, irrespective of any other provisions of the Plan or any award agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) <U>Term</U>. The term of each stock option granted to a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
shall be ten (10)&nbsp;years from the date the option is granted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Compensation Limits</U>. Notwithstanding anything
to the contrary in this Program, all compensation payable under this Program will be subject to any limits on the maximum amount of <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director compensation set forth in the Equity Plan, as in effect
from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>Reimbursements</U>. The Company shall reimburse each
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for all reasonable, documented, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel and other business expenses incurred by such <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director in the performance of his or her duties to the Company in accordance with the Company&#146;s applicable expense reimbursement policies and procedures as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>d63338dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated July&nbsp;26, 2019 (except for the last
paragraph of Note 8, as to which the date is October&nbsp;15, 2019) in Amendment No.1 to the Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1&nbsp;(No.</FONT> <FONT STYLE="white-space:nowrap">333-234020)</FONT> and related
Prospectus of Phathom Pharmaceuticals, Inc. for the registration of shares of its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:56%; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Ernst&nbsp;&amp;
Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;15, 2019 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g63338g03h86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g03h86.jpg
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M+SIPB<(G")PB<(G")PB<(G")PB<(J7]7/37LO>QWIRO6H=I4[5M_Z<MKF=H
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MU'A]A,!"E.K0L0/K)*N'S0UXJ!K.^JT'(2VQVQ*P"FCD,[\/RI4<C5Y]I9S
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M9IEW.,9PVZ+#S)S:\XS[L^!;&%=L^[/;W\T>I\A)B=-ZARL3N"7&8/+9"-Y
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MO8@.,%QY8%X RP[*KX/:M;JQU]1*O$R/M6L!]V;,B#66"+ .9\HTNV ,:>#
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M3BRFVVHLUQ/["U=CZPJTQ0A ?@'Q:>R' -Y))#7BMUK<C6C_ -)LR9&,N/\
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M<?<?R7IC_F[']RU_@3PI7VX1.$6'.6 +6H;) \1C"X3Y,0'9DRUY0TLF>*1
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MM0#7FN^JS7P=D_=>B*_$>HB56\35#25WU/!UY=:CO*@A2&(DYMDT>UM92Y0
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M;RA8_'K.5^'Q)8\R<C*5,]\^9ZSZNG/@5Y*G>Z?$1%27D^;V'S%^6VA:,I7
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MVN&Q:YK@0YI'(@@@CD5YP0@/40@^L52IPZ]6JV,@"J]7Z[ !A08T5#8:C0Q
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M'D"?Y*@[WIV^F-L+,L*=:;ER)C!-66/SEQ:-YR0^RJ$;V!(=DL1[G*[2*@.
M$!M@0-<*PX$U#I8Q/"TP58K6$+/@/=R\?/P('EZ\E]2OIH*',L#;%0U'>D5<
M1:++6[01MD0>/-/KK^_.F3333M<$QSF&DN36-[&R4^&?F#"("37A&) ^<@F]
M';>.WO\ IM]U'#W[]_\ DX_R^2E/2GI.=&7/=U'T2!T)L_7=_P!T6&88/+?
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MABW!D=OL0&N<-#J#+C$T7=3%8LY&VRQ#C*=2%UBS/:96EE:6Q,W?U,/ 'SR
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M-*M5P<[.(7C'E5(4;?0YCP*9>::>PM.&\]ZSK/3,FL-):CT_6&^2N8:_/@G
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M?/K%T!EY([:=1-4ZJZT330\J!1K!98YU(X5LG9AFQ.AY+(0VTU-+*&U(.\\
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M-4M+Y^N:AM\ $*0X$02<*3ZUO?7!,6TU$?6XTNVNF6@,*LHFEB;'TW\M_?\
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3(G")PB<(G")PB<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g63338g06o81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g06o81.jpg
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ME9976(2WN-+3UM<W020F,I?5&"-TLT)1<__$ !X! 0 " P$! 0$!
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M6]->O=>2+1/&.^EIBIKS<\(A+(O$) C(WI>T'/'-5[%CYR$.W"<E@8 Z\:Y
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MLX\^9. WUZ/'BCR"XO#-ZK[CET3E#K8IN%D()'&DZ,[7-1YM#X9:,KIS'?\
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MXT3^^3<E_GD(_E/#X^JS_6_PP?S:M?T/_P!LWM]6O!I_*IS^K+^7'WR;DO\
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M\7QW_$B/PSP:4M1B7?YE 2__ -<-^(5%SQ4XH(:JA,4BO,W4,$VW"0)H:RY
M0J10>)[&R5,[&2FZ %A*(KLL#LD#JB)1U]*=60/5XC9K=K&H <&C\SY-[%0K
MU-_E=)>+X[_B/_PR?\WHR<_\Q@)+D_QD/+A7_P#9CRJN4DX"\@N/HH.)%N>1
M^I3;D:,8,'!HIM/7MR9==FU2;JE"-V95HSN_?J)Y.W=VK5LV[854[ W12ZU/
M%_EE)>+X[_B1'X9C_FM%^,8#_F0_XAGK'+'/''/#+'+#+&V6.6-[98Y8Y6ZN
M.6.5NK:^-[7M>U[7ZE[?CM7^$_WG]4 H!0"@*0;^0X?28/WT/H"KT H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4!K[RN\F[=7J]D/U3*M5X<-Z'")R5I3W"FP
M<%&^34KE#1_OD.7&N+9U'% * D]Z+#_K%L+U:*_:F/5<[<3^'E;.2*_&:-*P
M[J?P-J]RF8^%4B3IUTJ**B@% * 4 H!0"@% * 4 H!0"@% * T(%ZVE>L-US
MB;Y:@W'M)[+Y=E(HS,(5L;3CF-142X(RAPY%&0^RI=JV7L7#YK*W(4J,21VN
M*0C8&(8Q0Q'58^%!A1.-,B2X='FZYS?>A H"DF_D']N$^]65"%Q>=/6A5J$B
M@% * 4 H!0"@% * 4 H!0"@% * 4 H"$KI5_'O4WHD>]\-ZYT;MWPCJ)Q)2W
M3X<NUN4^\5;>-J/Z&](I*H\6N% * AFZ;#RKM:_LC<:_L3E7Z1=R=_#]@RY+
M4+\*@3@MNH-^^OG'=(?$(LB JQ9H 4 H#["0#\Q!?HD=]31JE3SNCS[[7M*7
M==]S=_<9]E"K5@9B@% * I!OY#A])@_?0^@*O0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0&OO*[R;MU>KV0_5,JU7APWH<(G)6E/<*;!P4;Y-2N4-'^^0Y<
M:XMG4<4 H"3WHL/^L6PO5HK]J8]5SMQ/X>5LY(K\9HTK#NI_ VKW*9CX52).
MG72HHJ* 4 H!0"@% * 4 H!0"@% * 4 H"(DX?E$BYV"2+ AMT ##[%9PTBH
M"';H*:_+OV:3!!TV3?/(#"M5/@ZT=CH<0_23G6RVT -RC?*[:'HG2X^?QP97
M27%JGZYZDN1%T++M0Q% 4DW\@_MPGWJRH0N+SIZT*M0D4 H!0"@+>EI^\4BD
MFE%@YB0WC<>-'[ (ZT[H2 Y<.-<D;!P3#KT^W3!.[;M(8T[(GVR]701Z_'K^
MNL!%YI+I26^YT]3H#./TC5?[#Y"R_CD=?17846D,2B,X \.G_,X"*:E) Q@T
MKDT@DL'P8Q!P.Q@@6/1B;,Y@/-3'! %'EYJZ]?T,K..^Z4[TE=.S/GZYK]U_
MTA+J<0V9M\M%&1G(^+PM](0W$]U.A,?W#/) W*R!)K'HS']FA-:29F+6C3&.
MRUU+I9$HV.;#9$ZP:-"6$7-NDQ$N:Z^77$2-#72KX<P>N&3@:N\9-72PYWV.
M[M@JX03649.KHYJ)7<-<\\D%NQ9YI]D3RZS/+'J7N(/;0"@% * 4 H!0"@%
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M/.Z//OM>TI=UWW-W]QGV4*M6!F* 4 H"D&_D.'TF#]]#Z J] * 4 H!0"@%
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M1=3-RT'X)7D&:)=_(,DGR6-^P=I/9 7,GRH]%))@9.'#I@LV>D395R\ ]@F
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M]]KVE+NN^YN_N,^RA5JP,Q0"@% 4@W\AP^DP?OH?0%7H!0"@% * 4 H"#?I
MRG2,LN3[A;BJ*W&1@3+C-(,(P)A60UO%#>RWFIN95B1!0T>'/]>"90"V)CQ8
M4'B]CM'YPX^P!8:VL/#X[33,C)FS*^[3HFF3GO2]+YY"T=<@.D8#:GB6V24U
MWA+R@%YN:-.-'&0<KC9F::L$[(V(=C\X=2*4.#NQ(>6D\).0B$ 0\M@6P^1
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M<V8!,91$T#<.CKL3%V\A6OE+)"&<["981V10L8@N]D<0B@Q5,UZ9\1(S0@4
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M%9#-9A(46#Q/!7"]\,[MWC9=OG?&]\>R)9VM>]K=6A"XO.GK0N2A(H!0"@%
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MB\F$%Z5R_P!YVKK!N2=YFBN.J?Z<T<[]T?OGQW%-$=&4WOJS!H<4 H!0"@%
M* 4!K[RN\F[=7J]D/U3*M5X<-Z'")R5I3W"FP<%&^34KE#1_OD.7&N+9U'%
M* L3DK^C_P"?'JBU-_BHT/70']G-OV4GR4C>D."EF[KWFW/*.C_8>G)%7<\X
MU"@% =>?W)]XU\X?1[C][RW!6E\,/<J \I27LP)NS WW6L'DZ,]J/.S6M'F]
M!0"@% <YW,/5^RSG)7;!4+KN=&!;PXQ49DA<2/D&#M/$ (3RS;/&@]9NOABI
MAFG?))3+&V>&6%[]=C>UN2V'VIE<:2PP5XCJ.JG66/@HBDH9N'C(*@J4BH5^
MRE%P#"M.8AQ"O'3UE&V6F55AMI$:9:959HJ'1G ]6FK,#@UJG"1M8J"@XIS
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M:4=/%=M-,JK*MNV&I8V46XQM][;V7_2KIG^-2C_:=>0^I1A%_P!S5,]/3O\
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MI1A%_P!S5,]/3O\ 9"X_UIZC^(ZT^@HC^[C[VOLW^E;2O\P2/_:U/J481?\
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M@F<\1Z: 4 H!0"@% * 4 H"F&OS,6^C'_P!55J4QIPIZR%Q+P+ZC5*ON? 4
MH!0"@% * BEYY)\UH[MO6\PXS8[&E$!3A[R<[$AT0=)=K+%>-Q SLH+KYFU<
MWOCB4Y.Y2=OJ\FDVPZXP*BJ#)=9LJBQ5O@U:FBI/7DU;3ZN["HJ-22^2*O\
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M#&+"#N1;4F?M3RW?+U9S%$8FVG:R_P#&:X\<I*LM"JMRW7)D)8*^A\A0"@%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g63338g10h25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g10h25.jpg
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M>):7M]8A-U68N-35(C%SMM,D.7)T=G>U(T'7)35187'_Q  = 0$!  $% 0$
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MZ.[(5G:\DL)M+JUL ='!+*R$H I;\,C4RK"*R40XDY^KAC*M3CIR6)G#$:<
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M).^WIZ<SV<W]ARL9@,PP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@!0F81#HG?%U
MJ(S6#B9M=35N($KKEH7938HT',WIIN"]*(;"6(EH&4(!SZ8DDX<)"R#D>2X9
MNW*B"_BRS(MUMNX\_.,#U3//;X1:VMZLC%6\3OX,I*);6+9,KM.1^5J@FDI)
MY=NS]9JMD&Z**:*>Z0]IRMMMPHN\>^EDG2RCIZMMD,[VYBL,B*U^<S/K'V-8
M]7=>%)7,$6@&*D[)DT9WEAQ=PFPVE,L<HAH'$TG:[I?5%<L]UT!1@.U1XT6>
MN-F+%NDLZ63UWF9^#^XN1>'^PC4;U,ZVB)3+9J,IN$LI/.1\H%28H@-VUW>L
M9LENC,DFC7E;ED&4E::JNLC<A&PYT:Y55V(K.=U-]MK<^)B:I;;"37U95^3K
MKFI"41!D:TYBS6%;0I^RT> =HJR'HBV879HX\YQLT:,6[=!OY6W*J/F$E4U=
M5D]%.)<[WWBV*UMPQBL*PIBB4O@!68".0E>5+%Y:H&;OE7$@E"HG4(+,'W;D
MN]>R _J'2(1P6Y?.G3Q,4W>!F'EMD5F:.U,S/,Q"(BR(0>98=*EY;**[/ (5
M\(#EW1B72UJ1C!]$*^OM9L!=11X4DRPW2*\S=\D3C^@H=N9U<$G19DS39N'A
M7A!S?OMO-QSMY_4(9)V'O/GVVXB9)-UOHJ96.)MR45?%#5C!5@SEC*'C+;9W
ML\C:BJT;?D&VBN@XN1C:JVZL>(EV;Y\#4\C<4X:;))<Z2Y[+^QBV*][9C"@7
M5/JJYWL$H#IN%Z_&"A,(5.-M1#YJB08/SSCB; FC)SNBB&%FI R5=F$HXW&C
MSKQ!$FIL]XX;.>5SX[,Q-4L\MNW:). Q2J*XFQ/:/" L8FUNZHD2J;#1P@XF
M&]?AF ?0@X0UVV9;NPH1T-8K//-HNW+;EKJX5=<H)\ISS$+D7-?@)4P*& #
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M # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
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M++@96OUY[-N\4BS([;S,SXWX='.1<PY LQ&08 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !
M@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M& # !@ P 8 , & # !@ P 8 , & # !@ P 8 =9Z];OND5=UQBQ=O6@-&#;4
ML)@.',)_*V;%@Q9RTNW:,F31N63;M6C5NFF@V;()IHH(IZ))::Z:ZZ\?'C29
MI'TA0=)&D&%"QYC.'#AXWQ7%B1(N**Y'C18T>O3VF(\=AJ<AIAAAI"&F66D)
M;;;2E"$I2DB+Z;X#P/@J7@;!DJ5A#"\F5)PIAV1)DR,/TEY^0^]2(;CS[[SD
M13CKSKBE....*4M:U*4I1J,S$5_']>_SUVW]X\Q_K.=([J&DS]8F.OE=7_M
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M.OE=7_M .Y_@/O)PC\FZ-]2#X_KW^>NV_O'F/]9QW4-)GZQ,=?*ZO_: =S_
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ML6+@7407/B?68>V#VV^E'V+^^VR_S-BQ<"ZB"Y\3ZS'H2YH#7# !@ P 8 ,
M& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M 8 , & # !@ P 8 , .J=V$_7Y>'_=^R_P#.9K/B+I6^-'23^_V,?YBJ(^K^
MCOXO\"_N=AGYD@B(,Z".XA@ P 8 , & # !@ P 8 , & %P>@_O9U-_QS?\
M#B89[Y]S!\>>!O\ NQ'_ "C7QXYI_P#BCQ;T4+^9:,.R?GU\'S2# !@ P 8
M5I[G^Y[VL^K?=_X9R;*6TNDO.(>P^@_,//ES7&@& # !@ P 8 , & # !@ P
M 8 , & 'I89MQN P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
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MD.2FY9+@4UN;C;/B5M]SRYC(35/C<M^WB9^U[C)G74<HK&*^#I381L3A4/!
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M:>R3"%QJAR"^R=H'W-#&+RMYBM%9.2L.L08YF"77D0MO$W$@"FBYX)("8W4
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MC^UMMS^C7^_;;G^_GG HK??_ .M3I3]9B3?PC]I,I;#Z/20A[2Z?08M%D%#
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M9W]B]!$,B*W/[<YF)?R"BKM__K4Z4_68DW\(_:3*6P^CTD(>TNGT&+19!0P
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M-WEX3^3E'^IA\>]X?/+:WWB2_P#K&.Z9I(_6#C?Y5U[Z^':%@;O+PG\G*/\
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MM!VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[<<7=].(_'=3^M!VIX5[V</\
MB:G?5@]J7LW](R]_O=L#\PX[<<7=].(_'=3^M!VIX5[V</\ B:G?5@]J7LW]
M(R]_O=L#\PX[<<7=].(_'=3^M!VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[
M<<7=].(_'=3^M!VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[<<7=].(_'=3^
MM!VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[<<7=].(_'=3^M!VIX5[V</\
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MM1%GL\4C<?Y!LR&FSE;?48S&)_[0BR;\Z:RQ>D+F()R@& # !@!Z6&;<;@,
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M;9:UTIPP+%>O;JF+3=3L'U.$2>6Q7M.<1$PL_4"SJ 6&'3,+51#H]+U[#+S
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MSL9,24H)?D&"HRZ?Q=YGOS\@7].XMY6(1)V5XK!W2,.=1I>H QP>6KH<'CL
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M)/;7[*#Y?^VVWF$0>RC$?G7[0_O07?\ G3 EBY^L_6'LHQ'YU^T/[T%W_G3
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M.?\ 5&__ (@GGLGW/GQS:/\ ]M*_@9@\OTT_%;C/]EI_C(H[.F?90?+\, &
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M !/1:A0:J_2E4^ILDQ*2Q34,NFV3B'"U'2<,T'K-IS(CRN6\7'SW\>-!@ P
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M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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MP7K#MUQ9^GZE_P @_4'RM'A*?IIWW]M'7^GCM+PI^@:=_L%ZP[=<6?I^I?\
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M^K!:7HJ#?3AF-27V:#TN=.>&0])H-:^:'L6;9#(08%@ P 8 >EAFW&X# !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
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MX=.G"VVZSAPX6WW5665WW454WV44VVVVYYY /GP 8 , & # #TL,VXW 8 ,
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M,"T?M"S)K'ZQ;AGY^3:QLBJM'"/$N8GJR:8ZV=<D,SSK<B#3I)-T]^,Y#*+
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M:+TU#YJG#TI,_*P_5X8 5> >^E;/U7NO7XK]G<NXND_,0Q_'_P!/I%H<@R#
M"M/<_P!SWM9]6^[_ ,,Y-E+:727G$/8?0?F'GRYKC0# !@ P 8 , & # !@
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M%# "M/<_W/>UGU;[O_#.392VETEYQ#V'T'YAY\N:XT P 8 , & # !@ P 8
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M-6&_G+J>L96M5LF'0%$O-JZ&09E+0A,L^:Q*5EF+9DCK9=*Q W39E$IZ:8Y
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M&_IX9=>8Y*<"!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M& # !@ P 8 , & # !@!Y3'A#/?\[Q_7![,?C1-<_8N&O@YA_P#8E*_@&!^,
M\3_"7$/[<JW\?(%/LYL<&& # !@ P 8 , & # !@ P 8 <PG@#?][3U,_P :
M[OX<+@SI&D?X&5GH@?.D(=YT;?#6B]-0^:IP]*3/RL/U>& # !@ P K3W/\
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M\K#]7A@ P 8 , *T]S_<][6?5ON_\,Y-E+:727G$/8?0?F'GRYKC0# !@ P
38 , & # !@ P 8 , & # #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g63338g12v65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g12v65.jpg
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M&G$]DCRX!D@!W$]I3LTTMB;W+[4VU4@C*$R6B#=ZF+*3J9GI<64-*0TBEP)
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M)I6]!)1Q(6T=6R>?F\>O#'$W.X*C & 0D=]Z4?E)+ZS>8!-X P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@$)'O>O3Y:6^MGV 3> , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@$)(/O!#]-QK[1BL F\ 8 P!@# & , 8 P!@#
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M# & , 8 P!@# & , 8 P!@# & , A(][UZ?+2WUL^P";P!@# & , 8 P!@#
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MP0?K@# (2.^]*/RDE]9O, F\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M?NZ[<<;:\_\ OUVXXYXY]SGCCG!!_N , A([[TH_*27UF\P";P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# (2/>]>GRTM];/L F\ 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# (20?>"'Z;C7VC%8!-X P!@# & , 8 P!@#
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M+1\5$2\Q.":Z/@XP)T:_NTY^7#K<C9/@@8 P"$COO2C\I)?6;S )O & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , A(][UZ?+2WUL^P";P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , A)!]X(?IN-?:,5@$W@# & , 8 P!@#
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MIT([]_O\N)E_'?>E'Y22^LWF"";P!@# & , 8 P!@# & , 8 P!@# & , 8
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M$W@# & , 8 P!@# & , 8 P!@# & :9[Y2[0#2?A&N&LQ[.S%J$9=;CW5,5
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M 8 P!@# & , 8 P"$D'W@A^FXU]HQ6 3> , 8 P!@# & , 8 P!@# & , 8
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M3MPJDI(8&TG!*:3FCM!S!1GH8 P"$CWO7I\M+?6S[ )O & , 8 P!@# & ,
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MM8E^ZV"9M?S?]#[$_04_KE9-2><'IC;GTBA]3JYJJSV)XT8!="D/PTU#^M"
M?:L3G3M'XOKWT.L^AC.Y9WQA4?IE6]- >NQFE9NX, 8!"1[WKT^6EOK9]@$W
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!"2#[P0_3<:^T8K )O
M& , 8 P!@# & , 8 Y_HY\7'CY_T<?T>/_LP#378WA+KM@O7BU;YWZVQ%%:C
M[MO& V9""-J&R),;#:5( 6"Q0<_A5<RM#=\:Y-\.Y%,S;<%453"&;H_8$U9
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M  R;N5RX3C+9IU</ORV&X+! P!@$)'?>E'Y22^LWF 3> , 8 P!@# & , 8
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MIG HIW7$J..*[>DY3E.3EDRX>=8[0P!@$)(/O!#]-QK[1BL F\ 8 P!@# &
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ME6]- >NQFE9NX, 8!"1[WKT^6EOK9]@$W@# & , 8 P!@# & , 8 P!@# &
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MO?0ZSZ&,[EG?&%1^F5;TT!Z[&:5F[@P!@$)'O>O3Y:6^MGV 3> , 8 P!@#
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M $*)^$7NC_8JEOKVQ<PMSR?R:P?T]H>CJIFSF8_E5O\ T>H>DK1VDY@@SX,
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M(P;C6&BR^^WIUU=&K9+51;?^<IOQSOM[NW.99J=2HZC5*K4JO#$J"IU:@JM
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M@2@.3SJRP(NC5!,A8F;4J< I,K2.5,7,.GB,C9L V\1< ;\>H"M=V5?D]6T
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MK#'Q%OYZ$\*S#XA*)87E<U?GT(3%$"V\',UF9"%794=005D#K&$#H>3/ +)
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MKO+8)T>&66IM8-=6+QU]>K^8C$/"<V-(IVGS8ED0\$G;IJ$RF2.B]<@QKV,
MNY=+\;R'K]&34.5/QM@&ZWA>PZ*Y>9MS#&;(2BO]8[H?7;-N(_"O/2\Y/':I
MRZOP);HU+!/WLUGG=B^%KG%+R8GYR.MO"L**W&,9'K,5"2NRX'O 3$=LZE&L
MLKR'C+ O;FP"\94.$&H68H&JJ>4R)BP>2C*Z:M)3PF=/PY\[B,E5LQ*/;_B[
M_<$Z*2R3TSA<G@M6*QF]/";DM$^$IFDC?\N94KHT"VPSG 5U-IE "D0W( ;Q
M)2.H3L#C\8$('8['('2NPV-6M&I2HY>S2:))O!+>2ZMWDE+I1^;2LUW\9"BH
MUXTU@FG)J3GX\5+)&<G12)]HXA41=AVQEY66SUU,.7H78\WB?!@, ]I\/9$Q
MZQ&'2J8"RP][/&<SD(1TX*I$$1!MHR4$1MBV'Q<'>&:6/$I&X6U=REU:7YE)
M=YO-/+%!@'ZZ?T?]_P#Y<8!F7G7.P, 8!^2_^06_V2G_ (.< PTSL'7& 0<G
M<+M(U(735<FV<M@99PW<A17L\8;KHL'"B*XD'Z@Y]F2:2FNJC 5ZV<>R+K5)
MGZ@KZMZGM#R?5H)6:Z])S_Q.>]^'PVM2(M_V^]BB\ZD3F'1F>4],&4X!2=&<
M].A4?A79(Z4J*."E(0=KYUVBL(Q)1Z2--Q-_(BE> +-D)BMX"_<<?OO[6S//
M#/#+/OGSRH_[.V36*E$\,7)IW5K><M"RZ[077X0^)6/;K>@Z_CYB PH)*7<%
M:DJ)GDX(S<E&^M;ZX1S5K)0EBQUFYVEUL@DJ38)#P:F[5]*>44>2,B:CV^MF
MXDW)-KJV3V=692%0.%3>.GWTLXI9/4G/Q:IDGU2[A7-</;JVZ/GND.; H8(O
M4IS'@,%/C2$+7K[L&VJVO&"UE.9D;CEBZRZN^$ID?4#QT"M&Y>_,0]]HU)QD
MJ%%H8FWO(B@A4*:<\E.>#PF\)34GAI4L=)M/RYQC & 8$]L]NT@N?QDSU\+S
M%\U4Z\]ITDH8R!1YY!>+F$0-D0I S(2KH'N13*E)6ZV$BQ9:0:QIWHR4VT$<
MN_7CI2L4YJ4\GYL"\-V3O2^%!GG*;G+'*6>$]I9NJ)QW":]=E%(RA8I62'NT
M\+@< DW8.J)6_L('0<H\GXZ;3Z<0!SY+Y7QI#Y2_LIR(>2?@,EK&Q09ZON\C
MVS%PXJKTM,W%+'&2UXEFH+VB5UN2:DVIR2:GGAMF8?6IX0/P@=(4.VGMO0^O
M:^DKRNUK&;OC%!V'PCS*?Y*@2W-*2W@JEL('TDQ-KK22#32V.2>XN#:A4&DI
M "W+[176'%$L_++9EQ+J"CBBE#BIR^%_::G@L<)26;F=!0=RY>"!;MXGPB\=
M#F+ETEQINEPDY7;)*KI\)J<[;I\:*[;:\:;[<[Z>+TNW///'/.<BQ2>PX'@V
MMI(Y) P"TM\LYL_I6U6];2"01:?^T*4.(:<B@T,8D;21LQ+IX)3##) '/B7K
MY\\02'HHN1#W?GEUSRUTT><-UDX<Y.69,,IJ>*GI-?=+R'M3QVNJH?.D[B-P
M,O1L(UF XQ%)O&8-!CK:DP10W+C$N7$[US,I,?M)8Q$B4&U*#[$!%EDSNXK6
M,!UUWU5.:G.4MNK3X_',Y'=N.4IS;G@V\926E)+'5Y<*#>]C/"7!9(=/.*JA
MY&###)E=G%R%,S>)K* ?*[VEKT4D5LPE9:H42S&0>JZ9M4U*GL>;#O8FT&;I
M9 6!>C7J\3C2U^*6O/1AGH\A+AH]#QV1)Z(7@I3S;2QT/)F0?@YNT5D=HH;;
MQBQ"4=/;P"?PN)!C\=K2252F_P!3U#U)9TC9/XK)Y;,GNKD!+)Z; LB:)31D
M;!CQ!QDCNS)MGCJ8&W.>B7? K20J%J2E.>$YY.6<D;%\N<8P#*&!?YI!O]DY
M_P :YSAC^$_%YD<T'P5X_.RH2?O:0^0N_P##J94EY/J?F,/<[!P# & :[_"
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M6UK6'&(400KAP@0ZWWF^[*%K9D>T8]C(]<8R]V--LVL?*R$)+-5E1C>.1]P
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MBP36>%EFJ2CXH];C1K/11=SIIN[(D7;5@Q;Z\\K.WKENU;Z*+K)I[+\6O<N
MN0ZM[+2'=^IIYT$"2684^9>JS14#'!!V<10BZ4L0"X'M5@P1@0*K*[S0,[.B
MFRHY@ER<'.# ]'=%%0@VU67F\_,N!-Q:GOR?$O-Y.(E\ 6^G///8OQ:]RX$7
M(=6]\1Y.(E\ 6^G///8OQ:]RX"Y#JWOB/)Q$O@"WTYYY[%^+7N7 7(=6]\1Y
M.(E\ 6^G///8OQ:]RX"Y#JWOB/)Q$O@"WTYYY[%^+7N7 7(=6]\2DW#.F6Q
M.&=R.,MRLD=R ='Q3B7LTB!]]%-W"4J8AV*A+5R4=QM1H[3D#5DDNL'W;.-"
M.C;E%7C5>BU[EP%Q:M[\1^$ KVCW479/JL:Q)Q"WR[]P.>0 B/6B[QSJ^<-B
MBS)Q'5]A+A?4DW=(/U$-]U.'R+A)QMZX34UU7FLO,N!+A6E.>UOB5GY.(E\
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MNY+%F;L+[/BY%PC%I,/ ##0SDJ)3?!Q,R)QF9OQ;E9=E($HI[6GZ&C(RX>-
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M,\\?)U=1&LNR'=$Y,)##XG7,//[@/63!(T1I&TX<Q=K2D3:&P"1R)$W:ZFD
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M-UA,8W--Q$E+/'9I\OCT:/+L9P0, 8 P!@# & , 8 P!@# & , 8 P!@# &
2, 8 P!@# & , 8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g63338g14x63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g14x63.jpg
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M-#4Y4U9R<W1VDIBRLR,E456TT6$F)S9#4F*1TO_$ !T! 0 " 04!
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M?'S,DSC\DI>NX["*M<"6XYN8J(:.ALF@+1$6&&3%_IDH9%C(RJUTW;S+A[=
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M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
M#@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
M . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #
M@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
M. #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
M X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@ X . #@ X . #@!!6%=GK;==DHW2=DU-%
MHB,L<;;9^$M TZ5DEF12*U<;:B14OMJ-M@^@$!'[11<ZNX>X$R AEH\W2!OL
MN7^KO9I:Q6N1[/0?1T"I&=[&1>FYET].X>!+O7$8I:'8V"3R#3, 'HHA4P(*
M>&B'\B)V7)[8210C\4CD;'L_6U)";,.VS6),6J[_  =&:OC3M8.T8.,:LNA'
MSWZK;^@,UC,CX6MQ+9T\PSO678.'VW#IQ)XD)ES0Q7!0U'9G7LN!*Q.>1V4A
MA#8YB/%@Y-7T"#@F+?C7HH@@]=!WS4@@L@0WQHYU0@RL=NW<)([E?LWZ;A&3
MH]W<+=LRLP%DHW!AV 4%KNP$WL!E9N1(1_:P5Y*CO6<V2D<9C#IO8,1Q'L*'
M' -$E'7.K]/5NY;;I)ZNI4FUO7WEPZ=1"57O[>W<+K?>41ZU"V[Q4F9DXYP.
MAMLS4B->1I9(D/:4U+3T*EH5XVPYVPC)G1R,G-(\'V4](9:,%G:*J:>N>,I]
MW;KZ.(9B[^P5-OWYZ][3Y[ R+Z7@-!YF41-Y.#T2?CZ];SJ$1AU+YE U9-YZ
MNB4IC08<6R1;JM-!JA .2%#R;TDW]6W93M?NX[/3NW]H9BZ.GGYO;3TD,22W
MRE-9;P-U)X ,,L2X\]13Y4;;8 C!FQ2I+ELH3!D+3!+K.L:N8ZBV<D72#ITN
MT68NFS;4X.9HN$\*,I]^SG(KV,0:RW<Y;>8]]MIB;]0VU%[NA;6PX0W/>XXL
M_)-XT9."%@FDK%#W6[1&5 &CO?#]:+FMTU%P!)ZU8*%F.J9%NURP<M'+B#*V
M@L1WU&3^0)#@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #
M@ X . #@ X . &NZ(=T)P'L^1PWL/6\2JP.RIN;7KZ,#.'$RF=;PV'RIE'V(
MVWP[4*B*'GINP((EHGK&2Y9-^Z;N@+5!\\QA?2UBW'?4BV6N9\PJ2N>Q;=^S
MI]1[QDWK#V6EES5G<,\L2NE("6JNTK"A3N$"'"IT^@-A@$#($F3_ %VV31<3
M#5$RH+),F&^!^Q9KLBR5V1VU5R,K6MO(CUX@1W(S/2QGV"CB/*#=<#ZS)J%-
M20D_)BZ))BA[6.K;/"FW8=Z$90$6Q3V<ZZJF&VTB#KRIAE33>/-7J2SG93QQ
MKQE/O[/'809BZ]-.D4D;Y2#K _:2DLX-R\)'8_$9).@<H.0LNR!65%XI(F,3
M,$JT<Z:KN9*IK(2H<<R'*-!Q0G[7'O![)R.5W=ILI\+\U]F_4,Q<2Z=_0+-E
M_E(:O"*U\1U1=0T!O;A6N+N:VR)(1*55@/:4_)K7%ELBD7#M%[N?8B17L3+1
M<HB61(*LF6FYA/U1-E/ITTML/4B$9]2+9SWZ/7[$)[0.7MY_#8Y-6861QYE)
MQ;8RQ$2X7D')&C%[KZ5EDN&V7<+"W3EKE)UZ@[WT?-4U]$7[=H]T7:HU/307
M([E<7=P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < '
M !P < ' !P < ' !P < ' !P A=2O4$A2]N3FUVE\V%+E+*D1N2SF/2>+U6O
MF0NR2+A$0P=S5M"$+%3 0[55#6)QUM+$00=!HFS:CM&BSE%:;Z6MW^-M=^@J
M1&1WOMX$7;M'HLKI+%;'G5J3U2QIW&BEF$*:ES;0&C%-LP>SZ%<-U:XL*+NB
MD?(.-W8]!!9D2 F<DP11N1?Y5:IKY9+,9)5K%;34NH]H&F]SOKH?66P9 K'K
M+'X)#;=CLFE\JLR0WV5.&;<G4BP%#&I*Z.19E"LMAS"*"PH6."Q48',Q@9B+
M8ZY9^8HXV<++*YVU@SU*VEM@$FQ&7/>Y](M7KIU!$T#),RUU94PLPZ,J>&T/
M#7,E&1$&E$ZA@+Y\1C<9T;1 &$2.%-7;_;<E)S6'))]JV;:)ZM-,.,.!G?AK
M<^D"3;7JZABZ6>36I67S2931_(9HW<S>\X7=I8:U<BM1^FT7UF:IJOV^%!NZ
MVL(GA6P9>;E;+939VY)E]UV[I'*6G)S'ILT*Q>/2&4M>)W_AZ?;>/O\ J=-/
MJ6E/)X[*O'D:L61V%,I% G$-K!11:46@&?AY<LE9:D*4M1N 7W*D38Z--)<V
M9##KK=R@KEACV9F+[.<M_1T^V[8&0KF=_8]NHM$%Y,&I1T$*UZ;EQ23 GZU6
MLF^%*\IJ-+^Y.JI>,F ^.R)>'5\ 7F[F4N!+(?-9!+5BA VR02WTT9O/3N7$
MYM;D5O69[_#F$9"[MQ;"W?QZ!,>A*2#]?((K6L7/G2\,8R:2F(6).[M%]H-'
M9"46,-X&&=MT$'#F,QQTZ>(Q_!/9V19CEDARCU9LS:ZIP9WU%B*Q6&:^0)#@
M X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
M &OVK>@,=@VEB!YM;<XNB$VR_>';(B$^C=:H*3.4+&V)\=(Y#.HQ#P=E%'D?
M?L4\1]F[F"HL2TSJQ9,46:#=!*QJ,[:%ILX=5[=@H2;;3O?;I;MVC.773J]6
M_61M9;.NM26&MFV*6L$BB2=JN\"LD&[9LSCHW=5113<2'317]37>;N"B^7BV
M7[UUYB'HH,S/;T"Q%:]A'NN_)J4I6\OJ^7")!-'>]6V/8=BCA#]P*W&'%ID&
MBX.-1T[HD-36< :M9PN,Y@:**J*['<9IZRLX34WTY)J,_1;VZ=X@D$7IOX>C
MGZ2%L _)74:)BTY@+J0G'\%DD3,1","4(=4H8]"F)63L9<V([SP5 &\SFYB.
ME1@YO'W$X,&V*0AM[/+#C&=_6-68[WL5_8N<1D+I]'M?VL*]CR:-,FHZ"CMB
M$]ITR'V&[L XQ1KVJ*_C\D45K\[7@\"O&:XA47$,!PAD>='V+]LCN?3E'_FF
MA9/3T39!FYM/][^W#0,A:7XWTM>^F[9836J&OUZIK.%5LM+I!.]80":1QG*I
M7EEM(R@L9C9N(]LKCFS-J\?,A>C0<J_PV37?X::O'F57B[A92IG<[BQ%8B+:
M,C\"0X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
M X . #@ X . #@ X . &N S3H>KY#VUL"G:?B<2GL;A,2>4W)([5$?6>#9"_
MA1YL=5AR"8+*3Q=XY<81D#$;C;!+9;+4GJIE;.,VT^#Q,\VO$MOMQ%+6-5BV
M%IIP/8*.?LKM)#++G(?4I,)8&A&DM2$@]H>@9.SF%@J*=285-!@V+]?P49(3
M,S9::+-HX0NF.Q)X4UWK=.!LCBR#O9H9<>GCT[+<#$F9WW]^X]=F\RY^H8X>
MV+V0*MT2NTJM)R^@,_F;F)$0\.3-,I0Q-]39T4B^2SA3KS6#.2@M+9$N0HU9
M&$,1K<T4]DN"Q9ZE%7S$=BYMG;?I/=Q%?A7WZ7MIPTW%W>(S(J;[614H0?CY
MC/K(6&2\,$$Q.10&OQ<?DC60]=2DU=JD"4:@$>+M& NUTQH8:09GV*(G/I !
M]X8<+9SH^#S6ZSO\:W=P$GF+CJ1;--2ZMXMZL)EVFG3V#@"M@3 4 D<XC#&3
MS(5"1R\LCZ:E+7?)YB 46G766M8G'Q;2:QNJVJ&JT-EQ8 7+E8N3F+EV3&L&
M [%NW=6ZVPS[]FH$9GI?K(N&S4BZ=AC+G5<C:1HM.CEIE9TL?DU7T%(% 4AC
MB("/CS+NO%&DL<1YNC&Q?J;YW)V;_)T+@F[V&/LX3V8,$MFNN2K6*W.KOT[
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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MY<QXH^JP#_M&//QBH_H3S@_OXH?]6TG]*VOW>'+?>ER/GVS^CB_VX'U6 ?\
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M\H,@< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
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M\4^KO(=?;S.,(< ' !P < ' !P < ' !P < .RPYIQJ X . #@ X . #@ X
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M#]F7U@^W)%O^$K_1O'O@?(U_6!0_3,^JA]QCRH_,RJ^F)]9#]F7U@^W)%O\
MA*_T;Q[X'R-?U@4/TS/JH?<8\J/S,JOIB?60_9E]8/MR1;_A*_T;Q[X'R-?U
M@4/TS/JH?<8\J/S,JOIB?60_9E]8/MR1;_A*_P!&\>^!\C7]8%#],SZJ'W&/
M*C\S*KZ8GUD/V9?6#[<D6_X2O]&\>^!\C7]8%#],SZJ'W&/*C\S*KZ8GUD/V
M9?6#[<D6_P"$K_1O'O@?(U_6!0_3,^JA]QCRH_,RJ^F)]9$C1A)B9&CRXMRF
M\&E6+0D.>)>=Z)VQ?()NFCE+SL:[>C7;JIJZ>=KKMYNV/'&,_6YVS#EQJA$B
MSX;R9$.;&8EQ7T7R/QI+27F'D9B(\KC2TK3<B.RBN1'H.MY49^')D0Y3:F9,
M1]V-(97;,T^PXIIYM5C,LS;B5).QF5R.QF/NYJ1@#@ X 1)[[? J[4?>)LG\
MF"')+:727>*K^*?5WD. +S.,(< ' !P < ' !P < ' !P WI>0$^%?:WR>3W
MYR:QY1>SK]1BZ-O5ZR'+>YB&4. #@ X . #@!%@AV;*;36QH9"^MU^6?K6$K
M:0J22B%KT*RCFTB=PR)3O+%ABP+T@LA<>J@IJ"V<.-X^BT]9650;N'&4%-L3
M;B17Z? 1?@9VZ/$1VB7:"Y6';853[^F+L>1&UF#J4O 4Z5H-:24(U9)MV/NE
MV(57;\WV7J8Z[14329SID&D#8]J02AIZ:**IQ$9-BM>_?KV;?;B(S'FM;NN7
MH/\ CKT#6EWG^%9;O\(QS\BHUSX\_9+?COQW_P!51_\ XY1Q]-O(1^*?"'_3
MU/\ 7E3$3,9\/KX^MG'U\9Q^]SHL=N#*D.=7'*9:^DT--S=[,V[5-8E+&,D)
MLS;=JIAL*;^ORA4BV<(ZN/[#%M$W)'7+G;U9@VT4V]$CSF^'WO*#7*[)K.'J
MCB23B%EE"YE=C5>9'J+3*^1A,^=5IR6RZV3OWB''0]+2;Q\E&92L\C8XI66L
M&4JD,4NM0:&Q1''5(C4A^FQGH+CJ>5EN>;TI$9UM9M_?I3RFHQDT7*R'3269
M8^K6/7>\9R4SEM8"B "3O3$F7<NS";IK,HJCNL5+/&[EQH^<R2*M72C@N1T1
M7)1UFYV<D%F39?*F^8J5Y2)$>L5 V<4J9I=9DU"LNO2)Z'F<041M2YTY]IYY
M,AZKT1AY3L^6AMV928[QNRG([3N96(ZC@9AZF0N5P\ERH4MB'2VVV8:FG:+5
MEI1$B,N--*8:IM6=:2W#C*6W&J+S1-1T/N())6>A/YXU''!#:;2YN)D[AP\D
M@Q"2&41TA=O/[[='&2;W5L6<.O'^R%WZ3A5?_P#J[;<V!K%.)V(E2@,8CKS,
M&LNNOU>&U5Z@W$JK[^K[U2CHD$S.=>/5UR4AU;G\\S&\N8?H#LB#,=HE(<ET
MMMMFF2G*;"7(IS3/_):@OJ9-V(VU_P#K1'4VE'\TB%V3>[+!G8T "(&WPV.Q
MZ+PV+MXT&*FVL==ZP<0T#"#;\,N4=,5I!NV9-U71#1%+'K">NS5%LGIHGKON
M)/*/BK$T2E4V54I4.DTFBX?HK5'I\ZHLTI\L-P6($"I2:>Y,>C.5134=I;TI
M+:/OJ$FRAE*4I+:*'@?#U!DU"?'@QY52J-5K-4<J<V)!=J+)UR6[,F06)B(K
M3Z*>EQYQ#4=2U_>U&3JW5&I1T:.2^TW)YXUB<KGBDEG;UJR)) CY_!B7D%W&
M<,VY'U%YAV<<J.E]O0:.\N=\K*[;:_UV^V<[?2*_C=ZJ/L4*N8H76,32&(TM
M%,JE4*H5Z4X[:.U+\VD$_4G5/.'R:7S>5G69EJ9F-;4J/A1JGLNU>DT!-,H+
M#K\9<^GT\X5'CMMD;SD;EV39@MI:;+.;/))R((CT(B&3R8SLRS0&1]>530F-
MF<BS$6[('::,I OY7)7BBBL<,JQZ5E0PXX:>/'+ET+/*LWKS=1\[<([XT=JZ
M<RFP_+'&;A4MVMXBF1,05;W"9CT[&S=:ILFMU=]2U4FH+I5<G0(E2J$A]YUZ
M'4UQY#ZE27W6U$E]:>+Q97DQ>7*J#=*HL631:;[KN/3L*.4J?'I-,92A-2A(
MJ-)B3),"$RRTTU*IZ'F&4I8::61J90=$FZ_8 (U:'IC+YJ_8*/G(UN=2L927
M#T2BX=<<Y&JEPLB,M&))U'MW;+9@Y<H/'87UMOA%5AJOKC;\2.>56F,,5/$%
M>Q))B*DO1&JDC%KE=B-37(+L1Z(Y.I]6J#$68_3%/QCC//-/OT_EVB;7&)TB
MUM"1Y/9SKL&C4>B1Y"6&Y3D%>&TT>2Y%;F-R&Y2(<ZFPGGXK50)EXI#33C+,
MWD7#6B0;9GAEX4)D4A[<@1?OD!+/V>*1>/'#I(8P]87=^HCTUU-]&;/UITY<
M^K-M4T?6'"ZWF>D54VVZ\D3ILMN*U+F2I34&/YI!;D2'7FX<7E7'O-HJ'%J3
M'C\L\Z[R+)(;Y5UQS+F6HSYHS%BQUR'(\:.PY+>\XEK99;:7)D<FAKEY"D)2
MIY[DFFVN5<-2^3;0C-E0DB^#FF+:727>-0.558$VM:,/132 4FYL\<X%IN'I
M5&PXE#]1[WTJB?L_+*0YPY=9]!HDY]:0_P# \%L)?W1/?GWU:(N31<[? 3N,
M_P":0^.#AGG58K_"5O(MYBP/?;[)_<CO_P >-9?_ /7,ED_TNPQ2ZOZ/:0R;
M25H^_'7C.<J1I]#WF\DL&(EHT1(,"KD2=K:PI17!]#VF,VV8/V^YJ*/UV3IM
MG&BS-5#?.NN^=M<096/G_B5Q)'<N;^!V&6.0)$8>[/P-^UWR<;K_ #<2/DEM
M+I+O%5_%/J[R'7V\SC"' !P < ' !P < ' !P < ' #LL.:<:@. #@ X . #
M@ X . #@ X . #@ X . ''M\I3\)9Q_N+%/Y27/E5]E_^.!W_#5#_P#MCZ'?
M8S_BS1^?JMW11 =LV</'"+1H@LZ=.54T&[9LENNX<+J[8T21112UV4554WSC
M1-/37;??;.-=<9SG&.>8&67I#K;$=IQ]]Y:6VF64*===<69)0VVV@E+6M1F1
M)2DC4HS(B(S'?[CK;+:W7G$---)4MQUQ:4-MH25U+6M1DE"4D1FI2C(B(KF=
MA]Z (VZV0T;!BKC=R_4%-M$![M;9P42UUW5&H:IH[95?IZ[Z;*,T\;.--=]<
M[)XQMC.=4W2ZF\IM#-.G.K>E*@M);B2'%.S4$2EPVTI;,URD$I)JCI(WDD9&
M:"(R&G<GP6B6IV;$;2U'3+<4Y)903<59F29*S4LB1'4:5$EY5FS,C(E&9&/I
M2BTG7?N!2$</+%&:Z35V-2$$%'[5ROG.$&[AGHWRX076SKMA))5/513.N<::
MY\,\S(HE:<E/0FZ15')L=QMF1$13Y:Y3#SIF333T=+1NM..&1DVA:$J69'E(
M[#&JJTM$=N6NI0$1'FUNLR53(Z8[K3>KCC;QN$VMM!&1K6E1I3?X1D/2UCT@
M?9)X9 S#S(7110SAJ,>N,B4TMM]%=R>$D-\L-$MTE=5-G7HM=-D]]=LXSIMC
M&-FDU62<PH],J$@Z<E:J@3,*2Z<%+9J)Q4PFVU>;)0:%DLW\A)-"B58TG:SM
M2IS'FIOSX3)3C2F%RLIAOSQ2R2:"BYW"\X-1+2:2:SFHE),KD97:QX_L.5+Z
M@S&PE%%%PL4U&/<CDF[A=5J@NJ]PAZLFBNZ06;(J[*XT57151TVV43WUP*DU
M4XBYY4RH'!;;;><FE"DG$0TZXMEIU<GD^12VZ\VXTVM2R2MQ"T),U)412=1I
MY24PSG0REK6MM$4Y3'G*G&VTNN-I8S\JI:&EH<6DDFI+:TK41)41G]*,1E;E
MPU9MXQ(5W;["V6+5$*25</,-V[9VOEJAHVV4<80:/6;E;*.N_HV[MLMOYJ:Z
M6V^9N@5UUUEAJBU9U^23AQV6Z=,6Z^333+[ILMI9-;I-,28[SAH)61I]EQ5D
M.H-6)=8I+3;KSE4IS;+!H)]U<V,AMDW''66R=6ITDMFMUAYI&<RS.,NH*ZFU
MD7BC%)0X0=.F\;/KMF2KE%ZX1#D54&BS/Q];2=+:-MDVZK7PSZRFKMINAX9]
M+C7PY5NAUMUMYYJCU1QF.MUN0ZW3Y:VV'(]^7;>6EDTM+9L?*I6:5-V/.1"5
MU:E-K::<J=/;=?2VMEM<V,E;R'O^2MI"G"4XEVY<FI!&2_YIF/#:+R75$6XV
MCIS5 YMC4(OL)?X1,;9QXXU%J9;^80VSC.,XPTV6SG&?K<@Z)62;A.G2:F35
M2,DTYTX$HFYYF68BA+Y++*,TZD3!N';78)*J4PURFRJ, W(!7G-E,CFN&1;3
ME)Y3-'(N=XD$/C(""HC9MH5&$!F[QJD^::D&3EELZ9+^=Z%XVU<IIY7:K>;M
MZ)PEC9)3S=O,WSX9YIY<"= -E,Z%+A*D,HDL)EQGHQOQW+\F^R3R$&XRNQY'
M49D*L>51V&>-,B3"<5$E1Y1,NJ8>.,^T^33Z+9V7#:4HD.HN69M5EIN5R*XI
M_-(-0.653WV)*M^]S"/R9&<^YF OP&P7_A/#GZGACY)8Q_"[%/\ B.M_K.4,
MC<Y8..!P < (D]]O@5=J/O$V3^3!#DEM+I+O%5_%/J[R' %YG&$. #@ X .
M#@ X . #@ X ;TO("?"OM;Y/)[\Y-8\HO9U^HQ=&WJ]9#EO<Q#*' !P < '
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MQ;V)MS+?H72:QY%XQO3L)#X-7$W</G39P[/43UMDLM,0"3J:IKK$4LS5Q+(
M/4>EMM-B^U5K;MT=]$%%N21?"/F+7?M/V/T@9Z<="/H*_P##T#4-RPJ' !P
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M)8F26&3<9@--O2W"4@B9:==0PVLR4HE*S.N(19!*,C.YD22,RQUS5#2AP <
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M'-VWM[6OQW"QI!Y02!L5S+RNI99$7>F[=Z/R,@[#-WH%R0@E$4LTA-G"GJ[
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MNW@HRSW'8ZCV]<F9"ZB8J<N+1A:,4?R=@S6)$ #8ZJ9T'*%APINX+D6.''K
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ME-R!(X7/E0_AW]@/X6AGYM(7SP1Y7OQC8F_OX/ZJ@#V[Y*?Q?X=_NI_ZUG"
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M,1TY(@?OCGPQKXY\W&<YQCQSX8SGP\<XQ^YC.?#'CG]_PQX_N8X ?G #>EY
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M5S:QN@< ' ")/?;X%7:C[Q-D_DP0Y);2Z2[Q5?Q3ZN\AP!>9QA#@ X . #@
MX . #@ X . &]+R GPK[6^3R>_.36/*+V=?J,71MZO60Y;W,0RAP < ' !P
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M*5[AP[IWZJVMOL/8TD"AM[%M4?*;B-#8Y.(-[B!A\6S""65ISRQ2,#A&(V&
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M #@ X =EAS3C4!P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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M !P < ' !P < ' #LL.:<:@. #@ X . #@ X . #@ X . #@ X . #@ X .
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M2\]G^MBQ:NB.%!XYU[)%>LLFFR+9?V8/]*EMZDV]& 57@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@!$GOM\"KM1]XFR?R8(<DMI=)=XJOXI]7>
M0X O,XPAP < ' !P < ' !P < ' #>EY 3X5]K?)Y/?G)K'E%[.OU&+HV]7K
M(<M[F(90X . #@ X . #@ X =:!Y=+_&M=NO]X:V_,G6G/5GD\_ VB_W<O\
M6$L>3?*-^&=;_O(?ZNAC4MSF@X2' !P < ' !P < ' !P \M/[?7_2U_EQR#
MV'T'W .X=9_WFT_V9#_M:\\0GM/I/O'N9'Q$_DI[B'T\@6#@ X 1A[L_ W[7
L?)QNO\W$CY);2Z2[Q5?Q3ZN\AU]O,XPAP < ' !P < ' !P < ' !P __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g63338g17p85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g17p85.jpg
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M/Z<C(Q'7GW\_IR '7GW\_IR '7GW\_IR '7GW\_IR '7GW\_IR '7GW\_IR
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MS=G@N#F[,K1OCL3&R4O8=9,%R8^378NU_83:^Q?:980H
M                                        &)*Z7S.JLNS_ ,V+$H.L
M)]B7W%SO'"1C]GU=G[J:92]CV78XZNO&.O.<YNRO6_LYDVOL7VF6$*
M                                                      5)Y+\C
MK+Q[=QLFG18BU4O&K=\["F'1+._86Q25TUK>3V$SK$1 EK3N+,SL;6,7:K6)
MU8>Z(USVALE67Z;D[YH"(!9<TMILMIVO5D_4]</'NF]F\?\ 7VT+!!/;&WBK
MRGR:N^J:=2I+5"+U5TK'>+TNTT'^PB3Z\]A\\A&\/&XB,69&2A!E3C5KY*Z^
M[C7J.BS7REF?B>O?M=B%V+M?@C#:^Q>+,\(4
M                                # E\IUOB%M^\'8NQ=K\$3:^Q>+,\
M(4
M  QCZ%AI1=HZDHF,D7,>5Z1@Y?,&KM=D22:F92)&BSA)11L5^R.=H]*B8F'3
M4QFZ^%$C9)D"/8C1.D(#%,Q Z;U5"8URZEWVO<1&O*C&XH;VPJE7GW=,[CB$
M?!=U.+D(M+N(3N%625*51Z=8Y<9P%3=VOE+,_$]>_:[$+L7:_!$VOL7BS/"%
M                                                         P)?
M*=;XA;?O!V+L7:_!$VOL7BS/"%
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M7BS/"%
M   P)?*=;XA;?O!V+L7:_!$VOL7BS/"%
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MI=AKY2S/Q/7OVNQ"[%VOP1CM?8O%F>$*
M                            !@2^4ZWQ"V_>#L78NU^")M?8O%F>$*
M                                                        '-$U
MBU19.3]EU)=]9;*U7LU[9WKJ.>:=Y8'JU?V575DS/('9UOU3J#>M V'F2F(E
M%-&?F[GI>12BG#!:%5NTW#,&4BX&6FFQKLK3JJUUG2W&.K&,8_%C'5CKSG/X
MO_CGW<__ 'S[H&)BV\]!NRQQVDS%.B3!W*<2=O(LURRAV953O"1QDUC8>G:$
M07.Y*VRKE J*IE<%PF?. /,U\I9GXGKW[78A=B[7X(FU]B\69X0H
M                                                &!+Y3K?$+;]X
M.Q=B[7X(FU]B\69X0H
M                <8;>UE9GI$Z=&6D[%N[;V0[IY 52?I["%LD*RL=7MM(L
M5P=S>W&]D/?X2.I.FEY"J4#3+"S2<'6J\G<K=9-=N6K0PRI[VO'@UJU?+3Y:
MG5?<=1F+_J+:E$KKN,86"[:XO%1@GTUWQ[S,IBR5F4AHQW+=Z%FTMWL;O7J"
MS_O6X0D>Y2*]Q+).>U'*,3E=K'H_]QTVT1<K(HZP>QCG9VGKA'O9:V%E;GIB
M'U7MK6VS[;BHO*OI#7=3LDSO)K496FVK%;JNGV$97F%$0G$[X]0LTK(#*OV\
M:Z75O3I.O37REF?B>O?M=B%V+M?@C#:^Q>+,\(4
M                                   # E\IUOB%M^\'8NQ=K\$3:^Q>
M+,\(4
M   *!7#0<;9>8\9L=Q/T"U*M&%1EE]=J;.N^N[E5&D,^@Y-*T2%&J;J9J&X&
M;BTZ]HU@A5;O5:Q-,I.H,(]QL"8K=?K=<@A=GX_"UM]W:7] @ &!:^4LS\3U
M[]KL0NQ=K\$3:^Q>+,\(4
M                 # E\IUOB%M^\'8NQ=K\$3:^Q>+,\(4
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M8:^4LS\3U[]KL0NQ=K\$8;7V+Q9GA"@
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M4\J   &!+Y3K?$+;]X.Q=B[7X(FU]B\69X0H
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MMT=7V'05KY2S/Q/7OVNQ"[%VOP1AM?8O%F>$*
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MC\8OADJ?]J2^P#H>[]T.?&!<?SK7]U.Y[C72A\#+W^;9_P!^/PQ^,7PR5/\
MM27V /=^Z'/C N/YUK^ZCW&NE#X&7O\ -L_[\?AC\8OADJ?]J2^P![OW0Y\8
M%Q_.M?W4>XUTH? R]_FV?]^/PQ^,7PR5/^U)?8 ]W[H<^,"X_G6O[J/<:Z4/
M@9>_S;/^_'X8_&+X9*G_ &I+[ 'N_=#GQ@7'\ZU_=1[C72A\#+W^;9_WX_#'
MXQ?#)4_[4E]@#W?NASXP+C^=:_NH]QKI0^!E[_-L_P"_'X8_&+X9*G_:DOL
M>[]T.?&!<?SK7]U'N-=*'P,O?YMG_?C\,?C%\,E3_M27V /=^Z'/C N/YUK^
MZCW&NE#X&7O\VS_OS#\1)>-L54VU8X5VG(0EAY%;DFH621P?#>2BI&PIN6+Y
MME0A#&0<HG*=,V2ES^,IL8,4Q<='H*M]CO:Y,<7M=T^&U7=>G2MC^\+OM<M1
M>2M=BM=ZPS;/:9+CAAB<N;+B44+:3V-)II=WI?L=INZ]L(W;;945GMUW='&#
M+#;K-&X7,LUKLUW12Y]GFJ%Q*&9+C342J]C54TW; ;N-2@
M  <SM_<:=G;0Y)P5JDJ+4;WJDSVM(M91[8'R5GUP;N:'@W-NI1'UFAU=<7FH
M1SW:%J8['UZWE;8ZLB^G(.%AXEHGLJUIBI]_V=>_9HU'2)_%QTM%O8289-9B
M)DV#F+E(Z5;(/V,I'/6YVCUE(M'*:C9ZU>ME%4'C9=(Z#A%51)5,R9S%R(0M
M$<8./T$[J\A%ZFI[>1ITJM.0$B>/,ZD6\NJYB7B<B]?O%5W<TZCWE?KKR&5F
MUI',$[K=<=0O<"\!#J,@)::^4LS\3U[]KL0NQ=K\$3:^Q>+,\(4
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M3:,J.Z=4          P)?*=;XA;?O!V+L7:_!$VOL7BS/"%
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MJ]/^O>$?V98O^L&&C9]@_P"C^)/U]PS_ -EO\LX-RFL
M  P)?*=;XA;?O!V+L7:_!$VOL7BS/"%                       "L/&/_
M $>0/^T]MO\ XL(-.=#O]'I1_;'CG_Y+O-H]*&OH\_9=A'PMY9X;C-7
M                           <9=B-80O2&P?A/=6+M"%MNOVLK!.5HZ&G
MY1]?9FLV?6)5:56M_P!9?V2LPEHI.OX:.V>30%HG'<K0HZ!OLO)T:B2L_ #+
M^SJ^VFGLT;]=->C2CKG=JPWNU,MU,=N,-&ENK$_6'3HT9"S96S>?BG<4LX-#
M62.F*[+X13=F4S&3\1*0K_!>Y92.?,55VRHQ*,5#@!"5&>[^1]]90K2QW?6%
MUV+2Z/KF&I>O7JFD=B5G:VJX/5M3;3,DWU)"L+U7',Y=6R#FV9O+VYWN27-$
M3DXREX<6OA3A3_CN+X-?*69^)Z]^UV(78NU^",=K[%XLSPA0
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MZ5,M=GE3Y$F;-CNZQ6:9,\G+M,Z%0Q1.'WU6G14G ;(/#
M   !@2^4ZWQ"V_>#L78NU^")M?8O%F>$*                       %8>,
M?^CR!_VGMM_\6$&G.AW^CTH_MCQS_P#)=YM'I0U]'G[+L(^%O+/#<9JX
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M*:IT4B&T38HX9<4U02U'%"FE%$H(4W6BH2(/5GG0
M    # E\IUOB%M^\'8NQ=K\$3:^Q>+,\(4                       *P\
M8_\ 1Y _[3VV_P#BP@TYT._T>E']L>.?_DN\VCTH:^CS]EV$?"WEGAN,U<
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MRA_*<J_ZO\/_ !\'M1Z9?CBN;_2ZP?Q0/;+T6_%A>G^H-L]0#Q;<H?RG*O\
MJ_P_\?![4>F7XXKF_P!+K!_% ]LO1;\6%Z?Z@VSU ;SI/5LMJJ!M#&?MZ5WG
M;A?;'L"9G$*\G5VYY*R%8=U(-XA*5F$T$DU&65"Y*\['/;LE*DF4F.OTG1W@
MRW8*NR^;->=^P8BO*_L37MBB\+REW5!<TJ*V7NK-Y>5*L$%MM\,J7#%9\R:M
M%'Y1PJ"!0JOPL;XJLF*[?=4^P7/%<=@N:X+MP]8K#'>,5Z3(;+=KM#E3)ELC
MLMCBF1Q0S\K3DU]XFXXG$Z3*/?GC
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ML:0QVJW73;[)9X(IF&KR@@ACGVBSRY4+CC:A@3B3BB:A56TBZ@_0QI0
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MFPTY-GK>Y+3XM/DT5X?:_LI2IU^:^4LS\3U[]KL0NQ=K\$8[7V+Q9GA"@
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M^2I%ED6>S0110RI<J7"H88(7EA5(8%#!##"I$'K#S@
M      !6+FT_?17#+ES*1;UW&R4;QBWX_CI%@Y69OF#YGJJUN&CUD[;G3<-7
M;5PFFNV<H*)K(+)D52.4Y2FQ]:X888K\N6&*&&*&*]KNABAB2BABA=LDIPQ0
MNJ<+6AIIIK0SY-_Q107%?4<$44$<%TWE%#%"W#%#%#8YSABAB5'#%"TFFFFF
MJHYX\9.BAX+[ XV\?+[;]9;"E[9=]'ZGMUGEL\FN4K',G8K+0X"9FI'+*-W0
MSCF?=LD]<N>Y6#1JR;]M[4U;(($32+Z6]L87_9KUO.S2+59H)-GO"V2),'Y*
MNB+)*E6F9+EPYH[#%%%E@A2K%$XG2K;=6>8NG!N'K3=5V6B?9+3'.M%WV*=.
MC_*U\0YYLVS2XYD66&WPPK-'$W2%*%5HDEH)P_D<^CV^"+8/ZTG++[\1\_V[
M8D_3;-Z(N;U>?0]HV&?T&T^E[Z]8#^1SZ/;X(M@_K2<LOOQ#V[8D_3;-Z(N;
MU>/:-AG]!M/I>^O6 _D<^CV^"+8/ZTG++[\0]NV)/TVS>B+F]7CVC89_0;3Z
M7OKU@2-J3HR^&6C=AUK:NLM;W2#O-1<.W4!*2/('D9;631=]'/(ET9Q7;EMB
MP5F4(HP?ND<(RL.^13,H5=-,CA)%5/K6S%5^7A9IMCM5JD3+//2AF00W;=<F
M)J&*&-4FR+'+FP4BAA=8(X7HHW1M/M6+"=PW?:I5LLEEGR[1(<44J.*\KTG0
MPN*"*"*LJ?;9LJ.L,42I'!$M-4JI-7U'G3T8   8$OE.M\0MOW@[%V+M?@B;
M7V+Q9GA"@       !3'3NO*!;[_R;?VRC4^T/F^]';1N]L59A9MV@T+1:4N5
MJBYDF3E9)OA999;")#E3PJJJI@O9J&SG\^8!PIA>_L3],=JOS#=P7S:9/27:
M)$JT7M<]W7C/E2%AC#<Q29<VV6>=,@E*9,F1J7#$H%'''%3-$V]T8QQ'B&Y\
M/]&-GNB_;YNN1,P)*G3)%W7I;K#)F3G?]^RW-CEV:?*@BF."""!QQ0N+)!##
M6D*2G[Q(:6^"'5_^X%4]DC:'N<='GP#P9]%[C^XG@/;SC;X88I^D%[?>QXD-
M+?!#J_\ W JGLD/<XZ//@'@SZ+W']Q'MYQM\,,4_2"]OO8\2&EO@AU?_ +@5
M3V2'N<='GP#P9]%[C^XCV\XV^&&*?I!>WWL]#33>H6#IJ_8ZJUNR?,G"#QD\
M:4:L-G31VV5*NV=-7",619NX;K$(L@ND<BJ2I"J)F*<N,XY9& ,!V6?)M5EP
M3A&S6FS39<^SVB1ANYI,^1/DQJ9*G29LNQ0S)4V5,AACES((H8X(X5%"U$DS
MCG8SQA:)4V1/Q7B6?(GRXY,Z3.OV])DJ=*F0N"9*FRX[5%!,ES((G!'!&G#'
M"W#$FFT20/7'F@                                       #D3>=A7
MW\/N-IZ6P;=5<$NM%;Q&NFVZ-0OHJ=J\@PJ#B:M2VK5>2=;NYX1Y6Z]<(!A5
MY3C])YBG]TOFT&]FNMGB=305-&7]GY=WVT[-OR:V^NP&( &!:^4LS\3U[]KL
M0NQ=K\$3:^Q>+,\(4     K'OS_6!Q;_ #W+?\N;P-.=)_YT="_[1X_JCB4V
M=@'\W^E/]1X/K+<)9P;C-8@                          49Y!<_M5\>=
MP,-$R6LN2>VMF/=;1NVEZ]Q\T1<MRK0U%E[/8*?'3,[X)HN#QB3J?K,LR)V]
M+L"G3;]L4*9VW*IZ"[<.6R\[%%>$%KNJQV6&U1V-3+RO"18<]H@E2I\4$ORS
M6>DN;!%HZ]S/.WIB6QW7;H;NCLE[6VUQ66"VN5=EW3[>Y=GCG39$,R9Y%/(G
M-DQPZ5L6]$5_RHU,_(RZ3#]1+=7LL=SVHS_/F%?I!8?]QTO;C9_,.+?HY;_]
M@_E1J9^1ETF'ZB6ZO98>U&?Y\PK](+#_ +A[<;/YAQ;]'+?_ +!_*C4S\C+I
M,/U$MU>RP]J,_P ^85^D%A_W#VXV?S#BWZ.6_P#V$&\GND'C-L<:N0VK*EPP
MZ20]JV5HW;5 K))'@YNEE'GL%RH,_788KYYF(5PT9FD9%MARY[6IVA')U>P/
MV'8Y^A=.&H['>EVVN=?N%_(V6\+':9N6_P"PQ1>3D6B7-CRPYUFBRPNBJJO0
M?/O;%$%MNJ\[')N#%?EK7=]MLTK/AZWPP^5GV:9*EYHLCRPYHU5T=%5T9TMX
MG0<S6.+/&FM6.*D(*PU[0&FX.>A)9HNPE8:9B==5QA*14FP<D3<LI"/?-UVC
MUHX337;.45$52$4(8N/*WS,ESKXO6;*CAF2IMY6Z9+F01**"9+CM4V*".")5
M44,4+44,2;3336@];<TN9)N>ZI4V"*7-E7;89<R7'"X8Y<R"RRH8X(X71PQ0
MQ)PQ0M)IIIZ2?Q\T^D          8$OE.M\0MOW@[%V+M?@B;7V+Q9GA"@
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M[@'JXOS'D?K7:_\ M%C/(P?GY:/U1L?_ 'FW'3L>4/7
M !@2^4ZWQ"V_>#L78NU^")M?8O%F>$*        %8>/?EIRA_/X]_N!11IOH
MK_.'IG_:A:/JKA@V?TA?U+T7?J!)^L5_EGAN0U@
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MET+5D[M?*69^)Z]^UV(78NU^",=K[%XLSPA0    "L>_/]8'%O\ /<M_RYO
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M_;%9)"K0DA*L6<O95H9@>5ET8"-<+IO)A6*BTE)*13CD7!V+!,[QSA)N0RF
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M1Q*;.P#^;_2G^H\'UEN$LX-QFL0
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M5#%#E4#456TIW'SSZ(      &!:^4LS\3U[]KL0NQ=K\$3:^Q>+,\(4
MK'OS_6!Q;_/<M_RYO TYTG_G1T+_ +1X_JCB4V=@'\W^E/\ 4>#ZRW"6<&XS
M6(                                                8$OE.M\0MO
MW@[%V+M?@B;7V+Q9GA"@       !6'CWY:<H?S^/?[@44:;Z*_SAZ9_VH6CZ
MJX8-G](7]2]%WZ@2?K%?Y9X;D-8
M                 %%>052WC,[WUK+4AML1U66KS2&8&1J%W/6Z94%87?L3
M.\C5MIUTML@VUL:WC0*7@Y2BR5<N:3)]'V..BDZ[,V%H[DA5^.YTXES&OE+,
M_$]>_:[$+L7:_!&.U]B\69X0H    !6/?G^L#BW^>Y;_ )<W@:<Z3_SHZ%_V
MCQ_5'$IL[ /YO]*?ZCP?66X2S@W&:Q
M                  # E\IUOB%M^\'8NQ=K\$3:^Q>+,\(4        *P\>
M_+3E#^?Q[_<"BC3?17^</3/^U"T?57#!L_I"_J7HN_4"3]8K_+/#<AK
M                                               #XE;HE75<E3+A
M=9-%%57'7V1TFYECHDS[O5V*9G"^2]6/QJ&Z^O\ H ^P      K'OS_6!Q;_
M #W+?\N;P-.=)_YT="_[1X_JCB4V=@'\W^E/]1X/K+<)9P;C-8@
M                                      !\>YT<.,NNUE[H,B5OE7W>
MRRB4YE"I_CZNQP<YC8]SKZ\Y]T ?8         %8>/?EIRA_/X]_N!11IOHK
M_.'IG_:A:/JKA@V?TA?U+T7?J!)^L5_EGAN0U@
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MR_RS3[0&>'?P?(9(MW%<QX"VST,O\LT^T!GAW\'R&2+=Q7,> ML]#+_+-/M
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M-9:UKM6U-:5MI6J6])["ZW@+;/0R_P LT^T#+/#OX/D89(MW%<QX"VST,O\
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M:,^Z91:M<KDY+QXC37X[5]A=4"
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M>YP:*XC5/QU5_'66+ @
M               &)GX&$M4%-5BS1$=/URQQ,C V""F&;>1B)N$F&:T?*Q$I
M'NTU6KZ.DF#A=F^9N4E&[ILLJ@LF=,YBY A-OQ-XOLX!*JL^/6F&E;2L3:VX
MA&NMZDWC5;,S@Y6KMIURU1BB).Y-.K3LW5^ZG15E#UJ8E*^?)H>0=LE@KQU]
M>WQ()X/UZO-9OE5-,*] Q4E <A)G0D*O"PL9"DB].:'KL##:@UXR:Q+5FT0K
ME!CK%/(034B&#IFF)%PX5<.G:RQQ7R?RM)OO+\ 0
M                                    #3[[KVB;3J[ZD;*I];OM.DW4
M.]D:O;H9A/P+UY7IJ/L<"[=14F@Y9K.86P1,7.12ZB)E6$M',9!J9)TU05(!
M%K[BAQB?15?AG7'W3:D/4D)E&LQ.-<U1.-@R6"6CK#-YC6"461JV5E;##Q5A
M?+$2PLXGXYE-J*9E&R3HH$1]'5E.5XE:UV$\;,LW+<2MFVYLV=:L&4>XN&Q[
MM9)-[9;5)HQZ#5GAZ_.BV;)(-&S9A&1;&-AHIHQB(U@R;"O6^UEW@(
E                                             !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g63338g18f70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g18f70.jpg
M_]C_X1:*17AI9@  24DJ  @    ,   ! P !    < ,   $! P !    %@(
M  (! P #    G@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    I    !L!!0 !    K    "@! P !     @   #$! @ >
M    M    #(! @ 4    T@   &F'!  !    Z    " !   (  @ " " _ H
M$"<  (#\"@ 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HQ,#HQ-2 P,3HT.3HU-     0  ) '  0    P,C(Q : #  $   #__P
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M=X>7I[?'_]H # ,!  (1 Q$ /P#U5)!NLL;=4QAT>'S\0/;V5>VW.JJ+WE@
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M#T,L'\\M_K@&/\]2KQ;CK9:]D:0UQ,\>[ER5#NL,(C],/+]<:ZSKV6UCO?\
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MD,;N_.]JG]LPX!]>J'$!IWM@DSM ]W\ERJ6@NZ?CMV[I:P%NTNT-?[HKR/\
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MW'$^D[Z/T_>I5T=.K;['V-;$F,5HY<6L<?U3Z5;W+2#W>)57*S;Q:<?&!=8
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M;!1S9I;:.$))300Z      #E    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      !  2     $  @!(     0 ".$))300F
M   .             #^    X0DE- _(       H  /_______P  .$))300-
M       $    'CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !4    !   "0    D     !  !8R0  .$))
M300>       $     #A"24T$&@     #00    8              A8   -P
M    !@!G #$ . !F #< ,     $                          0
M       #<    A8                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   A8     4F=H=&QO;F<   -P    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (6
M %)G:'1L;VYG   #<     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     CA"24T$#      5(     $   "@    80   >   +7@
M   5!  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MBTL+Z\6Q[K+"V:WO=8TD!S ]C'_T>NIKOTKV>G3_ (/T?56P &@-:3#0&@_
M;5%F+E,&VMM# >0UI:/^BG]#.CFG_I)*7//&OP"B3$0..T*+</+8T,;Z0:T
M-$V: ?VDS<#++P7W$-UD->[\-P1L*9@@]@(X$#1229@.:9]5[_)[B1\= U3&
M,\<.'SD_E2L*>*ZZQ]G7\JNHP\^F!XF::_T8'YWJ?]M_Z12^K>X?6'':]V]\
M6R[77VGG=[O\Y:75>EN=U+(R/M5=)L#='5V%PV,J9O:]GYV\L].RM/T7I>SJ
MU>0W(KL]$.#JV5O9 +2QOT_:K/NP]OAL?)7UX6M[<N.Z_2OZ<3__U?54E\JI
M)*?JI)?*J22GZH;])_Q_@U27RJDD@/U4DOE5))+]5)+Y5224_522^54DE/U4
MDOE5))3]5)+Y5224_522^54DE/U4HO\ HGX+Y7224__9.$))300A      !5
M     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!!
M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-
M! 8       < !     $! /_A$^EH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V
M,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX@/')D9CI21$8@>&UL
M;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT
M87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z
M>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12
M968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M95)E9B,B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z<&AO=&]S:&]P/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(B!X;7 Z0W)E871O<E1O
M;VP](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!X;7 Z0W)E871E
M1&%T93TB,C Q.2TQ,"TQ-50P,3HQ-CHT."LP-3HS,"(@>&UP.DUO9&EF>41A
M=&4](C(P,3DM,3 M,354,#$Z-#DZ-30K,#4Z,S B('AM<#I-971A9&%T841A
M=&4](C(P,3DM,3 M,354,#$Z-#DZ-30K,#4Z,S B('AM<$U-.DEN<W1A;F-E
M240](GAM<"YI:60Z,$(Y-48Y,T-!0T5%13DQ,4$Q.#A!,S-!04,X-D8Y,3(B
M('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z,#DY-48Y,T-!0T5%13DQ,4$Q
M.#A!,S-!04,X-D8Y,3(B('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP
M+F1I9#HX-$0V,C<X1$5%0C8Q,44Y.41"0SDT03,X.3 V-# Y.2(@9&,Z9F]R
M;6%T/2)I;6%G92]J<&5G(B!P:&]T;W-H;W Z3&5G86-Y25!40T1I9V5S=#TB
M13DP.$0Q134U.3E!-S!$1C S0D-#-40X,S4U0S=%,$$B('!H;W1O<VAO<#I#
M;VQO<DUO9&4](C,B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS=&%N
M8V5)1#TB>&UP+FEI9#HP03DU1CDS0T%#145%.3$Q03$X.$$S,T%!0S@V1CDQ
M,B(@<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#HP.3DU1CDS0T%#145%.3$Q
M03$X.$$S,T%!0S@V1CDQ,B(@<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/2)X
M;7 N9&ED.C@T1#8R-SA$145"-C$Q13DY1$)#.31!,S@Y,#8T,#DY(B\^(#QX
M;7!-33I(:7-T;W)Y/B \<F1F.E-E<3X@/')D9CIL:2!S=$5V=#IA8W1I;VX]
M(G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.C W.35&.3-#04-%
M144Y,3%!,3@X03,S04%#.#9&.3$R(B!S=$5V=#IW:&5N/2(R,#$Y+3$P+3$U
M5# Q.C$Y.C X*S U.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB+R(O/B \
M<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240]
M(GAM<"YI:60Z,#@Y-48Y,T-!0T5%13DQ,4$Q.#A!,S-!04,X-D8Y,3(B('-T
M179T.G=H96X](C(P,3DM,3 M,354,#$Z-#DZ-# K,#4Z,S B('-T179T.G-O
M9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!S
M=$5V=#IC:&%N9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)C;VYV
M97)T960B('-T179T.G!A<F%M971E<G,](F9R;VT@:6UA9V4O:G!E9R!T;R!A
M<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P(B\^(#QR9&8Z;&D@<W1%
M=G0Z86-T:6]N/2)D97)I=F5D(B!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T
M960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V
M=#II;G-T86YC94E$/2)X;7 N:6ED.C Y.35&.3-#04-%144Y,3%!,3@X03,S
M04%#.#9&.3$R(B!S=$5V=#IW:&5N/2(R,#$Y+3$P+3$U5# Q.C0Y.C0P*S U
M.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB+R(O/B \<F1F.FQI('-T179T
M.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z,$$Y
M-48Y,T-!0T5%13DQ,4$Q.#A!,S-!04,X-D8Y,3(B('-T179T.G=H96X](C(P
M,3DM,3 M,354,#$Z-#DZ-30K,#4Z,S B('-T179T.G-O9G1W87)E06=E;G0]
M(D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!S=$5V=#IC:&%N9V5D
M/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)C;VYV97)T960B('-T179T
M.G!A<F%M971E<G,](F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<"!T;R!I;6%G92]J<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)D
M97)I=F5D(B!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP96<B+SX@
M/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$
M/2)X;7 N:6ED.C!".35&.3-#04-%144Y,3%!,3@X03,S04%#.#9&.3$R(B!S
M=$5V=#IW:&5N/2(R,#$Y+3$P+3$U5# Q.C0Y.C4T*S U.C,P(B!S=$5V=#IS
M;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*2(@
M<W1%=G0Z8VAA;F=E9#TB+R(O/B \+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R
M>3X@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q+SX@/"]D8SIC<F5A=&]R/B \9&,Z
M=&ET;&4^(#QR9&8Z06QT+SX@/"]D8SIT:71L93X@/'!H;W1O<VAO<#I$;V-U
M;65N=$%N8V5S=&]R<SX@/')D9CI"86<^(#QR9&8Z;&D^>&UP+F1I9#HX-$0V
M,C<X1$5%0C8Q,44Y.41"0SDT03,X.3 V-# Y.3PO<F1F.FQI/B \+W)D9CI"
M86<^(#PO<&AO=&]S:&]P.D1O8W5M96YT06YC97-T;W)S/B \+W)D9CI$97-C
M<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^X #D%D;V)E &0
M ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,# P,# P0# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $'!P<-# T8$! 8% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@"%@-P P$1  (1 0,1 ?_=  0 ;O_$ :(    ' 0$! 0$
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M&.1Q'^[FX[K&5^+^;"<5'<_8VY.RA"0C*4H\4_"]6/A]7\^,>/U8_P"FBO\
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M#9QI:&HGU>N,8SEZ)<$>/Z8^)_.X?5]/#_30D/G*XN-+O;Z&RB8V4/KRP&Y
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M%-Q,I6.W6\CA?A%.]NJA684+#[ 'P.G)/ADY83D+9/M"1)VCSGP<0]>/Q?\
MI+^+BX?X5>V\M6-O=Q2K)*T-O(\MK:,_[F*20$,46G+]MN(9F5.7P<,!F2&N
M>NG*)%1N0X9S_P I.,?YWX]7\2^;R_;O##;KO +J:ZG1_BY_6!+ZB_2TW_ X
MB16&LD"9'ZN"../]'P^#@_Z9H8^4+-HU5[R\=H_2^KR-*"T0@;D@2J\3O]II
M%>1OY\/BGN#8.T9 [1AOQ<7I^OC^KB_X[PQ59?+%O,X::[NI5/I&>-I%XRM
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MU/YVVR7&;ML&LF,@R?Q1_P!+Z8\"&N?+"W06.YNYKF#C,DOK%>=)E445D5*
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M3</Y.3<<*J?Z)THJ%^I6Y4#B ;>.@7AZ= ./3T_W?_&/X/LX%<=+TOZZE_\
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MO\(MR!!%S/O2E=TS4:_^\^#M=#]'S9F-V)_EV'\<Q'+;:IHHV)[^V*6]E7P
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M=(HL7U;2]2N-4FEAC<K(T1BH8Q P3B2;E2P9RM&X_ _P\..71D*=KIM1CCC
M)Y<7\[Q/5_J/\W_31_B=KVEZE<7\TD$;E9(HTAX&,1,REJK<JS*SIO\ RO\
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MN8;JVC2%F1& DCDX!0ZLA/VOLM]G$H#(_P E-=N=>_*[0[R]<SW*1/:3R/\
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M4K'499^9C,EM<(L%U\;#T4E>,!9@JG_6;]J)F7$0C#>0_P")4SE+8'_BE?\
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M>Y(W_*+0N#!N'UE'H:T87,A(/O0XA2PG_G+?_CA>6?\ F-N/^32X"D/=[?\
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MJO;\K@Q1<IS(AA"-MR]/B[^/V^& #<D,M/$&<Y1$=I>GBE^[X9<?%_7],?\
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MHC@I^RWT'; EHJZ^WOBK?J5^T WOT.**=Q1OLG?P/]<56E2#0U!\,4H9: R
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MVO-'<_H@6;Q"4^H;B;46(:G;ZRI-/^,?P9D3$>M_[%WNLCA!'B^)=?P1T_\
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M5D6K64KB.&]MY'/2-)8V)H*GX0?# JI]9T]HXY?K$?"8A8G5U*.3T"FM&/\
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MU>?+T/WOK8JPN>YUS2I/)7FK54F?4_*_EZ+5)DEKZ[6/Z3-N5DY;\C9SK]K
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M>5>(K7CPKTZ\/@_U?AR-EH\27>?QZO\ =>II;.R7CQMXQQX<:(HIZ8HE-OV
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MKQ&8],I2R3C_ +/@_P!ZD6A_D;Y7FTZ"YUQKF_U2YC62[F:9E!D<<FI3XO\
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M&:0QR_W96-FKOQ[#+1H<MU36=7C'56_Y6?Y:^JP71:58;D$PED8$A6XU*D5
MK]FOVLC^3R617)/YK'5VC1YTL#ILNI+;W#6<+F.618R>) !KQ'Q<?B^UQR'@
M2NNK/QHU?14M/-EM=7JV4-G=_6602A9(6C'!NC%I J@'!+"0+V3'*":0#?F7
MY=658G,J2-V9".]*G;899^4R5=-?YF%U:4^8_P PO*FH6]UH4SSQS.Q@F7A(
MAV(#<645Z-]I?V<MQ:3*")CDUY-5C(,7D4GK+<,]ZRW)@F@MX;B,DARI7X2S
M\69N)5EY_$O[I>>;@$$;=W$ZK>]_ZKV7\M8[M/._GIIH6BA>\0V[M$(PZ\I:
ML#0<]_VLU&K(\/'7\UV>F!\2?O>E9@.<_P#_TO5.*NQ5V*L.T6SU"_CG>+5;
MVR"2%2B'2I0W>M8(7 _V?QY?,@= ?].[G5988R <>/)M_P!!,/\ IKDC_L67
M@$ "M2.I/?[LH=,5V*NQ5V*NQ5V*NQ5V*I3YHY_X=U'@[1O]7DHZ1B5A\)W$
M;55_]5OAR>/Z@Y.BKQX7_.'7@_V23>1O0];45MGCDMU,01X+46T;$*P+5&SN
MU/CX_N_]V1_!+D\W1SNU;J'$")>KZY^++_CL?YO\?\,_H96[JB,[FBJ"6/@!
MN<I=0!9H,;COO,=Q8C5+>UM#9NGKQ6#<_K#Q$<E_>@^FDC+^QZ;*K?!ZG[>7
M5&ZWMV9Q8(S\.4LG'?!XG^3C/^I]?!_2X_Z7#_"N\V:);^;_ ";<6,,@1=0@
M2:TE8;!]I8B?:H'+!CF83M&@U4M%JA,C^[D8S_W$V%Z5Y[_,C1;6'2]4\FW5
M_-:((OKMJS%9 HHK?#'*FX&]'_V.7SPXY&Q*G>YNR=#GD<F/40QB?JX,G\/^
MRA_N4+K5UY__ #!2+0G\ORZ!H[3))J%W=%N1C1N050RQU_U55OCX_$F2@(8O
M5?$6S38]%V:3F&4:G-P_NH8_YTO].]>@@C@@C@B'&.)0B#P4"@S!)MXV4C(D
MGJK8H=BKL50,_#]*VM?5Y>E/QX_W5.4=>?\ E?R?[/+(WP'ESC_6_B<>=>+'
MG],_ZG\'U?[W_.1V5N0\,_-,2C\P=082#B/+\@6'F58GDQY 4IFYT?\ =#_A
MCJM5_>G^H\]BNKL:<XB:DEDR3V^RC]T7_>1,S GTS(R2LB+\3?%_E9GF(XOZ
MS@ GA_JI_;Q0),^E+(;,ZJ8KW3' +QNLD()MI2P#^I')R6'BC?&W'@OPMF/Q
M'ZOYOIE_Q3D4/I_G>J/_ !*O'K-]H\,-M:-'!=3*L]U>/P8VD#L>)B1B5:ZG
M"MP^TJ_M9#@$[)Y?S?Y[+C,!0Y_[A,(?('G2[TN35?\ $FK&Z>1)89 7X!*5
M)-)0&I_OQ>*)P^QD3J\8EP\$>%F--D(OBE:!&MZEJ0.E7\RWLA1EL-1<QK-)
M+''5[6Y5>(+? S0R<?B7[3<LF<<8^H;?SH_[Z+#Q#+TRW_I?[V2@UG%.;;R^
M9VFN[Z2&XN%8%8[2W!Y.3Q^/ZP\?P_"O%4=?C?GDN.KG_#'_ &<F/"#4>I_V
M,4B>]N)+6XN0!']=F:.&(481VR+1T4T5U$E8TE5T_></Y?AR\0%U_-_W309&
MB>__ '+V7\EW8^3"64U^LS=ZFE4S4=H?WGP#M=!]#.OM?$IW\>Q^>8+FNY!O
MA84/8?T.*J-Q?VEH0+NYAAY E#+(D9('79B*TQ5?#+;N%>*:-HF( (8%:G>@
M(/7%5CWMF;A(S/&D\R\X8^:\G0=U6OQK\L4KGNK:)HQ/+$K2'C K.J,[^"AB
M.1_U<5"@;^P65X1>0^JE3) TD9*\15N2AN2\?VL*%JZGI@A]<7L$:NQC242Q
M\"P%2 2W$FG[/VL4J<E]IJQB:6\@CB- LXFC536M/B![XH727.EQ0)++<0>F
MU"LYD11\0JM&9J&J_%\/[.-JVMSI[211K<0/+.O*!4=&D=1W1:_&/]7%6KFX
MTM)/JTD\"RU%8Y)41^3=/W1(.^ %5T=**D,X<,"RHI#*5'4CO3"K4FKV$/ 2
MW-M;AUY1EYD^)?Y@2153BJ*CX,0^\E-Z@&GWG%5[M(^['@GMMM[8J7(5441-
MAT'2O\<"4MOKF]#LEM<VLMTSA5MI#PXBA''[1+'EQ_9R<0.KEXL<#O,3$:^J
M/X_K.DOM18+/:K:RP1HIEK+0!SNS5%?W?$_#AH=4QPX^4N.)OT^G\>I9+J'F
M!U(6"T!- O[^HI3XO#ICPQ2,6&]S/_2+VNM82-9.%K55_?1&7X5(J=WK79.+
M?9_FP4%&'%R)G_1]/^]_K+1J>LF$RQK:JA966DH(*$,6!8D<: +CPCS3X.*Z
M]?\ I?\ >M?7M=+G]Q:%D!$H];97V^!C_,:_RX:'FO@X>^?^E1DUS<!&87-N
MBBG-2M2M>HY\Z=?VN.1II$8\N&5_C^'A0T6IZJ;&2262R$X=0A$W[N@')@QJ
M?BXJW'"8B^K?+3X^, #)PU_-]7]%N/4M=145X+42258$S]5\0/\ @<>&/FCP
M<)L@S_TBX7FNM%*9DMHBM"C<PVQ85J&( HI_FP5%B<6&Q7'+_-7+J&LB2))8
MK6'U&8']]R)"[DJIIVQH).'%1(,S7]%2;4-=BC9YXK3E& 6;UN+'H":5XKN?
MYL/#%GX&$G8SW_HHF*YU)XB9WM;>9&-:'U:KM1OM)QR-!IE#&#Z1.8_TG_%+
M&OKZ"_1+F>U^ILH8LS!)&V_94M_,&P\(KJD882A<1/C_ --%1BU#73(\*06C
MRBI"K,>7C2G792N$QCYMAPX:N\D1_571W^M/)&9(;-HFIZK+-4KN*[_M<<:'
MFB6'" =YW_5<+[7PS(D=JPW9"90II6FZCE48U%?"PU=S_P!*TNH:P[UBCM9
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MI)(JJ0HE')@W@M:+AX8LS@P\[G7]5'Z=->O&YN%BYJW$I$_J"E 0U>S?Y/\
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MM3GM_K:R-<!HRM2#62OV_A9O]7X\GPGAN]G.C@GX/B^(?#C+P_H]7^D_F_\
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M1?\ #+T_SOH_W/\ OD=D&]X;^9[4_,6^#1+Z0T"0M,5-?M-L&'MFXTG]R/\
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M?S6K?RUYAX63ZEI'J26DGU8D2QCE;16DL$#?">7*26;G)^U_PV)R1WHIGKL
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MYOBPA2U)?3-H^ANNH33RWCCUG@:T5Y"]N\A4-(JQ?!(J_P"5^S@5/;*.]%C
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MV_U33]0UFYLGEEMH7F>*WN9.4A5: "B#C\ ^T/L\?LY7 V0 7!T>3CG#%&0
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MLW_*SUSC_I52?R+Z(@=EN;RTF^H/<6SJ9-K21I)EE0U5FF,C</Y/BYXC-?\
MLO\ 9,(=K<5_1CE'Q>&?T_W\>''P2_VOA]2OJWEJV;36M="LKNRE6>WNN)B]
M*!FMY PYB$+\3<?M?[+&.0W<B&&GUTO$XLTH9!PSQ_5Q9/WD?X?$4M5T#7]4
MM[&^GM(3+:W#!K1UF,4D?U;T@Q7BS^H#_L<8SB+%L\&LPXI2A&4N&</K]''&
M?B<?]7A3CRM9W-I%(+RQ>,LDA6WA5X[8J5Y49&'][7X>60R$'D7!U^6,R.&0
M_A]4O5E_TW\S^)BB^4M0#69$)MH[&4&2XBAF2:]227GQN2&0<EYM^\I)RD_D
M1N.7>(/G_L7;GM*'JWXCD'TRE"4-/*,>'BP_5_-^CT>C^=)E&M^6G\PC3Y52
MXB@MH;JVDBF?TY1ZJ*JL*@U^(?$W^3E,,G#;J=)KQIC,7&4IRQY/1ZH>A)+K
M\O\ 59!]5N9YYKN_L6AO;M2S1?69[@2NQI_NKX./'[7]W_)DQG'/N+L<?;&,
M>J(C&&/)Q8X?Q^%#'P1_S_5_NOYR.N/*=O8ZN6TFVN["-XY+>\EMXP6DHM89
MX2 %26-ZK_Q;']K]G(C)8WIQH=H2R8JRF&0W&<..7T_ZIBR?SH3C_I)("#R[
MJDFJP7^HVS^M"LBM=VL,BSW)92B^MS/P1"G/A^\^+XER9F*H.1/6XQC,($5*
MO1DE'P\7\7[OA^J?\/'Z4^O-/OS8&S:;4(;^6->5W 7F1960,?W;4_=!S]GG
MS^'CE0D+O:G78LT./BK%+&#]$_1+@_K?S_\ -X4BD\L:O-;S74UG#:7$D+Z=
M(]I#+ZLBRE'DGFY"KNJ*Z0?RN_+U>.6^(.5_TG8#7XXR$1*4XB7C?O)1X(<'
M%P8L?\V/%PRR_P Z,?H5-0\JP(9CHL-_;"^L+BRN;>X]6=3#*M(C'R9V3T9/
MV?Y7?!')WUL48>T":\4XI>'DAEA*'#C_ 'D/KXO3'B\2'^YBKW'Y;WCW-ZD%
MQ(EC*8#8H9B/0K)'+=L5H=W:%?3_ )6^U@&H'Q_'"U0[<@(Q,@../'XGI_O/
M3.&#_2^)ZE;0/)FE0:C>:G=Z=+)J$-W/>03N@)?E(S1KR(Y,Z_S8)Y20 #M3
M7K.T\DL<<<9CPY0ABE'^;Z?5_1X4+IVFZ]875PHBG&FSW<DY15G68)*W(@!*
M1-(/YOLMDI2B1YTW9\V')$;Q\2,!#^#@]'^SX5'RYY6U>UO;"SEL88H[?BCW
MT4<D4S(H(9N=/MFO\WQ8<F0$$VSUNOQSC*0E(F?^3E*,X?Z7^:R:U:..1I7M
MM1E?B5,3<GB9)*[&H6O '*3\'59 9"@<4?\ 8S]/_%*UX+01?5?T;<QB3TFY
M6RGE5ARXD[!>'V6P"^=L,9G?%QPVXO[S\?Q-+%;7[6]JL&H0F!'2*4G@ 5^T
M&??<E5^+'EOLGBECN5XI<1$I1^K_ $L6[C2YHTGEE6];X12-;CU"0S48!0O\
MK?\ &N(E[F,=0"0!X?\ I.%--"B5;!:"='>I>.Z8O*#2E*GY9"?-Q=5*Y_P_
M\D_H1@8C?\,BXZ\@-'4=C4C%5(C%5TO4?(8A#HO[P8E*T]<*%Z_88?+]>!*V
MF*%Q^POTXJLKC2KI?M8I=']L84+3B%7K_=O]'Z\!2LPH=BKAUQ5Y/^<<$DNJ
MZ:T;(/2AF9A)+&AI520JN5+'X<V?9\@ 76ZX60PL7MG/:):W5N&4G]U*CCU8
MED8+L4KR!*_$CJR_ZO+,PP(-AQ.($40B)+S49X4BU-U>")7F+VB&2<PNRL4:
M2V"I$2_)EFF1$^+FK/D.&(WC_LOI9\1.Q:,>BV=N_P!6T]&](JDCW $[,./$
M?:HFZ#B[(O\ E8092.Y_WJD1 V#</Z&6;T8+/E&0TTGUI2TA+,7HLC\'4)^Q
M_E\OV\)XJYH'#W+(ETVT<7.G02P@".62VD$L]NT:E51:K00?9^-[AN+?M/@)
M,MI?C_BE $=XNDO9H[PW6KI%>7P)92C1_5U%4FJ$C58W;F?A5V?GRY?'R7"(
M"JCZ8J9&[EO)#?Z1=7J2(8P\4\9D9YH4+-SJI')OBZ?LY.^&/P8;DWYO4?RK
M]+_&7GXKR,GZ17U2U*<N4OV:=J9K=;_=X_ZKL=)]<_ZSTW-<YS__U_5.*NQ5
MV*L(\NZ]I6F1W,=RSJ9)2RB&WU.44I3<SHY_X#X<OR0,OQ%WNMTF3*8F-<OX
MIZ:'_3*4?]DS56# $="*C*'1$+L5=BKL5=BKL5=BKL5=BKL5=BKL506K6L]U
M82P6\GI3.!P>I%*$'J-\E$T6W3Y(PF)2%A?80&WLH(& K%&JGB685 H:%OB/
MTX)&RPR3XI$^:*P,78J[%78J[%4#,@.JVSF!F*Q3#ZP#\*<C'\)'^73_ (3+
M(GT'?K'T_P"F_P!RT3'[R)K^&?J_F_1_NO\ >H[*V]XC^9GJG\Q+X")2GZ D
M*S%.7Q!F/ OT7EFXTG]R/^&.JU7]Z?ZC#].E@MK5YYX@X7BEM$YH99)*JM>O
M[M/MO_D_M9E3!)V<6% ;J_&P%DVKZK;D32QRC3+6,I$A2JA2(TK*RJ)G_P!V
M<>4?^MD+-\,3_694*XI+]/U#49AZ&GM:ZF@5@EA.RPWBHG(L0SLKREI"J>H'
MEX_$N,XQ&\KC_N$PD3RJ7^Z7?6]:]-@-+I8T<R0^HC2N0PK*LW[*QD</L\?B
M1?\ =DG$<,+^K=;EW;.O=0U6VA5;I;32(70D1LR3W4D9Y*_%06D'[#K+QC]-
M6PQA$G:Y_P"X3*4@-ZC_ +I2A@TZ[LQ=Z7'(NK6B2"6.1DD#Q"51ZACEY,?@
MED]1HY/]U_ZV&1E$U+Z2@ $6/J4KJ[@O;$30VZPS*>%Q;1[4!7FKQC<A:'AP
MYO\ &K?LX8Q(-$L92L6'K'Y.\/\ " H*-Z\]=J"G):4^BF:S7_WCL=%]#-LP
MW,=BK8ZC%6Y!\9^> );CZGY'$H"S"E>!^[/SP*L/7"A4<?"ORP)6+]H84!SB
MCGYXA*Z/HWRP%5G?"A4XDH/F<BEVPV7Z3A5MEJY_7]&*N2@-%Z;U/CMBK'FA
M$^J7*"XO[8J69Y%H(=A3X-CVX\<MNAT=D#PXXFL<_P#=_P"<@S/"8@7NM6B:
M-N3 H:U()IL*;?9R5?U6_@-[1P&U97AFOHTCFU&"23@.02@-%"_&S5\.?Q9'
MIT:^$Q@21BD/Q]/^Y4GFMV0)ZVHI)'R<2*O-J.H6G.G'X0O_ !+#7N9<,@>6
M*C_O?Z*XR*EQ'SN-2^S'(B+\9)=>9#'?M\.-;=$"-Q.V'^+^C_1127&G7DLT
M$%O=+/*D@#CFHK0A@&9N"L,%$-1AD@!*1A0,?Q_.X6KR*2UTQ8Y1?423FKHZ
M22EF#?REOAK_ +'XL1N>B<<A+)8\/Z>Z48?])*4H^K^BSWFINDD7(%!RXDT
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M_5_I8JMP+31W26SMOKFASM(8S*8G>J.0W"5.++*(HOVU?^\7ERR()GS/#-)
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M<G'R1KU1&[5W)!<W%K=WEN1+IB Z@\3>H&;ESMX6$E9$E;UI/]V?8_U%QB"
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MH^FN!6E/*BGZ#A5T@/,XJN3<&O4#8X%4BI#;BF25>VT?S/ZL 58!A5=+U \
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M@2Y,<>HRVTI/Q1M&67>@'"BCO_K99 >3L=/BN-F F/Q]2$AU"X>18TUEG9J
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M, _U/_9?C\?UE6WNY/2EEFU2:1%'$21PLJASM\1*$=?\_LX"/)KGB%@"$?\
M.E_#_IEHU"X2):Z[ /AJ3)%\0+?9K6FVW^MC7DDX 3_=2_S9(Q9G%OZEQ>W)
M:A/K0P,L)!/PD50CP_:^+(WY-!@.*HQA_5E+U_TOXDM&H3D C6B1UJ(6.W;M
M[K_F[9.AW.4< _U/_9?C\?U41]:E6R:234YN;FD,PB<1CY_!4^'VO^&P5OR:
M_"!G0A'^E'B]?^Z:_2,ZMP_3ML>-!0Q L37>OWXUY+X ._A2_P!,BWN7CM:R
MWMU%.P_O&A9(N?>@,=0/]ED -^37"%RH1@1_6]?^Z01U*>N^M'XS_OEAN* ]
MO\^7^1D^'R<GP!_J?^R_'X_K*SW<B0QQOJLL=PYY"62)EC*?Y(*CQ_FX_P"Q
MP5Y-(Q@D^B/#_6]7^Z:34;IF$::U;N[$^G&L')F%.@ W+;?LX\([D^!$;G'(
M#^NK7EXL*!5U"YMY6.S3Q'C0==O37I@B/)ABQDG>$)#^A+_CR".H3\B1K+$'
MI^Y8^/M[?\+DN'R;_!C_ *G_ +)$3WC*\,?Z6D@F5><PN(B%/?8%5\/VO^)8
M /)KCBL$^&)#^'@DZVU"ZD8 :O%.IJ9([> E^/\ D4#'[++\6) [D3PQB/[L
MQ_KS]/\ G+KZ[$3(L6I7$+G<B:)JD'84'!3B!Y(Q8KW,(R']&7_'D.M]<R.D
M:ZRS.0  (&J2:=@/?_AL-#N;CBB!?A_[)5DU#T[MN&L& 0K1X[J/?E[_  IX
M_P"M@$=N37'#<=\?%?\ J<O^DE]O>7$TE#JHN44?ODM8#ZBMXU ;B.0_:Q(\
MF,\40/[OA/\ #XD_3_O4[M6 M4(9W#$_%*.+D _M"B_\1RL\W7Y.?3_-^E5*
M]QT.!BVS#D5.XZ8JY5*FO8"H.*N# BA^@^&!7$%4->YQ5H?$*-U['"KI =E[
M@?CBK2+\5/'%7/\ $:XJVFP)\!BJSCC:KZ$1T[D_JQ5;QQM5SCH/ ?VXJLXG
M#:NXG&U<!O@M7COYYN!J>E@4#>C-UH=^2>QS;]F#:3JNT#N&&Z,6N-;TV52/
MK5Q%,UVH)X-' A,;M2K1U]+X_L? OPMP^#,O**C(.-CWD"C]!2>\.ORP2>CI
MNM)<Z? \B(#--.M0 WV8D5N+LJ\/MJOQ_L5Y2!PCG*'J9X[/%W2]*9_EYKK+
M96]A>.J2/9O9M<>G"\=O)'RJKQ%3\:U_>KP^+_*RK5X[/$._B_K-FER;4>Y-
MGT71_).A7MCIMV^I#4?0(B,<0E24KQ>02,H^$D?!%R_=?%E(R2S3!(X>%M\.
M.*) /%Q,7TD:I>GS-/;3Q23ZU)#9V/%$=9Q:CU)$^';ER*Q^M_OW_=G[:Y>3
MACP#I#ZO\YQH$RXC_/\ I2QI8W\G6H^..&WNTM]0('QKZCM)(/Y=_35D?DK_
M  NGJ</M3K]Z3WCTM9/[L#N/J04LK#4D@^!8[=T@B4&H5$8*M&/VN0^+[7'_
M &/V;@/3[VLGU/8_RQ:OGOSZ/35.-ZGQJK#E\4OVB>I&:?6#]UC_ *KM=+_>
M3][T[->YS__3]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J@I>7Z2MJ-$%]*:JM_>DUCIP_R?Y_]ADX_0>?./]7^+\1_SFB7
M]Y'Z?IE_7_@^G^C_ #_\Q&Y!O>&?FZSKY[G8R#T_T!+2'F 6;D^_ D!LW.AK
MPO\ DH'5:S^\_P Q@UMID-W9O:1+)( $N]3$6_P(2!!P();X&61F_P!UR,D?
M\SYF2R4;/]6/_%.'&%BO\Z28:3>/>0:K;H7M;RX<7)CB4QF:&$",1!3V@0>H
MD:\E;EZG#(3@(\/4?CU?YS.$KL=4W\OVFD:HJ6&J,8%@9KF"^+>FUJZ&OK*Y
M#+5S\'!UX2?8_ERG-*4#Q#_2_P ]MQ1C+8_](I7)IL217%K!YYO#IK7"DQBV
ME,KA=O4C(D"^DO+MP5O@^#[.6"9L$XQQ5WL#$"QQFDWU?3]"TFR"Z;=?I*XU
M&)7GU4MS>=4 01&BJD0B'Q>FOQ?$C/R^'*L<Y3/J'#P_P?S6R<8P&WJXOXDE
MU.ZDL]#AC:622ZEN%N[*!@S>B;=@?6"C?]XW[KC\/JKE\(@R/^EE_2:9RJ(_
MTW]5!2Z? +=C)&]O:ZE(T]DKTCCCG12. 4!?@FD?AZG^Z_W?VDR<9[[;F/\
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MX5/Z?JX?#_K?[%*M2-]=WE[;0ZBL4K:_;"&:-"/3*V897IP_N0RKRC^SDXT
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M_/A_LD#R88\=RN4)W_.C^/QZDQT=V-DK%X7/)OBMQ2/KVV&5SYN-J1Z_XO\
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MP^I%PZ5YE2_U*8ZEIT<$L9;3Q^Z8HZ"L?):47ER^)D_V?J/Q; 91H;%QY:C
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M3KKR2LOEZVTA],53I\<2VVH+<(LRO NTHJ"E:K\7+]E\1E]5VG'VK68Y1/\
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M@UU3',(@5EY?SH\2*L=.96,D.FQ6I.Q2XD:2H-&JH')=CD92\VG-G!V,S/\
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MXA7N.N*N)X[#KU.*N*U((_:Q5W*A '3]>*M,*'V[8JUBKL5=BKL5=X8J\?\
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M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J@)F4:M:H9'5FBG(B7^[8
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M*1H1W5-1\M:9>R&%]1G>_4T%W>4]%U+59>"A!!'R_NOA95_;7!CS2B+H</\
M1_'J3/$#UW2VVN89+M=(\Q!FFAF]'ZS^\$T:\J31,RM&S)^]9XOWDBIS^!5C
MRR4:''!@) GADAGBDBYS7LZW4D5S':VD\1JTS(*2%2W%B!Q_W8W+^[CY\_@R
M5WL-MF%5N>]Z=^5"PCSAY]*-5VU%2XX\./Q2T'OMFOUO]WC_ *KGZ3ZY_P!9
MZ?FN<]__UO5.*NQ5*?,.IOINF274;1+(K(J"?U"I+N%"@0K)*SM7X%1&^+)0
MC9IR-)@&7((GBK^AP_\ 3SAA_II)9Y6U77=1O+N:[] Z:(XUMOJX<<9UDE6=
M)%F2.9)%I'R1TR<Q$ 5S<S7Z?#BA$1XO$L\7'P_W?##PY1\.4\4H?7ZHR76?
MF"\NY+2XAELSILLS0.RO,SEB#P7XHD$<E:;2?;Y?ZN)@!?.V.71Q@)1(R>)&
M/'_!P_TOXY<<?ZOTHC4]8O%O9].T^2V%Y';^L%G:7F*\J,(TC;U1\/V4?E@$
M15EKP::/ )S$^#BX?3P\/^FE+T?YWI7WFO+;:79WC26X:[*(DCNZP%I%+;.$
M8A=NKJN 0LD,<6DXLDH5/T7TCXGI_H\2IIM_>M]>74'M_5M7-%A,GP1E R\^
M:KR[_&GPM_L<91&U,<^*'IX.*IC^+A]4OZ/#_N4%INN7MY<6$RRV9T^[#JOI
M/,[M(J\@%+1QJC !N4<GQ_\  9*4  >=M^?20A&0K)XD*^K@_P"+EQ?UX_[Y
MO4M<OEGOK73WM!/9(KR^NTQ=5HKDF)(SS7B?V'^'&,!L3:,&EAPQE,3X<AX?
M3P?[N4_3_G(O4];6TCLN#VXDO7"0F:1EC8E>7PNJ/_L>7'ED1"[:<&FXS*Q*
ML?\ -KB_TO%%3M[_ %=M*U!^,%QJMJ9EAAC+JG-5Y1(YD"$=5JWV67]YA,18
M[F<\>+Q8#U1Q3X>*4OYO\<H\'%^/2E/EG4]>NKZS<WGZ3L+JW>2]<PQ0BUF7
MCQB#1,WQ$LP])^;<?C]3^:>2,0#MPG_=.9KL&&$)#A\+)"0CC]4I^-#^?Z_]
MWZ?ZK(M=AOIM&OH=/F%O?20R+:SDTX2%3P8GV;*H58ODZS32A'+$S'%#B'''
M^=%B_EO],Q^8X8[R>ZAA>UF)M+V[AN6ED5XOCB$(^%(@?B9V5F]1?W>6Y*X=
MON=OKO". F(A(\<?7BQSP\$?7Z9^)_%/^C_,^I*+V^UV[\ZRV5I?SQVT4YK;
M6M_;O+)Q^)E,<@ MXU'VH_WDO^IE@ $+(^QS,6+##2"<HQXC'Z\F+)PQ_P Z
M/][+^GZ8?UD\_,&XU.%+9[&:XC<1RMZ5N+G]XR\2JEH(Y%7P_><?M9#  >;@
M=CPQRL3$3O'Z_#]/_*V4/]@F-Z'L/*,IEN+GE'$'DFEN$BG4L0Q'KN."T^SO
M_JY6-Y.+BK)J10AO+Z8PE+'_ ,JX^I*_R[FU6Y2YN;N>XNHF>189I;J&XC $
MA*1\$ =)DC*^ISRS. -@YG;,<<"(Q$8';BC''+'+Z?KXI>F6.4_I2Y=4N1JH
M5M>4ZV-5]!K,7<1M3:&7[/H!:A_2_=</[_ZQ^WPR7!MR]/"Y1P1./^Z_<^#Q
M\?AR\;QN'_5?YOB>OB_NO"_A>D9BO,NQ5V*H&60C4K6/U^/**8FWXD\^)C^+
MEV].O^RYY.(]!-=8^K_3?[IHE+]Y$7_#+T?SOH_W/^^1V0;WAWYFM'_RLN\1
MD',^7W(DJU>/-J@ ?#]^;G1C]R/^&.JU7]Z?ZC#EO)4TF4VA].ZL9$NH64 ,
M49@)4+&OP.WIR2QJO[SC]G,O@'%ORDXHEZ=D_P!-EM;6\.E#C;1:GZ=WIZJ'
MXLSQ<FM9WDHS,LWPP-Q;[?'T_LYC2LCB_F^F7_%1;XD U_.]4?\ B43<Z_?Z
M'#!:VL<<>I72K+-/*%<6=O)7C6.K"6XDXMZ4?V5X\I,C'$)V3]/^[_XZR.0P
MV'U?[A0M_*_YE7>FG5AYEU)9':.:/C&PB"A=R8PP!*[?%Q^'@V2.;")</!%
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M44MXX(@O+DU"&4(:E[=AQ;C^\,L7#^\;[.58[,W7Z#BEJA7U&4O]]Q?PY?\
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MGS;ER]+E^_Q0T#Y]C^H.&U&YA6YD]&VX20EHC-%Q]65GED7BGK<?K\7!X?\
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M;X^O^]X?;7%"1SCSWRU.+GJ9B^L(XNBDE>/UB2L0AC?U.'I&.L^G2\?3]/\
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M_(PJZ'\Q=,G=?3LKL6R_5X[R[98PD$MU,]O''(OJ<V99XVCE]-75/A;EP^+
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M&:0NL;Q_"Z*?B^'"J#;RQY"348;&2"$:@@L$BMVD?U/]QXDELA0G?@D<K?\
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M_P!0N+:#ZR\4R)R$L]FH-T\3J'*/-$(Q'\1?@[1_M<OBQ$ ":_V7TJ9DU?\
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M.DPFADMWGC+GB%9@EM=;JI;C_=_[+*M/6[K.Q/#'$9;2]/JC/PY?]-</^_\
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M&7-"7D5Y8RA)]0@3X6;ZAI\;27#1BL;K*75>".C(_P"\GY?;]->63B1+D/\
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M@5%:OY3UB3REH>F:;)]5O+.**SO"DK(JVL\'U:[*,.LD8;UH?^+(UXXJD?\
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M:"RNCM!' ZE4:XK\19*\>$4;*W#X4D9_Y,9'E&/XBL1SE+^JR71K6VU6"?\
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M<:G'?ZOI_P YJHQEM]/U?YJ%D2&)T>U*PB^FC>.&-BR); J8W!;F:R5^"/\
M92-?57]YA!)&_P#"/]DQH7M_$7K_ .6#(?/WG_BM"M[&&?D6KO)M0]*9J]9_
M=8_ZKLM+_>3][T_-<Y[_ /_5]4XJ[%4KU^QN+[2Y;:W95E?C0N\T2T# D%H&
MCEZ>#9*! -ER-+ECCR"4N0\H2_Z:\4%'ROI5YIFE"UN[CZQ)ZDCJP:5U5'8E
M8U:9I)&5!L.38<DA(V&>MU$<N3BB.$5_1]7]/]WPP]3&-']4:Z+J);QYI)_4
MU!0X7TFE/IK%,@MT]4(BJY^/]W^Q_-)=+Z:V=MJ:\'A/AT(_NOZ?!Z^/'+Q9
M<'%+T_3Z_P"+^B*\UQ?6-:@C)N!/&B1V4<;B,.T\BB1TD]&4Q^@J!V?GR_U?
MVXXS0:>SI<.(GT\-\63;CX?#CZ(RAXD./Q.+TQX?^.C=<)N?*EK'=?6;>*Z6
M%+R5J&2*,K5S-^[<=N+?NU^-OV,$-I;-&E'#J9&/#(PXO#_FSE_#X?KC_N_I
M_G+O*;W"Z?<<X;E5($L"2N)!Q=20L1,</#I_=\?@P9.:.T1$SCO#^;+A'#]/
M^J>O)Q?U_P")*?*ZLFL1RP?6Y5E9C?.9 $6><2S,DT?U>'GZ)7AZO+DK2(F3
MR<G,UYO$0>#T_P!WMZO#Q\$.+'/Q<G#XG\S^C*3?F:-I]?<K]:-ZB"*SBAD$
M+&/AZLDT3^A)QHRB+^\^-O@;]E7./Z?)=#+AP_P<'U3XAQ^KZ(XYQ\2']?Z?
M^.F?FIDGT>S2Z,\%M.\<ER]%^'TP)5253%-]N152G!?B_P" >&/8FG$[/!CE
MD8\,I1N,/\[T<4/7C^F/]+_BHI:8L[^4=1@NK6Z<^C*/JLTW.1TEMU?TXI>$
M>WQ^E]C]W)R_EP2^H4RSF(U,#&4/JCZXQ]/IR</'/'Q3_F\?].* _+2SD4W\
M]W:\;M6CA6ZXHJM'&&5415AMZ<5W9^'[SFOQ?!Q2S4=*<GMS(/1&,O1O+@_I
M2_BE^\R_Z7B]'"S[,9T#L5>=:;I%TOY@/>C1Y(8([B<O=LU%+2)(5E4\:N""
M>7Q\%]=$X\H?ARI3'AU;T>?4Q.B$/$!EPP]']7A]'XC_ )*4O\H]%S%><=BK
ML5>/2SZ7!YBCT\06]P4O(T2ZBNB79Y-46X9$!ME62>!RIGCCD_=0?#SS. /#
M?X^G^L]G&.26 SN4?1]$L?\ -TWA<4OWWHQ9(_W4I0]>7^%[#F"\8[%78J@9
M6;])6RB2,*8IB8F'[QB#'0J?Y5_;_P!9,F/I.W\W_?-$C^\CN/IE_6_@^G_?
M?YJ.R#>\/_-D77^.[@*S"!M!EV4@?&&>FQZYN-%7A>?B!U6KOQ/\QYQ!"6LM
M01QPC](2%_B ]6.I5011ZR)S7BO%OYOA5\V).XIP -BG\VHI8RV5ZZK+8ZM!
M"VIVC+ZCO)' J?6T!JW,#]I9?C9&27]VV8L8<5CK#Z?^)<@RX:/27U?\4W>P
M^OK_ .@[>K?H58)TYDK"]W/1O5D!6K-&'3T4;BJ_'RPQ-0XS_'_N5D+EPC^#
M_=,W32?(EM;/Y?O;BV75II[?UK(VR,S3NG)6'P\I%V;E-Q;A\?\ -F"<F4GC
M%\+F>'C X3]3"IK9](\R06EVN^KW'Z-O%B>L340+!*1Q^":,M&O)3\4?+]K,
MT2XX6/X/7_Q3B&/!.C_%Z52VF2ZU^/3@B_HW2W6XDM^'![JY@8CU7! <K&W+
M]M45$^RDKX)"H<7\4_\ 8Q4&Y</\,/\ 9,8X.^D02\S,MQ-)-.]2:25(16)+
M,*CG+]MD;U.:?M9E@^KX.,1Z7MWY+ KY-/.M?K,]6-1W3QS3=H_WGP=OH/[M
MG'*OV17W.PS!<QQ)_::GL/[<54I[6VN4$<\ GC#*X64!EY1L'1J-W5E#+_E8
MJMN-+TR6.3UK6W;U)/5E#(K<G,?H\VKU;TOW7_&/X,"5&UT71K:]>^MK.&&\
MD7@]Q%$JN5H!3D!X*O\ K<5PE0W/H&B2ZI'JTFGPR:FH4I>M$GJ@J.(/*E>2
MC96^TN(59:^7]!M9WFM]-@ADDD6>1TBC!,B$LK=.JLS-_K,S8E5ZZ%HL,[RQ
MV,*2O)ZS2"%*F3GZO.H'VO4_>?Z_Q8%4SY:\MM*CMIUF7CB-O$SP)\,1!7@*
MC[/%G7_5=L4*</EKRW$JI;Z39\4<2KPB3:0(8PQ)'VO39D_U/APJK66BZ-8V
M4ME:645I:S5,UM @".&7@W,"O+X?A_U?AP*MM=%T>SO'O;.SMK:[D7@]PL:K
M(5H!2JT[*O\ K<5PJJRZ3I<L9]6PAE5O5+\T0J3<?WQ*D?[N_P!V?SX$J5GH
MNA6IMOJEE!";-G>U]*)4,;2BDA5B*UD'V_YL-(5KS2=(N6N#<6=O,;N-(;DN
M@D:2)"61')&ZHS,4_E;[.(2IVGE[0K;BL&G01!6#+PBC2CAUD#=*\O4CC?E_
M.BMB5;L-#TC3)9I-/T^&SDGIZ[PJJ%N))'+C38%FX_R\L0@K;3RUY<MG>6VT
MJW@G9Q,TD<:!BZL7#5&]5<\U_P K E=+Y>\O7,,D$MC;O'*5,BM&A!*NTBDB
ME:K))(_+^:1_YL5<_ECR\)$G;2;0O'$+=76%-H0I0)2E.'ILR?ZOP?9Q56L=
M'T>SLVL[*TAMK23EZD$:*(WY#BW-.C\E^'?]GX<50I\I^5UC@MCI%GZ,#M+;
MIZ*%0[4Y,*CJ>*\O]5/Y5Q5?_ASR[]:GO#IEJ;FZ)-S-Z2%W)(8DFG=D5F_F
MX_S8JJ7/E_0[EB]QI]O,SF5B[1JQ/KJ$E-2-_4555_YN*_RXJU:^7]!C@-I%
MI]M%'Z<D)C6)>+Q3$-(K"FXD8?O/YL50UYY.T.33GT^"UBLHV'$2011$\2ZR
M,I$BR(Z.T:>HKJW+C_DKBJ_2/*&@Z=IBV$-NDJ483-*D=9.4S7&X550*)G9T
M156-/V5Q56'EKRZ'NR^EVI-^"+TF)*RU;G\6V_Q_'_K_ !_;Q54_P_HHTTZ9
M'8P?HTU)LA&HBJ6YUX#:O/X_YN?Q8JMA\O\ EZ.%[=--MHHY$:.1$B0*R.P9
MU8 ;AF')J_:;%5:TT#2+74)M0AL;>*]N.7K721J)7YD%JL!7XBJLW\S?%BKK
MSRWY?O(!;W6G6UQ )7G$4L:LOJR$F1]Q]I^3<_Y^7Q8%2J3R%H<FOOK-P/7D
M*NJVTL</I 20_5V4L(Q*\?I518I)&C7E]G['!5,F\K>7'>[=M+M6DOA2\8Q*
M1+5@YY;;_&JO_KKR^UBJZ/RUY>CN);E--MEN+AEDFE6).3.CB522!U$@]3_C
M)\?VL562>6="DO+F[?3K4S7:-'=3&)"TB. '5ZC?F O/^;CA5N#1=#M]/ETN
MUT^".PN.0N+98U].3F.+\UI1^8%&Y?:Q5"/Y0T5?J")$MK9Z?<_7DL($C6*2
MY I'(_P\^49/)>++\7'ERXKBJ-O=*TW4I(WO+.&Y: ,(3*BOP#TY@$C;EQ7E
M_-BJG?>7?+UW_O;IUM=.9#.?5B1OWC*JLYJ-V9416_FXK_+BJ*FM(;M56>-9
M51TE4. P#QL&1A7]I&')<505[H.A7@,-Q86\\8E:X8O&IK,XH[;CJP^%_P";
M[.*KTT/1DMUA73[=8%8,L0B3AR6+T 0M*;0_NO\ C%\'V<54[;R_H%K$(;;3
M;:*(!U"+$G&DJA)!2G1T54?^9%X_9Q5=IFAZ-8*AL+&WM%B+F-XXU4@RA0_&
M@K\7!.7^HG\N*JKZ;I7U>:V:UB:"YD,T\;("))2P<NP[OS7ER_FQI4DTO\O=
M#M'O9)T%Y]?5(YA<QP4]..1I5J(HX@\GJ/S]5^<OV?BQ5-HM&T2",6\%G"D:
MB)1&D:@4MW,D(HH']U(>:?RO\6*M2Z%HK6!TPZ="; N96M>*B/U&?U"X4=&]
M3X^7\V*K+?R_HD,9@ATZ"*%P%>-$0*560R@%:4VE9I/^,GQX4+K?1=(M+R>^
MM+&&WN[FOKSI$@=PS<FY,HKNWQM_E_%]K $KTTS3#$(S:0^E%-]9CC"J MQS
M,GJA2*"3U&9^7\V$JD^H>3?+\]BUE:016"23+/)Z%O 0[H"%#I+')$ZKR^#X
M?@;[''$!5>W\F^6H-+MM/;38)(+5(XXC<HLI(B3TU+-3<\/A_EX_#QXX%1/Z
M%T43W$QLK?U;L,ES)'$E9%D55</L>0=417_FX+DD-6_EOR_:IPM-,MU4A@](
MU4GFGIMR\>4?[O\ U/AR(2CX%BC5(D5(50!4CZ<5&P &VP&$J%1Y*L:/MVH,
M0@KHR:UJWP[]!_$8"E95O\O\,*%P)$9-7%30;#YX$K>6_P!O[Q_M84!>VZKL
MC5WJ/\S@53/$=BGZOXY)6P6Z@AA]WXC K:L*[_"??$J\?_/2-CJ>DFA*^C-S
M7>E.2;YM^S#L75=HC<,+TN*-M1TN.YC,HO;:XLY[3<%XC$P0E057XU9>//FS
M>CR_N\RLA/#*OX2).+C^H7W)EI5Y!(US::FRW1T5'GCO8UWFM;1*^B[A1\2@
M)QY_'_NMY/L+E4X\I1VX_P"'^E)M@>DOX/\ <Q5/)^E)KA?5-1"FUNX#>:G)
M,!*X6/DJ+'"5IZ45/W2+_LVQU$_#],>GIBG!#CWE_G,C\Q6'E75[*XO?+L]I
M?36EO"ET1$D:?5Y$8>F9$!_8/#T_M1?#^TN8V*4X&IV&_+&$Q<*+%=*N;*.U
MU&"YCDN1Y;E2.&.6LC30W I'"S*JL429>*R? RQ?Y7%<R\@)((V\5QH$4;_R
M: O#+=:"M[=SJ;S5KJVAENX_@2*&'F$A B],*L?]ZR(C<?@^'[63AM.@-H _
MZ9A/>%G^(H&ZC<ZP3Q9*2QA >OI*5$=.("_8'VO^:ERT$<#6?J^+VC\M#<GS
MQY[]6OI_74$ /'[/*6O3WS3ZRO"QU_-=KI?[R?O>EYKW.?_6]4XJ[%78J[%6
M!6^DPV.IVLILKKZR;F*%)E6!EX*S$F2:!6?]K]XTWIM)]C]I^6096.;OYZ@Y
M,<AQ0X>"4N'U_5_0QY/3_5\/CX/J_FIAYAT>WN-46XN;::>#C&SF-()J&%B1
M2.2LW'?]XL//U/Y?M9&$J#C:+4RCCX8F,9;_ ,_']?\ 2C^[_J>)]"^:S:[\
MIZ:#!+6.."3T)#&SC]W2DJSA(WIR^R_#X_Y<;J98QR<&IGO'<RCQ1XOYW\'A
M>N/^;Q>EKRM96]NM_8V]O<6T4:Q(!,!$2WIT;CP54Y?S2QL_^M\"XY#=%>T,
MID83D82)XOI]?\7]+U?YDN'_ &2!TC2X;#5K%OJ=PEU)+Z;3!(!$(XH)1\4M
MNI#;_;]3TFD?T_\ ??'#*5@[N3J<YR8I>J/#7?/CXISA_!E_V/!Q\$>+^>J>
M9='@DO[F\N+2>>,(94:)()B'$)B% 5:X5/\ (1)$]3X_YL<<]JMCH=21",8R
MC$WP^KCA_'Q_\*XOZ4I1EP^E':QIYOM'L"T$LC*J\HF,,C#G%Q^-;FD<C[_M
M?%RR,)43^/\ <N/I<WAY9[C_ &<?IE_#X/JA%3T>U*Z+JUIIUJ\?$O%:PWR<
M4=OJT8 9.*CT^?PR?:]1N;\OBPR/J!*=5DO-CE.7]*<L7_#)?Q?SOYG\STQX
M5+R/HFI:<^H7%]96M@;PQ,D%JJI3T^:T=8OW?(*4Y.O[7/\ 85,.60-4;9]J
MZK'E$(PE/)P<7JR7+ZN'Z>/U_P [T_[[B9AE#J'8J[%78J[%78JI+#$M J*
MI)4  4)ZTQM))5<4.Q5V*H&4-^DK8A8RHBFJS?WH-8Z!/\D_M_[#)Q^@\^<?
MZO\ %^(M$O[R.P^F7]?^#Z?]]_FH[(-[P[\UTB/YA2D/^^&@2CT^!;;F]&Y
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M_;,7]:,_X.'_ $IAK4*KY5T[U;>8+;K$S1N%E:,+"P_>JR.LG\GQ(O&1D?\
M=\<K@?47%TTKU,Z,?5Q?T.+U?P>J/#_.^KZ>*/K6>2((QI%WZ,<AAD5>#!B
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MO/LQ^GC:TR?\Q]6UO3[B&&QU!;))[&Y9(*$,\\=S:JAYA@WPI(_PK_NOU?\
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M'"#ZHWI7#Q(I$;2'XHVB5A(J-*G[#>GD<,LL9>CZ?Z7TL\HQF-R^I(] T?\
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M17K0^^*N]-&(94#LO1F%2,*M,L3%3*JLR$E#0%E8]2#V.*N,:2*0J*P(HP8
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MMJI:0.8IRJK_ '9 ,=2_^4/V/]GED0> \OX?ZW\3CS(\6//Z9_U/X/J_WO\
MG([*W(>'_F4D?_*RKN1G!(T!QZ 9HY"O-JD/Q9/\G?-QI#^Y'_#'5:H?O?\
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MA)].WB,D,7H,_P :0Q^HN*MK<>:]1UF/4;>*XL["W$$EQI]TSP4*ETN(5/\
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M?V?N-<5;+ B@V)VIW'CBH>8?F^\T.MZ-<1/Z;Q12LM!L=P*,.C;%OM?S9LM
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M60ART\^[(S L'6-'])?V6^)V^/)0',_YL6,SN ]._*L3?XO\^<X^"#45$;<
MG(<I3U '/_6S7ZVO#Q_U7.TGUS_K/3<USGO_U/5.*NQ5V*NQ5"Q:?8Q.7BMX
MXW=N;,J*"7H1R) ^UALLI9)D426Y+*TDGCN988WGB_NI2JEEKUXL148V5$Y
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M+YBT73==@\E?HJVE>4PQI?-/'Z:H\;%_6DIQCN0R+Z,7!N>88Q2E#Q>+\?\
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MRIWQ5M#*XY%*$[<:#8>&*M@2@\&:G\M3VP);XCNX^BIQ5U8AXG\,5=S_ )5
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M,45K/F<:ZD<4X@T>[AC$4]C,YCH  WKP\]O3W]-T3XEX<_V\CCQ<'],?SO\
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M@M+:Z^KQ^G%9<>!B!H"Y)]3DI^%5X^DB_8DDR4ZK:_\ .;=;P>&. SG'C/\
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M\@_P6=OA-S/4'?<LI[>&:K7G]Y\'9Z'Z&8U(??=5Z'W/CF(YCI 21QZG<^!
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MD'E*/X]7I_TWI8K^7AG%SJR7"R&[C%JKSS+)$S1A&$:^E)%;E?3 /Q^G\?\
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M$6,&G<\1\1_RFQ5*=0/Z:\PP:1$2=.TEXKS56I59+C^\M+>IZ\*?6I?^C?\
MGR*60O4KQ7:I'Q?,_CDD-E@ 0NY&['^N*N6B@#[3D#Y_[6*M(*U9MS4T\!BJ
M[_=A]@!^.15S?LCW_4,5+;&BD^V(2X"@ Q5I>Y\2?Z8H#OV_D/U_[6*KL4J<
M\$-Q!+;S#E#.C12KXHX*L/N.*L)\D7+VLWZ)FGAMK^:%[-Q;VK"X-YI8%O-<
MW%Q1H7]2W-K) DJ\N'^_%P*OM-.NM2L]:T6XNECU#F+BWN;BY$U['+'(LEG+
M-#&/0A6)A'\,+?$O'DB\\59+H&LKJ^FK<M']7O(V:#4;,_:M[J/:6(_(_$C?
M[LB9)%^%L*JFI:K#I_HF6-W68R*'7C13'$TM#4@_&$XI_E8JE$?GJP>$RBUF
M!C<)/'5.:$CD %)!D;CR9E3[/"3E]G JZX\[V4%MZTEI/LO(JI1A42,CA2K'
MEPX<V;[/'_9<561C?IO7I3"K$+W43?:ZVH01_6+#06-I9CEQ2;4[EE@E?D W
M[JRB?TI)%5N+RS_[ZP*H:3'8Z);:OK=_,S7>G\K:6^G!U&6-FX,/3N(T6XEA
MK)'S@]-61EXM]GEBJOY'T]DOM2NG2V4VJQ:4&LH?J]N\\):XOI8HJG@LEW<,
MOVOM0_%B%9?A5W?%5J="/ G^N)0'?M_,?JQ5S]CX$8J6STIXXI:4U4?+%7+^
MT/?]8Q0MH5<<=UI]GZ>V25S=F0[U%1V/SQ5TE&4T^%P/U8JV:-L?A:AH1_#%
M5H^)0#\+D4!&*M;LH_9DZ^QIBJG(H8!EJO2G<J>Q_P!7%5:*42 CHZ_:7^/R
MP$*OP)4)9>0XH?AK1G'?_)7Q.$!#82@5#U;=E'4@>/MA5<V[J&["H0?=BK9W
M8%S10#M\Z=3BKB266GPKOOW^[%7$@<0HJ>6_S.VYQ5S@!"S'<=#_ $&*KOB;
MK\*_B<BJU& 4*HJ1M3P^>25M5HS5-3U'@*^&*MG[8/B"/NWR*O*OSIFDAU32
M60LGJ6\\;%7*EE+)5=NVZYM.SA8+K->2"&&QW"Z5;P7<\DK74JA[2%6**B_[
MKD=S\/#9V1$^+X/Y<S"#+8<G$!X=SS6WEHL'H0WM_'?7<;.\UA*I1%1:1A4G
MF6 1O(R-\7!?YOWN"$KY#A'\[_CJ91KF>(H(E KQW-M=6+A:S1RPLZGX0656
M 4]61%YI]O+!Y$28'SMOE(KLU[%+#-Q0^G'')(SQ.:QLI8)3<K_L71N/[&&^
MY&_5?;F'U8)KF%],A5TD6[NE62X:,T!].'X&0QL?[Q/A;[/->.1-]/7_ $?^
M/)%=?2C9)?JCKIU_>R7,%PWJ6M_&9#056(O+$R1NRLJ<F]-9?L? [Y6-_5$?
MUHLSML3_ %9(*X6ZM;[ZG/(:M)%ZJLQHXY*4J.XW5E_R<M%$6&!L&B];_+$Q
M'SYY^XAP_P!=CYEBI!WEIQ  H*9JM9?A8_ZKL]+_ 'D_>].S7.<__]'U3BKL
M5=BKL5=BKL5=BKL5=BKL5=BJ%OK5;JSGMF/%9HVC9J*U P(Z,&!_V2\<(-&V
M6.?#(2_FGB4-+T/2]*A:/3[6&VYT,IBC2,NP% 6X 5PRF9<VS4:K)F-SE*?]
M8\7#_IG:_(L>BWKF8P!87)F"\BOPG?CWQAS"=(+RQ%<7J^EC7E1+J'5_3N4%
MLTD<S1P1NLJ21"12@HC,L(@#<=N/J\^7VLNR53L^T#&6*X^O>/JEZ>&7#ZO^
M&>)_L.%D%WYET2UE$$UT@F,JPF,?$RNYH.0'0?Y65#'(]'78]%EF+$=JXDL\
MUPP37$"7<L*V:HQ].ZE-O$TA(HPE0\BZ@?W?'[+9+$:Y.7V?(QB3$2XO]KCX
ML^'^I_-_I*OU:9/*CPHR7YXDP^D690I>JA"C+(_HK]EE=9'X?SXWZ^YK\0'4
MV;Q_SN+^K_%Q>F/B?U>"/$A?)\T,]Q/);ZI+K42QJC7LBLOIL*5A'2/_ "F^
M#UE_W?)(V'**'+A;NT8F,0# 8#?]W'^+_;/Y_P#LO#_U.,4'%+(-8%O]>]-/
MK?(>7!ZOJ<>?]_SIZOI5_>\>/U/]CGDR-N7^?^/^DG(E$>%Q</\ !_C7IX?^
M%\/]WQ_P?\I'\7"SK,9T+L5=BJ!F=AJ=L@E15:*8M"1\;$&.C*?!*_%_K+DX
MCTG;^;_OFB1/B1%])>G_ $G^Y_WR.R#>\._-MYE\]7!$(:)=!E+2&,'XN3["
M0*S+M^S^UFXT0_=?\E ZK5G]Y_F,)LH('NW%P>%CZ)NK2S"&0R.$:%6 ''XE
MF^W^]Y+)'Z?^[%S,F2!M]5^IQ(B^?)<?7UV:0(#9:3IL5$B,=1$I(15$;,P>
M:9T7^\?A\'/_ "<0!C'\Z<D?7_1C%.=#T<WLWI>7_6T^Z?D(IY)SZ4P!#RQ7
M*']TSR*GP,J<>?P-^[^S3ER5]?J'^Y_JM^.%[1])_'U(DZ=Y^C#<]*-('6"8
M*CF0NP%5C8/ZABE)5_W;>G\*_P ^0XL/>RX<O<HZWH=_91PCS+SOK@IZGU:*
M=EMK:)^-4"QFAN'D5FY?$J+P;XG;X98L@E]&P_V4O^.L<N,CZM_]S%(V6?0Y
M8-3L7>XL+AI(I(I$7D0#R:"5(RJ.SIP9&1DYLO\ -E^V3TGZFGZ-QR=?6UKZ
MEJVG P13J7O+*1#'^[MRSEV+>H"JPNG)N:_8_9]7!C)WXNGTR60&U?Z5ZS^3
MCE_)SL(S'']9GX*=CU3K7<-_GRXYK-?_ 'GP=GH=X?%FJ?87Y#,)S'+U;Y_P
M&*M, 66O6AH>XZ9)7,65:D5 (W'7KX8J[B"/@.Q[=L5:5@57F*'Q]_8XJHW=
M[;Z?:3W=Y*L5I;J9)97-.*]?I_XV;X<52);-M5=M3UP?5=(B7U[71[CX454'
M(W%\IV,@ YI"W[JW_:YS?8BJ3:E>W.OZA:4MRSS<;C1M,N01#%'&PXZKJ" A
MBO(?Z%:/]IO^+.;6ZED$AT[RCH4MQ*TET>7.66H:ZO;R8T4?Y<T[\8T3[*+Q
M5>,:8H0'E+RI=6 N-9UMUN?,6IL9KR>/XH[96IQM8/\ BJ%%1.?VI.'+[/'"
M%*4_F%J5[K4D?D?1_P!_=7/IW.M72MQCM;)6Y()I!\2FYD3@J+^]>-9./\^
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M^K_%^(_YS1+^\C]/TR_K_P 'T_T?Y_\ F(W(-[PW\VE/_*P)7]1*C0)@L1+
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MKR K0T[TQ5$$UV=?I&_]N*N!;]E@P]_ZXJU0#L5/MN/PQ5Q:NQ93[,*8J[Y
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M4?Y@T6?4GAIZ<MO&&#6LK2(A8D4?E&0U5I3C_E9&$Z<?1ZH8@><9?SX\,O\
M-]:Y-(NET(Z>[QSS$$(T@<QH"_)5V82MZ:_8/J<VX_;7!QCBMC^8CXW& 8C^
MCP\7_$>O^+T\/]%;HVAWFG7$DEQ?R:ASC51+<5]5*=56A]/A_L/5_P!^22X9
M3!Z,M5JHY8@1B,6_TP^C_BN/_.X/YD((9/+%\+WZV;VD/UCUOT6O,6M.5>7V
MN?J_M_[XY_\ 'OR^/#X@JJ_SFTZ^'!P\._#P^-_EO^)X/X?]5X?\K_"R;*G6
MNQ5V*H"9%.K6KF%V*Q3 3@_ E3'\+#_+_9_U,LB?2=^L?]\X\Q^]B:_AGZOY
MOT?[K_>H_*W(>(_FL9QY^D)2MN-"E+.$!((:0T+D?#49N-%7A?\ )0.JU?\
M>?YC#4MA-I(@CD6*74&6LDG) MI&P]24.I X\V7BK?#,J-QS*,ZE_5_W;BB/
MI_K?[E/-#N+2YFO-1@"FYMD2VMDF2(36UFD?U?DAC%)'E;EZC_L?99.649(D
M5$\CZOZTF_'(&R.?^]3&W\N0:]#!!#<FWU2PYBQN.)D3T0.36TZ5K)$P_P!E
M']I,K.8XR37IE^.)F,0F /XA^.%)_J'YCVEO+IZW6B>E'/%";@SH%0A:!"C
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MF<7>F)$*"K_64._(#X616W]*3_@,5=_B>3GP-Y8*_0J1=*0?B^%JQ_"_P/\
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MKOTKIO\ RT+^/],4N_2NF_\ +0OX_P!,5=^E--_Y:%_'^F*'?I73?]_K^/\
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MK_7&UIW^']9_Y96^]?ZXVM._P_K/_+*WWK_7&UIW^']9_P"65OO7^N-K3O\
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C_2Y)SX\J_!6E:^V*K]L5=BJ&EGE]-_\ 1Y.A[Q^'^OBK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g63338g19t07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g19t07.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4]\:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,3DM,#<M,C54,#<Z-#(Z-#@K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3DM,#<M,C54,#<Z-#(Z-#@K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#$Y+3 W+3(U5# W.C0R.C0X*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^-C@\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!
M4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!
M0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!
M04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W
M;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX
M.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9B\X04%%46=!4D%%04%W15(F(WA!.T%!25)!44U2068O
M14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!
M06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#
M05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-
M<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.
M55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O
M4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T
M95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B
M;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-
M1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.
M0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:
M2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6
M<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA
M2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM
M<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T9867$W1EA9
M<3<F(WA!.T9867$W1EA9<6QV;6)3-W)6=DQU<#9885A45TXQ9E=S,79"94I8
M;$4X<UI66$9+2#1383='=FAI<G@K2#AL4$YO,4\R=34W8E)M=$DF(WA!.UIR
M<5-,4S!K:CE#0F)J-G%1<UAQ-EI-<$%.<R]X2VMC,WA$.3=8:WI+<&1&+W=!
M-#8K6DQ393%&=2ML6$U9,&1B1U-A8VU*-UA52%,F(WA!.TY:3#(R4S-T23%D
M-&I(>6IK8W)++W=#,BLR2U@P16EL5593>%EQ04-Z57%A9'I3;4M'.%9D:7)S
M5F1I<G-69&ER<U9E9F9M6"M8=78F(WA!.V5B8C)&<E!517,W4T=X;7-J2%5!
M>698<#129$-4;$1..$@Q5TIG=D%Q,TQA<6EP>%94+TUJ4U!Z1C%F5#E*<W1"
M3&%F8TET,TYF>3(F(WA!.T8T.$-)56E-5G9':CA95$LQ6F5A>'-%47-N>$UO
M,WA624E0>7DO334Y33!A-75.82MS83%A,EAP,V]U3#8V:61P2G!,8U122F-2
M3$TF(WA!.SA0-VDP5E1*1V%S-6,W8W571E9E,R]+8GIT3$)R1&$Q<F<Q5SEU
M.4-V9$AS2EHW:31A2DIR<4-'0EI417E&6758;V,U1U-R175A.'$F(WA!.T1!
M<5=E679Y9"]-+U536'0O36%"-&(W-CE:3$YF86AW:C13,W!6145957A!=WDR
M<V8W<VIJ>&5N*U=Q;55V-5DO;59D,G=G,518:W8F(WA!.VEQ-F-Y<V(R.6I1
M=EIZ5W-K<4=%2U9R+T%+4$MY>C=Y37II;T9!8TMR3DDO2S,X>3=70WES6G9-
M66DP-D='=W0W:4-Z=3=Q,T)H9V$F(WA!.S!&>$9#<U-2:4=I45A(1U)+32]Q
M,&)I1D)W2SE..'$R5W-74&QR4S=,5W)K6&UR5S%T1D9F6&%S>D-36D5!9"M4
M0D=A<#=K5D]+<' F(WA!.VER<U9D:7)S5F1I<G-69&ER<U9D:7%(=DQ796-+
M27)Y83 T,7%94D5E5F9(,5DU96YT:7%'+U)6.2\Q96)Z+V=,4#A!-THX5F0K
M:7(F(WA!.S<O<3@S;B]!5V8X03)4-'$W.498,R]6-790.$%G3% O04Q*.%9D
M*VER-R]Q.#-N+T%!1FXO=T)K*TMU+U)6.2\Q96)Z+V=,4"]S;G@F(WA!.U8S
M-DMV=CA!<3@S;B]!5V8O6E!I<5,V:')E;E='<VI2<G)8=%)7*SE"3'%12EIP
M3$9&0DEZ;W-S.#AD;3!-2V-O6#-K9&5M2V]29D\F(WA!.VYL2G)W5VMF;E)P
M2D-I>2MP2#E494%2=$A,34AA9&)C=W%V<#(P:$I,,$9..3)7<7%S4$YN;$9O
M=E94>C5B=DAY0T)K=71-649I=DTF(WA!.TM+4D=R1E)51')I<E9V-7(X<E0V
M6615:C@W2TQ&16AK;&QE5W=J.4U82V,T4DER=TLP8E-+87%R04UF1$974V%(
M93(Q.6\Y;&8R;# F(WA!.SDY85AK2UA.=&1Y2T5A4TM:4DI'>%5*1G@K1FAT
M>$(X9#A64G5+;U,V<V)M95AN1G%&>&%R4VYP>$QB;&$K4#<R2U)V>'A64B]2
M5CDF(WA!.R]W0EAM."\T0WHO-THX5F0K:7(W+W$X,VXO05=F+UI0:7)V,%9F
M9CE8;3@O-$-Z+T%/>69&6&9O<2LO-G9.-2]W1FXO04YK*TMU+U(F(WA!.U8Y
M+S%E8GHO04E#>B]W0WEF1EAF;W$K+S9V3C4O=T%"6B\X05I0:7%15R]M8E)*
M>G%$9C1K=F],8E-P2EEB*RMU<E=/,7,P:V=L.4,F(WA!.U)"9'HR:V1U-5=5
M8V9H8S1Q:')4>C$U374Q;&MH.#A59VE94G1D4TY:>%%&,FML:595;6MT,&ED
M;6$S96=6:E92>4AW:T5Q<6PS-7HF(WA!.SAN5W1Q8G%B>C-%64%),TQX>F%F
M3#A%,&]H4C92=W-E0FMA:&8W239K,$)X5D589FU0>3EA,DYL9GDK8U-B5%5P
M:W0Y4&UI97AL1G@F(WA!.TLX9VE#=RMN035K;S=$;'AR>#9T44%N1E4X+U)6
M.2\Q96)Z+T%)0WHO=T-Y9D95>'A6,DMU>%8R2W5X5C)+=7A6:% U;5AF;DM0
M.$$F(WA!.U%L;C57=D4P*S5V<G573S9U-59J34UC4U=S<VET2S!K3GIX5#%6
M5&]O3$=I8VLU8V=Q=VI6+WI:+TYA>79O,71V3#A.-V%02F1Y;C F(WA!.V)7
M8W-T<F%833!8<',U=49P3SA.=4I)=F=P2C9I.%(X4'A&5DQ84'I6+TYI1U4R
M.7)O,&)3=S(K;C-**W)7,'I,3%!*3&%V8U=W;6LF(WA!.V%34&=9-7!O,DY!
M>6-#,5)T:7%T6B]M-RMA33!-13=E5S1Y1W1P1V$S:W1P-V56-7ET.#!45F%A
M5EE62#%31E=J8FMA>40T:%9A<7 F(WA!.S<U1B]-8GIT<E!N1390<65K:$Y*
M1G9*2DAQ<3)K.6US:%5J9S1&>$Y)>48O:4)H6F5A,#5C:4110EAP*TMU>%8U
M3C5X,&XX=E!-6&XF(WA!.UA52G(O6&QS3E$P+U0R,"]523=M,&<K<G!B>"](
M3'AU-S)";%9W=6]R>CE'54=J3'EX5DPP+TMN.'5:461-6'IC<W,V44IB4WAF
M5TPF(WA!.U9P4TQX8G%'1FEO4'=T2BML;45954)3949",DI63&(S>6PK5#4Q
M0U186E!/<7AV<&MR5'9':VM24U%R8TA6-GAX,%HU,59R,5-':'(F(WA!.SA.
M1G)8;%965SAV9FQ6*U=M;#(Q3$QZ;DUK,$UK:S%P4&1Z44Q*0W1G,#A&=S!%
M539R15E16EI1>FU.;#,U2V4K2W98+TM-1VLR,VPF(WA!.V938E12-WA.43!U
M>G1)8E=Z=DDS4U9:63=D0D5'-7@Q4G9S8C W-$948D98;6YM-UA0>D-S9DYM
M<UA':WIX+V]84CE*1C-$<# X87,F(WA!.TQY-F%'-TMW=VA9=E=K9C%9-&58
M1V1E23(T<UA"5E9)8D@X,5!Z5VPX>D13-3E"=&MS9G)C5FQ*<4IT-6\T;#5Y
M9D9C<2\Q;"MC4&\F(WA!.U)U.6%$:7I+:$YD,DMP4F5F;DXK8FEX,G0U1#5D
M8S%K=EEP3%),1V1L-&=7:E=Z>6\P:7EC;%HU;W534VA4=2]&9W1-5E1Q+R].
M4#@F(WA!.WIB965%<'!&=4QA-FUV,'%,3S9N93!3,'5$1D(V=G!4+W9V<E,X
M94Q+14$S9C1K0GA6;"\U5BMC=DTO;6I4=%%N.'<V5BMI<FDR=5 F(WA!.U1H
M:4UB4F-K2T%N-%AK;$QH6'%O:T9!+U5+3VU"5V(T<3=&6&@Y;F]V-5=A,T1R
M9W1V3E%T65!-;#!L,C1V3%,R<TIZ3&0S3%AL=3$F(WA!.W9,9%<Y=E!/<D]J
M0U!K,&DP0G!U3597,C,U82]L4SEH3$)"-3%I=4QC<$I#5U<W=%I706Q&,4-W
M1$%S>DYY,6QV=%9027@K3D=+<%8F(WA!.V,K4E!Y5F$S,416<'9/1%17,VU"
M;75*;TEY<GE*.5I+86]614U39E=9>39766]S;GA5*T5F1S(V<DI6.&@O;'I9
M,D]N5S O;D-.0F\F(WA!.S$R4DY08S-52')Y>GHS14XW-D8P,')(:7I35VMB
M8U9#4'0W;D98<U="6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T8F(WA!.U=&-F@K5C)K6&-U<S-#>4Q"9F$Q9'<S,&UO<D1'8G%&-UEW3D-K
M8W)6<D=J,G%V=V176&M4='941E=0860K46UN,F,P-W)Q,#A9:F4F(WA!.T)T
M23E*1D17;C%D8E!J27!F;GIK3#9D2%@Q3U-51WEI<'%Q:'HO>FIF-6(Y5FY'
M<EAQ:')55UI196M60TQ9+V\X34MQ85 V3F99<V$F(WA!.VMB2T%Q:C<O05!)
M9E),-3=T-VY5<FQN=F9R5%A40EEX>6QU,G5M375W,F%0.4E4:$%0:#,K24U1
M359:,35B,$=$471+1VY1>71,2#8F(WA!.SEZ8S@S04(U6&1X2F-U3G5W95EH
M9F)&53!X5C)+=7A6,DMU>%8R2W5X5GAR5&)R:7)Z5B]Y2CAS:E(W2%,W5U%7
M361P8GE79'AC5W,F(WA!.T5-8S$U0D]S87I*9'91.'I*-DLQ9%%R:CEL:&EQ
M6&%2+W=!-"M71G%U;50S;70S3GIQ3VYW,G1U,'EX47AX=D1:>7AZ>%%C078Y
M,G,F(WA!.S!+=%=V<4AO6'!T:7%Y,"\U>'4X=5=U;GDR565R,WAJ;%%2*V\T
M:$QQ9W0W:3(T9SA+9EEV6D]O,DY+54%!>%9-6F9Y23!'5G)P;78F(WA!.S5X
M.5I&>6=!5DM2<&1W,V-5:4I7=7=B57!P1DQ625EJ9FE/3TMV4V)E15%7.%5+
M;6]I4E5".6Q&3593+U503D=H869D4S)T-61#2V4F(WA!.T)B4C552T]E2S,Y
M=V)7,DY656HY-4]H6#(V;6<S>%9,>BM:4&M%4U))3F9S5U=:955C-GI),$)!
M5UHR4')G;4PT5G1P3UAX9D1496XF(WA!.TIA<6]H9E!(;$(W<#=73%8W5V5E
M3WEF5DI&:&M%;U=Y44E43WI2.&Q#15-Q5G%F:4<V,49C5E%L:BM:;FM7-VME
M26%V1F%427-43D0F(WA!.V9R2EE3575#4D123'191U!Q52M'9S,R4&-9<6E)
M=GI!.&I3>'EU3F8P.49G16IZ:5,U:6I+2D9/8EHS6EA:4T5%=S1C+W-K.41U
M358F(WA!.U0V3U-/4TY:23)$>'5!>4]P<4-$=4-#3S)+=#1Q-T9816=#<#)!
M>%9I<69M;#5#94PQ5C%:4%1O>DUX:6U8:6]J17%S,55(1EI9,E8F(WA!.V]M
M3S!O231C<6I&53DP;E=D33%E,2MT86)/3&TS*T@Y-&]91#0T,6Q(,F=0,DI&
M*UA4<41I<4YX5C)+=7A62TYA.#(K6&1&;5=$53<F(WA!.W=15%!&2F-,2'=E
M4FI(17)/>'!'<F)K23-&97)54$5':'A6=34X,BM7<DMZ=&)Z5712:#!U1SA"
M83)'<$XY4FMB:E1K4%-U=E)K0D8F(WA!.U)51F%J1E5R="]Z5#AG,T=R5S)L
M46%X2$IE6&-5='AB.%5L351144=26DIV6#1E:4EW64AO-65H<%5%,49653$P
M+WIB-58Q2S93,# F(WA!.S=78D<Y=7!537-D=F(S34US:E)G06PQ4D=*2S!)
M,WA63F-69&ER<U91*V]A:%HV9%EZ,S$W2TEB5S-1>513=%4P565W<5-F041C
M.7,F(WA!.U99+T@K6FYK=5)':U<Y:T5+>4Q#,#<R;#)K46Q:1$E9>DDP45%.
M1V=*;%=T639(;GAO8U9:1EI8;'1F5V-&-6%V-G1T8V]S<T5G0D$F(WA!.UI(
M2$I71E%$46<Q>%97>%8R2W5*0494<T)I<D@Q."\K5$AT9G)53W(R.#A"=#=I
M.%9O1SE9=F(R:W9O>E-O<UE:;E53+T%/25!)+UHF(WA!.W)I<4EU=D]0;&%X
M=')7-3%053=F4VMV5EHW5DY39C9H2S9P478K-G5V4FM(1V\U07)T,WA605(O
M;5HU1VLQ;4Q2:S%64#!H3DA.4$@F(WA!.T=9-5%H:70S:U-747I&4%-#2S!$
M+T57;V%61WA'2W!L<"]M,WER<58P;'!P,G,R3C=D4V]:63=E,W596EI':D%"
M3'%I35-6;U)V:7$F(WA!.V$T<7AZ6'9),FTV,7%S5V]Z,U9Z07EI,E<U=#1$
M14DW:&)+-"MT,F]L-7AV25!3;G%W.4XQ<E5G,4<R2W-69B]!2G@Y.&US<V=7
M+S$F(WA!.U-*,T9L4U=/94I*1F)4<DM3>'0S4GA&54U)-5,U.%A!-V)9<6UU
M9R]L1C5C,%-E-6UT8GI52D=U<DM7=VM-<S9L<5A#47!.3TI64EHF(WA!.U)-
M-'19+VDU,$)(=V=6>%9*<GHO04IX-3AP6%5&,4,K<#9L1W0V>4YD0S,K;S(V
M3C9C8S!A9U%W,FE1;TM83&XT14974$DO1G9I<78F(WA!.V0O:THU5'5,=2MU
M5'%/<5)M*VQL=4=H5V5*;UDW:6$U3C P,&-5:TQO2D%F9U5K1VDO-5AX67$Y
M1'-,3T]Y<V)E>FE:;6ET;VMH4G F(WA!.T1Y8W)';U5&;3=M9S-/2W$K2W5X
M5G!W5U5G359*0D%957%08U9"1TMS1'-F>6$X=E<X9V4V=G(S53%K:U-454DW
M,%=B:2LY1B]59U<F(WA!.SA+5S!B5$-'4W)+4V57+T9I>6A60W%F*U8O2CEL
M-6(K<TI:6&0Q2F%Z<$-K9&I.27!T;T1#<$1.8GA+<4-->DUX95-M>&)O0C!X
M5E F(WA!.W-69&ER<U99;#5R+T%#>3AU*UHY6&@Q82]A5DQY0S)K<S%-66=D
M5VIK5G=/4WIX5$)U4'%S95 R1TY/871284MQ8VXU5V582DQ,4G(F(WA!.TXU
M8FMX-D=P4S!)35,X<3-L=&5N;7%X:$%05G-K059&5E%P2V=!56]Q>'DR+W=#
M8V-0255$5T)&>G%,:E0W1S4P,DI';6EO,$8T8F<F(WA!.WEC*TU3;FPO<&HP
M24DW9E-R8DI.02]+-U%D1G9"9E$S3C-C6&@Q4V97-7 U,FAR3&583G)*87EL
M>$A&1W9&;&U:*TMG04UD='9H>%8F(WA!.VU'2W5X5C)+;V)5-T58*VYZ,EIN
M;'1V6%%P-CA"5EI%<BLP<%E/=&9:;$E08T59<7=/=R])9GE,6C(Y,V)E;3%X
M0F5):5-2>7<R4V@F(WA!.U-R:#-D9E-T-'9J8S%!63%-65EI3#!X=&ER35!,
M2&PU9$$P;$Y.5%5,,U5L4C-D8FY56G98;F\U<44U.%4K1F5I:6UW>%9.8U9D
M:7(F(WA!.W-666ID9FQL-69U8E%7>GDS2$)9.51J2$PP6D)45C=T3#)C;$I9
M;FIB:DQ'3T%:4T]/>D)S5E=J.')F3#1T=$ET>&-86512;WA&8D8F(WA!.UAI
M5&M0<FQV9F9'<7AQ9R]E,FE,>%)654E3<6=#;$973C(S+T%$:F@U0V=A=TEU
M9%)C8699,T]M>$DP,%9'9W9$8T=4;GAI53AV.$$F(WA!.U1(;U%2,BML5S)3
M84(K5C)G-DQE0RMH=6)U-'9$<6LK='I4>G1$5U<X=6)74S%L3&E/2TYE3$Q-
M>CA604%9-V)F1&ER34U643,V4&<F(WA!.R]N;2\U2'IF.#$T<3<Y2'=F>GIF
M.&HU=BMA.%9D*VHT4#4U=BM2.#,O3F5+=2]2.$@X.#,O22MB+VUV1EAF;RM$
M*V5B+VMF3B]W03$F(WA!.S1Q-SE(=V9Z>F8X04DK8B]!2G)X5C,V4&<O;FTO
M=T-2.#,O3F5+=2]2.$@X.#,O22MB+VUV1EAF;RM$*V5B+VMF3B]Z6&ER=C!F
M0B\F(WA!.U!.+WE0;2\U<GA6,S909R]N;2\U2'IF.#$T<3<Y2'=F>GIF.&HU
M=BMA.%9D*VHT4#4U=BM2.#,O0418:7)V,&9"+U!.+W=!:C5V.$$F(WA!.VUV
M1EAF;RM$*V5B+T%*2'IF.#$T<3<Y2'=F>GIF.&HU=BMA.%9D*VHT4#4U=BM2
M.#,O3F5+=2]2.$@X.#,O22MB+VUV1EAF;RM$*V4F(WA!.V(O:V9.+WI8:7)V
M,&9"+U!.+WE0;2\U<GA6,S909R]N;2\U2'IF.$%.94MU+U(X2#@X,R]!0U!M
M+W=#83A69"MJ-% U-78X06MF3B\F(WA!.WI8:7)V,&9"+U!.+WE0;2\U<GA6
M,S909R]N;2\U2'IF.#$T<3<Y2'=F>GIF.&HU=BMA.%9D*VHT4#4U=BM2.#,O
M3F5+=2]2.$@X.#,F(WA!.R])*V(O;79&6&9O*T0K96(O:V9.+W=!,31Q-SE(
M=V9Z>F8X04DK8B]!2G)X5C,V4&<O;FTO=T-2.#,O3F5+=2]2.$@X.#,O22MB
M+VTF(WA!.W9&6&Y(-6DK6'9Z03%0>E1+,FE36'-7;7IA571T83-&=&1347A1
M6'AE-7)--E(V:EE5-&@T4U=-13E12T)D=#%6=&YP+W=#6FQX-7HF(WA!.W1D
M5W5,5SEG,&E7-T1(5&)I-U1H8G=I,71O<$AK*W$S=U%K>7A3=D=N<'I+9597
M15I9:TMV57-69&ER<U9D:7)S5F1I<G-69598=FPF(WA!.S<X,&)I-W-94')L
M,398<C9P0SDY-GEO26]:-W%15W0Q2TQA-G1!-W!B8T1(2#9%:3$R26I0>$)6
M;%AK0E!.,79A,T9J-6IG;%HT1G0F(WA!.VUG,5-794]4-GE8:$%K55%O5V%%
M=SA&5BM42&TU6F=A2$975C1Q-T9867$X.3@W-E@K654O;5=A-3AV3DPY5V93
M2C=E,6-Z;4M#0SDF(WA!.SE'-C13.$)C>'$X:E-0071*3&%244)Y1&]24FQ6
M0SAS4'I:3VMA0F(V8F145V-I;5DV;S='>FYU16EE+W0Q9VIL930Y9%AK:7-(
M;4PF(WA!.T]H4$M23W!Q05971F%F;T@O3U)Q-GAP1V\S16MX;&HP>2M&+TA,
M9E)',2]33'1E1S):-V1*=E1B-V-'=U%O=E%!8V9H5EIX-5%I+TXF(WA!.S!A
M=$9C82]02V1.3V]Z=R]5-7AP,TUA6CE69#=E95IR568W,"]706E/23(T9F%O
M=D=J0E8V3FER<U9D:7%6*UHP.'=384)E>"M8;6@F(WA!.U176&HT5V(S3$UK
M87-X05IY>7!,.%-R57(X0DA+;&1S5F55,DAL:C@V6F)'6#9Z95A.<G%I45=5
M:3--:S=34G9C4G=P13A)4T\O.$$F(WA!.U,T0GDP<W(K:6YX3%1J3W!P:%8V
M9#5,;3$K6'DW8D18=%!F5'13:$)H:VAL=5DW>5)X2#A+>E!.14%P36Q/4DAB
M07%E67$W1EA(<#0F(WA!.V4K2W9).5HP6#@W6'-D3W1R4SAA4S-I9E9L,4,T
M5V5&8BM:6G!,<U=B;%4K<7<P5T5W1U P-6\V3V1W;UAK<7%:,U9J*V%Z85HU
M96<F(WA!.S K4V)4:DA!5C%C4GDR,#AN3G)Y,VI5=3DK,F]/5U,P8658-%I8
M*TUC950W5E998EIA2B]Z:UHK;DY-,5-8,45F.4<S+W="971N=F\F(WA!.S)T
M1C%#4C=X<EEM051-<D%C-$MB1E9',C-(6E9M=FQ#3#@S4G$P5GAR.#AP,# V
M:E!$.51N1VYC>'!N,58S=#4U;712+W94.5E#230F(WA!.VIB:#EQ:3AA3498
M;S)+;V(O8VXO04U5+SA0:7)V.7EF+T90+T%!*TMU+S-*+W=$1E O1#1Q-R]C
M;B]X5"]W05!I<G8Y>68X07A4+W<F(WA!.RM+=2\S2B\X52\X040T<3<O8VXO
M04U5+SA0:7)V.7EF+T90+T%!*TMU+S-*+W=$1E O1#1Q-R]C;B]X5"]W05!I
M<G8Y>68X07A4+W<F(WA!.RM+=2\S2B\X52\X040T<3<O8VXO04U5+SA0:7)V
M.7EF+T90+T%!*TMU+S-*+W=$1E O1#1Q-R]C;B]X5"]W05!I<G8Y>68X07A4
M+W<F(WA!.RM+=2\S2B\X52\X040T<3<O8VXO04U5+SA0:7)V.7EF+T90+T%!
M*TMU+S-*+W=$1E O1#1Q-R]C;B]X5"]W05!I<G8Y>68X07A4+W<F(WA!.RM+
M=2\S2B\X52\X040T<3<O8VXO04U5+SA0:7)V.7EF+T90+T%!*TMU+S-*+W=$
M1E O1#1Q-R]C;B]X5"]W05!I<G8Y>68X07A4+W<F(WA!.RM+=2\S2B\X52\X
M040T<3<O8VXO04U5+SA0:7)V.7EF+T90+T%!*TMV+R]:/"]X;7!'26UG.FEM
M86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!0
M1$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E
M;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO
M;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIC<F5A=&]R
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y,:7H@5V%L=&5R<SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@
M(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CYG,3ET,#<\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \
M9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @
M(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE
M.B @(" @(" @(" @(" @(%-4,#(R+F%I)B-X03M5<V5R;F%M93H@(" @(" @
M(" @(" @(')R,C,P-S(X)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R
M,RU*=6PM,C Q.2 Q,CHP-SHP-"8C>$$[15-4(%1I;64Z(" @(" @(" @(" @
M(" R,RU*=6PM,C Q.2 P,CHS-SHP-"8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @
M(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F
M(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ
M*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS
M=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ
M*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.TAE;'9E=&EC828C>$$[2&5L=F5T
M:6-A+4)O;&0F(WA!.TAE;'9E=&EC82U";VQD3V)L:7%U928C>$$[)B-X03LM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G,3ET,#<N86DF(WA!
M.U5S97)N86UE.B @(" @(" @(" @(" @<G(R,S W,C@F(WA!.TQO8V%L(%1I
M;64Z(" @(" @(" @(" @(#(T+4IU;"TR,#$Y(#$R.C(Y.C$S)B-X03M%4U0@
M5&EM93H@(" @(" @(" @(" @(#(T+4IU;"TR,#$Y(# R.C4Y.C$S)B-X03M3
M8W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E
M<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!
M<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M
M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE
M=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O
M;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[2&5L
M=F5T:6-A)B-X03M(96QV971I8V$M0F]L9"8C>$$[2&5L=F5T:6-A+4)O;&1/
M8FQI<75E)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @
M(" @(&<Q.70P-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(Q
M,S@P-28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C4M2G5L+3(P,3D@
M,#0Z,S(Z-38F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C0M2G5L+3(P
M,3D@,3DZ,#(Z-38F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C
M>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC
M('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L
M:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@
M8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M
M96YT.B8C>$$[)B-X03M(96QV971I8V$F(WA!.TAE;'9E=&EC82U";VQD)B-X
M03M(96QV971I8V$M0F]L9$]B;&EQ=64F(WA!.R8C>$$[+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S$Y=# W+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,C$S.# U)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" R-2U*=6PM,C Q.2 P-3HP,3HU-R8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" R-"U*=6PM,C Q.2 Q.3HS,3HU-R8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.TAE;'9E=&EC828C>$$[
M2&5L=F5T:6-A+4)O;&0F(WA!.TAE;'9E=&EC82U";VQD3V)L:7%U928C>$$[
M)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G,3ET,#<N
M86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(Q,S X,S<F(WA!.TQO
M8V%L(%1I;64Z(" @(" @(" @(" @(#(U+4IU;"TR,#$Y(# W.C0R.C,X)B-X
M03M%4U0@5&EM93H@(" @(" @(" @(" @(#(T+4IU;"TR,#$Y(#(R.C$R.C,X
M)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A
M=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @
M(" @("!&;&]W($-H87)T)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE
M8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A
M<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L
M;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!
M.R8C>$$[2&5L=F5T:6-A)B-X03M(96QV971I8V$M0F]L9"8C>$$[2&5L=F5T
M:6-A+4)O;&1/8FQI<75E)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO
M;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @
M("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @
M(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M9R\B/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S
M/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L
M<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \
M>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I
M<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ
M=SXU.34N,C<U,SDQ/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XX
M-#$N.#DP,3,W/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0
M;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53
M:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F
M.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y(
M96QV971I8V$\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A;6EL>3Y(96QV971I8V$\+W-T1FYT.F9O;G1&86UI;'D^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y-961I=6T\+W-T
M1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y
M<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,#PO<W1&;G0Z=F5R<VEO;E-T
M<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS
M93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9I;&5.86UE/DA67U]?7U]?+E!&0CL@2%9?7U]?,2Y01DT\+W-T1FYT
M.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^2&5L=F5T:6-A+4)O
M;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A;6EL>3Y(96QV971I8V$\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT
M1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@
M,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/C P,2XP,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT
M.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE
M3F%M93Y(5D)?7U]?7RY01D([($A60E]?7S$N4$9-/"]S=$9N=#IF;VYT1FEL
M94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1.86UE/DAE;'9E=&EC82U";VQD3V)L:7%U
M93PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/DAE;'9E=&EC83PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0@3V)L:7%U93PO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R
M:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E
M/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1FEL94YA;64^2%9"3U]?7U\N4$9".R!(5D)/7U\Q+E!&33PO<W1&;G0Z
M9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @
M(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M
M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P
M3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P
M5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @
M(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HV.$4U.#-!-S@Q045%.3$Q
M0D4R-CE"-#$R0C@P1$%$13PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HV.$4U.#-!-S@Q045%.3$Q0D4R
M-CE"-#$R0C@P1$%$13PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C1&030R.3E#,#)!1$4Y
M,3%"1#1&.3-$-$%&,44W-C$P/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-
M33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F
M.FEN<W1A;F-E240^>&UP+FEI9#HV-T4U.#-!-S@Q045%.3$Q0D4R-CE"-#$R
M0C@P1$%$13PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F
M.F1O8W5M96YT240^>&UP+F1I9#HV-T4U.#-!-S@Q045%.3$Q0D4R-CE"-#$R
M0C@P1$%$13PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C1&030R.3E#,#)!1$4Y,3%"
M1#1&.3-$-$%&,44W-C$P/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E
M9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C1&030R.3E#,#)!1$4Y,3%"1#1&.3-$-$%&,44W
M-C$P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#$Y+3 W+3(S5#$Q.C4Q.C,Y*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#HV.$4U.#-!-S@Q045%.3$Q0D4R-CE"-#$R0C@P1$%$13PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP
M-RTR-50P-SHT,CHT."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@
M0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ D (< P$1
M  (1 0,1 ?_$ !X  0 " @,! 0$            &" 4' P0)"@(!_\0 /Q
M 00" @ #!0@"  4# @< !0,$!@<""  !"1B6%%97U-81$A,5&568V!87"B$B
M(S$F-CAXMR5!87:4L;7_Q  7 0$! 0$                  0(#_\0 ,Q$
M @$"!0,#! $$ @(#      $1 B$2,5&AT4%AD5)QDH&QP? B S+A\1-B0H(C
M<J+_V@ , P$  A$#$0 _ /OXX X X X X X X X X X X X X X X X X X
MX X X X X X!&YG*&,(A\KFA1-PL,B$;.R@BBTPZ4=*L0 MT5=IMD^^\>E'&
M;=HIBCAWECUDIWCCWWUUW]O /E&;;I;I.]3::\22T_%$IO5H[LC,C<CHO4>S
MZ8#/M55JVC\R<L'%7S*QXA7DUO561.H>RS/O9Z.6Q+M"3QN":MFB72A)@O\
MNG[?;N=&J54Z<+<6E-NKZ++/I'U)'MGXA.R[;Q$;RIB.[OWMKQ1\2I/7.P:[
M#ZYZ'P3<S\S*6="^CDD<ERA&H3DQ!B7"G;=\%?'W+=(C[4NW9#V'L:C5(6FA
M.E.$VYF:HRB#N;:;X7W4>QFF=.2;Q.[#UJIVR?#\%7Q*KR):259+Y]95IDIT
MLR"N9533VFY67JXL<B;KO(W&!K &(BY$#D.=C6A1PO\ B3K'9?G@BI33>&6J
MHA56B'UZY$%C'B'[_P!PZB:EOX9M<Q#&KY\89?2:"[?QRAZ@Q.W5JTZ#2MF!
MM0W1TWBYR)P*5$9,.=+Y1W #$C+9K'!S9V@W2?/7AA/WC>"X:9=G:B6IRJE6
ME*ZA]_<]2M/;RVUK3Q$;G\.O::]!>U2#+5R);<U)>7550JGIB/CA"QNZKD]?
M3>,UN@RA3U9(^HB2CQ)B-8O^QS9RL_4=_F"+833+2PJI*+M-3.CE>3V>X,#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'D_P"-+MG:FGFBLFGM"2)Y%;ZGEGT[
M3E.FQL.%6&5:RR=SP5V5Q$00R#DK"7&%X((F*(D'D!*.'9#-M[$T5>8(=<&J
M$G5#RAO3)/KT*_5'XDLUVU\3O7[7.@W=UP"E*VUGN6Z]GXM=VOBU3RFRG;LE
M%ZYJ=7I&RX0.F886$E95:0-R%?KQH8>?YD1)+LJ.%+CF@TZ<-#;AMM)-.=9R
M9Z@;H[2Q32G5^WMH)J#)R>/U,!8%5HR&<MF9>1DC<A#12/@!KEW@HW1>F9"?
M%CFV:J:F/2KG'[$\^_LP[&$I:6NN1YE3'QK2=4.MF8]=^C5WU!/J"U=C6XT>
M@<CGE8F3%DT0;LH%5Y$TX=P\G(1=?R0&=-*+.8B;=D"O3<*;2(_E#UETV4&L
M$Q#3EX>JAQ/U7='3WD\6@I$:$W?4UCC1O&::_P!'47B&NS_TR;CP;97:PS%Q
M%4U+'8L;&%QLTF46C4T#6')^G;=^ "X*C0TA$+>VYIY!33>F<FW:^2S<KZKZ
M'>M+QAWFO\9L\JCKE;VSU/Z6G(73&[FV\3D-30F,QFYDDHF$L)C!Z_)D ANS
MC48D$D'Y3<;#@<<!QDF4Q8HYMQ2:3O$%1,72=5Z4YNIM?*_37M8GL^\7)H-L
MG<*%P/6VT9=5NF$5/R"Y]H&IR'"ZOBV K7(M>6+!H+/.6DBD4R7-HA*W&0P.
M/(.<S97LO(G4<"ILLRPF'*]ZLEK>%^7>,C4=];6;24QX=_ACVP%N"5+VKL-L
MOI)&+5F4X@=2]2^2UWL,]?R*4PZ11L9$%8)&RN ,D,CCI_#! HF,S$_BC"Z+
MQ1R]<"I)U5*,E4U$]%;._DDKKQKF[*>R1NYTYN#JA8%OF<\/JP]BDIW66<?C
MUO-)RA!0)(7 5"R,_DL?(.7@XL?=M!+1G&QY1@T:D)"=S<B&P*B5FIC%';WR
M_P!%28KXO.P5,W/XA=H[3166O*IK;9VO=--9M?@\CUZ!1]K<LH8CB(:/%+(<
MY"3#0@=CV!BP)?8LYESNNXO&4GS5J@@2'HBDA<*:IPYM-O/)3?Z19)-OP6IC
M?CHUS*JV=8Q_7V92;:CO9N+:F =7H5:=239"5V=-HT[FL9/ ;ZCL@>54YJMY
M%1I5Z^GN3O!,.0&.AY 4DATF1S$P/6*8G$Y5IC+.9M'4BUV^*3N$+F6AX6':
M46=3YBY-O)EKG>=8W6M#@Q8D^B$=4*?EE2S4D_91Z80V0LENY3&+PB_;Z#'&
MT>,Q]FOF4[2ZR!4K^5TXIE-3JL[>5X,E7_BIFH6PMR(X1:W]MM@)SXH.V^HN
MN%+IX5#6Q!4?2*8D\9$H3%'$#%P]2UE&ELG'4VFW9B=N\23;(_[8EBX?C1,/
MLDJ4V[Y-QY?@F#KQK02$5A#!+4NYG6Q9S;TQH]--94Y76R,O@U[LH6]F8A!.
M;.CJ%?22#21JF.P&SM$X+"8,7;XRXS38B%OQQ<'=1&*=5,>9<-?XF\FBFYZ6
MZ,%M@N4J24T79-"WS/=<;CJR5'X[+EHO95?- !(L@(F$465 RH&L/DPK-J98
M8H(+.NGJ2":[-%J1?"5*(O*:E/L7>X,C@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@' Z:MGS9PR>MT7;-X@LU=M7*6"[=RV<
M)Y)+MUT5,<DUD5DL\DU4E,<L%,,LL,L>\>^^N >"!KP-2J]/6+J%$O$ V+@^
MA,S_ ,R>1_5D;#ZL).(*]E)$A)F8$3=18(YL9W5P.;/$I!_KA1=JW.M6R@@V
M;=]DS!!^_?W]Z&\=\3I3JM>_2.DQEVT>>>XI3X4]F,=@Y=L1KSOQ<&M,HGM2
M4K4$Q'1*IJ9G+(Z"H^*)1>,NU5;( 2/)FY<==.R3G <BTZZ</5$<E%T4D>L!
M,5E2Z4TI=YZ^S18JMM$",6V>I[;:QM@IM<MNU=JO)M7BYB0Q&&1K"P6,ELO&
MQU9V99Q%F+%B#C11)N#2%A!C84HR0Q=9X^U9Y]Y._P"]>1BM$))N>ND=6]>Y
M4N5^"P (5UG"8#L]8E7&A'B/S/Q):^G0."0@V8@-DRL<4:,H6Q#R/$A&2T;C
M+PCT2&N20G+-RJVQ;D![A!53K@N-S,)S3A<SE;O,VS+::@Z #M:;1MW8BQ[V
MM':;9JZPT8B$ONBUF<0!.!=?PWM14! H-#8(# QB'QOVY3HL8:L&RO9<PBW?
MJ]HYIY8J".J4DDDE>%.;S=V]/H>A7!D< < < < < < < < < < < < < < <
M < IYM)I]'-J9QJ=*9=,304-JGL,!V4%1 </8.QLWGL.#%1D*_.W3O/I8>VC
M3HR_*ME&22BZSA3I/O)+'K[W8J;4QU4/VZ^32]B>'F5E%Z;7;(P+9FR*>N/9
M.LZ,J*-3:)1N*$2U%0>H3[:1'AT&[/I/F9-:S7R3O$ZL:9Y)BDR"^8Y!1S@@
MX3%55DH32;<.;M_O,D%\7;7&Y-MJ/H#66JA\IRB]D;=4+EL#.8Z0 M2=;T)!
M"A&<2J;)*2%;MN_.,9''HA^1-,1AK\8QF@Z=#'#5LLGF%#2;;]+CW:A?NA6G
M8[P_K)KG6_=J4D'%U^)'NOO'3KK5+J;Y"*:JAK7L*(0Z6CH!B/C2)&'0*NJM
MADK>MY=/"(Q4R:D$F4&E,A*RW;A1(557IRI5+GJ[V\NULD;FJ[PA89&]+]6-
M79;8IE8Q5>QE2[=;"2T<T1+K[&7+"2N4ME >4/3':3S&'FY)@$$#G7:>1@?#
M(7%A&&.*C?-;$3$Y;5I41HLK?O<P3OP78R6EEN10WM+<!+2R\-F"NVMEZ7_X
MQ73>,3"V#<F$38J)D5M= U;*?U2]EH$.47KIN]8-E4AC))4LH^35)KBX\K*4
ML,]LLLIBTO[FV#_A6Q [JOO%K-U<\V'J[X;!6'?=H6:T!!.Y(%6L>40PH6A$
M?'**Y#^XVPBD,;005[8HIFV$OG;O\')QW^'F)B<TN/[4DOI^^?!87;/2>%;5
M5Q0]8NY,5KN/T%?U'WQ&,(X.8O\ VQ>BWCAS'X>NB_4PP:AB"*^#-R[0[R=M
MD4,.T,<LN^^")Q/=->;%9B/A*5\1JJU:JSMV9)L+4\2![XCS\MB!"=O!,S>S
MV.SW*MF:':WX*\8P=QU%AB86[Z*]MW"JO:7XN&'7!<3_ /RZ?H[&+M;P>*HM
M>/[+L25JS03)[VW#A6[\+E[2.1$HK3%TU['AL;C&8V.2-B8C<[C/Y<T(LC@&
M6CE&IL6>)CU?9^^V[I$%4U'9-?1MO\YJ"/O_  >TBU81MJ0VLL!MLO ]B@&S
M-;;(Q>I:6A;* S>,@W\7%1<'1L8BXZNEZTS!%BF):*ENR#TR5>J/7QW-CUT(
MX+CN[2FH:;G=Z.ZT)8?\+&22:%T!E(MV=@)??=$;4&=M&U]3YA%9PN9FDF$/
M8^=A8:M#B"L*KNK$0CK%C$H##$6,?A^73MV.9*NB+E3L3%G"23IP_9SW9'C7
M@ZQ/!L:E-<;$V55E]L-Z]@-[ZCO %%X6:(5A,]CV;,185<.89)6A.,SFNB0)
MFD->LB^#(B1_ :9+/$FN#UB0!5:J4Z<,763E/WD[L"\'N!Q(A3TWD=\618MR
MPG=5YO7:MKR4%$V92[+:?0Y[!\@SP !:# ,#@XX(X;H@8_&FZJ0;INK@WSS3
M=YXIBNMWA)+#AB]E,_?4NIJOJ7']63&TA@#+C,K4VBVDL+:,ZB78,F.$5.V$
M%B89Y%1.3///)Z)')1-NLV>O/N/%E':V*N'6*>'VC+<QV4?G\EMN"#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&+.&6$="F) 4[=8C 0L@9(Y,!Q$
MP^Q8"VBSUYVS$!VC\N5==-T%.VXX4Q>D7RWW&S%HX<JI(Y@>?7ZK.F?[KLC_
M  -WQ_K5P6'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V
M\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR
M/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V
M\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR
M/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V
M\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR
M/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V
M\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR
M/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KDLI06T=/;--I.\J1U8KE"'
MKBFQSNP:,O.DU<%32;]5AT+;W97%>N)$GW@,=^UK1U(JB,RZ;X$U&F;YEBX$
MB/\ :?V+"\ < < Z!0DT##")=_VXZ8BF#LD\[:,GI)UTT8MU'3CML.&MW9%^
MXZ12S[19,&KEZZ4^Z@U;K+YX)Y >>OZK.F?[KLC_  -WQ_K5P6'V\KD?JLZ9
M_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU
M<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9
M_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU
M<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9
M_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU
M<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9
M_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU
M<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9
M_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU<"'V\KD?JLZ9_NNR/\#=\?ZU
M<"'V\KDY</%3TW4Z^]B5V.^SKO[/^K1'>W#O[?LZ[_\ &>MN/?\ ^?\ Y^S[
M/_U_Y=\D^_AO["'V\KD]%.4@X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X!6"Z=V-/M;Y4P@VP&S]#4K,R@!K*AL5M"U(9!Y
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MQK5BS*Y@J_6B?3INT8$):Y4+"JE?P_BL+I_D\H_NO.2Z9YFZMPO$@L:H*O\
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M(C>C,4EX9['Y$*[(AW8\LPZ(B"#QGV]%OV1%K^-^.R=MG*:2V *UUFBKM2Z
MZW4A+(K,Z[POYF5A2:B$<&R?<?<2Q88S;*"'0+%FYKJQKXEE?EV348[52'LC
M,8(-!BZ;1^.1:OV#%TW&G4W;^/TII6Z29@HYX;.HL4G8:;AH/,TV47L)6VX?
M5#RZKI)Z\PJTEBSL_P#[ AVNA&?NJ3C4E:GWSL^)<B8*V; #[A0Z :##'?3[
MH3$XBVF2GS$[DD4T'UD6M%6UU8G+E"*]I)7FM \[;MGND%;O0>)$TK?4H;_-
M?]/J6%@901DG4ASAF2_^8))S;[G^8X='N@EY?A3YSW+D\$' ' ' ' ' ' '
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M<-<1QE7.0:#8L.HF:/0<3))[ YFRE\+GA%V:;20&]%%5Q_08FXF\='^[F[:
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M)6J\H>:_6CX[5;ZR"_-<8*_35\7P)6J\H_6.UFM677VXWI5W?7_C[>IB%_\
2/_\ *XP5^FKXO@F*G7\_8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g63338g25i85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g25i85.jpg
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M 0$! ?_  !$( ,P!T ,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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MLGLR8[%K(F!IE\IWHUX0'O3CH<19O"+QD^=M73EPHN@X534UWY%*[U+R, 8
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M,(0X(B8N!ES9I)VXG67O5>7ERZ\^3G.PD'AG5') -714C8=DJ1FM'#(C\3;
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M_A-,V70[UIP+WC!\QK.F?JKCWNVQ\IY<N=9G(HP!@# & , 8 P!@# & , 8
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M)R(B9'VY25# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"/K:_P *K,^[Z9_Z<)9*;T]J
M?$A=R^Q?@?NJ?\+JV_\ T&'?Z='87>OM7XA-R>Q/@5]D$C & , 8 P!@# &
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MX,\P\D@'D?'#%J]7)#_BXBY1;\_&C-C\+]_Y5C\)0UW5U9[TYMX*,P!@# &
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MVW^*Y \4;KM%TE4G&B6_&WN<<\<RF2\B;EY^1%ZQ]9/^K/:G(G*N1=SE)4,
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M:KU]1M)<<^[QQS_]?U_KXYXY_P#[QS[G/'_ASQ[O'_QP4C & , 8 P!@# &
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M*OWKWAJYI[,D[MI<'E)4, 8 P!@# & , 8 P!@# & , 8 P!@# & 68=NK8
MPL()BTR14C0@O-J(/@9P3<-DHL2>QR_($5ED;<O-M]?B@T#C0_B5))D/)HF
M*1QX.44^31C5"IJ9Y^Q=G+N4I<N62+U;?8J9ES->3%2?Q5C+OD\8C3 RJ\<
MV1]+5J7>Q_ATJF%.NQOZG CB0#]$##420U3*L&;QN@5;,B.KEDWI*D7/:5M@
M# & , 8 P!@&D[]*UN;T0JQ]9DJ]G<]WXH*/35OLL/F'@G'%>Z$J=KF\H?2M
M;F]$*L?69*O9W'%!1Z:M]EA\P<<5[H2IVN;RA]*UN;T0JQ]9DJ]G<<4%'IJW
MV6'S!QQ7NA*G:YO*'TK6YO1"K'UF2KV=QQ04>FK?98?,''%>Z$J=KF\H?2M;
MF]$*L?69*O9W'%!1Z:M]EA\P<<5[H2IVN;RA]*UN;T0JQ]9DJ]G<<4%'IJWV
M6'S!QQ7NA*G:YO*'TK6YO1"K'UF2KV=QQ04>FK?98?,''%>Z$J=KF\H?2M;F
M]$*L?69*O9W'%!1Z:M]EA\P<<5[H2IVN;RBG(K^E"SR#B?B*'=(*9BX7X>3*
M?%0*>2$8PX(&7[@H4=\-6L921U6>OW2[A;;77CCWV_O=>-4]=--7%#1Z:M]E
MA\P<<5Y-V"5.US>45']*UN;T0JQ]9DJ]G<<4%'IJWV6'S!QQ7NA*G:YO*'TK
M6YO1"K'UF2KV=QQ04>FK?98?,''%>Z$J=KF\H?2M;F]$*L?69*O9W'%!1Z:M
M]EA\P<<5[H2IVN;RA]*UN;T0JQ]9DJ]G<<4%'IJWV6'S!QQ7NA*G:YO*'TK6
MYO1"K'UF2KV=QQ04>FK?98?,''%>Z$J=KF\H?2M;F]$*L?69*O9W'%!1Z:M]
MEA\P<<5[H2IVN;RA]*UN;T0JQ]9DJ]G<<4%'IJWV6'S!QQ7NA*G:YO*-C[PK
MN],B\0WK O?\HK\+6I-&RY9 ^(X!-/CK'9M'&$>>)$.7Q!HR<<+NMC:FBB'D
M?)I\(:<Z[[<[[<<>8:7:/Q:-8LF'0V9+3%JPV.%D8V-V<KI6JW5:YR9)P>:+
MGR]1ZCH?I#+I-A*XE-6CJ/2W-6X*.1TC<HF1.1VLYK5S7A%14RR3(R29JYM0
MP!@%M?<6]R/6'JY>G8(1'V4K)U%79V;,8V2>KCF!EP'1U5T8.GS5%PX:HK<\
M^YNLBBKOIQ^OC3G/J8)A[<6Q;#\-?(Z%EVS' Z5K4<YB/7)7(U51%5.950^5
MCF(NPG",1Q)D39GTJLEAL3G*ULBQIFC5<B*J(O.B*:F/TK6YO1"K'UF2KV=S
MV/B@H]-6^RP^8>,\<5[H2IVN;RA]*UN;T0JQ]9DJ]G<<4%'IJWV6'S!QQ7NA
M*G:YO*'TK6YO1"K'UF2KV=QQ04>FK?98?,''%>Z$J=KF\H?2M;F]$*L?69*O
M9W'%!1Z:M]EA\P<<5[H2IVN;RA]*UN;T0JQ]9DJ]G<<4%'IJWV6'S!QQ7NA*
MG:YO*'TK6YO1"K'UF2KV=QQ04>FK?98?,''%>Z$J=KF\H?2M;F]$*L?69*O9
MW'%!1Z:M]EA\P<<5[H2IVN;RCK3/Z4Y:,A$DP)WIC4I<*:8.Q9841L23.V!$
M<_0W;/&3QLM&]TG#9TW541614UVT43WVUVXYXYQQ04>FK?98?,''%>Z$J=KF
M\H_H?]*=M&/B1H('TQJ40%#,&@L2+'V))FC <.8(:-F3%FU1C>B3=JU;I)HH
M(IZZZ)IZ:ZZ\<<<<8XH*/35OLL/F#CBO="5.US>4=C]*UN;T0JQ]9DJ]G<<4
M%'IJWV6'S!QQ7NA*G:YO*'TK6YO1"K'UF2KV=QQ04>FK?98?,''%>Z$J=KF\
MH?2M;F]$*L?69*O9W'%!1Z:M]EA\P<<5[H2IVN;RA]*UN;T0JQ]9DJ]G<<4%
M'IJWV6'S!QQ7NA*G:YO*'TK6YO1"K'UF2KV=QQ04>FK?98?,''%>Z$J=KF\H
M?2M;F]$*L?69*O9W'%!1Z:M]EA\P<<5[H2IVN;RA]*UN;T0JQ]9DJ]G<<4%'
MIJWV6'S!QQ7NA*G:YO*-M#I[>A'LWU=HKL"7C[**D[>KB/3E]'!SU<BP"N#;
M7APH/:/G*+=PZ10Y_NZ++(I;[\?KVTXSQS&\/;A.+8AAK)'3,I69(&RN:C7/
M1BY(Y6HJHBKS(JGL^"8@[%L(P[$GQ-A?=JQ6'1-<KFQK(W-6M<J(JHG(JHBE
MR6?+/J# & 8VO%2[UR+P\>L+:_XO7X6RB:]FQ. \QP\:? 6.K:1C9&^5(\/A
M[-ZXY7:[ TTTT/(^34U<;[;;Z\Z:\<[1HCH_%I+BRX=-9DJL2K-8X6-C9'9Q
M.B:C=5SFIDO"9JN?)UFJZ8:0RZ,X2F)0UH[;UMPUN"DD=&W*5DKE=K-:Y<TX
M-$1,LES-<+Z5K<WHA5CZS)5[.YZ?Q04>FK?98?,/+N.*]T)4[7-Y0^E:W-Z(
M58^LR5>SN.*"CTU;[+#Y@XXKW0E3M<WE#Z5K<WHA5CZS)5[.XXH*/35OLL/F
M#CBO="5.US>4/I6MS>B%6/K,E7L[CB@H]-6^RP^8..*]T)4[7-Y0^E:W-Z(5
M8^LR5>SN.*"CTU;[+#Y@XXKW0E3M<WE#Z5K<WHA5CZS)5[.XXH*/35OLL/F#
MCBO="5.US>4/I6MS>B%6/K,E7L[CB@H]-6^RP^8..*]T)4[7-Y13DI_2A9Y.
M!6H.8](*9DX?4@++:BSD\D))CP2"OT"8MY\&=1E1+E9D^;(.$=N=>?[VG.FW
M&R>^^FSBAH]-6^RP^8..*]T)4[7-Y14?TK6YO1"K'UF2KV=QQ04>FK?98?,'
M'%>Z$J=KF\H?2M;F]$*L?69*O9W'%!1Z:M]EA\P<<5[H2IVN;RA]*UN;T0JQ
M]9DJ]G<<4%'IJWV6'S!QQ7NA*G:YO*'TK6YO1"K'UF2KV=QQ04>FK?98?,''
M%>Z$J=KF\H?2M;F]$*L?69*O9W'%!1Z:M]EA\P<<5[H2IVN;RA]*UN;T0JQ]
M9DJ]G<<4%'IJWV6'S!QQ7NA*G:YO*'TK6YO1"K'UF2KV=QQ04>FK?98?,''%
M>Z$J=KF\H_:?Z5E<VZFFG]D*L>/?[ZZ^[YS)5^KWW/''N_\ N[_^<A?HAHHB
MK_6K>S_ZL/F$I],5Y51/Z)4V_P#VYO*-3;/8CQD8 P!@# & , 8 P!@# & ,
M 8 P!@'H*_HS7U;KW]XFT?Y' LYP^E3UH;[LJ?F63I3Z*/59_O2W^56-A//-
MCTP8 P#'CXL_U:W=3[@YM_":9LNAWK3@7O&#YC6=,_57'O=MCY3RY<ZS.11@
M# & , 8 P!@# & , 8 P!@# & >H_P"$]]6STJ_=^@?\MXSDS3'UIQWWC/\
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M-1JN7?M=EFNU=JGDLSTEFEE1J,221[T8FYB/<KD:G4U%R3V'0Y<+8P!@# &
M>H_X3WU;/2K]WZ!_RWC.3-,?6G'?>,_S'7>AWJM@/NRK\B&0G-:-E& , UZ?
MTF?ZM\=^\95_^G[ STGZ*_6AWNRW^96/,_I7]5F>]*GY5DU,O!?D\8AOB6=;
M9',CT=C4<8>>),@9E<A'Q2/MMB%!6F,9($9$4>#V(K0@0>-!J#A=XWYY=.T$
MD=_+J)<<^QZ<12S:+8I'!')+*[T)6LAC=-(NKB-1SE;$Q'.?JM:KE1&KL1<]
MF9XUH'-%!I7A4L\D4434OHZ2:5L,::V&7&-1TKW-:S6>YK$57)]9R(FU4,VH
M\311BN^I?7ZS_P"R3U_)?VZ#MJ<4'(.T@KO56=@@1?7"9HH3"QWA>X]58ILO
M*1@.NH)#BMPQ: RR5RA#:4QPRV^%\;:$]^(,LXSB53^LXBS_ (?CIKB,>$OT
M?M5I'XI JPUD91RFRA?)9L3LI36(88EX*6-V2F_M9A[ZN"X;<_HV&O\ ^(9+
MB8;)B[=(:EF-F%3IP]ITE[.'.5L=:M ^]#7FFF198I$S*>LUSTY@@<I=KJI.
MF<BML-X>-X&7<(F$:ZM&0;OL) .T==CH#\H*^H9VE4R-H,X6]>\.P,,Y^.24
M6U?Q>2O3X]L<U7NU4QNQ(VBVYCD=.327#V)/!+BS)$PVSA-EUE8[.(-6XM1T
M[6ZLD_\ IMEU98FQN5F5JVN!UV/Q!:6!2W8]&<0D=!/%A$D:XG6Q:JVMPM?#
ME2DEML#G(L=?_4=%K0RND:V3./ZWL+I3);;Z6UE,*AZ4L&TPZ!LNP3^0#X!3
M0563]XW@&XP,3KBS3Q]^,KMF)22<\OV5<V2L*!EIXK"5IJ\>:M8VFRR+5;'8
M:>.VX+N.N6'2)V&I&ZS>DX' &R4I)K56.-K[+GYIJK9JHZ1E?TC@&HJR*N+4
MM8#+=P*K8HX"U)]'$Q-\C:U&-9M('1WHX*MJ21S*K69.UFU;6I&^PM=9U75B
MU9"F-GU5#(/WL@%1P3J=!;H/]&J5DTW@A9ITR-@I]8T.N=9_,GBD:C#DW2;*
M:-*J\E(SU3PLH08(RD7'9B#CJ<X>,%E,:&I;GL:/V+EC&+%&/'[\4%ABXY')
M6JS44; U)9D9?= ZYG%'<G8UZQ/D@DE6!KD3*GMTX*^D-:E7P:O?ET?H2V*S
MTP*2*S:AOJZ=5BB=)0;8;3REDIUY'-29D4\<?I"M4LK\0^[>97XC];N%"_7^
M0=<+QB71SY4: 3E5Q*O;6K6)-:Z+2.-W'8=;"S,@B0-A8P22 BKJ5M]"\6BD
M9B6VHA:&PZ#HM/NZ-4.!T7M(C,2BQ/#YL?X+A([DUFG:G6RV*6E6M/9'-(ZK
M)#(Q(EU)9I9OKI//85WP=)K_  ^E%3-^&R85B$&C_#)')3AJW*L"5GRPW;55
MDDD,;;+)8W+,B/AABA^HL$-?+KO&3B-%,X/3DMK9E1D#D[VS+2#^:V$0_K&(
ML=I7O#8*^CAY:7=19P2KB;4RT6]\!K0O85?Q&VW&R91P5?%FRCKA"O0B;$'6
M+T-IV(6(4JU'^ESS8J^JMG-[98T@QF!MFO><B\);96LS4DS8UC6*B9T:=0X>
MVO1FJMP^O,ZW;C]$@APEEIM5$C=#(L^"V'U;%%J_Z=5]FM!==]9SU>U5RN-$
M NC2'AUP]8=777^31$GTG=[V!.RQKK?'K2BO=5P1(\.G#J3E#>_;G>7A91H.
MUC\%C,9=UT=K!SKHV\NV<J^2^8^3'UTFG1UG$HIF8ZGHU=D>*2U)L"1C<D2)
MC/Z-P,D*O62Q+*EJ.VBYY*B(OU(XM'TT8@5M;#98'X Y;5A\F%1VX<>5ST5R
MS/D7&N'9-J)%7BB6K)45$3-%=E<C:T!\.4Q+>LQVUPO4JGZ<;=FJ]'Z040WZ
MQG&DFA;^KI/\#WAE\=<9D(F<UZW,[!;Q1Y:)CM)5C62;[F.5W$K$:ZOQA#Y=
M.QI,R'%8Z<F,W;RX39=Z1(N+1K%8;;BSX?#\3@?!!BCJRS-J,PFVZ+_3R2%Z
MZKV?5N5M%Y)L)DNQX-2HIBU9B5V)A,C98'5)M7T?$<+G9//A264A=;?B]1)?
MKYK,SZS'4-2U3T_.[ZZ4Q;M)3?0O?M,;L'NC\H*PH\/1Q6F#G6P!U5FQ^K3U
MQ1RFG9VOVSP79K!9W7YQ_P (3A.*BT"JRWQT&V<L\B]<NU\.QV7";VD281'5
MP/@K=]]]EZ/%),6@CMQT9+S8[+FOJN1+$;56NLSU8B<&_)<:C2HV<1P&+%Z.
MCO\ 6)+6.\+4P]F'OHR85'A%B2I)>BHNDK(YEMJNK2.RL)"Q'JO",S;\T%E]
M24_S6\UM./=)X#VSVZ$>(\WMJ#4LZI-&HY9$]8Z$_LVQZ?!ZAD#FL#4HF[).
M2BAP<"47D<LB:C9J9V4>? DTD\%RZMF"G+CUC!TTBT76G8OMO+<AFX27^J2U
MGW8FVXXJ[N">]\C$BAFS<S)N>:O-3HK5GN18#6QK_AS2E+M>@M!*4T*1Q_TN
M*S'2D6K)-8:DK&,C>LDT*HV3-VKE0%<,.N=G2"KK_8QSI6.MDGX;\?E<WK,5
M6W6IH@<N;:^CD3*&X-6MHS6O^LU?64!@#$::EQ:?QV0\CH=PL]"09P0>-G[3
M)M.Q.I';PYTN.NILTGEAKVGVL57@Z*8?',R.Q:J06<4LU9;+GQP,K21:T^22
M6$8Q6KC5&X7;DIXFV+ 6W7Z+QS3U&5<+:DE[^HR0ODKU;=BMA-:W'6:Q\S[,
M<BM@S='75RHYLVR.ONG_ !<'8$5U;@OAZ2*827M;U46FL=M][1A" -NH<OZW
MUT4LMQ0/!]\PBJ3UQ>A";-9<C1^B<T'ON10R,AFKG2/L6^!'9QOT+#GXO8TD
MBABP?&$@EI-Q!EA<:@Q2TVJF)<&U\VJE!M=T*W\Z[FZSI7JG"N7Z$M7!$O8D
MS"*VC4L\V,8.MB.\_#W5DP2?"ZK[:X;PCF1(YV(.L)/Z B3M74;$QKDC1(\+
M=;>L<JO(D'"13J!$&% >.-,G%ZQZ;/J'K'8/U$T7K=L&B:X"8. "LKJ1V7%R
MJ-AJZ",S(10X](,D8_HFJ570RFXIBL6'L>^;&IG8CH# F'RP-Q"UPF-96723
M)+"DB0W$C?#*^S(Z.3@VM59%5&(N*_"L)FQ![(X,$A;AOT@3NQ"*=V'5.#P1
M$JHR%8YUB6:DLC)HV58VR1K(YS4BVO5/S5$&Z?2;KC=(%2.]0X(Q^6W>C8W;
MYH=U;LJ-M6+67S3:HF<\!G916/::G3 D*S#!>OB/68Y)8F7T?!9&_$/^";X<
MV7+&-18I1D27&K#N T?2.E&[%ZLJN6"#TQ:\D<-O"+L;WN?)B7]5CBF9JR1-
M>W51SE*O@DN%7X^"P6NWTC2'A+LC<(M1(U)IUI-LQRRU,7I21QI&S#4PF26%
MZ+'*YCM=S$U24/\ ?H_\5/\ Y^,]?7<OL7X'C:;T]J?$XLD@8 P!@# & , 8
M P"L M@SJ-Q2:P6/R^1A879"<>2L"*BS#YE'YHE$BWQ]%TY.*;KILC>D>-?^
MU@^I!%?@<0_[6UX27_OY8DK5Y9H+$D$4D]595K3/8UTD"S,X.58GJFM'PD?U
M'ZJIK-V+FA?CLV(H;%>*>6."TD26862.;%82%_"0I,Q%1LG!2?7CUD75=]9,
ME*/R^6!@%P0CMEV? 5$]H$)V%N812)%L_8O:H'61+&<"<#BRJRY83O&$"N@K
M@.6<.'#@J'U;:C"3APX7>M%UEU=]_FOP?"9+K<1DPVB^^U6N;<?5A=81S$1&
M/256*_78B(C'YZS41$:J(A]-F-8O'27#8\3O,P]R.:M-MJ9M96O55>S@D>C.
M#>JJKV9:CE55<U555+?<^D?,& , ]!7]&:^K=>_O$VC_ ".!9SA]*GK0WW94
M_,LG2GT4>JS_ 'I;_*K&PGGFQZ8, 8!CQ\6?ZM;NI]P<V_A-,V70[UIP+WC!
M\QK.F?JKCWNVQ\IY<N=9G(HP!@# & , 8 P!@# & , 8 P!@# /4?\)[ZMGI
M5^[] _Y;QG)FF/K3COO&?YCKO0[U6P'W95^1#(3FM&RC & :]/Z3/]6^._>,
MJ_\ T_8&>D_17ZT.]V6_S*QYG]*_JLSWI4_*LGGVYT><UC & , 8 P!@# &
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M5?\ Z?L#/2?HK]:'>[+?YE8\S^E?U69[TJ?E63S[<Z/.:Q@# & , 8 P!@#
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M[LM_F5CS/Z5_59GO2I^59//MSH\YK& , 8 P!@# & , 8 P!@# & , Y4/\
5?H_\5/\ Y^,A=R^Q?@2F]/:GQ/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g63338g25v11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g25v11.jpg
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M(\]L:JSG%G0U(H;3&<.F8P.D^Y:D$U>1$TGB6B::TF*T_:/X)D,>$W5QL39
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MR, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MPYRX>NIE)([.HU;0B> EY0J0=\'60F3,Q9)!35JZ8J-44$4PS?.B6JT40O\
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M%?=-YW5<ZM^RZ_NR,1F<WW( DJMZ0LZ.&+NIO((V'_0 A,BB^GCIDU6'A_\
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M)(FP:EY?,#NZ#1!V34&" @)@T&#Q00''002/@A(P.*9,D0;GZHK+4G#!!@#
M& , 8!2Z_NB=/=B)>=F4ED=M0EY/:\'U!<PNJK"?08)>]2BB)XD,KRU6C1HY
M<$0[#:6S%@U+QIY%IBD#E\DC^LG_ $0FHPU%3:T^59TJMCS;EZ2U;=\;/1"4
M2^Y T6+3*FIR'CD.LHJ! 0 U1";/>OTJW!? =AH6*;%Q@B4%18E@FU*RH,*/
M.-.'S%#?4)_GG6?)S+SH3#B0(8P*7]VR+RJ+3<=8==6B9NYZ:L:L9,RC<FA[
M[>&%"P5Z%_1)-%I>>!RV+2:/R2,2%HY;J$!"CL<.<M0FRYKS^Q/="4!!.NL1
M,Q:$N).9=RV9G['GTUG,@<RF=6'84HX9IG)E,#SG1#1X5=,A@D0T:CV0P($
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$/9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g63338g27k60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g27k60.jpg
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M 0$! 0$! 0$! 0'_P  1" #> ET# 1$  A$! Q$!_\0 '@ !  $% 0$! 0
M          8%!P@)"@0# @'_Q !9$  " @(" 0 %!0@,"P<"! <$!0,& @<
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M #@ X . #@ X . &)MI_?(]_^K'_ /W,G-RU%U%\!@>L^L_B*#R1 < ' !P
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MAH'P\?0/HF=?6*O\I?V;C3+CX>H:!\/'T#Z)G7UBK_*7]FXTRX^'J&@?#Q]
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M+\G['RT4HE6MLN+I2:;WVV%P^5%@X . #@ X . #@ X . #@ X . #@ X .
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MTAIFHH<Y,"]D)A?L "!X"BAOD'C[B)ESZF[Z&5O?$R\@([WRMJ^%Q?/D"P<
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M]0FAG+#UMLTX$1,OG.)$4@9P!V=CK-;MB.ISLLSXZ["1A5VH0G;6=["ODL1
MZN/O(8B)EDT=ERO_ !M\;]A"-/ALWE[MQ\![I_**VD/V"9-J0B;M,)+ YC/M
M22 D"P+KO?J:T!CDBFE%.7Y=TN%FM/ASPDF%9XX%C!E0RC1Q;>9%W[B/81[Q
M-SOD5^VVTR\AF9R!8. #@ X . #@ X . #@ X . #@ X . '@8JE;B* =LM
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M +0 C'IT3-V4((.,2X8P+5Z:%@TGACPE/-A3J5:J(HO*6>-:M !PSZ&#'BC
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M"WTTSL@K.'N>5Q+FSSD[-R[G[7"PIH^LM<"!P+QJ!2X !1A@QPHJNDP%A$"
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M ' !P < ' !P [%O04?@2LOY;KY_05*YDO7V>9C5&KM\B&YKE!<. #@ X .
M#@ X . #@ X . #@ X . #@ X . #@ X . #@ X <V/W0[^XO$C^-;T_FM0\
MT;V]GF,W-G;Y#F=YH,PX . #@ X . #@ X . #@!T6>@'_RL?]A/_.3F;FSM
M\AHWM[/,=0G,QH' !P < ' !P < ' !P < ' !P < ' #3QZ6+]K0W^G9O\
M[:_YZ"?=R:N3'KQE\,+#W(^Y*_W^_P"E_P#R$:=N>@0]R X . #@ X . #@
MX . #@!N,]$[_BM]?^9K#_AV#SZ ?<.?ZKE-_P")@[_MQ0/37[K7Z> ?S<4?
M'#PW"<]^!Z<AP < ' #CT]/!^&I7OY!J-_6O87-4:NWR(9+U]GF8TM<N*!P
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M ' #HL] /_E8_P"PG_G)S-S9V^0T;V]GF.H3F8T#@ X . #@ X . #@ X .
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MAW]Q>)'\:WI_-:AYHWM[/,9N;.WR',[S09AP < ' !P < ' !P < ' #HL]
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M2-1D1$:CTE&1$1J5HDFZC+6>BE*;GGHI(M1$-Q7HG?\ %;Z_\S6'_#L'GO\
M?<.?ZKE-_P")@[_MQ0/3;[K7Z> ?S<4?'#PW"<]^!Z<C%J;\-A?_ .EIS_\
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MPMW7/(01ZBWW([<;]]BS&N_S$O=?O._K?%2I8)==Z\'0Z>UMF+A%@*11=3)
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M#C X . #@!S8_=#O[B\2/XUO3^:U#S1O;V>8S<V=OD.9WF@S#@ X . #@ X
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MJ[7U-1;G46"MWY[L%C645E(UO*$BK#5:&[1=6-0L(M]F[I5#:]-$#B%LM&L
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M(SM?.Q7/ROQR&X[KY?DZ^7OY>_D_9[ZZ^3Y>_P#O[^3Y>_D_T?+W_IX%1_>
M#@!C0TV]O8-FQ# \2KPX %.+&";0;4TD) T$@(DB&8PBG7B T:(V'' F,<R"
M$J'"7J,B*.;'/#J;<2\?01?@?AZCP_3/Y _P.;[^ES1']_>+%O+Q] N>X_#U
M'F\'99Y_%74$Y(N8),REY*0%)+#-('/);K#G*+),/G(/+F/)WE%E+!))#)EA
MWG%GEAWCEW*_I'V? A"/HEV_$QE=RHL-:_I#+GX,U#K4??FANW+3G3#N]_1Q
MWB68+\XNQ>J=\[OE]TJMF]I\)]YK/^,]R]7XE_@^\^ME[#KW'?W/U)Y=?DLJ
MI'KS_P!Z_338^1)L.'H_+71.=Z3TN+)YS2^2F^9YO0T+.Z6EI)T?+\*\MTSD
M;Z?T6318_P!\71=/Y7B2Y6G\D](T>C]%D,:&C\IJYWG-/2NUHZ.BK2UJ_3/Z
M#'^&W)^=W/\ TKYU]_5]X3_P_'O[:H__ *H>7?TW:O\ XG@S]E5;[>'TS^@Q
M_AMR?G=S_P!*^/ZOO"?^'X]_;5'_ /5!_3=J_P#B>#/V55OMX?3/Z#'^&W)^
M=W/_ $KX_J^\)_X?CW]M4?\ ]4']-VK_ .)X,_956^WA],_H,?X;<GYW<_\
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MB]GJ<F)V'I+N]46]C<Y&W>:DUY2ZD2+838"HXB4OQ1$,;C#7E577A+Z]N?\
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MVIPT&U+HM=K]'K,R\B-;12ZNLKNY=C5ZJ4O%R(FJ[1'1EE*05I99+:#,T()
M9Y$17WG??XY%<['KS,5$GT.7B?,2M!"?[R2:U)U3X_:;VAI%#LB!9J;?M*\8
MT\:#40VYDT-<[?NY%*:&-:\&K-FJ*:W ^V$LZEH*6;"0$Z9\-9F1VS(SUF0O
MD#Z//08**L5_HJ^DA5KS6<>?,LA3]7F19=]-;+9K;#G9\HJ_#"9343NQCDU^
MO@P+9UV%5J4/Q6:-5+T:%=(^&K1[-7>,ZNN_E_9Z_9Z[_9Z[Z_[^! < ' !P
M < ,6?"G\&#57\1L?]<['RR_I'V? A5'T2[?B8RFY46''=]UD?XOP+_\?D[_
M ,/C[SN[D:^GB+\VE?&HCHSEIU8;ZZO\*6..CG>0Z*#@ X . #@ X . #@ X
M . '8[]R;_N/ST_C/C%_->07.C>67Z>'?S:K\:<.]N1;Z&(_SJ3\*D.POG2(
M[R&+4WX;"_\ ]+3G_P"647)V'UE\#%?[?_+YC*7D"PMWK_5=(UEU99:FIS@9
MW.P&6BWV%D<<[LUH>&9Y]]%O;"W(,;,8UPV6"M&%.5D A3#B)TPP*T6 ;!<S
M$$5AR<>G@_#4KW\@U&_K7L+FJ-7;Y$,UZ^SS,:6N7%!7:W5[-<6XU?J-=>VI
M\9U+D(DK:A@\;E8P1Y33]C+5@Y1D_4,.&<LO<4.74<>.6>?R8X]]] 'O&HEZ
M-A*E$IML+@7-<TAT@U><3P@O.CU2G-05G$'G@*UZ:.DBW-?-W@9[^V5!]Q>\
M'B1R@%5RU5M3JR%TK/6^P>K> OR;G5+*GV/YR!*H(<9LF9:'M=\4&7PCRX2Y
M&S"8#1PR8Y]R]89]=]@$RN.C=JUVY?,K,%A<[M([LU3Z1TX:QVAP033X@,&<
M8T4*C&1B%B,9'W!B!V7G$,-/V:.%'C#U+%RMNV]^WM"Q^7:+?8:^V%DF?6&*
MD7+*O55A*IL[S"M.^TU<:X9X#S+'S+$+W%.PQDDC@E"83#D]9R819Q]998X]
MR F]OT)MFAL!DMGJSA=;#FE7! J&"]L79&!%NK0]KK\X H8$XQF92XR(?L2
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M3]U7]SHIIR@P'<:06:S4:IA"G56GN0(MH:,7(84U(HZD5U4RMG252HR*DT_
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M?/#%[;MC>4NJ?0^;HV!3%A.H=>FUM/L*'RBPT!<;HIIXVM26BVQ3:WF8;>>
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MRW7S^@J5S)>OL\S&J-7;Y$-S7*"X< ' !P < ' !P < ' !P < ' !P < '
M!P < ' !P < ' !P YL?NAW]Q>)'\:WI_-:AYHWM[/,9N;.WR',[S09AP <
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M8),UJ-@Z6XV!18KV8;$N&966E@58[&SHJ-VE3O-G R^/'JU?RZ\R+9UP(#@
MX . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
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MG/G#C2L7,=OPSP^9>5A(APCO>004(,NOP]?B,<$BCTC(=T(KW<SA51VFPKK
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M !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
M< ' !P < ' !P < ' "/VP0]A5;, J&P,:&U]R(M$E?-*K&4>2N)A#&DM".
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.. #@ X . #@ X . '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g63338g28q09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g28q09.jpg
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MR7JBU2L5TKK(>#Z'U&I=<YP"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M/-3P".XK-G+[+%[9FY061QLIDTY0O&4IZ7H.&C:]W"Y+/A:3>">*UW/ U/Y
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M4FV+Y[FE)@Y5LT3-135SP74OI"B@S7-PR;I,&IWSE.%KW6"EFX=)4)9Q?V-
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M"</][\:]2[#^V"V!*!$Y*[60R9L%V6M\]:1P7J6"NDL$CTI&E2FPR:,N32>
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MCI+(TWTJ?%&;:3T%MC<&T-8<>3O(<,0D4-US,=H1PR6:A$)B6B ]^7+CTF;
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M4;69KTRN32VS0]D@3FL[W4<$;GA#FN;2UO;=QD&X_P##78&H^4^N]TD'VO\
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M]+ZR%@NA=17:@D4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H"@.O*<+Z$D?KL9J=#Z5U,C2NA]:*_4$B@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!&?LK:^[1W+4N"U
M7(FP:+!+Q"*28#/624JUW/Y[)(6M)H=#<,T]G,=AZ+*2!OD@,";:B>K9/JE^
M7N3%RH1-9H-L+#C*2E/U:/HOQPQE(VMVYQXCVVS2,E>R.0QZ0#0L88 7HC$2
MN@)+PC;<$W9$S^3$H.>)$%ATXUU'<G8YUG<>3#]_CETL,W6#M 8IR[ZS$4'X
M*Z^A9C)XXE<DF@%[,93MR0PV:"H<6CDJWK.M;D=33/:)]LA'62SC&0PDP88N
M8(V6:0AN]*O'[,0@I9HFU$SZI;Y]9E_47'X3IJ038X%G.P3[*8L8VW]S$G-M
MWT; .@+)=$@7!#6K!DDS*RPBZ=')*ZM:]GQ=VZ<V33NME:A!F2+^3,=]!"/F
M]O4O%]+ZR%@NA=17:@D4 H!0"@% * 4!CW:VU(+I+7LGVGLHRH A,/8I/C9)
M 48//;6=/6HP>Q%@8ZP*R ^:+E7S$0$! A9$P9+/F0P8Q=/72"&88W(U1==)
M9PY'(1]X7V1) @X\QE#IR6-:?W,*$0XC#7^UA,CB6RBKV (C]9ST>8T9M\/:
M!3IP!E[DKK\X/:!UW68Q,@)D^^W"[;-29?C+G#QK?Z?GF]DIN4;ZTU?$R\QV
M$8*06=A2,/&@)=-H&:8GHT8CC"2CY *ENNIB((Q]<3B59>"/"+ILB)("W[T)
M.<M/$VB"F!TA#B3X=QWV).#6!@6[[BNW[Z'$VJ3UDX[W=)(.D.[-ETE.XN44
M5TNV[19)-3'+"P@J5 * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!0'7E.
M%]"2/UV,U.A]*ZF1I70^M%?J"10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * A_W9IAKM'GY"UI8+0D0L&9"DL1>P=:R@
MI$LX:X@X)(?:#S/#44YA#$T)E(;8*_\ 0V+IR;N3TH2N0/R&+Q41$C8G1TRW
M3[X/I)@*$"@/SG]YE_9R_=>@*)%_)F.^@A'S>WJ7B^E]9"P70NHKM02* 4 H
M!0"@% * P_O_ % +W[IG8NG#+Y$6PV!&W8+(HX AI.D+<YYI.AY.X(\@N.?Y
MCR#9J\2QO=F^050P=""@<N@Q+,@3E?WW$?6O.BGC,")<>,+[MDYZ(:(V'+MS
M7BQ&#0_-Z9VSL&8;=F6Q#$;G#G!],X7#-EJ;==1/9$"=%Y>UE\$A4) NRZ#Y
M.4FY4)GU):L):-.'TF<(#P.C>M][ MPQ39,L 1<<+/-"VBXPT:Q?39MZ0=3%
M &K:!AW*$3'C8_&9%$X[BSPC[DL^OI?3A6TA9.8[($I8#<^/J[WZS?%)))!)
M-!!--%%%/!)%%+#%-)))/&V":::>%K88)X86MCAAC:V..-K8XVM:UK4(/)0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 4!UY3A?0DC]=C-3H?2NID:5T
M/K17Z@D4 H!0"@% * 4 H!0%'<2*/LW!%H[.AVKH0-L9+-G!-D@X%A[]V[!4
MBBJOBHR&W[W<=A\YQ2:W[@MV%?\ TL^U _F$CCRG8[F>#*=D0C(+=H48Y=D"
MXOEB@;MVJ]^R(7RPSLB2_P!S4OCE;!;*^-^P!44G35=9RW1<MUEV2B:3Q!)9
M-19HJJBFX23<IX97S045;JI+IX*XX99HJ)JXVOAGCE<#V* 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0$/;H2%G_2/)3(.V?0-&"3%6,&G\K1F$+);.
ME+;7\3;O'^NR4HXS7%GFJ#&,BXB_C<<Y$8-"T.9GY$'CHX;LHD2FXG1O6GUW
MW>HF$H0* _.?WF7]G+]UZ HD7\F8[Z"$?-[>I>+Z7UD+!="ZBNU!(H!0"@%
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MI=)%/'^EGGC;[M""R\]S:?3^_P!K:UP_]EH;'_ISJ+X__KQTHFBVGOW2EO\
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MJ5FA5YA=LHCEGG@KEFDGYU;%ET]BVG6[+K-)14M/4XX8*2DH'&Z*)Q4<%*G
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M0C?!8</_ )$RSZ4)U53\OO"^V_**'LE7+;\G_@=87DU+VJL$JE=/.XB@% *
M4 H!0%ONO*@)Z%D?KD:H1I70^M%P4)% * 4 H!0"@*))?)R0>A"OJ"]?G6Q[
MTVIYNKO9J4^ZS/?*S_+JIVBC.0JM#!N"% * 4 H!0&Y' 'WV6K?S<X^CR5U8
M/FM>/+(W]%E+\U;:/&.<'XI,J?S["^<5DG216W4UK"@% * 4 H!0"@% * 4
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M+/I0G55/R^\+[;\HH>R5<MOR?^!UA>34O:JP2J5T\[B* 4 H!0"@% 6^Z\J
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M,1,M*R)F[>QA# +'[#'5W[]]ILI%_)F.^@A'S>WJ7B^E]9"P70NHKM02* 4
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MX074_P"J!KWZ8]^58WDB\&JYY[K/8;.*V\L'A-4O,=5[=:1S;5ZF>4B@% *
M4 H#Z:G0C?!8</\ Y$RSZ4)U53\OO"^V_**'LE7+;\G_ ('6%Y-2]JK!*I73
MSN(H!0"@% * 4!;[KRH">A9'ZY&J$:5T/K1<%"10"@% * 4 H"B27R<D'H0K
MZ@O7YUL>]-J>;J[V:E/NLSWRL_RZJ=HHSD*K0P;@A0"@% * 4!N1P!]]EJW\
MW./H\E=6#YK7CRR-_192_-6VCQCG!^*3*G\^POG%9)TD5MU-:PH!0"@(I.G"
M^"LY??)"%?2SK^NX\G_AA8GZ>G['63IO*#X'6YY/0]LJY\S*K7E210"@% *
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M%'TJ_D-J7Y62#YG:U2#GN>#.0WGVT_Y?1%L>:A[_ &5WFBH=LI"$NM<Q=\4
MH!0"@% =!'1G>]O6_2)*/40-;4>9[XH?VIMOY*SS7KSF_&5#^KME?+5XD(JT
MY7D4 H!0'!!]E'_""ZG_ %0->_3'ORK&\D7@U7//=9[#9Q6WE@\)JEYCJO;K
M2.;:O4SRD4 H!0"@% ?34Z$;X+#A_P#(F6?2A.JJ?E]X7VWY10]DJY;?D_\
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M?!6<OODA"OI9U_7<>3_PPL3]/3]CK)TWE!\#K<\GH>V5<^9E5KRI(H!0"@%
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M!<!69^#WDP0U+XLD7&X+,U)6,#KKV#)DB+4ZE''-EG8^3 AK62BGRC0G9LS
MRI%_)F.^@A'S>WJ7B^E]9"P70NHKM02* 4 H!0"@(H^E7\AM2_*R0?,[6J0<
M]SP9R&\^VG_+Z(MCS4/?[*[S14.V4A"76N8N^* 4 H!0"@.@CHSO>WK?I$E'
MJ(&MJ/,]\4/[4VW\E9YKUYS?C*A_5VROEJ\2$5:<KR* 4 H#@@^RC_A!=3_J
M@:]^F/?E6-Y(O!JN>>ZSV&SBMO+!X35+S'5>W6D<VU>IGE(H!0"@% * ^FIT
M(WP6'#_Y$RSZ4)U53\OO"^V_**'LE7+;\G_@=87DU+VJL$JE=/.XB@% * 4
MH!0%ONO*@)Z%D?KD:H1I70^M%P4)% * 4 H!0"@*))?)R0>A"OJ"]?G6Q[TV
MIYNKO9J4^ZS/?*S_ "ZJ=HHSD*K0P;@A0"@% * 4!N1P!]]EJW\W./H\E=6#
MYK7CRR-_192_-6VCQCG!^*3*G\^POG%9)TD5MU-:PH!0"@(I.G"^"LY??)"%
M?2SK^NX\G_AA8GZ>G['63IO*#X'6YY/0]LJY\S*K7E210"@% * 4!TH?8MOO
M_MO_ *H,\^F70M>5<KW@Y4?/=7[!:)ZOR/>$M>\R5GMUG'>Q5="R(H!0"@%
M* 4 H# 03C#I*+[+(;<B$3?PF<FR+HO)G4'FD[AD>F1-\3D9MV^G4$C$F%0.
M<NESLPE<@R<2Z-&E<9%)#<@3SP,DW;Y43-REW]>)GVA!C=;4.M5YVZV=G$!=
MI\]$JAG$G1LY;D<FJ[%,4JZPNW<)((&\PZ* 2\D013D-@3=L#L4L);HLTPF\
M#W(KK#7D&*GC<.AP&-%),W#,SCH,P28W?,X^V6:AF=T4+8H-V@])RYNBV:)(
M(77=.G2B>;IRLLH!>Z""39!%LW3Q20;I)H(I86[&"226%DTT\+?U8X88XXXV
M_JM:UJ \M * 4 H!0"@(S.DN@TVG$,U@UA4.E,P<L).<7?-XM'RT@79(*BFR
M:2SM(2T=J-TE%,;X)J+8X89YVOCC>^5KVJG?/"R:RCRDR>R,H<G; MNWZ:JV
MU:-+6:*Q;*KUJTE7HXZC1P04E/!4:"GBHH(XDX88Z10PQ1)I-M2+.<V6W;#L
M*VLJ*6V[9LJQJ*L674:.@I+5M&IV?1TU)!6Z2**"BCK=-0PTD<,+444,#B:3
M3:2(?_M?M]?@2V[^S:9?Y+5!_:LY3O\ ;C+S^$,H/[<7$]L/(#\N,C_XFL7Z
MZ/M?M]?@2V[^S:9?Y+3VK.4[_;C+S^$,H/[</;#R _+C(_\ B:Q?KH^U^WU^
M!+;O[-IE_DM/:LY3O]N,O/X0R@_MP]L/(#\N,C_XFL7ZZ/M?M]?@2V[^S:9?
MY+3VK.4[_;C+S^$,H/[</;#R _+C(_\ B:Q?KH^U^WU^!+;O[-IE_DM/:LY3
MO]N,O/X0R@_MP]L/(#\N,C_XFL7ZZ/M?M]?@2V[^S:9?Y+3VK.4[_;C+S^$,
MH/[</;#R _+C(_\ B:Q?KI.5T><3E,-T J'E\:/Q0M>>2-W87) Q$&1NT79A
M<475F11LU<W;K9)*XI+=R[FIDFI;#*]\,NQLIYJEAVUD_P EGVOMZR+4L2O_
M '26O3_85KV?6[-K?L-)15%4=-]C5RBH:;V*D<$2@I,S,B<,6:W)RHKSB+6L
MJVN4&&N6/:=GVM4_M#9M#]E697:M7ZM[+!2UUQT7L]5I*6B]D@44+B@SLZ%1
M0MI31O35DSPD4 H!0'#O]DK:&WEL_G;J^0:TTQM?88!KQ1@8=R;@VNI?+1#8
MLVVUO%XX%KD@ <@R1(H-"#!TLR46Q<I-GK1?-+%)RCEG8#DJM*SZID[6Z*MU
M^I56D=LUF-4=8K5!01N!U*SX5&H*2.&)PN*&)*)*3<,2G-,KURL6;:-;RCJ=
M+5*A7:U1*Q:M Z2KU6GIH%&J[:$3@<='1Q0J)0Q0MPMS2BA;4FCGI^U Y:?B
MN\BOV)[+_EFO3/MY8OPQ9?QA5/ZQYA]H[:^![4^+ZW_1'VH'+3\5WD5^Q/9?
M\LT^WEB_#%E_&%4_K#[1VU\#VI\7UO\ HC[4#EI^*[R*_8GLO^6:?;RQ?ABR
M_C"J?UA]H[:^![4^+ZW_ $1]J!RT_%=Y%?L3V7_+-/MY8OPQ9?QA5/ZP^T=M
M? ]J?%];_HC[4#EI^*[R*_8GLO\ EFGV\L7X8LOXPJG]8?:.VO@>U/B^M_T1
M]J!RT_%=Y%?L3V7_ "S3[>6+\,67\853^L/M';7P/:GQ?6_Z)]&CH;8K*(3T
M9W%"+3.-GHC)Q$-DZ):.2<.0 'A:RVR9J[12(B"K=H09**M7"#E/!RW2R4;K
M)+8VNFIAEE5_+FFH:QE7;--04M'34,=/1."EH8X:2CC2JM FX8X'%#$DTU--
MWIK%%I\A:&FJ^25BT-/14E#305>D4=%3014=) W6J=I101J&*%M-.32N:>#)
M-JZF=M% * 4 H!0"@/#D@CDNDYR3QNNBFLBDK>W]--)QDCFOAC?^K%7)NAEG
M;^NZ6'_"@/-0"@% * 4 H!0%(D"2JX$V@BGFJLL()))))XWS45549+8)IIX8
MVOEGGGE>V...-KWRRO:UK7O>O@M2".DLRT:.CABCI*2H5N"""!.**...KTD,
M,,,*FXHHHFDDE-MI(^RSHX:.T*C21Q0P005RK1QQQ-*&&&&F@<443=RAA2;;
M=R2F<NGVM/(?\!^UO\!R7_+:TO>T[RK_ .V^6W\-6M]5-IGMF<G7Y<Y)_']F
M?61]K3R'_ ?M;_ <E_RVGM.\J_\ MOEM_#5K?51[9G)U^7.2?Q_9GUD?:T\A
M_P !^UO\!R7_ "VGM.\J_P#MOEM_#5K?51[9G)U^7.2?Q_9GUD?:T\A_P'[6
M_P !R7_+:>T[RK_[;Y;?PU:WU4>V9R=?ESDG\?V9]9'VM/(?\!^UO\!R7_+:
M>T[RK_[;Y;?PU:WU4>V9R=?ESDG\?V9]9'VM/(?\!^UO\!R7_+:>T[RK_P"V
M^6W\-6M]5'MF<G7Y<Y)_']F?63:SA+H_<D.Y,ZYD4LU9L"-@!Z<PL^,G(D<%
MC&=W<%DK)K9R^>,D6Z/?#QP@U1[HICW1=9)+#LYYXVO[AS<>3?E R?Y8LE+6
MMW(K*BR++JU';ZK%H6E8=HU.IT#I\F[7J]"J:L4]7@HJ/V6GI:.AH\Z)9]+2
M000SBB2?DW+AESD9;/)CE'9UDY59/6G:%8CL9T%2J-KU&M5JF]AMVS*>E]CH
M*&GCI(_8Z&CI*6/-A>;1P11N4,+9/M6T H * 4 H",GID87,=A]&CRJAL B<
MFG,P.16((A8I#@12320PLVV?!WSA(6""M7I0@HW9-7+Q9-HU6R2:MUW&=L44
M5,\>V9#4]!5<J['IZS3457H*.FIG24U/2045% G5*Q"G'24CA@A3B:A6<U-M
M)7M'4LNJ"GK62=LT%6H:6L4])04*HZ&@HXZ6EI&JU5XFH*.C44<34*;:A3DD
MW@CYVOVBW-S\3GE1_P!/>V_Y1JSGW0V!\.6/\9U+^N5=^YS*'X"MGXKKW] ?
M:+<W/Q.>5'_3WMO^4:?=#8'PY8_QG4OZX^YS*'X"MGXKKW] ?:+<W/Q.>5'_
M $][;_E&GW0V!\.6/\9U+^N/N<RA^ K9^*Z]_0'VBW-S\3GE1_T][;_E&GW0
MV!\.6/\ &=2_KC[G,H?@*V?BNO?T!]HMS<_$YY4?]/>V_P"4:?=#8'PY8_QG
M4OZX^YS*'X"MGXKKW] ?:+<W/Q.>5'_3WMO^4:?=#8'PY8_QG4OZX^YS*'X"
MMGXKKW] Z$OL;/C;R*T]SBVK)]MZ#W3JV-O>*TU!,I!L;5DYA 1V;=;:TF_;
M!VI63 AC!P4<,1A)Z@/27S=JM![UPFCDBU7S3\SY5+5LRO9/U*BJ5HU"N4L-
ML4%)%1U6N5>L4D-&JE7X7'%!14D<2@44<,+B:S5%%"IS:GZ=R4V3:M1RAKE-
M7K,M"IT45CT]'#2UJIUFKT<5(ZY4(E1J.FHX(7&X8(XE"GG.&&)I2A<NVZO
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M_1(@\-SL")N]&OT>GUWWWX21)CK%.9(ZVUZCL5TJ]V"E!XFG.GBZ 9JL[F6
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MWNL&,53A\_*;!'81C2LP6;LV0>4MW0\\TC&[P4F*MG3:T<# X_+;/97X:!N
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'"@% * __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g63338g29j70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g29j70.jpg
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M #\ W^      !3BGNN9?)R3^DXB)Q+G3D4C&F9>5"HQ!(
M
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M2B/6Q[Q"63XPXN]RWI24D#4]US+Y.2?TG$1.)<Z<BG#&F9>5"HQ!(
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M2:!R)(V:,,LK_>"SUO<3D4^;$J8<526^F7%\2TS,R (
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M$I8'MSQ.HCAY!45,/Q\24R4 @
M                     "G%/=<R^3DG])Q$3B7.G(I&-,R\J%1B"0
M   "$CI5N[VI_)!\],E#7+;N;9ZC<0TET@[+P6J&P%;>.('T)LBF%(2V
M3/\ 11?[!NOZW@_X.3C8=:0;#V0N,JO^BTH4KMLMD*D]QTYSU&$N(O45#
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M51A[;9E4B%?7#7*Z]8>/D(265$45(->%S-\?&0B:8TG\+DE\3O7R:L#B
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MW?-ZR.K#T]I=(V]T9R(7-W%&@'R/4I3EY0J?0"_BW(ZRUMC-R./6+9RMG67
M[2PNOHQ-4T6=HHD'9*2I>3 F&YFE];ZHJ*DI7YI@1$G*<R3>Q6Z_N.DA>N0[
MK.[>EL/LZO*EL:T.-B^66HD7TC )//*7966&VA8\BGEA1F,M<(EZ=UACK-X3
M3D->3.-:/E?,I]O.K C3"ZFCC>7Z*)EOK)56\N"2)X%5;\I8YSJ<?K9S>U)U
MA<>T0?X#M9$-9I9F'R;3.KPQ9=4VIV4AQF2$FRQ+MU??#4Y;(T.SJU'(G+*%
M#E5E(2."WEREX
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MYJ/?4;3^ 3BD;[MKWA&_.4O(Y[4ZX-CS4/<'6=@
M                  !$E9L9MCD=:LYA1<?L%A@54SUPE<=D3*YK)"H^%"BW
MR!.#[64PG4,9J\06$VZNCC*(G&8I8$U6UA)FC3+B]U0]QASJZV!R22=^]R=_
M/WT3*DGLXK^%65%7*$3R,-$IBCN<B5+F1V2:'HS%S6[)']I<R>IUAJ-W9W]
M@?V9X1F)W-H?4"%Y;5:5R2)U18XELF_BSQU:7*"O#=3D$2.E;9VWAJXIE)PH
M:U&9 Z2_1>H,SG.7IT3S)]?9JC=G[X3<D,T?7N7HU1$D>')S4B9KE4JYXI6I
MI"]1^1OU>11ZD$6DBV81]Z=&A*O<VN2N#@RNREW3K5.AJC*GX5C,5<T^#3#"
M43C$HBM1E)U,4CQK:(G\?&=2K%/=<R^3DG])Q$3B7.G(I&-,R\J%1B"0
M     "$CI5N[VI_)!\],E#7+;N;9ZC<0TET@[+P6J&P%;>.('T)LBF%(2V
M  67Y_=ZYN_[RG'/T-:HVK]C+V3L@9Z+]&CS6_V0K8.I7#4ASL$:IXW FJ<
M  )V_<XW?0*^^RZX/5(T8[LH[4HGNR!YXR-8KVWPW<<=S"G1-%8RT0
M&&_/[YIEI^,@OYC1(8 MHMPRNV>K?K901F:U]W6ZJ_EI[U;I<UMQJ&-E0
M9"<5OEXA'B9=ZCR49QM;-W&QWQO$]$TB8DL[[DE=^+''2,$:,8],YYX@
M#L&1CN:CWU&T_@$XI&^[:]X1OSE+R.>U.N#8\U#W!UG8
M                        1K<B9#Q9A]X&-,N67Y5DU=6%BE<_LBCY;:,
M@V43PV6$H8UULIJ^DK>S25TS$J7L-R4S5VA<C7P.$016J?9=$&/#7[\$WY2Q
M8M&#&2'1N/H8JQ-D=;%#VK0-"75(E4R22R*8/IQ6F=ML&.DGEKH]R1Z59SMG
MKUKPZKEF^.MUV/SKKIKJ(/;   4XI[KF7R<D_I.(B<2YTY%(QIF7E0J,02
M        0D=*MW>U/Y(/GIDH:Y;=S;/4;B&DND'9>"U0V K;QQ ^A-D4PI"6
MP   "R_/[O7-W_>4XY^AK5&U?L9>R=D#/1?HT>:W^R%;!U*X:D.=@C5/&X$U
M3@  !.W[G&[Z!7WV77!ZI&C'=E':E$]V0//&1K%>V^&[CCN84Z)HK&6B
M   PWY_?-,M/QD%_,:)# %M%N&5VSU;];*",S6ONZW57\M/>K=+FMN-0QLJ
M  #(3BM\O$(\3+O4>2C.-K9NXV.^-XGHFD3$EG?<DKOQ8XZ1@C1C'IG//$
M   =@R,=S4>^HVG\ G%(WW;7O"-^<I>1SVIUP;'FH>X.L[
M                          " 7I"FU/IR;<3I>Z2";M"2M8:Z-:9=Q[(E
MD?K9$[MG(@]SCB^7U1RNXR6+-8C*H;#;+=)'$[8A-MU"TQ9FEY<F="&F2RA&
MD'-,&=<LIX,J*G@DO@)^@.    4XI[KF7R<D_I.(B<2YTY%(QIF7E0J,02
M        0D=*MW>U/Y(/GIDH:Y;=S;/4;B&DND'9>"U0V K;QQ ^A-D4PI"6
MP   "R_/[O7-W_>4XY^AK5&U?L9>R=D#/1?HT>:W^R%;!U*X:D.=@C5/&X$U
M3@  !.W[G&[Z!7WV77!ZI&C'=E':E$]V0//&1K%>V^&[CCN84Z)HK&6B
M   PWY_?-,M/QD%_,:)# %M%N&5VSU;];*",S6ONZW57\M/>K=+FMN-0QLJ
M  #(3BM\O$(\3+O4>2C.-K9NXV.^-XGHFD3$EG?<DKOQ8XZ1@C1C'IG//$
M   =@R,=S4>^HVG\ G%(WW;7O"-^<I>1SVIUP;'FH>X.L[
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M]]1M/X!.*1ONVO>$;\Y2\CGM3K@V/-0]P=9V
M                $-/-9R.C/)>53!&1 MHM%>/532R]&>W45332/2.NHO8=
MUJ6R2UM3LH@[5.+#E=<>_I6?.C6?D371:-I?X.W1J'3.8+D*%6.28,&.]AG.
M2;\M&6_>0D+Y4WJ=QUIQ?8J!@-E#XJF=6UU&60I!(W7"F3VY9L2J]B5'M409
MI!*7=(T+Y:4]*V2.-"Q]?4[<8RLVFKFO2&:CBE_XR7S#!EZ0&QGG0MR;:]@;
MVS0!XI2*7$2F=)]&)*JE%[<JK(XJ,K7$(W.8A'G>(/$ ?:_+E=AQJ=H5)I:E
MW7P-@?',Z.:3)_')4^,R(N+#AP_"7KI;E^[2>0Q^%7HP1&C9D\G&)$C+*9$I
MC[I)GEV(A9<<C$0CLP3L4@7O"21O\FB#YMNDW]^G,,$E;&C-C=X5Z9N(EC^/
MCWIB,S%/=<R^3DG])Q$3B7.G(IQQIF7E0J,02          0D=*MW>U/Y(/G
MIDH:Y;=S;/4;B&DND'9>"U0V K;QQ ^A-D4PI"6P   "R_/[O7-W_>4XY^AK
M5&U?L9>R=D#/1?HT>:W^R%;!U*X:D.=@C5/&X$U3@  !.W[G&[Z!7WV77!ZI
M&C'=E':E$]V0//&1K%>V^&[CCN84Z)HK&6B       PWY_?-,M/QD%_,:)#
M%M%N&5VSU;];*",S6ONZW57\M/>K=+FMN-0QLJ   #(3BM\O$(\3+O4>2C.-
MK9NXV.^-XGHFD3$EG?<DKOQ8XZ1@C1C'IG//$     =@R,=S4>^HVG\ G%(W
MW;7O"-^<I>1SVIUP;'FH>X.L[
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M@35.   $[?N<;OH%??9=<'JD:,=V4=J43W9 \\9&L5[;X;N..YA3HFBL9:(
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MDX1_ Q\(WJ<3"1+MIT_</+EENX>NVD1IEJY:9:DJ8%1<9[(_0/X@
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M&"-&,>F<\\0    !V#(QW-1[ZC:?P"<4C?=M>\(WYREY'/:G7!L>:A[@ZSL
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M">*]A8IC5'+Q6&W:M,72LS5AXRRVS?95)-,HI=8?QG]@
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MIG//$     =@R,=S4>^HVG\ G%(WW;7O"-^<I>1SVIUP;'FH>X.L[
M-1SW5[\G_"ORQN[T)6HS38;_ .YI[@*/YR*,)V9_^UH#NB/YN%-+H9W,!@
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MB[$@UVT0LL=CK:F:&1I1Z;[;[ZI6YM1ID:?7???;4DG3&VVV<9SD05"
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MU'OJ-I_ )Q2-]VU[PC?G*7D<]J=<&QYJ'N#K.P
M                  P8O&IN(W(\RS7212B2R641R&K*JM%+QZN>V$TXQ%F)
MU?%*RO)O7%#R[WY-RVYUD,C*40.80R4]GW>'=J4L*HE<J1&B454]Z(O*F;E,
MQ8DPJ8O'&B/K)-(IBH:DN$N\FEIK2?(W;&IF^Q9[N>QM#"V'JM"]M$^3T[4D
MV.+)T-4]G5;'J3A!40  "G%/=<R^3DG])Q$3B7.G(I&-,R\J%1B"0
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M1CN:CWU&T_@$XI&^[:]X1OSE+R.>U.N#8\U#W!UG8
M                     18W?Q<LBP.445NV:\6^)%_P6%1BPXBP96/A\9N5
M#B9S.K)!&ID0FF%6R..&RZ!-E?.C42YH+2BJA7I*G QIRS$Y4H%HY(LD62JB
MWOUQSW\BDIP'$   *<4]US+Y.2?TG$1.)<Z<BD8TS+RH5&()          (2
M.E6[O:G\D'STR4-<MNYMGJ-Q#272#LO!:H; 5MXX@?0FR*84A+8   !9?G]W
MKF[_ +RG'/T-:HVK]C+V3L@9Z+]&CS6_V0K8.I7#4ASL$:IXW FJ<   )V_<
MXW?0*^^RZX/5(T8[LH[4HGNR!YXR-8KVWPW<<=S"G1-%8RT0      &&_/[Y
MIEI^,@OYC1(8 MHMPRNV>K?K901F:U]W6ZJ_EI[U;I<UMQJ&-E0   9"<5OE
MXA'B9=ZCR49QM;-W&QWQO$]$TB8DL[[DE=^+''2,$:,8],YYX@    #L&1CN
M:CWU&T_@$XI&^[:]X1OSE+R.>U.N#8\U#W!UG8
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M&XAI+I!V7@M4-@*V\<0/H39%,*0EL    LOS^[US=_WE..?H:U1M7[&7LG9
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MSVIUP;'FH>X.L[
M *<4]US+Y.2?TG$1.)<Z<BD8TS+RH5&()          (2.E6[O:G\D'STR4-
M<MNYMGJ-Q#272#LO!:H; 5MXX@?0FR*84A+8   !9?G]WKF[_O*<<_0UJC:O
MV,O9.R!GHOT:/-;_ &0K8.I7#4ASL$:IXW FJ<   )V_<XW?0*^^RZX/5(T8
M[LH[4HGNR!YXR-8KVWPW<<=S"G1-%8RT0      &&_/[YIEI^,@OYC1(8 MH
MMPRNV>K?K901F:U]W6ZJ_EI[U;I<UMQJ&-E0   9"<5OEXA'B9=ZCR49QM;-
MW&QWQO$]$TB8DL[[DE=^+''2,$:,8],YYX@    #L&1CN:CWU&T_@$XI&^[:
M]X1OSE+R.>U.N#8\U#W!UG8
M         !3BGNN9?)R3^DXB)Q+G3D4C&F9>5"HQ!(         !"1TJW=[4
M_D@^>F2AKEMW-L]1N(:2Z0=EX+5#8"MO'$#Z$V13"D);    ++\_N]<W?]Y3
MCGZ&M4;5^QE[)V0,]%^C1YK?[(5L'4KAJ0YV"-4\;@35.   $[?N<;OH%??9
M=<'JD:,=V4=J43W9 \\9&L5[;X;N..YA3HFBL9:(      ##?G]\TRT_&07\
MQHD, 6T6X97;/5OULH(S-:^[K=5?RT]ZMTN:VXU#&RH   ,A.*WR\0CQ,N]1
MY*,XVMF[C8[XWB>B:1,26=]R2N_%CCI&"-&,>F<\\0    !V#(QW-1[ZC:?P
M"<4C?=M>\(WYREY'/:G7!L>:A[@ZSL
M             #%VT^64 J2PRJ_?XS8#L6A(J<^<36,M#$XQ&L];WL!YJRG"
MY:6IDK?,'%1/9ZPN3 D30"(S<^.ZZ)GJ;:1>.N"!W4B9?&:^O@/]<?N6=;<D
MDR=17S;)]-MDR]:Y%.&T/<T["C(;XFZM*EU>X3,)?&=L2E#,$>6$AJ>W-7\(
MLDUCSRG9Y+!I:SLXA4D7]4]US+Y.2?TG$1.)<Z<BD8TS+RH5&()
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M.YJ/?4;3^ 3BD;[MKWA&_.4O(Y[4ZX-CS4/<'6=@
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M4;3^ 3BD;[MKWA&_.4O(Y[4ZX-CS4/<'6=@
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M.IU-NK_?U<#BTERLL)R96ZORD5:.)R
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M\ZFJHVYQ%)EY33= <2[FF&7Z8_A=Z1"ZG<M7F9W[R89R24L-Z>%,9/X.TZ0
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MK32).O:"Y7\2MS7T]^2*LO#CRIOK>":G)9W,U1%7#]F^B89+/DR*IL)#M.@
M          "^=2?_  7C_P"VF_\ QW'4WA[WZJ=K&#O_ *(7=' Y@
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M?VB%55PDHB)@/?$$@
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M+YFJ_P#;EGQA<<TX9L-BYCCJ27LRSOX[^]X/B;Z5_%?3$F"]D7P_IBSV'$Y
M
M
7                           !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g63338g30a16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g30a16.jpg
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M 0$! 0$! 0$!_\  $0@ [@'* P$1  (1 0,1 ?_$ !\  0 " P # 0$!
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M     1Z/>]N_:%X^\@B/WS[92$$@
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M(<YIW2/(;\K5T?EDA;F&-&,JZ1OT=D$@8X'.G&.D:,^WJS^$[.1O^"
M  &F?(3G52O&JQ8U6U@(9^O<G:/,4TE;]$XL6\Q6IX#*+&9JFCL[LQT/=&Y0
MVQMWL![3L).8Z@D[NET2NCPY-*)A;%;H43$9QG^=F?[F);#Z53BY7,AY&QE?
MK83VNXQR"IXI-UK&P,14>D$CMH^TD2%JA$HDDJCL==-X:Z4O93!/5KRYQ]K9
MI9&%T+;ESS+]/$6"=&=7/GU1$\7CC+E;JU+;\.NR.*YA =W1=$RW3Q4V2!<V
MFMJ&0FDM34O<E#(6JVU7&$,3HXK(<^Z."-O6M<TC4H8%*34]G,,,/+*(
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M,RMU2*8JI5QEP,:6=P9S9S8QSLMDZ^6&.",B9S_//,_O;U @
M                               !'H[[V\=H7C[R"(V>F?;*0@D
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MS:*W$$5\W=8+)8IKXJJ%S=SBNFS555W2*ONE/0T]+0TZ>CEI3G;<+U*B@
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MB:,Q4TYB8F*C.)B=<3&N)?=>-%E!0
M           1Z.^]O':%X^\@B-GIGVRD()          !6'TIWQ.5]\YA/X6
MD8IIOU_J_P *^>-7[DO=:'>J_3/$/FQ3]ZW:HK&:2]X   "WSHG_ (0O/Y'7
M7VTV%]=X[WSNE^0PEVF)%/=]IWO@3RV(_N7&N4&@:F(   #GVV!Y^3;M=)/7
M*T9F7EPC;^FVKMZQHI=W!]AZ'9NQH(B.)V   EL!\^X5VMCGKA&.V[>$;!TV
MR]O5N.\>#[=T.T]C3=!,:9LZP
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M'3;+V]6X[QX/MW0[3V--T$QIFSK
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M(CB=@  ); ?/N%=K8YZX1CMNWA&P=-LO;U;CO'@^W=#M/8TW03&F;.L
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M1CMNWA&P=-LO;U;CO'@^W=#M/8TW03&F;.L
M            52W1(I(Q<VT3BG(L63P$C;CXPRA]2WMR&JFO:3D,CEKR@:4;
MO#:]VE%;V@586B]JR8V2^NFV/)%QA22=VPR-3LTDQ\GB]?%'-Z>7/+U-QN37
M)Z#\7HS$'Z8E%K5<^F6\&BC:?)H=#D:MX31"63QP-<I-.GZ.QUG0(XQ"GX_"
MA6OSNI<_%C423DUQU-*(804=(3!BM#G,JK[&.B2_=U:H?,\+J[VC\FE<76P)
M!.690K2S97I&V:#F3I2LD,Y>-BX>0RUO:3^4ZFLC#'%\O)RRXX_/YZX;3T[<
M+)=,9)E;"SOS"A4(6%7HW2E.D;G\@YW8D#JXH%S4F6+LHU<7=E;A!Y#INHWP
MCG$6ES#KDS9C,4'D)W'?>WCM"\?>01&STS[92$$@          K#Z4[XG*^^
M<PG\+2,4TWZ_U?X5\\:OW)>ZT.]5^F>(?-BG[UNU16,TE[P   %OG1/_  A>
M?R.NOMIL+Z[QWOG=+\AA+M,2*>[[3O? GEL1_<N-<H- U,0   '/ML#S\FW:
MZ2>N5HS,O+A&W]-M7;UC12[N#[#T.S=C01$<3L  !+8#Y]PKM;'/7",=MV\(
MV#IME[>K<=X\'V[H=I[&FZ"8TS9U@          ICY8<T[XJ6_IY7\,>V-)&
MF#W,>+4ZR-MB]27XTAT?>5??%:@O8XWKKG!3OIU\YZFFVI>O[NFN!GONX[X?
M=-P+NH8FPMAZ\;LJ+HNR+F_1*JT718[574?TVX+KO"OTZ^MHS64\[3:JZE1T
MI_JT9BA&JC"Z>Y+N*8!Q=N?W!B&^K#;JZ\[P_I3])K*F\[59ZNE^BWS>-BJ=
M&IJZ44*&519ZJC.4?UJ432G7,M=?UC/*'_J.,_R>S>R'Y-^MKNS_ .+7-]@7
M?_ _1OU<-RW_  R\_MFV_P 9^L9Y0_\ 4<9_D]F]D'ZVN[/_ (M<WV!=_P#
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M2$F9SU?.4N]QJ"=*.>-<:^/CY=FW+;U:EF/";B1<-4<OKODU@R>=2JHJQB3
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M/!SUQ<^OQS&7/Q1EJF/$O0!Y  !'H[[V\=H7C[R"(V>F?;*0@D
M%8?2G?$Y7WSF$_A:1BFF_7^K_"OGC5^Y+W6AWJOTSQ#YL4_>MVJ*QFDO>
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MY,R25G;&,;9+*R:;DO3.>KIDPS.N,9WV[H>BCOO;QVA>/O((C9Z9]LI""0
M        5A]*=\3E??.83^%I&*:;]?ZO\*^>-7[DO=:'>J_3/$/FQ3]ZW:HK
M&:2]X   "WSHG_A"\_D==?;387UWCO?.Z7Y#"7:8D4]WVG>^!/+8C^Y<:Y0:
M!J8@   .?;8'GY-NUTD]<K1F9>7"-OZ;:NWK&BEW<'V'H=F[&@B(XG8  "6P
M'S[A7:V.>N$8[;MX1L'3;+V]6X[QX/MW0[3V--T$QIFSK
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M<H- U,0   '/ML#S\FW:Z2>N5HS,O+A&W]-M7;UC12[N#[#T.S=C01$<3L
M!+8#Y]PKM;'/7",=MV\(V#IME[>K<=X\'V[H=I[&FZ"8TS9U@
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MVR]O5N.\>#[=T.T]C3=!,:9LZP
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M  !+8#Y]PKM;'/7",=MV\(V#IME[>K<=X\'V[H=I[&FZ"8TS9U@
M                             TPYMU]+;)@<&8(C339<"@J?'*G3+FEK
M^0;5^RKH!.8RY31A@5JSF!5S.99LDD)L5CZ*:.3K'XR?)CITKC$K-BZ>,/!,
M3EQY--J^X%NY\L01:55P_P =B# 5-W9QN=SDU:2FRK'C+@GI)RI*JY+NJ5RP
MR6/=3N58L#=+R+$9'6K'3R51@EM,FT?F3RC:"<]7IV:\HR\?+^<MC;3BS7-Z
M5#)%U?2&-11!2R&$L!C \D*_&DK+>6F(5=&(I$5#Y[K51[YK"65GF$&=5JB
MQ5 M8H=64J;W>02:8V"F9"-6K;Z_8W#COO;QVA>/O(/,;/3/ME(02
M   "L/I3OB<K[YS"?PM(Q33?K_5_A7SQJ_<E[K0[U7Z9XA\V*?O6[5%8S27O
M    6^=$_P#"%Y_(ZZ^VFPOKO'>^=TOR&$NTQ(I[OM.]\">6Q']RXUR@T#4Q
M    <^VP//R;=KI)ZY6C,R\N$;?TVU=O6-%+NX/L/0[-V-!$1Q.P  $M@/GW
M"NUL<]<(QVW;PC8.FV7MZMQWCP?;NAVGL:;H)C3-G6
M                        "/1WWMX[0O'WD$1L],^V4A!(          *P
M^E.^)ROOG,)_"TC%--^O]7^%?/&K]R7NM#O5?IGB'S8I^];M45C-)>\   !;
MYT3_ ,(7G\CKK[:;"^N\=[YW2_(82[3$BGN^T[WP)Y;$?W+C7*#0-3$   !S
M[; \_)MVNDGKE:,S+RX1M_3;5V]8T4N[@^P]#LW8T$1'$[   2V ^?<*[6QS
MUPC';=O"-@Z;9>WJW'>/!]NZ':>QIN@F-,V=8
M                   (]'?>WCM"\?>01&STS[92$$@          K#Z4[XG
M*^^<PG\+2,4TWZ_U?X5\\:OW)>ZT.]5^F>(?-BG[UNU16,TE[P   %OG1/\
MPA>?R.NOMIL+Z[QWOG=+\AA+M,2*>[[3O? GEL1_<N-<H- U,0   '/ML#S\
MFW:Z2>N5HS,O+A&W]-M7;UC12[N#[#T.S=C01$<3L  !+8#Y]PKM;'/7",=M
MV\(V#IME[>K<=X\'V[H=I[&FZ"8TS9U@
M              CT=][>.T+Q]Y!$;/3/ME(02          "L/I3OB<K[YS"
M?PM(Q33?K_5_A7SQJ_<E[K0[U7Z9XA\V*?O6[5%8S27O    6^=$_P#"%Y_(
MZZ^VFPOKO'>^=TOR&$NTQ(I[OM.]\">6Q']RXUR@T#4Q    <^VP//R;=KI)
MZY6C,R\N$;?TVU=O6-%+NX/L/0[-V-!$1Q.P  $M@/GW"NUL<]<(QVW;PC8.
MFV7MZMQWCP?;NAVGL:;H)C3-G6
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M^?0V-0H2T.JK4O???PI:J7;]?J_NF*C.^;Z:]7&/W-<_LU[O=V[G]^<@C_\
M>O6\T           %8?2G?$Y7WSF$_A:1BFF_7^K_"OGC5^Y+W6AWJOTSQ#Y
ML4_>MVJ*QFDO>    M\Z)_X0O/Y'77VTV%]=X[WSNE^0PEVF)%/=]IWO@3RV
M(_N7&N4&@:F(   #GVV!Y^3;M=)/7*T9F7EPC;^FVKMZQHI=W!]AZ'9NQH(B
M.)V   EL!\^X5VMCGKA&.V[>$;!TVR]O5N.\>#[=T.T]C3=!,:9LZP
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MF9-W"TZ5,2:>=OG]FA>FVV?[A] _5PW$_ *[OVV^/YB^Y?/INK^&%L_8[J_
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M          &:ZB][?_\ O;/_ ,KQ\5/;Z/WR^2KX_1^]F4>'R
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M\\&(*(Z_4ZW5Z_>M->MU>MMU>MW>YUMNYW.[D$Y9;'D@
M                            -16_C,\-K@\.[;/-6=VDZ%F4RMQ;"YPU
M+'R5E2FSI4_O"E=#K%A#HH1JSK!2M;.VN;BYIV=GCK>A3%%D$I"TGK/F]FS5
MEMB>3K>=&>7Q[=O'.J8_,/32'CU:CG*T\J;9C"FY6W>-F1-OJVR-0K61EQ?<
M/VCFE4OCC(BX9/S-6F),K]+XRG\?R=.TN+XY/>'XZ(J()&>K++\Y?Z]7/FRU
MQS?GCS]>WGUZMMXRP-L5CC#&6=$G;FF/,S:R-J!)LHW3(T+6C)1)4Q!BLT]6
M84223H7H:J/.4F8UQNH.-.VWWVAZ>\       !@JY*:\KAK66K=$J5M;8Y*F
MDI(I1G*MDK[)'6%[(Y>V[Z*2-4<@B["R2=+'%^--E+6[R).\(CDREL+VWF)R
M_/5XI1,9^J>OC8^EM 6"^,4B8B;&2+-)6F=6\YQ<E5M:.D/,=6QS;2Y1"EJR
MVI$>TO+64Z+$V[8Q[Q=&_M"U:PN;B2T'F)3)SV:O9K\>K7Z=B,I_.>KGC7/J
MU9IQ350O%:.TK7+'E)JUO6A1*&*L"^7FQ8A;B0RE_<Y6E9)0_O2"*N4AVD2=
M*IC<1(;V%K):"BB3W!'LUHV&)G/XSMV1Z_&1&7'Z.+;MYO%&IGX0]
:                                _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g63338g34u44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g34u44.jpg
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M@I*RPH3_V@ , P$  A$#$0 _ -_B@!0 H 4 * % "@!0 H 4 * % "@!0 H
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M=WF&?J@2% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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MG+-^008)=4FI;!51F,?+VS6NFC;%OG:ZEL[X8Y %;H 4 * % "@!0 H 4 *
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MJ0C,XB47E0<=ACL"".!XQJ.)+]?Y=5^G=TZCV[@N/DZKK]6K<T;6KS#.>O\
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M&1ZC&;:@2% "@!0!!/I-?D&<F?H_M]_A:J1\XN7L,4K^:?)VD-#NKPLA0 H
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M!G)GZ/[??X6JD?.+E[#%*_FGR=I#0[J\+(4 * % "@!0 H 4 * % "@!0 H
M]+"L<9 4 * % "@!0 H 4 * % "@!0 H 4 1;YE?R'??2EQU_P!Q>JJ"#U<I
M=I"4E!(4 * % "@#7ZZ3/Y1[7Z.(Q]Y2*OEI^V-_FW'_ -H4;\;5Q]"/V8_\
MMG?]R53\-3AUZ5Y2'H@* % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M!SX66!FQ@XN,?M%VKYD@LGEA8(,C+0>@6\4Y0Z-%2<Y"[S50M*XOMG7.D)8
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MP\$[DGYE9_ZC7IF-PO\ U=VHZ-<[PSMX-.&UG^?-AX)W)/S*S_U&O3,;A?\
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MG@J/$HO<A-Q'>J[0HU'>1D1)TG<6G1>>X>T97"1LAY"\H>3\3UT5F&R83)]
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M:KY8S#Z'(3]\R^O%6'WZ=-_85/\ OYP]@X#OH6Y]M3ON88ZC*Z2'<04 * %
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M6\Q'6MUY2G<=+RU.+5(7=BFM,-N% "@!0 H W_=1?RGUA]'D*_ML;7TLH?\
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MRULD@A2KS5I.[&,RXB.^_P!.C0.\>/1X!$@(2*Q4((C,8C0D<!CL<CXUF'!
M08AHBP%!@PD<BW8"Q0QBW09#Q[)N@T9M$4F[=%-)/#"P4"L4 * % "@!0 H
MBWS*_D.^^E+CK_N+U500>KE+M(2DH)"@!0 H 4 :F735?+&8?0Y"?OF7UXLP
M^_3IO["I_P!_.'K[ =]"W/MJ=]S#'49720[B"@!0 H 4 * % "@!0 H 4 *
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M$&K"Q9S >0;+8)+MEG((X$.L;J)XID 9D288YN!I)DZ7 +EH 4 * % "@!0
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M-?D&<F?H_M]_A:J1\XN7L,4K^:?)VD-#NKPLA0 H 4 * % "@!0 H 4 * %
M"@#TL*QQD!0 H 4 * % "@!0 H 4 * % "@!0!%OF5_(=]]*7'7_ '%ZJH(/
M5REVD)24$A0 H 4 * //Q_XFK_N/"?Z;]8?W+L6O2>"?Z+N?:LO[F*/,V%OZ
M5(^RH?WLH:\M=FCK * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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M&V7F/M(2FJ!(4 * % $$^DU^09R9^C^WW^%JI'SBY>PQ2OYI\G:0T.ZO"R%
M"@!0 H 4 * % "@!0 H 4 * /2PK'&0% "@!0 H 4 * % "@!0 H 4 * % $
M?N4,-ED[TN= P</C(9.WD^KI4. ]\1PE0RG MK0F=$AC4B7<-!35^^%1QZV'
M9DGC-AD^4;INWC5#-1PFZA!ZM&G5U&0MWX[-[>AIM7VH<<OW<J;BW2Z^X1>K
M^7K(/CLWMZ&FU?:AQR_=REQ;I=?<%ZOY>L@^.S>WH:;5]J''+]W*7%NEU]P7
MJ_EZR#X[-[>AIM7VH<<OW<I<6Z77W!>K^7K(1JCO(C?XOE\%U?\ $]L5_%-G
M,<9!.(7)9EIZ3$-!LVK9L-:;"'&X)-SRH6!2+-IDDO")LFW>ES:)$GK<F^=8
ME(NXFXL6^_5N;?%I(OST<@B]6-JUZ;K[[KB]]>B\:E/_ !-7_<>$_P!-^L/[
MEV+7I'!/]%W/M67]S%'FG"W]*D?94/[V4->6NS1U@% "@!0 H 4 37Z-L4,.
M=(#PO#&AS P(*<F=,L"8HHS;D!I%BZG81%RS?,7::S5VT<)9Y)+MW"2B*R>6
M6"F&6-[VOH+5+6W9JO+;4I"T4F<I"T*-*DJ*.X9*2HC(TJ(])&1D9'J'(+*(
M0Y::@-N)2M"ZM 2M"TDI"TJD-D:5)41DI)EH,C(R,M!C8@U'O'C'MWG?QLT,
MJ;C'(+;40Y.<JY*2V<YXCZQT>"UMIX5QPVV(&Z+7!@$<K;>Q$3@<A,VLCD(W
ML)*AF^""O6NK]KUA,I]6A6=JM1)MVFPGZ316D1"K4NH.2YRZI!6JH$XX?_ Y
M2.HV#:;5J<.\KDCM&%4:1.M)2J:;C-3FL5>M/+F'1(E.:B044F<A-.-IHO\
MC<G(0E\G7$:#;*X[U# <=WAQNY&!=M1B.DP'(/;FI^C+Z2"0[$Y%.N,&N^-Z
M$FN5C$0?ZH #X!$\%$'1?5R8Z0+LYD\9L2+56173%+J74>YX;)VGU6EN0G74
M.TR%,M999J+2RJ\FJ&UBO/IF.JDO:21+QFTJ8)2DF37RR^:-8U4:35&YK+2V
MZI.A62M6[*JIT>+22=QV&50FDQF"N4N)BNFE]24K2;GR#.]5T2>!FBM);SX3
MO(_,M'92F5'^DPX7:FDFW0CBS>80C5NV79< <LD8;QQ^_ 1EQAB\CSAHJ7:
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M * % "@!0 H 4 * % 'I85CC("@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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MJ+26T8A"UHQL1:D8Z5(7B*-.,A7SD*N,L9*O^I)WD>V0J :62F.(/&L>DL@
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M69;'0Z67)!()1NF:E+,KDEBZ-S^5Q(-)@($JLQ&RN\=7)I8?]:!2)FT#T;D
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MR_N8H\S86_I4C[*A_>RAKRUV:.L H 4 * % "@!0 H 4 * % "@!0 H 4 *
M% "@!0 H 4 * % "@!0 H 4 * % "@!0!ZXW'?Y/^C/H=UE_902O%E2_B,__
M %LK[]P>VJ9_#:?_ *&)^';&8JPAG!0 H 4 * % "@!0!!/I-?D&<F?H_M]_
MA:J1\XN7L,4K^:?)VD-#NKPLA0 H 4 * % "@!0 H 4 * % "@#TL*QQD!0
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MRS.=,_IAF9J._<+FS_KAY*=OCTLM1_429?GJ9XJ?O+,YTS^F&9FH[]PN;/\
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M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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M[%GVS@9H6LUVO+=718N"CYY'8%QHJ,DS'21&"R2EU6CT$\PFHYCF@VAL 96
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MKJ1IS!U%4<RXL _2=#K/ ##L@Z13BX)A$@G8B52B8C(N$*R VQC>M=BW+,6
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M0%X,A"\P%Q>/3<@M+-;3&'MEX\=>!<9$)[D?%F*#IJZ6";CU;8Q1ETA.K>H
MN48!M%TC))Q'M/C,V5M9/;6WY*\"2X#11"[/9CC$5/EFHW-0R\(Y-H/$7JZ8
M"7R\%)6A8,-!<?\ 3BW??SZM(RH[Y@Z7"1V!G96YFD;>["=244)BB6NYK.I,
MPD,,V1&M.RR.F6VJPD]',R ;:TPC, P<)DW @Y(C8YO&B9I!TDXR!=[^D_R'
MV!<OM%2]F7<PJ1FI0H,U<?V\VP;P:=!F!R'QH!"9&9R!R231L)%7YH8QV/!D
M#$=2-]_0!&0HC#PX:_8%F[ %QZN.[E& 8YTD.O)4W2;A-;SA_)'1(()8 F9G
M7KQN_?26;\6(*"L@>:RY88FW<E.6D'NZ<.\FW<-XO.&ZB:BPX58R"[WY#/\
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MRSI\8-GI >)DCA\Z9?OS!LR0?%"CUV_=N'"@0+JH 4 * % "@!0 H 4 * %
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M_=%2[/KGXUPIW*5*/GI(DW[;JGS]XZ>.L%7#A93,%Y[H_0?5&K8ZLR<Q_6L
M!.!HYN''+AX='1BS 0U/6E346R59#D,VHYM)\<9&W8H9)MD3V-C":6)"UG%
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:@!0 H 4 * % "@!0 H 4 * % "@!0 H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g63338g35m07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g35m07.jpg
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MC*G O*A6J$B@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M92F"#7XN"!D'_*)^R*$&P_7KE94VVU\87=@=-CF8Y+@]*;^XJIN<IO9H<MR
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M4?H!'ZTOFW969YPC><O#=>3]B97FZ"YLZ,ZUUYV(H!0"@% * 4 H!0"@% *
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M;LXWSPRQ[/9QO:P%-Q]L2OS*A]N<4(RIP+RH5JA(H!0"@% * 4 H!0"@% *
M4 H"R-F>YOL'R(E?F%_7G+8[$;4][D[]611WEF-DMGL^2GG\.<DU45%N@H!0
M&(^:/O:O+_RLXQ_U,(U9?U-#;!MQFB4>C/BO[J@FP"RF=8_TY.<H=74E1 H!
M0'H?^IN_>QHC]+^W//;2M9-%+9:_^Q07X:FT.A5L0A_ML=^*A/36.C(XH!0"
M@-%NHQXKTE\I8=Y[1K6G3:;3$WSQ(/6+LSOI<-M*69LG/,FSG8JITL9% * C
MFZTGN*\!/DY3^ENK:O6ZG+M(Q7?!'<[C2FW3[[;,!F5QS: ( *L"-&10"@/6
MSXN^+-QU^@K4?H!'ZTOFW969YPC><O#=>3]B97FZ"YLZ,ZUUYV(H#S^/5.'O
MC4?_ /S1K+TOV;6R6A-L7>YVB_P(,UHT7-E+G-$)SB,.=ZLG&+A0"@% >P7%
M_:S'?F(1YO;UI&^_BO?]QOTE-Y'/\)U_ML>BA&X;Z1O$PR9#RA*^S0<P Q66
MQ@7+04N',S*#B0\E@?+:/RQ9->-NP[V6ZSW7'AQJ $'PERQ1#X7C<L&2T/B@
MV1^9]L)=[BWL'SH7''NEQQG"K%W9-QL.;/I9(=;R[8+J;&XV8PV/*M=;MY"<
M@E3<Q&-X@/".LI[L?DYM)S.PPH6(C3L&Z"QV.!(R*$XMUPPEY?.B,\B(4F6=
M*;CC)#4@=BY-M[7T3>QLU'H1JG7D@AD>U5IN\H:Z?'S!_JF(JP @F'93(;HZ
M$CY/K^0/)/J$HV=3.^>NDUY[+US 82[WYY<N]55W;]Y*8>A_1IU'&)/)!WY7
M-P-M)+ =?8QC6T6.1B'/4YQ#Y?R1G*,T/2.,PD2_8NHC)^0KTSJUCKA:!#H\
M]!#[2-C*FPX0W9!A5QHBK6O)D\%_Y&2-?=(?B[KIA)60LWM1_G+NTS..W)/7
MH6RZ]IKQ_GZSIL(A&M8E&A[AY(^-L <OKL ;=-UB^E>:J=W9E%T/#"7'TR^T
MLC+HC<-TM?K:W$.=@1H+:0A"PLK'1FC1DN !XP"E<<BT7$2W#22AWMXJ,F\G
MQC&SR;PEOV/NRSM^)V^T>KK+J!A+6OYK[?-BWC9W1O3VT#QY-;M.:V]=@M[O
M%I+1I9ZW<Q8#*(>+G$JE<XDC&';-A<2BVW%E7$LF!,T+-SJ?S>31A9J%:14V
M$&A1[)$0K2K2N3^V3%D3)PFN[_HV\<RH>8-B6T^0BTKV%A)A4ZV2S-ZA 3*6
MPR8:F/:4DD(-MHUI<-"';$S!)&2;%)EZS<-M%"O>IHIL9Z1:(K8B<)=Q."_=
MKN[N3%O7G\3OI*ZV+&8R<B>R9\X4#[\CNV$H_LE^'D<0AT=*\O=-<P]ZQ[7@
MJ-QN)&$"VX)IHJ"1[,C,9'*F<4#-5U@3)LNZ,)G 1JF1,5/_ %5GD4KFLND%
MQHTUZSW.JIAN/79V%-R$:'2R#/\ 5<,EA/5)09!A#[3DE/174H9[(8JY9ZYB
M62TU)Y+[T5>L7)%3;V9 J4<O 5I5JJY>''??CW\6+>*H^Z3/',A,HC-59KNU
MH0A!+:+V/X!I/"HZ3'L=L[!V9L^01QAL&/Z[%[;"1MI,=M3!^V%QS88:QQOF
M&'SI:7LP E%J&$O2N3>K3S%B/)HN^ZBXB,ELY!$TL-KX%!^H6\?C91:4D&O'
M621=ER=D>RX^3V"M#A;\&(SUN*U80=:?=R2.HQ>0%,CQQP;@:PC)P>W%^?\
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MV*J=+&10"@(YNM)[BO 3Y.4_I;JVKUNIR[2,5WP1W.XTIMT^^VS 9E<<V@"
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M9CP<5'.(ZV?!F40>8DGQ5=)=P+8 6CVV0T8081YNQ;%6X8@,B<'=R$6;D4.
M'60CITY?"9EQ]L2OS*A]N<4(RIP+RH5JA(H!0"@% * 4 H!0"@% * 4 H"R-
MF>YOL'R(E?F%_7G+8[$;4][D[]611WEF-DMGL^2GG\.<DU45%N@H!0&(^:/O
M:O+_ ,K.,?\ 4PC5E_4T-L&W&:)1Z,^*_NJ"; +*9UC_ $Y.<H=74E1 H!0'
MH?\ J;OWL:(_2_MSSVTK6312V6O_ +%!?AJ;0Z%6Q"'^VQWXJ$]-8Z,CB@%
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M?-NRLSSA&\Y>&Z\G[$RO-T%S9T9UKKSL10"@% * 4 H!0"@% * 4 H!0"@%
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M@;QAV>"X!]AQ[M'";;P85D?-EI55:I_;>7?.#3*(B*BUR<-R7IO7KC-WZY'
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MMH<B-6+:HRT8RS+I[;*2'05\$HGA)\8)M;9=@.6H=S';X(9J-8+KJX&;8S%
MAGX ?8G@WA*V&39"^?%I52E,MWAR'-A&5KA9*-8\B8T\-V_N&MR_4)Y#OI!(
MXE%.-0QZ783HQ$VK@X7V(T;0],*UY&K>#-HYM]9I(-)H8&Z.C4L$L8BH8!.@
MVT@;>Y1LTO'9#+N.&NYYEW\>*^[E.>ILY6KJ5NI6JX.*_%^U3'6J%H%>J9M=
M@LGF]X]!8<P*O(0.[M.#^Q6&6KLI?L71D#$&]M.&VK^\$P4Y'[?/3?7=HJY(
MD2,>UA(K%&[3/,LO%F&NXB<=W#N^ (Z3_P JTW*7_O8KZW4I>F7&EU?@D_5
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M9P5HF5$6_?3$;/5R.)N2U_RS?_H)?]O&OSGZ#]Z 4 H!0"@% * 4 H!0"@%
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M557?O+FH0;DM?\LW_P"@E_V\:_.?H/WH!0"@% * 4 H!0"@% * 4 H!0"@%
$* __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g63338g35q69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g35q69.jpg
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M_\0 'P !  (#  ,! 0$           8'! 4( @,) 0H+_\0 51   @(" @$
M!0<(!P8#! 8+! 4#!@('  $($1(3%!4)%AA8E]76%QDA5UF5F-<B-E9VE):U
M&B,D5=38,3)!"B8G824S-5%UM#0X4F5Q<G1XD;&W_\0 '0$! 0$  @,! 0
M          $"! <#!08)"/_$ %X1   # P<%"PD' @0"!P0+   !$0(%(0,$
M!C%!46$'$G&!\!875I&5EJ&QP='4%5155Y.4T]7A$Q084Y+6\2(R"$)BER,S
M)#0U4G)TLW6"LK0E-T-&8V1S@Z*DTO_:  P# 0 "$0,1 #\ _OXX . #@ X
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M_F-M_P!#Q^-VD7 -R\KS[PP?A3<G"YZ\G33XP?G6+M^J*K?YC;?]#Q^-VD7
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MHQ*$VR\)I(R\R(B(FV6Y=EMAIEIDC'1SKQP05\1#KRV225JX4NB[*W3N5^K
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M>G*$T7_W6?5__D@WR,GO#FB/.)T^+']4O/VQ'Y5AP < ' !P < ' !P < '
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M>S8NN_(_+-BW0O-ES#N]D;<G;*E%I:M#PT,!9L>DLZNH#W1J,)#7X@RFLC6
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M95"1A$R_MX[5U7X+8/HYI7=F][AY/V70%C98D*]'';(M6P[9\VE(H]_H-_\
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M"@R"96\6S/$U47S3QKA,V,)X"YK+A6WWPHA[75[?4E:M$-6V&L8_7DSJ6!A
M+VGM@[$,K'JR8_,DO&6@E-KJ103)+?/'CW@MSSM8^(Q4P,K'XBN(@LP.;&L]
M3N8&:?=C!8:ME!2VQ-.OO%5@[KUNNM+I"AI#Q_7-KG87=I9KH*Y/'V(8WMM=
MUNLCJ<+89@*R0=K@PEM6%(D3JPURM,3F(,G= O&%0ZUJ2JR!GT)QXJ,K%$K6
MLJ^\D@59U+C*:!Y1T:PI*]8<J*Y"LCNE59PMIE5KQ%CN"NIF4"K[!;]%9"
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MIZ]+'QY]'_KZ$NR/3Z/_ %]'_P!/\%)Y;;9WDK2U'?2WYF&?DH\VRA^^T;\
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M4B1<=L"755K'7W,BAP < /G9!\H"+%)(>[TO:$]08G>25>I]J^=5:/CLUO\
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M/+!>641,8N@%!('%AA]W4!5='%#;8A:O(*' !P < ' !P < ' !P < ' !P
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MR0%7%<[";H83++#&7D-HST$J%IVK!.,Z]0Z*Y!0X . #@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@ X . #@!'HOZUG_W>4_ZDZX 2'@ X . #
M@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
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M";6XN<ITTW?].=7V\>L)>E&?_#8CYQC=?[N+'ESCZ"9U% 0B(JA48/R>WCL
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MUEZG>?767J^MUZ> 'OX . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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MFYOMWV_^,^-YZBWI;*#_ +F4]_<(;Y3_ /1M#.8=#_DH?1HH/]I-S?;OM_\
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M%57[FR.GI]FU&2\5[ 'U6T]I2K1!LGX[8M<772JD%6_46(RIB"UY#;J55+6
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MM  9-+8UIX17V6(+9NS. 5M ;G'LI6)8>%H)MIQZ/K$>$7AEJ_"PU^RS,W[
M^OY*8(\FZ;6;B4I-7;Y8=@UI#BS9:\*>(PDK2T.%G1]4:5^P.4<T MC<N3 0
M& T4XXW;)&T"(BVZ!Y;'HNJ6%NLV_P!E8\S6^FQV2UJG-@1BHQVPE,(]:KM[
M('KNQ;0AKSM9<%A3FJUMHV0M3IEIN-0<M.S5[1%$OTW_ $N4(1/NALHP=;^*
M=0!U+3ZRY;V:1AWJZRU!V<,1..05ALA]5[I8"9/G6AZL79ZH^M*DJ*2P""G
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MQ&+%8]M27]NL6RKCTU]M0K(SQ+V0RQ?1X8:]K*M\0;EC54%DMLZ=,J,JNGT
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MG[>]6?X<+\X,5.2'IM[/_C.D^1F+#)=U+Z?_ -%[-PQ)[C]'_P!;CUEZ?T<
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M,*YT3TFPP"Z*=Y[1ZQ1)&FM=?N^V/;FFUQMTX;&/&T;)4(="S;,*-WK,\X^
MF.2$N8W7W>5.*[GCDQGKV62R7'(;+O#N+MT]8"LS_%[2C%S7F1-*4R 5];>
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MO-K]ISLO^%_Q4_EWQY6</!.:<K/CQ0>27]PLG?)+G\*'T7O-K]ISLO\ A?\
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MN43UPO?F;0KY4&ZBA'JQ=G.BE?S$.M7[L^LY9^__ )=ZPU3^G_Y?HKG7?_\
MCOKC<;E$]<+WYFT*^5!NHH1ZL79SHI7\Q%+5?SF7.;&IA>Z7V+5=;6/>#[QY
MKNWR6M";54O9:BUN*6"N:(U=IENZ%=8;$EG4J6YU:[ ]_*7PE3#Q%=$X]JYI
MX?VDTD:D6ZRT==$T1QU=7>.@@?)+Q_9N;O7P-SZT)<ZV7-V]\7QW%'[:JJJ_
M)W#863CUC,8Q0:]/U[L_*[S[@2%]XB-,Q"<L8NXAW&-;<0T<7D[JEWU0R:':
M*S?55UV/+K,EFEM]8#QK;N"H.[G-@P <LU[,\[!6HBFZKZ@,VP2 ,1W<:[)+
M 6="S3C@2ZA%*NRK;I[%&97_ "G\;K6#96=<WCJ]PMIU9AN5H/"N*64)'5)^
M^\,+">5[WU#$IPFZ]UG-]?N$4[O$ G*$W/"#(AE61W5 I7XZA-M=;=UAMP-D
M?K&^5B]AIB! W$]9;"M<%1IH43$8)C[MGGD$;F'-'-F&3U&3#ZW>$T4<F.>&
M,1*Q18W !P < ' !P AVQ+HOUOK^];$;CE%JJ%3K/=&8H6..1A*^K)#GAHXF
M.??6&14PP,D<&.7?6/<N6'67?77IX*, '-QOD:QU<Q8Q;U?ZI$PAHW=Q(K],
M,;B6:N,IF]84*ZOCG9SNE-V":E6@8+"\83T1>L.B#[<(@ESCX@KTBU+6G0M5
M?7WQ8H:;8VK&X\!E@>9>L6HW9BA'<W(JZ(XNWEI.J0Z6T9<L?KJ\Q9/7*F\&
M)7 @L[A6P]6AL;B64J+R+ %+R"90A,T^[%=K4 FB.K;$>C#S9TZ66^7(X;%9
MVBMB(K3JJW+2VS2WE%[4JVF>OA*Z&YXEU^+"^W6L@XR;'BHN)JQE\X%?OZ0,
MX\5FGLMRW86 I;;=>FJ(_'_EW5Q;$71%2%H)> W%8%D56(VI=^LL*W%K/5%N
MFG6UNWN[,D*2D;( *326=(C6VF/'%K5S'Z+',[)FV[5&=R61$6RW'217XP$G
MU;Y)U^\JZ.(V7'K+Q;I*J-BA#%QD&D[M5)?WH9\OGG-[DRJ<"ZI6U;,T+]C/
MT]K+15$)/-V!D;#)-2]!IMI&EVZ1ZK/Y9:QJ%W?4%X-8(':4-G,-A!E5"R+
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M ' !P < (]%_6L_^[RG_ %)UP D/ !P < ' !P < ' !P < ' !P < ' !P
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M_7L;5/HZ_P#GW_\ %3C?'?GJARG>SH-^]PW#NKUDT!]K2O\ :@Z$YVH.O0X
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MI/M;@Y8H+&K-1%8&"C2VVS2**YUW/')TT[B[]IPAQA58<#XC$4A=7(*' !P
M< ' "/1?UK/_ +O*?]2=< )#P KJ;;6NAK)>:B3:01K#K6JK;O=UY,)P_:&J
M-86A ;N4J87 (L3V*9A(5\.),E7XQ0_$(A>S0>B:APQJ ;M!=ZK:*:CV"D<C
METZQU5==T[N6,@&$JJM50[L%SF,PA%.$'E5E0%R1FBC$#8R=1E0PS8Y1XP!^
M,KQ5%%./O[!T-#4%E5+NYKG' @B**J@J\W13G 8:&8X@:)9'D7U@.+*1)CUU
M'%#G-EC'VPM#&P2;J>'O#&3J6/V>674>.?KX^KW)WG[/K#KOT^CU^Y/]WZG_
M )O7_H>CUOT< (PIN]9>,6JM4?.42C,:KVTOPMO"N /22@PL@9VY $2GHP?)
MB)E@-B;E.3#E*2+A..*5+" 2C*:+#T^O+'AZ,,Y._6SQQ]$<?6/>>??I[Z_H
M8=98]YY?^7'K+'T]]>GK@!Y^GK_[^O\ P[[_ /'_ -.O1Z>__P"'7IZ]/?\
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MAIH&%AH%EO&B/RE$'R$&;<67VS$UFSFJPIY8=4HZ 8NGQKT=SRM&?M>,TD7
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MAF'EQHSYJ25TVPZ!PMOS==V%<;2:[$U$FI=::B R72B;%4>L=]\R*' !P <
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M !P < (]%_6L_P#N\I_U)UP D/ !P < ' !P < ' !P < ' !P < ' !P <
-' !P < ' !P < /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g63338g38z28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g38z28.jpg
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MMM08&24V-T-$5F1R<W9WA9:T)C,X14928F-EAI&RQ(.$P^&AQ=+_Q  = 0$
M @(# 0$              P0! @8'" 4)_\0 8Q$  0," @8%! @.#@@% P4
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MCQD!.M^^I0LDI3$QJ@N(](MM%U<861JS(M>-('>32;5LW*H24B57V<CL]?\
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M0R,6QA;!+%3)8UU&T(H\D(F*>Q<<G(J(JBBH_>MB B0SE4R;;]=QD2,^ 3,
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M ,&4O])T'Z=2EVTMG\!\-FE?F_K8GOYEDC?9#]%@ !O5;_0MUZ_Y*G[#&/\
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MH\76F:S7:.U5]-<A1BAJ:*J,U+4Q5%MK*<9/T=5/"9)G,<Y[H7TW(\38*O\
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M+J0L[(%F#)]'1LW&P=JFX*#ML5'R3EZ^80]TA(V/MT0S=/Y!5K&S;5 9!^!
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M_J_Y5:+Q_"#P)?+\I_F_Q<ERI>+JCXD?YY5?Z9X"#XTGYH4WZ_\ *"7[X_\
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MVM_Q7?(F8ZQ\(6SNQJ0X;2.G B0P!_PO\(E$ _K#M'RB&=R>Q^8\=+N$26.
MSONTM('^C5YXD+K+IB(_8XQ'M&ZT\?\ ^\MB]WT^8OI[<_31F_EXA>%#N/8>
MY6R>,'3U#DJ@4V2LW<_ *)^_EXE6TN;H+U9/'QY>*T4P<X>D.O)1O':.]8.X
M]A[E/DZ@5Q/Y>CMRPJZMAS!Z ZLDCX\O%0'>>T]ZD)S]':&6F>B.?>5&_=S\
M"L@CXG2.;*)72?B_F]F21\>7BHY.'/P5LG/T=H9:9Z(Y]Y4#]W/P*M$YNGL#
M+2K2<.?@K)/%#IZQR<;AV#N4:NDY^CM#-V>D.?<576@FU1!UNNZB52YU^GO%
MM1)2G7>0D;#%ZX7K0XZ]>@9O2>%?HB^I,9-&LDXD67@WJ+"8CE88E;KTPO*(
M/U6,.1K8;NRX9C(99[3GW_/+:M';-O'+>#EQ'S^86PVSBH[-IVX0E6UH93[&
MYW6/L;*XW-"^S[6;9V%XB[(XL+..B62S-4A474.BSCVR)8=PP6,4ZZZRA\'?
MLRY;!N66[OAWG/BN^LPMDPB81,(F$6.9??,Q^44OT3%X19'")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(O('NL'WEH5^ZM2/XJC9X*]G%]3=&GW_%O]GAM>P/8G_NN._O>&OZU^6IFP
M9_95M/\ H^?_ ,HZSG2/L7?]-[W_ #6J?[UM*[9Z>?\ 12U_SAI_[MNB]:R>
M,'3U#GNGWH_![PO)C_1/+O"LDY^CM#-E"K!.?H[0R9GHCGWE%.3Q@Z>H<M*)
M^_EXE6">,'3U#FS/2'/N*B?Z)Y=X5T.8/0'5F[M[>WQ">\_!\%83YB^GMR9F
M_EXA0'<>P]RMD\8.GJ')5 ILE9NY^ 43]_+Q*MI<W07JR>/CR\5HI@YP](=>
M2C>.T=ZP=Q[#W+'3]BK]4B'M@M,[#UJ!C4A7D9N?DV4-$,$ YUGLE(KMF;5(
M/E4763('RCEVGIJBKF93TE/-55$IT8X*>*2::1W4R*-KGO/J:TE4YIH:>-TU
M1+%!$P9OEFD9%&P=;GO+6M'K)"\P];N[3;!>BW+F,?J3(:S6)IPR=Y-&X8]F
M9G5+O*F);E(N(2B.&YU W'5C;+(JII@94&RF](BO;%CZ&,>7G0?);8[-3OR.
MOO,PIG@;R#11MGKVN W"6EB:3LTQDXMZ^NG27A2V:3&5K[E,W/W.VQZ]N?#Z
M9>Z*D+2>+)WD#;HG9GPG8:[JCJEMO:ZEJ-9V0K54]!RQ<ZI(ZSNK*\EV5=D8
MI@Y=QB4TZ^"D36U'4^]10A4*Y%2[^8:.'??+CGD:QD#M_IXTZ+;9@FQFKJ<6
MTM7?3)3B.SMIF0OJ(Y)&LE,+?*IJD,@8YTSJF6*.%[6:O)DKXP[Y^&<=5V)K
MIJ(,/5%/:]&8ON3IG2,A>QKG1B5WD\<.E*X",0QR/D:YVGFYC'EOM*3GZ.T,
MZD9Z(Y]Y78;]W/P*R"/B=(YLHE=)^+^;V9)'QY>*CDX<_!6R<_1VAEIGHCGW
ME0/W<_ JT3FZ>P,M*M)PY^"LD\4.GK')QN'8.Y1JZ3GZ.T,W9Z0Y]Q5=:TZX
MRD<A9J O<(YQ-Z,M6>I$;J&6(H"6I(I628@(NO5R&LS1A 6>R5RJR-;L-Z&9
MEX%E'*"^3@8J>F6E=EW\=,SCCEOV9;<OGMR6KN&>[;GLS'JS69V8FR;'26.8
MM81M$QK*?MC>'?-JO-4OX6Q);%(&8W5S6;&=6>C7UF2.#]^I)*J#*.S+3+ 2
M1,C'I)Y=OWY[L_DV;"C=V[+:>?KV[?A6P6:K9<:L-SI]1/%IVNV5JL*3CP(Z
M%)89V+A3R\@/  &,662=-C2#P143 &S0%EAXPGW'W1=[),P-YR565U"H,%.,
MJQ-WBH0]EDC,RQU>E;+"Q\X_-(N!:1Y642[>HOW1GSHIFS,$&Z@N7!111X:@
M"7&1ZDS'6O[2OE&<!:#(7.IK%I''!=#)6*'4"H"W(Y4<!:!(\$(#B$V;Q1;O
MMR3BB-')S\$J"HE9'JW[O6F8Z]V_U+EF$6.9??,Q^44OT3%X19'")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(O('NL'WEH5^ZM2/XJC9X*]G%]3=&GW_%O]GAM>P/8G_NN._O>&OZU^
M6IFP9_95M/\ H^?_ ,HZSG2/L7?]-[W_ #6J?[UM*[9Z>?\ 12U_SAI_[MNB
M]:R>,'3U#GNGWH_![PO)C_1/+O"LDY^CM#-E"K!.?H[0R9GHCGWE%.3Q@Z>H
M<M*)^_EXE6">,'3U#FS/2'/N*B?Z)Y=X5T.8/0'5F[M[>WQ">\_!\%83YB^G
MMR9F_EXA0'<>P]RZFJVT/H1=-0K!I34]8=.+%J75'+IG8:)$V^$>6J,=,>$6
M105A47AGRJL6H4R$L5NBL,4Z*9K(\F<E,D'(:O#.(J&VTUYK+)=*:U5C6/IK
MA-15$=)*V3;$X3N8(P)F^="7%NN9Y\6FPYKXE/>[/55L]MIKG0SU],YS9Z.*
MJA?4QN9Z;3$'Z9,9\V4 '5N\V31=L7<3QXTCVCI^_=-V+%BW7>/7KQ=)LT9M
M&R1EG+ITY6,1%NW;HD.JNNJ<B221#**&*4HB'RH6/D<V.-CI))'AC&,:7/>]
MQ#6L8UH+G.<X@-: 220 ,U=F<U@+WN:QC&%SG.(:UK6YESG..0:UH!))(  S
M*T2KO=3NY^V&9E8!GM/Z?LWT1)KQ+AQ/EGZS"N7#4P)JN(NQV&&C*_+QASB)
M6\M&R;J-=E**S5TLW,14_9,O1-TBTL$=1)A6XO9/$R9K:<TU5.UK@2&RTU-/
M+40R@>E#+$R5A.BYH=F!PR'I!P;/+)"R_P!&U\<CHW.F$T$3G-.1='/-%'#+
M&3Z,L<CHW#:UQ:03A-K7NF.SAL_[/UGU3H>K&E6KES<M5(?32HTB^UBX*3]O
M?H*EC5Y)O6YEVX;5B%.'?2ROS';%38-QCFRX2\C&-G%S!_1?B;$.(J6U7"T7
M:S43'B>YUE?;ZJB%/1QN!E;$ZJ@8U]7/^Y4T8#LY':Q[=3%*YL.(\=V.SV:H
MKZ.XV^Y53FF*AIJ2L@J3-4O!##(()7.;3Q'W2=Y+<F-T&G6O8T^+^SMW-':H
M[I-#1FTMMK;0U[@*9=##/T6L*%/,667@GPF.WF(" ?N&M-TPJD@BIQ]:1CH)
M^>48&[X$A&<:\82$CWCB/I-PIT:32X9P3AV@J*VB^EZ^I!$-+#/'L=#45$;7
MUMTJXW#1J3+.S4R#5F=\K)(XNJK-@>_XWCCOF)[S5PTM5[M20'.6>2)^9;+#
M"\MIJ"G>"'0!D3M8PZ8B:QS'O]I]GWN1VPKL_)M74=H^PU/L[44SC;]:3-M0
MI(ZJ?W22Z,&]9-:/&.$5 %5%U$5-@\(?@F%R<R20DZ<O_2WCG$!>V2[OM=*[
M,>1V4.M\8!WM=.Q[ZZ5KAL+)JN1A&?FC2=GV/:>CW"MH#7,MS:Z=N1\HN9;6
M/)&T$1.:VE8X':'1T[' Y'/8,O2Y@Q8QC)K'1K-K'Q[)!-NS8L6Z+1FT;I%
MJ2#9LW(FB@BF4 *FDD0A"%  *4 SKS622ODDE>^21[M)\DCB][W'/-SG.)<Y
MQXDDDKEH:U@#&-:QC?-:UH#6M:-@#6C(  ;  ,@KQ.?H[0R=GHCGWE:OW<_
MK((^)TCFRB5TGXOYO9DD?'EXJ.3AS\%;)S]':&6F>B.?>5 _=S\"K1.;I[ R
MTJTG#GX*R3Q0Z>L<G&X=@[E&KI.?H[0S=GI#GW%5UH!M T:1'5>FL%Y_21E"
MWM>[3\7(:A5F8J#N#L<;'T6.<0%8U/TWNE$L2EPN+!%H];DE3OY%Q 4B0.DJ
M^2K[1JWL#<=Y]0VY\=Q!W+1P[,O7LV[.(^?Y,MAMFJ67E=,2I.U2KO8*V7.L
M/%D=1[5JTR6<UZQOXM1:.OES2)8)F/6Y.55JD_</G$40_>ET[%ZQ=-V^#O\
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M-QM?'.(:UN%:HN<2  !=;2223L  VDG8 NT.G@$X5M0 ))Q%3  #,DFW70
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M6QY+M.6FFBCD>\NF>[-^M/T%72TWJTLD\B!;!/&^1SRZ5K2)F2/<?]=@TW-
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M)JHJIF*HFHF8Q#D,4Q3"40'.J7-+26N!:YI+7-<""T@Y$$':"#L(.T%<\!!
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M;+,GI/$6=5HMJG'U5Q6M!EX=I#J+D)-+1$;)?&PA<5X],L;RA#4I2:(5F:8
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MD0B2**92IIIE*0A0*4 #R,YSGN<YSBYSB7.<XDN<XG,N<3F223F2=I.TKT
M&@-: UK0 UH    R  &P #8 -@"L<I?^;!_AB'U9A93E+_S8/\,0^K"+PY[O
MELUNM;]C(^JL5 "I<=FR?"\HN$5$7#Q33Z>Y+!:AQZ92%X16S9,*_<'ZHF $
MF=.6$ ,)N"/:_0_??:K% M\K]&EOD/DI!.316PZ4U$\];G'74K!Q?5#JS7 ^
MD*U>760UC&YSVN37C(9N--)HQU+1U!HU<[C]C >M<2KW=331/<:F.TVO*)+:
MT156_H=VJZSY!61=;0+)D-:C9QP@<?V0]/7R-M9)!GPB K% Z2)P#"5,+,V
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M:<M,;P&.?+DS2<'F1[<O ;1WZHC<,7FU PTDDIO32=%*69:0N]-]/UFQ(0X
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M4;,]"5Q81'#HEOU"TRH5S3ZH5:AU"+;PE3I==A:I68=H E;14!7HYM$Q$>@
MB(\4S8-$$""81,()@)A$PB(]"5-3/65-15U,CI:BJFEJ)Y7>E)-,]TDCW>MS
MW%Q[5VK##'3PQ4\+!'#!&R&)C=S(XVAC&CU-: !V+DN0*5,(F$3"+CMNJ=;O
MM5LE(N,.RL-3M\'*UJRP4DEQS"8@IMBO&RL:\2W@)V[UDY6;J@!BFX"@B0Q3
M !@FIJB>CJ(*NFE?#4TTL<\$T9R?%-$\/CD:>#FO:".&S:,E'-#%412P3,;)
M#-&^*6-PS:^.1I:]CAU.:2#VKXW8&K]T=[D;M2:XZ%[).D%EUOT^U>4926GC
MN3TSO>HE;D8%)9RM6[.S6J$A"L(N^5%C(/*O<U))R6*5.T"1E8E6'^#KM/TS
M+/@GI&L%JNV(KE!:JRVA[*UL=?244T<Q#1/3N%4R5\E'4O8RHI0P:T!VKCE$
MNO:>E(XL38.NU?06>CEKJ:L(=3%U+45,3XQF8Y6F%T;65$+7F*<N.@2W2>PQ
MZIRV,J?<S^Z6]T U=TSU0[I7>XRN:34V:)*FTN6E8 MA4KZ[ID^DJW5Z;IJV
M&I5;X4MXYG#SEBFYY*XLV1&ZSMI*/622*?Q*C'6!L'6ZNH,#4DD]QJ8S'Y>(
MYC )VM>QD]14USO**CR<R/DAABA=2N<7!KHV/)/TX<+XHQ%64M7B>H;%1P2!
M_DI?'K3&2USHXH*5NIAUH:&22R2"=K<BYKW-R'N%=:#4[74;=I?*P[,*/88"
M=HK^!:((M&)*O*1SF!7BF;=),$&C=.+6,U:I)) FV(5,$B 4A0#PG#<JVWWY
MEXIIWMN%%=1<8*AQ+GBLIZKRF.9Q)S<[7,#W$G-QSS.U>MI*&FK;0+=/$UU'
M56[R*:$ -::>:F$+XP ,FC5N+1D/-V9;E\0M$V7]:+7M5,^YUOYF92K<'KS-
M2-E:($%*+9L(I@@TG]4TFYR&("SW32*0?5\[LX)N2OXY@F)%9+<?]&[EC/#M
M%@E_2S%3TQJZK#%-#1R/.E/)+/*Z2DL;G@@EL=YG=%5B,9L,4TKLVP[/%E%A
MF\U.*&]'LDT[::"^S25+&C*)D<489/= T@C2DML37TY><G:R.,9.EV_<S5Z[
M"U"O0-3K<<WB*[6(6,KT#%-"\!K&0T*R0CHN/;$$1$J#-DV0;I%$1$$TR@(B
M/AS\W*RKJ*^KJJZLE?/5UM1-5U4\AS?-45$CIII7GBZ21[GN/62O:=/3PTE/
M!2T\;8J>FABIX(F;&Q0PL;'%&T<&L8UK1Z@%R(G/T=H9JST1S[RIE.3Q@Z>H
M<M*)^_EXE6">,'3U#FS/2'/N*B?Z)Y=X5T.8/0'5F[M[>WQ">\_!\%83YB^G
MMR9F_EXA0'<>P]RMD\8.GJ')5 ILE9NY^ 43]_+Q*MI<W07JR>/CR\5HI@YP
M](=>2C>.T=ZP=Q[#W*?)U KB?R]';EA5U;#F#T!U9)'QY>*@.\]I[U(3GZ.T
M,M,]$<^\J-^[GX%9!'Q.D<V42ND_%_-[,DCX\O%1R<.?@K9.?H[0RTST1S[R
MH'[N?@5:)S=/8&6E6DX<_!62>*'3UCDXW#L'<HU=)S]':&;L](<^XJNM7=6)
MO7ZCVVI+TFWZ;S\%J+?FE-C:?>*1-,UZ\=:J6*?,X0O%8MB*JS<RE8<)"D_I
MDFX(:1*<KD2- 16L#++:#LX@[]O4>U:G,;CO(&1'BNZ--HZR1M;4+;H:)@;$
M^G)^7E&$#=[-?X7E4M*N7ZKJ*F[9#P$JT8O#KF<HUY.*:1E=!08F)(:/:MSF
MU^?4LC=M_)VKG^%E,(F$3")A%CF7WS,?E%+]$Q>$61PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%
MIU(?A&1_=[O^//G1$_U7/]_F_KN7<L/U-2_>(O[-BXBTH-%:7-_J(TI52:Z@
M2L4C!2EZ;UR'1N,E"-12.VAW]G39EFWD4W.@@9"/</E&B1D4C)HE%,@A<==+
MG);8;2^XU[[5!/Y5#;'U=0ZWPU+\P^HBHC(::.=X<X.E9&)'!S@7',JJ:"A9
M52W%E%2-N$L38):YM-"VLDA:6Z,,E2&"9\3=%NC&YY8-$9#8%S8G/T=H924J
ML$Y^CM#)F>B.?>44Y/&#IZARTHG[^7B58)XP=/4.;,](<^XJ)_HGEWA70Y@]
M =6;NWM[?$)[S\'P5A/F+Z>W)F;^7B% =Q[#W*V3Q@Z>H<E4"FR5F[GX!1/W
M\O$JVES=!>K)X^/+Q6BF#G#TAUY*-X[1WK!W'L/<I\G4"N)_+T=N6%75L.8/
M0'5DD?'EXJ [SVGO4A.?H[0RTST1S[RHW[N?@5D$?$Z1S91*Z3\7\WLR2/CR
M\5')PY^"MDY^CM#+3/1'/O*@?NY^!5HG-T]@9:5:3AS\%9)XH=/6.3C<.P=R
MC5TG/T=H9NSTAS[BJZU?U8T?V8SV)A;M0GD+IS=)Z:*]AK;'ZG3&DECEK,QC
M^0$?,'T':*T::FFL6N+,QE4Y!8&"YFRY#M5C)GL NRR&T=F:U(;O.P]>>2[W
MHT E6JTQBV]KL=U:D,NX:6"U2[6>EW+9TL==%$\NU:,P?MFI#@@T77*NZ,W(
M3E#MRIO5-JMALXY]JY=A$PB811BLB *F%5, ;[^/$5"[D=Q 5'C1W[D]R9BJ
M#P]VXA@./W(@.$4F$6.9??,Q^44OT3%X19'")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6G4A^$9'
M]WN_X\^=$3_5<_W^;^NY=RP_4U+]XB_LV+\)XP=/4.:>]'X/>%E_HGEWA62<
M_1VAFRA5@G/T=H9,ST1S[RBG)XP=/4.6E$_?R\2K!/&#IZAS9GI#GW%1/]$\
MN\*Z','H#JS=V]O;XA/>?@^"L)\Q?3VY,S?R\0H#N/8>Y6R>,'3U#DJ@4V2L
MW<_ *)^_EXE6TN;H+U9/'QY>*T4P<X>D.O)1O':.]8.X]A[E/DZ@5Q/Y>CMR
MPJZMAS!Z ZLDCX\O%0'>>T]ZD)S]':&6F>B.?>5&_=S\"L@CXG2.;*)72?B_
MF]F21\>7BHY.'/P5LG/T=H9:9Z(Y]Y4#]W/P*M$YNGL#+2K2<.?@K)/%#IZQ
MR<;AV#N4:NDY^CM#-V>D.?<576FVU5-1E4L.FMJ/,U=O+,X6_P .XK=GT9O^
ML+&R4V=DM/$9[EB= <+/JC%Q]B:TI)>><P$X"TI*0T:BFFBZ?,Y.PWQ!SS R
MRSZ^?P+5QRV]HV@D9$C/<NVMG.6KDYI9%R55KNGE8B%Y6PD+&:7-I9E3A>MY
MEXWDW3-E-TRA2+.0<R"3@\TT7KQ#-I<'B)G\D<AWBN#OV_E_[GO66[N'+_L%
MWIF%E:>[4NFNG^IC_36CS%'J,S<M4+&6EA<9:N0\G8ZEIQ7XV9NUZ=P4L^9K
MO(IXO&1[BMP;QFH56&L=P83;<G'-#&S9I(S.W(;?5GN'S]2U=D<AEM.SAGEQ
M72^H-9J]/U5M&I#-MH3=O@!>=G_3N!TRL5"?2&IE48*M:7'P$50K0^GF;>NR
MQ'5G<VZLEB:C8V$N9L5DM+LGC1XI"9&T ;1GF<\]A.W?\&WYYZ[B3L.60 RV
M_/J.W/DOZN-$5THL=K8+NV-HC+HLSF[W%P<9WDD)VI2^LECDZU&ZB3+EZ^:O
M9:^774&+T[7DG3,C,VE]7U.D"D%0R$1%AMRX9<>P<.P#/M(ZT(RS&_CVC/B>
MTC;U9^I;XZ=W1*_U9"QDCEHA8LQ:ZY)1JSA)X#.<I-LFZ78$6KY$J:4A'!-U
M^0&+DB(MPD8T6KT6S85Q;IZ'9\^O:MP<PN1-SF35FCD147,611W))"D"A]\5
M% /!%=5%(." B8>&J7P .[>;<42RI.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N
M?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\C
MZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]
MZ81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.
M6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,
M\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV
M)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z8
M1.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N
M?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81.6N?,\CZV)]Z81:EOO#(/
MQ$>"(OG0B4W.416.(E-P>$7>',/!$Q=_,80\.=)3T\/E4Y\NI1[M-LT*W,>>
M[9]1Y;/42.HE=NPS2>3TP\DJ-D,>W2I<C[FW:/IG/X0#ZD*'W0>$/E^?YO1F
MGD\.B/IZE][[RMZQ_P &LNFDT3]*5'#WU+U_RE6"<_-O\'U?/FWD\7W=2_$K
M?U-0ZZ3[EJ#^%2^-2%.01W^*(^#_ +/[7SFR9E/%D/IVEX[="MZ_Y)FFND^Y
M*CXU+^LJ8IAX0?<&^7Y2?-_CY9U$7W93?%K/U11OFDS^I9QL^RI?7U5*L%,/
M"#[@WR_*3YO\?-FP1:0^G*;C[VKZOY*H7329'Z4J.W2I>O\ E.:M@<VX/UI3
MF#Y4OM<V=!%FWZ<I]_V-7ZO^%372:/U)4>C]E2]7\I4Z:A_N?UA7G^='Y_\
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M]O4]P\"I G50'>""?28P]@9M]#,'&JE^(S_-:?1!+]SQ_'=\B_OO^M\K=/\
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&! 0PB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g63338g45n03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g45n03.jpg
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M]7EZ/,\L74:O'&3V6L/E8)^.>#$L<5D!OH\:O"?/RY ]_&J+](F"*;IO/)(
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MD;C_ -[D5L2N?G)<D^\G7[8ZC]2<H[R'=NYF;S+#'W[=*->?_=8YJ\2#Y@$
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MZDXB</'N[/F5""8\G:DR2>[R:OE1:C(/'L*?/\^G&:"^$&H!K^_"Y):F+O\
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MX_P&.1%OM+C5F&FLEL)K*VX_Y+6@T$Y,KI2(M>9P/96&.5CGRN=+*RGNZ7+
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M(GT;^4W:/X_/]7W-7W^N<>ND>CHT:K5?",/N6XH?T_N'\W:YZ:ST7OXUO/\
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M9!4B=.R&)LJO2-B-TN*SV<P3S283,93$/854L/C+]JBTZ(2R+,:TL9D5"S%
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MF[$@BSF-DDD<GCLC5;),C\^78G<WT>1U)'J+:E6NBY5M'6>"F#UV;[$P7#K
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MG=V(5415!9F9B J@$DD #G7J[I$CR2.L<<:L\DCL$1$0%F=V8A555!9F8@
MDD :XU1<5&05@5U0VE==T]E PJNMJ@X:RK#QI._IDA'ARS"E0/[+Y)H)9(W=
ME[.7K[F@FK2R06(9:\\3%)89HWBEC<>U9(Y KHP]ZL 1\VOB">"S#'8K316(
M)5#Q3P2)+#*A]C1R1ED=3[F5B#\^M9S\@=#"SS#$[MU$.2/+) 0//LG#89X)
MX7K'+#-%)=-DBEBD:YDD;VM>Q[5:Y$<BIUM5VUN-U5TP&:9&4,K+BKS*RL.5
M96$!!4@@@@\$>8UJ&W-MM&9'W!@U=6*LK9:@K*RGAE938!# @@@CD'R.OE^J
M(X__ ._GIW^\W"O_ !OKZ_@QN7^;V<_LF_\ W?7Y_"C;/\XL%_:^/_O&MGTU
MU39'5A7>/6U9>TMC#[17V],>+:59\'F<SU@CPI9Q"H?.Q[/4@E>SS-<WS=VJ
MB:B>">K-)7LPRUYXF[98)XWAFC;@'MDCD"NC<$'AE!X(UMX+$%J&.Q5GALUY
M5[HIX)$FAD7DCNCEC9D=>01RK$<@C7QILCQ[(OC3['[ZFO?B.W-Q^Z^)K0&S
M^)[^N]/XPI+3V*>?XOMP/5B]MK2_1-%]6/UX6>=O?ZGJV:O@^LUIZ_K$$=FO
MX\,D/CUI>?"L0^(J^+!)VMX<J=T;\'M8\'7S!;JVO&]5LU[/J\\E6QX$T<W@
M68N/%KS>&S>%/'W#Q(G[9$Y'<HY&LSUX:R-:7V/R/X^Z>-CK-K;OU/KFUEC9
M+#49IL'%<;MYH9$1T<T55:V@MA+"YJHY)F#.C\JH[S=E[];[%[6W+G(S-AMO
MYG*0J2&FH8VY:@5@>"IFAA>(,#Y=I;GGW:T&5W5MG!R"',[APN*F8!E@R&3I
M5)V4^QEAFF24KY\]P0CCSYUV_ =GZVVM3KD.K]@X3L:A;(D#[G!LIH\KJXIU
M;YO9YCJ(XX:$A&]U6"61DK>R^9B=EZP<EB,KAI_5<OC+^+LD=P@R%.Q2F*\\
M=RQV(XW9>?+N *GW'6=C<OB<S ;6(R>/RM8'M,^.N5[L(;V]K25I)$5OG4D,
M/>-=YZU^MCK!Y%D^-8A5RWF6Y#1XO2P20PSW&16P%)5PS$R-A'BEL+,@82.0
MB9S8H6/F1TLCFL8CG*B=9%6I;O3+7I5;%RPP9E@JPR6)F"CN8K%$KN0J@EB%
MX ')\M8]JY4HPM8NVJ].NI56GM3Q5X5+D*H:69D0%F(506Y)( Y.LVBHY$<U
M4<UR(K7(J*BHJ=T5%3W*BI[T5/<J=8^LC7]Z-&L-19'CV4!/LL:O:;(JZ,LH
M"0^BM ;8*,X&58#0GE 3D0-+#F182AG/28>5%CE8QZ*G7O8JV:D@BMUYZLI1
M)!'8ADAD,<@[HY DBJQ1U^$C<=K#S4D:QZUJK<C,M2S7M1!WB,E::.>,21GM
MDC+Q,RAT;X+H3W*?)@#K,]>&LC6*N[VDQFI/O\DN*K'Z*J'>7:75W8"5536B
M1]O4*/L3YAPPQV=T\\Q$T<;>Z>9R=^O:O7L6YHZU6":S8F8)#!7B>::5S[$C
MBC5G=C[E523\VO&Q8KU()+-N>&K6A4O-8L2I#!$@]KR2R,L<:CWLS #Y]:?P
M+E!QMVG?NQ76F_M-9]DR>JK<>P_96'Y%=3L@:Y\THM957!1AD$3&N=(0+#-
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MLX,"I."IL ?\EU+H?P,K!A]!&IHD?^[S_P#(R_X'=0-/NU_Y2_K&IZ_W#?\
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M,TOWQ0]:7NWN%&U< QHNI!N;JTUI**3>3F#5D;:G9^'W!*$3  6937/& F9
MD84J.G=&V18XU=*RRND>6KX3?V&R5M)I(((<LKI76-Y29L1>@7M622)#P\BE
MN9!PH)')X!K/J_B;.<V!F<;4>".>>;$LCV&D2("'+T9F[FCCE<$JA"\1GEB
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M&33D2JZ25[EB>6R=K-93(9>\_B7,E<L7;#>?'BV96E94!^YC0MV1H/)$544
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M$SDSR2I,^&HR);M5:HCC?FQ9=(55G>.,(CJY(D/$]@ 0JL$.LK11P:ZN$'!
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=$8Y(2&"-8HD!/)(5%5?/S\O/66Z\=>^CHT:__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g63338g49l94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g49l94.jpg
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M$0'_Q #>  $  @(# 0$!            !@<%" ,$"0$""@$! 0$  P$! 0$
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MM(#"QMHV7ZX_:A.@G+83=*]+-%Z)ULOT-BWZFNY^9>V'Y@K/RGF?ROL:.O\
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M.EV^V4[8SWUZ5P[<NYSJH_T<,N7:1V?4Q)JQS3&P@9]1R4\# T!<%9BI%(P
MM@C<D7G-8R"0*"!-P '%C,V4((]%@Q5R'MRI8CNXSEI0A4UDZ9]*=MFR*C*E
M_8OLQ4U*3A)7-Q:CN3BY/ENXCWGE#D5C\[Z?C99?%X3EQ.3)44[YN4,A+E8_
M<S=;A%60>.E.,INMJ2A'L:8>A/>91N[*JS;1J)^QG(M53(]+C)K\/#3>_BU_
MUI;)+CWQ1L*OW=L@1_L>MIO:_/OVC7&\_P!O?MG!<;RGW?W>Y2^^IVK&[NO:
M<?LM7;V-:^]N4>Y_<[6W^V<JXGWA^\C-\WP/V'Y?L</RK(WO-^W<>^I_FFBQ
M_NM+OM]CGV=:?N-[[RZA$>Z2"EBX%-HU(:L2.RPZ8GDU!)B2'MD&J;AH4# G
M%;1PX^XIT92L!BDXQ> TPXL>B0:*$$SFLY#VW=N4ZN+Y94SJBL=/D*6Z[%&>
MZ5K^P7=@Y.#4(JIQ49)S>Y./!5P_O4J<"-W.^GI7UY$WF-<1DJ-]+E7LA1%\
MLWCV1BK5*R;OC*4X-5Q4&I_#X]TF)))P)[1J,I:K=T9T0/-I^3G)V5C I<A+
MT#\F#;90W]Q4)34@"U))B$LH9)HMDCT:$)2'(>VRMQ79Q?+NF%,ED)<A2G9:
MU#;.I_8-504E8W"2M<E**4UM;E+>']ZW1G1IY[T]'(LR(/$D^(R7&FE2L[E=
M\5RR=]DHNI1LA*B,7";=<E8E#N"8>A-N:@T-DU;IH%$](TR/=4R,2XJ:_#Y2
M;;Z<OU:6B3H]\3Z&K]W:( ?[&+2?VOSZ]HWPK/\ ;[[:,'QO*?=_=[I2^^IV
MO&[K?:4?LM5;V-*^]N<>XG9VMK[:[#XGWA^\G-<WP*P'Q^R,/RK(WK-^W4>^
MY_FFDL?[K6W[=04^RU3]QO7>? EC_1H 1#2RSJG.,1.:@V<B(J.2IPO[2)R2
MFID<< .US]QI<4T@.)&>?MQ ,\83=%A"#90N2WD/;ERS.SQG+1C.I+&USZ7V
MK-DE*5VF"N]%V;9*,>RU%..YMJ2XZ.(]YHPXY9'.>GY3JO;SG'B<F*R*NY%Q
MAC)\K+[::J4X.RQY"<Y1GL2BX2ZQL=Z8VVOQ1-J5 !V4/2(^-K!TY*#$36P%
M^]?>#<[H=6\ YX=%/K(_25%'I"RO0-\21^J'TN2/(^VBR:)3XKEWB1IDKHKD
M*5*=KV;)UR^P:K@M+-T)1L<MT-)QV/?PSX;WN>'EPKY[TZL^>37+&F^'RG"J
MA=WN5VP_-D[K):T[+8SJC#99K7/N1[>1-8>@]N;F:39-6@9S8N%(T(C*ID1B
M]%,-,R(@3VN7AM$!*]AV_ 4*--X""#M)C $>U;&#9P^O'/\ ;Y8U4)\;RCRU
ME;K)+.I498_<D^W&/V3<;>TXP[KE*.]2GVM)*"[<N*]X'G7V0YK@5QTL%0I@
M^*R'.&7V81=UEGYHE90\A3L5"A":JE&KON47;+A1L'10!PW:ZS*I4%H5A@YZ
M%-4TD3#D2#;OHXI/&1F6JIU%U(&/Q3B-4:<PB4_QWDT'^)S=V?[=RCF=CC.5
MC*<$L7=GTR[,NWHW=I@KOQ[OUJ,.RU#Z-VOUG'C\1[R1?&_=<YP$XU6MY^WB
M<F/W%?=U4<;7E)?:R[']O=9]RNY_<V[?[9T1QSIS;.ZD M:G@OQSVC/9G 5-
M2D38ACX$[F%<VN#9JX J'!T4*34@RE8%*<LH!)H=D#V:$17.N1]LOO*IOBN8
M^P5$E9#\QHWRM;AMG"?Y?I""2L4H.$W)RBU..UJ75EPWOB^.OJCS_IQ<I+*A
M*FS\GRNW#'4;>Y7.O\WW66RDZ7&U60C!0L3JD[$X910Q=!B<WTU-9%6E-"B/
M!31M$=54B.7-<HTB;2QN[LO#:)1+NS;<"E9FD11"0W11Q0/:/$H0S>K7G^WR
MQJ(6<;RCRXY&ZZ2SJ5&=&Z;5=<?LFZ[-CK7<E*R.Z,I=O22C'OV\5[OO.RK*
M>:X&/'3PU''@^+R'95D[*T[;;/S-*ZEV*V2IC"J2C.$>\W!RG^$+#T.6IA8G
M"RZK4I4)@]S\E+4\C2'2,K;RH/ &,'F6HJ!%AA81%)][4 <];4@$=X: +1(;
M?G^WDJ\U8_&<K&V:_P"JY9U,E2^VE_>2P8]]=W=/2#I^AJ&NJWO&+Q/O'"[C
M99G-\!.BJ7_?4.*R8/(7>E+3&D^4FL5]APKUL63_ '8RMTVR54<7N-]/^X5:
M<-L4YJ2#>TYZ%TW3$JVTIX\%$M+5-JEH^N+2E2ZFKQIS *PJRRP%%C!L@6QZ
M&#M+DO;#[Z%CXGF?RY4-2A^8T=QV[HN,U9^7[5!14TZW6VVXRWI1:ET7POOI
M^53I7J#TW^<O*C*%OY-E=I8ZA-3KE5^<;I6RFZY1M5L8QC&475)S4HY=4Q=!
MC<Y,:BLFK2&A4S:(B*-154B4+F9^\6KS.+ZO!:*<E^;-Z)6^"4DA"9_'E?QW
M\4+U>I5G^WRQL:%W&\I++A=KD26=2HV5?7]%47A-U3ZU_7*5J^F?T?6MGH7\
M5[ORSLVS&YK@8\=9C;<2$N*R)3IOUJULOL7)Q5]6BN_M0A3+6=?]S^W+N?$+
M#T(6NAQCA956*6Y$1L,\3):ID:15(5'O1>:$R-*S+25%Q@K3.8F(\J@IRWL\
MHPWS>4P)1:_/]O949D<?C>4CD3E_U92SJ91J6R*TNBL*+N?<4Y:PE3],HPTU
MBY2F+Q/O##)XZ>9S? SQ*H_]Z,.*R(2R)=VQZXTGRDEC+LNJ&ED<G^Y"=FNV
M:KAB/AOJ#X>&F^MFF_BC;V \MV^I:5>Y@Q[2 PL;:-E^N/VH3H)RV$W2O2S1
M>B=;+]#8M^IKN?F7M?\ F"L_*>9_*^QHZ_S&CN=W<FI]S\OV[-FL=G;UW:2W
MZ+:_/_)??7\F='_L'IO\^^Y4E;^3979[&QIU]G\XW]WN:25O>VJ*<>TV]RS"
MUAZ$&X2TQ!9-6IFM8@T7"$BJJ9&J6,+E[:V#VJD2TNTDQ4C2;;REA?HD$MPO
M5.*'ZG@4(!O3IS_;Z./B1R.-Y265"S7)E'.IC&V&V:VTQ>%)TRWNM[I2M6V,
MH[=9*4?1R>)]X)9G(3Q.;X&&#93IA0EQ61*=%O<J>[(FN4BLB';5T=D(8[WS
MA/?I6X3(F+H,#C$S5]DU:H:D;=LJ:I$U52)*M?73VIT'I7'EIEHJ28ZBTB-1
M@] \EP'ZA!H_4\#0@*79_M]+'RXT<;RD<J=FN-*6=3*-4-L/IMBL).Z6Y6/=
M&52TE%;=8-R8W%>\$,W LR^;X&>!73IF0CQ61&=]N^U[\>;Y22QX=MTQV3AD
M/="<M^EBC##_  WU!\/E)OK9IOXGT]F'G.WU+RKW../;0$EE-I;-]<?M1;H!
MR",W:O:P18BA:+]#6P[,WW/S+VP_,'9^4\S^6=A)5_F-'<5NYMS=GY?M<-FD
M5#MIJ2<M[3VKSOR7WT_)U3_[!Z;_ #W[IR=OY-E=EX^R*5:I_.-ZM5FZ3M[S
MBXM1[2:W/++F'H4Q;,C&ZRJL3(%Q8=0-,JJB1JU,=-]ZH3A#DRHNTTI<G!MF
M+4D:"G*;-Z4&EG>/E+V49U*,_P!O8TX<<CC>5E?!_P#:<<ZF,;EVY+^S%X4G
M2^XX2UG*[Z(RAIK)3CZ&5Q/O#/)Y*6'S? PQ;8_]&,^*R)RQWW82UR9+E(+)
M785E>E<<;^Y*%FNV#KG^DK%T&!SC9JVR:N/:$K)LB6(D]52).N>)!Y736G)C
M7CM%02Q->AG(]^RG$+C-Z(-UZ_\ &A]+-N?[?/&R84\;RD<N5^M$GG4N-=7T
M?19%82=L^EGUQE6OJA]'T/?JCBO=^.=A69'-<#+CH8KCE0CQ>1&R[(_NZ64V
M/DY*BKK3_:G"Z7T6?W?[BV8C4;Z>]Q(DXK8IS<C+>U2AP<]4Q*M-*F/#1H (
MVQ*T?7%M2E=25Q:DPQ6)6:686:6#1 =EB&9W'R7MA]].Q<3S'Y<Z(J$/S&CN
M*W=-RG*S\OVR@XN"5:K33C*3FU)*/G+A??/\KKI?J#TW^<K*E*=OY-E=J6.X
M5J%<:OSC=&V,U;*5KME&49PBJHN#E/)KF'H@Q1,Q-]EU4F3+C@;@)2JII(J.
MCI&GD@\PN3G%VHE#*#1,(3$^A)P-FM*1!/\ #8 [)%U:,_V\C7A+(XSE96P7
M_:<<^F*N?;:3I3P9=A=W2>DW=]"<-=7O7=RN)]Y)V\D\/G. A3;)?8*?%9,W
MCQ[T9-9+7*164^PI5ZUK&_NM6Z;4ZGR$,7087-D-4615IK01'!)I"B*JJ1$K
MW*5>[W$L+NU+Q6B:2U,NG0U*;M"80J-V2287[3YC F%YGG^WSQKX5\;RBRY9
M.ZJ3SJ7&%&^#[<X?9)SLV*<>XI0CNE&7;TBXRY*^*]WUG8MEO-<"^.AAN.1!
M<5D*RS*[=B5M5GYFU52K75-TRA;-PA.'>3FIPQ8(YTWIH:"3+6IX3X2]K3WQ
M>&FI0%M<(^,EK"@;6YMW< E#:Z)CRE@C59BE06:$\H.B ;*%LWM/D?;+[RZ<
M>*YC[&5$55#\QHWPM3GOG.?Y?I.#3K48*$'%QDW.6]*/0CPWOBN/QZY<_P"G
M'R<<J<KK/R?*[<\=QJ[===?YONKMC)7.=LK+(S4ZTJH.N3L[RM@Z+&*9>PV;
M5"<*Y<49 M*:EDBD4=;].PSCDTFV7:R;4G5#9-A3A-3Z; A4:V=L&P[]'7#3
MG^W26'W^,Y63A!K*TSZ5WI]O12IUP7V8JS6;C/O-P^C=K]9VLCB/>63Y+[7G
M. @K;4\#=Q.3+[>ONMN.3IRL?N9]G2"G7]LE9_<V;7VUS%L70>G-N--LFK1L
MY46VD=$0*ID0%ZN8^Y%9 7M$OW:(R43!J0C(4[;QD'';2EC(]J\X]'@Q+/\
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MC>K59ND[>\XN+4>VFG)["Y^>G[", 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MNAH@NA2IJDK>:B$1[/ZXSPZ"  O.#S";7KIYEBO=_P!,QR>4]6#[8L<:Y_T
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M4\E03^.N(^@6U:\TN:VJ]N".QVENB/QXK<XRO1%GH5B $._^(!-V8$!B;>A
MV+>]:P-'_ IV#]W<D639+?4T)NR./TR?':0L$6]%NDJ6)3J01,"PV31ZN;'<
M&-)75CO["2W*C%:%B=7!406D/&(O02#=@%<9):LVWP9& , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#Q+YHX?N:S*I^&[XO&S(
MK2"7LB^KA#R[]4\ AZES)AO=5D7?5@7BRG-D<+&6PB321H:)-H24:!0X(5!9
M):D*0?Z8VY)/IXZ?Y&M$XXRZ1>N#KT7)K1ZT*D#WUI=\O:^3$47JO<&>HVZ?
M,1D\M;E"5F44HIN(^,26('AD^CRI('9B=1M04:!)L)>AI26Y>'A_D22UJ@[C
MD%CVQ\P^)U]&3UM8]1,<^JVI5T0L</4,HYIYF2S*AI!6T*2#<4[$0BZ"@<MG
MTK9VPUL,4+U$J0#WXG 2[)@3CIM?P-^&R%S=7TS\R*7!ADKU&+(Y;Y<9J^=5
MD?=DB"8/++%.G0OK"P"4IR!+WAF/DJ M:D+_ (],8N)"8$(C ZW3.JT7XFD%
M<\>] 0BH?D\/;U;75UEF0"RN75]CT5/(W4X8?2:%#RU8S,\KGA'#:4B%B1Q-
M6[\M(9P#=WM0%.8>$I9ZYX@CP:<EK+P\S%:;IXW_ "S'_P"6 JYGNQUZJ5U[
M*N>TZ@-2S,ZDGF72.0.A:7KPSHKW**I$D,->',,_5*#G@N4$.NAI/8=N^@E"
M#INWZK;^W0CY//71<8NJ_DD2JVS@1CO#I>Z.:;TEZ./GH$[#5B.30*:1;HIT
M-.+) GC+C33A:<<0.Q>]E&OSJRIP#_[.L#6.B^2U-IX13M@LOR2+BI-+5\L9
M[ /YE[+B,7J8J-.*:6"52!?=),&C#/%M)@N1BEV0.2$#<G+*V(\LXGT];T(/
MB,Z_W-?F8>^N'+BD?,MP67:MVV5TU<$(X4ZBK6@ZQ;ZH@->IF&3791QD:DI!
M4;K]E%*9M.GTIE1M"$A2N&G3^J;HM*)0:$T JDE))=%J1BQJ+OKGBRN&KY%8
M'877K?3<7Z+E,BK&0Q2KGP,8=$W'5C)HTTLR:HJ1@,@22F82P2>--Q;DJ6%'
M*EX2O3V=O1F@33371:Z%05;R_P!P<Q.,%EUA1V"645TG0=\4ETD72,8L=?,2
MKCLU/:/3D*M>U=K'1Z;'- PV[(I5#RW!&0E(2ZFB0O?E2E$!)%;B_#R9,*3Y
MOZ5K5/\ *;?+YE-[="T9#X34;>X4VHKR Q%^Y#Z2!16XQ7%D3IOK2MH],YU5
MD43/;S%'(A[4^K%W94A=%QBLH*H:01N/731,TPC_ "9THAXN<^12Z%M(NLK+
MY%5=DR]N.B+DG*1]"U]SM)ZW7<VK&DQ-M<984\Z!8X!.T;1Z6C5@D[MOR[%O
M>\AO='=NUZZZ&T%M\Z=RW4Z7'T)6</@<>>>=67G>(<Q1NVH;8K;;[X[<?$MM
MTS!PK Q([M; VLG1]H2)W@YZEP1J0.C*V$F;\4PR]8,IQ71^?^9LY65T'\\S
MOKZ86ES-TY+"^NI5 >DJ@'$>>I[9#W.8U(^;*BKPOG">D1MC>4U5V16<H@3B
M@/:Y@:RM1:)R+4A4^7:[T*1K5+1KH:Z&(K/KGJ:W9*^E=K<7,<VYGXF;62 \
M9<MMO2=7-3W"859B*6UPGF;?RK<L7+'3:EW2M*8#86RI3DXPC"F&7Z>P0OBO
M)]7XO_<VH:+75<U]5WU<TXJGJ&>5_P!-<\\G.]5RF \Y6?8,C?9=5K/;#5*J
M\L&(P:&"=JJLY:"5M:PI*_MS&W#VL.+]4@:-2453.FL4NG1LAD5Y[N: <>?)
MYK%[@;^9.:;Z%YP?;>9&)*)^W72!!4]MAE!\E7,^U:!.UQ=W?R&]8NT8)'[2
M,.@F"",&Q"ZK=)^6A$>H:/N5YZ;Z=MU@J:=SJ%U_:_RKKR-BC(Q&*%-VP[GZ
M2W,[V?'*Y(7FH&F<3.N@O2&0)V@)_J*7-M2)@>"A01K8)K1)OXEH=#W[8]_1
M&YVSDWEFU6B=SRJ8ISA"NKK+I6P:FDL<EMZ6$CBKFA0QB;0.-6NHJV@XFX.D
MYD3X8)&Q)'!"E1I?:UJ@W:81))K<^AI1:?/O47.5;=-T*IJ%+-ZILY-QET)6
M2/E*LK/D,1A$EYNOGFRN;C@OP^M/E\H43&4T]!X])T:<D>QNPVA[/**,4!4"
M'#:<6T_/KXF]/5-L0?H6*5+,&JG^\(\TU3<YC@;>=4TI<U6] <W/[I6DP9FZ
MR8C4-ATXXOUWUW(VI\6QB2IT#&^I$25WT:I1FE@&8GIA)Q>G0FO$ENS6*,<@
M2WDCFC@DN?JA?!:!N"9<W_4%;M^-_P!235*=V#?=9QZ-1PF*.Z0Z O4?02!T
M:8^)[:F1L%M"F]=-HX)+X? J?YG-3VI8,NL997]=36:$+?E._,6K5 HC$;<W
MPE98T[D'-!\(@B<2),> ^62\F/+Q-R#7BH6!1G;+"+18O""+6G_\2*"F?'W0
MD!Z2H[G.IXI(T7*SK"^R9U1UIM!*XQGY$EUR<UR>"O\ 1$D$D"-4P0M-9\J*
MD<"/WL&DJ98O9"M:+:T.A4TI+35^/3]YM)SC<6]59Q3RR/AZVC[3J(FHH58[
M%8U.OD/J/F4VH87\.R&WHO=<CB+E5<XVW&M1I,-W$7-:Z/H7$H6A(B=K#4XR
MUU<M5HSU-@LQ13^*M4N;F>6,*-V]N]%IG$5?(3*$GL#BL;#/>D8DJ)O>FSUS
M40C"?6)!ZR<99H/$LP(MC#6A+L 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M)/,M]3!8="8,RV+T? W>F+0K%Z?N?%;L7N!M\LNV.T!9ICY'G9LW'U9S,+;
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M@R7I/H!764O:T$BA )3)5=VR.0="*64B'6C5=NP 9C?%(RE=G(Q(<M:R2VU
M8TCV@%?GU^G0VX^6-RRZ4#0E6O\ ,H;2T8G\EHBH6Y])AG.0*9MMI<"(N@72
M1AN*8*)U*G:PY(6[F%^V&GHVD?O$@\X9/G.\A0S-ZOIX&K,=J(K7:J[9E#2"
MP0V!T'=6K237!SG-6&81"LYI#I\SNDP0]D1ER+I:^.:)0@.1HV>MY(G<UJ-&
MXHT7D(6LH0)QK7Z?'R_;H<#9R7$ZQK@EUWRY[)6 ?F&7N\=$P2O*FUJ6V+S
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M53+J$1XVW;06P5\D%D,L[EC-"D#=3]EV>>I''JM+52-X7GK($6W^8H6DI 5
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M?8U;!884A<J N#DJO+RB%QB?@:!';8MMSLHBKJLG[>4$:-H9IV"MU;4E=2U
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M(*#66OAU_ P]ZM?RQ#YZB>Y9T/7M$V*O,AB]I65G>;14+NJ=:B>+BCT>>FY
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MCE"<\HWU@GJ21A]2TZ$DY\;.:6UG=K<I7IE7.X;#WZ>S*_9ZXVT3/4T_E*Z
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M1+)Y9#E=G%E?%OE7L[+9\S:2C$S)=3[[.WR #2B,4N2'9NO*09HJ%48Z_O\
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MG:2U0]".2"%"K?\ M\B<+8'P#.XJ]6A(JPJA=!.2#)#7)]@2V#%IXM$FFC3
MNDB9VUY>$ $LNA=72-*J)WY=KFUO?D"TLGP6$'^%)K+P^)U%'9'*9'UE3F50
MFQ(E+3J\A0'YCG_/M@1NR[6J9?.]06#?"T5?HN0^V%%RI];7L&V\HLQ0TK)
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MTB:3EAZ@YU5&>@).*I*/@;)<R\KE<Q3Z_!11P0NU7VP_Q2<QD4B7R>46]&I
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M&@A+<=)6X>Q:<?3&,Q\300"]7;W.W.\P:K5ZECJHKMF+\].CE&^M[$D#%)H
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MU%6%B6T$YT,9U9DYBM56U;],S@J(E(5QGM+TRRZJ"M#2&; ,1<D:=:WL:@0
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M :968*2,<D?4SH6-22J3$JD!'G*&4(PL8;GT^1VZ@H-\C-I+KFMJ\%EXVI\
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M^>)[')K <JD*^&2L.FB.R$;E5Z<\DU('TRBUJ@C8!DC\N GHO#H01DX+W6K
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M,I9,(DT*8ZTV3"6$FU87#(?>L)?XW,E)ZN9P2X5E=,<@7I#EZ98DD:':M,K
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MJBTYA9]K21_DNKLF=BUG8D#M1(>84Z4ZII8J)GU2PQ2/Z6:C#JQQ:01Y:Y&
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MC94SC2EI(]I&,Y.R.&R="V).2+ WM_M\M"R>;.&X9S3*6651Z=3"5KF:%V-
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MJJCF_I"@7JV: K?J2N;\+4P:)6EUO#'.*V!SMT'$+4121&&IDCZ[OJ;J!/\
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ME:"7QWMB4Q3J5!88:\<6EH(7*YN_&OC06\Z0&A6+?:4H% A><O!5+^E:^?\
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ME;5LAHE2-T<144ZO;)V7'96TS)I>]!<$%%="1V?M#DS V$29JD!BHO?E*>$
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M;-#X$!U;")#($S,D(6G+FXH:Y=MH$6D%3?F^NGQ_S,C)>99U;+O3_P!1E/\
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M]HC*2I7/WL!KVC/ K-.)*T9Y V]="BGWYE<-CA[TVN=$W8%\KI!*'>]6E/\
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MTNZB&'JD2V5S5V+**KJVY)>D#;6X3K(UIK2R1*TI<X.:% E$2C)TH]ET7[&
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ML=JLTU=''3B\UW8JUI9G.-,B8A HB0H^_C<0&%+W'V#9.BAN,DEU*O5\,74
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M!   =;WO>]ZUK6L _>MZWK6];\=;^G6]?3K>M_P;UO & , 8 P!@# & , 8
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M@R1JTP32Q!"84(\H)@!"),4A",&QZ$$0DY(S-:WKZ0!V+^#6]X!^PJ$X]E!
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MI9A9Q99Q)@#2C0!,*-+$$99A8PZ$ PL8=[", P[UO6];WK>MX!^\ 8 P!@#
M& , 8 P!@# & , 8 P!@# (S-/\ ,Z6?Z,OW\EJL!>)QP7_,B'?Z*Q[^2$>
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M$%HJN1W.-NYG/]BSJ8OM7!G4N:I5[-%33VPE:E:CE04232P>MQFTTFNOFO\
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MYN@AH?7*W&MLV^A,AEKJ_<!,V//VVUA,'#3CJ"AC@EI;%M*UF:>CI!\2EZ9
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M<6X+IY"K"ZZKSZQI%\*:/"O_ ,;T@TD\VFSS_P#\)]E\OZ/A@RR^L$& , 8
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M0'S2')0J!*99&DX4NW;2H1[ZUDA3;8%B%N?=*-F*@Z)VRN#FF(5^;P]F.4%
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MK.ZH&=J=&E6#2/05+8Y-<>;TR@@>A%')T*<L8=@)+T$-68W=45;M\D,GW6L
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M=V!<24[.]HM $T:0JC%B!<H*")N^*.&J/EH(ZT@D+A9UK%/JB)27F-\,D!<
M(:USFFYOJ#52)T>@&2=T.1F2=(,U8$8CS]-^SS"=!/T(0Q Y:L[M(<!SZI;.
MI:>'77'O9:RAT C,Q30:"S*'*;=U6])GT<PI9HR+K=E%:K"A-0$;H!Z.CY\O
M0&)--:=W"TB"F*!R37@3*?<$HYW-[^F:FPDZ<5WP/IB$EH3X4G<-Q771E.<Q
M5(H<"E9K\4)SU'".<O:QE: FTO [^@(16DWG/$W=$OV\RQKIYHF<X6U#)JXL
M.(Q2:U=7%EU&)7859 M")N\-MQH@K9*W+43%*HP$J5-BBO$!Z$1ZI2@.3F*T
M2M.<2JV,L$]/'P-9%WRT'AY;F&%O=R1]775</]ER&LDA-3IDLN/4W+?<*O:?
M);.>"9<".RA 0NBI[<WIVQI92!!5D*E19YR$H)@N_P _,F<R^70V2WV@(K$0
MHBEEB]"3]<3N )%)2X5]=,TCT2J;%@-OY(%6V/ZF0-!AQFA;7:6!4B 7[/HD
MP-QUIO\ +H!)5;6]LMGMS)(8S<-\7E'#5=>$.;*=-;9Z7IOI:.HY:U$R=M-D
M4;C;W3B9L<B0J$RAW3*O6+.1'$%;P-QB1_+<5O2.['*5VPR*IM?D0F#5+W%D
MK,#;'&"236X&ZU7!=#V57+W%>BCZ,#(B1^RGK35*U:28YGJ=GG;* &[^"/4[
M!@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#'NS4W/K4YL
M;PC)<&EY;UK4Z(% =B3KFYQ3&)%J,\.MZV(E2F.$ 6O'7B$6\ UN)XXY^/(:
MM26$%S1>WQ1NB*QPDSDZJ2I(E:H0?6J%]E$>1+4,1>YL1 E(VH+X:W[=2T6_
M2+/ 7H(0B[F<)O$_,"E*6C6U4B<DY::5$["[22:.QAZJ;%R,J3ORT]RDBH]?
M+W,J7N@??9XC'<D*\[12D&A[P-S+?B,3B--Q!Z![V"B9]/4RG\JD\G<$2;SN
M4G?'.521[>G0T*)$F1ICEPP@$/R@3HR2P;%Y2_' \3Y+[EJ"OM&;GMK5M"-$
MN1;,;N7SF,1K13P:C:G$IJ,V\NB+R.1C>_(3PD;\#=DK2!Z#Y3B]B#1OP(G)
M>E:3BMI1BF'2P8T*QY-[_,'&$3XRJW.+((Y"7&P5[S.$!;C[?$F,V,MAAQ"Q
M8460=L0-:%^F'>PT;6OD9]NO>CW=%$')IN6J71NL%Y41V!+VZQ(@M13>0)%)
M2-6Q1!4F>#2)*\I59Y91B5$(X\!@PAV'0MZU@:,A4PZCJJ#MO1SJ^GR *3EA
MI:GJU]I&)0J,(0O,)26 BW'BP&:V_&[CRT&Q!+\NPG>)?\.L#1O]Y)WB_P"H
M&Q3)VE%/X?)Y3"S6P$KA$7F$1=)G'2G.4(8>%6]Q\;\F6,Z1&^KPDGC5>CY!
M@$7KS&ZT6(-&0&H^R.>[F;$+O&K#C34CDEE3ZKJ[#*I5#&=?:[W7$A%%)"XU
MLTADJQVD;.)^+&0F\2"5IP0A-]G"2<08:#BUXDX,Z3YU)4Z1G7Y2I2O;Z.+Z
M2F6G!@*=R8K279D=T0)]T;[]+TN(\R3P]HUZP/$'Z8?$-'\#(N=QQ8=8J;7K
MHA?>T<#L(6M/1ZN-3M?)1 >0,:X$<4%R%OC[D-H6>KM7KVX'HA3FZ^D8/)L-
M.NCZ%/TGVK35T0V+SH[;[3;-8"<MQK1-?!D1K=[LQD$QAD1T@@[&IEKBY/#2
MB:O,8H$(LHT@)8Q#+T .Q8#BT6>+I/G4,<;9B*_:5#$7ES5LK/*16G!M1QU>
M&\]&F7M+:^;??=BYS1*7%.6<04:(TH9Y81!UL8=;#1^&G4B-V=?\\T)$K+E,
MWLV)*%=3(&A;,81'Y1%G*P4!\D=6IAB[6;%CGQ$J;ETE?'U$E1B7B1IA&*0"
M,.+*\QF@46R=)K[IDQ-(S'"T:Z8ET&:VAUL9D>9]"T[Q6A+T!-M"58*<A_5$
M18TP]6 D(E)H23#=ZT48/6P[V&C,W$K=J>?.Z^/P6SZ\FC\U-C:]NC)$IK&Y
M&[MK,\D)U30[KVUG<UBU&V.J9648F4& "4>6: 0!"T+6]AHUXD$CG4_.DI1&
M.#;=%<)TVK4FE))A/,O8F$QSM2OI 9%Y5"68AX7(CG=];W@O0 D)PF#/+-*-
M*T,HXH8PT:.:=]'UE7%X4;SY*E;RDL'HA!9BZMMD,RE3'50JH:65[DS>\OY>
M_9&1R4MKX ;>4=X;7;). 7OS@T$0:/37R()6?;//UJHY6\L,K]RQ.&32W8"^
MS:;B;(7$BG^F)G%H))QI760.B(2UF=7R7)-M"\LL2-P3[V8$P/G)T:*XM%Q$
M7A2JH4# FM^KE K3 (RL0D6!$S16,6$P!0C('HMV%N7@"::$.]M_M&M"%K7\
M.]8)HSH$="T"I6M[8FO&GU#D[R<^$M3>19D+-6N<S2EMQJF(MZ0M[$>MDZ<I
MW2",0%A$K %43O9>M& \P:,Q%J='U93,_I.M9VZ.2&3W]*G&(P,")G6N+<2X
M-R9'XK90Y)0"31EE7OSRU,B56IV$I0^/;>B#_&J@8"3:U^!QS_J/G>L#75+-
MKFKAF=&"45]#I"QCF#"?((X_VC*V.%P=+(F).O-=&$EZ?I$E $]642062,1P
MQA) ,>@2;\"^\$& , 8 P!@# (S-/\SI9_HR_?R6JP%XG'!?\R(=_HK'OY(1
MX!*L 8 P!@&!E/\ FQ(__ 7?^3U&"KQ,97?^S^"_Z'1G^1$."$QP!@# & ,
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M7/JL] R(E:U,F5O"Y,WK'=2B:DYQ@#G!6G:FY0J&63H8P)R##-ZT  MZ R&
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MC8D(#5+:,8TY";:48QB33\#T%P9& , 8 P!@# & , 8 P!@# & , 8 P!@#
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M]!V_## Z#WU;?V?0?[T';\,,#H/?5M_9]!_O0=OPPP.@]]6W]GT'^]!V_##
MZ#WU;?V?0?[T';\,,#H/?5M_9]!_O0=OPPP.@]]6W]GT'^]!V_## Z#WU;?V
M?0?[T';\,,#H/?5M_9]!_O0=OPPP.@]]6W]GT'^]!V_## Z#WU;?V?0?[T';
M\,,#H/?5M_9]!_O0=OPPP.@]]6W]GT'^]!V_## Z#WU;?V?0?[T';\,,#H/?
M5M_9]!_O0=OPPP.@]]6W]GT'^]!V_## Z#WU;?V?0?[T';\,,#H/?5M_9]!_
MO0=OPPP.@]]6W]GT'^]!V_## Z#WU;?V?0?[T';\,,#H/?5M_9]!_O0=OPPP
M.@]]6W]GT'^]!V_## Z#WU;?V?0?[T';\,,#H/?5M_9]!_O0=OPPP.@]]6W]
MGT'^]!V_## Z#WU;?V?0?[T';\,,#H/?5M_9]!_O0=OPPP.@]]6W]GT'^]!V
M_## Z#WU;?V?0?[T';\,,#H/?5M_9]!_O0=OPPP.@]]6W]GT'^]!V_## Z#W
MU;?V?0?[T';\,,#H/?5M_9]!_O0=OPPP.@]]6W]GT'^]!V_## Z#WU;?V?0?
M[T';\,,#H/?5M_9]!_O0=OPPP.@]]6W]GT'^]!V_## Z#WU;?V?0?[T';\,,
M#H/?5M_9]!_O0=OPPP.@]]6W]GT'^]!V_## Z#WU;?V?0?[T';\,,#H/?5M_
M9]!_O0=OPPP.@]]6W]GT'^]!V_## Z#WU;?V?0?[T';\,,#H/?5M_9]!_O0=
MOPPP.@]]6W]GT'^]!V_## Z#WU;?V?0?[T';\,,#H/?5M_9]!_O0=OPPP.@]
M]6W]GT'^]!V_## Z#WU;?V?0?[T';\,,#H/?5M_9]!_O0=OPPP.@]]6W]GT'
M^]!V_## Z#WU;?V?0?[T';\,,#H8M]4V\[LCPTEP*"DC<VIP;@'#L]XV H:U
M(<F"8/0:OV+80;-\=ZU]/AK!>A8\<;3F:/,+0H&6:>U,S6VGFD^;T3#D*$A*
M8,KSA /TQC*WL/CK6_#^'6"&9P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M:>MY_.[MJ([+5"4/*F4-:D)P%Z-4J0[UX@XI+4[/0O?DUHJW+,B:B!Q-=7,
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MWQE0RRLF2 5FKK*R(^IDB6<654<45MB3H)=+%-<R::[99NY%HF](QI0[=BB
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M)2MQBS@ML109 4J2M*V;W\GQ(>!^]3Q"'O: 00;!Q7AU_9%T]L]JV/0%X0*
M0%7&3D^DM(/LGBTBBS7M5*62UKX*JEX]QR5VM.+2!R/C\?3JUFR(O&9&<S'
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M/_R2DP9?B2G!!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M);^:OI;_ "^D_P $<%U^2'[/DM_-5TM_E])_@C@:_)#]GR6_FKZ6_P OI/\
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MPTQVR]B\F@ZT&K(RZ<W4>\.4C>%]>-(W64JA+W1Q3J79 M3N1KRAD:MUCRE
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M3;T+8RO8Q;-\VOTP>'TAT+HP08 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M?Z \T?>Y:7X)8'0>]NQ?Z \T?>Y:7X)8'0>]NQ?Z \T?>Y:7X)8'0>]NQ?Z
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M-4U@BSG%L-@M%1=NMV+QWGZ:5O(38:I1V!(YK7BS:]<B-D,K3*M+5Y^@( -
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MDZAU+R@K52LC36 YA362CD+>J0@<'$UM7-@PJ0E*C3C%0S+3IH;^8,C & ,
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M::S@-.)&[%KDRDU*-M <F,!L_0ME:$6+7F\0[\ )%@# & , 8!Q'&Z()-.$
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M"DB"/M!"I!(I(8!!KSKEQP;EI^WB>YV#C& , 8 P!O\ ^3^'_!X_1_U^&_#
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MT;*S=(NXODPDX(+8;LSW=9*2-R='656S:9+%)M$5$@E00-S0J-T5+6T!@2R
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M2+>QEK1Z%Z8(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP"D#.9^=#G)@>#:)J$UTBLH?9M&7 RNHF-4P3"3O89/(I,T'":=C0/CY)RP.
M:I25L)ISD6!4+>U  F:%U?Q)C,*JK&PG%C=YY7D)FCK&27-/'7*51=E?US&G
M>C&TYX3-2IT1*CD"9T/9D9B@LL00'&(R!#UL1)>PB:M$57\X\^NLL?9XZ4?4
MKG-I.4X$2*6.->Q1=(7HIWCBN'O ')W5-1JY7IZB2\YK6^<>]K&X>TQWG)\
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M,S0O,E1N*D@K8"CC "%;;\3G?N?J*E$;%#I%3=8/45$S1*.ZCSC!8TI:"V&
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M?B3[ & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & >5<([9[1N,5@/M(<%P&8US#[GNJG&B5RGLUI@KU(U
MM)6C*ZI?'L^(ZH22C84[F]Q)0<00-:H'H@8-[%OQ\<&W&*Z-O7\/]R<?7_\
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M ,RO^[GJ#]_EJ_LSX&D/B_X?[CZ__F5_W<]0?O\ +5_9GP-(?%_P_P!Q]?\
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MM5(.5[AZ3;I? 7*,+QM$T>PIJG5I%R1,-0F+,2'%)CU/KIU.J79_'_<F;/\
M,T!.6-6SUYS[83U<9Z62.S-!!O443,BB)QVOTT]<):3/'1P:(NZG,^G)&TK&
ME,:)84^* D;%I&+3C@FSY]#=GFJRYA;=,UK/YG&2V)REM951+]N2-0ATSR99
M-:RB<O?W!D:"7)R=&!L;)&]JVX"9>/2CQ1[,#LPH99@QEI)Z(OK!!@# & ,
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MCCRW-1IH5"I/Z !F%B+Q-$8KW!T:@3G-\EK,ES4Z+:#"%LD@T[B4@9XZ]Q)
M[*;"F30PMKVR"CM6[ 6NE0&\\)J@E]2 0@($7HL\:VHX">V.FVZ5: OK$M<U
MIWJP"F>/*(=8"-5<+ :[07X-=JX=R8:0-@TW$N#Z4F3OI2=<I1,2Q4L( $]"
M;H-J),N[*Z;;9Y"F%92A#RC3.>DUH$P5FG"A-$DA[&?[O4OJF0QHM6H(ESGM
M,K8--.SC2TBL W()))*DP ;4?F)=T=#O2"OY&^T*SL49?YC7L1D(203%VD8C
M)K(IPA7+HVWHD8VE07%T,5)3+"/;E2T"LTPT) P ]GP-J+GZ?O><0F0\^2&L
MW][<X/+31O#E'8;$#I(\V0WJW>#&-9#$H40"6H7DDN,.3B>>S)G*,OAR4W;D
MB5*]-I[>>(DNNI2"/MR^Y57WOC]G%4N5E%JY8G5H6V2#8G9GB5BMT:T@ 4JC
MLG"F>G5>\,ZDDHHQ2?[L$M6$#*-2?Q0NU:^)B)SWO=<!?W%D<*;@I\T:2I*T
M.Z!&EL;;T_MD#E[>VJ9W$P*(\E0N4)>BW\Q*UMBIR3N.W0(Q $<!0G+/%VKX
MFR5[]06G +?@E65S6!4HW-HJS+AO#ZU3 A!'7F3NKRWMJ]V4M*$\T3$P!8Q>
M\R"T^SBAJR=''HQ#3@5#*2:U*_K_ *?OJQ6'H1[<(D1!G* \]K9/%H8DBDM7
M/K+9*,F=A3J'91(HX@1R#4J*8T#JSMR':@6FI80!2#UQ[V,&DM#%V;WE,V #
MLNK*!HK CP(HT*HZ[:C]A>V.+DIVP%GS!R+]R,S$C@:Q_<5D<) 8N2K2WQO&
M(?\ $C"#!5'XD]CW3%ZRVE+<EQ]0+8[.019A6TU'V!L>G%X4OEC2:7U[#F9]
M135OC38>^L4B8$KDY"&8E;26YP*VH&046-0,-%KH46F[SZ!CR,IDDE#NKA)(
MJDK%FF0#F![ _JY)M8IC%G^DWQ_VF-;>GB6-Q@(XB0JSD#@E'[0VJW<T V\L
M-J^)(2NY+H6I"SE%3$-X4JEB6>DS1ZUW-WFB=6[L2B6L,,2:KIX 4XTPG4'L
MTOVN*)]J7#UMN&0?L!&!M1#F#NOHMU$0_N=<L3$Q+4!*<LQ;%9_J-1L!$OG$
M>6V-+%[.TRER<X>[)V-O A3-2C9A"E6$9AYZ<S0RQ=J+=B?8U\.-C55&)A0H
M(JP6=*2T@Q@339;(XFS+W^:Q1&SO:=6R-;>;(FI9#=NCHJ3".)1MBPD8DNDP
M5#B0)M6GB?)OV5=[1==DUO"Z.#*([7JDA>)Z4MLV1K7AH9VU:LD; UC2M:U&
MHE4@-*3Z93C@I$6RU 3/!63L!HPVK374[[1T'<LLH:<6&\*PP<1-Z0N+.$DB
M$*>EBNK*F<FJKS9TZH6><Q50:^O\$<7MW0N3BJ;5[:B6D*E B1)48DX T2>G
MR*_7=G]"PXV,H&VGW2XXVZ;DJ./3-=%I)74UG:&)06#/@7QSAQK000R/,E5R
M]2XD)6]"> YJ9E @)TXSMEH@VI_)DXYTZ#Z#LN=R!DE1#*?'#(1<#U%GILA4
MF9FR3OS!.F!!"5<,6R!H9]EQ?46>M;]%QVJ6KA" H";LH(\!I+J5LA[!Z,5,
M"Y_C<+4S:/I81$@/+BIA,JCD@;9^3':LC=@,<8;PP]2E5/L?L*QSEJX"].:D
M2E,ZI&6 0BSO9PT1(A=K]$''R(]LHAD5M482N"ET$I*LY$J1NRX9S<VP!8>*
M&"2AE5>N82CI2K)"<WC2' ]CWK],PL-J+!8>E;9DE&6S::",N)[Y 8W5=HD1
M1MC!QSRK:ML3'+++K%I9/*YK7!V>6%D7F-9A9BM0(I_2#3G'@TG-&)IUT*1(
MLSMMVCLC97^5RV'RB&MLCCBF11&IHB:.2R^"3*B&];)6M-*85*F8^/2]BM=R
M]G+((\FQ,QIA ]:(/P72.IL16=G])JIY+8U.V ((9'H;T@?$9>6 "U^F[I7U
MXG0V"N<B9$D B[1%G4V&D!&G2HU*Y.]%&;6  4'6@X)HC1YDZI[(5/%.H[)>
M'RMXZ<R5=$;%?QP-K@Y;W8S%&;-U9\G3O<AI:W$*%EG<D;6PQ W$-B4 2DV@
M)UB;1^]F$:TCY&#DW5_="1H92EJQYB1;5\3,<CE:RLTL51OKZX2!WF4"="'E
MRJ2UT#4U$5O(8NT*"R6)3[:[B7$:,3J0^N0&V)8R?H/K^7)9@BBKI.EUDE6,
MX)2*L;4=;0N2,4):Z^LB3IR"6R<\W2EOA:UR>6)I3A,=GZ5A<3E&DI1J$9X3
M0!I%?@3"&]']6N-H-,?8C"[;.=E\+-6L:J,.M305F95E>GN"T#^N?:7/GE9K
MW]W\7%N.4*)8C?DY>P$C9#"3T0Q&HZ$@H"RNWK5L*%#>S%[)$V9BJ5\L0M^C
MT4BL94II''W%9.VOW8OK\R>2"3#6)@ ;!M+HT(VM1^DO+.+&$C8-12,N??75
M+9T ICQS"[.U0N]R0>LDBQ#7"G:V'%+KBM4M3(W!U*0;+<(-(JSB938J7BUO
M;4Y>[5&C= <#!A#2.GS,!8/2?7C7;<N30ZMY6KK]+9:QVK]N5P)I6%V)5=,P
MBQVB](DPO38XK'MJE<FF;*VN454O25M]X*#2$R72I"<,W 26GS)):O1W1L=A
M7/$@AL/FKR6LHI)85^/""NFXW;4^V!"TL9KP"EC=CD,@;US;9BX]V<&UI;7!
M6E2-FREA"=,;LS 26KU*Y%*_F,-I+J>>Z.N@QJGPV=L#PGJ5[,"2J;9?[9'9
M:7%:99136PU3E&1B8T48]SI&LM0AT[;<-B-T<+I$Z3-<O6#&<KBDMD4NADP;
M)1I!7L4!6T/FF[6E[U(XL)YB<OF\6J2&PU4TDQ1ZW)4;@QH8^80D?!"<5"@]
MB="\#2/EX&9'T)TU]958));(G>"1=R!.H6X-(HNSQP,MLBGG2KH7(W$I0\4U
M9"QZ9; G3O(MLR!&MC6ES0D)5)G )8O/J$27[S9CB&SK(LV&O3E.)3()^WDM
ME;K$$VD\#05\Z#F#Y!F]QLV$E-K5%X8VNK7!I/O11*PMO", U)B,XX\Y&8/5
M)):%G]C_ /")U3_5PO'_ '8RC!%XK\3@XO\ ^#OD_P#JTT3_ +KHM@2_J?XF
MRV"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MN7^!Z,X,C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# /.;Y8'^P.V?Z\WS!?_6;=F#4_ZOW+_ ]&<&1@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#7#L?_A$ZI_J
MX7C_ +L91@J\5^)P<7_\'?)_]6FB?]UT6P)?U/\ $V6P08 P!@# /-&&?,<:
M)DON!235Z9MAU3MMPJGA\6V_7^Y1#5U.NKDTK$-^5@6/<WHE/-MM"A2Q*5:=
MS+.2!+$JTC,/(*-&]C+]>^YN48T[S!C?KD9&E;!4LG62$Y:SRLEITGA$NC,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8!YS?+ _V!VS_ %YOF"_^LV[,&I_U?N7^!Z,X,C & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&N'8_
M_")U3_5PO'_=C*,%7BOQ.#B__@[Y/_JTT3_NNBV!+^I_B;+8(, 8 P!@'F;)
M_ENH)\]/:ZQ;_L6;HBH'<=?5XO>8O7F[,B+#=,;>(F\M\GN N/:G%ILD58GL
MTIF;W@X28)A*52X:<%B-,I+&MVG@BJ&7@FVI1;SBTSB0G0[G2#K+L<*V9&F4
MQB6+S'.VNG*BZ-1GL?\ Y;QV0H&\A?62DIP)?5S@:@]Z^QH!JBB0K]C6Y)=/
M$L*[/E>0RZ5\P&X7)/FECGC]9,C?HV8RQ*1-+6\V))6*3F/\*1/C<>V1N7-I
MS"6@][FI5RT;4+T"A)C0A4:$4]#,3#Y<9$H=)>H2=!V%'6:>O5E[EC,@BL!5
MC70BQ;\6]+"A*)S<652H;?<EGO[R MR"$2L]D=-I#/XY.G6 #=\C\67\L>L;
M#C\&:=S)P2N4-2="1T;Q(H-7U@DN,+Z5L[ZU)TUDQV8L3A'FR1,K^0G RNND
MYVDY!8P+$RX!H@:#>S:-<HNNL1@CD%KM-<,7\/795BZ:Q"L]0EI()3MC7 T3
M6FC"C;PA:4B#1X%YN]'&;4[+%]!8<&>C\3H_6;TU^5MH^_V,_JA@:+XCZS>F
MORML_P!_L9_5# T7Q'UF]-?E;:/O]C/ZH8&B^(^LWIK\K;/]_L9_5# T7Q'U
MG=-?E;:/O]C'ZH8&B^(^LWIK\K;/]_L9_5#!=(_$?6=TU^5MH^_V,_JA@FB^
M(^LWIK\K;/\ ?[&?U0P72/Q'UG=-?E;:/O\ 8Q^J&":+XCZS>FORML_W^QG]
M4,#2/Q'UF]-?E;:/O]C/ZH8&B^(^L[IK\K;1]_L8_5# T7Q'UF]-?E;9_O\
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M^(^LWIK\K;1]_L9_5# T7Q'UF]-?E;9_O]C/ZH8&B^(^L[IK\K;1]_L8_5#
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M5I')"6FBHXW@I%1#NTH73<.5$O*YF4)F]A?*5EZAP=WB2)Y 6B"W>^TK>>D
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MT:BB![DW3LZFT&N>L5#RF:@OD?8:M9V%N<R#?6 ZLRU48>[*3F\PI*4#4?\
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MXL_QMUA=JR9)*S;4J]1I74E7LI:"'&MS;HIJ$:^/[*8>86YN"G1Z0>Z9DDO
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M9@U/^K]R_P #T9P9& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MOY:F/LZS8(Y-U<3^+) X0=G+AK/8 8J3#9#*&YXL=F(6MZ16->@TN"-60G"
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M'_=C*,%7BOQ.#B__ (.^3_ZM-$_[KHM@2_J?XFRV"# & , 8 P!@# & , 8
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M _V!VS_7F^8+_P"LV[,&I_U?N7^!Z,X,C & , 8 P!@# & , 8 P!@# & ,
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M0=#C,E@# & , \YOE@?[ [9_KS?,%_\ 6;=F#4_ZOW+_  /1G!D8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , UP[
M'_X1.J?ZN%X_[L91@J\5^)P<7_\ !WR?_5IHG_==%L"7]3_$V6P08 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%;6-3=27 0S);7K*!V2
MFCJ\QS84\ZB;'*26=><6$A0H;BWI$M"E$K(#HL_0-:">7KR&:$'Z,%3:\"R
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M_7F^8+_ZS;LP:G_5^Y?X'HS@R, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@'G-\L#_8';/]>;Y@O_K-NS!J?]7[E_@>C.#(P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!KA
MV/\ \(G5/]7"\?\ =C*,%7BOQ.#B_P#X.^3_ .K31/\ NNBV!+^I_B;+8(,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8!YS?+ _V!VS_7F^8+_ZS;LP:G_5^Y?X
M'HS@R, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M:H2-P!F[++ #9F]^4.M>&L&6]7J3O!!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!O>M:\=_1K7T[WO^#6L#QZ
M(TO<N;$EA_XX]N4.F<(D'2JKH$*$WVIT:'J'N=)K( SM>AD^=$XJ-/"LA>$6
MA#1F)0:\-B%O6L^EAS4L/Z*XV594,%8^O1-35RLD_BEM3C\4S^A</W>O]*?]
M?CJ>0X_U'B^CX\)O6VNVG*KY>&;;9H])PCVHSI:T5L;'U26K(!1_,%@4[:L9
MG5@6L@D)861OC7O!3)E9#I(7 VMH9$$\(VV.,;3KGAG;WF+*W-$)2^J]C,$
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M&QQZ\C%HJE?QED,7%HG/ G;F-61RYX]OW"A'CM(9$IM79"E;.833D.62*D*
MKA"ZPL,KJ&JIE6ZI_4CD*5.WJ)A1CW5PY!#7$A,L?DY[6]JTJ@O1HR3S$H!"
MV>$\ ?/U\;U#CT\IEYLXV_;Y&1"Q1^EZ[+U;MFM5'K%-/35:^6AX'I[WXX/B
M?<?U1ZMR:.1?"<]S>)GQHBJ)2G'%YBGD51EURE"F2LIC9"3BIPC8TE6ZY/;
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M'["KZO4K05#B(8C7.Z5CG)2^%S]KE$L!"DRME=#'8MQAR8A  EN6,FR!B\'
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M=L:,3,EC8U$,F7'\C=C.6OW"Y+,BIU9"C9=A\55I&R%L5.+@I;KM*F6,;;)
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M;@(7T%G&\']W9?7VK()7?2K*XPK7]_9+33^YJU",='JM%U>Z!^XYWH#V=_\
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MMUXKL>RJ*BD3;86GC\^:H>\3XQ7*0N[DWJ)]3EC6$VQ%H]@;RTOOUC6PC05
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M2AV(QX*TF7&&G'B*+T)KUO8];U] M_1F4WKI\C>U:Z?,DC[*'1L&WFDIDQ:
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MZ-;%]&/$OU(RQLM9]&.3H-H<Q@8B'=$-RTG1^4P"1>4D6(T@/;]*1Z5KD@=
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MFE"GU2M[ I:4IH20$G&;%X:T68X;WH/T>'F%O-:Z#J1<+K$'0MD8SVA6E:E
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M*6=?(E",1S<J2C1*SS$NQF*VLE6>F"/0-[V(3<,1PS@"UX:$4/S_ .'(R=?
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M\5H82RPF#]0P( Z&9Y= ]0>@ZT(?D#O80>87T^&M[UK",G[R@8 P!@# & ,
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MYI"]5.;:;$VW+5B>Q)O*$+7:A5L2BC9@62A9:ZJ!WE#A#E:1A<3$#A[M;5I
M$Z<1@RUO+=G>C78W1&A6;;>U)TV]N$6ZNU&^'65EJBKDYQW1W2BVWHG'T^5]
M8?I-GR%D^%HX.O.>/R:XVZSBN2E@X>/.SC7QF/S&*W.[/Y2K'ARM5N;1&ZCO
MWX]DK;5&,L>3R>DNRH;Q'R76%-F2!DMRKXC'&>QHY%9G$VA"Y.#/ %C:G:7J
M5'R.+G:8R97LD8EC6K5!+&$)IS8Y)]#39UZ>3].9/J;D,[DMDL"^R4JY3A.3
M2=B;:BHRZ[=>DHK5=%.#ZGC<-[B_I_\ 4'ZB_7/K+U^L7)]"\SGWVX%^3B9-
MLZX6YL+)6U8RHR%WGC;TJLBJMR3<*\S$M:N*M<&SYB]AS'HE94TAGS %GGEQ
MP\@^6RZ+DP%9'$Z*K#HS$J=C[FD:) US1"O,?]H90I C;!D&ZUM9K8BP(O0A
M/T=AXV''D(4S<JJ9_1"7<4F[=T[I)N+@UV]U2UEJOZ?%R^TQ<S])WI7@/2E'
MKC%XS*>1QG%93CC8N0\V%\I\DLC)Y6^N5M%F)."PN]QU;MR%.+:QVE*61;46
MK?NPIUK,N=.%G2AA(BJE$00W6;6$5(BCJILJQ5#H3?C8M4STVUTI]2KXVWMW
MNU4['[4H5'KJDJHX3GOSK\WTJZ[GBQIKM[B;;KMGN2JKT[#7;[3[JLE+<HK2
M2TC**V'PW-^K?TTSPN8EZ:JX;"Y.6;&;E9Q_(Y+R:X\?@1K?"V0CA+C91Y.&
M???WZ\:';NJ[=-U-<<-41$>+>PH0C%-X6G:&>[E;74J5-(9$_P #>F6.+(7\
MO>8U>;[I1%MRPIC;&/H]Y3I2$[<7HCV303@$C1:-\_KY'J7TYE3^VR7*7%J5
MK<8QL4I*?(0MZO5;G+'3;<GKKJM5+33],YW]0OL'ZCO7ISU#._(]NH7<G*5%
M%.;5=?#+]<8O(KNS<X.ZR[@:IV3G?)S[K=<K(Y+AM_=G\]_,+L.AU%=ORJR)
M8BDD2NQB)B9]G5K'GYID4@55MJOSK:D"F7RTB?UX2THI46!*0ZKEQ1C@G"<6
M'0"34.<#F/2&'RL<RI4USKLIEO[=DHN,5;W.U%0ALLU=75P47M>C\5+'HWW4
M_2MZ5]RX>J^,AQ&#D8>=Q%SR5Q_(7TVT41S_ +U<91'%QGA9SMGQLG9/&IIE
M&BUUS;E9#)V=ZJIGIY^Z9B-JT"DD"+V>HHA D\L9I[$8VQ,LB27FTRUZW9<8
M?3=NTSK_ % 0N 3D: E0<<>> !96S=@/3>)P/)\'5PEF!RS@]<B=FQUSE*47
M0X1[<H](6=S;HY-))/5Z=)?COLG[@^S7&>SV?Z)]T+,6S=SV5FRQK<+*R+KJ
M)</;BU?E^12NUB9OWO8<+;IUPA"$I2FH;J[I!R&OOV;I^C7N4SR52"+Q%[E-
M(\^O#D': ^;-L3?9G("[@5@D$?3)U<D5?&+7%S%AB8Y"8=$33@A- >,0^'U#
M'B<9X=6/37"^R,;LA+KL<HPBZ5MEJHIPG9M34M+4M5HM/*]]\7VO].6^DN.X
M7C,+%YK/Q\?E^;JK^M8EF33B4/BXNB^4HT1^UR.1C5&R-T8\G"MRA*N*CJU%
M:.^8,4164OF2>P)5-JQ.Z(1L/MUWQ1B<GI3.Z(C37"7Z:I/B&=QU WDV@U+D
MI>D:UW]F$J"M*;T24>T9'N7\IZ2UNQL=U0QK_MW+2F3457?-SC![82;=;B^J
MCKIM<Y26Y_M'->Y'Z69V<QP/I^7%X7IWF8\%.[9Q&3=75'#YG(LRZ<278P[Y
MS?'64V-VU8O<[;QYY61=%7V8M-0/S'0Z,EI+U8/U@M]==&P2 N;Y:D-4"CK7
M+I12$KA1,E;C)I)"'%[=6-GE;8WKAN+JH;'<IL,4J"4A0#P<CY;T9TQW&K[1
MW8\[%&J?U.,;HSVO9'11DZI26V*E!V**<FT^[=[G_I*;7!68_%_^K6\MP.9F
MUT\;E1[]F+C\OC9;QYK$QW"FJZWC<B^E48T,C%EF0JJLOG*N6W1]0])2CF.G
M8U,M+I7:D3Z8JRRER>7/D<2/C=7<%O\ 135N0OS^WR"7-;J[1^"-Y)8C@+W1
M8I],.C!JE/G$9\_#D>%Q^;R;\;2O LP;:EMC)IV3QW!N,7&+2E-O_P 8I>2C
M'33\*J]=^T7#>\?/\OP':P?16=Z/Y'CX2Q:;Y4V9V9PD\2R=-,Z,6RNJ_,G.
M2BZ<>JO<W&--.U0UE8ZE^:2XPE[1%3>30:226>Q9G .46+#I<.$P.?5V-FMF
M7-#DC=GXYY<ZPL%I2N3 3L2+2PA4>).@0A-VB(]JW/\ 0L<A/MPLIA5-_17*
M&ZR%FM46G%)*RMN,WI+1I;I3TW/]AY+US^B[$]18^1/CL/DN(P^,R;7]M@96
M,LO-PLY6\9BVUSJI55?(X-ME&;+2[M3KK5N3DN"R+/0?E%RODJ,*8YT8QO!-
MHGH2;(E+T6Y-;M VISL*5S<2:I80O;A>"@FKHTP-I:D6M#*,]O+,":/8Q>'R
M//0XIW*_AY1^QU[<8Z-3:KA#6V:?_P#=E*6G@_I:T6A_+'O=B>V4^9ARWM-D
MX\O1D;'@8U+KLJS;*\'&P]W)YD+%]+Y'(OR)5KI)=F<90BHQUVRSP#\.& ,
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M25\*TG+./]D5-9JEH:S=B'L!83=F^8P/@+8-;\VHUIX=2Z1\&S'U%(&YS<+
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M\B\&:YTOBC>HBRD]O<F8"=KB#D_*?2>R$(S4+9M01M,'97GUI2=\[?5Z8_\
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M\VM-Y]'-B@;(UU*@JZK:U)JV>M=167+V]<TGK)%7I$C,(5+U+PL7F)$8@&;
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@#^' ,$3&F)._*9.G:TB=^6H0MJUS(+]%0L1%G:/+*5
M;+V$"C99H?$(QZV,.OHUOP^C,RW:="Z]-#.9%NUZ^!#C 004,TTLDHLT\01'
MF +  9P@!\@1&C#K0C!!!]&M[\?#7T9L'+@# & >&M3VOW^RM],54P0N<I5
M:67MTA=[7J.3KT26?G5%9<WB\C=)P(8BS"MV.Q,\=6D."QN-)&K$2%&;YBEV
MOU'D,#TE;;DY]MM3C]RG&-5L4W7WJX2BH?\ ^-SL3BI)Z:N2ZQ/](_7'H?\
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P"I;\#H5%74'>O'0JEL<.]?P^.MPYYUO
M7_S\%7B><M:_[.H#_P#7-?\ ,B)_^Y?^X_\ TA0?^Y__ )O_ /0?_>^&8CX>
M9M^/_B>@E ?YC&_[;_\ Z?.?^W__ #[_ .PD_P#9?_R#_P#)O_OO/FD9E^[]
MQ>&4R, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!2%_\ ^8I'^V__ #@;
M?]@'^?7_ +!=_P"W_P#Z?_\ RG_]YZ61FH^/E^\\ZKB_V16I_P#7,?\ 9Q./
?_IC_ /2__-AT_P#?O_S/_P#"?_>>.1^'F:__ $3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g63338g60n53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g60n53.jpg
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M 0$! 0$! 0$! ?_  !$( *@"70,!$0 "$0$#$0'_Q  ?  $  04! 0$! 0
M        !P4&" D*! ,! @O_Q !4$  !! ,  0 & @D0!@D#!0 % @,$!@ !
M!P@)$1(3%!46&"$X45>1EI?1U1<Q.5-55EAT=Y*4MK?3U-8*(B,R4G@D-T%Q
M=9.QL[@E)S0S8F9VE?_$ !T! 0 " 04!               ! @,$!08'" G_
MQ !6$0  !0("! <(#0D( 0,%     0(#! 41!B$2,4%1!Q,487&!P147D:&Q
MT=/P""(R4U165Y.5EK72U",V-T)257*4X18D<W5VDK3QMB4F8C-%1H*B_]H
M# ,!  (1 Q$ /P#OXP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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M !@ P 8 , & $4]NZA$XURVW=&EQ/CU (45L=!4IQN/-.FB,,#7XL^2TAU4
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M18, & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
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M /;1_P 2?YVOSX /;1_Q)_G:_/@ ]M'_ !)_G:_/@ ]M'_$G^=K\^ #VT?\
M$G^=K\^ #VT?\2?YVOSX /;1_P 2?YVOSX /;1_Q)_G:_/@ ]M'_ !)_G:_/
M@!^ZWK?ZV];_ .[?KP _< & # !@ P _/7K[NOPX /7K[NOPZP >O7W=?AU@
M ]>ONZ_#K !Z]?=U^'6 #UZ^[K\.L 'KU]W7X=8 /7K[NOPZP >O7W=?AU@
M]>ONZ_#K !Z]?=U^'6 #UZ^[K\.L 'KU]W7X=8 ?OK]?ZV # !@ P 8 , &
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MU@7&GDI#(^)(FK3J.R_.>8B-NK2J0\RU[;B0"A<VZ?4>J@%GJI,>5N%,>$V
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M2]?5VF,C>WJ[1N$R@R!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
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M=SD996"K-:]B;&")!>R]@3G;FOJOMZ.T3+8P_/",N <MPNESY]?03#C#%CA
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MD.Z>@HD)0M2S)1DE*5&JQ).WR^5%/^D__39__0EOM3/^AR/^B.14*<DMR?\
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M)M@/ZI4'\ '?&X0?CSB_ZR5C\8'U<?'S[QO(OR<U#]$8[TG!7\FV _JE0?P
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M":5A1V-O?!IW,D#(>UR]QMS4,H=C,R&XTJ6R_ GGVBPD>/7(H]>IU5'U:0&
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M_L_.H^\'T^HG[]:E^,8?_&8Y/(]X>^:7]T.41_?V?G4?>#Z?43]^M2_&,/\
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M^1_V \ISU+P>_F?1OX)GVC+'E7A%_/.M?Q0?LR$-1&<S'"0P 8 , & # !@
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M-VK&!X=6>J#K-9Q#1$5A<5ZL1Z'.CQ&JC(AI8;8E+6_"ER8<HF(L6.[(I<B
MY)8CLMR5/)00][O?SLEY$N=3J&7)0K3:+>#+GH%@-$ 9>UF-'9ZV4S[(Z-,-
MLDDMOQTV8:<VXIO6YRIGMN>WJ7.%2IO.)?DX?PQ/EQJW6:_39U4BU2I2Z;/K
M=0[IR5(Y35U1)Z6Y:4.-%5XE1TS07*>/TEDK3HP!!:0IIBLUZ'&?I5+H\Z)
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MD*I_6_B,9#946# #DI]*+]N[U[^)\X_LQIV9D>Y+K\IC"OW1]7D(:_<L*A@
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MGWD>8_B<$_PF.\UP3?)Q@SZO4W\.'?0X1?COB?Z9F^F#ZL'CI]Y'F/XG!/\
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MJ7P_GY2GA)#5.K7-WC!$_P!$M_0R9ABE5$U9Q]889D6>.-CQW[E<3,^2-EV
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M@P 8 , & ')3Z47[=WKW\3YQ_9C3LS(]R77Y3&%?NCZO(0U^Y85# !@ P 8
M, & # !@ P 8 , .E3T+WVN_2_Y:"7]1Z/F)>OJ[3&1O;U=HW"909 P 8 ,
M& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M 8 , & # !@ P 8 , & # !@!_FG>GC_ &6+RW_\3Y'_ & \ISU+P>_F?1OX
M)GVC+'E7A%_/.M?Q0?LR$-1&<S'"0P 8 , & # !@ P 8 , & # #OB_T7+]
MCYZG_P WG0_[(.#9YVX6?SDB_P"31O\ F5 >CN"/\V9?^=2O^%3QTC9U@.T@
MP 8 , & ')3Z47[=WKW\3YQ_9C3LS(]R77Y3&%?NCZO(0U^Y85# !@ P 8 ,
M & # !@ P 8 , .E3T+WVN_2_P"6@E_4>CYB7KZNTQD;V]7:-PF4&0, & #
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M # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
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M$Y>I_P!#\O\ 6K%.S^D&%6Y\#^I1SB?7!F[;&GVB)SWJ#Y$D $='ZC7X_3
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M>,AGK,.'F8CG..@")T4E*M<P87H(@^Y;YU=)B:Y54BK(OOQ9VL<V/1B1-X'
ME62L-<SM0,O7KYC\OBS%O73R9\T:;2+)<$<\$$H==Y%:+PW/,^/72*E$(GP5
M!ZV?L;$\9*[,0(UB'0;96.9 QH0[(A'.RQ+>3^A#\0;'<N80%M6>O=U;?Z';
M:0G/AO;O(&Z=>US2^UFI1 HVF'.C%K1$JMBJ!W5;E=*Z%0.7AC-$.W$R<HUD
MZ'7:R'ZK&59&T.L"466H/5V";&R9@H&7KZ^NVVW.? @, & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !
%@ P _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g63338g70f21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g70f21.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M-:+1] S-W+2'1UU(]!+622IZPCX!8D6?LVBP27-@\^>!*ZYO&I+<(RD16T]
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M?1T.TAK8)I/JK2I$KDF&62:>9F0/4?K)9=)%(WS81&"KBJDZW5?U8K9>%%Y
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M^&F#5KT?K(2+!L, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M.R7]%&_2*._?#3!JUZ/UD)%@V& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M?F9I27]%&_2*._?#3!YM>C]9"18-A@# & , 8 P!@# & , 8 P!@# & , 8
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M=^^&F#5KT?K(2+!L, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# *J/JJ[S>NJGUS3#T(XR7K4.,HOJ+G>"'K<.*X/K[[=U*0N3T0 ,
M 8 P"85Y^O\ !_IA&?OIEGC2.;O_ +%[^!H^BB<ZHVL.>\9.OQE+2[ P!@#
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M@$=DOZ*-^D4=^^&F#5KT?K(2+!L, 8 P!@# & , 8 P!@# & , 8 P!@# &
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MO"I+<(RH16T]C\P(PIPW0DC0.YW548IO'YL2P)H\JI):$P!$M&9,)&203L^
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MB-EG))74KFM4K3\D3,N'/A+'&#08 P!@$=DOZ*-^D4=^^&F#5KT?K(2+!L,
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M&W.H<L8 P!@%J;U*GYR':3ZD8SZ>-,B*V]BN$:^]W=28+3V-8OV>ZWEDO!9
MA8 U0=^TWC^YZF:&J:.3VIP]'W3);1L*KR,Z$7Y4PEG/J,2$S.KVT:=JQ^QO
M@/(_>6TRE7'XY(3[IU7XB?5TP,S.!CX5,ALF!>M.K N'_/7G3(KP^2\,.=7
M1> 2@Y.HF\MKM&JPL62RN.S4O9[G3M+<R9JUG,AB$6A,160M XF2L >.BL6$
M1F/CI&TCX%%82+:.EV PTDEKS)M1%EZL!-%.TW7FPP4X;5#,Z^[62*#*,^)+
M4E#V#4%ESU!?@XP%JZ.X^\G8L0,6#.7'O@^XD1</LV18.>&W*Y+1JR<!)>I,
MZSD9'!2>AL.*,:,B8W0J.9D=1QIBL+,,.'C=-QPR*C7''"[ BU]L]H>-%?\
M>W<:*);<\\Z^OR,'T\ 8 P".R7]%&_2*._?#3!JUZ/UD)%@V& , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , Y"MK?M1LGZ?3'TB(Y="B<UHVKN>[9*44SGE
M+UE_WK1 <^@^88 P!@%V_P!2G?L([9_6W O0XAD#VW\80;4Z3WS!/MIW%T9U
MVC=PT6N<A\F,8 P"JCZJN\WKJI]<TP]".,EZU#C*+ZBYW@AZW#BN#Z^^W=2D
M+D]$ # & , F%>?K_!_IA&?OIEGC2.;O_L7OX&CZ*)SJC:PY[QDZ_&4M+L#
M& , Y-/<OSO^UG\25Y_W/E&7$@>)8/V7#]T<E,XYCJ,=J1#>WQC;G4.6, 8
MP"U-ZE3\Y#M)]2,9]/&F1%;>Q7"-?>[NI,%I[&L7[/=;RR7@L@0L :I/$ ;7
MN9M.KQ-,65=T?6"5A+[(?0R@99& <X?"X/<=#K6%(>8;,!Q$1;.[RJ2,SKZ'
M M1DLVC%ES*&.'D->-)1[^ 1LDI+-,WW+^:(2VAJZL&3^&I.*S34ET8L"<0O
MMY'HQ(;BA(BBY8]=3JP[G2@EF3B 0^ 0!I5.\T8&@5B/(XUK\.:B+ [JT+CG
M<@9/W#L)I=3R32I/NT]>7"802N2/3-(4<S@'A]E =HUV[J]QUG["]6Y7UMNF
MN1F\ E\7$2OF*S&M)Z!N%*O2<=9GHQ8(E6I>(D:BY,O'I3JL@NY0T&<JS:PS
MGD5<.=):<Y8-P:&-[OMYUJ'R^>00C<$2'26M ;F13!H0<.F+-D-8'^8H7X&F
M735(-)" &5\MXM(@\:?ER\?D[X;'3#%D:(LV*PS)3];3MAUO?*01%M<D(W7L
MHDZ#0YMN4]I=$##*6)P!R(?-ETDUX\43L!5*O_>Z2)B'F\]52A*:.\H5T%;#
M!,J[NZI+:(RH16M@1J9DH2Z0:R=F"(:.UAGNI\:%LWO/''&O#P._*QN2B1YT
M?RZ"ORL;D(QF_7? BK=H!,9+^BC?I%'?OAI@U:]'ZR$BP;# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & <A6UOVHV3]/ICZ1$<NA1.:T;5W/=LE**9SREZ
MR_[UH@.?0?,, 8 P"[?ZE._81VS^MN!>AQ#('MOXP@VITGOF"?;3N+HSKM&[
MAHM<Y#Y,8P!@%5'U5=YO753ZYIAZ$<9+UJ'&47U%SO!#UN'%<'U]]NZE(7)Z
M( & , 8!,*\_7^#_ $PC/WTRSQI'-W_V+W\#1]%$YU1M8<]XR=?C*6EV!@#
M& <FGN7YW_:S^)*\_P"Y\HRXD#Q+!^RX?NCDIG',=1CM2(;V^,;<ZARQ@# &
M 6IO4J?G(=I/J1C/IXTR(K;V*X1K[W=U)@M/8UB_9[K>62\%D"%@#3WXBJ$=
MF787K)5SH_0-9SDG ;JF=<VC;=TW13$W>$H^8JX.;K"HI-0MN4_-@)B0CI&B
M=/'5RTH;<"P.J#*#2)- SN.&R5(JRG*6:67#-%]56<]T@?,:[">'#8$:+S&7
MQ8!,*C[+TW,9^?GQ*Z3L9< B=H5'/)8"LUPU'&+3BX,L&.%JWFKAB/*3*$-(
MR979LWA#=!,8P*GJ7KP*:G 0 7V5VEUKP&.]2+I[+H,>N'7[J*-Z<797%C!^
MFH.FSTEF\I["$"4J:U-+Z7C\AFDK*.)Y!HK%9!,B,1C40K,RTEC8F\0U&RU2
M2M,*JK2*EU/)Z2=2U5K7+"6<\&AIZD74CMZ,O*\)_42=$1<'+V>I0$/.6!.C
M$"F4L>7X>L<+,E*JF=9VK'J/MZN0A5S,_AO"&\IALPO9)M8I6 /N)U*Q$*&T
MTE7/RDI3PJFBJJJ9]%IT>NE'@RV8C:L MKL"U  O<H4NF?65, 9"INRMDW\7
MM&(R1[14%1L*<6QS;<J9D@I -4<9K0R%AWP2Y+Q42VC; )IURP9)U(E==4I>
MO0>]]1.LUH4F4C?E%>P/<54O6RK>K-=N82<D)DG/(Q61<\YTLJPFQN)1=M%I
M,=&J1SC6&AWDU8@RRDO=:30L@8:)-255!5GZUGPXY3->2_HHWZ11W[X:8/-K
MT?K(2+!L, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!R%;6_:C9/T^F/I$
M1RZ%$YK1M7<]VR4HIG/*7K+_ +UH@.?0?,, 8 P"[?ZE._81VS^MN!>AQ#('
MMOXP@VITGOF"?;3N+HSKM&[AHM<Y#Y,8P!@%5'U5=YO753ZYIAZ$<9+UJ'&4
M7U%SO!#UN'%<'U]]NZE(7)Z( & , 8!,*\_7^#_3",_?3+/&D<W?_8O?P-'T
M43G5&UASWC)U^,I:78& , 8!R:>Y?G?]K/XDKS_N?*,N) \2P?LN'[HY*9QS
M'48[4B&]OC&W.H<L8 P!@%J;U*GYR':3ZD8SZ>-,B*V]BN$:^]W=28+3V-8O
MV>ZWEDO!9 A8 U>>(1#G4MDE8(6B0[ -NJG$3L%O..>N56,KD/#+;6)PO>OC
M-CUXTJFYYI)*^3C*4[:MM 4"-PX>=4U4L\>Y%NP+D<-F=$IU2G557.N:(F2O
M#F/M](JXC%,=5#-KQ&BXU44]-1ZQ'KT&G6Q_K^-GP.MY983*HK!F5&Q.+/%*
MDD5JP5K';!FD8B]5)RN.$)@^!<0Q9^'91IN"UK*?Y[<LL\Y&-=TK7KV?B$0-
M /#WAZ]TE)! 9)1_<RF>P?76SJUJU^PDX<AY3&UN%7]1WRYB3$"W)\D@<0J4
M[I84?6?P,J-5&2)ZU4&4DD_I55_15%FOJ2:(O6M2F[S!H, 8 P".R7]%&_2*
M._?#3!JUZ/UD)%@V& , 8 P!@# & , 8 P!@# & , 8 P!@# & , Y"MK?M1
MLGZ?3'TB(Y="B<UHVKN>[9*44SGE+UE_WK1 <^@^88 P!@%V_P!2G?L([9_6
MW O0XAD#VW\80;4Z3WS!/MIW%T9UVC=PT6N<A\F,8 P"JCZJN\WKJI]<TP]"
M.,EZU#C*+ZBYW@AZW#BN#Z^^W=2D+D]$ # & , F%>?K_!_IA&?OIEGC2.;O
M_L7OX&CZ*)SJC:PY[QDZ_&4M+L# & , Y-/<OSO^UG\25Y_W/E&7$@>)8/V7
M#]T<E,XYCJ,=J1#>WQC;G4.6, 8 P"U-ZE3\Y#M)]2,9]/&F1%;>Q7"-?>[N
MI,%I[&L7[/=;RR7@L@0L :4_%#8U@)NOKE8%A5M1-]<B:ZND$A3EN*W1M*1P
MY^?J@D^N*K7]/T/?:M<D(:J,; 9-8LF$0H%PQE8P$[GH/W2DKP-F<M:I@6K*
MM=2UI/1ARR2M393U4<QY[UYJLC$@*T9BQ6.[%XZ'4MO:]D$@A<D_)#'8JV=Y
M)+?AG'RK-TB6C3[0ZY29Q]\,$H-1*(_00P&%PKX2V$!EG1'K9*I:7G+*/V-6
M$GDA!<O+7_7SL!V!ZTMYH6=[^V/B\V$=?K/K4-+S1!3_ 'OSLB'DC3O;CC98
MAMMQQS@37\JT1?9-%EZC)B$PN-UW%A$,B+%8='@:*R(]LZ)EC;SUW+I=\[<O
MS1Y\3-ER#Y\Z<OB!0N1?$B#UPN[>NEW"RBFPP2G & , CLE_11OTBCOWPTP:
MM>C]9"18-A@# & , 8 P!@# & , 8 P!@# & , 8 P!@# .0K:W[4;)^GTQ]
M(B.70HG-:-J[GNV2E%,YY2]9?]ZT0'/H/F& , 8!=O\ 4IW[".V?UMP+T.(9
M ]M_&$&U.D]\P3[:=Q=&==HW<-%KG(?)C& , JH^JKO-ZZJ?7-,/0CC)>M0X
MRB^HN=X(>MPXK@^OOMW4I"Y/1  P!@# )A7GZ_P?Z81G[Z99XTCF[_[%[^!H
M^BB<ZHVL.>\9.OQE+2[ P!@# .33W+\[_M9_$E>?]SY1EQ('B6#]EP_=')3.
M.8ZC':D0WM\8VYU#EC & , M3>I4_.0[2?4C&?3QID16WL5PC7WN[J3!:>QK
M%^SW6\LEX+($+ &IWM/)+F@ES-+0/(%J #Q ;(HE ^VL!A__ %)TXK6$P<1@
MR:A?;VC?_HVR:\2$RB,#S0.TH+(',&C31B])RNTH*'D$AB9(;)*6?1@7_P#*
MUIUS3-)%,VNJ5?@JTH>&Q^.V4-N(<7?SJQU;/!H@VD;FIFX;"E=MR0U$1\:>
MDP(F%K2*;%4X8$$E"S,)%DA E(L3X9>[W PJS7!+)+JJ,B,&!@'AHKLO0QNQ
MY?4HZTHHM/X&$>R*4@U7VS/0<&$E%0<@>)&'B3<&3XB9I+WHF:(DD^<0THLT
M'RA(2\>-451F2X95#?LQU_TXJK;:X(%PG>(B/2"I5OA"RY0G8*7*AVT2,@E^
M%.45A4J?R*/B8R_640:GS9P.#$JO"Y-DR7"2UU8,.@D4!NJI;3+RT#75AQ69
MF8(\T82T;'RS8@Z"+*$309)5RFEMSRHQ5-1J2@T2;;V\:J<C4C#)N]B8$LU9
MC!+I+^BC?I%'?OAI@U:]'ZR$BP;# & , 8 P!@# & , 8 P!@&"TF\0NAXW?
M$WZ\(A;FETYKYL4:2)] *<G,VBVD]%U:VNGBI&)V/BWJ+^RR=9OAL@#!$4_<
M)-Z5$Q-L6VF1-E'UAM<K*>!-*Z93]2X3S9IXK_65XUD*2<2[+)S"/60G4N]6
M..MMJ(6J7GB-=/[=/!04&4!\%B"D.K)AQ,YBISJAI'Q12.)/.>"4ICC H%RN
M=,$YS26&7W^<)L8C9\=+(Z E(?A_P)DH44?%\%1)0"3X'&6*!%EP1!G&8\T%
M?^YG*7NP288,2@YQ[8S(,VSM%9'0:GVL 8 P!@# .0K:W[4;)^GTQ](B.70H
MG-:-J[GNV2E%,YY2]9?]ZT0'/H/F& , 8!=O]2G?L([9_6W O0XAD#VW\80;
M4Z3WS!/MIW%T9UVC=PT6N<A\F,8 P"JCZJN\WKJI]<TP]".,EZU#C*+ZBYW@
MAZW#BN#Z^^W=2D+D]$ # & , F%>?K_!_IA&?OIEGC2.;O\ [%[^!H^BB<ZH
MVL.>\9.OQE+2[ P!@# .33W+\[_M9_$E>?\ <^49<2!XE@_9</W1R4SCF.HQ
MVI$-[?&-N=0Y8P!@# +4WJ5/SD.TGU(QGT\:9$5M[%<(U][NZDP6GL:Q?L]U
MO+)>"R!"P!AI.NA]"VC.9%/K,(WY.7LB?ZOMXF8[4=E6=5!M=6Z#?EA'J>CU
MJA:N%#M]6^BBK9.);^W+[K+*J;[KJ\[C,UJP5:$G[93,C:NJRNJ4@<>J^IH:
M KZO8FW=MHY$(PP2&A Z+\B\+O\ AFT2_P!NF[XJ0?DGJVW.RSI^\<NW"BBZ
MZF^P*JJLU6:D^P8& :SZPZK7!'NWUK6!(1M<".OLYC\P3D$5"3.7S.-VH4EE
MDV!+ KEW2]A 2P6I)4*82;@C9Y6 S1.'V+-24@F.D35(V*?8P(964M/5@]>7
M1/ GJ//0O12[(Q7-/5B-+561&[]4NC?6FY#[F1RL:]@ZO3V=')H^EU0"48$_
M2FJLY1FLE%CD)*4K16-D8]"SZVQ;3=^)'C-TDU7!6TJ)5Z7AZSW;J9UGM.FI
M!&5+#=0'D'3_ %ZC'6FNGL+/R$V:L2.QN5/B_%BV,R-0^+-8I)'HD?&./@N(
M)3AJT/DYP[XE;IJ\8^W JS]JK@P3R3G^2&;4E_11OTBCOWPTP>;7H_60D6#8
M8 P!@# & , 8 P!@# & , U+FO#_ +;)^)(%[EL+1KZ+PT61W-DU(7 RD+N.
M>QM*K/)VRH*VC\:E Z&6S7#&2[Z64'F$_AQ^=1[@:)A 1RR9"A9QF-KKZ,OO
M6J>=,V9:Y+EF>/VGX0;VP>M/6^MR<JI:S;AIN67O/['D-[526G%5W98'9P+-
M4;8GDBAS25CS;65"IG*QM@5X3<G"VT?(1$,(3U;IZ#2P,91J2Y42K M:(F1%
ME^7';G1-:.*7I&G:=>2XS/W=45;7];.IW(^=N9!-'$'B@F,K2LY[-R\W]]I"
MH,V+$>-WCO?AV[5XV=.-O76W&B^SJ/5< 8 P!@# .0K:W[4;)^GTQ](B.70H
MG-:-J[GNV2E%,YY2]9?]ZT0'/H/F& , 8!=O]2G?L([9_6W O0XAD#VW\80;
M4Z3WS!/MIW%T9UVC=PT6N<A\F,8 P"JCZJN\WKJI]<TP]".,EZU#C*+ZBYW@
MAZW#BN#Z^^W=2D+D]$ # & , F%>?K_!_IA&?OIEGC2.;O\ [%[^!H^BB<ZH
MVL.>\9.OQE+2[ P!@# .33W+\[_M9_$E>?\ <^49<2!XE@_9</W1R4SCF.HQ
MVI$-[?&-N=0Y8P!@# +4WJ5/SD.TGU(QGT\:9$5M[%<(U][NZDP6GL:Q?L]U
MO+)>"R!"P P!@# & , 8 P".R7]%&_2*._?#3!JUZ/UD)%@V& , Q,[M=M8K
MTDZ]2>_I=&RDM8A3$1BXT$.*@HVV>2.=20;%(]\()?*'H^-0R,(E2C94]*#3
MKW.,8:*<M6A0HJ/$OAE$FLC'"4^)FC"&%1R27]3>R$?@,\5JL?.;%(-:ZTAM
M:GKINU[05=@A9?2=;M[J(%)>S;RM\VI?>9/!=22*'V*X9[,Y..';#-SAK3+L
M2:SS59\J*A,NH?B,5YV\G;J$ *XGU?;&ZP=WG4A>9/X*];VQ2["RS=2O9LP'
M1&5R$Q#73.8ADDG,6F[$*;T'&Q#C5+=YJ:'!@5)99Y%E.I?6B3]7@J[$,&HP
M!@# & 5 _5)_:CLQU]N_K4&HJ_[BIT3(:JEA,\,K.QI9"6)DBUER;5L^)M8Z
M5'HOG:#;GENBX<Z**IH\\IZ;<:?Z9-%JZ$0J)4"*MQ"'4&FMNJ6X9=M4JBN7
M[3#+3E55EA7K#2LLJM:HDD5:R$[:D8BT,B$*=PZ)4Z@L/:&^;>,46DOG#+;2
M/D1&FT=MLHTTB5(JS5$J*UWQE?B&_/B[7_\ /EG?F7)2Y+6-= 0?^G43X1%?
M*RR?_<$8_J%*^*/C*_$-^?%VO_Y\L[\RXY+6-= 0?^G43X0Y663_ .X(Q_4*
M5\4?&5^(;\^+M?\ \^6=^9<<EK&N@(/_ $ZB?"'*RR?_ '!&/ZA2OBCXROQ#
M?GQ=K_\ GRSOS+CDM8UT!!_Z=1/A#E99/_N",?U"E?%/<NL/B)=]Y'V4Z\QX
M_P!S^T!H$>O*I@QL,4O*QWPPL(*3T Q)#"+%S(E&[Q@_9KK-7;5PFHBX;JJ(
MJZ;)[[:\\^*V,V.NH7$GCN!PEV\=P^F-NVV(?166V&V*.\:9;9:1TBLM,M(B
MLJBS1414.A";*+(WL5ACI['8L\=O8A0G;QANGTEIEMANDNV6V&F5>25EIE51
M46I454.FWE52V P!@# .0K:W[4;)^GTQ](B.70HG-:-J[GNV2E%,YY2]9?\
M>M$!SZ#YA@# & 7;_4IW[".V?UMP+T.(9 ]M_&$&U.D]\P3[:=Q=&==HW<-%
MKG(?)C& , JH^JKO-ZZJ?7-,/0CC)>M0XRB^HN=X(>MPXK@^OOMW4I"Y/1
MP!@# )A7GZ_P?Z81G[Z99XTCF[_[%[^!H^BB<ZHVL.>\9.OQE+2[ P!@# .3
M3W+\[_M9_$E>?]SY1EQ('B6#]EP_=')3..8ZC':D0WM\8VYU#EC & , M3>I
M4_.0[2?4C&?3QID16WL5PC7WN[J3!:>QK%^SW6\LEX+($+ # & , 8 P!@#
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M*Q-;6+$)P3@[Y,=+6,:.,2KD$Y6>EQC?9\DU54VU:.2D>D(IJ0TXW8.BL>D
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MG4BK-99#U[)N\>H+IU,N9W>TCELOZ*]T"/-<2P,/:Q]6S8*.KC?KO+)XS2B
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MJYK6F3.INJ,2:5&69?3G-4FBHC*LRDM4U5:D547!D/W7=)>U$%H2=K&[QO\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8! )I9L1K\K  TG=$FKVS)>E!8G[B 'C#5Q)%Q)0T@U)O1
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M79/U&16# P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8!B59W3>L[6L*P[$D!>7,GUD45(:-+AP[P0@"8)27_ -H1LL8P?!2"?-G<
M1] ;$D3I/WR';144T NP[L:J];NAF?G\B(?]"4!)\V0_F$UFDKD5O'*HD5A'
M=](X"W)D:DMMK; 5,0Q!!63>.CR*PX1$R2 [GAVJ"%H$N7^\N<D)(\"?W2/
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MQ\<5$/RM;QY@V<'F10V!9</',;*B"[E0CR$\GG+XJ9E8,# & , 8 P!@# &
4, 8 P!@# & , 8 P!@# & , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g63338g74s47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g74s47.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M:I),98K#5:-QB24!5W'VV;\XV6R!M['0]>!J F\Y3K=S#TDG9FD:+#LFE3G
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M?09UV+IW#)S!Y&''8@:-&+8A6FL+7%-RI5X0=MBD!$19EDR;!WX<8WF8B=X
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M<C84V33+$A,Q(E.VL1Z9QC<0S*#=M( DY=]8[,4@5_DYK%UJ[EE879FQ>XB
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MC&_T@_[!_>]?O0U5[^_[F4GW]W7>7?W+/7?W==?W]]_<;_EUU_M[[_EQS?\
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M/.WK+:#XK9116(Z\4#!,0@BB,4AA&EE:QR+K1?9H*:T%@H3FRP9A:[=:\ [
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MTUU];XYV/H ^N_LM.QC?Z0?]@_O>GRY3_P 3$OZ:Z^M\<['T ?7?V6G8QO\
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MU];YNYV/H ^N_LM:.QC?Z0?]@_O>GRY3_P 3$OZ:Z^M\<['T ?7?V6G8QO\
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M/85+S)80>Q1"R&=NWW7#W573;=8859**X!$6+=>X7(EH7+&RVI4YV2COM&N
MF<AR&9&)]]^@\VFB==F$:VTIC-2^W1U$?52VT-HNNW&760#<=(-=$2'RGYXQ
MG98 A2F<4,Z)&9=,JIQ/RE6IM+.G,;VB!"S24+(4R5BXU*3E(([D(FR \^VI
M>[ );H((:MRW?&QN7U)D^\++# >/."=$5Z:G."'LL=LGQ5(N'<:R8 A8F1*5
M,2Q&ZI^W[W?MT\R5KB!B%UXG"E6BH TO)/U4?IUJ$"HNJ]Z_>AIZQ5U/(M>[
M611BK(O)*N+72U$>26Q(HK3^93JW3M-2B&S+++V.E[+'>MK*2[K6B(R5ISN
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M*O5S4Q&^T1B.GR^3_KXHO_OKVK#?!Z\'K2N3^C5,GT]?;748_P WZ S QJX
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M/S-Z[T9<PO6/2&8Z? #L53ZO=AV]1>'MY-=(2\+>2RN$N]*L?!0J8S=,6\>
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M3_S_ /X=\^9>K/D/^K_T'7UETK_J?^S_ -FMOU#_ -'C_P"[_P"KKGRMU?\
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M34-&<;14U4B*>7.(JBU.\6%P!^Y,D7N%RC4'+I;BOC:ID\ILP01=)$P](J7
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M:ZDE"I0Z\HTUK$Q!-J ;!B9E;9[;."P(-L.;18+:-&@5_"+R#616MY',JHJ
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M->*PM$ 8G8*_%G='NZ2]*^5 P956WY#UU'_"B+IJO&?+Z,2#>)*R*OL]K?P
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M*(:&\56<Y7<3G@#C!'HJ->W#7@(PW42<9-:M&9JLIXN_V ')& 'EXRH,KFN
MMR#%'3)DB#8A!Q+.XOE,3-C8S73CLG%FR6$MJN9;']\RQJV&O#SB378 Y.F)
MJ:%P0@C7N\/BX6SC!1%):/WO]G6=O*#GL=8\P"=R&_*6D:+) 8U.IHVF!^R
M/HS;V.Z1-]5K>;=TZ^#O9[0\>HL83X/4N9<H"JG*JR[@-A%,2$\Z_C^IEBZO
M6;ECHAE[Q+E=QUB\55N,I>1,73E*%DZR\CYW=3+O &$N6UV50XQ Q^1Z782'
MVDX@+S,/CQ;!TT5Z 6EY.[%\"3&+OU@L,QWD]F!3DS6)PJPNR7*:J[WWX+IZ
MIMI*P@^=Q=,YH7WJ7Z[,:AHNNPP>WL-ZO;/XR 0[::M<47NS,-1LE@2,M]Y
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MA;.1[@1B*V39,I;D9B97$17 ZK+ 7:W].EM!2[Z7)KJTLAY4:4-B [5_R<6
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M)AS C$SL "1E/R"(S,^D:M%4\I^F7O5AO>"7H#<+7IY<P)2F]F+^O&DLE#X
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MJ,[1S.;P71#V]-X+HCHOK&]F<UU5A.G1!G7^-FWTYA.S?$EE<.XMN/NN7:8
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M"5M\G;ZTZD#;Y?DXY*->G8WPD\*F"'/PR\/C_P"OT9TX6_\ 7RQL[_\ ;JY
M_GO0<N'7Q=(:AD^_'KO[\]:IF7?W_P#/D%[YX+U#XZ^-R#+L^,?BHG9FWQ?B
M%U:$;;SZ;#EXUZ'C_!CP>,)D_"?PT.8B/S^A.EB_\V*G6<_LZ^??\B]._P#9
MFE_1.=6_C^\=OUU>+/\ Q%ZO_?&K'^)7P;_5)X8_L#TI^Z=/[.OGW_(O3O\
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M).,_>Z_3RN'K=6V\B()5BRK918+4%@4--^(L5H$ 4A#U+MVC].%>O"8=O (
M/<E2A]IW0NZDWV(E5-3:?LJ_G[16E_+.I,$=DW4IYT%CU:O;?=\C5G=G6WJY
MPW6%$6]CJDM@D8AP[*B*JI]6J>HC/BZG])D-S''#KET79+(7LO<EZJ+H)N';
M21PBAY*5KDQ2J1K!)%R.7R2R/6]'5H%2R(2FG1E.-QU'$4O+MOIXIS*[MCN%
M?B[#&"!N:)62XCQ 4Q#!'?8EIWI]F#$A^W1B@WZEG$;:->U;^ID:SYYMB+P
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M;V?FH^L9]WIQQ7TV0^S5OQ>N.:)0ZAE[KWF3*?J//N#&84,CARF_#W\/&7/
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M -R:PRDV=UNVE7%,1<<NLO=++\=/L^$IW(1AGNIGUUG6[(UK/P,O]:+\'?\
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M--%TF*K1P$F"#9M*8AX2R82N(L@;U;R,D,>'P*WLUL0B3OE=9 *ONM\M)E(
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M''S/$AE;V@7O\V\1EA2\4K?S8V53^NM/UHPUH3Y_5)BL5\'8*8&474'8R$'
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-C33C33C33C33C37_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g63338g76g88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g76g88.jpg
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M !<! 0$! 0                 ! @/_Q  R$0 " 0(& @$# P0" @,
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M7F=!#L_3':]$W>A'?]U&O,Z"'9^F.UZ)N]"._P"ZC7F=!#L_3':]$W>A'?\
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M#,E5XEBE8=&Z-I3$2W?Q/D^@CH_%IAL5'^QF^Q:O,L;1NGL(4%D*AY2[N6?
M$:Y1/CXB2)FY".J5.9N''!\N'"<J>[FC F3O-ST@7Y.5GLXER@8QT:PT_2H;
M5]779N")X]@2/(>_\@DF?HKB<>CUFDKI7'!Y(3R("B=B:S.6RK=@86D1*2N#
M>DP)'8W?4J).J<UBW-E=EJ=-CSYN;\>/B[B>5\/[$EO!5S&*E=%!NQ5,B@%
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M%9;;[U1GS9K_ -/:R9+KN>>>1#F* 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@([EU!(CK%,E-L0OR$6E=<!EB:,B
M-U;T3LU,A_E8EU@>YNS6XXLR)Q:D9!RWYG-$HL]A4AM48?;Q77VY; ,W1'=\
M_G5DZ9J&,LS:(&6RZ8AE_91*Y-2-PYC>*->@R]!L2)9TR[C+:R.UFQ! !0M:
M\7\V9FJ]P>U*/-:L16Y,(TU&;;3>M/:ET) $NIA'9$F#"IXA:<@>(IF%9!+M
M;IC)T,<?*<_MT=@1'*BE*+L[-(SJ;AKD:QB)$DB1@FE(7"+#(/9ER_C,V.&/
M&U90RNZE4:K*\5I=Q2:_0XT.ZI,4.3/@,I1B"<-?8V(]6S?<6-#Z56Z/,R"2
M(0C-,!JSQS:V"/)$.RT=)V=')H(XMX:8L;"0/[<2(KFM)E<<2UK2!E?BM<M)
MU>FJ6L/2U?!Y2?J;AT7#IVZSQKGL?"1&)1BQS6/QT2M46E!M),6O$B!T7+GD
M-31S*9BS<$P472 %H#V/R%Z8RYB^:&*Y"W/7#E@_4%A;TBWPXG[/2E#VR7J6
MAT;#\JJ)GUYV(BL_BG/KPL60ZO;HK-9!, W:"94<$Q::@=\;2H7AQ(CXD+,X
M,I:/X2S$6CJQD6IK&)RR.0QR0"19IZU\4KY2/8DGJ)VPY@1O$K:I[%  @UVQ
ME@DXP(U<%HF>.WF4W%M;6QA;K.9EY6S(N$+WIHSR(J@I-([..\+KFQM<R$C;
M7AB;A8FB:=M:\?O!W>0MW54:;&11KF1:M;#*'*;#M>&QR?L3OK4^B;TTL+=C
M=S"350RV[#9YD8HO!VO+C5%A0_18V\MBA4T,_"'._$8VU.XD4F53Y]:1)UQB
MZAHNIE%DC4U@B<8JX.F*7R"*WR0<,8MJX]0PHUK7\I_<QLADEQEF/+GP;;EA
M*$7R6#"F%Z9L5G#IE'W=6@:%81NM_P T]'L:X=089V)*X=8N8'G6(6+8^%7:
M>=>324TL98FB4P<;P@2DELQ-0/)1L3AKRA024)O36@.&1@QD; K4NC0IS?M,
MB;D&HFJ<.''UVV(^WGFW:J%$$RRJ,R/!FO\ ",+Q8PD$>N$JAUDE.VT,WNEI
M@O4Q D1-$H!Y"&M]WP4-#!MO81]W/C8L.%2D8M68![$S.XJ2=YFMDJ5T?VB-
MR"9(W<VZ5"&W.Q8(WQY'<:Z"BD>/$JP(;@[J2G4JDF+7N.-H-@Q2^0\)B.61
MTK!8[DQK# ',C$'S]U(;*\.A-C<6!2D9DX1HO_+1_6)X>L?34T?V+VE%-= 6
M.#=P")&DV^6I+!(E !.,&P>7E#Z9R2E<LP@EYQEI.'LC:WK\[=PC6.[J]HFY
MEY5X7!YSH&5,YN: 1*>>%)60"ZF+*7%@Z.$6KVQL:M:K83)J:<'!;Q#"P4CC
M8O-D4VL@"Z?*<ND1$4M#[CX9+DDA@@^2@B507C+:X/B5SM*$8P*\,>4Z32=/
M2B(\PSF0?J2!IR:0JU)(#GUMBW926"B(=?I_7HHMR1G)#T(#,CE3B_?#F^4%
MDDB(N]-46E"P'7%P&T+C%MQIW=M;+&^_)FQ"1K544M5I5*UV:/4(* 4 H!0"
M@% * 4 H#\W\W\67\X[>+\G%MW-EG-WL<7W\<<\VV\W^S=['%W/Z<<W>S=[/
M'/Z^SS^GZ4!GGJ9L;LC+ASO0(3#&<?!YEKQ*@8&Q[&X@>JR=IO;B?7:-)8:$
MK]*2H.'KW!<1.1KPH7N.($3)Q;$N^#X$;_:S?%'45I++K53RTXKMM.Q"\>;=
M;>&FM.V1Z\1P(L4T0_N,YP6E$P!C+Y[;8VBIN)8<;"XU3L PB"S:=7Z-0(R,
MI'RL(XT#;P:KV3&/LS/;S>F1J!84J'1J:TK6FU5!*FONT\EF_P A,LKKQP)O
M97HZ<#\Y,0EZA'(>A#D7FP#K,F0Q=)KO\TQL=3>E9%LEJ!IU6N#ZT,@%=9F'
MF=#*0K:UB-6[\2ZJE#2*A!0"@% * 4 H!0&5,E$^]HIM1#$/!VS$$FN"4S0A
MD%_CG)J:^M#G&NK ,^MUQH1$4EX=EG:S,_W\OXK%H.MM $OS>>DECSPS-@Z.
ME5[.-*(>M-_/CQ]==%K,$F VQ>QCQOA.FNYM&P&,QV#ZW#LN1%A83?.4DTBY
M7J5Y#"49&5.:L7&D0%<\HA)&FQA.'$4XV+)SF<5)8Z<J^$2 (669K,1])*\P
M=N+M.3L[V/2@THV Q,6&)[!HF*]>I,UV9H=DI_2G[[LV(N;5+A"X6RH"ZL@0
MFU%B:6F9<W@9R2$8['_S*H<BAN5) :5^4Z>--'=.JB8-?FAX:"!K0/;"ZMSX
MRNB7$M;'=H7)7)K<D6>WB_ K0+T67,D6)<UG/%^)0GRY,62WGBZR_GCG]:&3
MDJ 4 H!0"@% * Q+ZCW4 D35Z7R4%9Y?C&#&0,U+7['!V<TA<MF]=.Q\VF)>
M.N47.&(.,AO-%@>QIV,.L6%#EA3J2)7(UZEB?4B:/B9/G&L*G>L:Q&^_FBM4
MCN9.IM*]DFR8*#,C11KZKUZC2!7XV'SV"IPGR/WF4)BC1@EQQ;IPGZ%TCH):
MOP S,)8+![+,1$A56O!$I,"I+D<F,'5#[B+E4)UJ]:*E=$]7YHZ47E,LL];A
M[% FR!8VFP2XYX;'R@O:5H<RP%)N/]K&J.+<;W$\I!NSZ]YPQ!*IS-,V*AR&
MAN$!YL2%=[F=HD=B9(X1X5N+Z)"C>\ZW4:J+[;J-$(=)G,F!&K*3%024'K;Q
M>WR/P .B)U'!HY_X6/H8DS),^;/9C%,RNUC37.UJ9Z6(D25R=4N!:MS6<#+_
M -38E*@% * 4!0/7_04/@G879R<;#-Q,6B>;EJ,)C5S8TK<R0>.FQ:3RG-P^
M-.29QSY7M/,LRE[M(9%GSM[1<AN3,3)@Q*L;3PO4C3Q2DHTU=XHO2H0R-=-<
MWPB\.Q"?;)(S2 M60\Y%=70Q'#GRZ=C68AA@VUZ!GJ9Y"R2<^M4M*HDB"0B@
M6%<(N Q!8\*EF @*LCL[I,&;A^?E1FJW%6Y==Y?MK<[V?]-P+E,!@^,SB0GE
M6)Q)H_-.E3KPS,>%G>BELF)@UZ9+Y):G3(\..(2?A/+ :5W9VC(@)DF=P(,?
M*E=Q@9.<3P&:)C7,L7J>RL>X&CNS1Y#<IR$>S9@GS8)#$X1 L(]C\%VQ9B$!
M-^V*@^1Y+/707=Y)ENPSDU\4Q4%O[TZ)%@H$-C8#W(V4";4[BYW9Q4TFO"U=
M6_#C2'Y^=:VL,^=/^096<38^G_8 ;,IA*W_3K VDD>0JMC@#$XST]V:9]GF@
M.:@)YEV17E21R>7IGI,;&KB?J$Z*Q>PW,(JE0"_PMZ$GPE2OFLM1,QX\*/WD
MBW9OI3N^P<C[&FJ*7XD8+=@5L?/Z8H.M6T$M3I$SI&HH$L+(%QG,+C+8UC'(
M1=G@%2E9)'C:%(7]0Z%DBWL9^/N17C>6@%BB-:3YI7:'6NOQ2E9L!-/]EP[:
MB2-F'+9V'395*#J+L3FWDVJY=E,@>!QE8G5X8(B,X2;5IV$$852OEV)%C_FC
M<@7O1X\7%9>B*L;2Q,S:$J$H?GSJ[NG%MVV5JB'I#D44D$*O"6;X:NNA7#*K
M%>0#VI208E*;!^7([+(_)"C864[)M<WZ1YLXL($3Y9(N!.P#:UWQ$JUZCAU5
MDC<H%5BXL4S1J?\ *4MDHT_:B5)F[D8Z:)XW5:+*;)#S/'T4:WDVO2:RX6QH
M>T?"1A,,AO)9GNX(%?RID1VQ!C<.&3':16Y[G^]+RZX>&RU0O&6YEW<_OV1C
M,VE4[GVUE^T 1L3#K0K9 T=$(I$IEU5=9SLA3X?:XYRT@C)VP;&QBV#I1(C@
MY>V6%"04Q%*QE:1\7O?LK&T8DN4)I%?HXFTT>G@ZW+G3UDN2U\\,#=L:/BT1
M;G-,>I]RPS%"RQ<2FKT+Q^,Q.>O$(%UDLH&^'<$RQ>'CP.6MQ4)S%D94#=:Z
MCCDF?,ZE;E%6*(I7#_:Z4K-5%8=57@N5.T!I9JM@S':1?*>"$I[CN<$F!.RX
MW/&^=GR-_1X!3BWXDV6M&!PL?/UX=;+5_*&U);9:V*>,OZXAD@O-HTES)G9/
MVF9[?BN_#!O+S?\ *./GW"IB=1ESXC/BWYDX]Y@5<CEN'DNYYLR8?W?.3Y;R
M^XXLRBIQ,>5!FS"T,;)<SMIE!K&URPQZXZ?;-R_)/ E).MN>/[H^CQ)&.Q(&
M"('#9['*9-'.Q6#ASD\=8XC;(>!V%TP ;NJ>Y>4<$0IS[Y^?GYV:;HVVFVE6
M?AZ4C2L^=#Z'J&!0"@% * 4 H!0"@% * KO$L XHLF/:B7,93D>\FSDBQW(&
M=AO9K6^P,O (+C6%+&K$Y<.BVY_M=<4=V$=RV]"S\H\CM<U<)55J'AQ5BMS&
MRCEO[C7V L4#J9Z4XBG(3]N.Q![/N6S(S6L_RUE.6D4:KA;'=:Z.?Q;&V<"]
MN>UYNX;;E?*WG'RUIOV_%^8'XV7\_<JE.73PSS.UMSGFD<%[27%3//$AOLFP
M<AF0&)D&P34(##TJ9(\<SP5QC9O&(''H1',+FZI_(.!@*:G=G*!PVQ%C_P *
MA9_CZ5K>M7]C1(.&DP8(BP>B7.KHC$QQD&DCF^K;G%[<4S$V)6O N>'"ZS'<
MO=5>)+8H<%MUEERI7DS9^;+>;_TX&3L= * 4 H!0"@% 5T!]?[!79.>-D'4M
MS$[W, ?#L=#;&I9K4>.,@")$Q@O^6VITY=%U[IC*CD_+3-V48T#)Q[Y8V-V=
M,O\ @R9PR"S1*TOW'1Y$D!8DNV+_ +1_-.2_.^Z\"$!<A/P:VW$EQ"DDF\B6
ME/!#\4NOS9%UYG<T\LWP7%:FM;K5W#IGY5<I$X32-Y(XV(U%LV)3R)>1FB%(
MZ.Z2*6Z+^',-P%@H#-L8R<%38Y-)6'KWQ!BD$?ER1@8<;YC'['<42&4:# F'
MX,[,Z-.8I6@G'Y\J?I--_1(FKT"\ZYQ=E LY"SDCH['4AR,_K!4,PQL"I"&2
MC!V,GIKCZ.,#Z4V P:A7.V;&U,.4H)7#G)RJ='A_>'ES<'!0#<_GW_/18JA!
M0"@% * 4 H#/.<=.Y>*IDEB7X#G<$BQ7L-"8; TV,<H04KFU)G&P%7)646*H
MT4():BR\1+$2&5RYO7MI-A/05[OY9G%:*6JF]=:]#2:\J?*AQ7T[;/<A%XZ7
M9$,"$AP[K[L$W1G!T^Z_1+KEL"QF\1<2C);R)Q-#J/7M,61?(F&1 =H"SLIA
M1K:0U\6&@%*0^C<FIO+64?0KK'! ZAFNM&VK5_G<T#+X-;BZZ*A[*\JVV,XO
M1."A,((>55C@ZE*!A2#$</2@AO6W7VHX];U1&_-R#.@6*LI_:"FJ5S;'($2V
M.0R0!I=I'QJ0J)EV<W$2K.YQG#<-,B8!A]MA=HL!8-^>_E,@.6IM+B_"=S(_
M<'[EC.I&Q9!=H>$[8QI6 #%$Z59C7BMSSYG7[%]J$% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4!#?9(Y=\TR>-B?HJK*LN>R0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)
MXV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0[OCH=DCEWS3)XV)^BJ2K+GL0
M[OCH=DCEWS3)XV)^BJ2K+GL0[OCHF2H44 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M+0S+Y<S5)/><2KB^7KK'@FR:]-=M-M7<ODB7&& XE,4L6Q!#(2#!TH&DF#9
MW,>UD.;$2T;%Q@Z1 !+&[ I01$VCL7A^ 0?,^"]:]JR,@;OCUR9LCZX<A-*E
M6IET5FOO6I+LX:52I).+?VUA=P%-DVE)-6G:/;G5U?$_PQ)"3: )"C&7W)1E
M;RWYE6<7<[Q^QI^/8U-N=+<MR-EV;/;@IF?[=NY*YXNFK*Z&9S-M4,[,:Q <
M;K*=N<D@$NZFY[&TL3.[S6V;!+@O)I2#$(W!;_(@L>H;VZ/C965X1;%A3#,@
M%PP_$ ZK$B-4N:FKG+&BM&NJ4='5],H7V2FR)-<A4D%(D#-?88WDG_8U/(K:
M;DZN53#@'V9V'<18"NBE1'+8QBS@O/'NU63FO$G/:-S!FWV4;%<[ERU..BXF
MI;3<M+PHT4UE^-EKX)@RZ5;3!NM>E$.BCH/$B.#;CU+.L>!&R,P:MV2'E)D;
MQ\G.X]/L4 JJ4D+0)/3DH7DPFD;QQ.98'3+F<5#CRPI&5Y$E2WZHGYLZ?O:*
MRH69]%=[V#7F'=55@9K(>0,+SQLC*D[ :O9R91#)/@Y(,\F<WQ)'3N7NVMTK
MD?$;H7(\48Y@&"#XT^R7\I-#,\EZH:(2]N>!93EN4XPI0EX23>JC2A9&0-=-
MR[2#9$AC0$UKRY=VX.CZ.Y):"Z7CCEJUS.Q (*XS5.HJI003;EG>-<@B1(75
M",+&J&';@I9G)'?D3M9DH=!D2529I,6:UO1SJZT^*P,9]*N5FQWM)0@E0EV.
M,9Z@.18V%\<]31KL3R& QMT_!G2HO;2*9H7;TYW%4@YUR-V,QMR%E1,R/C>E
MX%"V],RF3]C:Y$3^>$OMN7-2/F:)ZN:3_!HEI5K\7:\Q1(J8@&QE@D"495,9
M==!U!-<\3W8F<W8?&!,=1&,YS^\D4A'A+P.A0ZG)21"P"0Y@R6\HA\+]EORO
M)!3+<^DO"X12.$=.-L'_ #G&#<6'M=S209XBJ3XEFK;5FVZE62Y*%16111]1
M+137V#BO4("!XJC*]Z5-*'%'8I)(WCX:TR<E,R&2C)JR+WT:;P_]6_$+*DG%
MVL57YTUTB29]>M<-J5<JZMD^S#;#PZQ:50:;Q0&.<7G9*9.4YGYNR  ,JE1U
M97T #<,7#2$&!G#(F"/BQJZY"4Y7I\SY\+$V]Q)7Y^?C^2-J&E-7Z2FFKG7A
M#9;2.4IBLZF/RRZQ\ER[DZHPY!<97OCF]IKFLHCUIGQ"\*3JY$,.-S:.95$I
ML=[6H9?F1;ELPO-ZAJ1WX4UJ\$Z85;$W[R]$5;WP2^AI[-.Y+J9QX*C+"JZ:
MI%'MYA>=7#%ISJSL!L$_DK=,[@(@Q5FC>+BAGGL?9\4MXD1(UQHJQN<@FK2W
MC0=DO= POQ?-,5HTM*JQW7IIGI=.$P[Z[#/+;&=@G)<H0JR!)##)PME6+B-/
M'D'#C,\7BLN*1,(02C<TJEZ9M?RD9'L8L@(L;H%-3F]91%:Z*0Q:857RW.[M
MXTT^ODUNH9% * 4 H!0"@% * J;!4&%\9[!;N2H_KA]2.['RU$YT"I6I8X*'
MAN9P;6B'H==\!0F5-:)(@<,Y0 /2QOPMB]Y3YF/.VJE"I*MSJ6Y(*W*P[*/_
M --_<\.L$!$T/W[3XCG*+O*"<]JI5FH?1M6=8YX+ <['@AG0M)*G=&ENPXGK
MVQUQM=&Y+PZMG";,GXQN:OG+FQX0MLONV5#GS3+8:0$" J"E@U\U$BB4<)7'
MB:?9?UT&P[$O:F$8UA>QD^A(7>R5YPZQCC,]K.S-0WMH44R'*TD28SKF)^3#
MR:\5-*>*+%\ZZ3MX4.=35$.:WMC$19E)7_(5D;0.,C6_E.5'A;LI*]M[8E2.
MK_D;T]UR=#D>5V'.XWH\%UV%+<IYP8KN;++>:&3L= * 4 H!0"@% 9 @.OVZ
M/U4*ISGF$=9YN5II>).8PD9^W"ERR[76"7@C5-#/9">MN?3I7'3%*C=%N;%C
M,2>^2,1C)A7E>FU=*8X$.C:R#HT\L4;5-,JJ_-<TQ.U*4H>W''3((X6V4U>D
M:/\ 9V<R&)80$MEDI&-R,014XDCJ33<91":9\.)2PP(S+29HD-]%# @F,A)R
MJT\<B'$+N+._<9W$HS* S4=%6.$]Z?3ZDX;*ZQR=+UDAKP%<.ABYHQ!2>+61
MN+".-\!CRXGX4;[(*B\^C]H5%8$\S< C7.O36>C38]F\<#3@<E#1E<K#I6Q8
MA$_Y^WK7?SH31J-&$E1%#24/E)V3JWWDP/GYG'49^92P@C@,(RUU>0^,6^4I
M#;F<W/T02Q*TC2G?B%H:\N.RSX,UH$S U-./@&Y?\)<*GY6I9NA!0"@% * 4
M H#)?9K3R5'+8N:YVA^%M<9XYV9U?%-;#%KV +'00R1<O"W:25#>6L^9#%LF
M\%H 8M4CIT\C!"7@7>E"V.Q)0VN3APX*>6./Z/Y_'^<:3HDVZ.:?3K<EQ[T^
M.L$>],J/&4T;"KZ(96B<FD(N+U+FA>ST;CC4Z:H"6O#5@2H7OA47/Y1( ^_9
MT#LO0(N&[XWGR/F1:E2)'&C-_?\ Y6\?J3^Q8*9XA=)3(@IO26,;$+)U&8G.
MR:U$C5D[VZ@RA [Q &W)LB6W(N%4$@*<,G//"ETQH\JN.FD26-3JR&[]RB&2
MNNB&N>P<#J#C+-)*B4HG@(B49QLS?/$PS_892<%?/':AL4X.\QL+ OCMZFG@
M@%,3A& O8[L+)P%X%V8A=5KASPE%;3TW\)?2FL7-%*$% * 4 H!0"@% * 4
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)QT,^*_"Z/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g63338g79w07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g79w07.jpg
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M9',72]T ?M>K-1KE?_$MBW$W\ 1G.W/MF^S#7\?&=8ZJ$L"4'-B3O"\<E#%
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MK\8Q[+H*?V"UC&FSVNTVTI"EWVE+:UJQ?CYN(=?71$C[O*I-8D[!\KO)QR>
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ML>+92K"WR<IM3?A;"8K$Q<EOFGFH=1R,QAW=9$9E!$FM",BDGDAHYPSN!QP
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M&.,8XQGI=8:>3E+B$J\__=CSCSX\?G'\9_'],_C^/],<I*@\'SR/(X)'!_\
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M\^7V/^U;L;5#31:/IBI+U+=W$^JM:>W+.X/J>BFOEJRPO%R9K'Q$)23]IHP
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MI,9R,Q*3\D"4C+;C\1UE;S#3F5MIUEFNU:5HV//'E6'LRGV/N>.1P>#GSO\
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M<M#@X2^D9F2\4^&/M2^U*UUI=;7ZJ2:ITU6L.?2"&.;;R)S&LULD\K6!Y>&
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M_P!?.?;X\^,>/.?YQX\8_.,^<><<I+HIX+ $>"I/##_RGS_+*^1X\^_)Y^G
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MX^GD^/R//(_=C@^_[OS  /GQY\$'R?KGIL_J(ZGJE9L-VD:YW')IH2_;&UU
MM\J'K"GU.VEM16B]5+9)&LV?9.U*2 6#KI.A25#IALB#DWUHX'9UG"NA*/9Q
M]<G@#^OZ_C[Y''Y>?Y?</ \?D/W^<VO^_+0%;$K5$CZSW21&VW3$_L$&V"&K
ME0.UG.I!]-AVY5L*5<+?"&Y #1"7.9HU?'GM6#2EIOS<P!681=L?/GQIQQX]
MQ_7\OYYJ54]1S3MV1 &U>B[5L%]+;49T^)UE6T:IMUGG6R9IZT;P'O.6"G[7
ML&K0X9^E5(DDG/L.Q [E.-R!8R_1:I]P9?XQQ_7D?4#Q]3QSY_?DFZ-[1C-[
M7Z#"K U;&O;GU<T3V1UZ0)0W8-I<A[5LFTQ1<99HJ"$X9'3 '5>F2 RACDAB
M7)(6-;9(E CCI*F"./XD?PRVW&1CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,9T![7O&E]N=S=D&=ZG'8VJ->B3%7%CX+I;$^P3*FVH5'
M%"'0J%2?EG6648-LN9?BQG&T-M2)"8[B^?G7U?ONA^LOMPZGO=?WVCZ0Z;IW
M=34K0/<%C93:=6J14Z3T1ZH>?:2W;Z.9(H6552201N<]IUM/;:SI2A%IX0VR
MO2Q6)'<1]D*6&]0R2B4]O"0+%$1PS>6*J2!FM]=]Q6KJD()WB'3I9(/NT[@1
MKJI6(\^"C.B*_(>5(MTEU4*2E]EAXR(!0R&&XT<BK[TYB8E [&%:O[-.MMM]
MD-*UOH=++:I==[ 4NFM1L]A)KHGI:Z1S)N9':"821QR7J>OAL=L4=@_',)^V
MMP;^\U=;J25*;6ECEU$/JWK,$*S,)9U';64!U()$4LSQ\LR?JAVDR<CL(-]X
MK.$K5UV9(U))CZI # D.DV0S*)@W]KVTR5:'MIJN)0UUJ/6VXD2P&<3%M$)2
MQ<" \ZB,Z32PS](7_M[VM'5;WJJ3HZ6/I#75*$.BVEV6U0?K#<7K:5@-09:S
MI'JTBAV-T3E+,K5*]:1UA>T(TXF+I"O+8J:]=FK;*>25K<$2QRC6UHHRY^)[
M9 38+-!%V<QKZCNH+"/EJY=I]C6'L<]U/U#.$,5,ELC[?LZV!F2+DM@"%.2)
MD$ ])G28T%67!M29L!HCE^*PEG+J?:C#;>%J\R^UOJ?9?::_V0=&6*<>GM=4
M?#=5;BBEIIH]?1OR3U]<\T[Q5V[ZVG38WK/J11B/O'  7NS>].48-$.I-HDK
M68Z'?KZTK1]IFEA57F"HK,>)+)@AC 8\\'D\G@3K<>\A@/7[0=T3IAR[Z?U.
M^.KI_8I0VT K^5M/0A4:#68"&'99&.UB3 PF4QEUQB-)C2I QB(\PZ[Z!N_M
M\N4M;MMA]G_0[;[HKH]ZVMV/4MJ^FNUO<DD%.*OJ:ZQO-:B42U^V9.XQQ212
M254BDB=]-5Z0BEGK0[C:BGM-D'GAHQPF>?@AY&>P_<%C8]KGM/ 9E95D+*0,
MT6[^1B0K3 [6>MI-JV1N4:HC JAFQ0JX,"?$:,5M;$@_+CYCSWI1L 59&H2B
M%B3$CM2'51I$J-"=SKG_ &B8K-3H>MTOTO+MNI^N*OQ-;47=G!K*M#B]<UAC
MEV,L1CL/+>U]M*H"0"6&)9&,4DL4#6H^BVCDVS["^M:AJI DEF*!IY)N8HI^
M5@5NY L,T9D)+]K,0.Y59AM=H[@V:F"*Y6#.GY$[L&?B'"TK4(.VC9T6L5X*
M[-<^_P!HMR8ZX(R'-$P73$5I,>1GZ3]S[\=KV/N;C;?;3M='3UNIO=%O/]H^
MPAV%N3HS7[FK8AU6MHO.PV6VW(B^'J06*D#78D$4A]#YI'C0J[8U?I>"W+8L
M1;14TD#0Q+M)JTB-8GF"#T:U7N[Y'21Q$W++\W@*3R!@@'?ZL3=+U[9!BA'&
M+G<+64IE-UH$F)+D;66&JA(S,$SUPX;F0V'R,.!)EJ&K?9*K4/C19SN$Y5K]
M=_VBM5/T/K.I[O3U^/>;K<6]'I.EJ$PNVMQ<K&!3-2L-# QI"2S!6FF-9I$M
MN:\45A^.;T_1=A-M/0BNPM4JUH[=O82IZ25HI Y"2H'<>J1&SJ@?AHQZC%!E
MF=+7W;%ZC6)S:>GUZCDBYD%@1$<M,6SK-L2HRY,B2AV# BQ6&X?EAA?MD2%K
MD+>:6W'5'S\GJ?0W4/6&_BV;=6]%GHV6I/7CI0MMX=L;\<T1EDE#P5H8HU@Y
MCC;B20F1G1EC,9[N?VM/6TV@&NVGZ3617,K"LU?T2K=JJ0[LS%_F8>%': >3
MW>*O4#T]J;0N^6U^^,2]6<A<=L5%NG$Z/*A"45@5":@4X>B7 EM,X*KE9;I<
M%S/SO9;2N7)QA/LPWCGL%OJ:S;Z6H=+/7A6K0N/<2R 3/*[M*P23D\=B&4D
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M ?;)LT%=*EIQ#&Q:]G=4VP#B%ELUHD]D;=N7:UDE@K*)B["S<FX>S%7 =*G
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M+Q_3ZHAKF%G_ +TN6]><<C^R>E7]OKOIP'_DBV\@_B* YQ_:[=M^QT%U*?\
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M)PLHXV_*ELL-(5NMMK^E-=_9*^O3LLD?44:>M&;LO97#"+AH@J^6!G!/<0"
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MPF77/;A;[OQ1FGGV]KI]+LM]<6CJZS6)B"\C<A(:\*\=]BU.W$=>",'EY)&
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MH/"*H\9W.MU>NT]2.CJZ=>C4B_9AKQB->3QR[D?-)(W'+RR,\CGR[,?.;;S
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MIJ^H0GZE==FC5S&$XBR\O1O+68/56^)!^.*@%B42"ND;]XX;U8UB"2^/8.&
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M$Z79MGPM<U"?6=:Z_P!)V^YDT6AZI6>./,)L.]*Y0:\((QF0\\Y7;O-L=JJ
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M3;JFIKBV\HYU&CZ0W.]BDN0QPT=3!_WK=[29:.JK@'@]UJ4?KG!\&&LLTH)
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MW7W<-,8?86K"DJSA-J.%GDBCX8M,W8H'OR2 #]?O/[QQEYI H=S^PBEB2>/
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MM+7*/.<#Z\ZVEGJTF)-C-!'K??C7N76[''S&=D/*)4O7Y&5$:A2QDZ-$AO\
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M(TEM1]\IAA_CZTL?'[\US]==)1GM.]IL?NB]:?\ AZ,4G/[LPF/6A]/&5_\
M(]L;$M*L_P"3%7ZQ]H3"',^/QAJ3'TYB(YY\?C*)&<9_G&?'YY<_L-U*O^TI
MU8?_ (VUU*$#[R#>Y'\.?PRW_;SI@_[.[:F\<CT=1N) ?R*T>WS^?'XY^_\
M3!]27O\ Y96^UAG'C.4J%]/.QSN%XQ_5/SZ[C9\?]N,?\_'']BMR/VY=/'_X
M]WK!_A9./[<:4_L0[I__  :+;'W_ #JC/S_I>NM/G/G5O<_"<8SGY,]--_\
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M.,9"T?7]H_M+=M\ O%I%<3->=* *_-)&%[%RN'\*)]E@%T,56JR$R/8X^]7
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MUS0-K6S6MT=?"1:O6M0SF;&TP5./6.[;F+;<AUC65;JU>#E3QFW?:]1$3>(
MYF7-G,G@4.# >E2V\.;6'46;%.&U !(9I;JF(E(Q%!12DTMJ661TC2'ONK'W
M,0%,<A9@%S4S[BK6N35)R8Q##282@/(99[SW5AJ10Q(\LD_92>3L4%F$D852
M6'.G?W\>O/ZCD#%GK%'K,'6]$V.1V#.HE[@5*"WM+:;VFM=U%^1*K3<MF\V>
M_CSM?9J<N+%.Q2@ V-='YG ;*P"O_P!GMEZ0?TXS*UJQ56LMBNTS&I4%ZS,
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M=H:WE*1\7M@\< #[S_/C_P!/S!R1S[G[A^[WYX_EF@$S7;@'5Q\Z,3OQZ59
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M/UT1J+79$ZC67:LEO6J%03$6J:=:O@K:$\&_%>R\J2$^,H9L41O,938Y<+&
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M1#BH7.SC,U:8[*52\I3E&,RE81C,C.$YRG&7<K\)SG&/Q^.5&64A 9)"(_\
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M;0H4<>C+D6:W8),!S+G-H-?%6 ?9SF$D!EJ0]LEMP?([@3Z< (^LA)^A4',
MVY)B4I1>IP>#8DY6NOO[']J0CCV0<>WG,E7_ $YA&PS(Z^=X]LV[N-=X4ELD
M.IMH;33^N%.G)_*$U/1->?17""X[2U0'BEY?M$HS':8DSHK,O&<XI;9F-6CH
M01THSX,B<O:<?\]AOF'/OQ&$"^0"1DK1#D/;D:RX\A6^6!?_  Q+\IX]N6[N
M?J,[& @,)61(\!6PXNO@A,9N&+"A!\04)&PVL>&H@\= 98APXS>/PVQ'9;:1
MC\)3CFL9F=BS,68GDLQ)8G[R3R2?SS. "@*H"@>    !]P \#,IR,G'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8S5;/1:7=DPT7&I5NU('M&F(";"%'&
M$PF;("(U>PM1,$(\C$=!RM%RM?+)9]F" 4E/&2OEARWV7+T5B>#N]":6'N,9
M;TW9.XQ2++&6[2.?3E1)$Y_9=5<<,H(LS5J]CM]>"*;M$@7U8U?M$T;0R@=P
M/ DB=XGX_:C=D/*DC,$4T]J@W.@$S&M:*2)"BM/.#",VJA'YXXSKYLFS12<&
M8Y"S(B3J>P;-1ZU)8<;=#1C!:,/4PP2FMOW$NW(U9([5A$=)XW59I K)9*&P
MC -P5F,<9E!![RB%N2BD6WHTI&5GJ5W9'@D1FAC+*]4.*[JQ7D- ))!$0>8P
M[A> [ XHQH'1EAB46 >T]K(Q!U@.A!M<PB5'K<V'1PP[[1]O#56+(&N, P\)
M=?K[T04/;8'QY $'):CI?#CG(U2;'81M8:.[:C:VS2662Q*K6';O[GF(8&1V
M$LH+MRQ$D@)X=@:'UNOE%=9*-1UJ*J55>O$RUT7L[4A!0B-%].,JB *#'&0.
M47CCR>NV@IM@MELFZ4U5,L]\&6 +=3\N@5:27M@>V#(H:U"["0>%KDEQUF$P
MH@VPPYSC\<W"C,1R;<III"<5#9[%8X85OW%BKM&]>,69@D+PN9(7B4/PC1.S
M/$R@&-B2A!.0=7K6DFF:A3:6RDD=B1JT)>9)E"3)*Q0EUE15656)$B@!P0,Q
MCO5WK8_6'*6_H33[U2>L*;<_6WM=51T-*M7Z>9J+ECECUBE1Y9R55&&ZQ/*R
M6W9I"O?(%G/R!KST9=0VVT$HG&QNB81^B)1:F$@A]4S"(-W\B,3'U50$*LG#
MJ P!%'Z(U1B] ZVB83+ZQB-6'TS-Z0@,I7LX,AA'HLY!9HN48E20=D3HW2Z;
MB4V'C4VN,7LX(> F;?\ HNNYL10+)$P@$H9/+9'9FRX<L ,& IC+[RT2P@P8
M(DX='#X<9BW^D+WH)6^,M?#QN)(X?7E])'5VD5E3N[599'>12 .)'=QPS,3=
M_1]'UWL_!U?B)$,<D_H1>J\918RCOV]S*8T2,@D\QHJ'E54#U530^DZ+5K+1
MZ7J/6]4IUSANCK?5Z]2Z\( VJ \'Q7G8=C%P1[$,W&< )2$4R2:DMY$I2.]O
MTB<,X3;"_8FBL3W;4T\#!H999Y7DA8/ZH:)V8F,^I^LY4CY_F]_.(==0KPRU
MX*56&"=2L\,4$21S*4](K*BJ%D!C_5D.#\GR_L^,V2)KC7T"4.FP:/4H<P19
MR%U%2HM=$QY VXEJ_/J92U07FHB'(EB(U8J3K<TRPI!"2"(31+TA<"4\PNT;
M5E@RM8F97A6NX,KD/ DJS)"P)^:-9D254/*B15<#N .7!5K*R,M>%6CF:PA$
M2 I.\30O,I ^65H7>)I!\QC=D)[6(.<D5\#+.B[1*#"Y-D!C3(8,??@173(D
M18Y 678!@TDMI4R% -RJW7Y!:)&>;8(/!!+DI#JQ\7+5L2R+&\(D<12/'))&
M&(1WB$BQ.R<]K-&)90C$$J)' X[CS=,4;2),8T,L:21QR%071)3&TJ*_'<JR
M&*(NH(#&-">>T<1V T#HVJ@+55:UI[68&LWJ5B;=*^)I%<@!K7)1G&6G+"-C
M#FX9=,?&,(BM3F7VHK>,-1T--8]G,F38[":2&66[:DEKKVP2/8E9X1]1$Q8E
M.?KVD$GR>3F+'K=?#'-#%1J1Q6&[IXDKQ+',1[>J@4*_'T# @?0#,[;M4ZQO
MYFK6*\Z]I=P/4>9DA3C%FK0@V2K,W,T:2^I"3",20^.<P4"A2J<Q5MX06"AB
MB<8GB1\B-1#<MUDFCKV9X(["]LZ12O&LJ]KIQ(JD!AV22)YY^221/V78&Y-3
MJ69(9;%:">2NW=!)+$DCQ-W*W,;,I*GO1'\$?.B/^TBD<:N:=U/4+>>V!5-:
MT6MWFT9)YL5N!U4*+L1E1LA&+G%$"\.$S.D*.EX<,L<4M[.3)2'$(D\RIL9A
M]$RW;DT$=::U8EKQ=GI0R32/$GIJ4C[49BH]-&9(_'ZM&94X5B#$5&E!/)9A
MJ5XK$W?ZL\<,:2R>HXDD[W50Q]1U5Y.3^L=59^6 (DCF+F5CC&.,8XQCC&.,
M8XQGID-*>8>90^]&6ZRXTB3'^+YXZG$*2E]GYVGV/F:SG#C?S,/->]*?D:<1
MY1FEU+HZAVC+*RB1.WO0D$!T[U=.Y2>Y>]'7D#N5AR#4C!'1BBR!65C&_=V.
M 02C]C(_:P':W8Z-P3VLIX(U*K4&L5!Z;.%PWY!PHVRT9M!J=,.VDRW'6ZY'
M8(V J]*).P8KK\AR );?:#BOG=:%#X+"_BQJ];I-=JFEFK1/)<LJBV]E;FEN
M;*VL99D2Q>LM)8>&-G=H*RNM6MWLM:"%#VYM-EN]CM%BALRI'3K,[5==4ABI
M:VHT@59'KT:R15TFE5(UGM%&M6>Q&LSS..[(KK'7]@#NHON4E>;/:9CH8Z#K
M <VV'7^FA]IL+ED-CLG8PU@Z8#PI6(T"IB2$Y4, (:Q#=03<AAI(K;\^../Z
MX_KG[\U '!]S^1S#$>L[3S6K8H?9]U!CM3-DW:^)P,HQT3,.D2'UK-K*#;'5
M2D-^R!6E/P:Z2;9:6"8FD'QJ8\Z:_+5/=[^!Y]_?^'OCCG^OZ_KV^N;A?M,R
M=B19P@YLN[-UL]#-@[96XC%30+L54,&E%$ %8<K;LD0Y!'+=JK9\._#/RZ])
MD9GSY)]H8>&QSQ]/\?'\\<'[_P"OPS6ZGUL%UFW K-(OMO.CZEL+9^S:C59H
M^D0A@2S[8EWN18UNEQ-3@VTL/BL[&L\46,)6)Z$A+\&208(S10R3$<_A^_S_
M )G_  R?Z_K_ *YJUAZLL;'LFY%;*M1:=K[8-T(V(+10JQ#$1ELUURK6B"1,
MH1D5S[VT41'Q<)$(6R7GA$.. #"TYE-RQR7/']'[^?O_ -/\\C@'^OKF)G](
MZ$2 / 7[',BQ2$P[(-1@]#U $ %$FZX'K+<EZH#-?1ZHY80,0-B=6[1/$$2X
M4F9L2HCJ!A"*+'3W'_UY^AY^_P#K@8X_Z^!Y]O\ 3^9_=)6KNM=-U':YUQJ9
M4ZR8/0_H+A\OVE$:YQX@BN"*ZNPM11D=<F;46Z^^NM3FW6I,%FRV6 XN1!GQ
MV(<$\_U[>2?\_P##''\?;\_W9[6^O@]NV-E_US;U4YG9,K;K.M<LU?%>;OTQ
MR1.>G9,)KR;:L/\ J*7)MZ JSV6TV1WWYDJ!H;!(<_Z<_7_3V\>WMD_U]/Z_
M]!G%OG7E>QH\H79MJWV;7#P@,)N5<D0Z/-%G5!7I+B3(9,^I2G:#8"3,GZ,F
M4H[@1:4QH10.T'LL9![CGCZ#\#]W\_/[^<C@_>?Q_P"GW?P_GYR1KKKIJ^T6
MQ46PG)4Z'89KLAV5.!5 LVU Q8&CL*OR@1BO3ZV9 QV([ "3&,")LPD%P[]7
M/47>R60!X//]>W&3^_\ K^OO_?E>F>E=-;F4F3)O-U)M48Q1[ &B%XU/+(&D
MJ'M8AML9&K#Y&LRIE& 32\]NN$@U/D!_EI8.M5N/-C013N)T]Q_KGZ@#G^OK
MD< <<?3^OZ_]1GMKG2;6%8)@R0Z?-<<$!*D-=E3ZMK8I89A*E:N%:C!FF;>4
MI,VS!7$5D$#FR!80E $KL B//8BQHL^P#S;N/]<_7SQ[Y':/'X?E_F/^F3%I
M72P32(,T" E9Q"(;-(-KB*&UZO A+K8@8'^EKE5J8@'6Z_%EH%I*E&A@UA$\
M]/)D<I9;D,0XM)//]?U^7Y95DS<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8RI'9KN)KWK>NO5! BP;8WQL'#C&JNOFMV&RN
MQKS*QEQ'W!^/CW1JE2X*VGGCMYL>8H07!AD7F<D9<)<!>;4HR6NY^Y8:\?F:
MS+XBC'W<^[R'V6->6)('CGG,:>TD'"<&29_]G#'YD;\>/]U?!Y=N  #[\<97
M"N],=J=GC S9GJ*64=:!T28P9IG337Y&8WU[H#K+F) U[9$IMQF;O6\#\8:^
MKF'5XI,*:HG%$B"068SAO*:]#44Q:Q"A(*R7I /B9.?!](>17C/T"_K"."6#
M#+"U9+!$EU@P]UJH?U*?=ZG_ -LP\<\_)SR "ISLW%BA@,; #!1T .'%Q(\
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M;4Z#'F. 2$LB3DNSP#Q^/'\R?P_#VR.>#Q^'[_?@>Y^_ZYC;KVWV[2"\NK2
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M,.E"5B/%2[TA3'MS,E*7\?C]O,>Q:EM3FQ-VER(E[0O"!((TABC"\^$6*-$
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M@:8U;"64V8EOL@B<-<V1@]4:_,_4(1Q[<^Y/^0/W>_G_ -<<_P!>_/Y?O/\
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AC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g63338g81j47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g81j47.jpg
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M 0$! 0$! 0$!_\  $0@ 3 $2 P$1  (1 0,1 ?_$ !X   (" P$! 0$
M      D*  @%!@<$ 0,+_\0 3!   00" 0($ @0'"P@+    ! $" P4&!P@
M$0D2$R$4%0HB,4$6%S@Y=K6W(R0U46%U=WB1M+89,S8W0G&7UQ@G,D-25EAR
MEKC6_\0 '0$  @(# 0$!            !P@ !@0%"0," ?_$ %<1  (" 0,#
M 0,&" D&"0P#  $" P0%  81!Q(3(0@4,14B-T%1818C,G1U@;.U%S0V0E)Q
M=I&5)#,U<[*T&"9#8F.AMM35)2=%4U155G)W@H7299+!_]H # ,!  (1 Q$
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MBK<*NXQFN7MZYH0V8#&,A8GO)\"RQG1/\V/*OMU;[7LT;QBA+U<SMZU*J\^
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M[=#&R5I1SR49$J1/&I^!->2%P/R771SM]#NF-JL:XVVM0]O:EBID,G'9B/'
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M&HQC&(C6L:U$1K6M1$1K6HB(B(B(B(B(G;I-2222222>23ZDD_$D_63IT
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M8TNG)8FJOVJC7%RJB?<KW?Q]-O[+KDIO=.?17VXX'V%QG03^L1C^X:43VIE
MDV._'SF3<BD_<C8(J/U%V_O.C#^%X7(9P"XOS2.5SF:[41%=W[^F!D%V#$WW
M^YL0[&M^[RHG;VZ!_5U G4G=R@< Y,/^N2K7D8_K9B?UZ.72!S)TTV@Q^(QA
M3]4=JQ&/^I!I8CE#^>D,_K;Z1_7&N^FUVA] \?\ 8O/_ +#)Z4?>'T]R?VUV
M_P#ML7IVWI ]= =#H\6J..7P\.2[9&->U,<Q&1$<G=$DAV7A4T3_ /W1RQLD
M:OW.:B_=T4.BY*]3MJ$'@^]71^IL3?5A^M20?Z]"WK4H;I?NP, 1[K1;@_:N
M6Q[*?ZPP!'WC0O/HYLCUQWEG$KG+&RZTQ(QG?ZK7R@[-;(Y$^YSVPQ(Y?O1C
M?XNB[[4('O.RVX]3!G@3]9"R8@@?J+-Q_6="#V6B?=MZKSZ"? $#Z@6CRX)_
M6%7G^H:9:Z5+38Z2V\>**./G8Y[&HUQ&FM>2S*B(BOD0O)H$<[^-4BAB9W7W
M\K$3[$3I\?9U)/3S@GD+G<F%^X=E1N!^MB?ZR=(1[1H ZBD@<%L%BR?O/?;7
MD_J 'ZM.183*^?#,1GD<KI)L8H99'.55<Y\E4(][E5?=55RJJJONJ^_2,WP%
MO75'H!;L@#[ )G T]>/8M0HL?BU.LQ_K,*$ZV?K$UF:G4U-(Y>"G^<0T_P#H
M]M7]F64]=!>O7T8YS\YPW[WIZYZ= OI0P7YMF?W1=T\;USZUT+U.IJ:G4U-3
MJ:FDC?"\_.UZ[_3CD1^R[;73^=7?H6R?Z/VO^^,+KG[T@^FK&?I#<_[IS.G<
MND#UT"UJ^<>^%9@GV=\7R#W7[/X)+^WK,Q_\?H_GE;]LFL/(?Q"]^9V?V+Z3
MD\!G\NB?^A38/ZTQ'IX_:,^CU?T_C/V-[2+>SC](C?H#)_M:6K^_2(]DY+58
M5QNU17EDBXOF=[L+,\D@BD?'%:V&#C8C68X//Y%3UX ?PQNC)!I?-#\4ZN*\
MBS"POC&_LQ8JI-?W5F941[E"OC*-1B 6ABR#W9;3+S^2TGN,"!UX;L$J<]KL
M"2O:ARMN&AM3#12.E._8RE^V@)"S2X]*,516X/SEC]^L.4;E>\Q/QW(I%I?"
M(X5Z$PKBOJW=EC@V)YMMC:E21EUIFV14]??&T(9-F:/58UBZV4!3,>'K !8(
M[9]<D!UE=..D.)E&AK@P*AULW[N._O#+X"/(7,?AL/,M*''U9Y:T=EUBC>:W
M<\3(;3RR.Q@$O='%!XQ&@=I9);CT1V#MNAL[#[@EQU+(9K,0O=FR%J"*S)61
MII$AJT_*KBJL4:*)S%VR2V/(97*+%'$84S&,:L15!L,>HS@E;Y%#,J0"A59V
M[>11YQWQ*WM[>7R=NWMV[= ]+=J)_)'9L1R \ATFD1P?M[E8-S]_.CE)4J2I
MXY:M>6/CCQR0QNG'V=K*5X^[C25_C=8?B6$\W2:K#<7QW$JLG5."69%;C-)6
MT($]D63D+"K"8.J&$'E.);!"T@M\;IYFQ1I)(Y&-[/IT!O7;_3])KURU=F7,
M9&)9;=B:S(L2+6[(E>9W98T+,50$*I8D <G2#>T#1I8_J"\-"G5I0OAL;,\5
M2O%6C:5VLAY62%$5I&"J&<@LP502>!ITK$/]$\7_ $=I/U:-TAM[^.W/SJQ^
MU?3[T?XE3_-:_P"R3256IW-K?&OD:>YHJISMV:*OK*D?[N9L[+A1(D5W;N\D
MB>"*%$]Y'RQM;W5R=WTS(,O0,>,=_P#YN\2_S?7YJ8BD[GT^I55F;[ #S\-(
M+AB(NOQ\A[/_ #C99/G>GSGS%U$'K];,RJOVDCCXZ=WZ0'70354^=?Y%7+3^
MKCN?]GV0=7'IY_+W9?\ :G _O.MJF]1?Y [U_LKG_P!UVM+P_1WO]>'(3^BG
M'_\ %\/3.>TY_)[;/Z9L_P"XMI8/9?\ Y0[G_0U7_?ETV5TF6G1T//Q7/S>W
M)K]$:#_'F)]$WHW])FT_SVS^[;NACUF^C+=OYC7_ 'C2T*WZ.9_ 7+?^=M)_
MW/:?1A]J'^,;*_U.?_V\/H-^RU_%][?Z[;_^QF=<\^D65A46=\7+ET3T"-Q+
M9U9#-Y5]-Q59<8>43$COL\[(;<1ZM[]_*]%ZV?LP3(<=N^ $>2.[B9F7Z^R:
M"\B'C["T#C]6M7[4<+C);0L$'QR4<O"K?47AGHNX_K"SH?UC1P_#9NP,@X'\
M63JTB(D<?4>/4DLD3VO:P_&O7QRT'<K55$E$LZHL69B_69-"]CD1S53I?NJE
M>2MU%WA'*I1FS5FP 1P3';[;4+?U/#-&ZGZU8'Z],)THLQ6NG&SI(F5U3"UJ
MQ*GD"6GW5)E/_.2:%T8?4RD:N]T/]$+2N/TC&[K9\CXFXY$7$^WJZ7<MV<"C
MT68:MOSM: 51<D??S-B-*QNXAA>J(DCZ^=K558W=F\]EZO*M7>=HH1!-8P5>
M.3CYKRUH\M),@/P)C2U S#ZA*OVC2?\ M2V(FM;+JAP9X:^>L21\_.6*S)B8
MX7(^H2/4G53]9C;[-&G\,ZH*I.!7%L(R%T$LVK*NW8Q[5:KA<@,/O@9D1?\
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MQ\Y'8N9=U(67X5@^*9-I//:.KLSX 2[C"KW+MD9KB.0PX_&2ZU.JLG7'R;$
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MDV.JPP\1?DAH$MJ'"D,_#'0!Z:X#>%[8&VFJ;[?%XZQC?Q52KMS&R7*L#3S
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M@.Y)U6N:]>>=)"LBR2>8L&/E[.WA 3M7B4;6K*77F!: E=ELDG)',1L7SEN
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M:Y/,[SH ^FUN2IOC!VD2.1UENJ4E#>-A-C;L+AA$\3#YDC<=CKP>"/0<:/\
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M617BOY):E_.TX;;]SI7R<]4M(8O(P@ENQ6YHE"@2'L7ACK2VI,.T1JW#-2X
M.;!BF%U2@5[[0QUC;'D%%DVEO=7-@YD7QUU?71]A=W!;88(R+,\J6(<>)[(8
MU:SV:O;BS%_-9)HVN7YO)*(4$4,:HB0P001@GQUZU>**O A9BL42*S,06+3X
M#"4-N8>AA,8DBTJ$/CB,S^6:1G=YI[$\G"^2Q9L2RV)W"J'FE=E500HZAUJ-
';C4ZFIK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g63338snap003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338snap003.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M6X/>@#OM'CNK>P2TNHR#;*D22-/YK3 1KEB=J\[MPZ#.,\9P #0H * "@ H
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M/ED53C!ZXQ0!ES>)[F/6KBRBTQ9H4E:UB9;D"66<0>=MV$ !2N1N+9SVP<T
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M*TQ=+M7B^TSW4LDAEEGGV[Y&/<[0%'  P !@"@"]0 4 % !0 4 % !0 4 %
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M6SVK)-)(LI24*!(P0( 26S(#CL,$@&EHVIZE/KFJ:=J7D9MPDD1BA>,88O\
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M.XKL^\,9S]T8H Z2@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H @N[."^@\BYCWQ[T?&2/F5@RGCT(
M!H I7/A[3[J^>\D6X$DBE9%CNY8XY,KMRT:L%8XXR03P/08 +UM:Q6D7EP[P
MG& SLV, # R3@8'04 0?V39?V=!8>1_HL#1M&FX_*8V#)SG/#*#^'- %?4/#
MFF:H5-Y%-)M+=+F1=RMC<C88;D.!E#E>.E $3^$]%>>[F:T??=!@_P"_DPFY
M@S&,;L1DLJL2F"64'J,T 2'PUI9TW^SS%,;?K@W,I8MO#[]V[=O# $/G<".#
M0! G@_1HKFUN(4NX9;9-B&*_G3(WESO <!R6))+9+9YS0!/9>&]+TZ::6TAE
MC>5@Q_TF0A0&+!5!;Y$R3\BX7MC% #M.\.Z7I7VG[';LGV@;7W2N^%&<(NXG
M8HW-A5P!DX% #1X9T@7EK="U(DM8UCC'FOLVJ"%W)G:Q )P6!(SQ0!+I&A:=
MH44D>GP-&LA!.^5Y" !A5!8DA0.BC '. ,T 68[*WBFN94B&^Y(,I))W84*.
M#[ "@#%B\"^'8H6@-E)-$R"-DN+J6964!E4$.QR ';&>G&.@P ;=K:1V<9CB
M:5@<?ZV9Y#PH4<L2>BCZG)/))(!$=*LFT]; P_Z,K!@FX]0VX<YSU&: *^H^
M'=-U7!O(YG(+'*W,B9# !D.UAE#M7*?=..10!$_A71I+JZN&M&,ETC(X\Z3:
MN<;BB[L1L=JDLH!)&<YYH >/#6EC3C8&*=K=@P8/=2LS%F#;BQ;<7!48<G<N
M."* *X\&Z*DUM-&EY%+;*RH\5_.A.Y][;B'&\EN26R3WS0!8MO#6EV=W-=6\
M,L<LK;B1<R87Y]Y"#=A%+<LJX#=P: )-.T'3M)N;BXLX&22<_-NE=PHR3M4,
M2$7))VK@>U $">%=&CGL94M&5K&..*%1-)MVQY\O<N[#[<D@L"03D<T 3Z3H
M.FZ)YW]GV[1>;@-NE=\*,[57<3M09.%&%&3@#- &E0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MR"<YSD>E '2>*;6SFU&PEUG3)-2TA(Y T*VC72K,2NQFB56)^4. V#C)Z9H
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MS@[J .,\5P:;XY\2>.+BZU"UB.F6BV&G++.JEI4.]R 3_>7;G_:H ]7^'OB
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MQR6MX%B257B"N^#AP-QRN#UZ4 =Y0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 17%S!:0-/<S1PPKC<\C!5'..2
M: '+-$TSPK*AE0!F0,-R@YP2.V<'\C0 ^@#+L?$FA:G'-)8:UI]VD !E:"Z1
MQ'GIN(/&<'K0!J4 0?;;7R?.^TQ>5YGE;]XQOW[-N?7=\N.N>.M $] !0 4
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MEC+#T)[T .AMH+< 0P1Q 9P$4#&>O2@"6@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H YGQ?HVH^(4M-+MC!%9,S
M2W4ES%YT;[1A8R@=6.2V[.<#R^>P(!AVVD^(QXAL[FYM;TW"Q6T#WD=VB0,(
MI9!*TD8?+>8A!4%6VEOX2#0!M>#XM=C5AK,%U"8K*VMP9YTD\V5 XDD&UF^\
M2O)P3QD4 <_!HFMZAX;L+"71;C3Y[#219,\LT):5SY0.PH[?*/+)RVW^'@\X
M #5]&\4Q_9+;2X[]X[>YD>.9M0=B(_,#!7)G4MD9P7$OIA1U );'1O$-MJ%S
MY%O?V\;:@\TK/>J8ID:_213&@<[ (?,W#"D[L8;L >AT % !0!RWC+2M1U Z
M=<Z9;B:YL'>XC4R!,NHRJY/3<1MSZ,<T 8-OX7U^VM);?RBQGG:>?9*H661E
MMRSXSW=93ST_$9 &Z?HOBJXO-06]2_M;*YG@.Q=0?<JB5C)M?SW(&P@97R\X
M^XN!0!W&@P7=KHEM!>F0SQ@J3))YC$ G;ELDDXQR23Z\T :- !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M.(FSD\K'\GOP>,8H ["@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M4%Y:OO@G0.C8(R",C@\CZ'F@">@ H * "@ H * "@ H * "@ H * "@ H *
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ML(M+TZ"Q@9VB@0(I<@DCWQ0!:H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M8'B/>1@Y H VM(\1VFLW,MO;13+)#'OEWA<1MYCQ[#@GY@T3Y SC'7D4 ;%
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MBZ.VHRL\<EQ?W37,KQQ[!D@  #)Z!1WY.3QF@#6H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MP #KJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0?M  V[BV<#D4 1RP>*9)[2$ZMJ?FI*PCG-K'MW/:Y&\+'C:LF1D@8S@DG%
M'3>$-2O=:T)=6O T8O9#+!"P7]U%P%&1USC=DD_>],  &]0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M&Y5)(!([ E6Q]#Z4 5X-*TZUOKB^M["VAO+C'G3QQ*LDF.FY@,G\: += !0
M4 ,FABN8)()XDEAD4H\;J&5E(P00>H(H (HHX(4AAC6.*-0J(@PJ@<  =A0
M^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H PO$ O8K[2+VSTRXU 6TSF2*W>-7
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MZ@B@#I* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,C6M,OKZ:PN
M-.O;>TN+21G!N+9ID8%"I& Z'OUS0!CR^#+HFV\G58D!9'O-UKN,S"X,Y*8<
M"/+LW4-P1W&2 0KX*U..QEMX]=BB<*(X'BM7B*IO+L'*2AB3GJK)CGKDY -7
MPWX9/A\DF]:Z)M8K?+*03LDE?<26))/FXY_NY[\ '04 % !0 4 % &/KOANP
M\1/9+J5O!<VUM(SM!-$'5R4*CKT(SG- '-ZKX,O(]$2TL)V>=(X+2V>"-(OL
MR)*2'.6P<(V" ,GG YP "74?A\^H:B&;6'CTV.%H8;14?]VIMVAQ_K-AQN+
M[-W8DB@"PG@RYE:]GO\ 4K>6ZNWF=F@LS&BF2".$84NQX$>>O.3TH ZN"+R;
M>.+.=BA<^N!0!)0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 SPWX-TSPM/=2:=PLX V?9X$V $X&Y(U=NO5V8^^<D@'0T % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_+4'9%'(3EF'&)D'KG/'J ;.FW3WNF6EU+"T$DT2R-&Q!*$C.."1^1- %J@
MH * ,7Q+?ZCI]G#)IZ !I,2S?8Y+OREP<'RHR';)P..F<GB@"@OC:S@O-'L+
MM5>XU%$VRP31B,N200$=Q*1D<X0XS@G@X +WAWQ-!XC@,L5E=VG[F*=%N0F7
MBD!*.-C-@'!X.",<@4 86G>)]:BTBPO]6FL94U#3Q>1_9;1T,)_=DJ0TIWC$
MG7*XV]#G@ LV?Q&T?4)KR"QBFNKBW<(D,,D+O/E]OR@2?)SVDV'';K0!9@\;
M65Q+;JNGWPCD9$ED9$"V[/(T2*_S9R74CY0V,@G - '34 % !0 4 % !0 4
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M75HJYE\V15D8,7#,FXAL,S%=^XKGKGF@#HZ "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M,V2-OWN,YZ"@#!\+MK5CX5TB\RJWFIK;()[K4KF_5@R%BYC<J$;V4XYQG@4
M-M?'FJW]]J-G9S6$FR>"*WF:W^5-\_EMN59V9B 0<-Y;=,J,\ %K_A,M0,D,
M%Q<Z=#)Y3 PLDBR7;!I$9H<,2H78&(PV >64?-0!6A\=WT=Q>6OG6!6"UBD1
MEQ(+<$Q!I)F$Q?"[V8AD3A3\YZT 6E\;7IO["!;S2IUE,*KY4<F=0#SM$S09
M;@(JAS_K!ANH7#D [Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M"IJ.FVVJV36EVKF(LK9CE:-U*D$$,I#*01U!% $EE9P:?90V=JA2"%0J@L6.
M/<G))]23DGDT 3T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % '/>([74[C4M$;2Y(H98YY"TLULTT:#RF'*JR]<XSF@#F;2;
MQ)IPLK7-XC^<[*D%AF&Y=KN3S/,)#&) A5E^9<[CRV,4 2OJ/B*QLV>_U'44
MCN!"6E6RC:6W)E=2L2"/YC@)P0YP2: +;2:QK7@G1I[:8OJ$EU&WGRVY^0!R
M-[1C'0<XX^HH IS7&KZ=#:6^GV^H6DZY\U8K/SEN[O<N?-D*'$; Y\P;.">5
M*[0 +=ZCXDL$N;BYO[Y;>>>9,BTC)MD%ZL4?E )EF:)B0&WEB 0#T(!TWA"^
MN=1\.1W-U/+/(9[A!)+$(G95F=5W* ,':!Q@4 ;E !0!RWCBTAN]/M!<6[3Q
MI-NVOIK7\.=I'[R!#N8<G!'0X)]P#'L+?6K75;>]MX;JUA%O8PM:)%N25=\H
M;)<%AM4@X# KGYLT 5=$U#Q=JC_9YKG5;2"6YBVW,EH@E2,QS%A\]NBC#)&#
ME6QD?,0PH C&OZ[<W.GVEW=7B75Q&D4]D+(>4=UD96W/LRLOF9^3<#M'W><T
M +=W/BO2/#J6=M-JLUR#%Y,J6J KF$$QG;!)A0W RN<\,X[@'8^&9+V4:E-?
M6YA>2>)ES#Y9;-M#D] 6^;<,G)&W'\.  ;M !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M8(X4F>:-8G*JKE@ 2Q 4 ^Y( ]210 Z&:*XA2:"5)8I &1T8%6!Z$$=: 'T
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M,] P7?\ \#H Z2@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *MQ?Q6MY9VKJY
M>[=D0@# (4L<_@* (Y-:TJ&\GLY=3M([J"(SRPM.H>.,=79<Y"^YXH HWWC'
MP_8Z$^L'5K.:S"N8VAN$;SF4$E$.<,W'3- %Q]=TB.XN[=]5LUFLU#W,9N$#
M0J>A<9^4<CD^M %BQO[/4[..\L+N&[M9,[)H) Z-@X.&'!Y!'X4 6* "@ H
M* ,[5M7&E"W5;.XO;BYD,<4%N4#L0I8\NRKP 3R: ()/%&E6D0EU*ZBTQ-D;
MYOIDA(+[L*06R#\IZC![$X. "S)KFD17GV.35;-+K9YGDM.H?;@MNVYSC )S
MZ T 5_\ A*O#OV%;W^W]-^R,YC6?[7'L+#&5#9QGD<>] %EM:TJ.\N+-]3M%
MNK:/S9X3.H>)./F9<Y4<CD^HH ;:Z[I%[=):VFJV=Q</$)TBBN$9FC/1P <E
M>>O2@#0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M7KA=H[<G% %M/"!C\9'71>[H3*9_L[F8[9#%Y6Y<2B,?+ZQD\GGI@ ZB@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H I7>H?9=0T^U\K=]K=TW;L;-J%L
MX[],4 4[CQ5HUI>W-I-=.LMLC/(?(D*?*NXJ'"[6<+SL!+8[4 6#K=DNAS:P
MWGQVD,;R.)8'BD 7.?D<!@>. 1SQCJ* ,R+QG8P:-;7NK0S65Q(9$DMHXI+A
MHGC)#@[%)P,9W$ 8P: +3^+-%CO9[1[MED@1G9C!)Y9"@%MK[=K$ C(4D@G'
M6@"NWC/3%GAQYPMWAE=V>"1)4='B01^25W[F,RX&,GC .X4 6[?Q/I=W/;06
M\EQ))<#*A;27"?,RXD.W$9W(PP^TY4CJ* ->@ H Q?$>JZEH]G%<V&GVMXIE
M2*03W30%2[JBXQ&^>6YZ8 [T 17'BJTL2UK>874XX2[PQ"1X0X0OY?G; NX@
M$@'#8YQ0 L/C'1I+7SFN&3$1E.(9"I"E VQMN'PTBK\N>3CJ"* +EAK^FZE?
M3V5K.[SP9R&A=%8!MK%&8 . >"5)P>O6@#2H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M&P,I9B74?>&.3VP0#4T^2YDL8C>>3]I VR^0Q*;@<'&><9'0].E %F@ H *
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M*@=BH ).<$XW$DDMU/<F@"W0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
% !0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g63338snap004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338snap004.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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A 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
